Rank,Title,Status,Study Results,Conditions,Interventions,Sponsor/Collaborators,Phases,Funded Bys,Study Type,Results First Posted,URL
1,"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution",Completed,Has Results,Healthy Subjects,Drug: AC-170 0.24%|Drug: AC-170 Vehicle,"Nicox Ophthalmics, Inc.|ORA, Inc.",Phase 3,Industry,Interventional,26-Jul-17,https://ClinicalTrials.gov/show/NCT02756624
2,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002,Completed,Has Results,Glabellar Frown Lines,"Biological: Botulinum toxin, Type A|Other: 0.9% sterile, unpreserved saline","Evolus, Inc.|PPD",Phase 3,Industry,Interventional,27-Feb-19,https://ClinicalTrials.gov/show/NCT02334436
3,A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001,Completed,Has Results,Glabellar Frown Lines,"Biological: Botulinum toxin, Type A|Other: 0.9% sterile, unpreserved saline","Evolus, Inc.|PPD",Phase 3,Industry,Interventional,26-Feb-19,https://ClinicalTrials.gov/show/NCT02334423
4,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity,Completed,Has Results,Schizophrenia With Impulsivity,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,11-Sep-18,https://ClinicalTrials.gov/show/NCT02194933
5,Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA,Completed,Has Results,Osteoarthritis,Device: Supartz|Device: Euflexxa,Bioventus LLC|Seikagaku Corporation,Phase 3,Industry,Interventional,23-Jun-16,https://ClinicalTrials.gov/show/NCT02110238
6,Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: CT-P13|Biological: Remicade,Celltrion|Pfizer,Phase 3,Industry,Interventional,11-Apr-18,https://ClinicalTrials.gov/show/NCT02096861
7,Aripiprazole Once-monthly in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole once-monthly,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,16-May-16,https://ClinicalTrials.gov/show/NCT01959035
8,Brexpiprazole in Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Brexpiprazole|Drug: Quetiapine extended release,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,29-Mar-16,https://ClinicalTrials.gov/show/NCT01810380
9,PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus,Completed,Has Results,Normal Pressure Hydrocephalus,Drug: [18F] Flutemetamol,GE Healthcare|i3 Statprobe,Phase 3,Industry,Interventional,5-Jun-12,https://ClinicalTrials.gov/show/NCT01053312
10,Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily,Completed,Has Results,Renal Failure,Drug: LCP-Tacro|Drug: Prograf,Veloxis Pharmaceuticals|PPD,Phase 3,Industry,Interventional,10-Sep-15,https://ClinicalTrials.gov/show/NCT00817206
11,Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: pirfenidone,"Genentech, Inc.|Hoffmann-La Roche",Phase 3,Industry,Interventional,29-Mar-17,https://ClinicalTrials.gov/show/NCT00662038
12,Phase 3 Study of MAP0004 in Adult Migraineurs,Completed,Has Results,Migraine Disorders,Drug: MAP0004|Drug: Placebo,"Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan",Phase 3,Industry,Interventional,29-Oct-13,https://ClinicalTrials.gov/show/NCT00623636
13,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: 23 mg SR in Study 326|Drug: 10 mg IR in Study 326,Eisai Inc.|Eisai Limited,Phase 3,Industry,Interventional,19-Jun-12,https://ClinicalTrials.gov/show/NCT00566501
14,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg),Eisai Inc.|Eisai Limited,Phase 3,Industry,Interventional,5-Feb-13,https://ClinicalTrials.gov/show/NCT00478205
15,Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.,Completed,Has Results,HIV,"Drug: TMC125, Darunavir; Ritonavir","Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Phase 3,Industry,Interventional,10-Nov-09,https://ClinicalTrials.gov/show/NCT00460746
16,RNF and Betaseron® Tolerability Study,Completed,Has Results,Relapsing Remitting Multiple Sclerosis (RRMS),Drug: New Formulation of rebif - human interferon beta-1a|Drug: Interferon beta -1b,EMD Serono|Pfizer,Phase 3,Industry,Interventional,4-Mar-10,https://ClinicalTrials.gov/show/NCT00428584
17,Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects,Completed,Has Results,Healthy,Drug: [18F] Flutemetamol,"GE Healthcare|i3 Statprobe|Medpace, Inc.",Phase 3,Industry,Interventional,21-Jun-13,https://ClinicalTrials.gov/show/NCT01265394
18,Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study,Completed,Has Results,Post-operative Pain,Drug: Ibuprofen/acetaminophen|Drug: Ibuprofen/acetaminophen (higher dose)|Drug: Nurofen Plus®|Drug: Panadeine® Extra|Drug: Placebo,Reckitt Benckiser LLC|Premier Research Group plc|Aptuit Inc.,Phase 3,Industry,Interventional,17-Sep-18,https://ClinicalTrials.gov/show/NCT01229449
19,A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib,Completed,Has Results,Macular Degeneration|Choroidal Neovascularization,Drug: Verteporfin photodynamic therapy|Drug: Pegaptanib|Drug: Triamcinolone acetonide,Novartis Pharmaceuticals|QLT Inc.|Novartis,Phase 3,Industry,Interventional,2-May-11,https://ClinicalTrials.gov/show/NCT00242580
20,Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels,Completed,Has Results,Brain Fibrillarab Levels,Drug: [18F] Flutemetamol,GE Healthcare|i3 Statprobe|Covance,Phase 3,Industry,Interventional,4-Dec-13,https://ClinicalTrials.gov/show/NCT01165554
21,Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Biological: Interferon-beta-1a FBS-free/HSA-free,EMD Serono|Pfizer,Phase 3,Industry,Interventional,9-Jul-10,https://ClinicalTrials.gov/show/NCT00110396
22,A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention,Completed,Has Results,Coronary Arteriosclerosis|Acute Coronary Syndromes,Drug: Prasugrel|Drug: Clopidogrel,"Eli Lilly and Company|Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,16-Sep-10,https://ClinicalTrials.gov/show/NCT00097591
23,"IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose",Completed,Has Results,Iron Deficiency Anaemia,Drug: iron isomaltoside 1000 (Monofer®)|Drug: iron sucrose (Venofer®),"Pharmacosmos A/S|BioStata|ClinStar, LLC|LabCorp",Phase 3,Industry|Other,Interventional,22-May-18,https://ClinicalTrials.gov/show/NCT02130063
24,Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole and aripiprazole once-monthly|Drug: Paliperidone and paliperidone palmitate,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,3-Dec-15,https://ClinicalTrials.gov/show/NCT01795547
25,Ibuprofen Extended-Release Dental Pain Study,Completed,Has Results,Pain|Post-Operative Pain|Third Molar Extraction,Drug: Ibuprofen 600 mg Extended-Release Tablets|Drug: Placebo,"SCOLR Pharma, Inc.|AAIPharma|Jean Brown Research",Phase 3,Industry|Other,Interventional,23-Mar-11,https://ClinicalTrials.gov/show/NCT00707057
26,The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study,Completed,Has Results,"Macular Edema, Cystoid|Retinal Vein Occlusion",Other: Standard Care|Drug: intravitreal triamcinolone injection,"The Emmes Company, LLC|National Eye Institute (NEI)|Allergan",Phase 3,Industry|NIH,Interventional,19-Jan-11,https://ClinicalTrials.gov/show/NCT00105027
27,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.",Phase 3,Industry,Interventional,30-Aug-17,https://ClinicalTrials.gov/show/NCT01844830
28,A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults,Completed,Has Results,Obesity,Drug: VI-0521|Drug: topiramate|Drug: phentermine,"VIVUS, Inc.|Medpace, Inc.",Phase 3,Industry,Interventional,3-Sep-12,https://ClinicalTrials.gov/show/NCT00563368
29,Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: Flutemetamol (18F) Injection,"GE Healthcare|Medpace, Inc.|i3 Statprobe|i3 Research|Quintiles, Inc.",Phase 3,Industry,Interventional,11-Sep-14,https://ClinicalTrials.gov/show/NCT01028053
30,A Study to Evaluate the Efficacy of Investigational OTC Eye Drops,Completed,Has Results,Ophthalmic Solutions,Drug: F# 13418-148 Eye Drops|Drug: F#13418-158 Eye Drops|Drug: F# PF-004390 Eye Drops,Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide,Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT03198000
31,OTC Mouthpiece for Snoring,Completed,Has Results,Snoring,Device: Zyppah Anti-snoring Appliance,"Zyppah, Inc.",Phase 3,Industry,Interventional,14-Dec-17,https://ClinicalTrials.gov/show/NCT03128307
32,Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD,Completed,Has Results,"Chronic Obstructive Pulmonary Disease, COPD|Low Peak Inspiratory Flow Rate (PIFR)",Drug: Revefenacin|Combination Product: Spiriva Handihaler®|Drug: Placebo for Revefenacin|Drug: Placebo for Spiriva Handihaler®,Theravance Biopharma,Phase 3,Industry,Interventional,31-Dec-18,https://ClinicalTrials.gov/show/NCT03095456
33,Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study,Completed,Has Results,Attention Deficit Hyperactivity Disorder,"Drug: amphetamine extended-release oral suspension, 2.5 mg/mL|Drug: Placebo extended-release oral suspension","Tris Pharma, Inc.",Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT03088267
34,Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Completed,Has Results,Lambert-Eaton Myasthenic Syndrome,Drug: Amifampridine Phosphate|Drug: Placebo Oral Tablet,"Catalyst Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,24-Dec-18,https://ClinicalTrials.gov/show/NCT02970162
35,Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis,Completed,Has Results,Scalp Psoriasis,Drug: DSXS topical|Drug: Vehicle topical,Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,6-Dec-18,https://ClinicalTrials.gov/show/NCT02933866
36,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,Completed,Has Results,Post-surgical Pain Following Extraction of Molar Teeth,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 650 mg|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,30-Aug-17,https://ClinicalTrials.gov/show/NCT02912650
37,Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy,Completed,Has Results,Breast Cancer|Neutropenia,Drug: F-627|Drug: Placebo,Generon (Shanghai) Corporation Ltd.,Phase 3,Industry,Interventional,26-Mar-19,https://ClinicalTrials.gov/show/NCT02872103
38,A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine,Completed,Has Results,Pain,Drug: Ibuprofen/Caffeine|Drug: Ibuprofen|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,8-Apr-19,https://ClinicalTrials.gov/show/NCT02863575
39,A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain,Completed,Has Results,Pain,Drug: FDC IBU/APAP 250 mg/500 mg|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,5-Mar-18,https://ClinicalTrials.gov/show/NCT02837952
40,Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentin Sensitivity,Drug: stannous fluoride|Drug: sodium monofluorophosphate,GlaxoSmithKline,Phase 3,Industry,Interventional,27-Feb-17,https://ClinicalTrials.gov/show/NCT02832375
41,A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers,Completed,Has Results,Fever,Drug: Ibuprofen 250 mg / Acetaminophen 500 mg|Drug: Ibuprofen 250 mg|Drug: Acetaminophen 500 mg|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,7-Dec-18,https://ClinicalTrials.gov/show/NCT02761980
42,A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Completed,Has Results,Hypogonadism,Drug: Oral Testosterone Undecanoate|Drug: Axiron Testosterone Topical Solution,"Clarus Therapeutics, Inc.|Syneos Health",Phase 3,Industry|Other,Interventional,23-Feb-18,https://ClinicalTrials.gov/show/NCT02722278
43,Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) ophthalmic solution 0.02%|Drug: Latanoprost ophthalmic solution 0.005%,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,1-May-19,https://ClinicalTrials.gov/show/NCT02674854
44,An Open-Label Safety Study of A-101 Solution,Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution,"Aclaris Therapeutics, Inc.",Phase 3,Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT02667288
45,"A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis",Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution|Other: Vehicle Solution,"Aclaris Therapeutics, Inc.",Phase 3,Industry,Interventional,13-Nov-17,https://ClinicalTrials.gov/show/NCT02667275
46,A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.,Completed,Has Results,Seborrheic Keratosis,Drug: A-101 Solution|Other: Vehicle Solution,"Aclaris Therapeutics, Inc.",Phase 3,Industry,Interventional,13-Nov-17,https://ClinicalTrials.gov/show/NCT02667236
47,Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: DSXS|Drug: Placebo,Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,10-Dec-18,https://ClinicalTrials.gov/show/NCT02618759
48,Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: DSXS|Drug: Placebo,Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,7-Dec-18,https://ClinicalTrials.gov/show/NCT02595073
49,Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: PG324 Ophthalmic Solution 0.02%/0.005%|Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Drug: Latanoprost Ophthalmic Solution 0.005%,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,4-Jun-19,https://ClinicalTrials.gov/show/NCT02558400
50,Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension,Completed,Has Results,Open-angle Glaucoma|Ocular Hypertension,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Timolol Maleate Ophthalmic Solution 0.5% BID|Other: Placebo,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02558374
51,Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,Phase 3,Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT02549339
52,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,Phase 3,Industry,Interventional,25-Dec-18,https://ClinicalTrials.gov/show/NCT02547363
53,Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up,Completed,Has Results,Actinic Keratosis,Drug: LEO 43204 gel|Drug: Vehicle gel,LEO Pharma,Phase 3,Industry,Interventional,25-Dec-18,https://ClinicalTrials.gov/show/NCT02547233
54,A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Tiotropium,Theravance Biopharma,Phase 3,Industry,Interventional,31-Dec-18,https://ClinicalTrials.gov/show/NCT02518139
55,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Phase 3,Industry,Interventional,31-Dec-18,https://ClinicalTrials.gov/show/NCT02512510
56,"Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia",Completed,Has Results,Any Ear Nose or Throat Conditions|With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities,Drug: Cocaine HCl 4% Topical Solution|Drug: Cocaine HCl 10% Topical Solution|Drug: Placebo Topical Solution,"Lannett Company, Inc.",Phase 3,Industry,Interventional,16-May-17,https://ClinicalTrials.gov/show/NCT02500836
57,A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain,Completed,Has Results,Post Operative Dental Pain,Drug: Diclofenac potassium|Drug: Ibuprofen|Drug: Placebo to ibuprofen|Drug: Placebo to diclofenac potassium,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-Oct-16,https://ClinicalTrials.gov/show/NCT02476422
58,Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: TD-4208|Drug: Placebo,Theravance Biopharma,Phase 3,Industry,Interventional,31-Dec-18,https://ClinicalTrials.gov/show/NCT02459080
59,A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief,Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Sodium Based Eye Drops|Drug: Systane® Gel Drops|Drug: Genteal® Lubricant Gel Drops,Allergan,Phase 3,Industry,Interventional,4-Jan-17,https://ClinicalTrials.gov/show/NCT02455050
60,A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis,Completed,Has Results,Psoriasis,Drug: Ixekizumab,Eli Lilly and Company,Phase 3,Industry,Interventional,21-Oct-16,https://ClinicalTrials.gov/show/NCT02387801
61,"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest",Completed,Has Results,Actinic Keratosis,Drug: Ingenol Mebutate|Other: Vehicle,LEO Pharma,Phase 3,Industry,Interventional,3-Oct-18,https://ClinicalTrials.gov/show/NCT02361216
62,Pharmacokinetic Comparison Of All FK-506 Formulations,Completed,Has Results,Renal Failure,Drug: Prograf vs Envarsus XR vs Astagraf XL|Drug: Prograf vs Astagraf XL vs Envarsus XR,Veloxis Pharmaceuticals,Phase 3,Industry,Interventional,18-Jan-16,https://ClinicalTrials.gov/show/NCT02339246
63,EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD),Completed,Has Results,Generalized Anxiety Disorder (GAD),Drug: Extended-release lorazepam|Drug: Placebo,"Edgemont Pharmaceuticals, LLC",Phase 3,Industry,Interventional,26-Sep-18,https://ClinicalTrials.gov/show/NCT02305797
64,A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness,Completed,Has Results,Muscle Soreness,Drug: Diclofenac sodium gel 1%|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,5-Apr-16,https://ClinicalTrials.gov/show/NCT02271854
65,Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: AR-13324 Ophthalmic Solution 0.02% BID|Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Other: Placebo,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02246764
66,Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth,Completed,Has Results,Surgery,Drug: 2% CHG Cloth solution|Device: Vehicle Cloth|Drug: Active Comparator|Other: Saline|Other: SLS,Medline Industries,Phase 3,Industry,Interventional,30-May-16,https://ClinicalTrials.gov/show/NCT02224625
67,A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban,Completed,Has Results,Bleeding,Biological: Andexanet|Other: Placebo,Portola Pharmaceuticals,Phase 3,Industry,Interventional,25-Sep-18,https://ClinicalTrials.gov/show/NCT02220725
68,A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban,Completed,Has Results,Bleeding,Biological: Andexanet|Other: Placebo,Portola Pharmaceuticals,Phase 3,Industry,Interventional,27-Sep-18,https://ClinicalTrials.gov/show/NCT02207725
69,Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Open-angle Glaucoma,Drug: AR-13324 Ophthalmic Solution 0.02%|Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Other: Placebo|Drug: AR-13324 Ophthalmic Solution 0.02% BID,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02207621
70,Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Ocular Hypertension|Open-angle Glaucoma,Drug: Timolol maleate Ophthalmic Solution 0.5% BID|Drug: AR-13324 Ophthalmic Solution 0.02%|Other: Placebo,Aerie Pharmaceuticals,Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT02207491
71,A Multi-Center Study Evaluating the Safety of AC-170 0.24%,Completed,Has Results,Atopic Disease (Including Allergic Conjunctivitis),Drug: Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.",Phase 3,Industry,Interventional,26-Jul-17,https://ClinicalTrials.gov/show/NCT02132169
72,Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: Oxymetazoline HCL Cream 1.0%|Drug: Vehicle to Oxymetazoline HCL Cream,Allergan,Phase 3,Industry,Interventional,2-Aug-16,https://ClinicalTrials.gov/show/NCT02132117
73,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: AGN-199201|Drug: Vehicle to AGN-199201,Allergan,Phase 3,Industry,Interventional,10-Mar-16,https://ClinicalTrials.gov/show/NCT02131636
74,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis",Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%|Drug: Matching vehicle control",Pfizer,Phase 3,Industry,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT02118792
75,"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis",Completed,Has Results,"Dermatitis, Atopic","Drug: AN2728 Topical Ointment, 2%|Drug: Matching vehicle control",Pfizer,Phase 3,Industry,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT02118766
76,A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: Oxymetazoline HCL Cream 1.0%,Allergan,Phase 3,Industry,Interventional,21-Sep-16,https://ClinicalTrials.gov/show/NCT02095158
77,Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery,Completed,Has Results,Post Ocular Surgical Inflammation and Pain,Drug: Dexamethasone|Device: Punctum Plug,"Ocular Therapeutix, Inc.",Phase 3,Industry,Interventional,30-Mar-16,https://ClinicalTrials.gov/show/NCT02089113
78,Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Primary Open Angle Glaucoma|Ocular Hypertension,Drug: T-2345|Drug: Xalatan,Nephron Pharmaceuticals Corporation,Phase 3,Industry,Interventional,22-Aug-18,https://ClinicalTrials.gov/show/NCT02059278
79,Patient Experience Study of Deoxycholic Acid Injection,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic Acid Injection|Drug: Placebo|Other: Cold Compress|Drug: Lidocaine / Epinephrine|Drug: Loratadine|Drug: Ibuprofen|Other: Compression Chin Strap,Kythera Biopharmaceuticals,Phase 3,Industry,Interventional,3-Jul-15,https://ClinicalTrials.gov/show/NCT02007434
80,The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery,Completed,Has Results,Inflammation|Cataracts,Drug: IBI-10090|Drug: Placebo,ICON Bioscience Inc,Phase 3,Industry,Interventional,23-Apr-18,https://ClinicalTrials.gov/show/NCT02006888
81,US Phase III Study of APD421 in PONV,Completed,Has Results,PONV,Drug: APD421- Amisulpride for IV injection|Drug: Placebo,Acacia Pharma Ltd,Phase 3,Industry,Interventional,6-Sep-18,https://ClinicalTrials.gov/show/NCT01991860
82,Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method,Completed,Has Results,Acute Pharyngitis|Sore Throat,Drug: flurbiprofen|Drug: placebo,Reckitt Benckiser LLC,Phase 3,Industry,Interventional,24-Aug-17,https://ClinicalTrials.gov/show/NCT01986361
83,"Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)",Completed,Has Results,Influenza,Biological: Flublok® Quadrivalent Influenza Virus Vaccine|Biological: Fluarix Quadrivalent® Influenza Virus Vaccine,Protein Sciences Corporation,Phase 3,Industry,Interventional,2-Aug-16,https://ClinicalTrials.gov/show/NCT01959945
84,CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study),Completed,Has Results,Breast Augmentation|Breast Reconstruction|Breast Revision,Device: The Contour Profile Gel (CPG) breast implants,"Mentor Worldwide, LLC",Phase 3,Industry,Interventional,11-Nov-16,https://ClinicalTrials.gov/show/NCT01959880
85,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Completed,Has Results,Otitis Media With Effusion,Drug: OTO-201|Drug: Sham,"Otonomy, Inc.",Phase 3,Industry,Interventional,11-Nov-16,https://ClinicalTrials.gov/show/NCT01949155
86,OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement,Completed,Has Results,Otitis Media With Effusion,Drug: OTO-201|Drug: Sham,"Otonomy, Inc.",Phase 3,Industry,Interventional,15-Jun-16,https://ClinicalTrials.gov/show/NCT01949142
87,A Pharmacokinetic Substudy of the TDE-PH-304 Protocol,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: UT-15C SR|Drug: treprostinil diethanolamine,United Therapeutics,Phase 3,Industry,Interventional,27-Oct-16,https://ClinicalTrials.gov/show/NCT01934582
88,AM-101 in the Treatment of Post-Acute Tinnitus 1,Completed,Has Results,Tinnitus,Drug: AM-101,"Auris Medical, Inc.",Phase 3,Industry,Interventional,9-Mar-18,https://ClinicalTrials.gov/show/NCT01934010
89,Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain,Completed,Has Results,"Pain, Postoperative|Tooth Diseases",Drug: ibuprofen + caffeine|Drug: ibuprofen|Drug: caffeine|Drug: placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,16-Nov-16,https://ClinicalTrials.gov/show/NCT01929031
90,Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Latanoprostene bunod,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,5-Jun-18,https://ClinicalTrials.gov/show/NCT01895972
91,"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.",Phase 3,Industry,Interventional,9-Nov-17,https://ClinicalTrials.gov/show/NCT01881113
92,LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris,Completed,Has Results,Psoriasis Vulgaris|Plaque Psoriasis,Drug: LEO 90100|Drug: Vehicle,LEO Pharma,Phase 3,Industry,Interventional,9-May-16,https://ClinicalTrials.gov/show/NCT01866163
93,A Study to Compare a New Eye Drop Formulation With Refresh Contacts®,Completed,Has Results,Contact Lens Lubrication,Drug: carboxymethylcellulose based eye drop formula|Drug: carboxymethylcellulose sodium based eye drop solution,Allergan,Phase 3,Industry,Interventional,29-Sep-14,https://ClinicalTrials.gov/show/NCT01844388
94,Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous fluoride|Drug: Sodium monofluorophosphate,GlaxoSmithKline,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01827670
95,Assessment of Fluticasone Propionate on Ocular Allergy Symptoms,Completed,Has Results,Allergic Rhinitis|Seasonal Allergic Rhinitis,Drug: Fluticasone propionate|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Apr-14,https://ClinicalTrials.gov/show/NCT01817790
96,AM-101 in the Treatment of Acute Tinnitus 2,Completed,Has Results,Tinnitus,Drug: AM-101|Drug: Placebo,"Auris Medical, Inc.",Phase 3,Industry,Interventional,28-May-18,https://ClinicalTrials.gov/show/NCT01803646
97,Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,Drug: BOL-303259-X|Drug: Timolol,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,21-Nov-18,https://ClinicalTrials.gov/show/NCT01749930
98,Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open-Angle Glaucoma|Ocular Hypertension,Drug: BOL-303259-X|Drug: Timolol,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,7-Nov-18,https://ClinicalTrials.gov/show/NCT01749904
99,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,Completed,Has Results,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Drug: CTAP101 30 μg capsules|Other: Sugar pill to CTAP101 30 μg capsules,"OPKO IP Holdings II, Inc.|OPKO Health, Inc.",Phase 3,Industry,Interventional,17-Aug-16,https://ClinicalTrials.gov/show/NCT01704079
100,"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.",Phase 3,Industry,Interventional,10-Oct-17,https://ClinicalTrials.gov/show/NCT01685242
101,Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors,Completed,Has Results,Myopia,Device: LASIK correction of myopic refractive errors,Abbott Medical Optics,Phase 3,Industry,Interventional,26-Jun-15,https://ClinicalTrials.gov/show/NCT01663363
102,Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery,Completed,Has Results,Post Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: Placebo Sufentanil NanoTab PCA System,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,3-Feb-14,https://ClinicalTrials.gov/show/NCT01660763
103,Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,Completed,Has Results,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",Drug: CTAP101 30 μg capsules|Other: Sugar pill to CTAP101 30 μg capsules,"OPKO IP Holdings II, Inc.|OPKO Health, Inc.",Phase 3,Industry,Interventional,17-Aug-16,https://ClinicalTrials.gov/show/NCT01651000
104,Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions,Completed,Has Results,Enamel Erosion,Drug: sodium fluoride|Drug: no added fluoride in a silica base,GlaxoSmithKline,Phase 3,Industry,Interventional,31-Jul-13,https://ClinicalTrials.gov/show/NCT01641237
105,Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter,Completed,Has Results,Coronary Artery Disease,Device: Emerge™ 1.20 mm PTCA Dilatation Catheter,Boston Scientific Corporation,Phase 3,Industry,Interventional,6-Nov-13,https://ClinicalTrials.gov/show/NCT01635881
106,A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model,Completed,Has Results,Dental Caries,Drug: Fluoride|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,26-Aug-13,https://ClinicalTrials.gov/show/NCT01607411
107,The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Mar-14,https://ClinicalTrials.gov/show/NCT01592864
108,Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity,Completed,Has Results,Dentine Hypersensitivity,Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Jun-14,https://ClinicalTrials.gov/show/NCT01592851
109,A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-15,https://ClinicalTrials.gov/show/NCT01569841
110,Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate,Completed,Has Results,Healthy,Drug: BG00012 (dimethyl fumarate)|Drug: BG00012 placebo|Drug: ASA|Drug: ASA placebo,Biogen,Phase 3,Industry,Interventional,13-Jun-16,https://ClinicalTrials.gov/show/NCT01568112
111,A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC),Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.",Phase 3,Industry,Interventional,3-Oct-17,https://ClinicalTrials.gov/show/NCT01551056
112,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PL2200 Aspirin Capsules|Drug: Immediate-Release Aspirin Tablets|Drug: Enteric-coated aspirin caplets,PLx Pharma,Phase 3,Industry,Interventional,4-Sep-15,https://ClinicalTrials.gov/show/NCT01515657
113,Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: Dexamethasone|Drug: Placebo,"Tesaro, Inc.",Phase 3,Industry,Interventional,4-Nov-15,https://ClinicalTrials.gov/show/NCT01500226
114,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: Dexamethasone|Drug: Placebo,"Tesaro, Inc.",Phase 3,Industry,Interventional,4-Nov-15,https://ClinicalTrials.gov/show/NCT01500213
115,Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy,Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: Rolapitant|Drug: Granisetron|Drug: dexamethasone|Drug: Placebo,"Tesaro, Inc.",Phase 3,Industry,Interventional,4-Nov-15,https://ClinicalTrials.gov/show/NCT01499849
116,Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.,Completed,Has Results,Cataract,Drug: Loteprednol etabonate|Drug: Prednisolones acetate,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,11-Jun-19,https://ClinicalTrials.gov/show/NCT01475643
117,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Based Eye Drop Formulation A|Drug: Carboxymethylcellulose Based Eye Drop Formulation B|Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Drug: Carboxymethylcellulose Based Lubricant Eye Drops,Allergan,Phase 3,Industry,Interventional,14-Mar-13,https://ClinicalTrials.gov/show/NCT01459588
118,Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery,Completed,Has Results,Peripheral Vascular Disease,Device: Omnilink Elite™ Peripheral Balloon-Expandable Stent System,Abbott Medical Devices,Phase 3,Industry,Interventional,1-Oct-12,https://ClinicalTrials.gov/show/NCT01396525
119,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,Completed,Has Results,"Pain, Postoperative","Drug: Naproxen Sodium ER (BAYH6689)|Drug: Naproxen Sodium IR (Aleve, BAYH6689)|Drug: Naproxen Sodium ER Placebo|Drug: Naproxen Sodium IR Placebo",Bayer,Phase 3,Industry,Interventional,7-May-13,https://ClinicalTrials.gov/show/NCT01389284
120,Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Completed,Has Results,Pain|Inflammation|Cataract,Drug: Bromfenac Ophthalmic Solution|Drug: Placebo,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,6-May-14,https://ClinicalTrials.gov/show/NCT01367249
121,Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.",Phase 3,Industry,Interventional,12-Mar-15,https://ClinicalTrials.gov/show/NCT01366209
122,Ibuprofen Sodium Tension Headache Study,Completed,Has Results,Pain,Drug: Ibuprofen Sodium|Drug: Standard Ibuprofen|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,30-Jul-14,https://ClinicalTrials.gov/show/NCT01362491
123,Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy,Completed,Has Results,Allergy,Biological: Short Ragweed Pollen Allergenic Extract|Biological: Placebo,Greer Laboratories,Phase 3,Industry,Interventional,5-Feb-15,https://ClinicalTrials.gov/show/NCT01353079
124,Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study,Completed,Has Results,Diabetic Macular Edema,Drug: Fluocinolone Acetonide,Alimera Sciences,Phase 3,Industry,Interventional,4-May-15,https://ClinicalTrials.gov/show/NCT01304706
125,"Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo",Completed,Has Results,Acne,Drug: Tretinoin|Drug: placebo,Spear Pharmaceuticals,Phase 3,Industry,Interventional,18-Nov-14,https://ClinicalTrials.gov/show/NCT01243450
126,One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction,Completed,Has Results,Aphakia|Cataract,Device: enVista,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,22-Aug-13,https://ClinicalTrials.gov/show/NCT01230060
127,Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain,Completed,Has Results,Pain,Drug: Novel Ibuprofen|Drug: Acetaminophen|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,20-Aug-12,https://ClinicalTrials.gov/show/NCT01216163
128,Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: Desoximetasone Spray 0.25%|Drug: placebo,Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,3-Jul-14,https://ClinicalTrials.gov/show/NCT01206660
129,Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis,Completed,Has Results,Endogenous Anterior Uveitis,Drug: Difluprednate 0.05% ophthalmic emulsion|Drug: Prednisolone acetate 1.0% ophthalmic suspension,Alcon Research,Phase 3,Industry,Interventional,15-Nov-12,https://ClinicalTrials.gov/show/NCT01201798
130,Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle,Completed,Has Results,Bacterial Conjunctivitis,Drug: Besivance|Drug: Vehicle,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,1-May-13,https://ClinicalTrials.gov/show/NCT01175590
131,VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV,Completed,Has Results,Smallpox Vaccine Adverse Reaction,Biological: ACAM2000,Cangene Corporation|Centers for Disease Control and Prevention,Phase 3,Industry|U.S. Fed,Interventional,26-Mar-19,https://ClinicalTrials.gov/show/NCT01158157
132,A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX),Completed,Has Results,Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome,Drug: cangrelor P2Y12 (platelet) inhibitor|Drug: Clopidogrel - 300 or 600 mg (study arm)|Drug: Clopidogrel 600 mg post cangrelor,The Medicines Company,Phase 3,Industry,Interventional,18-Jun-13,https://ClinicalTrials.gov/show/NCT01156571
133,Study of 0417 Ointment in the Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: 0417|Drug: Vehicle of 0417 test product|Drug: Tacrolimus Ointment 0.03%,Fougera Pharmaceuticals Inc.,Phase 3,Industry,Interventional,30-Sep-14,https://ClinicalTrials.gov/show/NCT01139450
134,"Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo",Completed,Has Results,Acne,Drug: Tretinoin microsphere 0.1%|Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%|Drug: placebo microsphere gel,Spear Pharmaceuticals,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT01135069
135,Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery,Completed,Has Results,Cataracts|Inflammation,"Drug: Difluprednate ophthalmic emulsion, 0.05%|Drug: Prednisolone acetate ophthalmic suspension, 1.0%",Alcon Research,Phase 3,Industry,Interventional,19-Jun-13,https://ClinicalTrials.gov/show/NCT01124045
136,To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery,Completed,Has Results,Pain,Drug: Acetaminophen|Drug: Placebo Control,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 3,Industry,Interventional,28-May-12,https://ClinicalTrials.gov/show/NCT01115673
137,Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis,Completed,Has Results,Inborn Errors of Bile Acid Synthesis,Drug: Cholic acid,"Retrophin, Inc.",Phase 3,Industry,Interventional,9-Dec-16,https://ClinicalTrials.gov/show/NCT01115582
138,Confirmatory Study Nepafenac 0.3%,Completed,Has Results,Cataract,"Drug: Nepafenac Ophthalmic Suspension, 0.3%|Drug: Nepafenac Ophthalmic Suspension, 0.1%|Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle|Other: NEVANAC Vehicle",Alcon Research,Phase 3,Industry,Interventional,30-Nov-12,https://ClinicalTrials.gov/show/NCT01109173
139,Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution|Drug: Bimatoprost 0.03% Ophthalmic Solution,Allergan,Phase 3,Industry,Interventional,27-Apr-12,https://ClinicalTrials.gov/show/NCT01099774
140,Clinical Evaluation of a 1-Piece Intraocular Lens,Completed,Has Results,Cataract,Device: Tecnis ZCB00 IOL (control)|Device: Toric Intraocular lens,Abbott Medical Optics,Phase 3,Industry,Interventional,2-Jul-13,https://ClinicalTrials.gov/show/NCT01098812
141,A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers,Completed,Has Results,Pancreatic Disease,Drug: ChiRhoStim|Drug: Placebo,"ChiRhoClin, Inc.",Phase 3,Industry,Interventional,2-Dec-11,https://ClinicalTrials.gov/show/NCT01087801
142,Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste,Completed,Has Results,Hypersensitivity,Device: Arginine/Calcium Carbonate|Device: Nupro - Fluoride Free,Colgate Palmolive,Phase 3,Industry,Interventional,19-Feb-10,https://ClinicalTrials.gov/show/NCT01072188
143,Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Completed,Has Results,Inflammation|Pain,Drug: Loteprednol etabonate|Drug: Vehicle of Loteprednol Etabonate,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,13-Jan-12,https://ClinicalTrials.gov/show/NCT01060072
144,Study of 0416 Ointment in the Treatment of Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: 0416|Drug: Vehicle of 0416 test product|Drug: tacrolimus ointment 0.1%,Fougera Pharmaceuticals Inc.,Phase 3,Industry,Interventional,3-Oct-14,https://ClinicalTrials.gov/show/NCT01053247
145,A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis,Completed,Has Results,Pharyngitis,Drug: Placebo|Drug: Flurbiprofen,Reckitt Benckiser LLC,Phase 3,Industry,Interventional,21-Sep-17,https://ClinicalTrials.gov/show/NCT01049334
146,A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis,Completed,Has Results,Pharyngitis,Drug: placebo|Drug: flurbiprofen|Drug: acetaminophen 650mg,Reckitt Benckiser LLC,Phase 3,Industry,Interventional,21-Sep-17,https://ClinicalTrials.gov/show/NCT01048866
147,"A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study",Completed,Has Results,Multiple Sclerosis,Device: RebiSmart™,EMD Serono,Phase 3,Industry,Interventional,22-Dec-10,https://ClinicalTrials.gov/show/NCT01036165
148,Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse,Completed,Has Results,Dental Plaque,"Drug: Fluoride|Drug: Triclosan, fluoride|Drug: Chlorhexidine Gluconate",Colgate Palmolive,Phase 3,Industry,Interventional,3-Dec-09,https://ClinicalTrials.gov/show/NCT01024738
149,Clinical Research Study Efficacy of a Prototype Oral Rinse,Completed,Has Results,Dental Plaque,Drug: Iodine|Other: water,Colgate Palmolive,Phase 3,Industry,Interventional,26-Nov-09,https://ClinicalTrials.gov/show/NCT01021007
150,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Completed,Has Results,Cerebral Arterial Diseases,Drug: Dotarem|Other: TOF MRA,Guerbet,Phase 3,Industry,Interventional,25-Aug-15,https://ClinicalTrials.gov/show/NCT01012674
151,Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF),Completed,Has Results,Cerebral Arterial Diseases,Drug: Dotarem|Other: TOF MRA,Guerbet,Phase 3,Industry,Interventional,25-Aug-15,https://ClinicalTrials.gov/show/NCT01010932
152,Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery,Completed,Has Results,Inflammation|Pain,Drug: Vehicle of Loteprednol Etabonate|Drug: Loteprednol Etabonate,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,9-Jan-12,https://ClinicalTrials.gov/show/NCT01010633
153,Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers,Completed,Has Results,Aspirin-Associated Gastric Ulcers,Drug: PA32540,POZEN,Phase 3,Industry,Interventional,17-Feb-16,https://ClinicalTrials.gov/show/NCT00995410
154,Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA),Completed,Has Results,Iron Deficiency Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate Tablets|Drug: IV Iron (standard of care),"American Regent, Inc.",Phase 3,Industry,Interventional,18-Oct-13,https://ClinicalTrials.gov/show/NCT00982007
155,Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function,Completed,Has Results,Iron Deficiency Anemia|Impaired Renal Function,Drug: Ferric Carboxymaltose (FCM)|Drug: Iron Sucrose (Venofer),"American Regent, Inc.",Phase 3,Industry,Interventional,18-Oct-13,https://ClinicalTrials.gov/show/NCT00981045
156,Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan/Fluoride toothpaste|Other: antibacterial plant extract,Colgate Palmolive,Phase 3,Industry,Interventional,27-Aug-09,https://ClinicalTrials.gov/show/NCT00966953
157,A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Completed,Has Results,Gastric Ulcer,Drug: PA32540|Drug: EC Aspirin 325,POZEN,Phase 3,Industry,Interventional,21-Jan-16,https://ClinicalTrials.gov/show/NCT00961350
158,Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers,Completed,Has Results,Gastric Ulcer,Drug: PA32540|Drug: EC-Aspirin 325 mg,POZEN,Phase 3,Industry,Interventional,17-Feb-16,https://ClinicalTrials.gov/show/NCT00960869
159,"The Multicenter, Open-label, Single-use Autoinjector Convenience Study",Completed,Has Results,Multiple Sclerosis,Device: Rebidose®,EMD Serono,Phase 3,Industry,Interventional,30-Dec-10,https://ClinicalTrials.gov/show/NCT00958009
160,Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis,Completed,Has Results,"Mucositis|Pain|Unspecified Adult Solid Tumor, Protocol Specific",Drug: Fentanyl sublingual spray,INSYS Therapeutics Inc,Phase 3,Industry,Interventional,5-Sep-13,https://ClinicalTrials.gov/show/NCT00956254
161,Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: SPARC0912|Drug: Reference0912,Sun Pharma Advanced Research Company Limited,Phase 3,Industry,Interventional,30-May-16,https://ClinicalTrials.gov/show/NCT00947661
162,Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension,Completed,Has Results,Open Angle Glaucoma|Ocular Hypertension,Drug: SPARC0913,Sun Pharma Advanced Research Company Limited,Phase 3,Industry,Interventional,5-May-16,https://ClinicalTrials.gov/show/NCT00945958
163,Compare the Clinical Efficacy of Prototype Toothpastes,Completed,Has Results,Dental Plaque,"Drug: Fluoride|Drug: Triclosan, fluoride|Other: Metal salt",Colgate Palmolive,Phase 3,Industry,Interventional,23-Jun-09,https://ClinicalTrials.gov/show/NCT00926029
164,Study of Postoperative Analgesia in Bunionectomy,Completed,Has Results,Bunion|Hallux Valgus,Drug: SKY0402|Drug: Placebo,"Pacira Pharmaceuticals, Inc",Phase 3,Industry,Interventional,5-Aug-13,https://ClinicalTrials.gov/show/NCT00890682
165,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Completed,Has Results,Allergic Conjunctivitis,Device: contact lens with ketotifen|Device: contact lens,Vistakon Pharmaceuticals,Phase 3,Industry,Interventional,23-Nov-10,https://ClinicalTrials.gov/show/NCT00889252
166,Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery,Completed,Has Results,Pain|Inflammation,Drug: Bromfenac Ophthalmic Solution|Drug: Placebo Comparator,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,26-Jan-11,https://ClinicalTrials.gov/show/NCT00853970
167,Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.,Completed,Has Results,Peripheral Vascular Disease,Device: Absolute Pro™ Peripheral Self-Expanding Stent System,Abbott Medical Devices,Phase 3,Industry,Interventional,7-Sep-12,https://ClinicalTrials.gov/show/NCT00844532
168,Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement,Completed,Has Results,Malocclusion,Device: OrthoAccel Device|Device: Sham Device,OrthoAccel Technologies Inc.,Phase 3,Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT00830947
169,SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization,Completed,Has Results,Liver Neoplasms,Drug: SonoVue®,"Bracco Diagnostics, Inc",Phase 3,Industry,Interventional,3-Aug-18,https://ClinicalTrials.gov/show/NCT00829413
170,Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial,Completed,Has Results,Breast Augmentation|Breast Reconstruction|Breast Revision,Device: Mentor Siltex® Contour Profile Gel Mammary Prosthesis,"Mentor Worldwide, LLC",Phase 3,Industry,Interventional,5-Apr-16,https://ClinicalTrials.gov/show/NCT00812097
171,Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide,Completed,Has Results,Sinusitis,Device: Stratus Microflow Ethmoid Spacer,Acclarent,Phase 3,Industry,Interventional,14-Jul-14,https://ClinicalTrials.gov/show/NCT00791934
172,SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization,Completed,Has Results,Liver Neoplasms,Drug: SonoVue-enhanced ultrasound|Other: Unenhanced ultrasound,"Bracco Diagnostics, Inc",Phase 3,Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT00788697
173,Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis,Completed,Has Results,Chronic Allergic Rhinitis|Nonallergic Rhinitis,Drug: Astepro Nasal Spray (0.1% azelastine hydrochloride)|Drug: Astelin Nasal Spray (0.1% azelastine hydrochloride),Meda Pharmaceuticals,Phase 3,Industry,Interventional,2-Oct-09,https://ClinicalTrials.gov/show/NCT00783432
174,The Efficacy of a Toothpaste to Reduce Sensitivity,Completed,Has Results,Dentin Hypersensitivity,"Drug: Triclosan, Silicon dioxide, fluoride|Drug: Triclosan, fluoride",Colgate Palmolive,Phase 3,Industry,Interventional,17-Sep-10,https://ClinicalTrials.gov/show/NCT00763269
175,Collection of Gingival Crevicular Fluid From Periodontitis Patients,Completed,Has Results,Gingival Diseases,"Drug: Fluoride|Drug: Fluoride, triclosan",Colgate Palmolive,Phase 3,Industry,Interventional,1-Mar-11,https://ClinicalTrials.gov/show/NCT00763048
176,Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan,Colgate Palmolive,Phase 3,Industry,Interventional,14-Dec-10,https://ClinicalTrials.gov/show/NCT00762515
177,Investigate Oral Bacteria in Adult Population,Completed,Has Results,Oral Bacteria,"Drug: Fluoride|Drug: Fluoride, Triclosan|Drug: Stannous Fluoride",Colgate Palmolive,Phase 3,Industry,Interventional,14-Feb-11,https://ClinicalTrials.gov/show/NCT00762177
178,Compare the Clinical Efficacy of Prototype Toothpastes.,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan and fluoride|Drug: Herbal Ingredient and fluoride,Colgate Palmolive,Phase 3,Industry,Interventional,20-Oct-10,https://ClinicalTrials.gov/show/NCT00761930
179,"ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial",Completed,Has Results,Vascular Disease,Device: ArterX Surgical Sealant|Device: Gelfoam and Thrombin,"Tenaxis Medical, Inc.",Phase 3,Industry,Interventional,31-Jan-13,https://ClinicalTrials.gov/show/NCT00759681
180,Evaluate Clinical Research From Commerical Oral Care Products,Completed,Has Results,Gingival Diseases,Drug: Fluoride|Drug: Triclosan/Fluoride|Drug: Chlorhexidine Gluconate,Colgate Palmolive,Phase 3,Industry,Interventional,18-Nov-08,https://ClinicalTrials.gov/show/NCT00759187
181,Investigation of Dental Plaque and Gingival Index,Completed,Has Results,Dental Plaque,Drug: Sodium Monofluorophosphate|Drug: Triclosan/Fluoride/Copolymer,Colgate Palmolive,Phase 3,Industry,Interventional,25-Nov-08,https://ClinicalTrials.gov/show/NCT00759031
182,Train New Examiners Via Modified Gingival Margin Plaque,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan/Fluoride,Colgate Palmolive,Phase 3,Industry,Interventional,20-Nov-08,https://ClinicalTrials.gov/show/NCT00758563
183,Clinical Study to Compare Dental Plaque Control,Completed,Has Results,Dental Plaque,Drug: Fluoride|Drug: Triclosan/Fluoride,Colgate Palmolive,Phase 3,Industry,Interventional,19-Nov-08,https://ClinicalTrials.gov/show/NCT00758394
184,Clinical Study to Evaluate Dental Plaque,Completed,Has Results,Gingival Diseases,Drug: Triclosan/Fluoride|Drug: Fluoride/triclosan,Colgate Palmolive,Phase 3,Industry,Interventional,25-Nov-08,https://ClinicalTrials.gov/show/NCT00758290
185,Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses,Completed,Has Results,Breast Reconstruction|Breast Augmentation|Breast Revision,"Device: Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface","Mentor Worldwide, LLC",Phase 3,Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT00753922
186,DisCoVisc Comparative Evaluation,Completed,Has Results,Cataracts,Device: DisCoVisc|Device: DuoVisc|Device: BioVisc|Device: Healon5|Device: Amvisc Plus,Alcon Research,Phase 3,Industry,Interventional,30-Jul-10,https://ClinicalTrials.gov/show/NCT00732225
187,Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes,Completed,Has Results,Dental Caries,Drug: Sodium Fluoride (NaF)|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Jun-13,https://ClinicalTrials.gov/show/NCT00708305
188,In Situ Caries Efficacy of Fluoride Toothpastes,Completed,Has Results,Caries,Drug: NaF|Drug: Placebo|Drug: NaMFP,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Jun-13,https://ClinicalTrials.gov/show/NCT00708097
189,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Completed,Has Results,Cataract,Drug: Bromfenac|Drug: Placebo,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,26-Jan-11,https://ClinicalTrials.gov/show/NCT00704418
190,Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.",Phase 3,Industry,Interventional,25-Nov-13,https://ClinicalTrials.gov/show/NCT00704353
191,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Iron Dextran,"American Regent, Inc.",Phase 3,Industry,Interventional,25-Nov-13,https://ClinicalTrials.gov/show/NCT00704028
192,Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Standard Medical Care (SMC) for the treatment of IDA,"American Regent, Inc.",Phase 3,Industry,Interventional,25-Nov-13,https://ClinicalTrials.gov/show/NCT00703937
193,Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery,Completed,Has Results,Cataract,Drug: bromfenac ophthalmic solution|Drug: placebo,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,9-Dec-11,https://ClinicalTrials.gov/show/NCT00703781
194,Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: Loteprednol Etabonate|Drug: Vehicle of Ophthalmic Loteprednol Etabonate,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,23-Sep-10,https://ClinicalTrials.gov/show/NCT00699153
195,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Completed,Has Results,Osteoarthritis,Drug: PN 400 (VIMOVO)|Drug: celebrex|Other: Placebo|Drug: Rescue Antacid,POZEN,Phase 3,Industry,Interventional,6-Dec-11,https://ClinicalTrials.gov/show/NCT00665431
196,Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis,Completed,Has Results,Osteoarthritis,Drug: PN 400 (VIMOVO)|Drug: celebrex|Drug: Placebo|Drug: Rescue Antacid,POZEN,Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT00664560
197,A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients,Completed,Has Results,Hypertension,Drug: Nebivolol|Drug: Metoprolol ER (TM),Forest Laboratories,Phase 3,Industry,Interventional,20-Sep-10,https://ClinicalTrials.gov/show/NCT00648895
198,Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage,Completed,Has Results,Photoaging,"Drug: adapalene gel, 0.3%|Drug: tretinoin 0.05% emollient cream","Galderma Laboratories, L.P.",Phase 3,Industry,Interventional,24-Feb-11,https://ClinicalTrials.gov/show/NCT00647556
199,Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery,Completed,Has Results,Ocular Inflammation,Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment|Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,23-Sep-10,https://ClinicalTrials.gov/show/NCT00645671
200,Staccato Loxapine in Agitated Patients With Schizophrenia,Completed,Has Results,Patients With Schizophrenia and Acute Agitation,Drug: Inhaled loxapine 5 mg|Drug: Inhaled loxapine 10 mg|Drug: Inhaled placebo,"Alexza Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,29-Jun-17,https://ClinicalTrials.gov/show/NCT00628589
201,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo|Drug: glimepiride,Novo Nordisk A/S,Phase 3,Industry,Interventional,15-Jun-11,https://ClinicalTrials.gov/show/NCT00620282
202,Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216),Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Drug: HZT-501|Drug: Ibuprofen,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,17-Jun-11,https://ClinicalTrials.gov/show/NCT00613106
203,Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects,Completed,Has Results,Infection,Drug: omiganan 1% gel|Drug: chlorhexidine 2% solution,Mallinckrodt,Phase 3,Industry,Interventional,25-Jan-10,https://ClinicalTrials.gov/show/NCT00608959
204,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,Completed,Has Results,Diabetic Retinopathy,Drug: ruboxistaurin|Drug: placebo,"Chromaderm, Inc.",Phase 3,Industry,Interventional,28-Jan-16,https://ClinicalTrials.gov/show/NCT00604383
205,BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Arena Pharmaceuticals,Phase 3,Industry,Interventional,7-Feb-13,https://ClinicalTrials.gov/show/NCT00603902
206,BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo,Arena Pharmaceuticals,Phase 3,Industry,Interventional,7-Feb-13,https://ClinicalTrials.gov/show/NCT00603291
207,Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis,Completed,Has Results,Allergic Conjunctivitis,Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%|Drug: placebo comparator|Drug: Bepotastine Besilate Ophthalmic Solution 1.0%,Bausch & Lomb Incorporated,Phase 3,Industry,Interventional,26-Mar-12,https://ClinicalTrials.gov/show/NCT00586664
208,Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Olopatadine Hydrochloride Nasal Spray 0.6%|Drug: Vehicle,Alcon Research,Phase 3,Industry,Interventional,9-Feb-10,https://ClinicalTrials.gov/show/NCT00578929
209,Safety Study of Olopatadine Nasal Spray,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Olopatadine 0.6% nasal spray|Drug: Placebo Nasal Spray,Alcon Research,Phase 3,Industry,Interventional,3-Feb-10,https://ClinicalTrials.gov/show/NCT00578331
210,TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension,Completed,Has Results,Ocular Inflammation Associated With Blepharaconjunctivitis,Drug: Tobramycin 0.3%/Dexamethasone 0.05%|Drug: TOBRADEX,Alcon Research,Phase 3,Industry,Interventional,14-Jan-10,https://ClinicalTrials.gov/show/NCT00576251
211,Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males,Completed,Has Results,Fever,Drug: Intravenous acetaminophen plus oral placebo|Drug: Oral acetaminophen plus IV placebo|Biological: Reference standard endotoxin (RSE),Mallinckrodt,Phase 3,Industry,Interventional,21-Sep-10,https://ClinicalTrials.gov/show/NCT00564629
212,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.",Phase 3,Industry,Interventional,29-May-15,https://ClinicalTrials.gov/show/NCT00548860
213,Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose|Drug: Standard Medical Care (SMC),"American Regent, Inc.",Phase 3,Industry,Interventional,13-May-15,https://ClinicalTrials.gov/show/NCT00548691
214,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,Completed,Has Results,Cancer,Drug: Fentanyl sublingual spray|Drug: Placebo,INSYS Therapeutics Inc|National Cancer Institute (NCI),Phase 3,Industry|NIH,Interventional,5-Mar-14,https://ClinicalTrials.gov/show/NCT00538850
215,"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)",Completed,Has Results,Gastric Ulcer,Drug: PN400 (VIMOVO)|Drug: PN 400 (VIMOVO),POZEN,Phase 3,Industry,Interventional,20-Aug-10,https://ClinicalTrials.gov/show/NCT00527904
216,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen,Completed,Has Results,Gastric Ulcer,Drug: PN400 (VIMOVO)|Drug: Naproxen,POZEN,Phase 3,Industry,Interventional,28-Dec-10,https://ClinicalTrials.gov/show/NCT00527787
217,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Completed,Has Results,Cataract Extraction|Pain|Inflammation,Drug: ketorolac,Allergan,Phase 3,Industry,Interventional,1-Oct-09,https://ClinicalTrials.gov/show/NCT00524264
218,A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery,Completed,Has Results,Cataract Extraction,Drug: ketorolac eye drops,Allergan,Phase 3,Industry,Interventional,1-Oct-09,https://ClinicalTrials.gov/show/NCT00521456
219,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops,Allergan,Phase 3,Industry,Interventional,30-Nov-11,https://ClinicalTrials.gov/show/NCT00509873
220,Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males,Completed,Has Results,Fever,Drug: IV Placebo|Drug: IV Acetaminophen|Biological: Reference Standard Endotoxin (RSE),Mallinckrodt,Phase 3,Industry,Interventional,21-Sep-10,https://ClinicalTrials.gov/show/NCT00493311
221,Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis,Completed,Has Results,Spinal Surgery|Vascular Surgery,Biological: rThrombin,ZymoGenetics,Phase 3,Industry,Interventional,12-Jan-12,https://ClinicalTrials.gov/show/NCT00491608
222,"A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",Completed,Has Results,Mixed Dyslipidemia,Drug: ABT-335|Drug: rosuvastatin calcium|Drug: simvastatin|Drug: atorvastatin calcium,Abbott,Phase 3,Industry,Interventional,7-Dec-09,https://ClinicalTrials.gov/show/NCT00491530
223,Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Fluocinolone Acetonide,Alimera Sciences,Phase 3,Industry,Interventional,13-Feb-14,https://ClinicalTrials.gov/show/NCT00490815
224,Rebif New Formulation (RNF) Quality of Life (QOL) Study,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Rebif New Formulation Non Titrated|Drug: Rebif New Formulation Titrated,EMD Serono,Phase 3,Industry,Interventional,2-Sep-09,https://ClinicalTrials.gov/show/NCT00472797
225,Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men,Completed,Has Results,Hypogonadism|Primary Hypogonadism|Secondary Hypogonadism,Drug: Testosterone Undecanoate 750 mg|Drug: Testosterone Undecanoate 1000 mg,Endo Pharmaceuticals,Phase 3,Industry,Interventional,7-Mar-17,https://ClinicalTrials.gov/show/NCT00467870
226,A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia,Completed,Has Results,Insomnia,Drug: zolpidem tartrate sublingual tablet|Drug: Placebo,Transcept Pharmaceuticals,Phase 3,Industry,Interventional,20-Jan-12,https://ClinicalTrials.gov/show/NCT00466193
227,Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: Gel-200,Seikagaku Corporation,Phase 3,Industry,Interventional,22-Aug-11,https://ClinicalTrials.gov/show/NCT00450112
228,Gel-200 Versus Placebo in Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: Gel-200|Device: Placebo,Seikagaku Corporation,Phase 3,Industry,Interventional,15-Sep-11,https://ClinicalTrials.gov/show/NCT00449696
229,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b),Completed,Has Results,Inflammation,Drug: Difluprednate|Drug: Placebo,"Sirion Therapeutics, Inc.",Phase 3,Industry,Interventional,2-Jul-09,https://ClinicalTrials.gov/show/NCT00430092
230,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a),Completed,Has Results,Inflammation,Drug: Difluprednate|Drug: Placebo,"Sirion Therapeutics, Inc.",Phase 3,Industry,Interventional,2-Jul-09,https://ClinicalTrials.gov/show/NCT00429923
231,Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS),Completed,Has Results,Crohn's Disease,Biological: adalimumab,Abbott,Phase 3,Industry,Interventional,23-Oct-09,https://ClinicalTrials.gov/show/NCT00427921
232,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia,Completed,Has Results,Cervical Dystonia,Drug: incobotulinumtoxinA (Xeomin) (240 Units)|Drug: incobotulinumtoxinA (Xeomin) (120 Units)|Drug: Placebo,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,31-Dec-10,https://ClinicalTrials.gov/show/NCT00407030
233,Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat,Completed,Has Results,Pharyngitis,Drug: celecoxib|Drug: celecoxib followed by placebo|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,12-Mar-09,https://ClinicalTrials.gov/show/NCT00402987
234,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia,Completed,Has Results,Anemia,Drug: Oral iron tablets|Drug: VIT-45,"American Regent, Inc.",Phase 3,Industry,Interventional,10-Dec-13,https://ClinicalTrials.gov/show/NCT00396292
235,Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate tablets,"American Regent, Inc.",Phase 3,Industry,Interventional,18-Nov-13,https://ClinicalTrials.gov/show/NCT00395993
236,BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management,Completed,Has Results,Obesity,Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo BID,Arena Pharmaceuticals,Phase 3,Industry,Interventional,7-Feb-13,https://ClinicalTrials.gov/show/NCT00395135
237,TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine,Completed,Has Results,Migraine Disorders,Drug: Combination Product (sumatriptan succinate / naproxen sodium)|Drug: RELPAX(eletriptan) 40mg Tablet,GlaxoSmithKline,Phase 3,Industry,Interventional,12-Feb-18,https://ClinicalTrials.gov/show/NCT00385008
238,"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Ramipril|Drug: Hydrochlorothiazide|Drug: Amlodipine,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,25-Mar-11,https://ClinicalTrials.gov/show/NCT00368277
239,Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects,Completed,Has Results,Human Immunodeficiency Virus Infections,Drug: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs),Abbott,Phase 3,Industry,Interventional,1-Feb-10,https://ClinicalTrials.gov/show/NCT00358917
240,Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients,Completed,Has Results,Postpartum Anemia,Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate tablets,"American Regent, Inc.",Phase 3,Industry,Interventional,5-Dec-13,https://ClinicalTrials.gov/show/NCT00354484
241,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: fluocinolone acetonide|Drug: Fluocinolone Acetonide|Procedure: Standard of care laser photocoagulation,Alimera Sciences,Phase 3,Industry,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT00344968
242,VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Completed,Has Results,Anemia,Drug: Ferrous Sulfate tablets|Drug: Ferric Carboxymaltose (FCM),"American Regent, Inc.",Phase 3,Industry,Interventional,25-Nov-13,https://ClinicalTrials.gov/show/NCT00317239
243,Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease,Completed,Has Results,Anemia,Drug: Ferric Carboxymaltose (FCM),"American Regent, Inc.",Phase 3,Industry,Interventional,10-Jun-15,https://ClinicalTrials.gov/show/NCT00317226
244,Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Rosuvastatin Calcium|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,25-Mar-09,https://ClinicalTrials.gov/show/NCT00300482
245,Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Mixed Dyslipidemia|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Atorvastatin|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,25-Mar-09,https://ClinicalTrials.gov/show/NCT00300469
246,Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood,Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335|Drug: Simvastatin|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,25-Mar-09,https://ClinicalTrials.gov/show/NCT00300456
247,"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.",Completed,Has Results,Dyslipidemia|Coronary Heart Disease|Mixed Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335 and atorvastatin calcium|Drug: ABT-335 and simvastatin,Abbott,Phase 3,Industry,Interventional,23-Jul-09,https://ClinicalTrials.gov/show/NCT00300430
248,Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008)|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,4-Apr-14,https://ClinicalTrials.gov/show/NCT00297167
249,Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy,Completed,Has Results,Pain|Cancer,Drug: BEMA Fentanyl,BioDelivery Sciences International,Phase 3,Industry,Interventional,5-Oct-12,https://ClinicalTrials.gov/show/NCT00293020
250,Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.",Phase 3,Industry,Interventional,13-Jun-11,https://ClinicalTrials.gov/show/NCT00287729
251,Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone|Drug: Placebo,"Genentech, Inc.",Phase 3,Industry,Interventional,13-Jun-11,https://ClinicalTrials.gov/show/NCT00287716
252,Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),"Drug: ecallantide|Drug: Phosphate Buffer Saline (PBS),",Shire,Phase 3,Industry,Interventional,11-May-10,https://ClinicalTrials.gov/show/NCT00262080
253,Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation|Graft Rejection,Drug: Everolimus|Drug: Mycophenolic Acid (MPA)|Drug: Cyclosporine A (CsA)|Drug: Basiliximab|Drug: Corticosteroids,Novartis,Phase 3,Industry,Interventional,10-May-11,https://ClinicalTrials.gov/show/NCT00251004
254,Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia,Completed,Has Results,Anemia,Drug: Venofer|Drug: Ferrous Sulfate,"American Regent, Inc.",Phase 3,Industry,Interventional,9-Mar-10,https://ClinicalTrials.gov/show/NCT00236977
255,E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Completed,Has Results,Heartburn,Drug: rabeprazole sodium|Drug: placebo,Eisai Inc.,Phase 3,Industry,Interventional,5-Nov-09,https://ClinicalTrials.gov/show/NCT00236197
256,E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers,Completed,Has Results,Heartburn,Drug: rabeprazole sodium|Other: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,1-Oct-09,https://ClinicalTrials.gov/show/NCT00236184
257,A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients,Completed,Has Results,Obesity,Drug: Sibutramine hydrochloride|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,15-Apr-10,https://ClinicalTrials.gov/show/NCT00234832
258,Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: CYPHER Sirolimus-eluting Coronary Stent,Cordis Corporation,Phase 3,Industry,Interventional,8-Feb-10,https://ClinicalTrials.gov/show/NCT00232739
259,NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS),Cordis Corporation,Phase 3,Industry,Interventional,23-Mar-10,https://ClinicalTrials.gov/show/NCT00231283
260,"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older",Completed,Has Results,Osteopenia,Drug: Zoledronic Acid|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,10-Jan-11,https://ClinicalTrials.gov/show/NCT00132808
261,Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,Completed,Has Results,"Heart Failure, Congestive",Drug: 123I-mIBG (meta-iodobenzylguanidine),GE Healthcare,Phase 3,Industry,Interventional,5-May-17,https://ClinicalTrials.gov/show/NCT00126438
262,Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease,Completed,Has Results,"Heart Failure, Congestive",Drug: 123I-mIBG (meta-iodobenzylguanidine),GE Healthcare,Phase 3,Industry,Interventional,13-Dec-16,https://ClinicalTrials.gov/show/NCT00126425
263,Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency,Completed,Has Results,Growth Disorders|Insulin-Like Growth Factor-1 Deficiency,"Drug: rhIGF-1 (mecasermin, Tercica, Inc.)",Ipsen,Phase 3,Industry,Interventional,30-Apr-10,https://ClinicalTrials.gov/show/NCT00125164
264,Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer,Completed,Has Results,Colorectal Cancer,Biological: Bevacizumab|Drug: Capecitabine|Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin calcium|Drug: Oxaliplatin,Hoffmann-La Roche|National Cancer Institute (NCI),Phase 3,Industry|NIH,Interventional,6-Sep-12,https://ClinicalTrials.gov/show/NCT00112918
265,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Staphylococcal Skin Infection,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,1-Feb-10,https://ClinicalTrials.gov/show/NCT00107978
266,Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Bacterial Pneumonia,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,8-Dec-09,https://ClinicalTrials.gov/show/NCT00107952
267,Study of rhASB in Patients With Mucopolysaccharidosis VI,Completed,Has Results,Mucopolysaccharidosis VI,Drug: N-acetylgalactosamine 4-sulfatase|Drug: Placebo/rhASB,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,6-Mar-09,https://ClinicalTrials.gov/show/NCT00104234
268,Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema,Completed,Has Results,Angioedema,Drug: Icatibant|Drug: Placebo,Shire,Phase 3,Industry,Interventional,24-Dec-13,https://ClinicalTrials.gov/show/NCT00097695
269,Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B,Completed,Has Results,Chronic Hepatitis B,Drug: Placebo (PLB)|Drug: Adefovir Dipivoxil (ADV)|Drug: Lamivudine,Gilead Sciences,Phase 3,Industry,Interventional,3-Jun-11,https://ClinicalTrials.gov/show/NCT00095121
270,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,Completed,Has Results,Staphylococcal Skin Infection,Drug: Telavancin|Drug: Vancomycin,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,8-Dec-09,https://ClinicalTrials.gov/show/NCT00091819
271,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,Completed,Has Results,Breast Cancer,Drug: capecitabine [Xeloda]|Drug: Taxotere,Hoffmann-La Roche,Phase 3,Industry,Interventional,23-Jun-11,https://ClinicalTrials.gov/show/NCT00089479
272,Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI,Completed,Has Results,Mucopolysaccharidosis VI,Drug: Placebo|Drug: N-acetylgalactosamine 4-sulfatase,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,17-Aug-09,https://ClinicalTrials.gov/show/NCT00067470
273,A Long-term Safety Study of Once-daily Travatan,Completed,Has Results,"Glaucoma, Open-angle|Ocular Hypertension",Drug: Travatan,Alcon Research,Phase 3,Industry,Interventional,12-Apr-10,https://ClinicalTrials.gov/show/NCT00051168
274,SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.,Completed,Has Results,Transient Insomnia,Drug: SM-1|Drug: D+Z|Drug: D+L|Drug: Placebo,Sequential Medicine Ltd,Phase 3,Industry,Interventional,5-Jun-19,https://ClinicalTrials.gov/show/NCT03331042
275,"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain",Completed,Has Results,Acute Moderate-to-severe Pain,Drug: sufentanil sublingual tablet 30 mcg,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,15-Mar-17,https://ClinicalTrials.gov/show/NCT02662556
276,Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion,Completed,Has Results,Healthy|Hypoxia,Device: Arterial line|Device: Motion,Medtronic - MITG,Phase 3,Industry,Interventional,5-May-17,https://ClinicalTrials.gov/show/NCT02247765
277,A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin,Completed,Has Results,Eczema,Device: EpiCeram® Skin Barrier Emulsion|Drug: Colloidal Oatmeal Cream,Johnson & Johnson Consumer and Personal Products Worldwide,Phase 3,Industry,Interventional,7-Sep-15,https://ClinicalTrials.gov/show/NCT02120833
278,Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria,Completed,Has Results,Hereditary Orotic Aciduria,Drug: uridine triacetate,Wellstat Therapeutics,Phase 3,Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT02110147
279,A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: Bimatoprost 0.01%|Drug: Bimatoprost 0.03%,Allergan,Phase 3,Industry,Interventional,6-May-15,https://ClinicalTrials.gov/show/NCT01830140
280,Nicotine Mouth Film for Craving Relief.,Completed,Has Results,Smoking Cessation,Drug: Nicotine,GlaxoSmithKline,Phase 3,Industry,Interventional,30-Jan-14,https://ClinicalTrials.gov/show/NCT01702532
281,Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy,Completed,Has Results,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo,Paion UK Ltd.|Premier Research Group plc,Phase 3,Industry,Interventional,23-Jan-19,https://ClinicalTrials.gov/show/NCT02532647
282,A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle,"Almirall, S.A.|Allergan",Phase 3,Industry,Interventional,6-Feb-17,https://ClinicalTrials.gov/show/NCT01974141
283,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,Completed,Has Results,"Pain, Postoperative",Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: DPH 50 mg,Bayer,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01495858
284,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,Completed,Has Results,"Pain, Postoperative",Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 440 mg (BAYH6689)|Drug: DPH 50 mg,Bayer,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01280591
285,Multiple Dose Dental Pain Study Of Ibuprofen Extended Release,Completed,Has Results,Pain,Drug: Ibuprofen 600 mg ER|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,15-Aug-18,https://ClinicalTrials.gov/show/NCT01266161
286,Caverject User Study,Completed,Has Results,Erectile Dysfunction,Other: delivery system,Pfizer,Phase 3,Industry,Interventional,28-Mar-12,https://ClinicalTrials.gov/show/NCT01008605
287,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Completed,Has Results,Pediculosis,Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse,Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,4-Aug-14,https://ClinicalTrials.gov/show/NCT00927472
288,Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Quillivant Oral Suspension XR|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,26-Jun-14,https://ClinicalTrials.gov/show/NCT00904670
289,Safety and Efficacy Study of a Eye Drop for Eye Allergy,Completed,Has Results,Allergic Conjunctivitis,Drug: alcaftadine|Drug: Placebo,Vistakon Pharmaceuticals,Phase 3,Industry,Interventional,8-Dec-11,https://ClinicalTrials.gov/show/NCT00889330
290,"A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing",Completed,Has Results,Tooth Extractions,Device: Hemcon Dental Dressing|Device: Gauze with Pressure and/or Gelfoam,"HemCon Medical Technologies, Inc",Phase 3,Industry,Interventional,9-Jan-13,https://ClinicalTrials.gov/show/NCT00707486
291,Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients,Completed,Has Results,Friedreich's Ataxia,Drug: Idebenone,Santhera Pharmaceuticals,Phase 3,Industry,Interventional,4-Aug-11,https://ClinicalTrials.gov/show/NCT00697073
292,GORE Embolic Protection With Reverse Flow,Completed,Has Results,Carotid Artery Stenosis,Device: GORE Flow Reversal System (GFRS),W.L.Gore & Associates,Phase 3,Industry,Interventional,5-May-09,https://ClinicalTrials.gov/show/NCT00594100
293,"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia",Completed,Has Results,Friedreich's Ataxia,Drug: Idebenone|Drug: Placebo,Santhera Pharmaceuticals,Phase 3,Industry,Interventional,29-Dec-11,https://ClinicalTrials.gov/show/NCT00537680
294,Evaluation of Pigmented Skin Lesions With MelaFind(R) System,Completed,Has Results,Melanoma,Device: MelaFind(R),"MELA Sciences, Inc.",Phase 3,Industry,Interventional,11-Nov-09,https://ClinicalTrials.gov/show/NCT00434057
295,A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma,Completed,Has Results,Fatigue|Multiple Myeloma,Drug: armodafinil|Drug: Placebo,Oncotherapeutics|Cephalon,Phase 3,Industry,Interventional,6-Nov-14,https://ClinicalTrials.gov/show/NCT01160380
296,"A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001",Completed,Has Results,Respiratory Tract Diseases,Biological: DR-5001|Other: Placebo,Duramed Research|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,25-May-12,https://ClinicalTrials.gov/show/NCT00382408
297,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.",Phase 3,Industry,Interventional,31-Jan-17,https://ClinicalTrials.gov/show/NCT01745380
298,"Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults",Completed,Has Results,Anesthesia,Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Drug: Tetracaine HCl 3%|Drug: Placebo,"St. Renatus, LLC|Triligent International|Rho, Inc.",Phase 3,Industry,Interventional,30-Aug-17,https://ClinicalTrials.gov/show/NCT01710787
299,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: Dolutegravir,ViiV Healthcare|Shionogi|GlaxoSmithKline,Phase 3,Industry,Interventional,25-Nov-13,https://ClinicalTrials.gov/show/NCT01499199
300,"Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation",Completed,Has Results,Premature Ejaculation,"Drug: PSD502, contains a mixture of lidocaine and prilocaine|Drug: Placebo",Plethora Solutions Ltd|Shionogi Inc.,Phase 2|Phase 3,Industry,Interventional,26-Sep-16,https://ClinicalTrials.gov/show/NCT00556478
301,An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy,Completed,Has Results,Diabetic Neuropathy,Drug: Placebo|Drug: E2007 (2 mg)|Drug: E2007 (4 mg)|Drug: E2007 (6 mg)|Drug: E2007 (8 mg),Eisai Inc.|Eisai Limited,Phase 2|Phase 3,Industry,Interventional,8-Feb-13,https://ClinicalTrials.gov/show/NCT00505284
302,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: tadalafil|Drug: placebo,Eli Lilly and Company|ICOS Corporation,Phase 2|Phase 3,Industry,Interventional,19-Aug-09,https://ClinicalTrials.gov/show/NCT00384930
303,Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model,Completed,Has Results,Caries,"Drug: 0 ppm F (placebo, negative control)|Drug: 250 ppm F as NaF (dose-response control)|Drug: 500 ppm F as NaF (dose-response control)|Drug: 1100 ppm F as NaF (positive control)",Domenick Zero|GlaxoSmithKline|Indiana University,Phase 3,Other|Industry,Interventional,20-May-19,https://ClinicalTrials.gov/show/NCT03383783
304,Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis,Completed,Has Results,"Cystitis, Interstitial",Biological: Certolizumab pegol|Drug: Placebo,"ICStudy, LLC|UCB Pharma",Phase 3,Other|Industry,Interventional,22-Mar-18,https://ClinicalTrials.gov/show/NCT02497976
305,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Completed,Has Results,Diabetes Prevention in Women After GDM Who Are at High-risk,Drug: DAPA/MET XR|Drug: DAPA|Drug: MET XR,Woman's|AstraZeneca,Phase 3,Other|Industry,Interventional,30-Apr-19,https://ClinicalTrials.gov/show/NCT02338193
306,Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome,Completed,Has Results,Scleroderma|Raynaud's Syndrome,Drug: Onabotulinumtoxin A|Drug: sterile saline solution,Johns Hopkins University|Allergan,Phase 3,Other|Industry,Interventional,22-Dec-16,https://ClinicalTrials.gov/show/NCT02165111
307,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,Completed,Has Results,Polycystic Ovary Syndrome|Disorder of Glucose Regulation,Drug: Metformin XR|Drug: Saxagliptin|Drug: Saxagliptin-Metformin XR,Woman's|AstraZeneca,Phase 3,Other|Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT02022007
308,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,Completed,Has Results,Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma,Drug: Topical Dapsone 5% Gel|Other: Moisturizer|Drug: oral antibiotics,Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,13-Jan-17,https://ClinicalTrials.gov/show/NCT01931150
309,"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial",Completed,Has Results,Fibromyalgia|Neurocognition,Drug: Milnacipran|Drug: Placebo,Duke University|Forest Laboratories,Phase 3,Other|Industry,Interventional,29-Aug-14,https://ClinicalTrials.gov/show/NCT01829243
310,Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone,Completed,Has Results,Heroin Dependence,Drug: Intranasal challenge drug,New York State Psychiatric Institute|Indivior Inc.,Phase 3,Other|Industry,Interventional,8-Sep-17,https://ClinicalTrials.gov/show/NCT01760473
311,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes,Drug: Liraglutide|Drug: Placebo,Kaleida Health|Novo Nordisk A/S,Phase 3,Other|Industry,Interventional,13-Mar-15,https://ClinicalTrials.gov/show/NCT01722266
312,Accelerating Gastrointestinal Recovery,Completed,Has Results,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Drug: Alvimopan|Drug: Placebo,Jamie N. Bakkum-Gamez|Cubist Pharmaceuticals LLC|Mayo Clinic,Phase 3,Other|Industry,Interventional,24-Oct-16,https://ClinicalTrials.gov/show/NCT01704651
313,High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status,Completed,Has Results,Hypovitaminosis D,"Drug: 100,000 IU cholecalciferol|Drug: Placebo","Massachusetts General Hospital|Bio-Tech Pharmacal, Inc.",Phase 3,Other|Industry,Interventional,28-Sep-17,https://ClinicalTrials.gov/show/NCT01689779
314,Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin,Completed,Has Results,Intraoperative Complications|Thermal Injury|Electrocoagulation,Device: Covidien Triad monopolar generator,"University of Colorado, Denver|Medtronic - MITG",Phase 3,Other|Industry,Interventional,1-Mar-13,https://ClinicalTrials.gov/show/NCT01664806
315,"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status",Completed,Has Results,Glioblastoma,Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy,"EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA, Darmstadt, Germany",Phase 3,Industry|Other,Interventional,4-Nov-14,https://ClinicalTrials.gov/show/NCT00689221
316,Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure,Completed,Has Results,Peripheral Artery Disease|Hypertension,Drug: nebivolol|Drug: Metoprolol succinate,Thomas Jefferson University|Forest Laboratories,Phase 3,Other|Industry,Interventional,3-Dec-14,https://ClinicalTrials.gov/show/NCT01499134
317,Improving the Understanding of the Response to Vitamin D Supplementation,Completed,Has Results,Vitamin D Deficiency,Dietary Supplement: cholecalciferol|Dietary Supplement: Placebo,"University of Wisconsin, Madison|Merck Sharp & Dohme Corp.",Phase 3,Other|Industry,Interventional,25-Nov-16,https://ClinicalTrials.gov/show/NCT01465178
318,Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.,Completed,Has Results,Retinal Vein Occlusion|Macular Edema,Drug: Ozurdex,Retina Macula Institute|Allergan,Phase 3,Other|Industry,Interventional,31-May-17,https://ClinicalTrials.gov/show/NCT01449682
319,Study of Botulinum Toxin and Recovery of Hand Function After Stroke,Completed,Has Results,Stroke With Hemiparesis,Drug: Botulinum Toxin commonly known as BOTOX®|Drug: Placebo,NYU Langone Health|Allergan,Phase 3,Other|Industry,Interventional,31-May-19,https://ClinicalTrials.gov/show/NCT01422161
320,Brain Imaging and Treatment Studies of the Night Eating Syndrome,Completed,Has Results,Night Eating Syndrome,Drug: escitalopram oxalate,University of Pennsylvania|Forest Laboratories,Phase 3,Other|Industry,Interventional,9-May-17,https://ClinicalTrials.gov/show/NCT01401595
321,Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica,Completed,Has Results,Post-operative Pain,Drug: lyrica,University of Texas Southwestern Medical Center|Pfizer,Phase 3,Other|Industry,Interventional,11-Jun-14,https://ClinicalTrials.gov/show/NCT01391858
322,Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients,Completed,Has Results,Rheumatoid Arthritis,Biological: abatacept,Arthritis & Rheumatic Disease Specialties Research|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,13-Mar-17,https://ClinicalTrials.gov/show/NCT01351480
323,Savella in Treatment for Provoked Vestibulodynia,Completed,Has Results,Vestibulodynia|Vulvodynia,Drug: Milnacipran,University of Tennessee|Forest Laboratories,Phase 3,Other|Industry,Interventional,2-Apr-14,https://ClinicalTrials.gov/show/NCT01304589
324,Efficacy Study of Adalimumab to Treat Interstitial Cystitis,Completed,Has Results,Interstitial Cystitis,Drug: Adalimumab|Other: inactive drug,"ICStudy, LLC|Abbott",Phase 3,Other|Industry,Interventional,16-Jul-15,https://ClinicalTrials.gov/show/NCT01295814
325,Preoperative Alignment of Total Knee Replacement,Completed,Has Results,Knee Arthritis,Procedure: trumatch group|Procedure: control group,VA Palo Alto Health Care System|DePuy Orthopaedics,Phase 3,U.S. Fed|Industry,Interventional,8-May-13,https://ClinicalTrials.gov/show/NCT01242085
326,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Completed,Has Results,Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Drug: Metformin XR plus placebo|Drug: Metformin XR plus liraglutide,Woman's|Novo Nordisk A/S,Phase 3,Other|Industry,Interventional,26-Jul-19,https://ClinicalTrials.gov/show/NCT01234649
327,Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery,Completed,Has Results,Cystoscopes|Baxter Anaesthesia Brand of Desflurane|Sevoflurane,Drug: Desflurane|Drug: Sevoflurane,Ohio State University|Baxter Healthcare Corporation,Phase 3,Other|Industry,Interventional,29-Nov-12,https://ClinicalTrials.gov/show/NCT01219881
328,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Completed,Has Results,Hyperparathyroidism|Chronic Kidney Disease,Drug: sevelamer carbonate|Drug: placebo,"Kenneth R. Phelps, M.D.|Genzyme, a Sanofi Company|Phelps, Kenneth R., M.D.",Phase 3,Other|Industry,Interventional,31-Jul-14,https://ClinicalTrials.gov/show/NCT01191762
329,Ranolazine and Pulmonary Hypertension,Completed,Has Results,Angina|Pulmonary Arterial Hypertension,Drug: Ranolazine,Northwestern University|Gilead Sciences,Phase 3,Other|Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01174173
330,Cerebral Perfusion Pressure Using Precedex and Other Sedatives,Completed,Has Results,Endotracheal Intubation|Continuous IV Sedation|ICP Monitoring,Drug: Standard-of-Care plus Dexmedetomidine|Other: Standard-of-Care,"Duke University|Hospira, now a wholly owned subsidiary of Pfizer",Phase 3,Other|Industry,Interventional,2-Nov-15,https://ClinicalTrials.gov/show/NCT01169467
331,Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: pioglitazone,"University of Miami|Takeda Pharmaceuticals North America, Inc.",Phase 3,Other|Industry,Interventional,11-Nov-14,https://ClinicalTrials.gov/show/NCT01156597
332,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Completed,Has Results,Gastric Bypass|Parathyroid Hormone,Drug: Paricalcitol|Drug: Cholecalciferol|Drug: Placebo,"Kerstyn C. Zalesin, M.D.|Abbott|William Beaumont Hospitals",Phase 3,Other|Industry,Interventional,22-Mar-17,https://ClinicalTrials.gov/show/NCT01138475
333,Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375),Completed,Has Results,Insomnia|Obstructive Sleep Apnea,Drug: rozerem|Drug: Placebo,University of Pennsylvania|Takeda,Phase 3,Other|Industry,Interventional,3-May-17,https://ClinicalTrials.gov/show/NCT01048242
334,Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency,Completed,Has Results,Hypopituitarism,Drug: Human Growth Hormone (1-134)|Drug: Placebo,"Stanford University|Genentech, Inc.",Phase 3,Other|Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT01007071
335,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",Completed,Has Results,Pancreatic Cancer,Drug: Pasireotide (SOM230)|Other: placebo,Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals,Phase 3,Other|Industry,Interventional,1-Feb-16,https://ClinicalTrials.gov/show/NCT00994110
336,Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis,Completed,Has Results,Leukemia|Fungal Infection,Drug: Voriconazole,M.D. Anderson Cancer Center|Pfizer,Phase 3,Other|Industry,Interventional,12-May-11,https://ClinicalTrials.gov/show/NCT00904995
337,Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype,Completed,Has Results,Smoking Cessation,"Drug: Nicotine Patches|Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|Drug: Nicotine patches, then varenicline (Pre-Quit)|Drug: Nicotine patches, then nicotine patches (Pre-Quit)|Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)|Drug: Nicotine patches, then varenicline (Post-Quit)|Drug: Nicotine patches, then nicotine patches (Post-Quit)","Duke University|Philip Morris USA, Inc.",Phase 3,Other|Industry,Interventional,26-Dec-12,https://ClinicalTrials.gov/show/NCT00894166
338,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,Completed,Has Results,Anxiety Disorders|HIV Infections,Drug: Escitalopram,Duke University|Forest Laboratories,Phase 3,Other|Industry,Interventional,10-Mar-14,https://ClinicalTrials.gov/show/NCT00887679
339,Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma,Completed,Has Results,Allergic Asthma,Drug: RhuMab-E25,"Duke University|Genentech, Inc.",Phase 3,Other|Industry,Interventional,21-Oct-09,https://ClinicalTrials.gov/show/NCT00829179
340,Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients,Completed,Has Results,Hematological Malignancies,Drug: Ibandronate|Drug: Vitamin Supplements,M.D. Anderson Cancer Center|Roche Pharma AG,Phase 3,Other|Industry,Interventional,11-May-18,https://ClinicalTrials.gov/show/NCT00824993
341,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Completed,Has Results,Invasive Fungal Infections|Hematologic Malignancies,Drug: Posaconazole|Drug: ABLC,"M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.",Phase 3,Other|Industry,Interventional,6-Jan-16,https://ClinicalTrials.gov/show/NCT00750737
342,Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement,Completed,Has Results,PAIN,Drug: Pregabalin|Drug: Placebo,Asokumar Buvanendran|Pfizer|Rush University Medical Center,Phase 3,Other|Industry,Interventional,19-Dec-12,https://ClinicalTrials.gov/show/NCT00729690
343,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,Completed,Has Results,Human Immunodeficiency Virus Infections,Drug: Efavirenz 600mg|Drug: Boosted Lexiva,Georgetown University|GlaxoSmithKline,Phase 3,Other|Industry,Interventional,2-Jul-13,https://ClinicalTrials.gov/show/NCT00727597
344,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,Completed,Has Results,Acne Vulgaris,Drug: drospirenone and ethinyl estradiol|Drug: Placebo tablet,Massachusetts General Hospital|Bayer,Phase 3,Other|Industry,Interventional,5-Mar-13,https://ClinicalTrials.gov/show/NCT00722761
345,Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL),Completed,Has Results,Breast Cancer,Drug: Zometa,Milton S. Hershey Medical Center|Novartis,Phase 3,Other|Industry,Interventional,24-Apr-14,https://ClinicalTrials.gov/show/NCT00712985
346,Comparison of Intraoperative Warming Devices,Completed,Has Results,Total Knee Arthroplasty,Device: VH2|Device: Bair Hugger,Mayo Clinic|Dynatherm Medical Inc.,Phase 3,Other|Industry,Interventional,2-Dec-09,https://ClinicalTrials.gov/show/NCT00711867
347,Abuse Liability of Suboxone Versus Subutex,Completed,Has Results,Opioid-related Disorders,Drug: Heroin|Drug: Naloxone|Drug: Low Bup Dose|Drug: High Bup Dose|Drug: Low Bup/Nal Dose|Drug: High Bup/Nal Dose|Drug: Placebo (PCB),New York State Psychiatric Institute|Schering-Plough,Phase 3,Other|Industry,Interventional,5-Dec-16,https://ClinicalTrials.gov/show/NCT00710385
348,Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon,Completed,Has Results,Type 1 Diabetes|Dawn Phenomenon,Drug: Lantus (glargine),Massachusetts General Hospital|Sanofi,Phase 3,Other|Industry,Interventional,21-Oct-14,https://ClinicalTrials.gov/show/NCT00694122
349,"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy",Completed,Has Results,Major Depressive Disorder,Drug: Aripiprazole 5mg|Drug: Aripiprazole 2mg|Drug: Placebo,Massachusetts General Hospital|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,19-Jul-17,https://ClinicalTrials.gov/show/NCT00683852
350,Safety of Vitamin D Supplementation in Older Persons,Completed,Has Results,Vitamin D Deficiency,Dietary Supplement: cholecalciferol (vitamin D),University of Miami|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,7-Mar-16,https://ClinicalTrials.gov/show/NCT00681590
351,A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS,Completed,Has Results,Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Leukemia,Drug: Procrit,"M.D. Anderson Cancer Center|Centocor, Inc.",Phase 3,Other|Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT00656448
352,Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda,Completed,Has Results,Porphyria Cutanea Tarda,Drug: Deferasirox,University of Texas Southwestern Medical Center|Novartis Pharmaceuticals,Phase 3,Other|Industry,Interventional,10-Feb-14,https://ClinicalTrials.gov/show/NCT00599326
353,The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning,Completed,Has Results,Major Depression|Bipolar Depression|Schizoaffective Disorder,Drug: Razadyne|Drug: Placebo,"Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 3,Other|Industry,Interventional,3-Dec-12,https://ClinicalTrials.gov/show/NCT00566735
354,High Dose CVVHDF Compared to Standard Dose CVVHDF,Completed,Has Results,Acute Renal Failure,Device: Standard dose of dialysis|Device: High dose of dialysis,University of Alabama at Birmingham|Pfizer,Phase 3,Other|Industry,Interventional,12-Mar-10,https://ClinicalTrials.gov/show/NCT00561431
355,The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression,Completed,Has Results,Psychotic Depression,Drug: Aripiprazole,Massachusetts General Hospital|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,20-Aug-12,https://ClinicalTrials.gov/show/NCT00556140
356,Study of Paliperidone ER in Adolescents and Young Adults With Autism,Completed,Has Results,Autism,Drug: Paliperidone ER,"Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University",Phase 3,Other|Industry,Interventional,16-May-17,https://ClinicalTrials.gov/show/NCT00549562
357,Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Methylphenidate Transdermal System (MTS)|Other: placebo patch,University of Utah|Shire,Phase 3,Other|Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT00506285
358,Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism,Completed,Has Results,Alcohol Dependence|Schizophrenia,Drug: Acamprosate|Drug: Placebo,Yale University|Forest Laboratories,Phase 3,Other|Industry,Interventional,15-Jan-16,https://ClinicalTrials.gov/show/NCT00463346
359,The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients,Completed,Has Results,Abdominal Obesity|Hypertension,Drug: Carvedilol CR + Lisinopril|Drug: Lisinopril + HCTZ,St. Paul Heart Clinic|GlaxoSmithKline,Phase 3,Other|Industry,Interventional,8-Nov-13,https://ClinicalTrials.gov/show/NCT00459056
360,Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis,Completed,Has Results,Gastroparesis,"Device: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.",University of Mississippi Medical Center|Medtronic,Phase 3,Other|Industry,Interventional,3-Dec-12,https://ClinicalTrials.gov/show/NCT00432835
361,Open-label Ziprasidone Study for Psychosis Treatment in Adolescents,Completed,Has Results,"Schizophreniform Disorder|Schizoaffective Disorder|Psychosis|Depressive Disorder, Major|Bipolar Disorder",Drug: Ziprasidone,New York State Psychiatric Institute|Pfizer,Phase 3,Other|Industry,Interventional,13-Jan-17,https://ClinicalTrials.gov/show/NCT00421954
362,The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery,Completed,Has Results,Coronary Artery Disease,Drug: AndroGel 5 Grams|Drug: Placebo,Icahn School of Medicine at Mount Sinai|Abbott,Phase 3,Other|Industry,Interventional,5-Jan-17,https://ClinicalTrials.gov/show/NCT00413244
363,Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss,Completed,Has Results,Non-Hodgkin's Lymphoma|Lymphoma,Drug: Zoledronic Acid|Drug: Vitamin D|Drug: Calcium Carbonate,M.D. Anderson Cancer Center|Novartis,Phase 3,Other|Industry,Interventional,20-Jun-13,https://ClinicalTrials.gov/show/NCT00352846
364,Exercise and Testosterone Therapy in Elderly Men With Physical Frailty,Completed,Has Results,Physical Frailty|Hip Fracture|Elective Hip Replacement|Hypogonadism,Drug: Transdermal Testosterone gel (1%)|Behavioral: Supervised exercise training,Washington University School of Medicine|Solvay Pharmaceuticals,Phase 3,Other|Industry,Interventional,21-Feb-18,https://ClinicalTrials.gov/show/NCT00345969
365,Efficacy of Lansoprazole in Chronic Post Nasal Drip,Completed,Has Results,Larynx Disease,Drug: Lansoprazole Tablet|Procedure: PH and impedence testing|Procedure: manometry|Drug: lansoprazole|Drug: placebo,Vanderbilt University|TAP Pharmaceutical Products Inc.,Phase 3,Other|Industry,Interventional,21-Aug-12,https://ClinicalTrials.gov/show/NCT00335283
366,Exercise to Treat Depression in Individuals With Coronary Heart Disease,Completed,Has Results,Depression|Heart Diseases,Behavioral: Supervised Aerobic Exercise|Drug: Sertraline|Drug: Placebo Pill.,Duke University|Pfizer,Phase 3,Other|Industry,Interventional,24-Jan-13,https://ClinicalTrials.gov/show/NCT00302068
367,Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays,Completed,Has Results,"Otitis Media, Serous|Negative Middle Ear Pressure|Rhinitis|Otitis Media With Effusion|Otitis Media, Secretory",Drug: Triamcinolone acetonide nasal spray|Drug: Placebo nasal spray,Mayo Clinic|Aventis Pharmaceuticals,Phase 3,Other|Industry,Interventional,15-Aug-11,https://ClinicalTrials.gov/show/NCT00279916
368,Pramipexole Conversion to Ropinirole Controlled Release (CR),Completed,Has Results,Parkinson Disease,Drug: Requip PR|Drug: Mirapex,"Rajesh Pahwa, MD|GlaxoSmithKline|University of Kansas Medical Center",Phase 3,Other|Industry,Interventional,24-Aug-12,https://ClinicalTrials.gov/show/NCT00275275
369,Nitric Oxide Administration for Acute Respiratory Distress Syndrome,Completed,Has Results,Acute Respiratory Distress Syndrome,Drug: Nitric Oxide|Other: No Intervention,Children's Hospital of Philadelphia|Mallinckrodt,Phase 3,Other|Industry,Interventional,24-Apr-15,https://ClinicalTrials.gov/show/NCT00240487
370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,Completed,Has Results,Cytomegalovirus Infections,Drug: valganciclovir|Other: Placebo,Scott Palmer|Roche Pharma AG|Duke University,Phase 3,Other|Industry,Interventional,29-Apr-13,https://ClinicalTrials.gov/show/NCT00227370
371,"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression",Completed,Has Results,Bipolar Disorder,Drug: Divalproex Sodium ER|Drug: Placebo,University Hospitals Cleveland Medical Center|Abbott,Phase 3,Other|Industry,Interventional,17-Jul-19,https://ClinicalTrials.gov/show/NCT00194116
372,Study of Aripiprazole (Abilify) in Children With Symptoms of Mania,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole|Drug: Placebo,University Hospitals Cleveland Medical Center|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,5-Dec-13,https://ClinicalTrials.gov/show/NCT00194077
373,Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole|Drug: Placebo,University Hospitals Cleveland Medical Center|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,5-May-14,https://ClinicalTrials.gov/show/NCT00194012
374,Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Dapsone Gel|Drug: Dapsone Gel Vehicle,"Almirall, S.A.|Allergan",Phase 3,Industry,Interventional,6-Feb-17,https://ClinicalTrials.gov/show/NCT01974323
375,UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy,Completed,Has Results,Multiple Myeloma,Drug: Thalidomide|Drug: Ara-C|Drug: BCNU|Drug: Cisplatin|Drug: Cytoxan|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Filgrastim|Drug: Recombinant GM-CSF|Drug: Interferon-alpha-2b|Drug: Melphalan|Drug: Vincristine,University of Arkansas|Celgene Corporation,Phase 3,Other|Industry,Interventional,22-Sep-15,https://ClinicalTrials.gov/show/NCT00083551
376,Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions,Completed,Has Results,Pancreatic Solid Lesions|Pancreatic Mass,Device: Standard technique EUS-FNA|Device: Capillary suction technique for EUS FNA,Johns Hopkins University|Boston Scientific Corporation,Phase 3,Other|Industry,Interventional,13-Apr-17,https://ClinicalTrials.gov/show/NCT01936467
377,A Home Exercise Program for Women With Infants & Young Children,Completed,Has Results,MomZing Exercise Videos Online|Standard Exercise DVD,Behavioral: MomZing Web Program|Behavioral: Standard Exercise DVD,"University of Hawaii|Klein Buendel, Inc.",Phase 3,Other|Industry,Interventional,12-Apr-16,https://ClinicalTrials.gov/show/NCT01738984
378,Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation,Completed,Has Results,Tonsillectomy,Drug: Dexmedetomidine|Other: Placebo,"Peter Davis|Hospira, now a wholly owned subsidiary of Pfizer|University of Pittsburgh",Phase 3,Other|Industry,Interventional,25-Nov-15,https://ClinicalTrials.gov/show/NCT01528891
379,Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA),Completed,Has Results,Obstructive Sleep Apnea,Drug: budesonide and montelukast|Drug: Placebo,Romaker & Associates|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,3-Dec-18,https://ClinicalTrials.gov/show/NCT01089647
380,Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females,Completed,Has Results,Vaccination,Behavioral: Girls OnGuard,Emory University|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,12-Aug-14,https://ClinicalTrials.gov/show/NCT00813319
381,Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR,Completed,Has Results,Attention Deficit Hyperactivity Disorder,"Drug: Dexmethylphenidate|Drug: Mixed Amphetamine Salts, ER|Drug: placebo",Seattle Children's Hospital|Novartis,Phase 3,Other|Industry,Interventional,19-Apr-17,https://ClinicalTrials.gov/show/NCT00393042
382,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Completed,Has Results,Myocardial Infarction,Drug: Bivalirudin|Drug: Unfractionated heparin|Device: Bare metal stent|Device: Paclitaxel-eluting stent,"Cardiovascular Research Foundation, New York|Boston Scientific Corporation|The Medicines Company",Phase 3,Other|Industry,Interventional,4-Dec-17,https://ClinicalTrials.gov/show/NCT00433966
383,Collagenase in the Treatment of Dupuytrens Disease,Completed,Has Results,Dupuytren's Disease,Biological: collagenase clostridium histolyticum,Stony Brook University|Biospecifics Technologies Corp.|Endo Pharmaceuticals,Phase 3,Other|Industry,Interventional,9-Dec-10,https://ClinicalTrials.gov/show/NCT00260429
384,Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Completed,Has Results,Keratoconjunctivitis Sicca,Drug: cyclosporine|Drug: vehicle of OTX-101,Sun Pharma Global FZE,Phase 3,Industry,Interventional,8-Apr-19,https://ClinicalTrials.gov/show/NCT02688556
385,A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,31-Oct-17,https://ClinicalTrials.gov/show/NCT01999322
386,Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain,Completed,Has Results,Moderate-to-severe Acute Pain,Drug: sufentanil sublingual 30 mcg tablet,"AcelRx Pharmaceuticals, Inc.|U.S. Army Medical Research and Development Command",Phase 3,Industry|U.S. Fed,Interventional,19-Oct-17,https://ClinicalTrials.gov/show/NCT02447848
387,Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents,Completed,Has Results,Hypoglycemia|Diabetes Mellitus,Drug: Nasal Glucagon,Eli Lilly and Company,Phase 3,Industry,Interventional,26-Jun-17,https://ClinicalTrials.gov/show/NCT02402933
388,In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste,Completed,Has Results,Tooth Erosion,Drug: 0.254% w/w sodium fluoride and 5% KNO3|Drug: 0.454% w/w stannous fluoride|Drug: 5% KNO3,GlaxoSmithKline,Phase 2|Phase 3,Industry,Interventional,20-Feb-19,https://ClinicalTrials.gov/show/NCT03296072
389,Bimatoprost for the Treatment of Eyebrow Hypotrichosis,Completed,Has Results,Eyebrow Hypotrichosis,Drug: bimatoprost solution|Drug: Vehicle to bimatoprost solution,Allergan,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01765764
390,Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Completed,Has Results,Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma,Drug: TH-302|Drug: Gemcitabine|Drug: Placebo (5 percent dextrose - D5W),Threshold Pharmaceuticals,Phase 3,Industry,Interventional,2-Dec-17,https://ClinicalTrials.gov/show/NCT01746979
391,Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis,Completed,Has Results,Cystinosis,Drug: RP103,"Horizon Pharma USA, Inc.",Phase 3,Industry,Interventional,16-Jan-18,https://ClinicalTrials.gov/show/NCT01744782
392,Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: PL2200 Aspirin Capsules|Drug: Enteric-coated aspirin caplets,PLx Pharma,Phase 3,Industry,Interventional,4-Sep-15,https://ClinicalTrials.gov/show/NCT02008942
393,Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.,Completed,Has Results,Renal Failure,Drug: LCP-Tacro|Drug: Tacrolimus -IR,Veloxis Pharmaceuticals,Phase 3,Industry,Interventional,15-Aug-16,https://ClinicalTrials.gov/show/NCT01962922
394,Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD,Completed,Has Results,Attention Deficit Disorder With Hyperactivity,Drug: NFC-1|Drug: Placebo,Aevi Genomic Medicine,Phase 2|Phase 3,Industry,Interventional,29-Mar-18,https://ClinicalTrials.gov/show/NCT02777931
395,Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs),Completed,Has Results,Severe Hemophilia A,Biological: Human-cl rhFVIII,Octapharma,Phase 3,Industry,Interventional,3-Feb-14,https://ClinicalTrials.gov/show/NCT01341912
396,Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,Completed,Has Results,Keratoconjunctivitis Sicca|Dry Eye Disease,Drug: OTX-101 0.05%|Drug: OTX-101 0.09%|Drug: Vehicle,Sun Pharma Global FZE,Phase 2|Phase 3,Industry,Interventional,14-Dec-18,https://ClinicalTrials.gov/show/NCT02254265
397,Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Completed,Has Results,Overactive Bladder,Biological: onabotulinumtoxinA|Drug: normal saline,Allergan,Phase 3,Industry,Interventional,5-Mar-13,https://ClinicalTrials.gov/show/NCT00910845
398,Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin,Completed,Has Results,Hypotrichosis,Drug: Bimatoprost 0.03% solution|Drug: Vehicle solution,Allergan,Phase 3,Industry,Interventional,19-Sep-12,https://ClinicalTrials.gov/show/NCT00907426
399,Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing,Completed,Has Results,Inflammation|Burns|Ulcers,Device: Mepilex Border Ag,Molnlycke Health Care AB,Phase 3,Industry,Interventional,26-Feb-13,https://ClinicalTrials.gov/show/NCT01214811
400,Clinical Study to Examine Brushing on Dental Implants,Completed,Has Results,Gingival Diseases,"Drug: Fluoride|Drug: Triclosan, fluoride",Colgate Palmolive,Phase 3,Industry,Interventional,25-Jan-11,https://ClinicalTrials.gov/show/NCT00762619
401,Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Perennial Allergic Rhinitis,Drug: Placebo Nasal Aerosol|Drug: Prednisone capsules|Drug: Placebo Prednisone Capsules|Drug: Beclomethasone dipropionate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,4-Jul-12,https://ClinicalTrials.gov/show/NCT01133626
402,Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence,Completed,Has Results,Eyelashes,Drug: Bimatoprost 0.03% sterile solution|Drug: vehicle sterile solution,Allergan,Phase 3,Industry,Interventional,12-May-09,https://ClinicalTrials.gov/show/NCT00693420
403,A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops,Allergan,Phase 3,Industry,Interventional,30-Nov-11,https://ClinicalTrials.gov/show/NCT00518089
404,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm,Completed,Has Results,Blepharospasm,Drug: incobotulinumtoxinA (Xeomin)|Drug: Placebo,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,16-Nov-10,https://ClinicalTrials.gov/show/NCT00406367
405,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,Completed,Has Results,Toothache,Drug: Naproxen Sodium ER (BAYH6689)|Drug: Placebo,Bayer,Phase 3,Industry,Interventional,25-Jan-11,https://ClinicalTrials.gov/show/NCT00720057
406,Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model,Completed,Has Results,Allergic Conjunctivitis,Drug: AC-170 0.05%|Drug: AC-170 0.1%|Drug: AC-170 0.24%|Drug: AC-170 0%,"Aciex Therapeutics, Inc.",Phase 2|Phase 3,Industry,Interventional,30-Aug-17,https://ClinicalTrials.gov/show/NCT01332188
407,Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,Completed,Has Results,Influenza,Drug: Nitazoxanide|Drug: Placebo,Romark Laboratories L.C.,Phase 2|Phase 3,Industry,Interventional,8-Jan-14,https://ClinicalTrials.gov/show/NCT01227421
408,Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Completed,Has Results,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,Drug: Cohort 1 CTAP101 Capsules- 60µg|Drug: Cohort 1 CTAP101 Capsules - 90µg|Drug: Cohort 1 Matching Sugar Capsule|Drug: Cohort 2 CTAP101 Capsules - 30µg|Drug: Cohort 2 Matching Sugar Capsule,"OPKO Health, Inc.",Phase 2|Phase 3,Industry,Interventional,25-Aug-16,https://ClinicalTrials.gov/show/NCT01219855
409,"Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers",Completed,Has Results,Allergic Conjunctivitis,Device: K-Lens (generic name not established) and Ketotifen|Device: Placebo Lens,Vistakon Pharmaceuticals,Phase 3,Industry,Interventional,23-Nov-10,https://ClinicalTrials.gov/show/NCT00569777
410,Cryo-Touch II for the Treatment of Wrinkles,Completed,Has Results,Facial Wrinkles,Device: Cryo-Touch II,"MyoScience, Inc",Phase 2|Phase 3,Industry,Interventional,1-Oct-12,https://ClinicalTrials.gov/show/NCT01167140
411,Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI),Completed,Has Results,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Ultrase® MT20,Forest Laboratories,Phase 3,Industry,Interventional,10-Apr-14,https://ClinicalTrials.gov/show/NCT00513682
412,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Completed,Has Results,Migraine Disorders,Biological: Botulinum Toxin Type A|Other: Placebo (saline),Allergan,Phase 3,Industry,Interventional,7-Dec-10,https://ClinicalTrials.gov/show/NCT00156910
413,LapBand Adjustment to Improve Early Weight Loss,Completed,Has Results,Obesity,Device: EndoFLIP device (FDA Device Listing Number : D091203),Crospon,Phase 2|Phase 3,Industry,Interventional,4-Apr-13,https://ClinicalTrials.gov/show/NCT01060592
414,Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis,Completed,Has Results,Bacterial Conjunctivitis,Drug: Besifloxacin|Drug: Vehicle (Placebo),Bausch & Lomb Incorporated,Phase 2|Phase 3,Industry,Interventional,29-Mar-12,https://ClinicalTrials.gov/show/NCT00972777
415,A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo|Drug: Metformin (blinded)|Drug: Metformin (open-label),AstraZeneca,Phase 3,Industry,Interventional,21-Jan-11,https://ClinicalTrials.gov/show/NCT00374907
416,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP),Completed,Has Results,Pneumonia,Drug: Cethromycin|Drug: Clarithromycin,"Advanced Life Sciences, Inc.",Phase 3,Industry,Interventional,26-Feb-10,https://ClinicalTrials.gov/show/NCT00336505
417,Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear,Completed,Has Results,Ametropia,Device: Carboxymethylcellulose sodium and Glycerin|Device: Carboxymethylcellulose sodium,Allergan,Phase 2|Phase 3,Industry,Interventional,10-Dec-09,https://ClinicalTrials.gov/show/NCT00691197
418,Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis,Completed,Has Results,Staphylococcal Sepsis,Drug: Placebo|Drug: Pagibaximab 50 mg/mL,Biosynexus Incorporated,Phase 2|Phase 3,Industry,Interventional,24-Oct-11,https://ClinicalTrials.gov/show/NCT00646399
419,Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN),Completed,Has Results,Neuralgia,Drug: E2007,Eisai Inc.,Phase 2|Phase 3,Industry,Interventional,8-Feb-13,https://ClinicalTrials.gov/show/NCT00592904
420,Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis,Completed,Has Results,"Conjunctivitis, Allergic",Drug: Bepreve|Drug: Placebo|Drug: Bepotastine Besilate,Bausch & Lomb Incorporated,Phase 2|Phase 3,Industry,Interventional,26-Mar-12,https://ClinicalTrials.gov/show/NCT00424398
421,Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency,Completed,Has Results,Insulin-Like Growth Factor-1 Deficiency|Growth Disorders,Drug: rhIGF-1 (mecasermin) for a period of 86 weeks,Ipsen,Phase 2|Phase 3,Industry,Interventional,15-Apr-10,https://ClinicalTrials.gov/show/NCT00125190
422,"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis",Completed,Has Results,Sporadic Inclusion Body Myositis (sIBM),Drug: BYM338 (Bimagrumab),Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,10-Apr-18,https://ClinicalTrials.gov/show/NCT02250443
423,Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae,Completed,Has Results,End Stage Renal Disease|AV Fistula|Kidney Failure,Device: Venous Window Needle Guide,Vital Access Corp.,Phase 2|Phase 3,Industry,Interventional,3-Jun-16,https://ClinicalTrials.gov/show/NCT01471041
424,Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice,Completed,Has Results,Pediculosis,Drug: MALG (malathion) Treatment,Taro Pharmaceuticals USA,Phase 2|Phase 3,Industry,Interventional,3-Apr-14,https://ClinicalTrials.gov/show/NCT00752973
425,Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects,Completed,Has Results,Periodontal Diseases,Other: DFDBA|Device: Regenafil,RTI Surgical,Phase 2|Phase 3,Industry,Interventional,5-Aug-11,https://ClinicalTrials.gov/show/NCT00255970
426,Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran|Drug: Quetiapine,"Duke University|Forest Laboratories|Institute for Advanced Medical Research, Alpharetta, GA",Phase 3,Other|Industry,Interventional,2-Jul-19,https://ClinicalTrials.gov/show/NCT02720198
427,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,Completed,Has Results,Contraceptive Usage,Drug: Etonogestrel contraceptive implant,Medical University of South Carolina|American College of Obstetricians and Gynecologists|Bayer,Phase 3,Other|Industry,Interventional,4-Oct-18,https://ClinicalTrials.gov/show/NCT03585504
428,Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial),Completed,Has Results,Saphenous Vein Graft Disease,Drug: Atorvastatin 80 mg daily|Drug: Atorvastatin 10 mg daily,Boca Raton Regional Hospital|Pfizer,Phase 3,Other|Industry,Interventional,9-Aug-18,https://ClinicalTrials.gov/show/NCT01528709
429,Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants,Completed,Has Results,Osteoarthritis of the Knee|Coagulopathy,Drug: Pennsaid,"Nathan Wei, MD, FACP, FACR:|Medtronic - MITG|Arthritis Treatment Center, Maryland",Phase 3,Other|Industry,Interventional,26-Jun-14,https://ClinicalTrials.gov/show/NCT01511939
430,Sub-Q Versus IV Furosemide in Acute Heart Failure,Completed,Has Results,Congestive Heart Failure,"Drug: Furosemide Injection Solution (SCP-101)|Drug: Furosemide Injection Solution, USP","Johns Hopkins University|scPharmaceuticals, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT02579057
431,Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers,Completed,Has Results,"Diseases, Metabolic|Insulin Sensitivity",Drug: Intralipid|Drug: ClinOleic|Drug: Dextrose|Other: Saline (control),Emory University|Baxter Healthcare Corporation,Phase 2|Phase 3,Other|Industry,Interventional,31-Dec-14,https://ClinicalTrials.gov/show/NCT02185729
432,Regional Prophylactic Vancomycin in Revision Total Knee Replacement,Completed,Has Results,Arthropathy of Knee Joint,Drug: Vancomycin,Mayo Clinic|Vidacare Corporation,Phase 2|Phase 3,Other|Industry,Interventional,25-Nov-16,https://ClinicalTrials.gov/show/NCT02020031
433,L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: L-methylfolate|Drug: OROS-Methylphenidate|Drug: Placebo,"Massachusetts General Hospital|Pamlab, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,14-Nov-17,https://ClinicalTrials.gov/show/NCT01853280
434,Ozurdex for Retinal Vein Occlusion Study (ORVO Study),Completed,Has Results,Retinal Vein Occlusion,Drug: dexamethasone implant,Johns Hopkins University|Allergan,Phase 2|Phase 3,Other|Industry,Interventional,3-Apr-15,https://ClinicalTrials.gov/show/NCT01790685
435,A Pilot Study of Oxaloacetate in Subjects With Treated PD,Completed,Has Results,Parkinson's Disease,Drug: Oxaloacetate (OAA)|Drug: Placebo,University of Kansas Medical Center|Terra Biological LLC,Phase 2|Phase 3,Other|Industry,Interventional,17-Mar-16,https://ClinicalTrials.gov/show/NCT01741701
436,Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Lubiprostone,"Texas Tech University Health Sciences Center, El Paso|Takeda Pharmaceuticals North America, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,1-Aug-16,https://ClinicalTrials.gov/show/NCT01469819
437,"Building Recovery By Improving Goals, Habits, and Thoughts",Completed,Has Results,Depression|Substance Use,Behavioral: Group Cognitive Behavioral Therapy|Behavioral: Group CBT for Depression,"RAND|Behavioral Health Services, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,25-Jun-12,https://ClinicalTrials.gov/show/NCT01191788
438,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,Has Results,Apathy|Alzheimer's Disease,Drug: Modafinil|Drug: Placebo,Brown University|National Institute of Mental Health (NIMH)|Cephalon,Phase 3,Other|NIH|Industry,Interventional,4-Mar-11,https://ClinicalTrials.gov/show/NCT01172145
439,Telemonitoring Versus Usual Care,Completed,Has Results,Health Care Quality|Health Care Access,Device: Intel Health Guide|Other: Usual Care,Mayo Clinic|GE Healthcare,Phase 2|Phase 3,Other|Industry,Interventional,8-Feb-13,https://ClinicalTrials.gov/show/NCT01056640
440,Effects of Gastric Bypass on Blood Levels of Duloxetine,Completed,Has Results,Bariatric Surgery,Drug: Duloxetine,"Neuropsychiatric Research Institute, Fargo, North Dakota|University of North Dakota|Eli Lilly and Company",Phase 3,Other|Industry,Interventional,11-Aug-14,https://ClinicalTrials.gov/show/NCT00989157
441,Open-Label Extension Study of Kuvan for Autism,Completed,Has Results,Autistic Disorder,Drug: Kuvan®,The Children's Health Council|BioMarin Pharmaceutical,Phase 2|Phase 3,Other|Industry,Interventional,4-Jul-13,https://ClinicalTrials.gov/show/NCT00943579
442,Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders,Completed,Has Results,Pervasive Developmental Disorder,Drug: Aripiprazole oral product|Drug: Placebo oral capsule,Indiana University|National Institute of Mental Health (NIMH)|Bristol-Myers Squibb,Phase 3,Other|NIH|Industry,Interventional,28-Nov-18,https://ClinicalTrials.gov/show/NCT00870727
443,Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?,Completed,Has Results,Glaucoma,Drug: Triesence|Drug: balanced salt solution BSS,Wills Eye|Alcon Research,Phase 2|Phase 3,Other|Industry,Interventional,21-Mar-16,https://ClinicalTrials.gov/show/NCT00853905
444,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,Completed,Has Results,HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections,Drug: Maraviroc|Drug: placebo,"University of California, San Francisco|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Phase 3,Other|NIH|Industry,Interventional,19-Jun-14,https://ClinicalTrials.gov/show/NCT00844519
445,A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs,Completed,Has Results,Pre-diabetes,Drug: Rosiglitazone|Drug: Placebo Rosiglitazone|Drug: Simvastatin,University of Chicago|GlaxoSmithKline,Phase 2|Phase 3,Other|Industry,Interventional,12-Sep-13,https://ClinicalTrials.gov/show/NCT00831129
446,Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries,Completed,Has Results,Hypertension|Diabetes,Drug: nebivolol|Drug: Metoprolol,University of Chicago|Forest Laboratories,Phase 2|Phase 3,Other|Industry,Interventional,5-Nov-14,https://ClinicalTrials.gov/show/NCT00829296
447,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),Completed,Has Results,Allergic Rhinitis,Drug: ASP-1001 nasal spray|Drug: Placebo for ASP-1001,University of Chicago|Asphelia Pharmaceuticals,Phase 2|Phase 3,Other|Industry,Interventional,10-Jul-13,https://ClinicalTrials.gov/show/NCT00791102
448,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,Completed,Has Results,"Myocardial Infarction|Death, Sudden, Cardiac",Drug: Omega-3 Fatty Acids (Fish Oil Supplements)|Drug: Placebo,"Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline",Phase 3,Other|NIH|Industry,Interventional,1-Jun-17,https://ClinicalTrials.gov/show/NCT00729430
449,The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD,Drug: Esomeprazole|Drug: Budesonide,Mayo Clinic|AstraZeneca,Phase 2|Phase 3,Other|Industry,Interventional,6-Dec-12,https://ClinicalTrials.gov/show/NCT00728481
450,Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD),Completed,Has Results,Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders,Drug: Quetiapine XR|Drug: Placebo for quetiapine XR,University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|AstraZeneca,Phase 3,Other|Industry,Interventional,11-Oct-13,https://ClinicalTrials.gov/show/NCT00671853
451,Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis,Completed,Has Results,Chronic Pancreatitis,Drug: Triamcinolone|Drug: Bupivicaine alone,The Cleveland Clinic|American Society for Gastrointestinal Endoscopy|TAP Pharmaceutical Products Inc.,Phase 3,Other|Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT00658736
452,Hormone and Information Processing Study,Completed,Has Results,Mild Cognitive Impairment|Alzheimer's Disease,Drug: testosterone gel|Drug: placebo gel,University of Washington|National Institute on Aging (NIA)|Solvay Pharmaceuticals,Phase 3,Other|NIH|Industry,Interventional,14-Jul-14,https://ClinicalTrials.gov/show/NCT00539305
453,The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients,Completed,Has Results,Venous Thromboembolism,Drug: fondaparinux sodium|Device: sequential compression devices,"Mary Knudson, M.D.|GlaxoSmithKline|University of California, San Francisco",Phase 2|Phase 3,Other|Industry,Interventional,24-Dec-13,https://ClinicalTrials.gov/show/NCT00531843
454,A Study to Test the Use of Duloxetine for Pain in MS,Completed,Has Results,Multiple Sclerosis,Drug: Duloxetine|Drug: Placebo,"Brown, Theodore R., M.D., MPH|Eli Lilly and Company",Phase 2|Phase 3,Other|Industry,Interventional,6-Apr-15,https://ClinicalTrials.gov/show/NCT00457730
455,Disease Management for Smoking Cessation,Completed,Has Results,Smoking Cessation,Behavioral: High intensity disease management|Behavioral: Low intensity disease management|Behavioral: Comparison group|Drug: Bupropion,University of Kansas Medical Center|National Cancer Institute (NCI)|GlaxoSmithKline,Phase 3,Other|NIH|Industry,Interventional,7-Jun-17,https://ClinicalTrials.gov/show/NCT00440115
456,A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb,Completed,Has Results,Osteoarthritis,Drug: Synvisc (Hylan G-F20; hyaluronan injection)|Drug: Bupivicaine (local anesthesia injection)|Drug: Kenalog (triamcinolone; corticosteroid injection),"Hospital for Special Surgery, New York|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Genzyme, a Sanofi Company",Phase 3,Other|NIH|Industry,Interventional,7-Jul-17,https://ClinicalTrials.gov/show/NCT00398866
457,Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myelogenous Leukemia,Drug: Decitabine,M.D. Anderson Cancer Center|Eisai Inc.,Phase 2|Phase 3,Other|Industry,Interventional,4-Mar-13,https://ClinicalTrials.gov/show/NCT00398983
458,Lucentis (Ranibizumab) for Eales' Disease,Completed,Has Results,Eales' Disease,Drug: Ranibizumab,"Oregon Health and Science University|Genentech, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,11-Jun-19,https://ClinicalTrials.gov/show/NCT00384449
459,Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome,Completed,Has Results,"Fatigue Syndrome, Chronic",Drug: Duloxetine|Drug: Placebo,University of Cincinnati|Eli Lilly and Company,Phase 2|Phase 3,Other|Industry,Interventional,27-Jul-15,https://ClinicalTrials.gov/show/NCT00375973
460,Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation,Completed,Has Results,Heart Transplantation|Liver Transplantation|Bone Resorption,Drug: Zoledronic acid|Drug: Alendronate|Other: Placebo Zoledronic Acid|Other: Placebo Alendronate,Columbia University|Novartis Pharmaceuticals,Phase 2|Phase 3,Other|Industry,Interventional,15-Sep-16,https://ClinicalTrials.gov/show/NCT00297830
461,The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,Completed,Has Results,Alzheimer Disease,Drug: Memantine|Drug: Placebo pill,Stanford University|Palo Alto Veterans Institute for Research|Forest Laboratories,Phase 3,Other|Industry,Interventional,7-Apr-17,https://ClinicalTrials.gov/show/NCT00255086
462,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,Completed,Has Results,Bipolar Disorder,Drug: Lithium|Drug: Divalproex|Drug: Placebo,University Hospitals Cleveland Medical Center|National Institute of Mental Health (NIMH)|Abbott,Phase 3,Other|NIH|Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT00194129
463,"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans",Completed,Has Results,End Stage Renal Disease|Kidney Transplantation,Drug: Sirolimus,University of Michigan|Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2|Phase 3,Other|Industry,Interventional,5-Apr-17,https://ClinicalTrials.gov/show/NCT00189202
464,Implantable Cardioverter-Defibrillator Use in the VA System,Completed,Has Results,Cardiomyopathies,Behavioral: Clinical Reminder,Stanford University|Medtronic|VA Palo Alto Health Care System,Phase 3,Other|Industry|U.S. Fed,Interventional,7-Dec-16,https://ClinicalTrials.gov/show/NCT01217827
465,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Completed,Has Results,Opiate Dependence,Drug: Extended-Release Naltrexone|Behavioral: Motivational Enhancement Counseling,"NYU Langone Health|Alkermes, Inc.|New York City Department of Health and Mental Hygiene",Phase 3,Other|Industry,Interventional,7-Apr-16,https://ClinicalTrials.gov/show/NCT01180647
466,Rituximab in Rheumatoid Arthritis Lung Disease,Completed,Has Results,Rheumatoid Arthritis|Interstitial Pneumonia,Drug: Rituximab,"Eric Matteson|Genentech, Inc.|National Center for Research Resources (NCRR)|Mayo Clinic",Phase 3,Other|Industry|NIH,Interventional,25-Sep-12,https://ClinicalTrials.gov/show/NCT00578565
467,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,Completed,Has Results,HIV|Hyperlipidemia|Hypertriglyceridemia|HIV Infections,Drug: raltegravir,The Miriam Hospital|Tufts Medical Center|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,10-Oct-14,https://ClinicalTrials.gov/show/NCT00887653
468,Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea,Completed,Has Results,Rosacea,Drug: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Drug: Placebo gel,Massachusetts General Hospital|Medicis Pharmaceutical Corporation,Phase 2|Phase 3,Other|Industry,Interventional,15-Jun-12,https://ClinicalTrials.gov/show/NCT00823901
469,S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence,Completed,Has Results,Tobacco Dependence,Drug: S-Adenosyl-L-Methionine|Other: placebo,Mayo Clinic|Pharmavite,Phase 2|Phase 3,Other|Industry,Interventional,9-Sep-11,https://ClinicalTrials.gov/show/NCT00722124
470,Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women,Completed,Has Results,Menopause|Fracture|Osteoporosis,Drug: Teriparatide (PTH 1-34),Columbia University|Eli Lilly and Company,Phase 2|Phase 3,Other|Industry,Interventional,26-Jul-18,https://ClinicalTrials.gov/show/NCT00697463
471,Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN,Completed,Has Results,Parenteral Nutrition,"Drug: ClinOleic 20% Intravenous Emulsion|Drug: Intralipid, 20% Intravenous Emulsion",Emory University|Baxter Healthcare Corporation,Phase 2|Phase 3,Other|Industry,Interventional,1-Aug-14,https://ClinicalTrials.gov/show/NCT00672854
472,Testosterone Replacement Therapy in Chronic Spinal Cord Injury,Completed,Has Results,Spinal Cord Injury|Hypogonadism,Drug: Testosterone Transdermal System (Androderm 5 mg patch),VA Office of Research and Development|Kessler Institute for Rehabilitation,Phase 2|Phase 3,U.S. Fed|Industry,Interventional,7-Apr-14,https://ClinicalTrials.gov/show/NCT00266864
473,Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I,Completed,Has Results,Mucopolysaccharidosis I|Hurlers Syndrome|Hurler-Scheie Syndrome,Biological: rhIDU (recombinant human-Alpha-L-Iduronidase)|Biological: Placebo,"Genzyme, a Sanofi Company|BioMarin/Genzyme LLC|Sanofi",Phase 3,Industry,Interventional,19-Aug-09,https://ClinicalTrials.gov/show/NCT00912925
474,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,Completed,Has Results,"Heart Disease, Ischemic|Atherosclerosis, Coronary",Drug: Gadolinium|Drug: Adenosine,"Northwestern University|Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Phase 2|Phase 3,Other|Industry,Interventional,26-Sep-14,https://ClinicalTrials.gov/show/NCT01234870
475,"Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP",Completed,Has Results,Immune Thrombocytopenic Purpura,"Drug: Rituxan, Cyclophosphamide, Vincristine, Prednisone|Drug: Higher Dose of Rituximab","Weill Medical College of Cornell University|Biogen|Genentech, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT00774202
476,Lucentis Versus Mitomycin C During Glaucoma Surgery,Completed,Has Results,Glaucoma,Drug: Ranibizumab|Drug: Mitomycin (MMC),"Wills Eye|Genentech, Inc.|Novartis Pharmaceuticals",Phase 2|Phase 3,Other|Industry,Interventional,13-Mar-15,https://ClinicalTrials.gov/show/NCT00626782
477,Secondary Prevention of Osteoporosis,Completed,Has Results,Osteoporosis,Drug: alendronate with cholecalciferol|Drug: calcium carbonate with cholecalciferol|Behavioral: Falls prevention measures,"Hebrew Rehabilitation Center, Boston|National Institute on Aging (NIA)|Merck Sharp & Dohme Corp.|GlaxoSmithKline",Phase 3,Other|NIH|Industry,Interventional,10-Jun-11,https://ClinicalTrials.gov/show/NCT00421343
478,Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia,Completed,Has Results,Friedreich's Ataxia,Drug: interferon γ-1b,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance",Phase 3,Industry|Other,Interventional,1-May-18,https://ClinicalTrials.gov/show/NCT02797080
479,A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS),Completed,Has Results,Macular Edema,Drug: Ranibizumab,"Genentech, Inc.",Phase 3,Industry,Interventional,26-Jul-17,https://ClinicalTrials.gov/show/NCT02698566
480,Evaluation of N1539 Following Abdominoplasty Surgery,Completed,Has Results,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.",Phase 3,Industry,Interventional,14-Feb-18,https://ClinicalTrials.gov/show/NCT02678286
481,Evaluation of N1539 Following Bunionectomy Surgery,Completed,Has Results,"Pain, Post-operative",Drug: N1539|Drug: Intravenous Placebo,"Recro Pharma, Inc.",Phase 3,Industry,Interventional,29-Sep-17,https://ClinicalTrials.gov/show/NCT02675907
482,Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain,Completed,Has Results,Pain,Drug: Buprenorphine|Drug: Placebo,INSYS Therapeutics Inc,Phase 3,Industry,Interventional,14-Aug-17,https://ClinicalTrials.gov/show/NCT02634788
483,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study",Completed,Has Results,Friedreich's Ataxia,Drug: Interferon γ-1b,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance",Phase 3,Industry|Other,Interventional,18-May-18,https://ClinicalTrials.gov/show/NCT02593773
484,"Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia",Completed,Has Results,Friedreich's Ataxia,Drug: Interferon γ-1b|Drug: Placebo,"Horizon Pharma Ireland, Ltd., Dublin Ireland|Friedreich's Ataxia Research Alliance",Phase 3,Industry|Other,Interventional,8-Dec-17,https://ClinicalTrials.gov/show/NCT02415127
485,A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery,Completed,Has Results,Post-Operative Pain,Drug: Sufentanil Tablet 30 mcg|Drug: Placebo Tablet,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,13-Feb-17,https://ClinicalTrials.gov/show/NCT02356588
486,A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7),Completed,Has Results,MPS 7|Sly Syndrome|Mucopolysaccharidosis|MPS VII,Drug: UX003|Other: Placebo,Ultragenyx Pharmaceutical Inc,Phase 3,Industry,Interventional,16-Feb-18,https://ClinicalTrials.gov/show/NCT02230566
487,NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: NT0102|Drug: Placebo,"Neos Therapeutics, Inc",Phase 3,Industry,Interventional,17-Jan-18,https://ClinicalTrials.gov/show/NCT01835548
488,Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea,Completed,Has Results,Erythema|Rosacea,Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle|Drug: azelaic acid gel 15%,"Galderma Laboratories, L.P.",Phase 3,Industry,Interventional,10-Jul-14,https://ClinicalTrials.gov/show/NCT01659853
489,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Indomethacin|Drug: Placebo,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,17-Mar-14,https://ClinicalTrials.gov/show/NCT01626118
490,Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction,Completed,Has Results,Chalazion|Dry Eye Syndromes,Device: LipiFlow System,"TearScience, Inc.",Phase 2|Phase 3,Industry,Interventional,6-Dec-11,https://ClinicalTrials.gov/show/NCT01202747
491,Study of Indomethacin Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Indomethacin|Drug: Celecoxib|Drug: Placebo,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,19-Dec-13,https://ClinicalTrials.gov/show/NCT01543685
492,Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults,Completed,Has Results,Anthrax,Biological: BioThrax,Emergent BioSolutions|Department of Health and Human Services,Phase 3,Industry|U.S. Fed,Interventional,28-Nov-13,https://ClinicalTrials.gov/show/NCT01491607
493,Study of Diclofenac Capsules to Treat Pain Following Bunionectomy,Completed,Has Results,Other Acute Postoperative Pain,Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib|Drug: Placebo,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,19-Dec-13,https://ClinicalTrials.gov/show/NCT01462435
494,Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device,Completed,Has Results,Autoimmune Diseases|Renal Disorders|Hematologic Disorders|Oncologic Disorders,Device: Therapeutic plasma exchange,"Fenwal, Inc.",Phase 3,Industry,Interventional,23-Sep-13,https://ClinicalTrials.gov/show/NCT01210716
495,Evaluation of PillCam™ Colon 2 in Visualization of the Colon,Completed,Has Results,Colonic Diseases|Bowel Diseases,Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule,Given Imaging Ltd.,Phase 3,Industry,Interventional,8-Jun-12,https://ClinicalTrials.gov/show/NCT01087528
496,Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis|Hay Fever,Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,23-May-12,https://ClinicalTrials.gov/show/NCT01024608
497,Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment,Completed,Has Results,Osteoarthritis|Rheumatoid Arthritis|Chronic Low Back Pain|Chronic Regional Pain Syndrome|Chronic Soft Tissue Pain,Drug: HZT-501,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,25-Jul-13,https://ClinicalTrials.gov/show/NCT00984815
498,Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Phase 3,Industry,Interventional,16-Nov-15,https://ClinicalTrials.gov/show/NCT00839306
499,Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole ER|Drug: Ranitidine,Eisai Inc.,Phase 3,Industry,Interventional,23-Jun-15,https://ClinicalTrials.gov/show/NCT00838526
500,Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.,Completed,Has Results,Knee Injury,Other: CR Plug,RTI Surgical,Phase 3,Industry,Interventional,6-Nov-13,https://ClinicalTrials.gov/show/NCT00821873
501,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,8-Jun-12,https://ClinicalTrials.gov/show/NCT00790023
502,Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder,Completed,Has Results,Excessive Sleepiness,Drug: armodafinil|Drug: placebo,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,8-Jul-10,https://ClinicalTrials.gov/show/NCT00758498
503,Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID),Completed,Has Results,Primary Immune Deficiency,Biological: IgPro20,CSL Behring,Phase 3,Industry,Interventional,25-Jan-13,https://ClinicalTrials.gov/show/NCT00719680
504,Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients,Completed,Has Results,Chronic Gout Refractory to Conventional Therapy,Drug: pegloticase 8 mg i.v.,Savient Pharmaceuticals,Phase 3,Industry,Interventional,28-Jun-11,https://ClinicalTrials.gov/show/NCT00675103
505,Antibiotic Study for Dental Implants,Completed,Has Results,Periodontitis,Drug: Minocycline HCl,OraPharma,Phase 3,Industry,Interventional,27-May-10,https://ClinicalTrials.gov/show/NCT00662532
506,Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers,Completed,Has Results,Obstructive Sleep Apnea Syndrome,Device: OxiplexTS,"ISS, Inc.|National Institute of Neurological Disorders and Stroke (NINDS)|Carle Foundation Hospital|University of Illinois at Chicago|University of California, Irvine",Phase 3,Industry|NIH|Other,Interventional,11-Mar-11,https://ClinicalTrials.gov/show/NCT00591591
507,Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration,Completed,Has Results,Gingival Recession,Device: Gintuit|Other: Autologous palatal tissue,Organogenesis,Phase 3,Industry,Interventional,8-Nov-12,https://ClinicalTrials.gov/show/NCT00587834
508,A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021,Completed,Has Results,Healthy,Drug: DR-1021|Drug: Mircette®|Drug: Kariva®,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,10-Jun-14,https://ClinicalTrials.gov/show/NCT00544882
509,Duloxetine Versus Placebo in Chronic Low Back Pain,Completed,Has Results,Back Pain Without Radiation,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,29-Dec-09,https://ClinicalTrials.gov/show/NCT00408876
510,Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI),Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: Ultrase® MT20|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,12-Mar-14,https://ClinicalTrials.gov/show/NCT00408317
511,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,Completed,Has Results,"Pain, Postoperative",Drug: diclofenac potassium (XP21L)|Drug: Placebo,Xanodyne Pharmaceuticals,Phase 3,Industry,Interventional,22-Jun-10,https://ClinicalTrials.gov/show/NCT00375934
512,Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older,Completed,Has Results,Herpes Zoster,Biological: Herpes zoster vaccine GSK1437173A,GlaxoSmithKline,Phase 3,Industry,Interventional,31-Mar-17,https://ClinicalTrials.gov/show/NCT01751165
513,A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug,Completed,Has Results,Asthma,Biological: Lyophilized mepolizumab|Biological: Liquid mepolizumab|Device: Prefilled autoinjector|Device: Prefilled Safety Syringe,GlaxoSmithKline,Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT03014674
514,A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Peglispro|Drug: Insulin Glargine,Eli Lilly and Company,Phase 3,Industry,Interventional,20-Apr-18,https://ClinicalTrials.gov/show/NCT02132637
515,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,Completed,Has Results,Asthma,Drug: Budesonide HFA|Drug: Budesonide CFC,AstraZeneca,Phase 3,Industry,Interventional,7-Nov-12,https://ClinicalTrials.gov/show/NCT00667992
516,Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma,Completed,Has Results,"Lymphoma, Non-Hodgkin",Biological: Tositumomab and Iodine I 131 Tositumomab|Biological: Rituximab,GlaxoSmithKline,Phase 3,Industry,Interventional,2-Aug-10,https://ClinicalTrials.gov/show/NCT00268983
517,Effect of Sulodexide in Early Diabetic Nephropathy,Completed,Has Results,Diabetic Nephropathy,Drug: Sulodexide|Drug: Placebo,Keryx Biopharmaceuticals|Collaborative Study Group (CSG),Phase 3,Industry|Other,Interventional,23-Mar-18,https://ClinicalTrials.gov/show/NCT00130208
518,Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.,Completed,Has Results,Acute Post-surgical Pain,Drug: Co-crystal E-58425 (Tramadol/Celecoxib)|Drug: Tramadol (Ultram®)|Drug: Celecoxib (Celebrex®)|Drug: Placebo,"Laboratorios del Dr. Esteve, S.A.|Premier Research Group plc",Phase 3,Industry,Interventional,9-Jan-19,https://ClinicalTrials.gov/show/NCT03108482
519,Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,Completed,Has Results,Progressive IgA Nephropathy|Proteinuria,Drug: ACTH (Acthar) Gel,Mayo Clinic|Mallinckrodt,Phase 3,Other|Industry,Interventional,26-Jun-19,https://ClinicalTrials.gov/show/NCT02282930
520,Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab,Completed,Has Results,Macular Degeneration,Drug: 0.5 mg ranibizumab,"Charles C Wykoff, PhD, MD|Genentech, Inc.|Greater Houston Retina Research",Phase 3,Other|Industry,Interventional,20-Oct-17,https://ClinicalTrials.gov/show/NCT01748292
521,Study of APD421 as PONV Treatment (no Prior Prophylaxis),Completed,Has Results,Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Phase 3,Industry,Interventional,18-Dec-18,https://ClinicalTrials.gov/show/NCT02449291
522,Pharmacogenomics in Autism Treatment,Completed,Has Results,Autism,Drug: Risperidone,"University of California, San Francisco|Janssen, LP|National Institute of Mental Health (NIMH)",Phase 2|Phase 3,Other|Industry|NIH,Interventional,24-Jul-12,https://ClinicalTrials.gov/show/NCT00584701
523,Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis,Completed,Has Results,Chronic Kidney Disease|Anemia,Drug: Epoetin|Drug: Peginesatide,Takeda|Affymax,Phase 3,Industry,Interventional,26-May-14,https://ClinicalTrials.gov/show/NCT01478971
524,Octreotide in Severe Polycystic Liver Disease,Completed,Has Results,"Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain",Drug: Octreotide|Drug: Placebo,Mayo Clinic|Novartis|National Center for Research Resources (NCRR),Phase 2|Phase 3,Other|Industry|NIH,Interventional,21-Nov-12,https://ClinicalTrials.gov/show/NCT00426153
525,Glycine vs Placebo for the Schizophrenia Prodrome,Completed,Has Results,Schizophrenia Prodrome,Drug: Glycine|Drug: Placebo,"Yale University|Glytech, Inc|National Alliance for Research on Schizophrenia and Depression",Phase 2|Phase 3,Other|Industry,Interventional,29-Dec-16,https://ClinicalTrials.gov/show/NCT00291226
526,An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms,Completed,Has Results,Erectile Dysfunction|Lower Urinary Tract Symptoms,Drug: Placebo|Drug: Alfuzosin,Chesapeake Urology Research Associates|Sanofi,Phase 3,Other|Industry,Interventional,1-Aug-16,https://ClinicalTrials.gov/show/NCT00893113
527,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,Completed,Has Results,"Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip|Thromboembolism",Drug: Rivaroxaban,"Ortho-McNeil Janssen Scientific Affairs, LLC|Bayer",Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT01094886
528,Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease),Completed,Has Results,Mitral Regurgitation,Drug: metoprolol succinate (Toprol XL)|Drug: Placebo,"University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca",Phase 2|Phase 3,Other|NIH|Industry,Interventional,16-Apr-12,https://ClinicalTrials.gov/show/NCT01052428
529,Impact of Diabetes on Left Ventricular Remodeling,Completed,Has Results,Diabetes,Drug: Ramipril|Drug: Candesartan cilexetil|Drug: Allopurinol,"University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca",Phase 2|Phase 3,Other|NIH|Industry,Interventional,17-Dec-12,https://ClinicalTrials.gov/show/NCT01052272
530,Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: colesevelam HCl|Drug: placebo,"HealthPartners Institute|International Diabetes Center at Park Nicollet|Daiichi Sankyo, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT00993824
531,Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Phase 3,Industry,Interventional,24-Jun-16,https://ClinicalTrials.gov/show/NCT01253811
532,A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash,Completed,Has Results,Acne Vulgaris,Drug: CTGel/ BPO Wash|Drug: Soap Free Cleanser and CTGel,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,25-Jul-11,https://ClinicalTrials.gov/show/NCT00891982
533,Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults,Completed,Has Results,Obesity,Drug: VI-0521|Drug: Placebo matched phentermine/topiramate,"VIVUS, Inc.|Medpace, Inc.",Phase 3,Industry,Interventional,6-Sep-12,https://ClinicalTrials.gov/show/NCT00554216
534,"Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone",Completed,Has Results,Parkinson's Disease|Insomnia,Drug: eszopiclone|Other: placebo,"University of Medicine and Dentistry of New Jersey|Sunovion|Rutgers, The State University of New Jersey",Phase 3,Other|Industry,Interventional,31-May-13,https://ClinicalTrials.gov/show/NCT00324896
535,Risperdal Consta for Bipolar Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Injectable Risperidone (Consta) or oral antipsychotic,University of Pittsburgh|Janssen Pharmaceuticals,Phase 3,Other|Industry,Interventional,8-Feb-16,https://ClinicalTrials.gov/show/NCT00177164
536,Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery,Completed,Has Results,Deep Venous Thrombosis,Drug: Desirudin (Iprivask™)|Drug: Heparin,"Washington University School of Medicine|Barnes-Jewish Hospital|Canyon Pharmaceuticals, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,13-Jun-11,https://ClinicalTrials.gov/show/NCT00329433
537,Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis,Completed,Has Results,Cirrhosis,Device: BreathID (Methacetin breath test),Virginia Commonwealth University|Exalenz Bioscience LTD.,Phase 3,Other|Industry,Interventional,4-Mar-14,https://ClinicalTrials.gov/show/NCT01157845
538,Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation,Completed,Has Results,Reperfusion Injury|Liver Injury,Drug: inhaled nitric oxide|Drug: nitrogen gas,University of Alabama at Birmingham|Mallinckrodt|University of Washington,Phase 2|Phase 3,Other|Industry,Interventional,6-Nov-14,https://ClinicalTrials.gov/show/NCT00582010
539,Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans,Completed,Has Results,Endothelial Dysfunction,Drug: darapladib|Drug: placebo,"Mayo Clinic|GlaxoSmithKline|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)",Phase 3,Other|Industry|NIH,Interventional,15-Mar-17,https://ClinicalTrials.gov/show/NCT01067339
540,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Completed,Has Results,Late Effects of Surgery|Staphylococcus Aureus|Surgical Site Infection,Drug: daptomycin,Los Angeles Biomedical Research Institute|Cubist Pharmaceuticals LLC|Hartford Hospital|Western University of Health Sciences,Phase 3,Other|Industry,Interventional,29-Aug-16,https://ClinicalTrials.gov/show/NCT00701636
541,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer Metastatic,Drug: Carboplatin|Drug: Paclitaxel|Drug: ABP 215|Drug: Bevacizumab,Amgen|Actavis Inc.,Phase 3,Industry,Interventional,19-Oct-17,https://ClinicalTrials.gov/show/NCT01966003
542,Tadalafil for Sarcoidosis Associated Pulmonary Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: Tadalafil,"University of North Carolina, Chapel Hill|Eli Lilly and Company|United Therapeutics|University of Cincinnati",Phase 2|Phase 3,Other|Industry,Interventional,24-Jul-17,https://ClinicalTrials.gov/show/NCT01324999
543,"Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age",Completed,Has Results,Anesthesia,Drug: Dexmedetomidine|Drug: Midazolam|Drug: Fentanyl|Drug: Morphine,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 2|Phase 3,Industry,Interventional,11-Dec-13,https://ClinicalTrials.gov/show/NCT01508455
544,Evaluation of the Tympanostomy Tube Delivery System,Completed,Has Results,Otitis Media With Effusion|Acute Otitis Media,Device: tympanostomy tube,Acclarent,Phase 2|Phase 3,Industry,Interventional,11-Jul-14,https://ClinicalTrials.gov/show/NCT01202578
545,Astral VAPS AutoEPAP Clinical Trial,Completed,Has Results,Upper Airway Obstruction|Respiratory Insufficiency|Respiratory Failure,Device: Astral,ResMed,Phase 3,Industry,Interventional,26-Jul-19,https://ClinicalTrials.gov/show/NCT02683772
546,"Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir|Drug: Ribavirin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,20-Oct-15,https://ClinicalTrials.gov/show/NCT02032875
547,PinPointe FootLaser for the Treatment of Onychomycosis,Completed,Has Results,Infected Toenails|Onychomycosis,Device: PinPointe FootLaser,"PathoLase, Inc.",Phase 2|Phase 3,Industry,Interventional,9-Apr-13,https://ClinicalTrials.gov/show/NCT00935649
548,"A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021",Completed,Has Results,Short Bowel Syndrome,Drug: Teduglutide,Shire,Phase 3,Industry,Interventional,25-Dec-14,https://ClinicalTrials.gov/show/NCT01560403
549,Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension,Completed,Has Results,"Pain, Postoperative|Bunion",Drug: COV795|Drug: Placebo,Mallinckrodt,Phase 3,Industry,Interventional,2-Jul-14,https://ClinicalTrials.gov/show/NCT01484652
550,Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Disease|Cushing's Syndrome,Drug: Mifepristone,Corcept Therapeutics,Phase 3,Industry,Interventional,20-Nov-13,https://ClinicalTrials.gov/show/NCT01371565
551,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,Completed,Has Results,Colonoscopy,Drug: BLI800|Drug: Polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Phase 3,Industry,Interventional,10-Nov-10,https://ClinicalTrials.gov/show/NCT00856843
552,Emergency Contraception Actual Use Study,Completed,Has Results,Emergency Contraception,Drug: DR-104,Duramed Research|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,18-Oct-12,https://ClinicalTrials.gov/show/NCT00777556
553,Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD,Drug: LDX|Drug: Placebo,Shire,Phase 3,Industry,Interventional,1-Feb-10,https://ClinicalTrials.gov/show/NCT00697515
554,"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV",Completed,Has Results,Influenza,Biological: FluBlok Influenza Vaccination|Biological: TIV (Fluzone) Influenza Vaccination,Protein Sciences Corporation,Phase 3,Industry,Interventional,27-Jul-11,https://ClinicalTrials.gov/show/NCT00539864
555,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Completed,Has Results,Type 1 Diabetes,Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin|Device: Medtronic MiniMed Implantable Pump System|Drug: Aventis HOE21PH U400,Medtronic Diabetes,Phase 3,Industry,Interventional,23-Jun-11,https://ClinicalTrials.gov/show/NCT00211536
556,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,Completed,Has Results,HIV Infections,Drug: Emtricitabine (FTC)|Drug: Tenofovir Disoproxil Fumarate (TDF)|Drug: Efavirenz (EFV)|Drug: FTC/TDF|Drug: FTC/TDF/EFV|Drug: Lamivudine/zidovudine,Gilead Sciences,Phase 3,Industry,Interventional,13-Oct-10,https://ClinicalTrials.gov/show/NCT00112047
557,Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy,Completed,Has Results,Contact Dermatitis,Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens,Allerderm,Phase 3,Industry,Interventional,22-Dec-15,https://ClinicalTrials.gov/show/NCT00640614
558,MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication,Completed,Has Results,Uterine Leiomyoma|Uterine Fibroids,Device: ExAblate Enhanced Sonication,InSightec,Phase 3,Industry,Interventional,5-Feb-19,https://ClinicalTrials.gov/show/NCT00365989
559,Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study,Completed,Has Results,Atrial Fibrillation,Device: Vdrive Lasso navigation|Procedure: Manual Lasso navigation,Stereotaxis,Phase 3,Industry,Interventional,4-Jun-15,https://ClinicalTrials.gov/show/NCT01656772
560,A Study in Benign Prostatic Hyperplasia,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,20-May-13,https://ClinicalTrials.gov/show/NCT01152190
561,Concurrent Bupropion / Varenicline for Smoking Cessation,Completed,Has Results,Nicotine Dependence,Drug: Varenicline|Drug: Bupropion|Drug: Nicotine patches|Drug: Nicotine Inhaler,"Duke University|National Institute on Drug Abuse (NIDA)|Philip Morris USA, Inc.",Phase 3,Other|NIH|Industry,Interventional,1-Aug-14,https://ClinicalTrials.gov/show/NCT01303861
562,Treximet Early Intervention Adolescent Migraine,Completed,Has Results,Migraine,Drug: Treximet|Drug: Placebo,Premiere Research Institute|GlaxoSmithKline,Phase 2|Phase 3,Other|Industry,Interventional,4-May-16,https://ClinicalTrials.gov/show/NCT01016678
563,Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration,Completed,Has Results,Pantothenate Kinase-Associated Neurodegeneration,Drug: Deferiprone oral solution,ApoPharma,Phase 3,Industry,Interventional,17-Jul-19,https://ClinicalTrials.gov/show/NCT02174848
564,Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN),Completed,Has Results,Pantothenate Kinase-Associated Neurodegeneration,Drug: Deferiprone oral solution|Drug: Placebo,ApoPharma|Food and Drug Administration (FDA),Phase 3,Industry|U.S. Fed,Interventional,23-May-19,https://ClinicalTrials.gov/show/NCT01741532
565,Bimatoprost in the Treatment of Eyelash Hypotrichosis,Completed,Has Results,Idiopathic Eyelash Hypotrichosis,Drug: bimatoprost formulation A solution|Drug: bimatoprost solution 0.03 %|Drug: vehicle of bimatoprost formulation A solution|Drug: vehicle of bimatoprost solution 0.03 %,Allergan,Phase 3,Industry,Interventional,10-Feb-15,https://ClinicalTrials.gov/show/NCT01698554
566,Maxigesic 325 Acute Dental Pain Study,Completed,Has Results,Dental Pain,Drug: Maxigesic 325|Drug: Acetaminophen|Drug: Ibuprofen|Drug: Placebo,"AFT Pharmaceuticals, Ltd.",Phase 3,Industry,Interventional,6-Dec-18,https://ClinicalTrials.gov/show/NCT01420653
567,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Completed,Has Results,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Drug: normal saline|Biological: onabotulinumtoxinA 44 U|Biological: onabotulinumtoxinA 24 U,Allergan,Phase 3,Industry,Interventional,25-Feb-14,https://ClinicalTrials.gov/show/NCT01224015
568,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines,Completed,Has Results,Facial Rhytides|Crow's Feet Lines|Glabellar Lines,Biological: onabotulinumtoxinA 24 U|Biological: onabotulinumtoxinA 44 U|Drug: normal saline,Allergan,Phase 3,Industry,Interventional,3-Dec-13,https://ClinicalTrials.gov/show/NCT01189760
569,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines,Completed,Has Results,Lateral Canthus Rhytides|Crow's Feet Lines,Biological: onabotulinumtoxinA|Drug: normal saline,Allergan,Phase 3,Industry,Interventional,3-Dec-13,https://ClinicalTrials.gov/show/NCT01189747
570,Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older,Completed,Has Results,Influenza,Biological: GSK Biologicals' influenza vaccine GSK2186877A|Biological: GSK Biologicals' Fluarix,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Apr-12,https://ClinicalTrials.gov/show/NCT00765076
571,"A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Valsartan|Drug: Hydrochlorothiazide (HCTZ),Novartis,Phase 3,Industry,Interventional,10-May-11,https://ClinicalTrials.gov/show/NCT00386607
572,A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy,Completed,Has Results,Bunionectomy|Pain|Postoperative Pain|Acute Pain,Drug: CG5503 IR|Drug: Morphine|Drug: Placebo,"Grünenthal GmbH|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,25-Nov-09,https://ClinicalTrials.gov/show/NCT00609466
573,Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions,Completed,Has Results,Obesity|Type 2 Diabetes,Drug: VI-0521,"VIVUS, Inc.|Medpace, Inc.",Phase 3,Industry,Interventional,6-Sep-12,https://ClinicalTrials.gov/show/NCT00553787
574,A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs),Completed,Has Results,Facial Wrinkles at the Nasolabial Folds,Device: Dermal Gel Extra (DGE)|Device: Restylane|Drug: EMLA Cream,"Genzyme, a Sanofi Company|Mentor Worldwide, LLC|Sanofi",Phase 3,Industry,Interventional,22-Apr-15,https://ClinicalTrials.gov/show/NCT00444626
575,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Completed,Has Results,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Drug: G-Pen|Drug: Lilly Glucagon,Xeris Pharmaceuticals|SGS S.A.|Integrated Medical Development,Phase 3,Industry,Interventional,30-May-19,https://ClinicalTrials.gov/show/NCT03439072
576,Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD),Completed,Has Results,Borderline Personality Disorder,Drug: quetiapine extended-release|Drug: Placebo,University of Minnesota - Clinical and Translational Science Institute|AstraZeneca|University of Iowa|Mclean Hospital,Phase 3,Other|Industry,Interventional,28-Dec-16,https://ClinicalTrials.gov/show/NCT00880919
577,Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.,Completed,Has Results,Asthma,Drug: Budesonide|Drug: albuterol|Drug: Ipratropium bromide|Drug: Prednisone,Northwell Health|AstraZeneca|Jacobi Medical Center|Nassau University Medical Center,Phase 3,Other|Industry,Interventional,21-Jan-16,https://ClinicalTrials.gov/show/NCT00588406
578,Lamotrigine for Symptoms of Geriatric Bipolar Depression,Completed,Has Results,"Bipolar Disorder|Depression, Bipolar",Drug: Lamotrigine regular tablet formulation|Drug: Lamotrigine novel formulation,University Hospitals Cleveland Medical Center|GlaxoSmithKline,Phase 3,Other|Industry,Interventional,25-Oct-11,https://ClinicalTrials.gov/show/NCT00621842
579,PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Everolimus-Eluting Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Phase 3,Industry,Interventional,5-Apr-12,https://ClinicalTrials.gov/show/NCT01510327
580,Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients,Completed,Has Results,Burns,Drug: Caldolor|Drug: Placebo,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,11-Aug-11,https://ClinicalTrials.gov/show/NCT00606489
581,Contact Lenses With New UV-blocker Manufactured With Different Techniques,Completed,Has Results,Correction of Refraction Error|Attenuation of Bright Light,Device: senofilcon A TEST Lens|Device: senofilcon A CONTROL Lens,"Johnson & Johnson Vision Care, Inc.",Phase 2|Phase 3,Industry,Interventional,4-Jun-19,https://ClinicalTrials.gov/show/NCT03475875
582,"Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies",Completed,Has Results,Scabies,"Drug: Permethrin Cream, 5%|Drug: Elimite™ Cream (permethrin) 5%",Encube Ethicals Pvt. Ltd.|Novum Pharmaceutical Research Services,Phase 3,Industry,Interventional,14-Mar-19,https://ClinicalTrials.gov/show/NCT03178942
583,"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis",Completed,Has Results,"Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,23-Jul-19,https://ClinicalTrials.gov/show/NCT03054428
584,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glucagon,"Xeris Pharmaceuticals|The Emmes Company, LLC",Phase 3,Industry,Interventional,16-Nov-18,https://ClinicalTrials.gov/show/NCT03091673
585,A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps,Completed,Has Results,Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP),Drug: Dupilumab SAR231893 (REGN668)|Drug: Placebo|Drug: Mometasone furoate 50 micrograms,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,25-Jul-19,https://ClinicalTrials.gov/show/NCT02912468
586,Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: Adalimumab - GP2017|Biological: Adalimumab - US licensed Humira,Sandoz|Hexal AG,Phase 3,Industry,Interventional,18-Dec-18,https://ClinicalTrials.gov/show/NCT02744755
587,"Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",Completed,Has Results,Migraine With or Without Aura,Drug: Lasmiditan 50 mg|Drug: Lasmiditan 100 mg|Drug: Lasmiditan 200 mg|Drug: Placebo,Eli Lilly and Company|CoLucid Pharmaceuticals,Phase 3,Industry,Interventional,30-Jul-18,https://ClinicalTrials.gov/show/NCT02605174
588,Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE,Completed,Has Results,Hereditary Angioedema (HAE),Drug: DX-2930 - 300mg/2wk|Drug: DX-2930 - 300mg/4wk|Drug: DX-2930 - 150mg/4wk|Drug: Placebo,Shire|Dyax Corp.,Phase 3,Industry,Interventional,24-Apr-18,https://ClinicalTrials.gov/show/NCT02586805
589,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,17-May-18,https://ClinicalTrials.gov/show/NCT02585778
590,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,2-Nov-18,https://ClinicalTrials.gov/show/NCT02580591
591,A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting,Completed,Has Results,Bladder Cancer,Drug: Hexaminolevulinate hydrochloride|Device: KARL STORZ D-Light C PDD Flexible Videoscope System,"Photocure|KARL STORZ Endoscopy-America, Inc.",Phase 3,Industry,Interventional,2-Jul-18,https://ClinicalTrials.gov/show/NCT02560584
592,Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg,Completed,Has Results,Prostatic Neoplasms,Drug: LMIS 50 mg,"Foresee Pharmaceuticals Co., Ltd.|QPS-Qualitix",Phase 3,Industry,Interventional,12-Sep-18,https://ClinicalTrials.gov/show/NCT02712320
593,"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®",Completed,Has Results,Rheumatoid Arthritis,Biological: GP2013 - A Proposed biosimilar rituximab|Biological: Originator rituximab - Rituxan ® or MabThera ®,Sandoz|Hexal AG,Phase 3,Industry,Interventional,28-Dec-17,https://ClinicalTrials.gov/show/NCT02514772
594,A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Kidney Disease (CKD),Biological: Epoetin Hospira Arm|Other: Standard of Care Arm|Drug: IV Iron,"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Phase 3,Industry,Interventional,13-Jun-18,https://ClinicalTrials.gov/show/NCT02504294
595,Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma,Completed,Has Results,Asthma,Drug: Dupilumab|Drug: Placebo|Drug: Oral corticosteroid therapy (prednisone/prednisolone)|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,23-Oct-18,https://ClinicalTrials.gov/show/NCT02528214
596,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Other: Placebo for dapagliflozin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,6-Nov-18,https://ClinicalTrials.gov/show/NCT02460978
597,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Completed,Has Results,Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|PPD|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,6-Feb-19,https://ClinicalTrials.gov/show/NCT02452190
598,"Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale",Completed,Has Results,Severe Hemophilia A,Biological: rFVIIIFc,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02502149
599,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,20-Nov-18,https://ClinicalTrials.gov/show/NCT02414958
600,Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest),Completed,Has Results,Asthma,Drug: Dupilumab|Drug: Placebo|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,23-Oct-18,https://ClinicalTrials.gov/show/NCT02414854
601,A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Sarecycline,"Almirall, S.A.|Allergan",Phase 3,Industry,Interventional,4-May-18,https://ClinicalTrials.gov/show/NCT02413346
602,Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2),Completed,Has Results,Central Abdominal Bulging,Drug: LIPO-202|Drug: Placebo,"Evofem Inc.|Neothetics, Inc",Phase 3,Industry,Interventional,7-Jan-19,https://ClinicalTrials.gov/show/NCT02398188
603,Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants,Completed,Has Results,"Pain, Postoperative",Drug: fentanyl,"The Medicines Company|Incline Therapeutics, Inc.",Phase 3,Industry,Interventional,18-Sep-17,https://ClinicalTrials.gov/show/NCT02395653
604,ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,Completed,Has Results,Epidermolysis Bullosa,Drug: SD-101-6.0 cream|Drug: Placebo (SD-101-0.0) cream,"Scioderm, Inc.|Amicus Therapeutics",Phase 3,Industry,Interventional,16-Oct-18,https://ClinicalTrials.gov/show/NCT02384460
605,PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD,Completed,Has Results,ADHD,Drug: PRC-063 oral capsules|Drug: Placebo oral capsules,"Purdue Pharma, Canada",Phase 3,Industry,Interventional,4-Jun-19,https://ClinicalTrials.gov/show/NCT03172481
606,"Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne",Completed,Has Results,Acne Vulgaris,Drug: Sarecycline|Drug: Placebo,"Almirall, S.A.|Allergan",Phase 3,Industry,Interventional,7-May-18,https://ClinicalTrials.gov/show/NCT02322866
607,Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne,Completed,Has Results,Acne Vulgaris,Drug: Sarecycline|Drug: Placebo,"Almirall, S.A.|Allergan",Phase 3,Industry,Interventional,17-May-18,https://ClinicalTrials.gov/show/NCT02320149
608,A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy,Completed,Has Results,Bronchoscopy,Drug: Remimazolam|Drug: Placebo|Drug: Midazolam,Paion UK Ltd.|Premier Research Group plc,Phase 3,Industry,Interventional,12-Mar-19,https://ClinicalTrials.gov/show/NCT02296892
609,A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2963016|Drug: LANTUS®|Drug: Oral Antihyperglycemic Medication,Eli Lilly and Company|Boehringer Ingelheim,Phase 3,Industry,Interventional,24-Oct-17,https://ClinicalTrials.gov/show/NCT02302716
610,Trial of Linaclotide in Patients With Chronic Idiopathic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Linaclotide|Drug: Matching Placebo,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories",Phase 3,Industry,Interventional,19-May-17,https://ClinicalTrials.gov/show/NCT02291679
611,A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients,Completed,Has Results,Colonoscopy,Drug: Remimazolam|Drug: Midazolam|Drug: Placebo,Paion UK Ltd.|Premier Research Group plc,Phase 3,Industry,Interventional,9-Nov-18,https://ClinicalTrials.gov/show/NCT02290873
612,Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab),Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,16-Oct-17,https://ClinicalTrials.gov/show/NCT02277769
613,Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,"Dermatitis, Atopic",Drug: Dupilumab|Drug: Placebo (for Dupilumab),Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,21-Nov-17,https://ClinicalTrials.gov/show/NCT02277743
614,MSB11022 in Moderate to Severe Chronic Plaque Psoriasis,Completed,Has Results,Psoriasis|Plaque Type Psoriasis|Moderate to Severe Plaque Psoriasis,Drug: MSB11022|Drug: Humira®,"Fresenius Kabi SwissBioSim GmbH|Merck KGaA, Darmstadt, Germany",Phase 3,Industry,Interventional,19-Feb-19,https://ClinicalTrials.gov/show/NCT02660580
615,"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles",Completed,Has Results,Contraception,Drug: LF111 (drospirenone),"Laboratories Leon Farma, S.A.|Chemo France|Insud Pharma",Phase 3,Industry,Interventional,23-Jul-19,https://ClinicalTrials.gov/show/NCT02269241
616,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo for dapagliflozin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,29-Mar-18,https://ClinicalTrials.gov/show/NCT02268214
617,Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS),Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,17-Oct-17,https://ClinicalTrials.gov/show/NCT02260986
618,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide|Drug: Insulin Glargine and Insulin Lispro,GlaxoSmithKline|PPD,Phase 3,Industry,Interventional,29-Jun-18,https://ClinicalTrials.gov/show/NCT02229227
619,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),Completed,Has Results,Clostridium Difficile-associated Diarrhea (CDAD),Drug: Fidaxomicin oral suspension|Drug: Fidaxomicin tablets|Drug: Vancomycin oral liquid|Drug: Vancomycin capsules,Astellas Pharma Europe B.V.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc,Phase 3,Industry,Interventional,7-Dec-18,https://ClinicalTrials.gov/show/NCT02218372
620,Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress,Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: Placebo + ADT|Drug: Brexpiprazole +ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",Phase 3,Industry,Interventional,21-Aug-18,https://ClinicalTrials.gov/show/NCT02196506
621,A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis,Completed,Has Results,Atrophic Vaginitis,"Drug: Estradiol Vaginal Cream, 0.01%|Drug: Estrace® 0.01% cream|Drug: Placebo Vaginal Cream",Mylan Inc.|Mylan Pharmaceuticals,Phase 3,Industry,Interventional,6-Sep-17,https://ClinicalTrials.gov/show/NCT02195986
622,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Empagliflozin low dose|Drug: placebo|Drug: Empagliflozin high dose,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,31-Jul-18,https://ClinicalTrials.gov/show/NCT02182830
623,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Completed,Has Results,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Benralizumab Arm C|Drug: Placebo,AstraZeneca|MedImmune LLC,Phase 3,Industry,Interventional,26-Jun-19,https://ClinicalTrials.gov/show/NCT02155660
624,The Efficacy and Safety of PRC-063 in Adult ADHD Patients,Completed,Has Results,ADHD,Drug: Placebo|Drug: PRC-063 25 mg|Drug: PRC-063 45 mg|Drug: PRC-063 70 mg|Drug: PRC-063 100 mg,"Rhodes Pharmaceuticals, L.P.|Purdue Pharma, Canada",Phase 3,Industry,Interventional,7-May-19,https://ClinicalTrials.gov/show/NCT02139124
625,Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History,Completed,Has Results,Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Placebo,AstraZeneca|MedImmune LLC,Phase 3,Industry,Interventional,13-Jun-19,https://ClinicalTrials.gov/show/NCT02138916
626,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO),Completed,Has Results,Plaque Psoriasis,Drug: Etanercept|Drug: CHS-0214,"Coherus Biosciences, Inc.|Shire",Phase 3,Industry,Interventional,13-May-19,https://ClinicalTrials.gov/show/NCT02134210
627,To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: sarilumab SAR153191 (REGN88),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,20-Jun-17,https://ClinicalTrials.gov/show/NCT02121210
628,Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Etanercept|Drug: CHS-0214,"Coherus Biosciences, Inc.|Daiichi Sankyo Co., Ltd.",Phase 3,Industry,Interventional,26-Jun-19,https://ClinicalTrials.gov/show/NCT02115750
629,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Completed,Has Results,Bronchiectasis,Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation|Drug: Placebo,Bayer|Novartis,Phase 3,Industry,Interventional,1-Sep-17,https://ClinicalTrials.gov/show/NCT02106832
630,A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies,Completed,Has Results,Rheumatoid Arthritis,Drug: methotrexate|Drug: rituximab [MabThera/Rituxan],Hoffmann-La Roche|Biogen,Phase 3,Industry,Interventional,7-Nov-14,https://ClinicalTrials.gov/show/NCT02097745
631,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),Completed,Has Results,Pulmonary Embolism|Thromboembolism|Thrombosis|Venous Thrombosis|Venous Thromboembolism,Drug: BAY 59-7939|Drug: ASA,"Bayer|Janssen Scientific Affairs, LLC",Phase 3,Industry,Interventional,19-Dec-17,https://ClinicalTrials.gov/show/NCT02064439
632,To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis,Completed,Has Results,RA,Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,20-Jun-17,https://ClinicalTrials.gov/show/NCT02057250
633,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Completed,Has Results,Rubella|Mumps|Measles,"Biological: Priorix®|Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",GlaxoSmithKline|Parexel,Phase 3,Industry,Interventional,10-Apr-17,https://ClinicalTrials.gov/show/NCT02058563
634,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: adalimumab 40 mg|Biological: sirukumab 100 mg|Biological: sirukumab 50 mg|Drug: Placebo,"Janssen Research & Development, LLC|GlaxoSmithKline",Phase 3,Industry,Interventional,14-Sep-17,https://ClinicalTrials.gov/show/NCT02019472
635,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira,Completed,Has Results,Plaque Type Psoriasis,Drug: GP2017 Adalimumab|Drug: Humira ® Adalimumab,Sandoz|Hexal AG,Phase 3,Industry,Interventional,7-Apr-17,https://ClinicalTrials.gov/show/NCT02016105
636,Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,29-Mar-16,https://ClinicalTrials.gov/show/NCT02013622
637,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",Completed,Has Results,MDD,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,29-Mar-16,https://ClinicalTrials.gov/show/NCT02013609
638,Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms,Completed,Has Results,Major Depressive Disorder|Anxiety,Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,29-Mar-16,https://ClinicalTrials.gov/show/NCT02013531
639,Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy,Completed,Has Results,Major Depressive Disorder (MDD),Drug: ADT|Drug: Brexpiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,8-Oct-15,https://ClinicalTrials.gov/show/NCT02012218
640,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,7-Feb-18,https://ClinicalTrials.gov/show/NCT02006654
641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,20-Feb-18,https://ClinicalTrials.gov/show/NCT02006641
642,Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for Alirocumab)|Drug: Non-statin LMT|Other: Diet Alone,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,15-Mar-17,https://ClinicalTrials.gov/show/NCT02023879
643,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,19-Sep-17,https://ClinicalTrials.gov/show/NCT01955161
644,Open Label Study of Long Term Safety Evaluation of Alirocumab,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,24-Jul-18,https://ClinicalTrials.gov/show/NCT01954394
645,BAX 855 Continuation,Completed,Has Results,Hemophilia A,Biological: BAX855,"Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Shire",Phase 3,Industry,Interventional,1-May-19,https://ClinicalTrials.gov/show/NCT01945593
646,Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin,Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,21-Mar-17,https://ClinicalTrials.gov/show/NCT01926782
647,Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Completed,Has Results,Angiotensin Converting Enzyme Inhibitor Induced Angioedema,Drug: Icatibant|Drug: Placebo,Shire|PPD,Phase 3,Industry,Interventional,10-Oct-16,https://ClinicalTrials.gov/show/NCT01919801
648,"A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",Completed,Has Results,Irritable Bowel Syndrome With Constipation (IBS-C),Drug: Placebo|Drug: Linaclotide,"AstraZeneca|Ironwood Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,27-Sep-16,https://ClinicalTrials.gov/show/NCT01880424
649,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",Completed,Has Results,Heart Failure|Coronary Artery Disease,Drug: Rivaroxaban|Drug: Placebo|Other: Standard of care for heart failure and coronary artery disease,"Janssen Research & Development, LLC|Bayer",Phase 3,Industry,Interventional,10-May-19,https://ClinicalTrials.gov/show/NCT01877915
650,Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Sirukumab 100 mg|Drug: Sirukumab 50 mg|Drug: Placebo,"Janssen Research & Development, LLC|GlaxoSmithKline",Phase 3,Industry,Interventional,6-May-19,https://ClinicalTrials.gov/show/NCT01856309
651,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Completed,Has Results,Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms,Drug: Trabectedin|Drug: DOXIL|Drug: Dexamethasone,"Janssen Research & Development, LLC|PharmaMar",Phase 3,Industry,Interventional,6-Feb-19,https://ClinicalTrials.gov/show/NCT01846611
652,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,Completed,Has Results,Atrial Fibrillation|Percutaneous Coronary Intervention,Drug: rivaroxaban 2.5 mg|Drug: rivaroxaban 15 mg|Drug: rivaroxaban 10 mg|Drug: aspirin (ASA)|Drug: vitamin K antagonist (VKA)|Drug: clopidogrel|Drug: prasugrel|Drug: ticagrelor,"Janssen Scientific Affairs, LLC|Bayer",Phase 3,Industry,Interventional,31-Jul-17,https://ClinicalTrials.gov/show/NCT01830543
653,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Completed,Has Results,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo",ParaPRO LLC|Concentrics Research,Phase 3,Industry|Other,Interventional,16-Jan-19,https://ClinicalTrials.gov/show/NCT02485717
654,Brexpiprazole in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Brexpiprazole,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT01810783
655,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,Completed,Has Results,"Pneumonia, Bacterial",Drug: Amikacin Inhalation Solution (BAY41-6551)|Drug: Aerosolized Placebo,Bayer|Nektar Therapeutics,Phase 3,Industry,Interventional,26-Jun-18,https://ClinicalTrials.gov/show/NCT01799993
656,"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin 5mg,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT01792518
657,Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: Brexpiprazole|Drug: ADT,"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,9-Aug-17,https://ClinicalTrials.gov/show/NCT01838681
658,Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD,Completed,Has Results,COPD,Device: GFF MDI (PT003) with Aerochamber|Device: GFF MDI (PT003) without Aerochamber,"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,19-Apr-17,https://ClinicalTrials.gov/show/NCT02454959
659,Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: BI 10773 Placebo|Drug: BI 10773 / BI 1356|Drug: BI 10773 / BI 1356 Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,4-Apr-16,https://ClinicalTrials.gov/show/NCT01778049
660,To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN),Completed,Has Results,Rheumatoid Arthritis,Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide|Drug: subcutaneous placebo|Drug: intravenous placebo,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,26-Jun-17,https://ClinicalTrials.gov/show/NCT01768572
661,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),Completed,Has Results,Bronchiectasis,Drug: Ciprofloxacin DPI (BAYQ3939)|Drug: Placebo,Bayer|Novartis,Phase 3,Industry,Interventional,24-May-17,https://ClinicalTrials.gov/show/NCT01764841
662,Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease,Completed,Has Results,Cystic Fibrosis|Advanced Lung Disease,Drug: Lumacaftor|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,1-Nov-17,https://ClinicalTrials.gov/show/NCT02390219
663,Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Empagliflozin + Linagliptin|Drug: Empaglifozin placebo + Linagliptin placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,18-Apr-16,https://ClinicalTrials.gov/show/NCT01734785
664,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries,Completed,Has Results,Soft Tissue Surgical Bleeding,Biological: Fibrin Sealant (FS) Grifols|Device: Surgicel®,"Grifols Biologicals, LLC|Instituto Grifols, S.A.",Phase 3,Industry,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT01731938
665,Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,28-Oct-15,https://ClinicalTrials.gov/show/NCT01730053
666,Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,31-Aug-15,https://ClinicalTrials.gov/show/NCT01730040
667,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,Completed,Has Results,Atrial Fibrillation,Drug: rivaroxaban|Drug: uninterrupted vitamin K antagonist (VKA),"Janssen Scientific Affairs, LLC|Bayer",Phase 3,Industry,Interventional,10-Nov-15,https://ClinicalTrials.gov/show/NCT01729871
668,Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL,Completed,Has Results,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: Ibrutinib|Drug: Chlorambucil,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Phase 3,Industry,Interventional,4-May-16,https://ClinicalTrials.gov/show/NCT01722487
669,Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|Hyperglycemia",Drug: Metformin 500 mg bid|Drug: Metformin 1000 mg bid|Drug: Empagliflozin low dose qd|Drug: Empagliflozin high dose qd|Drug: Empagliflozin low dose bid|Drug: Empagliflozin high dose bid,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,19-Feb-16,https://ClinicalTrials.gov/show/NCT01719003
670,Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder,Completed,Has Results,Bipolar I,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT01710709
671,To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET),Completed,Has Results,Rheumatoid Arthritis,Drug: Sarilumab|Drug: placebo|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,8-Aug-17,https://ClinicalTrials.gov/show/NCT01709578
672,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo,Regeneron Pharmaceuticals|Sanofi,Phase 3,Industry,Interventional,28-Aug-15,https://ClinicalTrials.gov/show/NCT01709513
673,Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne,Completed,Has Results,Acne,Drug: ACYC|Drug: ACYC vehicle,"Bausch Health Americas, Inc.|Dow Pharmaceutical Sciences",Phase 3,Industry,Interventional,10-Jan-17,https://ClinicalTrials.gov/show/NCT01701024
674,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,Completed,Has Results,Atrial Fibrillation,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist (VKA)","Bayer|Janssen Research & Development, LLC",Phase 3,Industry,Interventional,3-Feb-15,https://ClinicalTrials.gov/show/NCT01674647
675,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Completed,Has Results,Helicobacter Pylori Infection,Device: BreathID® Hp System|Drug: BreathID® Hp Lab System|Diagnostic Test: Stool Test,Exalenz Bioscience LTD.,Phase 3,Industry,Interventional,4-Jul-18,https://ClinicalTrials.gov/show/NCT02905825
676,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",Completed,Has Results,Acute Schizophrenia,Drug: Brexpiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Quintiles, Inc.",Phase 3,Industry,Interventional,13-Jan-17,https://ClinicalTrials.gov/show/NCT01668797
677,Belimumab in Remission of VASculitis,Completed,Has Results,Vasculitis,Biological: Placebo|Biological: Belimumab 10 mg/kg|Drug: Azathioprine,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01663623
678,ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab,Completed,Has Results,Atherosclerotic Cardiovascular Disease,Drug: Alirocumab|Drug: Placebo|Drug: LMT,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,18-Mar-19,https://ClinicalTrials.gov/show/NCT01663402
679,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers,Completed,Has Results,Venous Leg Ulcers,Biological: HP-802-247|Biological: Vehicle,"Healthpoint|Smith & Nephew, Inc.",Phase 3,Industry,Interventional,14-Mar-16,https://ClinicalTrials.gov/show/NCT01656889
680,Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH),Completed,Has Results,X-linked Hypophosphatemia,Biological: burosumab,"Ultragenyx Pharmaceutical Inc|Kyowa Kirin Co., Ltd.",Phase 3,Industry,Interventional,25-Sep-18,https://ClinicalTrials.gov/show/NCT02537431
681,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II),Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,6-Nov-15,https://ClinicalTrials.gov/show/NCT01644188
682,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,6-Nov-15,https://ClinicalTrials.gov/show/NCT01644175
683,Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating,Completed,Has Results,Chronic Constipation|Constipation,Drug: Linaclotide 290 micrograms|Drug: Linaclotide 145 micrograms|Drug: Matching placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,26-Apr-16,https://ClinicalTrials.gov/show/NCT01642914
684,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: Placebo|Drug: Tiotropium low dose mcg|Drug: Tiotropium high dose,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,21-Dec-15,https://ClinicalTrials.gov/show/NCT01634152
685,Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.,Completed,Has Results,Chronic Inflammatory Demyelinating Polyradiculoneuropathy,Drug: Fingolimod|Drug: Placebo Comparator,Novartis Pharmaceuticals|Mitsubishi Tanabe Pharma Corporation|Novartis,Phase 3,Industry,Interventional,19-Sep-17,https://ClinicalTrials.gov/show/NCT01625182
686,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,4-Nov-15,https://ClinicalTrials.gov/show/NCT01623115
687,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH),Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,6-Nov-15,https://ClinicalTrials.gov/show/NCT01617655
688,"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)",Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Drug: Sirukumab,"Janssen Research & Development, LLC|GlaxoSmithKline",Phase 3,Industry,Interventional,5-Feb-18,https://ClinicalTrials.gov/show/NCT01606761
689,"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)",Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Drug: Sirukumab,"Janssen Research & Development, LLC|GlaxoSmithKline",Phase 3,Industry,Interventional,11-Jan-18,https://ClinicalTrials.gov/show/NCT01604343
690,A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Completed,Has Results,Relapsed or Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: ofatumumab|Drug: ibrutinib,"Pharmacyclics LLC.|Janssen Research & Development, LLC",Phase 3,Industry,Interventional,12-Oct-15,https://ClinicalTrials.gov/show/NCT01578707
691,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,Completed,Has Results,Colorectal Cancer Metastatic,Drug: AFLIBERCEPT AVE0005|Drug: FOLFIRI,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,27-Feb-18,https://ClinicalTrials.gov/show/NCT01571284
692,"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",Completed,Has Results,Bipolar I Disorder,Drug: Intramuscular (IM) Depot Aripiprazole|Drug: Intramuscular (IM) Depot Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",Phase 3,Industry,Interventional,24-Aug-18,https://ClinicalTrials.gov/show/NCT01567527
693,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,Completed,Has Results,Herpes Labialis,Drug: acyclovir/hydrocortisone cream,"Meda Pharmaceuticals|TKL Research, Inc.",Phase 3,Industry,Interventional,22-May-14,https://ClinicalTrials.gov/show/NCT01574612
694,A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia,Completed,Has Results,Acute Lymphoblastic Leukemia,"Drug: inotuzumab ozogamicin|Drug: FLAG (fludarabine, cytarabine and G-CSF)|Drug: HIDAC (high dose cytarabine)|Drug: cytarabine and mitoxantrone",Pfizer|UCB Pharma,Phase 3,Industry,Interventional,17-Jan-18,https://ClinicalTrials.gov/show/NCT01564784
695,Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction,Completed,Has Results,Atrophic Acne Scar,Drug: Normal Saline|Device: Artefill,"Suneva Medical, Inc.|ethica Clinical Research Inc.",Phase 3,Industry,Interventional,14-Feb-17,https://ClinicalTrials.gov/show/NCT01559922
696,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20),Completed,Has Results,Chronic Inflammatory Demyelinating Polyneuropathy|Polyradiculoneuropathy,Biological: IgPro20 (low dose)|Biological: Placebo|Biological: IgPro10|Biological: IgPro20 (high dose),CSL Behring|ICON Clinical Research,Phase 3,Industry,Interventional,4-Jul-18,https://ClinicalTrials.gov/show/NCT01545076
697,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),Completed,Has Results,Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,Drug: Brentuximab Vedotin|Drug: Methotrexate|Drug: Bexarotene,"Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.|Takeda",Phase 3,Industry,Interventional,16-Mar-18,https://ClinicalTrials.gov/show/NCT01578499
698,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),Completed,Has Results,Branch Retinal Vein Occlusion,Procedure: Macular Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321),Regeneron Pharmaceuticals|Bayer,Phase 3,Industry,Interventional,13-Nov-14,https://ClinicalTrials.gov/show/NCT01521559
699,Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim,Completed,Has Results,Chemotherapy-induced Neutropenia|Breast Cancer,Drug: LA-EP2006|Drug: Neulasta®,Sandoz|Sandoz GmbH,Phase 3,Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT01516736
700,Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term),Completed,Has Results,Hypercholesterolemia,Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,22-Dec-15,https://ClinicalTrials.gov/show/NCT01507831
701,Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery,Completed,Has Results,Bleeding,Drug: TachoSil®|Drug: Surgicel® Original,Takeda|Baxter Healthcare Corporation,Phase 3,Industry,Interventional,8-Feb-17,https://ClinicalTrials.gov/show/NCT01500135
702,Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,Completed,Has Results,Complicated Skin and Soft Tissue Infection,Drug: Ceftaroline fosamil|Drug: Vancomycin|Drug: Aztreonam,Pfizer|Forest Laboratories,Phase 3,Industry,Interventional,9-Nov-15,https://ClinicalTrials.gov/show/NCT01499277
703,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Biological: Placebo|Biological: Belimumab 200 mg SC|Drug: Standard therapy,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,25-Jul-17,https://ClinicalTrials.gov/show/NCT01484496
704,A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease,Biological: Epoetin Hospira|Biological: Epogen Amgen,"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Phase 3,Industry,Interventional,20-Jun-18,https://ClinicalTrials.gov/show/NCT01473420
705,A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin,Completed,Has Results,Chronic Kidney Disease|Chronic Renal Failure,Biological: Epoetin Hospira|Biological: Epogen (Amgen),"Pfizer|Hospira, now a wholly owned subsidiary of Pfizer",Phase 3,Industry,Interventional,13-Jul-18,https://ClinicalTrials.gov/show/NCT01473407
706,B. Lactis HN019 for Functional Constipation,Completed,Has Results,Constipation,Dietary Supplement: B. lactis HN019|Dietary Supplement: Placebo,Fonterra Research Centre|DuPont Nutrition and Health,Phase 3,Industry,Interventional,24-Jul-14,https://ClinicalTrials.gov/show/NCT01463293
707,"Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A",Completed,Has Results,Hemophilia A,Drug: BIIB031 (rFVIIIFc)|Drug: FVIII (PK subgroup only),Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Phase 3,Industry,Interventional,12-Dec-14,https://ClinicalTrials.gov/show/NCT01458106
708,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: dolutegravir 50 mg OAD|Drug: darunavir 800mg OAD|Drug: ritonavir 100mg OAD,ViiV Healthcare|GlaxoSmithKline,Phase 3,Industry,Interventional,27-Mar-14,https://ClinicalTrials.gov/show/NCT01449929
709,Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older,Completed,Has Results,Epilepsy|Monotherapy,Drug: Lacosamide|Drug: Carbamazepine-Controlled Release (CBZ-CR),UCB BIOSCIENCES GmbH|Eden Sarl|UCB Pharma,Phase 3,Industry,Interventional,2-Aug-17,https://ClinicalTrials.gov/show/NCT01465997
710,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: COBI|Drug: DRV|Drug: NRTIs,"Gilead Sciences|Janssen Research & Development, LLC",Phase 3,Industry,Interventional,28-Oct-14,https://ClinicalTrials.gov/show/NCT01440569
711,Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: high dose FDC|Drug: BI 10773 high dose|Drug: high dose FDC placebo|Drug: low dose FDC placebo|Drug: high dose BI 10773 placebo|Drug: low dose FDC|Drug: BI 10773 low dose|Drug: linagliptin|Drug: linagliptin placebo|Drug: BI 10773 low dose placebo|Drug: low dose BI 10773 placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,2-Apr-15,https://ClinicalTrials.gov/show/NCT01422876
712,A Study in Adults With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2963016|Drug: Lantus|Drug: OAMs,Eli Lilly and Company|Boehringer Ingelheim,Phase 3,Industry,Interventional,9-Oct-14,https://ClinicalTrials.gov/show/NCT01421459
713,A Study in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY2963016|Drug: Lantus|Drug: Insulin Lispro,Eli Lilly and Company|Boehringer Ingelheim,Phase 3,Industry,Interventional,9-Oct-14,https://ClinicalTrials.gov/show/NCT01421147
714,A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Placebo|Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,6-Jul-18,https://ClinicalTrials.gov/show/NCT01412060
715,A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Netupitant and Palonosetron|Drug: Aprepitant|Drug: Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Phase 3,Industry,Interventional,17-Nov-14,https://ClinicalTrials.gov/show/NCT01376297
716,12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01370005
717,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|Procedure: Macular Laser Photocoagulation,Regeneron Pharmaceuticals|Bayer,Phase 3,Industry,Interventional,20-Apr-15,https://ClinicalTrials.gov/show/NCT01363440
718,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,23-Apr-18,https://ClinicalTrials.gov/show/NCT01361607
719,An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Oral palonosetron|Drug: I.V. palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Phase 3,Industry,Interventional,17-Nov-14,https://ClinicalTrials.gov/show/NCT01363479
720,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma,Completed,Has Results,Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions,Drug: Denosumab|Drug: Zoledronic acid|Drug: Placebo to Denosumab|Drug: Placebo to zoledronic acid,"Amgen|Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,7-Mar-18,https://ClinicalTrials.gov/show/NCT01345019
721,A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma,Completed,Has Results,Advanced Liposarcoma or Leiomyosarcoma,Drug: Trabectedin|Drug: Dacarbazine,"Janssen Research & Development, LLC|PharmaMar",Phase 3,Industry,Interventional,28-Jan-16,https://ClinicalTrials.gov/show/NCT01343277
722,Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: Tiotropium low dose QD|Drug: Tiotropium high dose QD|Drug: Placebo,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,12-Jul-16,https://ClinicalTrials.gov/show/NCT01634139
723,An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Netupitant and Palonosetron|Drug: Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|Parexel,Phase 3,Industry,Interventional,26-Nov-14,https://ClinicalTrials.gov/show/NCT01339260
724,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols,"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,23-Apr-18,https://ClinicalTrials.gov/show/NCT01337089
725,"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B",Completed,Has Results,Hemophilia B,Drug: rFIXFc|Drug: FIX,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Phase 3,Industry,Interventional,18-Jun-15,https://ClinicalTrials.gov/show/NCT01440946
726,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo matching with Saxagliptin|Drug: Metformin IR|Drug: Metformin XR|Drug: Saxagliptin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,18-Apr-17,https://ClinicalTrials.gov/show/NCT01434186
727,Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Obesity",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01306214
728,Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: Placebo|Drug: Sitagliptin 100mg,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,15-Jul-14,https://ClinicalTrials.gov/show/NCT01289990
729,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),Completed,Has Results,Bacterial Infections,Drug: Tedizolid (BAY119-2631)|Drug: Placebo Tedizolid (BAY119-2631)|Drug: Linezolid|Drug: Placebo Linezolid,Bayer|Merck Sharp & Dohme Corp.,Phase 3,Industry,Interventional,7-Jun-17,https://ClinicalTrials.gov/show/NCT02066402
730,A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding,Completed,Has Results,Menorrhagia,Drug: Tranexamic acid,Ferring Pharmaceuticals|Xanodyne Pharmaceuticals,Phase 3,Industry,Interventional,26-Jul-11,https://ClinicalTrials.gov/show/NCT01280981
731,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,Completed,Has Results,Pain|Advanced Cancer,Drug: Nabiximols|Drug: Placebo (GA-0034),"GW Pharmaceuticals Ltd.|Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,23-Apr-18,https://ClinicalTrials.gov/show/NCT01262651
732,Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors,Completed,Has Results,Hemophilia A With Inhibitors|Hemophilia B With Inhibitors,Biological: Coagulation Factor VIIa (Recombinant),rEVO Biologics|Laboratoire français de Fractionnement et de Biotechnologies,Phase 3,Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT02020369
733,Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis|Athlete's Foot,Drug: Econazole Nitrate Foam 1%|Other: Vehicle Foam,"AmDerma|AmDerma Pharmaceuticals, LLC",Phase 3,Industry,Interventional,9-Jan-13,https://ClinicalTrials.gov/show/NCT01353976
734,Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB),Completed,Has Results,Exercise-Induced Bronchoconstriction (EIB),Drug: Albuterol Spiromax|Drug: Placebo Spiromax,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,19-May-15,https://ClinicalTrials.gov/show/NCT01791972
735,Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial),Completed,Has Results,Polycythemia Vera,Drug: ruxolitinib tablets|Other: Best Available Therapy (BAT),Incyte Corporation|Novartis Pharmaceuticals,Phase 3,Industry,Interventional,6-Mar-15,https://ClinicalTrials.gov/show/NCT01243944
736,Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older,Completed,Has Results,Epilepsy|Monotherapy,Drug: Lacosamide|Drug: Carbamazepine-Controlled Release,UCB BIOSCIENCES GmbH|Eden Sarl|UCB Pharma,Phase 3,Industry,Interventional,23-Feb-16,https://ClinicalTrials.gov/show/NCT01243177
737,Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure,Completed,Has Results,Influenza,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)",GlaxoSmithKline,Phase 3,Industry,Interventional,7-Apr-15,https://ClinicalTrials.gov/show/NCT01788228
738,VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection,Completed,Has Results,Genotype 1 Chronic Hepatitis C|Treatment Naive,Drug: Ribavirin|Drug: Telaprevir|Drug: Pegylated interferon alfa-2a,Janssen Infectious Diseases BVBA|Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,4-Jun-14,https://ClinicalTrials.gov/show/NCT01241760
739,Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: tiotropium high dose|Drug: placebo|Drug: tiotropium low dose,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,20-Oct-14,https://ClinicalTrials.gov/show/NCT01277523
740,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,Completed,Has Results,Breast Cancer,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Capecitabine","Bayer|Onyx Therapeutics, Inc.",Phase 3,Industry,Interventional,3-Sep-15,https://ClinicalTrials.gov/show/NCT01234337
741,Clinical Trial in Females for Female Pattern Hair Loss,Completed,Has Results,Androgenetic Alopecia,Drug: 5% Minoxidil Topical Foam|Drug: Vehicle Topical Foam,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 3,Industry,Interventional,3-Jun-14,https://ClinicalTrials.gov/show/NCT01226459
742,Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma,Completed,Has Results,Asthma,Drug: tiotropium Respimat low dose|Drug: placebo Respimat|Drug: tiotropium Respimat high dose,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,8-Aug-14,https://ClinicalTrials.gov/show/NCT01257230
743,Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01210001
744,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-May-14,https://ClinicalTrials.gov/show/NCT01195662
745,Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,26-Oct-12,https://ClinicalTrials.gov/show/NCT01194830
746,A Study in Second Line Metastatic Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Biological: Ramucirumab|Biological: Placebo|Drug: Irinotecan|Drug: Folinic Acid|Drug: 5-Fluorouracil,Eli Lilly and Company|ImClone LLC,Phase 3,Industry,Interventional,15-Jul-15,https://ClinicalTrials.gov/show/NCT01183780
747,"30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Pioglitazone 15 mg|Drug: Pioglitazone 45 mg|Drug: Pioglitazone 30 mg|Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC|Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC|Drug: Linagliptin 5mg|Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT01183013
748,"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A",Completed,Has Results,Severe Hemophilia A,Drug: Factor VIII (rFVIIIFc)|Drug: Advate®,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Phase 3,Industry,Interventional,29-Aug-14,https://ClinicalTrials.gov/show/NCT01181128
749,A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH),Completed,Has Results,"Hypertension, Pulmonary",Drug: ambrisentan|Drug: tadalafil,GlaxoSmithKline|Gilead Sciences,Phase 3,Industry,Interventional,28-Apr-15,https://ClinicalTrials.gov/show/NCT01178073
750,Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI10773 high dose|Drug: BI 10773|Drug: BI 10773 open label|Drug: Placebo identical to BI10773 low dose|Drug: Placebo identical to Sitagliptin 100mg|Drug: BI10773|Drug: Sitagliptin,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,16-Jun-14,https://ClinicalTrials.gov/show/NCT01177813
751,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II,Completed,Has Results,Asthma,Drug: placebo|Drug: tiotropium Respimat® low dose|Drug: tiotropium Respimat® high dose|Drug: 50 mcg salmeterol HFA MDI,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,7-Feb-14,https://ClinicalTrials.gov/show/NCT01172821
752,Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I,Completed,Has Results,Asthma,Drug: Placebo|Drug: tiotropium Respimat® low dose|Drug: tiotropium Respimat® high dose|Drug: 50 mcg salmeterol HFA MDI,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,7-Feb-14,https://ClinicalTrials.gov/show/NCT01172808
753,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy,Completed,Has Results,Non-Small Cell Lung Cancer,Biological: Ramucirumab|Drug: Placebo (for Ramucirumab)|Drug: Docetaxel,Eli Lilly and Company|ImClone LLC,Phase 3,Industry,Interventional,29-Dec-14,https://ClinicalTrials.gov/show/NCT01168973
754,Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773|Drug: Glimepiride|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,8-Aug-14,https://ClinicalTrials.gov/show/NCT01167881
755,Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2|Renal Insufficiency",Drug: BI 10773|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,16-Jun-14,https://ClinicalTrials.gov/show/NCT01164501
756,Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Allergic Rhinitis,Drug: BDP|Drug: Placebo,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,8-Oct-15,https://ClinicalTrials.gov/show/NCT01697956
757,Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI 10773 high dose|Drug: Placebo identical to BI 10773 low dose|Drug: BI 10773,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT01159600
758,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,Phase 3,Industry,Interventional,20-Nov-12,https://ClinicalTrials.gov/show/NCT01157078
759,A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,Phase 3,Industry,Interventional,20-Nov-12,https://ClinicalTrials.gov/show/NCT01153347
760,A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder|MDD|Depression,Drug: TC-5214|Drug: Placebo,AstraZeneca|Targacept Inc.,Phase 3,Industry,Interventional,29-Oct-12,https://ClinicalTrials.gov/show/NCT01152554
761,Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine,Completed,Has Results,Meningococcal Meningitis,"Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine",Novartis Vaccines|GlaxoSmithKline|Novartis,Phase 3,Industry,Interventional,14-May-14,https://ClinicalTrials.gov/show/NCT01148017
762,Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen,Completed,Has Results,HIV Infections,Drug: Subjects do not receive study medication in this study 202094,ViiV Healthcare|Janssen Pharmaceuticals|GlaxoSmithKline,Phase 3,Industry,Interventional,20-Oct-17,https://ClinicalTrials.gov/show/NCT02478632
763,The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis,Completed,Has Results,Psoriasis,Drug: Calcipotriene Foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,23-Sep-11,https://ClinicalTrials.gov/show/NCT01139580
764,A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,1-May-14,https://ClinicalTrials.gov/show/NCT01137474
765,BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 10773 low dose|Drug: Placebo BI 10773 high dose|Drug: BI 10773 high dose|Drug: Placebo BI 10773 low dose,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,16-May-16,https://ClinicalTrials.gov/show/NCT01131676
766,A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE),Completed,Has Results,Breast Cancer,Drug: docetaxel|Drug: paclitaxel|Drug: pertuzumab|Drug: pertuzumab-placebo|Drug: trastuzumab [Herceptin]|Drug: trastuzumab emtansine,"Hoffmann-La Roche|Genentech, Inc.",Phase 3,Industry,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT01120184
767,Long-term Study of Cariprazine in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,26-Jul-19,https://ClinicalTrials.gov/show/NCT01104792
768,Safety and Efficacy of Cariprazine in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine|Drug: Aripiprazole|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,29-Oct-18,https://ClinicalTrials.gov/show/NCT01104766
769,Safety and Efficacy of Cariprazine in Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT01104779
770,Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glimepiride|Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,17-Oct-13,https://ClinicalTrials.gov/show/NCT01087502
771,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Interferon beta-1a Placebo|Biological: Interferon beta-1a|Drug: Daclizumab High Yield Process Placebo,Biogen|AbbVie,Phase 3,Industry,Interventional,11-Jul-16,https://ClinicalTrials.gov/show/NCT01064401
772,"A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Obinutuzumab|Drug: Bendamustine,"Genentech, Inc.|Roche Pharma AG",Phase 3,Industry,Interventional,17-Nov-16,https://ClinicalTrials.gov/show/NCT01059630
773,Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Cariprazine,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,13-Jun-19,https://ClinicalTrials.gov/show/NCT01059539
774,Safety and Efficacy of Cariprazine for Bipolar I Disorder,Completed,Has Results,Mania|Bipolar I Disorder,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,12-Apr-17,https://ClinicalTrials.gov/show/NCT01058668
775,VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo,Completed,Has Results,"Hepatitis C, Chronic",Drug: Telaprevir|Drug: pegylated interferon (Peg-IFN) alfa-2a|Drug: ribavirin (RBV),Janssen Infectious Diseases BVBA|Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,19-Apr-13,https://ClinicalTrials.gov/show/NCT01054573
776,Safety and Efficacy of Cariprazine for Mania,Completed,Has Results,Bipolar Disorder|Mania,Drug: Cariprazine|Drug: Placebo,Forest Laboratories|Gedeon Richter Ltd.,Phase 3,Industry,Interventional,17-Apr-17,https://ClinicalTrials.gov/show/NCT01058096
777,Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease,Completed,Has Results,Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT01042977
778,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy",Completed,Has Results,Diabetic Peripheral Neuropathy,Drug: Tapentadol extended release (ER)|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH",Phase 3,Industry,Interventional,14-May-12,https://ClinicalTrials.gov/show/NCT01041859
779,"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",Completed,Has Results,Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT01031680
780,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301",Completed,Has Results,Acne Vulgaris,Drug: Tazarotene foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,6-Jul-12,https://ClinicalTrials.gov/show/NCT01017146
781,"A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne",Completed,Has Results,Acne Vulgaris,Drug: Tazarotene Foam|Drug: Vehicle Foam,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,6-Jul-12,https://ClinicalTrials.gov/show/NCT01017120
782,Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy,Completed,Has Results,Tobacco Dependence,Drug: Nicotine Spray|Drug: Placebo,"McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|GlaxoSmithKline|McNeil AB|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 3,Industry,Interventional,8-Jan-19,https://ClinicalTrials.gov/show/NCT02355665
783,Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B,Completed,Has Results,Severe Hemophilia B,Drug: Factor IX (rFIXFc)|Drug: rFIX,Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum,Phase 3,Industry,Interventional,4-Sep-14,https://ClinicalTrials.gov/show/NCT01027364
784,Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA),Completed,Has Results,"Arthritis|Arthritis, Rheumatoid|Autoimmune Diseases",Drug: Golimumab 50 mg SC|Drug: Golimumab 2 mg/kg IV|Drug: Methotrexate (MTX)|Drug: Placebo SC|Drug: Placebo IV,"Janssen Biotech, Inc.|Merck Sharp & Dohme Corp.",Phase 3,Industry,Interventional,13-May-14,https://ClinicalTrials.gov/show/NCT01004432
785,Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,26-Mar-13,https://ClinicalTrials.gov/show/NCT00996658
786,Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: Rabeprazole sodium 5 mg|Drug: Rabeprazole sodium 10 mg|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Eisai Inc.",Phase 3,Industry,Interventional,22-May-13,https://ClinicalTrials.gov/show/NCT00992589
787,NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain,Completed,Has Results,Pain|Back Pain|Low Back Pain|Back Pain With Radiation,Drug: NUCYNTA|Drug: Oxycodone IR,"Ortho-McNeil Janssen Scientific Affairs, LLC|Grünenthal GmbH",Phase 3,Industry,Interventional,29-Feb-12,https://ClinicalTrials.gov/show/NCT00986180
788,Dapagliflozin DPPIV Inhibitor add-on Study,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,14-Oct-13,https://ClinicalTrials.gov/show/NCT00984867
789,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Completed,Has Results,Thyroid Neoplasms,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer|Amgen,Phase 3,Industry,Interventional,10-Dec-13,https://ClinicalTrials.gov/show/NCT00984282
790,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",Completed,Has Results,Neovascular Age-related Macular Degeneration,Drug: Intravitreal Aflibercept Injection 2mg,Regeneron Pharmaceuticals|Bayer,Phase 3,Industry,Interventional,23-Mar-15,https://ClinicalTrials.gov/show/NCT00964795
791,An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,27-Sep-11,https://ClinicalTrials.gov/show/NCT00960076
792,An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Golimumab|Other: Placebo|Drug: methotrexate (MTX),"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,14-Oct-13,https://ClinicalTrials.gov/show/NCT00973479
793,Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,Phase 3,Industry,Interventional,27-Sep-12,https://ClinicalTrials.gov/show/NCT00954447
794,Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation,Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Linaclotide 290 micrograms|Drug: Matching placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,30-Jan-13,https://ClinicalTrials.gov/show/NCT00948818
795,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),Completed,Has Results,Macular Edema Secondary to Central Retinal Vein Occlusion,Biological: VEGF Trap-Eye 2.0mg|Drug: Sham,Regeneron Pharmaceuticals|Bayer,Phase 3,Industry,Interventional,27-May-13,https://ClinicalTrials.gov/show/NCT00943072
796,Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C),Completed,Has Results,Irritable Bowel Syndrome With Constipation,Drug: Linaclotide or Matching Placebo,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories",Phase 3,Industry,Interventional,30-Jan-13,https://ClinicalTrials.gov/show/NCT00938717
797,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: alemtuzumab,"Genzyme, a Sanofi Company|Bayer|Sanofi",Phase 3,Industry,Interventional,15-May-17,https://ClinicalTrials.gov/show/NCT00930553
798,"A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases",Completed,Has Results,Primary Immunodeficiency Diseases,Biological: NewGam,Octapharma|Premier Research Group plc,Phase 3,Industry,Interventional,16-Mar-17,https://ClinicalTrials.gov/show/NCT01012323
799,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: exenatide twice daily,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,19-Jun-12,https://ClinicalTrials.gov/show/NCT00877890
800,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen",Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: ABC/DTG/3TC FDC|Drug: Ongoing cART regimen,ViiV Healthcare|PPD|GlaxoSmithKline,Phase 3,Industry,Interventional,25-Feb-16,https://ClinicalTrials.gov/show/NCT02105987
801,"Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",Completed,Has Results,Ovarian Cancer,Drug: Pazopanib|Drug: Placebo,Novartis Pharmaceuticals|GlaxoSmithKline|Novartis,Phase 3,Industry,Interventional,19-Dec-13,https://ClinicalTrials.gov/show/NCT00866697
802,Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release 10mg|Drug: Desvenlafaxine Succinate Sustained-Release 50 mg|Drug: placebo,Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer,Phase 3,Industry,Interventional,6-May-11,https://ClinicalTrials.gov/show/NCT00863798
803,Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,20-Mar-14,https://ClinicalTrials.gov/show/NCT00859898
804,Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine,Completed,Has Results,Meningococcal Meningitis,Biological: MenACWY-CRM conjugate vaccine|Biological: Licensed comparator,Novartis Vaccines|GlaxoSmithKline|Novartis,Phase 3,Industry,Interventional,22-Jan-14,https://ClinicalTrials.gov/show/NCT00856297
805,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,Completed,Has Results,"Skin Infections, Bacterial","Drug: Retpamulin Ointment, 1%|Drug: Linezolid","Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,26-Aug-11,https://ClinicalTrials.gov/show/NCT00852540
806,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo,"Pfizer|Medivation, Inc.",Phase 3,Industry,Interventional,8-Feb-13,https://ClinicalTrials.gov/show/NCT00838110
807,Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy,Completed,Has Results,Tonsillectomy,Drug: Intravenous ibuprofen|Other: Normal Saline,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,3-Nov-16,https://ClinicalTrials.gov/show/NCT01332253
808,Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema,Completed,Has Results,Eczema,Drug: alitretinoin|Drug: Placebo,"Stiefel, a GSK Company|Basilea Pharmaceutica|GlaxoSmithKline",Phase 3,Industry,Interventional,9-Nov-17,https://ClinicalTrials.gov/show/NCT00817063
809,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina,Drug: Rivaroxaban 2.5 mg|Drug: Rivaroxaban 5 mg|Drug: Placebo|Drug: Standard of care,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer",Phase 3,Industry,Interventional,2-Jun-14,https://ClinicalTrials.gov/show/NCT00809965
810,High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam),Completed,Has Results,Primary Immunodeficiency Disease,Biological: NewGam,Octapharma,Phase 3,Industry,Interventional,29-Mar-17,https://ClinicalTrials.gov/show/NCT01313507
811,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,Completed,Has Results,Meningitis|Meningococcal Infection,"Biological: MenACWY-CRM197|Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Biological: Hib (Haemophilus influenza b) Vaccine|Biological: IPV (Inactivated Polio Vaccine) Vaccine|Biological: Pneumococcal conjugate Vaccine|Biological: MMR (Measles, Mumps, and Rubella) Vaccine|Biological: Varicella Vaccine|Biological: Hepatitis A Virus",Novartis|Novartis Vaccines,Phase 3,Industry,Interventional,9-Jul-13,https://ClinicalTrials.gov/show/NCT00806195
812,Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects,Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide|Drug: placebo,Shire|Nycomed,Phase 3,Industry,Interventional,1-Feb-12,https://ClinicalTrials.gov/show/NCT00798967
813,Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide hydrofluoroalkane (HFA) nasal aerosol|Drug: mometasone nasal inhalation,Sunovion,Phase 3,Industry,Interventional,31-Oct-12,https://ClinicalTrials.gov/show/NCT01287364
814,A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa,Completed,Has Results,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Drug: Placebo|Drug: Droxidopa,Chelsea Therapeutics|Chiltern International Inc.,Phase 3,Industry,Interventional,16-May-14,https://ClinicalTrials.gov/show/NCT00782340
815,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II),Completed,Has Results,Asthma,Drug: tiotropium 5mcg/day|Drug: placebo,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,27-Sep-12,https://ClinicalTrials.gov/show/NCT00776984
816,Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Mar-13,https://ClinicalTrials.gov/show/NCT00794664
817,Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures,Completed,Has Results,"Epilepsies, Partial",Drug: Placebo|Drug: 2400mg SPN-804|Drug: 1200mg SPN-804,"Supernus Pharmaceuticals, Inc.|Parexel",Phase 3,Industry,Interventional,11-Feb-14,https://ClinicalTrials.gov/show/NCT00772603
818,Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I),Completed,Has Results,Asthma,Drug: tiotropium 5mcg/day|Drug: placebo,Boehringer Ingelheim|Pfizer,Phase 3,Industry,Interventional,27-Sep-12,https://ClinicalTrials.gov/show/NCT00772538
819,Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis,Completed,Has Results,Back Pain,Drug: oxycodone IR|Drug: placebo|Drug: tapentadol IR,"Ortho-McNeil Janssen Scientific Affairs, LLC|Grünenthal GmbH",Phase 3,Industry,Interventional,7-Apr-11,https://ClinicalTrials.gov/show/NCT00771758
820,Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients,Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease,Drug: Mipomersen sodium|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,20-Mar-13,https://ClinicalTrials.gov/show/NCT00770146
821,Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma,Completed,Has Results,Melanoma,Biological: Talimogene laherparepvec|Biological: GM-CSF,BioVex Limited|Amgen,Phase 3,Industry,Interventional,17-Dec-15,https://ClinicalTrials.gov/show/NCT00769704
822,"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Completed,Has Results,Chronic Constipation|Irritable Bowel Syndrome With Constipation,Drug: Linaclotide,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,15-Feb-19,https://ClinicalTrials.gov/show/NCT00765999
823,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation",Completed,Has Results,Chronic Constipation,Drug: Linaclotide 290 micrograms|Drug: Linaclotide 145 micrograms|Drug: Placebo,"Forest Laboratories|Ironwood Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,30-Jan-13,https://ClinicalTrials.gov/show/NCT00765882
824,Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: placebo|Drug: exenatide,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,26-Jan-11,https://ClinicalTrials.gov/show/NCT00765817
825,A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response,Completed,Has Results,Hepatitis C,Drug: telaprevir|Drug: ribavirin|Biological: peginterferon alfa-2a,Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited,Phase 3,Industry,Interventional,21-Jul-11,https://ClinicalTrials.gov/show/NCT00758043
826,Naproxen Sodium Extended-Release Actual Use Study,Completed,Has Results,Pain,Drug: Naproxen Sodium ER (BAYH6689),"Bayer|Pegus Research, Inc.",Phase 3,Industry,Interventional,17-May-11,https://ClinicalTrials.gov/show/NCT00751400
827,Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin,Completed,Has Results,Type 2 Diabetes,Drug: exenatide,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,20-Mar-12,https://ClinicalTrials.gov/show/NCT00753896
828,Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,2-May-14,https://ClinicalTrials.gov/show/NCT00736879
829,An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT00734071
830,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Covance",Phase 3,Industry,Interventional,11-Nov-14,https://ClinicalTrials.gov/show/NCT00731549
831,Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT00731120
832,Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder,Completed,Has Results,Generalized Anxiety Disorder,Drug: Placebo|Drug: Vortioxetine|Drug: Duloxetine,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT00730691
833,"An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation",Completed,Has Results,Irritable Bowel Syndrome With Constipation|Chronic Constipation,Drug: Linaclotide,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories",Phase 3,Industry,Interventional,16-Feb-18,https://ClinicalTrials.gov/show/NCT00730171
834,Trial of Linaclotide in Patients With Chronic Constipation,Completed,Has Results,Chronic Constipation,Drug: Matching Placebo|Drug: Linaclotide,"Ironwood Pharmaceuticals, Inc.|Forest Laboratories",Phase 3,Industry,Interventional,30-Jan-13,https://ClinicalTrials.gov/show/NCT00730015
835,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,Completed,Has Results,Systemic Lupus Erythematosus,Biological: Belimumab 1 mg/kg|Biological: Belimumab 10 mg/kg,"Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,28-Mar-16,https://ClinicalTrials.gov/show/NCT00724867
836,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),Completed,Has Results,Human Immunodeficiency Virus Infection,Drug: lopinavir/ritonavir (LPV/r)|Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|Drug: raltegravir (RAL),Abbott|Merck Sharp & Dohme Corp.,Phase 3,Industry,Interventional,2-Feb-11,https://ClinicalTrials.gov/show/NCT00711009
837,Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,13-Dec-13,https://ClinicalTrials.gov/show/NCT00707980
838,Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease,Completed,Has Results,Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease,Drug: mipomersen sodium|Drug: placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Mar-13,https://ClinicalTrials.gov/show/NCT00706849
839,"Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",Completed,Has Results,Mantle Cell Lymphoma,Drug: Rituximab 375 mg/m^2|Drug: Cyclophosphamide 750 mg/m^2|Drug: Doxorubicin 50 mg/m^2|Drug: VELCADE 1.3 mg/m^2|Drug: Prednisone 100 mg/m^2|Drug: Vincristine 1.4 mg/m^2,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda",Phase 3,Industry,Interventional,17-Nov-14,https://ClinicalTrials.gov/show/NCT00722137
840,"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment",Completed,Has Results,"Hepatitis C, Chronic",Drug: Telaprevir|Drug: Peg-IFN-alfa-2a|Drug: Ribavirin|Drug: Placebo,Tibotec BVBA|Tibotec Pharmaceutical Limited,Phase 3,Industry,Interventional,11-Aug-11,https://ClinicalTrials.gov/show/NCT00703118
841,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: Mipomersen Sodium,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Dec-15,https://ClinicalTrials.gov/show/NCT00694109
842,A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel,Completed,Has Results,Acne Vulgaris|Acne,Drug: CT Gel|Drug: Clindamycin Gel (clindamycin )|Drug: Tretinoin Gel (tretinoin)|Drug: Vehicle Gel,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,2-Dec-10,https://ClinicalTrials.gov/show/NCT00689117
843,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,Completed,Has Results,Psoriasis,Drug: U0267|Drug: Vehicle,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,8-Dec-10,https://ClinicalTrials.gov/show/NCT00688519
844,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies,Completed,Has Results,Psoriasis,Drug: U0267 Foam|Drug: Vehicle foam,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,8-Dec-10,https://ClinicalTrials.gov/show/NCT00689481
845,"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: metformin|Drug: sitagliptin|Drug: pioglitazone,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,26-Nov-12,https://ClinicalTrials.gov/show/NCT00676338
846,"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT00673231
847,Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,13-Dec-13,https://ClinicalTrials.gov/show/NCT00672958
848,Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo,Takeda|H. Lundbeck A/S,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT00672620
849,Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS),Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide,Shire|Nycomed Germany GmbH,Phase 3,Industry,Interventional,24-Dec-14,https://ClinicalTrials.gov/show/NCT00930644
850,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo Gel|Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie",Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT00660387
851,Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Completed,Has Results,Venous Thrombosis,Drug: Enoxaparin|Drug: warfarin|Drug: Placebo for apixaban|Drug: Placebo for enoxaparin|Drug: Placebo for warfarin|Drug: apixaban,Bristol-Myers Squibb|Pfizer,Phase 3,Industry,Interventional,10-Apr-14,https://ClinicalTrials.gov/show/NCT00643201
852,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide Once Weekly|Drug: Insulin Glargine,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,4-Jul-12,https://ClinicalTrials.gov/show/NCT00641056
853,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide once weekly|Drug: sitagliptin|Drug: pioglitazone|Drug: placebo tablet|Drug: placebo once weekly,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,19-Jun-12,https://ClinicalTrials.gov/show/NCT00637273
854,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,Completed,Has Results,Eosinophilic Esophagitis,Drug: reslizumab,Ception Therapeutics|Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,23-Mar-17,https://ClinicalTrials.gov/show/NCT00635089
855,Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi,Completed,Has Results,Aspergillosis|Invasive Fungal Infections,Drug: isavuconazole,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,Phase 3,Industry,Interventional,11-Jan-16,https://ClinicalTrials.gov/show/NCT00634049
856,Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism,Completed,Has Results,Venous Thrombosis,Drug: Apixaban|Drug: Placebo,Bristol-Myers Squibb|Pfizer,Phase 3,Industry,Interventional,25-Oct-13,https://ClinicalTrials.gov/show/NCT00633893
857,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Completed,Has Results,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Autonomic Failure|Dopamine Beta Hydroxylase Deficiency,Drug: Placebo|Drug: Droxidopa,Chelsea Therapeutics|Chiltern International Inc.,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT00633880
858,A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV),Completed,Has Results,Hepatitis C,Biological: Pegylated Interferon Alfa 2a|Drug: Telaprevir|Drug: Ribavirin|Other: Placebo,Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited,Phase 3,Industry,Interventional,21-Jul-11,https://ClinicalTrials.gov/show/NCT00627926
859,A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring,Completed,Has Results,Fibromyalgia,Drug: Milnacipran hydrochloride|Drug: Placebo,"Forest Laboratories|Cypress Bioscience, Inc.",Phase 3,Industry,Interventional,3-Sep-09,https://ClinicalTrials.gov/show/NCT00618956
860,Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,7-Jul-10,https://ClinicalTrials.gov/show/NCT00614939
861,Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Darbepoetin alfa,Affymax|Takeda,Phase 3,Industry,Interventional,30-Jul-12,https://ClinicalTrials.gov/show/NCT00598442
862,Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Darbepoetin alfa,Affymax|Takeda,Phase 3,Industry,Interventional,30-Jul-12,https://ClinicalTrials.gov/show/NCT00598273
863,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Epoetin Alfa,Affymax|Takeda,Phase 3,Industry,Interventional,30-Jul-12,https://ClinicalTrials.gov/show/NCT00597753
864,Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,Chronic Renal Failure|Chronic Kidney Disease|Anemia,Drug: peginesatide|Drug: Epoetin alfa or Epoetin beta,Affymax|Takeda,Phase 3,Industry,Interventional,30-Jul-12,https://ClinicalTrials.gov/show/NCT00597584
865,Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",Phase 3,Industry,Interventional,7-Dec-15,https://ClinicalTrials.gov/show/NCT00597428
866,Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone,Completed,Has Results,Opioid-Induced Bowel Dysfunction,Drug: Lubiprostone|Drug: Placebo,"Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC",Phase 3,Industry,Interventional,3-Feb-16,https://ClinicalTrials.gov/show/NCT00595946
867,Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML,Completed,Has Results,Chronic Myeloid Leukemia,Drug: Bosutinib|Drug: imatinib,Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,5-Nov-12,https://ClinicalTrials.gov/show/NCT00574873
868,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin|Drug: Rivaroxaban placebo|Drug: Enoxaparin placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,27-Jun-12,https://ClinicalTrials.gov/show/NCT00571649
869,A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer,Completed,Has Results,Metastatic Breast Cancer,Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab|Drug: Docetaxel,"Genentech, Inc.|Hoffmann-La Roche",Phase 3,Industry,Interventional,13-Sep-12,https://ClinicalTrials.gov/show/NCT00567190
870,A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease,Completed,Has Results,Crohn Disease,Biological: Cimzia,UCB BIOSCIENCES GmbH|PPD|UCB Pharma,Phase 3,Industry,Interventional,21-Jan-16,https://ClinicalTrials.gov/show/NCT00552344
871,Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients,Completed,Has Results,Hyponatremia,Drug: Tolvaptan|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,28-Apr-11,https://ClinicalTrials.gov/show/NCT00550459
872,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi",Phase 3,Industry,Interventional,8-Jan-15,https://ClinicalTrials.gov/show/NCT00548405
873,A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Ortho-Novum® 1/35,Hoffmann-La Roche,Phase 3,Industry,Interventional,12-Mar-13,https://ClinicalTrials.gov/show/NCT01044498
874,Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Ciclesonide HFA Nasal Aerosol 320 mcg|Drug: Ciclesonide HFA Nasal Aerosol 160 mcg|Drug: HFA Nasal Aerosol placebo|Drug: Ciclesonide Aqueous Nasal Spray 200 mcg|Drug: AQ Nasal Spray Placebo|Drug: Placebo plus Dexamethasone HFA|Drug: Placebo AQ plus Dexamethasone 6 mg,Sunovion,Phase 3,Industry,Interventional,19-Jul-12,https://ClinicalTrials.gov/show/NCT01033825
875,"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,31-Mar-15,https://ClinicalTrials.gov/show/NCT01683058
876,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab|Biological: Interferon beta-1a,"Genzyme, a Sanofi Company|Bayer|Sanofi",Phase 3,Industry,Interventional,24-Nov-14,https://ClinicalTrials.gov/show/NCT00530348
877,Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain,Completed,Has Results,Constipation,Drug: N-methylnaltrexone bromide (MOA-728)|Other: placebo,"Bausch Health Americas, Inc.|Progenics Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,11-May-10,https://ClinicalTrials.gov/show/NCT00529087
878,An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS),Completed,Has Results,Sarcoma,Drug: Trabectedin|Drug: Doxorubicin|Drug: Ifosfamide,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar",Phase 3,Industry,Interventional,16-Sep-14,https://ClinicalTrials.gov/show/NCT00796120
879,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,2-May-14,https://ClinicalTrials.gov/show/NCT00528879
880,A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin,AstraZeneca|Bristol-Myers Squibb,Phase 3,Industry,Interventional,14-May-14,https://ClinicalTrials.gov/show/NCT00528372
881,A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation,Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: Arctic Front® Cryoablation Catheter|Drug: Flecainide or Sotalol or Propafenone,Medtronic Cardiac Rhythm and Heart Failure|Medtronic,Phase 3,Industry,Interventional,28-Aug-12,https://ClinicalTrials.gov/show/NCT00523978
882,"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Aripiprazole IM Depot|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,16-Feb-15,https://ClinicalTrials.gov/show/NCT01663532
883,Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis,Completed,Has Results,Other Osteoporosis,Drug: Placebo tablet|Drug: Risedronate,Warner Chilcott|Sanofi,Phase 3,Industry,Interventional,28-Oct-11,https://ClinicalTrials.gov/show/NCT00619957
884,The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy,Completed,Has Results,Nausea and Vomiting of Pregnancy,Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|Drug: Placebo,Duchesnay Inc.|Premier Research Group plc,Phase 3,Industry,Interventional,5-Sep-11,https://ClinicalTrials.gov/show/NCT00614445
885,A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.,Completed,Has Results,Arthralgia|Bunion|Hallux Valgus|Pain,Drug: Tapentadol (CG5503)|Drug: oxycodone|Drug: placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH",Phase 3,Industry,Interventional,23-Apr-10,https://ClinicalTrials.gov/show/NCT00613938
886,IGIV Study for Chronic ITP Patients Ages 3-70,Completed,Has Results,Idiopathic Thrombocytopenic Purpura,Biological: IGIV3I Grifols 10%,"Grifols Biologicals, LLC|Instituto Grifols, S.A.",Phase 3,Industry,Interventional,5-May-17,https://ClinicalTrials.gov/show/NCT00511147
887,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: placebo,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,2-Sep-10,https://ClinicalTrials.gov/show/NCT00603239
888,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),Completed,Has Results,Macular Degeneration,"Biological: ranibizumab|Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals|Bayer,Phase 3,Industry,Interventional,16-Apr-12,https://ClinicalTrials.gov/show/NCT00509795
889,Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy,Completed,Has Results,Face-lift|Facial Rhytidectomy,Biological: FS VH S/D 4 s-apr,Baxter Healthcare Corporation,Phase 3,Industry,Interventional,27-Aug-12,https://ClinicalTrials.gov/show/NCT00999141
890,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2),Completed,Has Results,Chronic Kidney Disease,Drug: Placebo|Drug: AST-120,Mitsubishi Tanabe Pharma Corporation|Kureha Corporation,Phase 3,Industry,Interventional,2-Mar-15,https://ClinicalTrials.gov/show/NCT00501046
891,A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1),Completed,Has Results,Chronic Kidney Disease,Drug: Placebo|Drug: AST-120,Mitsubishi Tanabe Pharma Corporation|Kureha Corporation,Phase 3,Industry,Interventional,2-Mar-15,https://ClinicalTrials.gov/show/NCT00500682
892,A Phase III Study of Apixaban in Patients With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Drug: Apixaban|Drug: Acetylsalicylic acid,Bristol-Myers Squibb|Pfizer,Phase 3,Industry,Interventional,14-Nov-13,https://ClinicalTrials.gov/show/NCT00496769
893,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Biological: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg,"Janssen Research & Development, LLC|Merck Sharp & Dohme Corp.",Phase 3,Industry,Interventional,11-Nov-13,https://ClinicalTrials.gov/show/NCT00488631
894,An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain,Completed,Has Results,Pain|Osteoarthritis|Low Back Pain,Drug: Tapentadol (CG5503) Extended Release (ER),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH",Phase 3,Industry,Interventional,23-Jul-10,https://ClinicalTrials.gov/show/NCT00487435
895,A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: MabThera/Rituxan|Drug: Methotrexate|Other: Placebo,Hoffmann-La Roche|Biogen,Phase 3,Industry,Interventional,25-Oct-16,https://ClinicalTrials.gov/show/NCT00468546
896,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,Completed,Has Results,HIV Infections,Drug: Dolutegravir 50 mg twice daily|Drug: Dolutegravir placebo twice daily,ViiV Healthcare|Shionogi|GlaxoSmithKline,Phase 3,Industry,Interventional,19-Feb-14,https://ClinicalTrials.gov/show/NCT01568892
897,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,Completed,Has Results,"Infection, Human Immunodeficiency Virus I|HIV Infection",Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV),ViiV Healthcare|GlaxoSmithKline,Phase 3,Industry,Interventional,17-Aug-11,https://ClinicalTrials.gov/show/NCT00440947
898,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,Completed,Has Results,Venous Thrombosis,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin followed by VKA","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,24-Jan-13,https://ClinicalTrials.gov/show/NCT00440193
899,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,Completed,Has Results,Pulmonary Embolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin overlapping with and followed by VKA","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,24-Jan-13,https://ClinicalTrials.gov/show/NCT00439777
900,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,12-Apr-12,https://ClinicalTrials.gov/show/NCT00439725
901,Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age,Completed,Has Results,Influenza,Biological: Influenza Virus Vaccine,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,1-Jan-10,https://ClinicalTrials.gov/show/NCT00885105
902,Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD),Completed,Has Results,"Polycystic Kidney Disease, Autosomal Dominant",Drug: Tolvaptan|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.",Phase 3,Industry,Interventional,2-Jul-17,https://ClinicalTrials.gov/show/NCT00428948
903,"Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.",Completed,Has Results,Facial Wrinkles,Device: Belotero|Device: Zyplast,"Merz North America, Inc.",Phase 3,Industry,Interventional,19-Jan-12,https://ClinicalTrials.gov/show/NCT00876265
904,Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life,Completed,Has Results,Impotence,Drug: tadalafil|Drug: Placebo,Eli Lilly and Company|ICOS Corporation,Phase 3,Industry,Interventional,2-Jun-09,https://ClinicalTrials.gov/show/NCT00422734
905,Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections,Completed,Has Results,"Candidiasis, Invasive|Candidemia|Mycoses",Drug: Isavuconazole|Drug: Caspofungin|Drug: Voriconazole,Astellas Pharma Inc|Basilea Pharmaceutica,Phase 3,Industry,Interventional,1-Aug-17,https://ClinicalTrials.gov/show/NCT00413218
906,Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.,Completed,Has Results,Schizoaffective Disorder|Psychotic Disorder,Drug: Placebo|Drug: Paliperidone ER,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP",Phase 3,Industry,Interventional,9-Dec-09,https://ClinicalTrials.gov/show/NCT00412373
907,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,Completed,Has Results,Aspergillosis|Invasive Fungal Infection,Drug: Isavuconazole|Drug: Voriconazole,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,Phase 3,Industry,Interventional,31-Mar-15,https://ClinicalTrials.gov/show/NCT00412893
908,A Study of Belimumab in Subjects With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Placebo|Drug: Belimumab 1 mg/kg|Drug: Belimumab 10 mg/kg,Human Genome Sciences Inc.|GlaxoSmithKline,Phase 3,Industry,Interventional,5-May-11,https://ClinicalTrials.gov/show/NCT00410384
909,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Completed,Has Results,Non-small Cell Lung Cancer,Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Placebo,"EMD Serono|Merck KGaA, Darmstadt, Germany",Phase 3,Industry,Interventional,20-Nov-15,https://ClinicalTrials.gov/show/NCT00409188
910,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Stroke|Embolism,Drug: Rivaroxaban|Drug: Warfarin|Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)|Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer",Phase 3,Industry,Interventional,17-Jul-12,https://ClinicalTrials.gov/show/NCT00403767
911,An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis,Completed,Has Results,Prostatitis,Drug: levofloxacin,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PriCara, Unit of Ortho-McNeil, Inc.",Phase 3,Industry,Interventional,16-Jul-09,https://ClinicalTrials.gov/show/NCT00402688
912,A Safety and Efficacy Study in Patients With Gastric Cancer,Completed,Has Results,Gastric Cancer,Drug: S-1/Cisplatin|Drug: 5-FU/cisplatin,"Taiho Oncology, Inc.|Quintiles, Inc.",Phase 3,Industry,Interventional,23-Apr-12,https://ClinicalTrials.gov/show/NCT00400179
913,The Effect Of Oral Ibandronate In Male Osteoporosis,Completed,Has Results,Male Osteoporosis,Drug: Ibandronate|Drug: placebo,Hoffmann-La Roche|GlaxoSmithKline,Phase 3,Industry,Interventional,21-Dec-09,https://ClinicalTrials.gov/show/NCT00397839
914,Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: Ketoconazole Cream 2%|Drug: Ketoconazole Cream 2% (G&W Laboratories Inc.)|Drug: Placebo,Encube Ethicals Pvt. Ltd.|Novum Pharmaceutical Research Services|ACM Global Laboratories,Phase 3,Industry|Other,Interventional,13-Jun-19,https://ClinicalTrials.gov/show/NCT03824912
915,E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: E7389|Drug: Physician's Choice,Eisai Inc.|Eisai Limited,Phase 3,Industry,Interventional,30-Jan-12,https://ClinicalTrials.gov/show/NCT00388726
916,"GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.",Completed,Has Results,HIV|Infectious,Drug: darunavir|Drug: ritonavir,"Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Phase 3,Industry,Interventional,19-Oct-10,https://ClinicalTrials.gov/show/NCT00381303
917,A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.,Completed,Has Results,Lupus Nephritis,Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Drug: Azathioprine|Drug: Placebo to Azathioprine|Drug: Placebo to Mycophenolate mofetil|Drug: Corticosteroid,Hoffmann-La Roche|Aspreva Pharmaceuticals,Phase 3,Industry,Interventional,6-Dec-11,https://ClinicalTrials.gov/show/NCT00377637
918,Effect on Weight Loss of Exenatide Versus Placebo,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: exenatide|Drug: placebo,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,4-Sep-09,https://ClinicalTrials.gov/show/NCT00375492
919,Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Autistic Disorder|Behavioral Symptoms,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,25-Jan-10,https://ClinicalTrials.gov/show/NCT00365859
920,A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain,Completed,Has Results,"Osteoarthritis, Hip|Osteoarthritis, Knee|Lower Back Pain|Pain",Drug: Oxycodone CR|Drug: Tapentadol (CG5503) ER,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH",Phase 3,Industry,Interventional,4-Sep-09,https://ClinicalTrials.gov/show/NCT00361504
921,A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: Golimumab|Drug: Methotrexate|Drug: Placebo,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,24-Aug-12,https://ClinicalTrials.gov/show/NCT00361335
922,[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL,Completed,Has Results,Hypertriglyceridemia|Cardiovascular Disease,"Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g","AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.",Phase 3,Industry,Interventional,5-Dec-14,https://ClinicalTrials.gov/show/NCT01408303
923,Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects,Completed,Has Results,Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations,Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie",Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT00360568
924,Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.,Completed,Has Results,Onychomycosis,Drug: Itraconazole 100mg capsules|Drug: Itraconazole 200mg tablets|Drug: Placebo tablets,"Stiefel, a GSK Company|GlaxoSmithKline",Phase 3,Industry,Interventional,4-Jan-12,https://ClinicalTrials.gov/show/NCT00356915
925,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Behavioral Symptoms|Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,23-Jul-09,https://ClinicalTrials.gov/show/NCT00337571
926,An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder|Attention Deficit Disorders With Hyperactivity|Attention Deficit Hyperactivity Disorders,"Drug: Vyvanse (lisdexamfetamine dimesylate), NRP104",New River Pharmaceuticals|Shire,Phase 3,Industry,Interventional,17-Jul-09,https://ClinicalTrials.gov/show/NCT00337285
927,Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease,Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie",Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT00335153
928,"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",Completed,Has Results,Advanced Parkinson's Disease,Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo gel|Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube,"AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie",Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT00357994
929,Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma,Completed,Has Results,Melanoma,Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine,Bristol-Myers Squibb|Medarex,Phase 3,Industry,Interventional,10-Mar-14,https://ClinicalTrials.gov/show/NCT00324155
930,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),Completed,Has Results,Autistic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,23-Jul-09,https://ClinicalTrials.gov/show/NCT00332241
931,Staccato Loxapine in Agitated Patients With Bipolar Disorder,Completed,Has Results,Bipolar I Disorder,Drug: Inhaled Placebo|Drug: Inhaled loxapine 5 mg|Drug: Inhaled loxapine 10 mg,"Alexza Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,29-Jun-17,https://ClinicalTrials.gov/show/NCT00721955
932,Study of Milnacipran for the Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Placebo|Drug: Milnacipran 100mg,"Forest Laboratories|Cypress Bioscience, Inc.",Phase 3,Industry,Interventional,2-Nov-09,https://ClinicalTrials.gov/show/NCT00314249
933,Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Completed,Has Results,Non-Hodgkin's Lymphoma,Drug: Bortezomib + Rituximab|Drug: Rituximab,"Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,26-Jul-11,https://ClinicalTrials.gov/show/NCT00312845
934,Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain,Completed,Has Results,Chronic Non-malignant Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo to match BTDS,Purdue Pharma LP|Napp Pharmaceuticals Limited,Phase 3,Industry,Interventional,15-Oct-10,https://ClinicalTrials.gov/show/NCT00312195
935,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: dolutegravir,ViiV Healthcare|Shionogi|GlaxoSmithKline,Phase 3,Industry,Interventional,21-Jul-14,https://ClinicalTrials.gov/show/NCT01328041
936,Natalizumab Re-Initiation of Dosing,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: BG00002 (natalizumab),Biogen|Elan Pharmaceuticals,Phase 3,Industry,Interventional,26-Jan-10,https://ClinicalTrials.gov/show/NCT00306592
937,Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole sodium enteric-coated spheroid,Wyeth is now a wholly owned subsidiary of Pfizer|Nycomed,Phase 3,Industry,Interventional,19-May-10,https://ClinicalTrials.gov/show/NCT00300755
938,A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s),Completed,Has Results,"Arthritis, Rheumatoid",Drug: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,28-Sep-11,https://ClinicalTrials.gov/show/NCT00299546
939,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,Completed,Has Results,"Infection, Human Immunodeficiency Virus",Drug: fosamprenavir (GW433908)|Drug: ritonavir,ViiV Healthcare|GlaxoSmithKline,Phase 3,Industry,Interventional,8-Nov-11,https://ClinicalTrials.gov/show/NCT00296504
940,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: 0.15% Azelastine Hydrochloride,Meda Pharmaceuticals,Phase 3,Industry,Interventional,28-Jan-10,https://ClinicalTrials.gov/show/NCT00660829
941,Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles,Completed,Has Results,Bilateral Nasolabial Fold Wrinkles,Biological: Autologous Human Fibroblasts (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.",Phase 3,Industry,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00655356
942,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),Completed,Has Results,"Infection, Human Immunodeficiency Virus I",Drug: Dolutegravir|Drug: Atripla|Drug: Abacavir/Lamivudine|Drug: Abacavir/Lamivudine Placebo|Drug: Dolutegravir placebo|Drug: Atripla placebo,ViiV Healthcare|Shionogi|GlaxoSmithKline,Phase 3,Industry,Interventional,2-Jul-14,https://ClinicalTrials.gov/show/NCT01263015
943,A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Biological: golimumab|Biological: Placebo; golimumab,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,16-Apr-12,https://ClinicalTrials.gov/show/NCT00265096
944,A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo injections|Drug: Placebo capsules|Drug: Methotrexate capsules|Biological: Golimumab 50 mg injections|Biological: Golimumab 100 mg injections,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,13-Jul-09,https://ClinicalTrials.gov/show/NCT00264537
945,An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: Golimumab 100 mg|Drug: Golimumab 50 mg|Drug: Methotrexate|Drug: Placebo injection|Drug: Placebo capsules,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,21-Mar-14,https://ClinicalTrials.gov/show/NCT00264550
946,A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis,Completed,Has Results,"Spondylitis, Ankylosing",Biological: golimumab|Biological: Golimumab (CNTO 148); placebo,"Centocor, Inc.|Schering-Plough",Phase 3,Industry,Interventional,13-Jul-09,https://ClinicalTrials.gov/show/NCT00265083
947,Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD,Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole sodium enteric-coated spheroid suspension,Wyeth is now a wholly owned subsidiary of Pfizer|Nycomed,Phase 3,Industry,Interventional,7-May-10,https://ClinicalTrials.gov/show/NCT00259012
948,A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches,Completed,Has Results,Migraine,Drug: Almotriptan Malate,"Janssen-Ortho LLC|Ortho-McNeil Neurologics, Inc.",Phase 3,Industry,Interventional,6-Dec-13,https://ClinicalTrials.gov/show/NCT00257010
949,"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Pentostatin,US Oncology Research|Astex Pharmaceuticals,Phase 3,Industry,Interventional,3-Nov-16,https://ClinicalTrials.gov/show/NCT00254163
950,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,Completed,Has Results,"Infection, Human Immunodeficiency Virus I",Drug: GSK1349572 (dolutegravir)|Drug: raltegravir|Other: GSK1349572 Placebo|Other: ABC/3TC|Other: TDF/FTC|Other: raltegravir Placebo,ViiV Healthcare|Shionogi|GlaxoSmithKline,Phase 3,Industry,Interventional,23-Jun-14,https://ClinicalTrials.gov/show/NCT01227824
951,Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy,Completed,Has Results,Seizures,Drug: Retigabine|Drug: Placebo,"GlaxoSmithKline|Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,25-Oct-11,https://ClinicalTrials.gov/show/NCT00232596
952,A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Enzalutamide|Drug: Placebo,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT01212991
953,"An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies",Completed,Has Results,Brain Edema|Brain Tumor,Drug: hCRF [XERECEPT (corticorelin acetate injection)],Celtic Pharma Development Services|Neurobiological Technologies,Phase 3,Industry,Interventional,31-Aug-12,https://ClinicalTrials.gov/show/NCT00226655
954,Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: lenalidomide|Drug: dexamethasone,Celgene Corporation|Prologue Research International|Celgene,Phase 3,Industry,Interventional,3-Mar-10,https://ClinicalTrials.gov/show/NCT00179647
955,"Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",Completed,Has Results,Pneumococcal Vaccines,Biological: 13 valent Pneumococcal Conjugate Vaccine|Biological: 23-valent Pneumococcal Polysaccharide Vaccine,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,9-May-11,https://ClinicalTrials.gov/show/NCT00574548
956,Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies,Completed,Has Results,Chronic Hepatitis B,Drug: Telbivudine (LdT),Novartis Pharmaceuticals|Merck Sharp & Dohme Corp.|Novartis,Phase 3,Industry,Interventional,25-Jul-11,https://ClinicalTrials.gov/show/NCT00142298
957,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: exenatide|Drug: rosiglitazone,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,28-Aug-09,https://ClinicalTrials.gov/show/NCT00135330
958,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Completed,Has Results,Pediculosis,Drug: Spinosad|Drug: Permethrin 1%,ParaPRO LLC,Phase 3,Industry,Interventional,11-Oct-12,https://ClinicalTrials.gov/show/NCT00545753
959,Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice,Completed,Has Results,Pediculus Capitis Infestation,Drug: Spinosad|Drug: Permethrin 1%,ParaPRO LLC,Phase 3,Industry,Interventional,11-Oct-12,https://ClinicalTrials.gov/show/NCT00545168
960,Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients,Completed,Has Results,Mucopolysaccharidosis I|Hurler's Syndrome|Hurler-Scheie Syndrome|Scheie Syndrome,Biological: Aldurazyme|Biological: placebo,"Genzyme, a Sanofi Company|BioMarin/Genzyme LLC|Sanofi",Phase 3,Industry,Interventional,16-Jun-09,https://ClinicalTrials.gov/show/NCT00146770
961,An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer,Completed,Has Results,Ovarian Cancer,Drug: Trabectedin|Drug: DOXIL|Drug: Dexamethasone,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar",Phase 3,Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT00113607
962,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: Paclitaxel (Taxane)|Drug: Docetaxel (Taxane)|Drug: Carboplatin|Drug: Cetuximab,Eli Lilly and Company|ImClone LLC,Phase 3,Industry,Interventional,5-Oct-10,https://ClinicalTrials.gov/show/NCT00112294
963,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,Completed,Has Results,Melanoma,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo",Bayer|Amgen,Phase 3,Industry,Interventional,23-Feb-11,https://ClinicalTrials.gov/show/NCT00111007
964,A Study of Monthly Risedronate for Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: risedronate,Warner Chilcott|Sanofi,Phase 3,Industry,Interventional,21-Jun-11,https://ClinicalTrials.gov/show/NCT00247273
965,A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV),Completed,Has Results,Pemphigus Vulgaris (PV),Drug: Mycophenolate Mofetil 2 g/Day|Drug: Mycophenolate Mofetil (MMF) 3 g/Day|Drug: Placebo,Hoffmann-La Roche|Aspreva Pharmaceuticals,Phase 3,Industry,Interventional,22-Jun-11,https://ClinicalTrials.gov/show/NCT00683930
966,A Study of Aripiprazole in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Aripiprazole+ ADT|Drug: Placebo+ ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical",Phase 3,Industry,Interventional,18-May-09,https://ClinicalTrials.gov/show/NCT00105196
967,Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy,Completed,Has Results,Parkinson's Disease,Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa,"Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis",Phase 3,Industry,Interventional,8-Mar-11,https://ClinicalTrials.gov/show/NCT00099268
968,"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine",Completed,Has Results,HIV-1,"Drug: Maraviroc + Zidovudine/Lamivudine|Drug: Efavirenz + Zidovudine/Lamivudine|Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine",ViiV Healthcare|Pfizer,Phase 3,Industry,Interventional,5-Oct-12,https://ClinicalTrials.gov/show/NCT00098293
969,A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Thalidomide|Drug: Dexamethasone|Drug: DOXIL,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Phase 3,Industry,Interventional,27-Nov-08,https://ClinicalTrials.gov/show/NCT00097981
970,Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia,Completed,Has Results,Myopia|Hyperopia,Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser,"Clinical Research Consultants, Inc.|Alcon Research|WaveLight AG",Phase 3,Industry,Interventional,11-Apr-16,https://ClinicalTrials.gov/show/NCT01028378
971,Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve),Completed,Has Results,Congestive Heart Failure,Drug: Irbesartan|Drug: Placebo,Bristol-Myers Squibb|Sanofi,Phase 3,Industry,Interventional,8-Jun-10,https://ClinicalTrials.gov/show/NCT00095238
972,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Biological: Cetuximab|Drug: Docetaxel,Eli Lilly and Company|ImClone LLC,Phase 3,Industry,Interventional,15-Oct-12,https://ClinicalTrials.gov/show/NCT00095199
973,Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC,Completed,Has Results,Crohn Disease,Biological: infliximab infusion; AZA placebo caps|Other: infliximab (IFX) infusion; azathioprine (AZA) caps|Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps,"Centocor Ortho Biotech Services, L.L.C.|Schering-Plough",Phase 3,Industry,Interventional,23-Jun-09,https://ClinicalTrials.gov/show/NCT00094458
974,Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy,Completed,Has Results,Castration-Resistant Prostate Cancer,Drug: Enzalutamide|Drug: Placebo,"Pfizer|Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.",Phase 3,Industry,Interventional,30-Oct-12,https://ClinicalTrials.gov/show/NCT00974311
975,XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors,Completed,Has Results,Brain Edema|Brain Tumor,Drug: hCRF|Drug: placebo hCRF,Celtic Pharma Development Services|Neurobiological Technologies,Phase 3,Industry,Interventional,13-Aug-14,https://ClinicalTrials.gov/show/NCT00088166
976,Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery,Completed,Has Results,"Pain, Postoperative",Drug: diclofenac potassium (XP21L)|Drug: Placebo,Xanodyne Pharmaceuticals,Phase 3,Industry,Interventional,13-Apr-11,https://ClinicalTrials.gov/show/NCT00366444
977,Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Exenatide (AC2993)|Drug: Insulin glargine,AstraZeneca|Eli Lilly and Company,Phase 3,Industry,Interventional,31-Jul-13,https://ClinicalTrials.gov/show/NCT00082381
978,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,Completed,Has Results,Complicated Intra-Abdominal Infection,Drug: CAZ-AVI|Drug: Metronidazole|Drug: Meropenem,Pfizer|Forest Laboratories,Phase 3,Industry,Interventional,1-Mar-16,https://ClinicalTrials.gov/show/NCT01499290
979,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,Completed,Has Results,"Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer|Amgen,Phase 3,Industry,Interventional,14-Dec-11,https://ClinicalTrials.gov/show/NCT00073307
980,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",Completed,Has Results,Erectile Dysfunction,"Drug: Vardenafil ODT (STAXYN, BAY38-9456)|Drug: Placebo",Bayer|GlaxoSmithKline|Schering-Plough,Phase 3,Industry,Interventional,21-Jan-11,https://ClinicalTrials.gov/show/NCT00655629
981,A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: trastuzumab (Herceptin®)|Drug: anastrazole (Arimidex®),"Hoffmann-La Roche|Genentech, Inc.",Phase 3,Industry,Interventional,13-Jun-13,https://ClinicalTrials.gov/show/NCT00022672
982,A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer,Completed,Has Results,Adenocarcinoma,Drug: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: 5-fluorouracil,"Genentech, Inc.|Hoffmann-La Roche|Chugai Pharmaceutical",Phase 3,Industry,Interventional,19-Jan-12,https://ClinicalTrials.gov/show/NCT00548548
983,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Completed,Has Results,Myocardial Infarction,"Drug: abciximab placebo; reteplase placebo, abciximab, abciximab|Drug: Abciximab; reteplase; abciximab placebo; abciximab|Drug: abciximab; reteplase placebo; abciximab placebo; abciximab","Centocor, Inc.|Eli Lilly and Company",Phase 3,Industry,Interventional,15-May-09,https://ClinicalTrials.gov/show/NCT00046228
984,Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.,Completed,Has Results,Asthma,Drug: omalizumab,"Novartis|Genentech, Inc.|Tanox",Phase 3,Industry,Interventional,27-Apr-11,https://ClinicalTrials.gov/show/NCT00500539
985,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Duloxetine|Drug: placebo,Eli Lilly and Company|Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Jul-09,https://ClinicalTrials.gov/show/NCT00105989
986,Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,Phase 3,Industry|Other,Interventional,10-Oct-16,https://ClinicalTrials.gov/show/NCT01994746
987,Phase III Cat-PAD Study,Completed,Has Results,Rhinoconjunctivitis,Drug: Cat-PAD|Drug: Placebo,Circassia Limited|inVentiv Health Clinical|Pharm-Olam International,Phase 3,Industry|Other,Interventional,14-May-18,https://ClinicalTrials.gov/show/NCT01620762
988,Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men,Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate|Drug: topical testosterone gel,"Clarus Therapeutics, Inc.|PharmaNet|Los Angeles Biomedical Research Institute",Phase 3,Industry|Other,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT01403116
989,18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment,Completed,Has Results,Prostate Cancer,Drug: 18F-fluciclovine PET CT,Blue Earth Diagnostics|American College of Radiology|IND 2 Results LLC|Syne Qua Non Limited,Phase 3,Industry|Other,Interventional,28-Jan-19,https://ClinicalTrials.gov/show/NCT02680041
990,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Phase 3,Industry|Other,Interventional,10-Oct-14,https://ClinicalTrials.gov/show/NCT02053610
991,CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Phase 3,Industry|Other,Interventional,28-Jan-14,https://ClinicalTrials.gov/show/NCT01998880
992,FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Rituximab|Drug: Fludarabine Phosphate|Drug: Cyclophosphamide,"Hoffmann-La Roche|Biogen|Genentech, Inc.",Phase 3,Industry,Interventional,23-Jan-12,https://ClinicalTrials.gov/show/NCT00090051
993,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Completed,Has Results,Acute Coronary Syndrome,Drug: Clopidogrel|Drug: Prasugrel|Drug: Commercially-available Aspirin,"Eli Lilly and Company|Daiichi Sankyo Co., Ltd.|Duke Clinical Research Institute",Phase 3,Industry|Other,Interventional,7-May-13,https://ClinicalTrials.gov/show/NCT00699998
994,NINDS CRC Chronic Migraine Treatment Trial,Completed,Has Results,Chronic Migraine,Drug: propranolol LA|Drug: topiramate|Drug: placebo,"Anne Lindblad|National Institute of Neurological Disorders and Stroke (NINDS)|Ortho-McNeil Janssen Scientific Affairs, LLC|The Emmes Company, LLC",Phase 3,Industry|NIH,Interventional,19-Jan-12,https://ClinicalTrials.gov/show/NCT00772031
995,Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy,Completed,Has Results,Epilepsy,Drug: Intravenous Carbamazepine (IV CBZ),"Lundbeck LLC|Ligand Pharmaceuticals|ICON Clinical Research|Quintiles, Inc.",Phase 3,Industry,Interventional,5-Dec-16,https://ClinicalTrials.gov/show/NCT01128959
996,Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen,Completed,Has Results,Colorectal Neoplasms|Neoplasm Metastasis,"Drug: Placebo|Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)",Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc,Phase 3,Industry|Other,Interventional,28-Sep-12,https://ClinicalTrials.gov/show/NCT00561470
997,Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne,Completed,Has Results,Acne Vulgaris,Drug: clindamycin / benzoyl peroxide gel|Drug: clindamycin gel|Drug: BPO gel|Drug: vehicle gel,"Stiefel, a GSK Company|Rho, Inc.|Quintiles, Inc.|GlaxoSmithKline",Phase 3,Industry,Interventional,30-Jan-12,https://ClinicalTrials.gov/show/NCT00776919
998,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Completed,Has Results,Cystic Fibrosis,Drug: Aztreonam for Inhalation Solution (AZLI)|Drug: Tobramycin Inhalation Solution (TIS),"Gilead Sciences|Chiltern International Inc.|ClinPhone, Inc.|Covance",Phase 3,Industry,Interventional,4-Jul-11,https://ClinicalTrials.gov/show/NCT00757237
999,CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a),Completed,Has Results,"Lymphocytic Leukemia, Chronic",Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil,"Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.",Phase 3,Industry|Other,Interventional,1-Apr-14,https://ClinicalTrials.gov/show/NCT01010061
1000,A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure,Completed,Has Results,Congestive Heart Failure,Drug: carvedilol controlled release|Drug: carvedilol immediate release,"CTI-1, LLC|CTI Clinical Trial and Consulting Services|GlaxoSmithKline",Phase 3,Industry|Other,Interventional,13-Mar-09,https://ClinicalTrials.gov/show/NCT00323037
1001,Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia,Completed,Has Results,Hypercholesterolemia,Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe),Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,6-Nov-15,https://ClinicalTrials.gov/show/NCT01644474
1002,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Completed,Has Results,Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral),Pfizer|Forest Laboratories,Phase 3,Industry,Interventional,2-Mar-16,https://ClinicalTrials.gov/show/NCT01599806
1003,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),Completed,Has Results,Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Doripenem|Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral),Pfizer|Forest Laboratories,Phase 3,Industry,Interventional,9-Mar-16,https://ClinicalTrials.gov/show/NCT01595438
1004,"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer",Completed,Has Results,Metastatic Colorectal Cancer,Drug: Bevacizumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: Fluorouracil|Drug: Cetuximab,US Oncology Research|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center|Prologue Research International,Phase 3,Industry|Other,Interventional,14-Mar-11,https://ClinicalTrials.gov/show/NCT00252564
1005,A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D,Completed,Has Results,Osteoporosis,Drug: SMC021 Oral calcitonin|Drug: SMC021 Placebo,Nordic Bioscience A/S|Novartis,Phase 3,Industry,Interventional,18-Oct-12,https://ClinicalTrials.gov/show/NCT00525798
1006,Fish Oil Study for High Triglyceride Levels in Children,Completed,Has Results,Hypertriglyceridemia,Drug: Omega-3-acid ethyl esters|Drug: Placebo,Samuel Gidding|GlaxoSmithKline|Johns Hopkins University|Thomas Jefferson University|Nemours Children's Clinic,Phase 2|Phase 3,Other|Industry,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT00915902
1007,Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression,Completed,Has Results,Affective Disorders,Drug: Ziprasidone|Drug: Sertraline|Drug: Haloperidol,"Duke University|Pfizer|National Institute of Mental Health and Neuro Sciences, India",Phase 2|Phase 3,Other|Industry,Interventional,4-Jun-13,https://ClinicalTrials.gov/show/NCT00340379
1008,Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,Completed,Has Results,Nosocomial Infections,Drug: 2% Chlorhexidine gluconate cloth,"Johns Hopkins University|Sage Products, Inc.",Phase 2|Phase 3,Other|Industry,Interventional,2-Oct-15,https://ClinicalTrials.gov/show/NCT00549393
1009,Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors,Completed,Has Results,Germ Cell Tumors,Drug: Aprepitant|Drug: Placebo,Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,6-Apr-16,https://ClinicalTrials.gov/show/NCT00572572
1010,Statins in Children With Type 1 Diabetes and Hypercholesterolemia,Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent|Hypercholesterolemia",Drug: Atorvastatin|Drug: Atorvastatin Placebo,Nemours Children's Clinic|Pfizer|Medtronic|Quest Diagnostics,Phase 3,Other|Industry,Interventional,21-May-15,https://ClinicalTrials.gov/show/NCT01236365
1011,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,Completed,Has Results,Complicated Urinary Tract Infection|Complicated Intra-abdominal Infection,Drug: Ceftazidime - Avibactam ( CAZ-AVI)|Drug: Best Available Therapy|Drug: Metronidazole,Pfizer|Forest Laboratories,Phase 3,Industry,Interventional,14-Dec-15,https://ClinicalTrials.gov/show/NCT01644643
1012,"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study",Completed,Has Results,Japanese Encephalitis,Procedure: Blood draw|Biological: IC51 has given in the parent study IC51-322,Valneva Austria GmbH,Phase 3,Industry,Interventional,29-Apr-15,https://ClinicalTrials.gov/show/NCT01246479
1013,Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Device: Medigus SRS endoscopic stapling system,"Aviel Roy-Shapira, M.D.|Medigus Ltd",Phase 3,Industry,Interventional,14-Aug-15,https://ClinicalTrials.gov/show/NCT00734747
1014,Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia,Completed,Has Results,"Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemias|Metabolic Diseases|Hyperlipoproteinemia Type II|Metabolism, Inborn Errors|Genetic Diseases, Inborn|Infant, Newborn, Diseases|Metabolic Disorder|Congenital Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid Metabolism Disorders",Drug: mipomersen|Drug: Placebo,"Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Mar-13,https://ClinicalTrials.gov/show/NCT00607373
1015,A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea,Completed,Has Results,Rosacea,Drug: Generic Azelaic Acid Foam|Drug: Finacea® (Azelaic Acid) Foam|Drug: Vehicle Foam|Other: Cleanser|Other: Sunscreen|Other: Towel|Other: Moisturizing Lotion,Actavis Inc.,Phase 3,Industry,Interventional,17-Jul-19,https://ClinicalTrials.gov/show/NCT03287791
1016,Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease COPD,Drug: Glycopyrronium/Formoterol Fumarate|Drug: umeclidinium/vilanterol,AstraZeneca|Parexel International Ltd|Cognizant Technology Solution|Center for Information & Study on Clinical Research Participation (CISCRP)|eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc,Phase 3,Industry|Other,Interventional,22-May-19,https://ClinicalTrials.gov/show/NCT03162055
1017,A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%","Dermira, Inc.",Phase 3,Industry,Interventional,5-Feb-19,https://ClinicalTrials.gov/show/NCT03127956
1018,Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX,Gilead Sciences,Phase 3,Industry,Interventional,3-Apr-19,https://ClinicalTrials.gov/show/NCT03118843
1019,Study of Mepolizumab Autoinjector in Asthmatics,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,Phase 3,Industry,Interventional,29-Jun-18,https://ClinicalTrials.gov/show/NCT03099096
1020,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%|Other: Olumacostat Glasaretil Gel, Vehicle","Dermira, Inc.",Phase 3,Industry,Interventional,5-Feb-19,https://ClinicalTrials.gov/show/NCT03073486
1021,A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment,Completed,Has Results,Hepatitis C Virus (HCV),Drug: Glecaprevir/pibrentasvir,AbbVie,Phase 3,Industry,Interventional,4-Mar-19,https://ClinicalTrials.gov/show/NCT03069365
1022,A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,"Drug: Olumacostat Glasaretil Gel, 5.0%|Other: Olumacostat Glasaretil Gel, Vehicle","Dermira, Inc.",Phase 3,Industry,Interventional,5-Feb-19,https://ClinicalTrials.gov/show/NCT03028363
1023,"A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",Completed,Has Results,Bowel Preparation,"Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder",Ferring Pharmaceuticals,Phase 3,Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT03017235
1024,"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",Completed,Has Results,"Infections, Meningococcal","Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)",GlaxoSmithKline,Phase 3,Industry,Interventional,3-Aug-18,https://ClinicalTrials.gov/show/NCT02986854
1025,Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis,Completed,Has Results,"Arthritis, Rheumatoid; Arthritis, Psoriatic",Drug: Commercial Formulation Etanercept|Drug: New Formulation Etanercept,Amgen,Phase 3,Industry,Interventional,31-Oct-18,https://ClinicalTrials.gov/show/NCT02986139
1026,"Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age",Completed,Has Results,Herpes Zoster,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A),GlaxoSmithKline,Phase 3,Industry,Interventional,16-Oct-18,https://ClinicalTrials.gov/show/NCT02979639
1027,A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma,Completed,Has Results,Asthma,Drug: Albuterol Sulfate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,3-May-19,https://ClinicalTrials.gov/show/NCT02969408
1028,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,10-Jul-19,https://ClinicalTrials.gov/show/NCT02964247
1029,"Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",Completed,Has Results,Actinic Keratosis,"Drug: GDC 695|Drug: Diclofenac Sodium Gel, 3%|Drug: Vehicle gel","Gage Development Company, LLC",Phase 3,Industry,Interventional,10-Jan-19,https://ClinicalTrials.gov/show/NCT02952898
1030,A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C),Completed,Has Results,Postpartum Depression,Drug: Placebo|Drug: SAGE-547 90 μg/kg/h,Sage Therapeutics,Phase 3,Industry,Interventional,13-Jun-19,https://ClinicalTrials.gov/show/NCT02942017
1031,A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B),Completed,Has Results,Postpartum Depression,Drug: Placebo|Drug: SAGE-547 60 μg/kg/h|Drug: SAGE-547 90 μg/kg/h,Sage Therapeutics,Phase 3,Industry,Interventional,13-Jun-19,https://ClinicalTrials.gov/show/NCT02942004
1032,"Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home",Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,Phase 3,Industry,Interventional,2-Nov-18,https://ClinicalTrials.gov/show/NCT02918071
1033,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.,Completed,Has Results,"Influenza, Human",Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine|Biological: Comparator Quadrivalent Inactivated Influenza Vaccine,Seqirus,Phase 3,Industry,Interventional,23-Jan-19,https://ClinicalTrials.gov/show/NCT02914275
1034,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/insulin aspart|Drug: Insulin glargine|Drug: Insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,28-Sep-18,https://ClinicalTrials.gov/show/NCT02906917
1035,Open-Label Treatment Extension Study,Completed,Has Results,Opioid Use Disorder|Opioid-related Disorders,Drug: RBP-6000,Indivior Inc.,Phase 3,Industry,Interventional,2-Nov-18,https://ClinicalTrials.gov/show/NCT02896296
1036,A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Tazarotene Cream 0.1%|Drug: Tazorac®|Drug: Placebo,Fougera Pharmaceuticals Inc.,Phase 3,Industry,Interventional,17-Aug-18,https://ClinicalTrials.gov/show/NCT02886715
1037,A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Tazarotene Cream 0.05%|Drug: TAZORAC® (tazarotene) Cream 0.05%|Drug: Placebo,Fougera Pharmaceuticals Inc.,Phase 3,Industry,Interventional,29-Aug-18,https://ClinicalTrials.gov/show/NCT02886702
1038,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,Completed,Has Results,Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: Omadacycline|Drug: Linezolid,Paratek Pharmaceuticals Inc,Phase 3,Industry,Interventional,30-Nov-18,https://ClinicalTrials.gov/show/NCT02877927
1039,Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis (SAR),Drug: GSP 301 NS|Drug: GOM-NS|Drug: GMM-2 NS|Drug: GSP 301 placebo NS,Glenmark Specialty S.A.,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02870205
1040,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Allergan,Phase 3,Industry,Interventional,29-Jan-19,https://ClinicalTrials.gov/show/NCT02867709
1041,"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: BI 695501|Drug: Humira,Boehringer Ingelheim,Phase 3,Industry,Interventional,8-Feb-19,https://ClinicalTrials.gov/show/NCT02850965
1042,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",Completed,Has Results,Avian Influenza,Biological: aH5N1c|Biological: Placebo,Seqirus|Biomedical Advanced Research and Development Authority,Phase 3,Industry|U.S. Fed,Interventional,4-Apr-19,https://ClinicalTrials.gov/show/NCT02839330
1043,Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis,Completed,Has Results,Psoriasis,Drug: Guselkumab|Drug: Placebo,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,6-Sep-18,https://ClinicalTrials.gov/show/NCT02905331
1044,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Allergan,Phase 3,Industry,Interventional,3-Jan-19,https://ClinicalTrials.gov/show/NCT02828020
1045,Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Secukinumab|Drug: Ustekinumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT02826603
1046,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,24-Jul-18,https://ClinicalTrials.gov/show/NCT02825251
1047,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Completed,Has Results,Asthma,Drug: Benralizumab|Drug: Benralizumab Placebo|Drug: Seasonal influenza virus vaccine,AstraZeneca,Phase 3,Industry,Interventional,1-Mar-18,https://ClinicalTrials.gov/show/NCT02814643
1048,Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Nintedanib|Drug: Placebo|Drug: Sildenafil,Boehringer Ingelheim,Phase 3,Industry,Interventional,11-Jan-19,https://ClinicalTrials.gov/show/NCT02802345
1049,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",Completed,Has Results,Cystic Fibrosis,Drug: LUM/IVA,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT02797132
1050,AMPLIFY - D6571C00001 Duaklir USA Phase III Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,"Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Drug: Aclidinium bromide 400 μg (AB 400 μg)|Drug: Formoterol fumarate 12 μg (FF 12 μg)|Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Drug: Tiotropium 18 μg (TIO 18 μg)|Other: Placebo to TIO 18 μg",AstraZeneca,Phase 3,Industry,Interventional,9-Nov-18,https://ClinicalTrials.gov/show/NCT02796677
1051,Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain,Completed,Has Results,Post Surgical Ocular Inflammation and Pain,Drug: KPI-121 1% Ophthalmic Suspension dosed BID|Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID,"Kala Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,17-Apr-19,https://ClinicalTrials.gov/show/NCT02793817
1052,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370),Completed,Has Results,Colorectal Cancer,"Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Drug: Cobimetinib|Drug: Regorafenib",Hoffmann-La Roche,Phase 3,Industry,Interventional,18-Jun-19,https://ClinicalTrials.gov/show/NCT02788279
1053,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Insulin glargine/lixisenatide fixed ratio combination|Drug: liraglutide|Drug: exenatide|Drug: exenatide extended-release|Drug: albiglutide|Drug: dulaglutide|Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",Sanofi,Phase 3,Industry,Interventional,12-Jun-19,https://ClinicalTrials.gov/show/NCT02787551
1054,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,23-Oct-18,https://ClinicalTrials.gov/show/NCT02773368
1055,Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients,Completed,Has Results,Hepatitis C,Drug: Alisporivir,Debiopharm International SA,Phase 3,Industry,Interventional,26-Aug-16,https://ClinicalTrials.gov/show/NCT02753699
1056,Study of Secukinumab With 2 mL Pre-filled Syringes,Completed,Has Results,Psoriasis,Drug: Placebo|Drug: Secukinumab 2 mL form|Drug: Secukinumab 1 mL form,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,26-Jun-19,https://ClinicalTrials.gov/show/NCT02748863
1057,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310),Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.",Phase 3,Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT02742441
1058,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,Completed,Has Results,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Biological: Evolocumab|Drug: Placebo to Evolocumab,Amgen,Phase 3,Industry,Interventional,31-Aug-18,https://ClinicalTrials.gov/show/NCT02739984
1059,Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: Valbenazine,Neurocrine Biosciences,Phase 3,Industry,Interventional,19-Dec-18,https://ClinicalTrials.gov/show/NCT02736955
1060,SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis,Completed,Has Results,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Drug: Liprotamase Powder for Oral Solution,Anthera Pharmaceuticals,Phase 3,Industry,Interventional,11-May-18,https://ClinicalTrials.gov/show/NCT02734810
1061,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,"Drug: Insulin glargine,300 U/mL|Drug: Insulin glargine (100 units /mL)|Drug: Background therapy",Sanofi,Phase 3,Industry,Interventional,19-Jun-19,https://ClinicalTrials.gov/show/NCT02735044
1062,A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis,Completed,Has Results,Genital Psoriasis|Psoriasis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,23-Mar-18,https://ClinicalTrials.gov/show/NCT02718898
1063,Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR),Completed,Has Results,Perennial Allergic Rhinitis,Drug: GSP 301 NS|Drug: GSP 301 Placebo NS pH 3.7|Drug: GSP 301 Placebo NS pH 7.0,Glenmark Specialty S.A.,Phase 3,Industry,Interventional,13-Sep-18,https://ClinicalTrials.gov/show/NCT02709538
1064,"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment",Completed,Has Results,HIV-1 Infection|HCV Infection,Drug: E/C/F/TAF|Drug: F/R/TAF|Drug: LDV/SOF,Gilead Sciences,Phase 3,Industry,Interventional,9-Oct-18,https://ClinicalTrials.gov/show/NCT02707601
1065,Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee,Completed,Has Results,"Osteoarthritis, Knee|Osteoarthritis, Hip",Other: Placebo|Biological: Tanezumab 2.5 mg|Biological: Tanezumab 2.5mg/5mg,Pfizer,Phase 3,Industry,Interventional,23-Apr-19,https://ClinicalTrials.gov/show/NCT02697773
1066,A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA),Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol|Drug: FCM,"AMAG Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,11-Jun-18,https://ClinicalTrials.gov/show/NCT02694978
1067,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lyophilized albiglutide DCC pen injector|Drug: Lyophilized albiglutide DCC pen injector matching placebo|Drug: Albiglutide liquid auto-injector|Drug: Albiglutide liquid auto-injector matching placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,30-May-18,https://ClinicalTrials.gov/show/NCT02683746
1068,Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition,Completed,Has Results,Short Bowel Syndrome,Drug: Teduglutide 0.05mg/kg|Drug: Teduglutide 0.025 mg/kg|Other: Standard of Care,Shire,Phase 3,Industry,Interventional,16-Oct-18,https://ClinicalTrials.gov/show/NCT02682381
1069,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo for Dapagliflozin|Drug: Saxagliptin|Drug: Placebo for Saxagliptin,AstraZeneca,Phase 3,Industry,Interventional,10-Oct-18,https://ClinicalTrials.gov/show/NCT02681094
1070,A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection,Completed,Has Results,Hepatitis C,Drug: DCV|Drug: SOF|Drug: RBV,Bristol-Myers Squibb,Phase 3,Industry,Interventional,29-Mar-18,https://ClinicalTrials.gov/show/NCT02673489
1071,Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL,Completed,Has Results,Opioid Use Disorder,Drug: Naltrexone|Drug: Placebo|Drug: Buprenorphine,"Alkermes, Inc.",Phase 3,Industry,Interventional,12-Feb-19,https://ClinicalTrials.gov/show/NCT02696434
1072,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,Phase 3,Industry,Interventional,4-Apr-19,https://ClinicalTrials.gov/show/NCT02670915
1073,"Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression",Completed,Has Results,Bipolar Disorder|Depression,Drug: Cariprazine|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,30-Jan-19,https://ClinicalTrials.gov/show/NCT02670551
1074,Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder,Completed,Has Results,Bipolar Disorder|Depression,Drug: Cariprazine|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,5-Feb-19,https://ClinicalTrials.gov/show/NCT02670538
1075,A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: ALKS 3831,"Alkermes, Inc.",Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT02669758
1076,Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg,Completed,Has Results,Moderate-to-severe Acute Pain,Drug: Zalviso™ 15 mcg,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT02662764
1077,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,Completed,Has Results,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Biological: Evolocumab|Drug: Atorvastatin|Other: Placebo,Amgen,Phase 3,Industry,Interventional,11-Jan-19,https://ClinicalTrials.gov/show/NCT02662569
1078,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",Completed,Has Results,HIV-1 Infection,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: ATV|Drug: RTV|Drug: FTC/TDF|Drug: B/F/TAF,Gilead Sciences,Phase 3,Industry,Interventional,2-Nov-18,https://ClinicalTrials.gov/show/NCT02652624
1079,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,Phase 3,Industry,Interventional,8-May-18,https://ClinicalTrials.gov/show/NCT02648204
1080,Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Drug: BI 695501,Boehringer Ingelheim,Phase 3,Industry,Interventional,5-Dec-18,https://ClinicalTrials.gov/show/NCT02640612
1081,Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Phase 3,Industry,Interventional,14-Nov-17,https://ClinicalTrials.gov/show/NCT02639338
1082,Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Phase 3,Industry,Interventional,6-Nov-17,https://ClinicalTrials.gov/show/NCT02639247
1083,Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: GP2015,Sandoz,Phase 3,Industry,Interventional,23-Feb-18,https://ClinicalTrials.gov/show/NCT02638259
1084,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: DFD06 Cream|Drug: Vehicle Cream,"Promius Pharma, LLC",Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT02635204
1085,A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study),Completed,Has Results,Schizophrenia,Drug: ALK3831|Drug: Olanzapine|Drug: Placebo,"Alkermes, Inc.",Phase 3,Industry,Interventional,27-Jun-18,https://ClinicalTrials.gov/show/NCT02634346
1086,Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: GSP 301 NS|Drug: Olopatadine HCl NS|Drug: Mometasone furoate NS|Drug: GSP 301 Placebo NS,Glenmark Specialty S.A.,Phase 3,Industry,Interventional,15-Aug-18,https://ClinicalTrials.gov/show/NCT02631551
1087,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,8-Nov-18,https://ClinicalTrials.gov/show/NCT02629861
1088,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,6-Dec-18,https://ClinicalTrials.gov/show/NCT02621931
1089,"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis",Completed,Has Results,Actinic Keratosis,Drug: Generic Fluorouracil Cream|Drug: Carac® (Fluorouracil) Cream|Drug: Vehicle Cream,Actavis Inc.,Phase 3,Industry,Interventional,17-Jul-19,https://ClinicalTrials.gov/show/NCT02616601
1090,Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,7-Jan-19,https://ClinicalTrials.gov/show/NCT02614196
1091,Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,29-Nov-18,https://ClinicalTrials.gov/show/NCT02614183
1092,"A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura",Completed,Has Results,Migraine,Drug: Galcanezumab,Eli Lilly and Company,Phase 3,Industry,Interventional,7-Jan-19,https://ClinicalTrials.gov/show/NCT02614287
1093,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy,Completed,Has Results,Hepatitis C,Drug: SOF/VEL/VOX|Drug: SOF/VEL,Gilead Sciences,Phase 3,Industry,Interventional,8-Nov-17,https://ClinicalTrials.gov/show/NCT02607800
1094,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy,Completed,Has Results,Hepatitis C,Drug: SOF/VEL/VOX|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,13-Dec-17,https://ClinicalTrials.gov/show/NCT02607735
1095,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,Completed,Has Results,Skin Structures and Soft Tissue Infections,Drug: Iclaprim|Drug: Vancomycin,Motif Bio,Phase 3,Industry,Interventional,11-Jul-18,https://ClinicalTrials.gov/show/NCT02607618
1096,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,Completed,Has Results,HIV-1 Infection,Drug: E/C/F/TAF|Drug: ABC/3TC|Drug: Third Antiretroviral Agent,Gilead Sciences,Phase 3,Industry,Interventional,13-Jul-18,https://ClinicalTrials.gov/show/NCT02605954
1097,Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),"Drug: SHP465 12.5mg capsules (one capsule daily)|Other: Placebo|Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)",Shire,Phase 3,Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT02604407
1098,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1,Completed,Has Results,Skin Structures and Soft Tissue Infections,Drug: iclaprim|Drug: vancomycin,Motif Bio,Phase 3,Industry,Interventional,19-Jun-18,https://ClinicalTrials.gov/show/NCT02600611
1099,"To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).",Completed,Has Results,Osteoarthritis,"Drug: Diclofenac Sodium gel, 1%|Drug: Voltaren® Gel|Drug: Placebo",Glenmark Pharmaceuticals Ltd. India,Phase 3,Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT02596451
1100,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dulaglutide|Drug: Placebo|Drug: SGLT2 inhibitor|Drug: Metformin,Eli Lilly and Company,Phase 3,Industry,Interventional,27-Apr-18,https://ClinicalTrials.gov/show/NCT02597049
1101,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,Completed,Has Results,Alzheimer's Disease,Drug: RVT-101|Drug: Placebo,Axovant Sciences Ltd.,Phase 3,Industry,Interventional,5-Dec-18,https://ClinicalTrials.gov/show/NCT02585934
1102,Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema (HAE),Drug: C1 esterase inhibitor [human] liquid|Drug: Placebo,Shire,Phase 3,Industry,Interventional,28-Nov-18,https://ClinicalTrials.gov/show/NCT02584959
1103,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier,Completed,Has Results,Herpes Zoster,Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A),GlaxoSmithKline,Phase 3,Industry,Interventional,26-Sep-17,https://ClinicalTrials.gov/show/NCT02581410
1104,Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis,Completed,Has Results,Chronic Plaque Psoriasis|Psoriasis,Biological: M923|Biological: Humira,"Momenta Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,12-Sep-18,https://ClinicalTrials.gov/show/NCT02581345
1105,"An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203",Completed,Has Results,Sporadic Inclusion Body Myositis,Drug: Bimagrumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT02573467
1106,DFN-11 Injection in Episodic Migraine With or Without Aura,Completed,Has Results,Episodic Migraine,Drug: DFN-11|Other: Placebo,Dr. Reddy's Laboratories Limited,Phase 3,Industry,Interventional,25-Jul-18,https://ClinicalTrials.gov/show/NCT02569853
1107,Usability of an AI for M923 in Subjects With Moderate to Severe RA,Completed,Has Results,Rheumatoid Arthritis,Biological: M923|Device: Autoinjector,"Momenta Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,1-May-18,https://ClinicalTrials.gov/show/NCT02722044
1108,Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,Drug: Glycopyrronium Topical Wipes,"Dermira, Inc.",Phase 3,Industry,Interventional,25-Sep-18,https://ClinicalTrials.gov/show/NCT02553798
1109,Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura,Completed,Has Results,Acquired Thrombotic Thrombocytopenic Purpura,Biological: Caplacizumab|Biological: Placebo,Ablynx,Phase 3,Industry,Interventional,22-May-19,https://ClinicalTrials.gov/show/NCT02553317
1110,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Saxagliptin, Onglyza|Drug: Dapagliflozin, Farxiga|Drug: Glargine insulin|Drug: Metformin",AstraZeneca,Phase 3,Industry,Interventional,18-Sep-18,https://ClinicalTrials.gov/show/NCT02551874
1111,A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age,Completed,Has Results,"Influenza, Human",Biological: Seqirus QIV|Biological: Comparator QIV,Seqirus,Phase 3,Industry,Interventional,18-Apr-17,https://ClinicalTrials.gov/show/NCT02545543
1112,A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.,Completed,Has Results,Dry Eye Syndromes,Drug: Carboxymethylcellulose Based Eye Drop|Drug: Carboxymethylcellulose Sodium 0.5%,Allergan,Phase 3,Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT02553772
1113,Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery,Completed,Has Results,Cataract,Drug: Dexamethasone|Drug: Prednisolone,ICON Bioscience Inc,Phase 3,Industry,Interventional,19-Jun-18,https://ClinicalTrials.gov/show/NCT02547623
1114,Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension),Completed,Has Results,Opioid Use Disorder,Drug: NTX/BUP|Drug: NTX/PBO-B|Drug: PBO-N/PBO-B,"Alkermes, Inc.",Phase 3,Industry,Interventional,9-Jan-19,https://ClinicalTrials.gov/show/NCT02537574
1115,A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection,Completed,Has Results,Hepatitis C Virus (HCV),Drug: Glecaprevir/Pibrentasvir,AbbVie,Phase 3,Industry,Interventional,10-Jul-19,https://ClinicalTrials.gov/show/NCT02966795
1116,Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis,Completed,Has Results,Hyperhidrosis,Drug: glycopyrronium Topical Wipes|Other: Vehicle,"Dermira, Inc.",Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT02530294
1117,Study of Glycopyrronium in Axillary Hyperhydrosis,Completed,Has Results,Hyperhidrosis,Drug: glycopyrronium Topical Wipes|Other: Vehicle,"Dermira, Inc.",Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT02530281
1118,Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13),Completed,Has Results,Bacterial Pneumonia|Community-Acquired Infections,Drug: Omadacycline|Drug: Moxifloxacin,Paratek Pharmaceuticals Inc,Phase 3,Industry,Interventional,29-Nov-18,https://ClinicalTrials.gov/show/NCT02531438
1119,Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Drug: dimethyl fumarate,Biogen,Phase 3,Industry,Interventional,27-Jun-19,https://ClinicalTrials.gov/show/NCT02525874
1120,Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection,Completed,Has Results,Helicobacter Pylori Infection,Device: Dual Mode BreathID Hp System,Exalenz Bioscience LTD.,Phase 3,Industry,Interventional,3-Mar-17,https://ClinicalTrials.gov/show/NCT02528721
1121,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-661 plus ivacaftor combination|Drug: Ivacaftor|Drug: Placebo (matched to VX-661 plus ivacaftor combination)|Drug: Placebo (matched to ivacaftor),Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,12-Jun-18,https://ClinicalTrials.gov/show/NCT02516410
1122,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-809|Drug: Placebo|Drug: VX-770,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,23-Oct-17,https://ClinicalTrials.gov/show/NCT02514473
1123,A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Pro-netupitant/Palonosetron|Drug: Netupitant/Palonosetron|Drug: Dexamethasone,Helsinn Healthcare SA|The Physicians' Services Incorporated Foundation,Phase 3,Industry|Other,Interventional,20-Jun-18,https://ClinicalTrials.gov/show/NCT02517021
1124,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Ixekizumab|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,18-Apr-18,https://ClinicalTrials.gov/show/NCT02513550
1125,Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Beclomethasone Dipropionate 640|Drug: Placebo|Drug: Beclomethasone dipropionate via 320 mcg BAI|Drug: albuterol/salbutamol|Drug: Beclomethasone dipropionate via 320 mcg MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,11-Sep-17,https://ClinicalTrials.gov/show/NCT02513160
1126,Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder,Completed,Has Results,Opioid Use Disorder|Opioid-related Disorders,Drug: SUBOXONE sublingual film|Drug: RBP-6000,Indivior Inc.,Phase 3,Industry,Interventional,29-Mar-18,https://ClinicalTrials.gov/show/NCT02510014
1127,Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Phase 3,Industry,Interventional,30-Mar-18,https://ClinicalTrials.gov/show/NCT02504541
1128,An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils,Completed,Has Results,Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence,Drug: Reslizumab|Drug: Placebo|Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication|Drug: Oral Corticosteroid (OCS),"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,13-Sep-18,https://ClinicalTrials.gov/show/NCT02501629
1129,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,Phase 3,Industry,Interventional,10-Aug-18,https://ClinicalTrials.gov/show/NCT02500706
1130,"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine (Intranasal Spray)|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral Antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,29-Apr-19,https://ClinicalTrials.gov/show/NCT02497287
1131,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,Completed,Has Results,"Depressive Disorder, Treatment-Resistant",Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,21-May-19,https://ClinicalTrials.gov/show/NCT02493868
1132,Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C),Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,14-Jun-19,https://ClinicalTrials.gov/show/NCT02493452
1133,Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: Umeclidinium/vilanterol|Drug: Placebo (umeclidinium/vilanterol )|Drug: Placebo (QVA149),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,2-Apr-18,https://ClinicalTrials.gov/show/NCT02487498
1134,Efficacy and Safety Study of QVA149 in COPD Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: Umeclidinium/vilanterol|Drug: Placebo (umeclidinium/vilanterol)|Drug: Placebo (QVA149),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,26-Dec-17,https://ClinicalTrials.gov/show/NCT02487446
1135,Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma,Completed,Has Results,Asthma,Drug: FF|Drug: Placebo|Drug: Montelukast|Drug: Albuterol/Salbutamol,GlaxoSmithKline,Phase 3,Industry,Interventional,8-Mar-17,https://ClinicalTrials.gov/show/NCT02483975
1136,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,25-Jun-18,https://ClinicalTrials.gov/show/NCT02483585
1137,A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).,Completed,Has Results,Rheumatoid Arthritis,Biological: PF-06410293|Biological: Adalimumab,Pfizer,Phase 3,Industry,Interventional,26-Sep-17,https://ClinicalTrials.gov/show/NCT02480153
1138,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Phase 3,Industry,Interventional,1-Jun-17,https://ClinicalTrials.gov/show/NCT02480712
1139,"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus",Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: IPP-201101|Drug: Placebo|Other: Standard of Care,ImmuPharma,Phase 3,Industry,Interventional,11-Apr-19,https://ClinicalTrials.gov/show/NCT02504645
1140,A Study With SAGE-547 for Super-Refractory Status Epilepticus,Completed,Has Results,Super-Refractory Status Epilepticus,Drug: SAGE-547|Drug: Placebo,Sage Therapeutics,Phase 3,Industry,Interventional,2-May-19,https://ClinicalTrials.gov/show/NCT02477618
1141,"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat",Completed,Has Results,Smallpox,Drug: tecovirimat|Other: Placebo,SIGA Technologies|Biomedical Advanced Research and Development Authority,Phase 3,Industry|U.S. Fed,Interventional,28-Nov-17,https://ClinicalTrials.gov/show/NCT02474589
1142,Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Selexipag,Actelion,Phase 3,Industry,Interventional,28-Dec-17,https://ClinicalTrials.gov/show/NCT02471183
1143,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,Completed,Has Results,HIV-1 Infection,Drug: F/TAF|Drug: ABC/3TC|Drug: ABC/3TC Placebo|Drug: F/TAF Placebo|Drug: Third ARV agent,Gilead Sciences,Phase 3,Industry,Interventional,11-Jun-18,https://ClinicalTrials.gov/show/NCT02469246
1144,Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: SHP465|Drug: Placebo,Shire,Phase 3,Industry,Interventional,20-Mar-17,https://ClinicalTrials.gov/show/NCT02466425
1145,"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.",Completed,Has Results,Acne Vulgaris,"Drug: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Drug: BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|Drug: Placebo",Glenmark Pharmaceuticals Ltd. India,Phase 3,Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT02465632
1146,"Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia",Completed,Has Results,Hyperlipidemia,Biological: Bococizumab 150mg|Biological: Bococizumab 75mg|Biological: Bococizumab 150mg placebo|Biological: Bococizumab 75mg placebo,Pfizer,Phase 3,Industry,Interventional,19-Dec-17,https://ClinicalTrials.gov/show/NCT02458287
1147,Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy,Completed,Has Results,Seizures,Drug: Retigabine|Drug: Placebo,"GlaxoSmithKline|Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,7-Nov-11,https://ClinicalTrials.gov/show/NCT00235755
1148,The EVICEL® Neurosurgery Phase III Study,Completed,Has Results,Cerebrospinal Fluid Leak,Biological: EVICEL Fibrin Sealant|Device: Hydrogel sealant,"Ethicon, Inc.",Phase 3,Industry,Interventional,4-Dec-18,https://ClinicalTrials.gov/show/NCT02457546
1149,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,10-Jul-18,https://ClinicalTrials.gov/show/NCT02456740
1150,A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc),Completed,Has Results,Systemic Sclerosis,Drug: Placebo|Drug: Tocilizumab,Hoffmann-La Roche,Phase 3,Industry,Interventional,3-Apr-19,https://ClinicalTrials.gov/show/NCT02453256
1151,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,Completed,Has Results,Chronic Stable Plaque Psoriasis,Drug: DFD06-Cream|Drug: Vehicle Cream,"Promius Pharma, LLC",Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT02445807
1152,Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Vedolizumab,Takeda,Phase 3,Industry,Interventional,14-Sep-18,https://ClinicalTrials.gov/show/NCT02425111
1153,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",Completed,Has Results,"Depressive Disorder, Treatment-Resistant",Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral Antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (New Antidepressant),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,24-Apr-19,https://ClinicalTrials.gov/show/NCT02422186
1154,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,7-Dec-17,https://ClinicalTrials.gov/show/NCT02420262
1155,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,18-Apr-19,https://ClinicalTrials.gov/show/NCT02417064
1156,"Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home",Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT02417961
1157,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 mg|Drug: Matching Placebo for Dapagliflozin,AstraZeneca,Phase 3,Industry,Interventional,31-Oct-18,https://ClinicalTrials.gov/show/NCT02413398
1158,"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Tezacaftor/Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,8-Jan-19,https://ClinicalTrials.gov/show/NCT02412111
1159,Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Dexamethasone,Amgen,Phase 3,Industry,Interventional,13-Dec-18,https://ClinicalTrials.gov/show/NCT02412878
1160,"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",Completed,Has Results,Treatment-resistant Depression,Drug: Esketamine|Drug: Placebo|Drug: Duloxetine (Oral Antidepressant)|Drug: Escitalopram (Oral antidepressant)|Drug: Sertraline (Oral Antidepressant)|Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,19-Apr-19,https://ClinicalTrials.gov/show/NCT02418585
1161,Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854,Neurocrine Biosciences,Phase 3,Industry,Interventional,30-Nov-18,https://ClinicalTrials.gov/show/NCT02405091
1162,"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients",Completed,Has Results,"Arthritis, Rheumatoid",Drug: FKB327|Drug: Humira®,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Phase 3,Industry,Interventional,26-Mar-19,https://ClinicalTrials.gov/show/NCT02405780
1163,"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis",Completed,Has Results,Psoriatic Arthritis,Biological: Secukinumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,28-Jun-19,https://ClinicalTrials.gov/show/NCT02404350
1164,Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment,Completed,Has Results,Major Depression Disorder,Drug: Adjunct brexpiprazole|Drug: ADT,H. Lundbeck A/S,Phase 3,Industry,Interventional,26-Jun-17,https://ClinicalTrials.gov/show/NCT02400346
1165,A Study Of Galcanezumab In Participants With Episodic Cluster Headache,Completed,Has Results,Episodic Cluster Headache,Drug: Galcanezumab|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,13-Mar-19,https://ClinicalTrials.gov/show/NCT02397473
1166,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Completed,Has Results,Cystic Fibrosis,Drug: VX-661/Ivacaftor|Drug: Ivacaftor|Drug: Placebo matched to VX-661/ ivacaftor|Drug: Placebo matched to Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,12-Jun-18,https://ClinicalTrials.gov/show/NCT02392234
1167,The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C),Completed,Has Results,Irritable Bowel Syndrome Characterized by Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,14-Jun-19,https://ClinicalTrials.gov/show/NCT02387359
1168,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infections|Complicated Appendicitis,Drug: Eravacycline|Drug: Meropenem|Drug: Placebo,"Tetraphase Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,18-Feb-19,https://ClinicalTrials.gov/show/NCT02784704
1169,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),Completed,Has Results,Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: Omadacycline|Drug: Linezolid,Paratek Pharmaceuticals Inc,Phase 3,Industry,Interventional,21-Mar-19,https://ClinicalTrials.gov/show/NCT02378480
1170,Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Etanercept|Drug: Methotrexate|Drug: Placebo to Etanercept|Drug: Placebo to Methotrexate,Amgen,Phase 3,Industry,Interventional,22-Feb-19,https://ClinicalTrials.gov/show/NCT02376790
1171,RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity,Completed,Has Results,Retinopathy of Prematurity,Drug: Ranibizumab|Procedure: Laser therapy,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,31-Jul-18,https://ClinicalTrials.gov/show/NCT02375971
1172,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Bevacizumab-Pfizer|Drug: Bevacizumab-EU|Drug: Paclitaxel|Drug: Carboplatin,Pfizer,Phase 3,Industry,Interventional,27-Jun-18,https://ClinicalTrials.gov/show/NCT02364999
1173,SMART-SF Radiofrequency Ablation Safety Study,Completed,Has Results,Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH® (RF ablation treatment),"Biosense Webster, Inc.",Phase 3,Industry,Interventional,17-Oct-17,https://ClinicalTrials.gov/show/NCT02359890
1174,Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine,Completed,Has Results,Opioid Dependence|Opioid Related Disorders,Drug: SUBOXONE|Drug: RBP-6000|Drug: Placebo,Indivior Inc.,Phase 3,Industry,Interventional,20-Feb-18,https://ClinicalTrials.gov/show/NCT02357901
1175,Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Drug: FX006|Drug: Placebo|Drug: TCA IR 40,"Flexion Therapeutics, Inc.",Phase 3,Industry,Interventional,1-Feb-18,https://ClinicalTrials.gov/show/NCT02357459
1176,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301|Other: Observational cohort,Acorda Therapeutics,Phase 3,Industry,Interventional,10-Jul-18,https://ClinicalTrials.gov/show/NCT02352363
1177,"""A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA""",Completed,Has Results,Narcolepsy|Obstructive Sleep Apnea,Drug: JZP-110,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,25-Jun-19,https://ClinicalTrials.gov/show/NCT02348632
1178,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA""",Completed,Has Results,Obstructive Sleep Apnea,Drug: JZP-110|Drug: Placebo oral tablet,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,23-Jul-19,https://ClinicalTrials.gov/show/NCT02348606
1179,"""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy""",Completed,Has Results,Narcolepsy,Drug: JZP-110|Drug: Placebo oral tablet,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,23-Jul-19,https://ClinicalTrials.gov/show/NCT02348593
1180,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4),Completed,Has Results,COPD|Chronic Obstructive Pulmonary Disease,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer|Drug: Placebo eFlow (CS) nebulizer,Sunovion Respiratory Development Inc.,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT02347774
1181,Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD,Completed,Has Results,COPD,Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: SUN-101 25 mcg BID eFlow (CS) nebulizer|Drug: Placebo BID eFlow Closed System (CS) nebulizer,Sunovion Respiratory Development Inc.,Phase 3,Industry,Interventional,22-Mar-18,https://ClinicalTrials.gov/show/NCT02347761
1182,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Completed,Has Results,Cystic Fibrosis,Drug: VX-661 Plus Ivacaftor Combination|Drug: Ivacaftor|Drug: VX-661 Plus Ivacaftor Combination Placebo|Drug: Ivacaftor placebo,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,12-Jun-18,https://ClinicalTrials.gov/show/NCT02347657
1183,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL,Gilead Sciences,Phase 3,Industry,Interventional,3-May-17,https://ClinicalTrials.gov/show/NCT02346721
1184,Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Biological: Etanercept|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 3,Industry,Interventional,18-Jul-18,https://ClinicalTrials.gov/show/NCT02346240
1185,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: FTC/RPV/TDF Placebo|Drug: FTC/RPV/TDF|Drug: FTC/RPV/TAF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,8-Dec-17,https://ClinicalTrials.gov/show/NCT02345252
1186,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults",Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TAF|Drug: EFV/FTC/TDF Placebo|Drug: EFV/FTC/TDF|Drug: FTC/RPV/TAF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,19-Oct-17,https://ClinicalTrials.gov/show/NCT02345226
1187,"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: GFF MDI (PT003)|Drug: FF MDI (PT005)|Drug: GP MDI (PT001)|Drug: Placebo MDI,"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,20-Feb-19,https://ClinicalTrials.gov/show/NCT02343458
1188,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.",Phase 3,Industry,Interventional,27-Sep-18,https://ClinicalTrials.gov/show/NCT02367911
1189,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,Completed,Has Results,"Secondary Hyperparathyroidism, Chronic Kidney Disease",Drug: Cinacalcet,Amgen,Phase 3,Industry,Interventional,18-May-18,https://ClinicalTrials.gov/show/NCT02341417
1190,A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension,Completed,Has Results,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Drug: LJPC-501|Drug: Placebo,La Jolla Pharmaceutical Company,Phase 3,Industry,Interventional,17-Jan-18,https://ClinicalTrials.gov/show/NCT02338843
1191,Phase IIIb Study of APD421 in Combination as PONV Prophylaxis,Completed,Has Results,PONV,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Phase 3,Industry,Interventional,4-Aug-17,https://ClinicalTrials.gov/show/NCT02337062
1192,Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies,Completed,Has Results,Scabies,"Drug: spinosad topical suspension, 0.9%|Other: Placebo",ParaPRO LLC|Concentrics Research,Phase 3,Industry|Other,Interventional,16-Jan-19,https://ClinicalTrials.gov/show/NCT02485704
1193,A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 3,Industry,Interventional,13-Aug-18,https://ClinicalTrials.gov/show/NCT02326272
1194,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,Completed,Has Results,Respiratory Syncytial Virus Infections,Drug: Suptavumab 30 mg/kg|Drug: Placebo Matched to Suptavumab|Drug: Suptavumab 30 mg/kg- 1 Dose|Drug: Suptavumab 30 mg/kg - 2 Doses,Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,6-Nov-18,https://ClinicalTrials.gov/show/NCT02325791
1195,Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,Phase 3,Industry,Interventional,14-Feb-17,https://ClinicalTrials.gov/show/NCT02322775
1196,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Glargine (HOE901 - U300)|Drug: Insulin Glargine (HOE901 - U100)|Drug: Background therapy,Sanofi,Phase 3,Industry,Interventional,11-Jul-17,https://ClinicalTrials.gov/show/NCT02320721
1197,ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC),Completed,Has Results,"Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis",Drug: Revusiran (ALN-TTRSC)|Drug: Sterile Normal Saline (0.9% NaCl),Alnylam Pharmaceuticals,Phase 3,Industry,Interventional,18-Jul-18,https://ClinicalTrials.gov/show/NCT02319005
1198,Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder,Completed,Has Results,Seizures,Drug: Cannabidiol Oral Solution,INSYS Therapeutics Inc,Phase 3,Industry,Interventional,25-Jul-18,https://ClinicalTrials.gov/show/NCT02318602
1199,A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema Types I and II,Biological: C1-esterase inhibitor,CSL Behring,Phase 3,Industry,Interventional,14-Nov-18,https://ClinicalTrials.gov/show/NCT02316353
1200,A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306),Completed,Has Results,Plaque Psoriasis,Drug: 122-0551 Foam|Drug: Vehicle Foam,"Therapeutics, Inc.",Phase 3,Industry,Interventional,26-Nov-18,https://ClinicalTrials.gov/show/NCT02368210
1201,A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis,Completed,Has Results,Pain,Drug: Paracetamol 1000 mg SR tablets|Drug: Paracetamol 665 mg SR tablets|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,7-Apr-17,https://ClinicalTrials.gov/show/NCT02311881
1202,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,16-Feb-18,https://ClinicalTrials.gov/show/NCT02305381
1203,Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab,Amgen,Phase 3,Industry,Interventional,19-Mar-19,https://ClinicalTrials.gov/show/NCT02304484
1204,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",Completed,Has Results,Asthma,Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|Drug: Placebo inhalation powders via ELLIPTA inhaler|Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler,GlaxoSmithKline,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT02301975
1205,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide,Novo Nordisk A/S,Phase 3,Industry,Interventional,23-May-17,https://ClinicalTrials.gov/show/NCT02298192
1206,Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: olodaterol|Drug: tiotropium,Boehringer Ingelheim,Phase 3,Industry,Interventional,4-Jun-18,https://ClinicalTrials.gov/show/NCT02296138
1207,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: SAR342434|Drug: Humalog|Drug: insulin glargine HOE901,Sanofi,Phase 3,Industry,Interventional,18-Jan-18,https://ClinicalTrials.gov/show/NCT02294474
1208,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis",Completed,Has Results,"Arthritis, Psoriatic",Biological: Secukinumab|Other: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,2-Jul-19,https://ClinicalTrials.gov/show/NCT02294227
1209,Actual Use Trial of Ibuprofen 400 mg,Completed,Has Results,Patient Compliance,Drug: Ibuprofen 400 mg caplet,Pfizer,Phase 3,Industry,Interventional,30-May-16,https://ClinicalTrials.gov/show/NCT02294019
1210,Addressing Involuntary Movements in Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: SD-809|Drug: Placebo,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,11-Apr-18,https://ClinicalTrials.gov/show/NCT02291861
1211,S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps,Completed,Has Results,Chronic Sinusitis|Nasal Polyposis,Drug: S8 Sinus Implant|Drug: Mometasone furoate nasal spray|Procedure: Sham,Intersect ENT,Phase 3,Industry,Interventional,9-Jul-18,https://ClinicalTrials.gov/show/NCT02291549
1212,A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA),Completed,Has Results,Spinal Muscular Atrophy,Drug: Nusinersen|Procedure: Sham procedure,Biogen,Phase 3,Industry,Interventional,21-Feb-18,https://ClinicalTrials.gov/show/NCT02292537
1213,Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age,Completed,Has Results,Influenza,Biological: Flublok Quadrivalent Influenza Vaccine|Biological: Inactivated Influenza Vaccine,Protein Sciences Corporation,Phase 3,Industry,Interventional,4-Oct-16,https://ClinicalTrials.gov/show/NCT02285998
1214,Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Sitagliptin|Drug: Placebo matching with Saxagliptin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Sitagliptin,AstraZeneca,Phase 3,Industry,Interventional,1-Jun-18,https://ClinicalTrials.gov/show/NCT02284893
1215,A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3),Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Phase 3,Industry,Interventional,15-Mar-17,https://ClinicalTrials.gov/show/NCT02284516
1216,Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery,Completed,Has Results,Von Willebrand Disease,Biological: Recombinant von Willebrand Factor (rVWF),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,31-Aug-17,https://ClinicalTrials.gov/show/NCT02283268
1217,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries,Completed,Has Results,Acute Blunt Soft Tissue Injuries/Contusions,Drug: placebo|Drug: Placebos,Novartis,Phase 3,Industry,Interventional,19-Apr-17,https://ClinicalTrials.gov/show/NCT02290821
1218,Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age,Completed,Has Results,Influenza,Biological: Flublok Quadrivalent|Biological: Inactivated Influenza Vaccine (IIV4),Protein Sciences Corporation|Syneos Health|Department of Health and Human Services,Phase 3,Industry|Other|U.S. Fed,Interventional,22-Sep-16,https://ClinicalTrials.gov/show/NCT02290509
1219,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control,Completed,Has Results,Asthma,Biological: Mepolizumab|Drug: Placebo|Drug: SOC,GlaxoSmithKline,Phase 3,Industry,Interventional,4-May-17,https://ClinicalTrials.gov/show/NCT02281318
1220,Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma,Completed,Has Results,Asthma,Biological: Tralokinumab|Other: Placebo,AstraZeneca,Phase 3,Industry,Interventional,16-May-18,https://ClinicalTrials.gov/show/NCT02281357
1221,SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis,Completed,Has Results,Exocrine Pancreatic Insufficiency|Cystic Fibrosis,Drug: Liprotamase|Drug: porcine (pig) PERT,Anthera Pharmaceuticals,Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT02279498
1222,DFN-02 Open Label Safety Study in Patients With Acute Migraine,Completed,Has Results,Acute Migraine,Drug: DFN-02,Dr. Reddy's Laboratories Limited,Phase 3,Industry,Interventional,28-Aug-17,https://ClinicalTrials.gov/show/NCT02279082
1223,A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: SUN-101 50 mcg BID eFlow (CS) nebulizer|Drug: Spiriva® 18 mcg QD Handihaler,Sunovion Respiratory Development Inc.,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT02276222
1224,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,Completed,Has Results,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),Drug: ADS-5102|Other: Placebo,"Adamas Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,10-Jan-18,https://ClinicalTrials.gov/show/NCT02274766
1225,A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: NBI-98854|Drug: Placebo,Neurocrine Biosciences,Phase 3,Industry,Interventional,11-Jul-17,https://ClinicalTrials.gov/show/NCT02274558
1226,Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: SAR342434|Drug: Humalog|Drug: Insulin glargine HOE901,Sanofi,Phase 3,Industry,Interventional,18-Jan-18,https://ClinicalTrials.gov/show/NCT02273180
1227,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,Completed,Has Results,Post-Ischemic Stroke,Drug: Placebo|Drug: dalfampridine-ER 7.5mg|Drug: dalfampridine-ER 10mg,Acorda Therapeutics,Phase 3,Industry,Interventional,4-Dec-17,https://ClinicalTrials.gov/show/NCT02271217
1228,A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease,Completed,Has Results,Dry Eye Syndromes,Drug: Refresh Optive® Gel Drops|Drug: REFRESH LIQUIGEL®,Allergan,Phase 3,Industry,Interventional,7-Jun-17,https://ClinicalTrials.gov/show/NCT02280473
1229,KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD,Completed,Has Results,Anemia of Chronic Kidney Disease,Drug: ferric citrate|Drug: Placebo,Keryx Biopharmaceuticals,Phase 3,Industry,Interventional,21-Feb-18,https://ClinicalTrials.gov/show/NCT02268994
1230,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: G-Pen (glucagon injection)|Drug: Lilly Glucagon (glucagon injection [rDNA origin]),Xeris Pharmaceuticals,Phase 3,Industry,Interventional,28-Sep-18,https://ClinicalTrials.gov/show/NCT02656069
1231,Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis,Completed,Has Results,Chronic Scalp Psoriasis,Biological: Secukinumab 300 mg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,28-Feb-18,https://ClinicalTrials.gov/show/NCT02267135
1232,An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO),Completed,Has Results,Psoriasis|Plaque Psoriasis,Biological: Certolizumab Pegol|Other: Placebo,UCB Biopharma S.P.R.L.|UCB Pharma,Phase 3,Industry,Interventional,13-Aug-18,https://ClinicalTrials.gov/show/NCT02326298
1233,A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients,Completed,Has Results,"Arthritis, Rheumatoid",Drug: FKB327|Drug: Humira®,"Fujifilm Kyowa Kirin Biologics Co., Ltd.",Phase 3,Industry,Interventional,20-Sep-17,https://ClinicalTrials.gov/show/NCT02260791
1234,Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD,Completed,Has Results,COPD,Drug: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler,"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,23-Dec-16,https://ClinicalTrials.gov/show/NCT02268396
1235,A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA,Completed,Has Results,Asthma,Biological: Benralizumab,AstraZeneca,Phase 3,Industry,Interventional,6-Feb-19,https://ClinicalTrials.gov/show/NCT02258542
1236,Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus,Completed,Has Results,Chronic Sinusitis,Device: PROPEL Mini Sinus Implant.|Procedure: Sinus Surgery alone|Device: Propel Nova Sinus Implant,Intersect ENT|Advance Research Associates,Phase 3,Industry|Other,Interventional,6-Oct-17,https://ClinicalTrials.gov/show/NCT02266810
1237,Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects,Completed,Has Results,Prophylaxis: Influenza,Biological: TIVc_LOT A|Biological: TIVc_LOT B|Biological: TIVc_LOT C|Biological: TIVf,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,7-Aug-15,https://ClinicalTrials.gov/show/NCT02256488
1238,Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women,Completed,Has Results,Vulvovaginal Atrophy|Menopause|Dyspareunia|Painful Intercourse,Drug: Estradiol|Drug: Placebo,TherapeuticsMD,Phase 3,Industry,Interventional,25-May-17,https://ClinicalTrials.gov/show/NCT02253173
1239,"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults",Completed,Has Results,Colon Cancer|Colorectal Carcinoma|Colon Cleansing,Drug: NER1006|Drug: Trisulfate solution,Norgine,Phase 3,Industry,Interventional,23-May-17,https://ClinicalTrials.gov/show/NCT02254486
1240,A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides,Completed,Has Results,Facial Rhytides|Glabellar Rhytides,Biological: OnabotulinumtoxinA|Drug: Normal Saline,Allergan,Phase 3,Industry,Interventional,25-Jul-17,https://ClinicalTrials.gov/show/NCT02261493
1241,BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis,Completed,Has Results,Gastroenteritis|Gastritis,Drug: RHB-102|Drug: Placebo Oral Tablet,RedHill Biopharma Limited,Phase 3,Industry,Interventional,20-Feb-19,https://ClinicalTrials.gov/show/NCT02246439
1242,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age,Completed,Has Results,Influenza,Biological: FluLaval™ Quadrivalent|Biological: Fluzone® Quadrivalent,GlaxoSmithKline,Phase 3,Industry,Interventional,12-Apr-16,https://ClinicalTrials.gov/show/NCT02242643
1243,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301 Low Dose|Drug: CVT-301 High Dose|Other: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT02240030
1244,Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV),Completed,Has Results,Bacterial Vaginosis,Drug: Metronidazole oral tablets 500mg|Drug: 1% SPL7013 Gel|Drug: Placebo gel,Starpharma Pty Ltd,Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT02237950
1245,A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides,Completed,Has Results,Forehead Rhytides|Glabellar Rhytides,Biological: OnabotulinumtoxinA|Drug: Normal Saline,Allergan,Phase 3,Industry,Interventional,23-Jun-17,https://ClinicalTrials.gov/show/NCT02261467
1246,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Completed,Has Results,Diabetes Mellitus,Drug: Exantide with Dapagliflozin|Drug: Exentide|Drug: Dapagliflozin,AstraZeneca,Phase 3,Industry,Interventional,8-Sep-17,https://ClinicalTrials.gov/show/NCT02229396
1247,Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Exenatide|Drug: Exenatide matching placebo,AstraZeneca,Phase 3,Industry,Interventional,18-Sep-17,https://ClinicalTrials.gov/show/NCT02229383
1248,Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction,Completed,Has Results,Chronic Heart Failure With Reduced Ejection Fraction,Drug: LCZ696,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,20-Feb-19,https://ClinicalTrials.gov/show/NCT02226120
1249,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Completed,Has Results,Epilepsy|Lennox-Gastaut Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo,GW Research Ltd,Phase 3,Industry,Interventional,27-Jul-18,https://ClinicalTrials.gov/show/NCT02224690
1250,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,Completed,Has Results,Epilepsy|Lennox Gastaut Syndrome,Drug: GWP42003-P|Drug: Placebo control,GW Research Ltd,Phase 3,Industry,Interventional,27-Jul-18,https://ClinicalTrials.gov/show/NCT02224560
1251,A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).,Completed,Has Results,Rheumatoid Arthritis,Biological: PF-06438179|Biological: Infliximab,Pfizer,Phase 3,Industry,Interventional,11-Sep-17,https://ClinicalTrials.gov/show/NCT02222493
1252,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,Completed,Has Results,Narcolepsy With Cataplexy,Drug: Xyrem,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,30-Apr-19,https://ClinicalTrials.gov/show/NCT02221869
1253,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,15-Nov-16,https://ClinicalTrials.gov/show/NCT02220998
1254,Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: fampridine|Drug: Placebo,Biogen,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT02219932
1255,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461|Drug: Placebo,"Alkermes, Inc.",Phase 3,Industry,Interventional,27-Mar-19,https://ClinicalTrials.gov/show/NCT02218008
1256,A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.,Completed,Has Results,"Influenza, Human",Biological: Quadrivalent Influenza Vaccine (QIV)|Biological: Trivalent Influenza Vaccine (TIV-1)|Biological: Trivalent Influenza Vaccine (TIV-2),Seqirus,Phase 3,Industry,Interventional,23-Feb-16,https://ClinicalTrials.gov/show/NCT02214225
1257,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",Completed,Has Results,Follicular Lymphoma,Biological: PF-05280586|Biological: MabThera®,Pfizer,Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT02213263
1258,BAX 855 Pediatric Study,Completed,Has Results,Hemophilia A,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Biological: PEGylated Recombinant Factor VIII,Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,27-Jan-17,https://ClinicalTrials.gov/show/NCT02210091
1259,Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo|Drug: Background Statin Therapy,Amgen,Phase 3,Industry,Interventional,16-Jan-18,https://ClinicalTrials.gov/show/NCT02207634
1260,Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: RBP-7000,Indivior Inc.,Phase 3,Industry,Interventional,28-Sep-18,https://ClinicalTrials.gov/show/NCT02203838
1261,A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab,Completed,Has Results,Psoriasis,Drug: Ustekinumab|Drug: Guselkumab|Drug: Placebo for ustekinumab|Drug: Placebo for guselkumab,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,17-Jul-17,https://ClinicalTrials.gov/show/NCT02203032
1262,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,26-Oct-16,https://ClinicalTrials.gov/show/NCT02201953
1263,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,16-Sep-16,https://ClinicalTrials.gov/show/NCT02201940
1264,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: SOF/VEL|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,14-Dec-16,https://ClinicalTrials.gov/show/NCT02201901
1265,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Completed,Has Results,Uncontrolled Asthma,Biological: Experimental: Tralokinumab|Other: Placebo,AstraZeneca,Phase 3,Industry,Interventional,21-Mar-18,https://ClinicalTrials.gov/show/NCT02194699
1266,"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",Completed,Has Results,Measles; Mumps; Rubella,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Jul-18,https://ClinicalTrials.gov/show/NCT02184572
1267,A Study of Golimumab in Participants With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Placebo|Drug: Golimumab,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,13-Nov-17,https://ClinicalTrials.gov/show/NCT02186873
1268,A Study of Golimumab in Participants With Active Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Drug: Placebo|Drug: Golimumab,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,21-Dec-17,https://ClinicalTrials.gov/show/NCT02181673
1269,"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",Completed,Has Results,Prostatic Neoplasms,Drug: Leuprolide Mesylate,"Foresee Pharmaceuticals Co., Ltd.",Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT02234115
1270,Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Fp MDPI|Drug: FS MDPI|Drug: FLOVENT HFA|Drug: ADVAIR DISKUS|Drug: albuterol/salbutamol HFA,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,14-Apr-17,https://ClinicalTrials.gov/show/NCT02175771
1271,"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults",Completed,Has Results,Urinary Tract Infection Complicated|Acute Pyelonephritis|Hospital Acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia|Bacteremia|Abdominal Infection,Drug: Vabomere|Drug: Best Available Therapy,"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)|Department of Health and Human Services|Melinta Therapeutics, Inc.",Phase 3,Industry|U.S. Fed,Interventional,11-Dec-18,https://ClinicalTrials.gov/show/NCT02168946
1272,Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI),Completed,Has Results,Atrial Fibrillation|Percutaneous Coronary Intervention,Drug: Dabigatran Etexilate 110mg|Drug: Warfarin 3mg|Drug: Aspirin|Drug: Dabigatran Etexilate 150mg|Drug: Clopidogrel or Ticagrelor|Drug: Warfarin 5mg|Drug: Warfarin 1mg,Boehringer Ingelheim,Phase 3,Industry,Interventional,31-Jul-18,https://ClinicalTrials.gov/show/NCT02164864
1273,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate (FF)|Drug: vilanterol (VI)|Drug: umeclidinium bromide (UMEC),GlaxoSmithKline,Phase 3,Industry,Interventional,10-Oct-18,https://ClinicalTrials.gov/show/NCT02164513
1274,Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months,Completed,Has Results,Hyperkalemia,Drug: Sodium Zirconium Cyclosilicate,"ZS Pharma, Inc.",Phase 3,Industry,Interventional,27-Jun-18,https://ClinicalTrials.gov/show/NCT02163499
1275,A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma,Completed,Has Results,Uncontrolled Asthma,Biological: Tralokinumab|Other: Placebo,AstraZeneca,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT02161757
1276,Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease,Completed,Has Results,Chronic Kidney Disease|Autosomal Dominant Polycystic Kidney Disease,Drug: Tolvaptan (OPC-41061)|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT02160145
1277,Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism,Completed,Has Results,Hypogonadism,Combination Product: Testosterone enanthate auto-injector,Antares Pharma Inc.,Phase 3,Industry,Interventional,9-Jan-18,https://ClinicalTrials.gov/show/NCT02159469
1278,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461|Drug: Placebo,"Alkermes, Inc.",Phase 3,Industry,Interventional,25-Jun-19,https://ClinicalTrials.gov/show/NCT02158546
1279,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study,Completed,Has Results,Major Depressive Disorder,Drug: High Dose ALKS 5461|Drug: Low Dose ALKS 5461|Drug: Placebo,"Alkermes, Inc.",Phase 3,Industry,Interventional,27-Mar-19,https://ClinicalTrials.gov/show/NCT02158533
1280,Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease,Completed,Has Results,COPD Patients,Drug: Symbicort|Drug: Formoterol turbohaler|Other: Placebo for Symbicort pMDI|Other: Placebo for Formoterol Turbohaler,AstraZeneca,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT02157935
1281,"16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis",Completed,Has Results,"Spondylitis, Ankylosing",Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,10-Apr-19,https://ClinicalTrials.gov/show/NCT02159053
1282,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dulaglutide|Drug: Placebo|Drug: Insulin Glargine|Drug: Metformin,Eli Lilly and Company,Phase 3,Industry,Interventional,7-Dec-16,https://ClinicalTrials.gov/show/NCT02152371
1283,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone gel (FE 999303),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,28-Jul-17,https://ClinicalTrials.gov/show/NCT02149264
1284,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),Completed,Has Results,Colorectal Neoplasms,Drug: Nintedanib (BIBF 1120)|Drug: Placebo|Drug: BSC,Boehringer Ingelheim,Phase 3,Industry,Interventional,21-Jul-17,https://ClinicalTrials.gov/show/NCT02149108
1285,A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Feb-16,https://ClinicalTrials.gov/show/NCT02152605
1286,A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Denosumab (CP2)|Drug: Denosumab (CP4),Amgen,Phase 3,Industry,Interventional,16-Aug-17,https://ClinicalTrials.gov/show/NCT02157948
1287,A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas,Completed,Has Results,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo,Allergan,Phase 3,Industry,Interventional,5-Apr-19,https://ClinicalTrials.gov/show/NCT02147197
1288,A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas,Completed,Has Results,Leiomyoma|Uterine Hemorrhage,Drug: Ulipristal acetate (UPA)|Drug: Placebo,Allergan,Phase 3,Industry,Interventional,4-Jun-19,https://ClinicalTrials.gov/show/NCT02147158
1289,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),Completed,Has Results,Acute Coronary Syndrome,Drug: Losmapimod 7.5 mg twice daily|Drug: Placebo twice daily|Drug: Standard therapy,GlaxoSmithKline|The TIMI Study Group,Phase 3,Industry|Other,Interventional,2-Jun-17,https://ClinicalTrials.gov/show/NCT02145468
1290,Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma,Completed,Has Results,Asthma,Drug: FS MDPI|Drug: Fp MDPI|Drug: Placebo MDPI|Drug: Albuterol/salmeterol HFA MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,12-Apr-17,https://ClinicalTrials.gov/show/NCT02141854
1291,A Long-Term Safety Study of ALKS 5461,Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461,"Alkermes, Inc.",Phase 3,Industry,Interventional,14-Dec-18,https://ClinicalTrials.gov/show/NCT02141399
1292,Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma,Completed,Has Results,Asthma,Drug: FS MDPI|Drug: Fp MDPI|Drug: Placebo MDPI|Drug: albuterol/salbutamol|Drug: Beclomethasone dipropionate,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,12-Apr-17,https://ClinicalTrials.gov/show/NCT02139644
1293,Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout,Completed,Has Results,Gout,Drug: Febuxostat IR|Drug: Febuxostat XR|Drug: Febuxostat placebo|Drug: Colchicine|Drug: Naproxen|Drug: Lansoprazole,Takeda,Phase 3,Industry,Interventional,3-Nov-16,https://ClinicalTrials.gov/show/NCT02139046
1294,Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities,Completed,Has Results,Actinic Keratosis,Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: Blue Light Photodynamic Therapy Illuminator (BLU-U),"DUSA Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,16-Sep-15,https://ClinicalTrials.gov/show/NCT02137785
1295,BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Drug: BI 695501|Drug: US-licensed Humira®,Boehringer Ingelheim,Phase 3,Industry,Interventional,8-Dec-17,https://ClinicalTrials.gov/show/NCT02137226
1296,ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study),Completed,Has Results,Dyskinesia|Levodopa Induced Dyskinesia (LID)|Parkinson's Disease,Drug: ADS-5102|Other: Placebo,"Adamas Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,6-Feb-18,https://ClinicalTrials.gov/show/NCT02136914
1297,"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects",Completed,Has Results,Asthma,Biological: Mepolizumab|Drug: SOC,GlaxoSmithKline,Phase 3,Industry,Interventional,2-May-18,https://ClinicalTrials.gov/show/NCT02135692
1298,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Drug: Atorvastatin|Other: Placebo for Bococizumab (PF-04950615;RN316)|Other: Placebo for atorvastatin,Pfizer,Phase 3,Industry,Interventional,14-Dec-17,https://ClinicalTrials.gov/show/NCT02135029
1299,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Carboplatin|Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Trastuzumab Emtansine,Hoffmann-La Roche,Phase 3,Industry,Interventional,8-Jun-17,https://ClinicalTrials.gov/show/NCT02131064
1300,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,8-Mar-18,https://ClinicalTrials.gov/show/NCT02128932
1301,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: Dalbavancin|Drug: Dalbavancin-matching Placebo,"Durata Therapeutics Inc., an affiliate of Allergan plc",Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT02127970
1302,A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics,Completed,Has Results,Asthma,Drug: Albuterol MDPI|Drug: Placebo|Drug: ProAir HFA inhaler,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,5-Feb-16,https://ClinicalTrials.gov/show/NCT02126839
1303,12-Week Study of Plecanatide for CIC (The National CIC3 Study),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,14-Mar-19,https://ClinicalTrials.gov/show/NCT02122471
1304,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,Completed,Has Results,HIV-1 Infection,Drug: FTC/TDF|Drug: F/TAF|Drug: Allowed third antiretroviral agent|Drug: FTC/TDF Placebo|Drug: F/TAF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,30-Nov-16,https://ClinicalTrials.gov/show/NCT02121795
1305,"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",Completed,Has Results,Healthy,Biological: HEPLISAV|Biological: Engerix-B,Dynavax Technologies Corporation,Phase 3,Industry,Interventional,10-Jan-18,https://ClinicalTrials.gov/show/NCT02117934
1306,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF|Drug: VI|Drug: UMEC|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,12-Dec-14,https://ClinicalTrials.gov/show/NCT02119286
1307,Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: ABP 501,Amgen,Phase 3,Industry,Interventional,24-Apr-17,https://ClinicalTrials.gov/show/NCT02114931
1308,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: Simeprevir|Drug: Sofosbuvir,Janssen Infectious Diseases BVBA,Phase 3,Industry,Interventional,12-Apr-16,https://ClinicalTrials.gov/show/NCT02114177
1309,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,Completed,Has Results,Hepatitis C Virus Infection,Drug: Simeprevir|Drug: Sofosbuvir,Janssen Infectious Diseases BVBA,Phase 3,Industry,Interventional,4-Apr-16,https://ClinicalTrials.gov/show/NCT02114151
1310,A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1),Completed,Has Results,Chronic Kidney Disease,Drug: PRT-201|Drug: Placebo,Proteon Therapeutics,Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT02110901
1311,"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients",Completed,Has Results,Schizophrenia,Drug: RBP-7000|Drug: Placebo|Drug: Risperidone,Indivior Inc.,Phase 3,Industry,Interventional,26-Oct-18,https://ClinicalTrials.gov/show/NCT02109562
1312,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,Completed,Has Results,Urinary Tract Infection Complicated|Acute Pyelonephritis,Drug: Meropenem-Vaborbactam|Drug: Piperacillin-Tazobactam|Drug: Levofloxacin|Drug: Saline,"Melinta Therapeutics, Inc.|Department of Health and Human Services",Phase 3,Industry|U.S. Fed,Interventional,26-Oct-17,https://ClinicalTrials.gov/show/NCT02166476
1313,12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D),Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: Ibodutant 10 mg|Drug: Placebo,Menarini Group,Phase 3,Industry,Interventional,27-Sep-16,https://ClinicalTrials.gov/show/NCT02107196
1314,Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.,Completed,Has Results,Hyperkalemia,Drug: Sodium Zirconium Cyclosilicate,"ZS Pharma, Inc.",Phase 3,Industry,Interventional,15-Aug-18,https://ClinicalTrials.gov/show/NCT02107092
1315,Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate/Vilanterol|Drug: Vilanterol,GlaxoSmithKline,Phase 3,Industry,Interventional,13-Apr-16,https://ClinicalTrials.gov/show/NCT02105974
1316,Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Mepolizumab|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02105961
1317,Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Mepolizumab|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT02105948
1318,Reversal of Dabigatran Anticoagulant Effect With Idarucizumab,Completed,Has Results,Hemorrhage,Drug: idarucizumab,Boehringer Ingelheim,Phase 3,Industry,Interventional,18-Aug-17,https://ClinicalTrials.gov/show/NCT02104947
1319,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Phase 3,Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT02102204
1320,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,21-Jul-17,https://ClinicalTrials.gov/show/NCT02100514
1321,The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,3-Jun-16,https://ClinicalTrials.gov/show/NCT02098395
1322,"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",Completed,Has Results,Poliomyelitis|Diphtheria|Haemophilus Influenzae Type b|Tetanus|Acellular Pertussis|Hepatitis B,Biological: Infanrix hexa|Biological: Pediarix|Biological: ActHIB|Biological: Pentacel|Biological: Engerix-B|Biological: Infanrix|Biological: Hiberix|Biological: Prevnar13|Biological: Rotarix,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Aug-18,https://ClinicalTrials.gov/show/NCT02096263
1323,"A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",Completed,Has Results,Asthma,Drug: Symbicort pMDI|Other: Budesonide pMDI,AstraZeneca,Phase 3,Industry,Interventional,10-Apr-17,https://ClinicalTrials.gov/show/NCT02091986
1324,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),Completed,Has Results,Epilepsy|Dravet Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo control,GW Research Ltd,Phase 3,Industry,Interventional,20-Jul-18,https://ClinicalTrials.gov/show/NCT02091375
1325,Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.,Completed,Has Results,Hyperkalemia,Drug: Sodium zirconium cyclosilicate|Drug: Placebo,"ZS Pharma, Inc.",Phase 3,Industry,Interventional,7-Dec-18,https://ClinicalTrials.gov/show/NCT02088073
1326,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Idalopirdine 60 mg,H. Lundbeck A/S,Phase 3,Industry,Interventional,10-Aug-18,https://ClinicalTrials.gov/show/NCT02079246
1327,Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,Phase 3,Industry,Interventional,17-Oct-17,https://ClinicalTrials.gov/show/NCT02075255
1328,Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis,Completed,Has Results,Chronic Plaque Type Psoriasis,Drug: AIN457 300 mg|Drug: ustekinumab 45/90 mg|Drug: placebo secukinumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,21-Jul-17,https://ClinicalTrials.gov/show/NCT02074982
1329,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Completed,Has Results,Immune Thrombocytopenic Purpura,Drug: Fostamatinib disodium|Drug: Placebo,Rigel Pharmaceuticals,Phase 3,Industry,Interventional,11-Jan-19,https://ClinicalTrials.gov/show/NCT02076399
1330,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection,Completed,Has Results,Hepatitis C Virus|HIV,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,21-Oct-16,https://ClinicalTrials.gov/show/NCT02073656
1331,Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF),Completed,Has Results,Atrial Fibrillation,Drug: Edoxaban|Drug: Warfarin|Drug: Enoxaparin,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,13-Mar-19,https://ClinicalTrials.gov/show/NCT02072434
1332,Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults,Completed,Has Results,HIV|HBV,Drug: E/C/F/TAF,Gilead Sciences,Phase 3,Industry,Interventional,4-Apr-16,https://ClinicalTrials.gov/show/NCT02071082
1333,"Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia",Completed,Has Results,Preeclampsia,Biological: Recombinant human antithrombin (ATryn)|Other: Normal Saline 0.9%,rEVO Biologics,Phase 3,Industry,Interventional,9-Aug-17,https://ClinicalTrials.gov/show/NCT02059135
1334,Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)|Drug: Insulin glargine (HOE901)|Drug: Metformin (Background Drug),Sanofi,Phase 3,Industry,Interventional,10-Feb-17,https://ClinicalTrials.gov/show/NCT02058160
1335,Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM,Completed,Has Results,Type 2 Diabetes,Drug: Insulin glargine/lixisenatide Fixed Ratio Combination|Drug: Insulin glargine (HOE901)|Drug: Lixisenatide (AVE0010)|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,10-Feb-17,https://ClinicalTrials.gov/show/NCT02058147
1336,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,23-Jan-18,https://ClinicalTrials.gov/show/NCT02054897
1337,"Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine GSK 1437173A|Biological: Boostrix,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Apr-18,https://ClinicalTrials.gov/show/NCT02052596
1338,Lurasidone Pediatric Bipolar Study,Completed,Has Results,Bipolar I Depression,Drug: Lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,20-Dec-17,https://ClinicalTrials.gov/show/NCT02046369
1339,"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",Completed,Has Results,Urinary Bladder Overactive|Overactive Bladder|Urgency Incontinence|Urinary Bladder Diseases\Urologic Diseases,Drug: Solifenacin succinate|Drug: Mirabegron|Drug: Placebo to match solifenacin|Drug: Placebo to match mirabegron,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,6-Jun-18,https://ClinicalTrials.gov/show/NCT02045862
1340,A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma,Completed,Has Results,Persistent Asthma,Drug: Beclomethasone dipropionate breath-actuated inhaler|Drug: Placebo breath-actuated inhaler|Drug: albuterol/salbutamol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,11-Dec-17,https://ClinicalTrials.gov/show/NCT02040779
1341,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma,Completed,Has Results,Asthma,Drug: Beclomethasone dipropionate BAI|Drug: Placebo BAI|Drug: albuterol/salbutamol 90 mcg|Drug: Beclomethasone dipropionate MDI|Drug: Placebo MDI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,12-Feb-18,https://ClinicalTrials.gov/show/NCT02040766
1342,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,15-May-17,https://ClinicalTrials.gov/show/NCT02034513
1343,Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,14-Sep-15,https://ClinicalTrials.gov/show/NCT02032901
1344,A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Sofosbuvir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,27-Oct-15,https://ClinicalTrials.gov/show/NCT02032888
1345,A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma,Completed,Has Results,Asthma,Drug: Beclomethasone dipropionate|Drug: Placebo|Drug: Albuterol/salbutamol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,5-Jan-18,https://ClinicalTrials.gov/show/NCT02031640
1346,"A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,30-Jan-17,https://ClinicalTrials.gov/show/NCT02030600
1347,Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass,Completed,Has Results,Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome,Drug: Levosimendan|Drug: Placebo,"Tenax Therapeutics, Inc.",Phase 3,Industry,Interventional,22-May-18,https://ClinicalTrials.gov/show/NCT02025621
1348,A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: ALKS 5461,"Alkermes, Inc.",Phase 3,Industry,Interventional,27-Mar-19,https://ClinicalTrials.gov/show/NCT02085135
1349,The Fibrin Pad CV Phase III Study,Completed,Has Results,Cardiovascular Disease,Biological: EVARREST™ Fibrin Sealant Patch|Biological: Topical hemostat,"Ethicon, Inc.",Phase 3,Industry,Interventional,15-Aug-17,https://ClinicalTrials.gov/show/NCT02040428
1350,12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients,Completed,Has Results,Primary Fibromyalgia,Drug: TNX-102 SL,"Tonix Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,7-Jul-17,https://ClinicalTrials.gov/show/NCT02015234
1351,Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: Prasterone (DHEA),EndoCeutics Inc.,Phase 3,Industry,Interventional,1-Jun-17,https://ClinicalTrials.gov/show/NCT02013544
1352,Epanova® for Lowering Very High Triglycerides II (EVOLVE II),Completed,Has Results,Hypertriglyceridemia,Drug: Epanova|Drug: Olive Oil,AstraZeneca,Phase 3,Industry,Interventional,15-Jan-16,https://ClinicalTrials.gov/show/NCT02009865
1353,Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: Lisdexamfetamine dimesylate|Other: Placebo,Shire,Phase 3,Industry,Interventional,1-Apr-16,https://ClinicalTrials.gov/show/NCT02009163
1354,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Atezolizumab|Drug: Docetaxel,Hoffmann-La Roche,Phase 3,Industry,Interventional,2-Jul-17,https://ClinicalTrials.gov/show/NCT02008227
1355,"16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients",Completed,Has Results,"Spondylitis, Ankylosing",Drug: Secukinumab|Drug: Placebo secukinumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Dec-18,https://ClinicalTrials.gov/show/NCT02008916
1356,Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: olodaterol|Drug: tiotropium|Drug: placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,20-Jan-16,https://ClinicalTrials.gov/show/NCT02006732
1357,Telotristat Etiprate for Carcinoid Syndrome Therapy,Completed,Has Results,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Placebo,Lexicon Pharmaceuticals,Phase 3,Industry,Interventional,25-Sep-17,https://ClinicalTrials.gov/show/NCT02063659
1358,Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU,Completed,Has Results,Epilepsy,Drug: USL261|Drug: Placebo,"Proximagen, LLC",Phase 3,Industry,Interventional,27-Nov-18,https://ClinicalTrials.gov/show/NCT01999777
1359,Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study),Completed,Has Results,Refractory Generalized Myasthenia Gravis,Biological: Eculizumab|Drug: Placebo,Alexion Pharmaceuticals,Phase 3,Industry,Interventional,7-Feb-18,https://ClinicalTrials.gov/show/NCT01997229
1360,Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy,Completed,Has Results,Transthyretin (TTR) Amyloid Cardiomyopathy,Drug: Tafamidis|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,3-Apr-19,https://ClinicalTrials.gov/show/NCT01994889
1361,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],Completed,Has Results,Acute Ischaemic Stroke|Transient Ischaemic Attack,Drug: ticagrelor|Drug: Acetylsalicylic acid (ASA),AstraZeneca,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT01994720
1362,Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Phase 3,Industry,Interventional,30-May-17,https://ClinicalTrials.gov/show/NCT01993940
1363,Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old,Completed,Has Results,Influenza,Biological: QIVc|Biological: TIV1c|Biological: TIV2c,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,8-Dec-15,https://ClinicalTrials.gov/show/NCT01992107
1364,Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older,Completed,Has Results,Influenza,Biological: QIVc|Biological: TIV1c|Biological: TIV2c,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,10-Dec-15,https://ClinicalTrials.gov/show/NCT01992094
1365,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,Completed,Has Results,Clostridium Difficile Infection,Drug: Cadazolid|Drug: Vancomycin|Drug: Cadazolid-matching placebo|Drug: Vancomycin-matching placebo,Actelion,Phase 3,Industry,Interventional,4-May-18,https://ClinicalTrials.gov/show/NCT01987895
1366,24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,16-Apr-19,https://ClinicalTrials.gov/show/NCT01989468
1367,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections,Drug: delafloxacin|Drug: vancomycin|Drug: aztreonam,"Melinta Therapeutics, Inc.",Phase 3,Industry,Interventional,28-Aug-17,https://ClinicalTrials.gov/show/NCT01984684
1368,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3,Completed,Has Results,Hyperlipidemia,Drug: Atorvastatin|Drug: Placebo to Atorvastatin|Other: Placebo to Ezetimibe|Drug: Ezetimibe|Other: Placebo to Evolocumab|Drug: Evolocumab,Amgen,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT01984424
1369,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,Completed,Has Results,Clostridium Difficile Infection,Drug: Cadazolid|Drug: Vancomycin|Drug: Cadazolid-matching placebo|Drug: Vancomycin-matching placebo,Actelion,Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT01983683
1370,12-Week Study of Plecanatide for CIC (The CIC3 Study),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide|Drug: Placebo|Drug: Bisacodyl,Synergy Pharmaceuticals Inc.,Phase 3,Industry,Interventional,21-Mar-19,https://ClinicalTrials.gov/show/NCT01982240
1371,The EVARREST® Fibrin Sealant Patch Liver Study,Completed,Has Results,Hemorrhage,Biological: EVARREST® Fibrin Sealant Patch|Other: Standard of Care (SoC),"Ethicon, Inc.",Phase 3,Industry,Interventional,11-Jul-16,https://ClinicalTrials.gov/show/NCT01993888
1372,"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",Completed,Has Results,Neisseria Meningitidis|Haemophilus Influenzae Type b,Biological: Hib-MenCY-TT (MenHibrix®)|Biological: Pediarix®|Biological: Rotarix®|Biological: Prevnar 13®|Biological: PedvaxHIB®|Biological: Havrix®,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Jun-18,https://ClinicalTrials.gov/show/NCT01978093
1373,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,Completed,Has Results,Dyspepsia|Helicobacter Pylori Infection,Drug: RHB-105|Drug: Placebo,RedHill Biopharma Limited,Phase 3,Industry,Interventional,10-Jan-17,https://ClinicalTrials.gov/show/NCT01980095
1374,Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure,Completed,Has Results,Thrombocytopenia Associated With Liver Disease,Drug: avatrombopag (lower baseline platelet count)|Drug: placebo (lower baseline platelet count)|Drug: avatrombopag (higher baseline platelet count)|Drug: placebo (higher baseline platelet count),Eisai Inc.,Phase 3,Industry,Interventional,27-Feb-18,https://ClinicalTrials.gov/show/NCT01976104
1375,Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF),Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Matching Placebo|Drug: Nintedanib,Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01979952
1376,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,Completed,Has Results,Acute Migraine,Drug: Acetaminophen 250 mg and Aspirin 250 mg|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,11-Jun-15,https://ClinicalTrials.gov/show/NCT01973205
1377,"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder",Completed,Has Results,Urinary Bladder Overactive|Urinary Bladder Diseases\Urologic Diseases|Overactive Bladder|Urgency Incontinence,Drug: Solifenacin succinate|Drug: Mirabegron|Drug: Placebo to match solifenacin succinate|Drug: Placebo to match mirabegron,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,12-Jun-18,https://ClinicalTrials.gov/show/NCT01972841
1378,Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure,Completed,Has Results,Thrombocytopenia Associated With Liver Disease,Drug: avatrombopag (lower baseline platelet count)|Drug: placebo (lower baseline platelet count)|Drug: avatrombopag (higher baseline platelet count)|Drug: placebo (higher baseline platelet count),Eisai Inc.,Phase 3,Industry,Interventional,27-Feb-18,https://ClinicalTrials.gov/show/NCT01972529
1379,"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: GFF MDI (PT 003)|Drug: GP MDI (PT001)|Drug: FF MDI (PT005)|Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®),"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,6-Feb-17,https://ClinicalTrials.gov/show/NCT01970878
1380,A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia,Completed,Has Results,Heterozygous Familial Hypercholesterolemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,19-May-17,https://ClinicalTrials.gov/show/NCT01968980
1381,Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615; RN316)|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,24-Jul-17,https://ClinicalTrials.gov/show/NCT01968967
1382,Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events,Completed,Has Results,Hyperlipidemia,Drug: Bococizumab (PF-04950615;RN316)|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,17-May-17,https://ClinicalTrials.gov/show/NCT01968954
1383,Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,Completed,Has Results,HIV-1|HIV Infections|Acquired Immunodeficiency Syndrome,Drug: E/C/F/TAF|Drug: DRV|Drug: Baseline DRV- containing ARV regimen,Gilead Sciences,Phase 3,Industry,Interventional,1-Nov-16,https://ClinicalTrials.gov/show/NCT01968551
1384,A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis,Completed,Has Results,Psoriasis,Drug: DFD01 Spray|Drug: Vehicle Spray,"Promius Pharma, LLC",Phase 3,Industry,Interventional,13-Mar-17,https://ClinicalTrials.gov/show/NCT01967069
1385,Long Term Safety of Naldemedine,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Phase 3,Industry,Interventional,30-May-17,https://ClinicalTrials.gov/show/NCT01965652
1386,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,Completed,Has Results,Opioid-induced Constipation,Drug: Naldemedine|Drug: Placebo,Shionogi|Shionogi Inc.,Phase 3,Industry,Interventional,30-May-17,https://ClinicalTrials.gov/show/NCT01965158
1387,Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium|Drug: placebo|Drug: olodaterol,Boehringer Ingelheim,Phase 3,Industry,Interventional,25-Nov-15,https://ClinicalTrials.gov/show/NCT01964352
1388,Actual Use Trial of Atorvastatin Calcium 10 mg,Completed,Has Results,Hypercholesterolemia,Drug: Atorvastatin calcium 10 mg,Pfizer,Phase 3,Industry,Interventional,27-Jan-16,https://ClinicalTrials.gov/show/NCT01964326
1389,A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis,Completed,Has Results,Churg-Strauss Syndrome,Biological: Mepolizumab|Drug: Placebo,GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID),Phase 3,Industry|NIH,Interventional,26-Jan-18,https://ClinicalTrials.gov/show/NCT02020889
1390,SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection,Completed,Has Results,Hepatitis C,Drug: SOF|Drug: RBV|Drug: Peg-IFN,Gilead Sciences,Phase 3,Industry,Interventional,5-Feb-16,https://ClinicalTrials.gov/show/NCT01962441
1391,A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-17,https://ClinicalTrials.gov/show/NCT01959529
1392,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",Completed,Has Results,"TTR-mediated Amyloidosis|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Familial Amyloid Polyneuropathies|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related",Drug: patisiran (ALN-TTR02)|Drug: Sterile Normal Saline (0.9% NaCl),Alnylam Pharmaceuticals,Phase 3,Industry,Interventional,6-Sep-18,https://ClinicalTrials.gov/show/NCT01960348
1393,"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC",Completed,Has Results,Chemotherapy-induced Nausea and Vomiting,Drug: APF530|Drug: Ondansetron|Drug: Ondansetron placebo|Drug: APF530 placebo|Drug: Fosaprepitant|Drug: Dexamethasone,Heron Therapeutics,Phase 3,Industry,Interventional,28-Dec-16,https://ClinicalTrials.gov/show/NCT02106494
1394,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF|Drug: VI|Drug: UMEC|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Nov-14,https://ClinicalTrials.gov/show/NCT01957163
1395,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Jan-17,https://ClinicalTrials.gov/show/NCT01952145
1396,"A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome",Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide,Shire,Phase 3,Industry,Interventional,14-Sep-15,https://ClinicalTrials.gov/show/NCT01952080
1397,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Jan-17,https://ClinicalTrials.gov/show/NCT02100475
1398,"A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis",Completed,Has Results,Psoriasis,Drug: DFD01 Spray|Drug: Comp01 Lotion|Drug: Vehicle Lotion|Drug: Vehicle Spray,"Promius Pharma, LLC",Phase 3,Industry,Interventional,6-Oct-16,https://ClinicalTrials.gov/show/NCT01947491
1399,5% Topical Ibuprofen (IBU) for Ankle Sprain,Completed,Has Results,Ankle Injuries,Drug: Topical IBU twice daily|Drug: Placebo twice daily|Drug: Topical IBU three times daily|Drug: Placebo three times daily,Pfizer,Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01945034
1400,Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,1-Feb-17,https://ClinicalTrials.gov/show/NCT01946412
1401,A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms,Completed,Has Results,Menopause,Drug: Estradiol|Drug: Progesterone|Drug: Placebo,TherapeuticsMD,Phase 3,Industry,Interventional,6-May-19,https://ClinicalTrials.gov/show/NCT01942668
1402,Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy,Completed,Has Results,Major Depressive Disorder|Irritability,Drug: Brexpiprazole,H. Lundbeck A/S,Phase 3,Industry,Interventional,15-Mar-16,https://ClinicalTrials.gov/show/NCT01942785
1403,Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017),Completed,Has Results,Relapsing Multiple Sclerosis,Drug: BIIB017|Drug: naproxen,Biogen,Phase 3,Industry,Interventional,25-Jan-17,https://ClinicalTrials.gov/show/NCT01939002
1404,A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211],Completed,Has Results,Bladder Cancer,"Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Drug: Docetaxel|Drug: Paclitaxel|Drug: Vinflunine",Hoffmann-La Roche,Phase 3,Industry,Interventional,11-Apr-18,https://ClinicalTrials.gov/show/NCT02302807
1405,Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Phase 3,Industry,Interventional,4-Apr-17,https://ClinicalTrials.gov/show/NCT01932970
1406,A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis,Completed,Has Results,"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,12-May-17,https://ClinicalTrials.gov/show/NCT01931839
1407,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,Phase 3,Industry,Interventional,3-May-17,https://ClinicalTrials.gov/show/NCT01928771
1408,Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 30 mg|Drug: Placebo,Celgene,Phase 3,Industry,Interventional,13-Jun-16,https://ClinicalTrials.gov/show/NCT01925768
1409,"Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets",Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,2-Jun-17,https://ClinicalTrials.gov/show/NCT01922739
1410,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,19-Mar-18,https://ClinicalTrials.gov/show/NCT01921205
1411,Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC),Completed,Has Results,Chronic Idiopathic Constipation,Drug: Plecanatide,"Bausch Health Americas, Inc.|Syneos Health",Phase 3,Industry|Other,Interventional,2-Jul-19,https://ClinicalTrials.gov/show/NCT01919697
1412,Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: azelastine hydrochloride and fluticasone propionate|Drug: Dymista vehicle,Meda Pharmaceuticals,Phase 3,Industry,Interventional,29-Jun-15,https://ClinicalTrials.gov/show/NCT01915823
1413,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,Completed,Has Results,Asthma,Biological: Benralizumab|Biological: Placebo,AstraZeneca,Phase 3,Industry,Interventional,25-Jan-17,https://ClinicalTrials.gov/show/NCT01914757
1414,Lurasidone Pediatric Autism Study,Completed,Has Results,Autism,Drug: Lurasidone 20 mg daily|Drug: Lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,25-Feb-16,https://ClinicalTrials.gov/show/NCT01911442
1415,Pediatric Schizophrenia Efficacy and Safety Study,Completed,Has Results,Schizophrenia,Drug: Lurasidone 40 mg|Drug: Lurasidone 80 mg|Drug: Placebo 40 or 80 mg,Sunovion,Phase 3,Industry,Interventional,22-Mar-17,https://ClinicalTrials.gov/show/NCT01911429
1416,Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults,Completed,Has Results,"Opioid Dependence, on Agonist Therapy",Drug: BNX sublingual tablets|Drug: BNX sublingual film|Drug: Buprenorphine,Orexo AB|Worldwide Clinical Trials,Phase 3,Industry|Other,Interventional,22-May-15,https://ClinicalTrials.gov/show/NCT01908842
1417,A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin),Completed,Has Results,Urinary Bladder Diseases|Urinary Bladder Overactive|Urologic Diseases,Drug: mirabegron 25 mg|Drug: mirabegron 50 mg|Drug: solifenacin 5 mg|Drug: solifenacin 10 mg|Drug: mirabegron 25 mg matching placebo|Drug: mirabegron 50 mg matching placebo|Drug: solifenacin 5 mg matching placebo|Drug: solifenacin 10 mg matching placebo,Astellas Pharma Europe Ltd.|Astellas Pharma Inc,Phase 3,Industry,Interventional,9-Oct-17,https://ClinicalTrials.gov/show/NCT01908829
1418,Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities,Completed,Has Results,Sleep Disorders,Drug: Circadin 2/5/10 mg|Drug: Placebo,Neurim Pharmaceuticals Ltd.,Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT01906866
1419,Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept,Completed,Has Results,Rheumatoid Arthritis|Psoriatic Arthritis,Drug: Etanercept / Autoinjector A,Amgen,Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT01901185
1420,Alternatives for Reducing Chorea in Huntington Disease,Completed,Has Results,Chorea Associated With Huntington Disease,Drug: SD-809,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,16-Apr-19,https://ClinicalTrials.gov/show/NCT01897896
1421,"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Completed,Has Results,Cystic Fibrosis,Drug: Lumacaftor|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,5-Dec-16,https://ClinicalTrials.gov/show/NCT01897233
1422,Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Completed,Has Results,Secondary Hyperparathyroidism|Chronic Kidney Disease,Drug: Etelcalcetide|Drug: Cinacalcet|Drug: Oral Placebo|Drug: Intravenous Placebo,Amgen,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT01896232
1423,Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation,Completed,Has Results,Chronic Idiopathic Constipation,Drug: Elobixibat 10 mg,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,9-May-16,https://ClinicalTrials.gov/show/NCT01895543
1424,An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Completed,Has Results,Schizophrenia,"Drug: ALKS 9072, Low Dose|Drug: ALKS 9072, High Dose","Alkermes, Inc.",Phase 3,Industry,Interventional,25-Aug-17,https://ClinicalTrials.gov/show/NCT01895452
1425,Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Secukinumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Jun-19,https://ClinicalTrials.gov/show/NCT01892436
1426,Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU,Completed,Has Results,Phenylketonuria (PKU),Drug: BMN165 20mg/day|Drug: BMN165 40mg/day|Drug: Placebo,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,12-Jul-19,https://ClinicalTrials.gov/show/NCT01889862
1427,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Completed,Has Results,Coronary Artery Disease,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,16-May-18,https://ClinicalTrials.gov/show/NCT01890434
1428,Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee,Completed,Has Results,"Osteoarthritis, Knee",Drug: Traumeel® / Zeel® Injectable Solution|Drug: Placebo,Biologische Heilmittel Heel GmbH,Phase 3,Industry,Interventional,20-Mar-15,https://ClinicalTrials.gov/show/NCT01887678
1429,Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: exenatide,Novo Nordisk A/S,Phase 3,Industry,Interventional,30-Mar-18,https://ClinicalTrials.gov/show/NCT01885208
1430,Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors,Completed,Has Results,Psoriatic Arthritis,Drug: Tofacitinib|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,15-Sep-17,https://ClinicalTrials.gov/show/NCT01882439
1431,"Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris",Completed,Has Results,Acne Vulgaris,Drug: CD0271 0.3% / CD1579 2.5%|Drug: CD0271 0.1% / CD1579 2.5%|Drug: Topical Gel Vehicle,Galderma R&D,Phase 3,Industry,Interventional,9-Sep-16,https://ClinicalTrials.gov/show/NCT01880320
1432,Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab AMD|Biological: Evolocumab AI/pen,Amgen,Phase 3,Industry,Interventional,23-Dec-15,https://ClinicalTrials.gov/show/NCT01879319
1433,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305),Completed,Has Results,Plaque Psoriasis,Drug: 000-0551 Lotion|Drug: Vehicle Lotion,"Therapeutics, Inc.",Phase 3,Industry,Interventional,13-Feb-17,https://ClinicalTrials.gov/show/NCT01882647
1434,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|Drug: Placebo DISKUS|Drug: Placebo NDPI,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Aug-14,https://ClinicalTrials.gov/show/NCT01879410
1435,Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study,Completed,Has Results,Psoriatic Arthritis,Drug: Tofacitinib 5 mg BID|Drug: Tofacitinib 10 mg BID|Drug: Adalimumab|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,6-Jul-17,https://ClinicalTrials.gov/show/NCT01877668
1436,Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan,Completed,Has Results,Hypertension,Drug: LCZ696|Drug: Olmesartan|Drug: Placebo of LCZ696|Drug: Placebo of Olmesartan,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-Dec-15,https://ClinicalTrials.gov/show/NCT01876368
1437,Safety and Tolerability of Glatiramer Acetate,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: GA 20 mg/mL|Drug: GA 40 mg/mL,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,14-Jan-16,https://ClinicalTrials.gov/show/NCT01874145
1438,"Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF",Completed,Has Results,Acute Heart Failure,Drug: RLX030|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Mar-18,https://ClinicalTrials.gov/show/NCT01870778
1439,DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: ELLIPTA|Device: DISKUS,GlaxoSmithKline,Phase 3,Industry,Interventional,4-Mar-14,https://ClinicalTrials.gov/show/NCT01868009
1440,Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants,Completed,Has Results,Liver Transplantation,Drug: Everolimus + reduced tacrolimus|Drug: Standard tacrolimus,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Nov-18,https://ClinicalTrials.gov/show/NCT01888432
1441,A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304),Completed,Has Results,Plaque Psoriasis,Drug: 000-0551 Lotion|Drug: Vehicle Lotion,"Therapeutics, Inc.",Phase 3,Industry,Interventional,11-Apr-16,https://ClinicalTrials.gov/show/NCT01871402
1442,Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures,Completed,Has Results,Hemophilia A,Biological: PEGylated Recombinant factor VIII (rFVIII),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,14-May-18,https://ClinicalTrials.gov/show/NCT01913405
1443,Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI),Completed,Has Results,Asthma|Chronic Obstructive Pulmonary Disease (COPD),Drug: Albuterol Spiromax®,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,8-Jun-15,https://ClinicalTrials.gov/show/NCT01857323
1444,Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age,Completed,Has Results,Influenza|Fever,Biological: Mammalian cell based flu vaccine|Biological: Egg based flu vaccine,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,3-Nov-14,https://ClinicalTrials.gov/show/NCT01857206
1445,A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab (TCZ)|Drug: Methotrexate (MTX)|Drug: Placebo (PBO),Hoffmann-La Roche,Phase 3,Industry,Interventional,26-Dec-17,https://ClinicalTrials.gov/show/NCT01855789
1446,Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia,Completed,Has Results,Hyperlipidemia and Mixed Dyslipidemia,Biological: Evolocumab|Drug: Standard of Care,Amgen,Phase 3,Industry,Interventional,11-Jun-19,https://ClinicalTrials.gov/show/NCT01854918
1447,"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: GFF MDI (PT003)|Drug: GP MDI (PT001)|Drug: FF MDI (PT005)|Drug: Placebo,"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,28-Mar-17,https://ClinicalTrials.gov/show/NCT01854658
1448,"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: GFF MDI|Drug: GP MDI|Drug: FF MDI|Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Drug: Placebo MDI,"Pearl Therapeutics, Inc.",Phase 3,Industry,Interventional,28-Mar-17,https://ClinicalTrials.gov/show/NCT01854645
1449,A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials,Completed,Has Results,"Hepatitis C, Chronic",Drug: Peginterferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Phase 3,Industry,Interventional,4-Sep-13,https://ClinicalTrials.gov/show/NCT01853254
1450,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3),Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,30-Dec-14,https://ClinicalTrials.gov/show/NCT01851330
1451,"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: basal insulin,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Jan-18,https://ClinicalTrials.gov/show/NCT01850615
1452,Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen,Completed,Has Results,Primary Hypercholesterolemia|Mixed Dyslipidemia,Biological: Evolocumab Pre-filled Syringe|Biological: Evolocumab AI/pen,Amgen,Phase 3,Industry,Interventional,9-Oct-15,https://ClinicalTrials.gov/show/NCT01849497
1453,A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin Degludec|Drug: Insulin Glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,14-Jan-16,https://ClinicalTrials.gov/show/NCT01849289
1454,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),Completed,Has Results,Metastatic|Uveal Melanoma,Drug: 75mg selumetinib|Drug: placebo|Drug: Dacarbazine,AstraZeneca,Phase 3,Industry,Interventional,28-Sep-16,https://ClinicalTrials.gov/show/NCT01974752
1455,Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence,Completed,Has Results,Opioid-Related Disorders|Opiate Dependence,Drug: Buprenorphine/naloxone sublingual tablets|Drug: Buprenorphine,Orexo AB|Worldwide Clinical Trials,Phase 3,Industry|Other,Interventional,24-Jun-15,https://ClinicalTrials.gov/show/NCT01848054
1456,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infections,Drug: Eravacycline|Drug: Ertapenem|Drug: Placebo,"Tetraphase Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Mar-16,https://ClinicalTrials.gov/show/NCT01844856
1457,Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Completed,Has Results,Differentiated Thyroid Cancer,Drug: Selumetinib|Drug: Placebo|Drug: Radioactive Iodine Therapy,AstraZeneca,Phase 3,Industry,Interventional,22-Apr-19,https://ClinicalTrials.gov/show/NCT01843062
1458,A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects,Completed,Has Results,Asthma,Biological: Mepolizumab,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Mar-16,https://ClinicalTrials.gov/show/NCT01842607
1459,Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Macitentan,Actelion,Phase 3,Industry,Interventional,31-Oct-18,https://ClinicalTrials.gov/show/NCT01841762
1460,The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT01836523
1461,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin aspart|Drug: insulin detemir,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-15,https://ClinicalTrials.gov/show/NCT01835431
1462,Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,23-Jan-18,https://ClinicalTrials.gov/show/NCT01831765
1463,"A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years",Completed,Has Results,Meningococcal Vaccine,Biological: rLP2086|Biological: Havrix (HAV)|Biological: Saline,Pfizer,Phase 3,Industry,Interventional,14-Jun-16,https://ClinicalTrials.gov/show/NCT01830855
1464,"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age",Completed,Has Results,Influenza,Biological: Flublok|Biological: Afluria,Protein Sciences Corporation,Phase 3,Industry,Interventional,18-Feb-15,https://ClinicalTrials.gov/show/NCT01825200
1465,Lurasidone Low-Dose - High-Dose Study Study,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,8-Jan-16,https://ClinicalTrials.gov/show/NCT01821378
1466,An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165,Completed,Has Results,Phenylketonuria,Drug: BMN 165,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,10-Sep-18,https://ClinicalTrials.gov/show/NCT01819727
1467,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: Insulin aspart|Drug: Insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,5-Dec-17,https://ClinicalTrials.gov/show/NCT01819129
1468,Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment,Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF,Gilead Sciences,Phase 3,Industry,Interventional,18-Feb-16,https://ClinicalTrials.gov/show/NCT01818596
1469,"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma",Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Bortezomib|Drug: Melphalan|Drug: Prednisone,Amgen,Phase 3,Industry,Interventional,1-Aug-17,https://ClinicalTrials.gov/show/NCT01818752
1470,Evaluation of Skin Testing Reagents for Penicillin Allergy,Completed,Has Results,History of IgE Dependent Reaction to a Penicillin Product,Drug: Penicillin skin test kit,AllerQuest LLC,Phase 3,Industry,Interventional,4-Jan-17,https://ClinicalTrials.gov/show/NCT01818336
1471,"A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy",Completed,Has Results,Hypogonadism,Drug: Testosterone Solution|Drug: Placebo Solution,Eli Lilly and Company,Phase 3,Industry,Interventional,2-Oct-15,https://ClinicalTrials.gov/show/NCT01816295
1472,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin degludec|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-Nov-15,https://ClinicalTrials.gov/show/NCT01814137
1473,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,4-Jan-18,https://ClinicalTrials.gov/show/NCT01813422
1474,ADAM-Afatinib Diarrhea Assessment and Management,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib|Drug: loperamide,Boehringer Ingelheim,Phase 3,Industry,Interventional,31-Oct-16,https://ClinicalTrials.gov/show/NCT01814553
1475,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: Delafloxacin|Drug: Vancomycin|Drug: Aztreonam|Drug: Placebo,"Melinta Therapeutics, Inc.",Phase 3,Industry,Interventional,24-Aug-17,https://ClinicalTrials.gov/show/NCT01811732
1476,"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)",Completed,Has Results,Chronic Kidney Disease (CKD)|Hyperkalemia (HK),Drug: Patiromer|Drug: Placebo,"Relypsa, Inc.",Phase 3,Industry,Interventional,15-Dec-15,https://ClinicalTrials.gov/show/NCT01810939
1477,Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia,Completed,Has Results,"Leukemia, Hairy Cell",Drug: Moxetumomab pasudotox|Drug: IV Bag Protectant for Moxetumomab pasudotox,MedImmune LLC,Phase 3,Industry,Interventional,27-Aug-18,https://ClinicalTrials.gov/show/NCT01829711
1478,"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin XR,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,6-Jan-16,https://ClinicalTrials.gov/show/NCT01809327
1479,Lesinurad and Febuxostat Combination Extension Study in Gout,Completed,Has Results,Gout,Drug: lesinurad|Drug: febuxostat,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,30-Jan-18,https://ClinicalTrials.gov/show/NCT01808144
1480,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,Completed,Has Results,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Drug: Placebo|Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,1-Sep-15,https://ClinicalTrials.gov/show/NCT01807949
1481,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,Completed,Has Results,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Drug: Lumacaftor Plus Ivacaftor Combination|Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated,Phase 3,Industry,Interventional,31-Aug-15,https://ClinicalTrials.gov/show/NCT01807923
1482,Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)),Completed,Has Results,"Subjects With Hyperlipidemia, Dyslipidemia",Drug: Evolocumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,23-Apr-19,https://ClinicalTrials.gov/show/NCT02729025
1483,Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip,Completed,Has Results,Osteoarthritis,Drug: Meloxicam Test Capsules,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,12-May-15,https://ClinicalTrials.gov/show/NCT01801735
1484,Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Antidiabetic background therapy,Sanofi,Phase 3,Industry,Interventional,14-Oct-16,https://ClinicalTrials.gov/show/NCT01798706
1485,A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium/vilanterol|Drug: Fluticasone propionate/salmeterol|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,29-May-14,https://ClinicalTrials.gov/show/NCT01817764
1486,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: E/C/F/TDF Placebo|Drug: E/C/F/TAF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,8-Jan-16,https://ClinicalTrials.gov/show/NCT01797445
1487,Safety Study of SPARC1104,Completed,Has Results,Spasticity,Drug: SPARC1104 modified dose regimen I|Drug: SPARC1104 modified dose regimen II|Drug: SPARC1104 modified dose regimen III,Sun Pharma Advanced Research Company Limited,Phase 3,Industry,Interventional,12-Mar-19,https://ClinicalTrials.gov/show/NCT01797185
1488,First Time Use of SD-809 in Huntington Disease,Completed,Has Results,Chorea,Drug: SD-809|Drug: Placebo,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,11-Aug-17,https://ClinicalTrials.gov/show/NCT01795859
1489,"Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)",Completed,Has Results,Primary Immune Deficiency Disorder,Biological: RI-002,"ADMA Biologics, Inc.",Phase 3,Industry,Interventional,5-Oct-16,https://ClinicalTrials.gov/show/NCT01814800
1490,3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis,Completed,Has Results,Allergic Rhinitis,Drug: Dymista Nasal Spray|Drug: Fluticasone propionate nasal spray,Meda Pharmaceuticals,Phase 3,Industry,Interventional,31-Mar-15,https://ClinicalTrials.gov/show/NCT01794741
1491,A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,20-Apr-18,https://ClinicalTrials.gov/show/NCT01792284
1492,An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA),Completed,Has Results,Giant Cell Arteritis,Drug: Tocilizumab|Drug: Prednisone|Drug: Tocilizumab Placebo|Drug: Prednisone Placebo|Drug: Corticosteroids|Drug: Methotrexate,Hoffmann-La Roche,Phase 3,Industry,Interventional,18-May-17,https://ClinicalTrials.gov/show/NCT01791153
1493,A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Human Insulin NPH|Drug: Oral Antihyperglycemic Medications (OAM),Eli Lilly and Company,Phase 3,Industry,Interventional,3-May-18,https://ClinicalTrials.gov/show/NCT01790438
1494,Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,5-Apr-17,https://ClinicalTrials.gov/show/NCT01789970
1495,Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet,Completed,Has Results,Analgesia,Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet,Pfizer,Phase 3,Industry,Interventional,28-Aug-17,https://ClinicalTrials.gov/show/NCT01789606
1496,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,Completed,Has Results,Hypertension,Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106),Bayer,Phase 3,Industry,Interventional,17-Aug-15,https://ClinicalTrials.gov/show/NCT01788358
1497,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT01788046
1498,Study of Meloxicam Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Meloxicam Test Capsules|Drug: Placebo Capsules,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,11-Mar-15,https://ClinicalTrials.gov/show/NCT01787188
1499,MultiPoint Pacing IDE Study,Completed,Has Results,Heart Failure,Device: MultiPoint Pacing|Device: Traditional Biventricular Pacing,Abbott Medical Devices,Phase 3,Industry,Interventional,30-Sep-16,https://ClinicalTrials.gov/show/NCT01786993
1500,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide,Amgen,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT01785875
1501,Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,Completed,Has Results,"Hyperparathyroidism, Secondary",Drug: Etelcalcetide|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT01785849
1502,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis",Completed,Has Results,Moderate to Severe Nail Psoriasis,Biological: Secukinumab|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT01807520
1503,Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR),Completed,Has Results,Allergic Rhinitis,Drug: BDP Nasal Aerosol|Drug: Placebo,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,12-Oct-15,https://ClinicalTrials.gov/show/NCT01783548
1504,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: E/C/F/TAF|Drug: E/C/F/TDF|Drug: E/C/F/TDF Placebo|Drug: E/C/F/TAF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,8-Jan-16,https://ClinicalTrials.gov/show/NCT01780506
1505,The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium/Vilanterol 62.5/25 mcg|Drug: Tiotropium 18 mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Jun-14,https://ClinicalTrials.gov/show/NCT01777334
1506,Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: Ixekizumab Auto-Injector|Drug: Ixekizumab Prefilled Syringe,Eli Lilly and Company,Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01777191
1507,Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium bromide 62.5mcg|Drug: Umeclidinium bromide 125mcg|Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT01772147
1508,Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium bromide 62.5mcg|Drug: Umeclidinium bromide 125mcg|Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,16-Apr-14,https://ClinicalTrials.gov/show/NCT01772134
1509,Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes,Drug: Lixisenatide (AVE0010)|Drug: Insulin glulisine QD|Drug: Insulin glulisine TID|Drug: Insulin Glargine (Mandatory background drug)|Drug: Metformin (Background drug),Sanofi,Phase 3,Industry,Interventional,4-Jan-17,https://ClinicalTrials.gov/show/NCT01768559
1510,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection,Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,26-Nov-14,https://ClinicalTrials.gov/show/NCT01768286
1511,Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer,Completed,Has Results,Endometrial Cancer,Drug: AEZS-108 / zoptarelin doxorubicin|Drug: doxorubicin,AEterna Zentaris,Phase 3,Industry,Interventional,31-Jul-18,https://ClinicalTrials.gov/show/NCT01767155
1512,Safety and Efficacy Trial of Testosterone Undecanoate,Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate,"Clarus Therapeutics, Inc.|inVentiv Health Clinical",Phase 3,Industry|Other,Interventional,21-Sep-17,https://ClinicalTrials.gov/show/NCT01765179
1513,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk,Completed,Has Results,Dyslipidemia,Biological: Evolocumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,15-Feb-18,https://ClinicalTrials.gov/show/NCT01764633
1514,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Placebo to Evolocumab|Drug: Ezetimibe|Drug: Placebo to Ezetimibe,Amgen,Phase 3,Industry,Interventional,22-Dec-15,https://ClinicalTrials.gov/show/NCT01763905
1515,LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo to Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Simvastatin,Amgen,Phase 3,Industry,Interventional,22-Dec-15,https://ClinicalTrials.gov/show/NCT01763866
1516,Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Ezetimibe|Biological: Placebo to Evolocumab|Other: Placebo to Ezetimibe,Amgen,Phase 3,Industry,Interventional,30-Dec-15,https://ClinicalTrials.gov/show/NCT01763827
1517,Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: NB|Behavioral: CLI|Behavioral: Usual Care,"Orexigen Therapeutics, Inc",Phase 3,Industry,Interventional,26-Nov-15,https://ClinicalTrials.gov/show/NCT01764386
1518,"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",Completed,Has Results,Moderate to Severe Palmoplantar Psoriasis,Biological: secukinumab 150 mg|Biological: secukinumab 300 mg|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,21-Feb-18,https://ClinicalTrials.gov/show/NCT01806597
1519,Long-term Open-Label Safety Study to Evaluate EN3409,Completed,Has Results,Low Back Pain|Osteoarthritis|Neuropathic Pain,Drug: EN3409,BioDelivery Sciences International,Phase 3,Industry,Interventional,12-Sep-18,https://ClinicalTrials.gov/show/NCT01755546
1520,Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries,Completed,Has Results,Parenchymous Tissue Surgical Bleeding,Biological: Fibrin Sealant Grifols|Device: Surgicel®,"Instituto Grifols, S.A.|Grifols Biologicals, LLC",Phase 3,Industry,Interventional,8-Feb-17,https://ClinicalTrials.gov/show/NCT01754480
1521,Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia,Completed,Has Results,Cervical Dystonia,Drug: Dysport®,Ipsen,Phase 3,Industry,Interventional,4-May-17,https://ClinicalTrials.gov/show/NCT01753336
1522,Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.,Completed,Has Results,Cervical Dystonia,Drug: Dysport®|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,16-Mar-17,https://ClinicalTrials.gov/show/NCT01753310
1523,Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,21-May-15,https://ClinicalTrials.gov/show/NCT01747629
1524,A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye,Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Phase 3,Industry,Interventional,24-Feb-17,https://ClinicalTrials.gov/show/NCT01743729
1525,Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: enclomiphene citrate|Drug: Placebo,Repros Therapeutics Inc.,Phase 3,Industry,Interventional,27-May-15,https://ClinicalTrials.gov/show/NCT01739595
1526,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: Boostrix,GlaxoSmithKline,Phase 3,Industry,Interventional,27-Dec-17,https://ClinicalTrials.gov/show/NCT01738477
1527,Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2,Completed,Has Results,Venous Leg Ulcers,Biological: HP802-247|Biological: Vehicle,Healthpoint,Phase 3,Industry,Interventional,26-Jul-17,https://ClinicalTrials.gov/show/NCT01737762
1528,Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia,Completed,Has Results,Hyperkalemia,Drug: Zirconium silicate (acute phase)|Drug: Zirconium silicate (subacute phase)|Drug: Placebo (acute phase)|Drug: Placebo ( subacute phase),"ZS Pharma, Inc.",Phase 3,Industry,Interventional,12-Oct-18,https://ClinicalTrials.gov/show/NCT01737697
1529,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Completed,Has Results,Peripheral Artery Disease,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,Phase 3,Industry,Interventional,30-Oct-17,https://ClinicalTrials.gov/show/NCT01732822
1530,IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1,Completed,Has Results,"Hepatitis C, Chronic",Drug: Ribavirin (RBV)|Drug: BI 201335 (Faldaprevir)|Drug: BI 207127|Drug: Faldaprevir (BI 201335),Boehringer Ingelheim,Phase 3,Industry,Interventional,18-Apr-16,https://ClinicalTrials.gov/show/NCT01732796
1531,"Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2",Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 207127-placebo: 8-week treatment|Drug: Ribavirin: 24-week treatment|Drug: BI 207127: 24-week treatment|Drug: Faldaprevir: 24-week treatment|Drug: Ribavirin-placebo: 8-week treatment|Drug: Faldaprevir-placebo: 8-week treatment|Drug: Faldaprevir: 16-week treatment|Drug: Ribavirin: 16-week treatment|Drug: RBV: 24-week treatment|Drug: BI 207127: 16-week treatment,Boehringer Ingelheim,Phase 3,Industry,Interventional,12-Feb-16,https://ClinicalTrials.gov/show/NCT01728324
1532,"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial",Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: Brexpiprazole|Drug: Seroquel XR|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,8-Jun-18,https://ClinicalTrials.gov/show/NCT01727726
1533,Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Completed,Has Results,Tourette's Disorder|Tic Disorder,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,16-Oct-15,https://ClinicalTrials.gov/show/NCT01727713
1534,Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder,Completed,Has Results,Tourette's Disorder|Tic Disorder,Drug: Aripiprazole|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,13-Feb-15,https://ClinicalTrials.gov/show/NCT01727700
1535,"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,9-Jun-15,https://ClinicalTrials.gov/show/NCT01727141
1536,A Study in Moderate to Severe Rheumatoid Arthritis Participants,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: Baricitinib|Drug: cDMARD,Eli Lilly and Company,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT01721057
1537,A Moderate to Severe Rheumatoid Arthritis Study,Completed,Has Results,Rheumatoid Arthritis,Drug: Placebo|Drug: Baricitinib|Drug: cDMARD,Eli Lilly and Company,Phase 3,Industry,Interventional,18-Jan-18,https://ClinicalTrials.gov/show/NCT01721044
1538,Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,15-Mar-18,https://ClinicalTrials.gov/show/NCT01720446
1539,Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers,Completed,Has Results,Herpes Zoster,Biological: Herpes zoster vaccine (GSK 1437173A)|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,25-May-17,https://ClinicalTrials.gov/show/NCT01767467
1540,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,21-Aug-14,https://ClinicalTrials.gov/show/NCT01718509
1541,SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder,Completed,Has Results,Binge Eating Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,21-Jul-14,https://ClinicalTrials.gov/show/NCT01718483
1542,NVA237 BID Versus Placebo Twelve-week Efficacy Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,11-Mar-15,https://ClinicalTrials.gov/show/NCT01715298
1543,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,Completed,Has Results,Lupus Nephritis,Biological: BMS-188667|Drug: Mycophenolate mofetil|Drug: Prednisone|Biological: Placebo matching with BMS-188667,Bristol-Myers Squibb,Phase 3,Industry,Interventional,21-Dec-17,https://ClinicalTrials.gov/show/NCT01714817
1544,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,Completed,Has Results,Tuberous Sclerosis Complex-associated Refractory Seizures,Drug: RAD001|Drug: Placebo|Drug: Antiepileptic drug (1 to 3 only)|Drug: open label RAD001 (only used for post-extension phase),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-Nov-18,https://ClinicalTrials.gov/show/NCT01713946
1545,A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin degludec|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-15,https://ClinicalTrials.gov/show/NCT01713530
1546,Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years,Completed,Has Results,Influenza,"Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,10-Feb-14,https://ClinicalTrials.gov/show/NCT01712984
1547,"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Jul-15,https://ClinicalTrials.gov/show/NCT01712516
1548,A Study in Participants With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Baricitinib|Drug: Methotrexate|Drug: Baricitinib Placebo|Drug: MTX Placebo|Drug: Folic Acid,Eli Lilly and Company,Phase 3,Industry,Interventional,15-Aug-17,https://ClinicalTrials.gov/show/NCT01711359
1549,A Study in Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Adalimumab|Drug: Baricitinib|Drug: Methotrexate|Drug: Adalimumab Placebo|Drug: Baricitinib Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,15-Aug-17,https://ClinicalTrials.gov/show/NCT01710358
1550,NVA237 Versus Placebo 12-week Efficacy Study,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Feb-15,https://ClinicalTrials.gov/show/NCT01709864
1551,"The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",Completed,Has Results,Multiple Sclerosis,Drug: Laquinimod|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,13-Mar-19,https://ClinicalTrials.gov/show/NCT01707992
1552,Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,12-May-17,https://ClinicalTrials.gov/show/NCT01707290
1553,A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/VI 100/25 Inhalation Powder NDPI|Drug: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Drug: Placebo Inhalation Powder NDPI|Drug: Placebo Inhalation Powder ACCUHALER/DISKUS|Drug: Salbutamol as needed,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Mar-14,https://ClinicalTrials.gov/show/NCT01706328
1554,"Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: E/C/F/TDF|Drug: RTV|Drug: ATV|Drug: FTC/TDF|Drug: E/C/F/TDF Placebo|Drug: RTV Placebo|Drug: ATV Placebo|Drug: FTC/TDF Placebo|Drug: E/C/F/TAF,Gilead Sciences,Phase 3,Industry,Interventional,10-Mar-16,https://ClinicalTrials.gov/show/NCT01705574
1555,Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,24-Apr-15,https://ClinicalTrials.gov/show/NCT01705145
1556,A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone Gel (FE 999093),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,6-Oct-17,https://ClinicalTrials.gov/show/NCT01703741
1557,"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",Completed,Has Results,Rubella|Measles|Mumps,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,Phase 3,Industry,Interventional,28-Jun-18,https://ClinicalTrials.gov/show/NCT01702428
1558,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV,Completed,Has Results,Chronic Hepatitis C Virus,Drug: LDV/SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,27-Mar-15,https://ClinicalTrials.gov/show/NCT01701401
1559,Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain,Completed,Has Results,Neuropathic Pain,Drug: pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,7-Jun-17,https://ClinicalTrials.gov/show/NCT01701362
1560,"Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men",Completed,Has Results,Male Hypogonadism,Drug: Oral testosterone undecanoate|Drug: Transdermal testosterone gel (AndroGel),"Clarus Therapeutics, Inc.",Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT01699178
1561,Safety Study of Albuterol Spiromax® in Subjects With Asthma,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,19-Aug-15,https://ClinicalTrials.gov/show/NCT01698320
1562,Long Term Safety Study of NVA237 vs QAB149 in COPD Patients,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: NVA237|Drug: Long-acting beta 2-agonist (LABA)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,16-Mar-16,https://ClinicalTrials.gov/show/NCT01697696
1563,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo matching Olodaterol|Drug: Olodaterol,Boehringer Ingelheim,Phase 3,Industry,Interventional,10-Nov-14,https://ClinicalTrials.gov/show/NCT01696058
1564,A Study of Ixekizumab in Participants With Active Psoriatic Arthritis,Completed,Has Results,"Psoriasis, Arthritic",Drug: Ixekizumab|Drug: Placebo|Drug: Adalimumab,Eli Lilly and Company,Phase 3,Industry,Interventional,27-Oct-16,https://ClinicalTrials.gov/show/NCT01695239
1565,Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium|Drug: Placebo matching Olodaterol|Drug: Olodaterol,Boehringer Ingelheim,Phase 3,Industry,Interventional,4-Sep-14,https://ClinicalTrials.gov/show/NCT01694771
1566,Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa,Completed,Has Results,Anemia|Chronic Kidney Disease (CKD),Drug: HX575 epoetin alfa|Drug: US-licensed epoetin alfa,Sandoz,Phase 3,Industry,Interventional,12-May-17,https://ClinicalTrials.gov/show/NCT01693029
1567,Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma,Completed,Has Results,Asthma,Drug: Mepolizumab IV|Drug: Mepolizumab SC|Drug: IV Placebo|Drug: SC Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,26-Jan-16,https://ClinicalTrials.gov/show/NCT01691521
1568,MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,Phase 3,Industry,Interventional,22-May-18,https://ClinicalTrials.gov/show/NCT01691859
1569,Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis,Completed,Has Results,Psoriasis|Psoriatic Arthritis,Drug: Apremilast|Drug: Etanercept|Drug: Placebo tablet|Drug: Placebo injection,Celgene,Phase 3,Industry,Interventional,4-Aug-15,https://ClinicalTrials.gov/show/NCT01690299
1570,Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF,Completed,Has Results,Infertility,Drug: AFOLIA|Drug: Gonal-f® RFF,Fertility Biotech AG,Phase 3,Industry,Interventional,18-Oct-17,https://ClinicalTrials.gov/show/NCT01687712
1571,"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",Completed,Has Results,Asthma,Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg|Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg|Drug: Fluticasone Furoate 100 mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Jun-14,https://ClinicalTrials.gov/show/NCT01686633
1572,Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: Oxycodone DETERx|Drug: Placebo,"Collegium Pharmaceutical, Inc.",Phase 3,Industry,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT01685684
1573,Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure,Completed,Has Results,Carotid Artery Disease,Device: MICHI NPS+f,Silk Road Medical,Phase 3,Industry,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT01685567
1574,Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury,Completed,Has Results,Spinal Cord Injury|Muscle Spasticity,Drug: Fampridine-SR|Drug: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,5-Feb-14,https://ClinicalTrials.gov/show/NCT01683838
1575,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin glargine new formulation)|Drug: Lantus (Insulin glargine),Sanofi,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01683266
1576,"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.",Completed,Has Results,"Meningococcal Disease|Infections, Meningococcal",Biological: MenACWY-CRM,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Oct-14,https://ClinicalTrials.gov/show/NCT01682876
1577,A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: QVA149|Drug: QAB149|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Mar-16,https://ClinicalTrials.gov/show/NCT01682863
1578,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life,Completed,Has Results,Measles|Mumps|Rubella,Biological: Priorix|Biological: M-M-R II|Biological: Varivax|Biological: Havrix|Biological: Prevnar 13,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Aug-18,https://ClinicalTrials.gov/show/NCT01681992
1579,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-15,https://ClinicalTrials.gov/show/NCT01680341
1580,TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome),Completed,Has Results,Carcinoid Syndrome,Drug: Telotristat etiprate|Drug: Placebo-matching telotristat etiprate,Lexicon Pharmaceuticals,Phase 3,Industry,Interventional,18-Sep-17,https://ClinicalTrials.gov/show/NCT01677910
1581,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),Sanofi,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01676220
1582,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: liraglutide|Drug: exenatide,Novo Nordisk A/S,Phase 3,Industry,Interventional,9-Jul-18,https://ClinicalTrials.gov/show/NCT01676116
1583,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,Phase 3,Industry,Interventional,3-Feb-16,https://ClinicalTrials.gov/show/NCT01675167
1584,Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures,Completed,Has Results,Dupuytren's Contracture,Biological: XIAFLEX / XIAPEX,Endo Pharmaceuticals,Phase 3,Industry,Interventional,20-Feb-15,https://ClinicalTrials.gov/show/NCT01674634
1585,Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency,Completed,Has Results,Growth Hormone Deficiency With Pituitary Anomalies,Drug: Macimorelin|Drug: Insulin,AEterna Zentaris,Phase 3,Industry,Interventional,9-Feb-18,https://ClinicalTrials.gov/show/NCT02558829
1586,"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults",Completed,Has Results,Hepatitis C|Human Immunodeficiency Virus,Drug: SOF|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT01667731
1587,A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma,Completed,Has Results,Melanoma,Drug: Vemurafenib|Drug: Placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,17-Oct-18,https://ClinicalTrials.gov/show/NCT01667419
1588,Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura,Completed,Has Results,Migraine|Headaches,Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet,Avanir Pharmaceuticals,Phase 3,Industry,Interventional,14-Mar-17,https://ClinicalTrials.gov/show/NCT01667679
1589,Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections,Completed,Has Results,cUTI,Drug: Eravacycline|Drug: Levofloxacin,"Tetraphase Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,11-Dec-18,https://ClinicalTrials.gov/show/NCT01978938
1590,A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel,Completed,Has Results,Adult Male Hypogonadism,Drug: Testosterone gel (FE 999303),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,20-Sep-17,https://ClinicalTrials.gov/show/NCT01665599
1591,The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Plus|Device: SYNERGY,Boston Scientific Corporation,Phase 3,Industry,Interventional,7-Jan-16,https://ClinicalTrials.gov/show/NCT01665053
1592,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: placebo|Drug: liraglutide,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Apr-16,https://ClinicalTrials.gov/show/NCT01664247
1593,"Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",Completed,Has Results,Metastatic Breast Cancer,Drug: Bevacizumab [Avastin]|Drug: Paclitaxel|Drug: Placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,10-Feb-16,https://ClinicalTrials.gov/show/NCT01663727
1594,Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery,Completed,Has Results,Vascular Surgical Bleeding,Biological: Fibrin Sealant Grifols|Procedure: Manual Compression,"Instituto Grifols, S.A.|Grifols Biologicals, LLC",Phase 3,Industry,Interventional,6-Apr-17,https://ClinicalTrials.gov/show/NCT01662856
1595,A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine,Completed,Has Results,Migraine Disorders,Biological: Botulinum toxin type A Dose 1|Biological: Botulinum toxin type A Dose 2|Drug: Placebo (Normal Saline),Allergan,Phase 3,Industry,Interventional,5-Sep-17,https://ClinicalTrials.gov/show/NCT01662492
1596,A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab,"Genentech, Inc.",Phase 3,Industry,Interventional,12-Oct-16,https://ClinicalTrials.gov/show/NCT01662063
1597,Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia,Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Ofatumumab,Gilead Sciences,Phase 3,Industry,Interventional,31-Mar-17,https://ClinicalTrials.gov/show/NCT01659021
1598,Open Label Extension in Adults With Binge Eating Disorder (BED),Completed,Has Results,Binge Eating Disorder,Drug: Lisdexamfetamine dimesylate,Shire,Phase 3,Industry,Interventional,15-Dec-15,https://ClinicalTrials.gov/show/NCT01657019
1599,Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease,Completed,Has Results,Anemia in Chronic Kidney Disease Patients Not on Dialysis,Biological: Darbepoetin alfa|Other: Placebo,Amgen,Phase 3,Industry,Interventional,8-Nov-18,https://ClinicalTrials.gov/show/NCT01652872
1600,"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Diabetes Type 2,Drug: Exenatide once weekly suspension|Drug: Sitagliptin|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01652729
1601,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Exenatide once weekly suspension|Drug: Exenatide twice daily,AstraZeneca,Phase 3,Industry,Interventional,16-Sep-15,https://ClinicalTrials.gov/show/NCT01652716
1602,Open-Label Lesinurad Monotherapy Extension Study in Gout,Completed,Has Results,Gout,Drug: lesinurad,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01650246
1603,Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Saxagliptin|Drug: Metformin immediate release (IR),AstraZeneca,Phase 3,Industry,Interventional,11-Apr-16,https://ClinicalTrials.gov/show/NCT01646320
1604,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Completed,Has Results,Cystic Fibrosis,Drug: AZLI|Drug: Placebo to match AZLI|Drug: Tobramycin inhalation solution,Gilead Sciences,Phase 3,Industry,Interventional,9-May-16,https://ClinicalTrials.gov/show/NCT01641822
1605,"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection",Completed,Has Results,Chronic Hepatitis C,Drug: Sofosbuvir|Drug: RBV|Drug: PEG,Gilead Sciences,Phase 3,Industry,Interventional,8-May-14,https://ClinicalTrials.gov/show/NCT01641640
1606,Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma,Completed,Has Results,Asthma,Drug: Mepolizumab|Drug: Placebo|Drug: OCS (prednisone/prednisolone),GlaxoSmithKline,Phase 3,Industry,Interventional,26-Jan-16,https://ClinicalTrials.gov/show/NCT01691508
1607,4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis,Completed,Has Results,Moderate to Severe Chronic Plaque-Type Psoriasis,Drug: AIN457 150 mg|Drug: AIN457 300 mg|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,25-May-18,https://ClinicalTrials.gov/show/NCT01640951
1608,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,Completed,Has Results,"Infections, Meningococcal",Biological: Meningococcal vaccine GSK134612,GlaxoSmithKline,Phase 3,Industry,Interventional,18-Oct-17,https://ClinicalTrials.gov/show/NCT01641042
1609,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS,Completed,Has Results,Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH™ Catheter,"Biosense Webster, Inc.",Phase 3,Industry,Interventional,15-May-18,https://ClinicalTrials.gov/show/NCT01639495
1610,Safety Study of Lifitegrast to Treat Dry Eye,Completed,Has Results,Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Phase 3,Industry,Interventional,3-Oct-16,https://ClinicalTrials.gov/show/NCT01636206
1611,Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE),Completed,Has Results,Plaque-type Psoriasis,Drug: Placebo|Drug: Secukinumab 150mg|Drug: Secukinumab 300mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,27-Sep-18,https://ClinicalTrials.gov/show/NCT01636687
1612,Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects,Completed,Has Results,Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,Phase 3,Industry,Interventional,3-Feb-16,https://ClinicalTrials.gov/show/NCT01633944
1613,Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study,Completed,Has Results,Polycythemia Vera,Drug: Ruxolitinib|Drug: Hydroxyurea (HU)|Drug: HU-placebo|Drug: Ruxolitinib-placebo,Incyte Corporation,Phase 3,Industry,Interventional,7-Apr-15,https://ClinicalTrials.gov/show/NCT01632904
1614,NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: NWP09|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,3-Feb-16,https://ClinicalTrials.gov/show/NCT01654250
1615,Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Women With Osteoporosis,Biological: Romosozumab|Drug: Alendronate|Drug: Placebo to Romosozumab|Drug: Placebo to Alendronate,Amgen,Phase 3,Industry,Interventional,12-Dec-18,https://ClinicalTrials.gov/show/NCT01631214
1616,"A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin",Completed,Has Results,Chronic Renal Failure Requiring Hemodialysis,Biological: Epoetin Hospira,Pfizer,Phase 3,Industry,Interventional,19-Jul-18,https://ClinicalTrials.gov/show/NCT01628120
1617,"A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",Completed,Has Results,Chronic Renal Failure Requiring Hemodialysis,Biological: Epoetin Hospira,Pfizer,Phase 3,Industry,Interventional,19-Jul-18,https://ClinicalTrials.gov/show/NCT01628107
1618,A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070),Completed,Has Results,Schizophrenia,"Drug: ALKS 9072, Low|Drug: ALKS 9072, High","Alkermes, Inc.",Phase 3,Industry,Interventional,27-Oct-16,https://ClinicalTrials.gov/show/NCT01626456
1619,Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies,Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Peg-IFN,Gilead Sciences,Phase 3,Industry,Interventional,9-Nov-15,https://ClinicalTrials.gov/show/NCT01625338
1620,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: LY2189265|Drug: Liraglutide|Drug: Metformin,Eli Lilly and Company,Phase 3,Industry,Interventional,9-Oct-14,https://ClinicalTrials.gov/show/NCT01624259
1621,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate/vilanterol 100/25mcg|Drug: tiotropium bromide 18mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Nov-13,https://ClinicalTrials.gov/show/NCT01627327
1622,Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps,Completed,Has Results,Chronic Sinusitis With or Without Nasal Polyps,Drug: Fluticasone Propionate,Optinose US Inc.,Phase 3,Industry,Interventional,1-Mar-16,https://ClinicalTrials.gov/show/NCT01623323
1623,12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device,Completed,Has Results,Nasal Polyps,Drug: Fluticasone Propionate,Optinose US Inc.,Phase 3,Industry,Interventional,24-Jan-18,https://ClinicalTrials.gov/show/NCT01623310
1624,"Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety",Completed,Has Results,Bilateral Nasal Polyposis,Drug: Fluticasone Propionate,Optinose US Inc.,Phase 3,Industry,Interventional,5-Dec-18,https://ClinicalTrials.gov/show/NCT01622569
1625,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age,Completed,Has Results,Rubella|Mumps|Measles,Biological: Priorix|Biological: M-M-R II|Biological: Kinrix|Biological: ProQuad,GlaxoSmithKline,Phase 3,Industry,Interventional,13-Sep-17,https://ClinicalTrials.gov/show/NCT01621802
1626,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Completed,Has Results,Type 2 Diabetes|Chronic Kidney Disease,Drug: Dulaglutide|Drug: Insulin glargine|Drug: Insulin lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,24-Jul-17,https://ClinicalTrials.gov/show/NCT01621178
1627,Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,30-Oct-14,https://ClinicalTrials.gov/show/NCT01620489
1628,Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Metformin IR|Drug: Placebo matching with Saxagliptin,AstraZeneca,Phase 3,Industry,Interventional,17-Mar-16,https://ClinicalTrials.gov/show/NCT01619059
1629,Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Macitentan 10 mg|Drug: Placebo,Actelion,Phase 3,Industry,Interventional,30-Jan-18,https://ClinicalTrials.gov/show/NCT01743001
1630,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),Completed,Has Results,Coronary Artery Disease (CAD),Drug: Regadenoson|Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI),"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",Phase 3,Industry,Interventional,8-Feb-16,https://ClinicalTrials.gov/show/NCT01618669
1631,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Feb-17,https://ClinicalTrials.gov/show/NCT01618162
1632,The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,28-Oct-14,https://ClinicalTrials.gov/show/NCT01617434
1633,"Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device",Completed,Has Results,Bilateral Nasal Polyposis,Drug: Fluticasone propionate,Optinose US Inc.,Phase 3,Industry,Interventional,5-Dec-18,https://ClinicalTrials.gov/show/NCT01624662
1634,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,12-Feb-15,https://ClinicalTrials.gov/show/NCT01614457
1635,"Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,23-Jan-18,https://ClinicalTrials.gov/show/NCT01610414
1636,Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies,Completed,Has Results,Colorectal Cancer,Drug: TAS-102|Drug: Placebo,"Taiho Oncology, Inc.",Phase 3,Industry,Interventional,21-May-19,https://ClinicalTrials.gov/show/NCT01607957
1637,Evaluation of a New Cardiac Biomarker Assay,Completed,Has Results,Acute Coronary Syndrome|Acute Myocardial Infarction,Device: ARCHITECT STAT High Sensitive Troponin I Assay,Abbott Diagnostics Division,Phase 3,Industry,Interventional,17-Mar-15,https://ClinicalTrials.gov/show/NCT01608100
1638,Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR|Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Saxagliptin,AstraZeneca,Phase 3,Industry,Interventional,20-Oct-15,https://ClinicalTrials.gov/show/NCT01606007
1639,Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100,Completed,Has Results,Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms,Drug: cabozantinib|Drug: prednisone,Exelixis,Phase 3,Industry,Interventional,14-Mar-18,https://ClinicalTrials.gov/show/NCT01605227
1640,Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION),Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV,Gilead Sciences,Phase 3,Industry,Interventional,1-May-14,https://ClinicalTrials.gov/show/NCT01604850
1641,BOTOX® Treatment in Pediatric Lower Limb Spasticity,Completed,Has Results,Pediatrics|Muscle Spasticity|Cerebral Palsy,Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo),Allergan,Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT01603628
1642,BOTOX® Treatment in Pediatric Upper Limb Spasticity,Completed,Has Results,Pediatrics|Muscle Spasticity|Cerebral Palsy|Stroke,Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo),Allergan,Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT01603602
1643,Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir,Completed,Has Results,Hepatitis C Virus,Biological: Peginterferon Lambda-1a|Biological: Peginterferon Alfa-2a|Drug: Ribavirin|Drug: Telaprevir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,21-May-19,https://ClinicalTrials.gov/show/NCT01598090
1644,Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma,Completed,Has Results,Melanoma,Drug: Dabrafenib|Drug: Vemurafenib|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,4-Dec-14,https://ClinicalTrials.gov/show/NCT01597908
1645,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Infection,Drug: Topical pexiganan cream 0.8%|Drug: Topical placebo cream|Other: Standard wound care,"Dipexium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT01594762
1646,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Infection,Drug: Topical pexiganan cream 0.8%|Drug: Topical placebo cream|Other: Standard wound care,"Dipexium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,14-Jun-17,https://ClinicalTrials.gov/show/NCT01590758
1647,A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma,Completed,Has Results,Melanoma,Drug: dabrafenib|Drug: dabrafenib plus trametinib placebo|Drug: Trametinib,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Aug-14,https://ClinicalTrials.gov/show/NCT01584648
1648,Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondyloarthritis,Drug: Apremilast tablet 20 mg|Drug: Apremilast tablet 30 mg BID|Drug: Placebo,Celgene,Phase 3,Industry,Interventional,17-Mar-15,https://ClinicalTrials.gov/show/NCT01583374
1649,Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study),Completed,Has Results,Venous Thromboembolism (VTE),Drug: Betrixaban|Drug: Enoxaparin,Portola Pharmaceuticals,Phase 3,Industry,Interventional,20-Sep-17,https://ClinicalTrials.gov/show/NCT01583218
1650,A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Insulin glargine,Eli Lilly and Company,Phase 3,Industry,Interventional,20-Apr-18,https://ClinicalTrials.gov/show/NCT01582451
1651,"An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.",Completed,Has Results,Cushing's Disease,Drug: Pasireotide sub-cutaneous,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Jun-18,https://ClinicalTrials.gov/show/NCT01582061
1652,"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.",Completed,Has Results,Renal Function|Liver Transplant,"Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.",Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,24-Jan-17,https://ClinicalTrials.gov/show/NCT01598987
1653,"Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification",Completed,Has Results,Intraocular Lens Replacement,Drug: OMS302|Drug: Placebo,Omeros Corporation,Phase 3,Industry,Interventional,22-Aug-14,https://ClinicalTrials.gov/show/NCT01579565
1654,Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids,Completed,Has Results,"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor",Drug: Denosumab|Drug: Placebo for risendronate|Drug: Risendronate|Drug: Placebo for denosumab,Amgen,Phase 3,Industry,Interventional,27-Jul-18,https://ClinicalTrials.gov/show/NCT01575873
1655,Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Romosozumab|Drug: Placebo|Drug: Denosumab,Amgen,Phase 3,Industry,Interventional,8-Nov-18,https://ClinicalTrials.gov/show/NCT01575834
1656,"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296",Completed,Has Results,Bipolar I Disorder,Drug: Lurasidone,Sunovion,Phase 3,Industry,Interventional,22-Aug-16,https://ClinicalTrials.gov/show/NCT01575561
1657,The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy,Completed,Has Results,Colorectal Cancer,Drug: Methylene Blue MMX®|Drug: Placebo,Cosmo Technologies Ltd,Phase 3,Industry,Interventional,6-Nov-17,https://ClinicalTrials.gov/show/NCT01694966
1658,"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Drug: Aclidinium bromide|Drug: Formoterol Fumarate|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,21-Apr-17,https://ClinicalTrials.gov/show/NCT01572792
1659,A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Chronic Pain|Low Back Pain|Analgesia,Drug: ALO-02|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,4-Apr-17,https://ClinicalTrials.gov/show/NCT01571362
1660,"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,18-Nov-15,https://ClinicalTrials.gov/show/NCT01570751
1661,Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS),Completed,Has Results,Restless Legs Syndrome,Drug: Rotigotine|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,26-Aug-14,https://ClinicalTrials.gov/show/NCT01569464
1662,"A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Rituximab|Drug: Bendamustine|Drug: Placebo to match idelalisib,Gilead Sciences,Phase 3,Industry,Interventional,27-Feb-18,https://ClinicalTrials.gov/show/NCT01569295
1663,Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: Carfilzomib|Drug: Bortezomib|Drug: Dexamethasone,Amgen,Phase 3,Industry,Interventional,11-Dec-15,https://ClinicalTrials.gov/show/NCT01568866
1664,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,29-Oct-14,https://ClinicalTrials.gov/show/NCT01614470
1665,"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Lurasidone,Sunovion,Phase 3,Industry,Interventional,20-Nov-14,https://ClinicalTrials.gov/show/NCT01566162
1666,Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity|Obstructive Sleep Apnoea,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,9-Feb-15,https://ClinicalTrials.gov/show/NCT01557166
1667,Perindopril Amlodipine for the Treatment of Hypertension,Completed,Has Results,Essential Hypertension,Drug: XOMA 985|Drug: Amlodipine Besylate|Drug: Perindopril Erbumine,Symplmed Pharmaceuticals LLC,Phase 3,Industry,Interventional,25-Aug-15,https://ClinicalTrials.gov/show/NCT01556997
1668,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",Completed,Has Results,Papulopustular Rosacea,"Drug: Azelaic acid foam, 15% (BAY39-6251)|Drug: Vehicle foam",Bayer,Phase 3,Industry,Interventional,27-Jan-15,https://ClinicalTrials.gov/show/NCT01555463
1669,A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo to match ranolazine|Drug: Metformin|Drug: Placebo to match metformin|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Phase 3,Industry,Interventional,23-Sep-14,https://ClinicalTrials.gov/show/NCT01555164
1670,First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: secukinumab 150 mg|Drug: secukinumab 300 mg|Drug: placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT01555125
1671,A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis,Completed,Has Results,End Stage Renal Disease|Kidney Failure|Renal Failure|Hyperphosphatemia|ESRD,Drug: ferric citrate,Keryx Biopharmaceuticals,Phase 3,Industry,Interventional,13-Jul-16,https://ClinicalTrials.gov/show/NCT01554982
1672,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Completed,Has Results,Irritable Bowel Syndrome,Drug: Eluxadoline|Drug: Placebo,"Furiex Pharmaceuticals, Inc",Phase 3,Industry,Interventional,30-Jul-18,https://ClinicalTrials.gov/show/NCT01553747
1673,"Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)",Completed,Has Results,Irritable Bowel Syndrome,Drug: Eluxadoline|Drug: Placebo,"Furiex Pharmaceuticals, Inc",Phase 3,Industry,Interventional,3-Sep-18,https://ClinicalTrials.gov/show/NCT01553591
1674,"A Study of Ustekinumab to Evaluate a ""Subject-tailored"" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Placebo,"Janssen Biotech, Inc.",Phase 3,Industry,Interventional,7-Nov-16,https://ClinicalTrials.gov/show/NCT01550744
1675,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection|Drug: Placebo,Kythera Biopharmaceuticals,Phase 3,Industry,Interventional,15-Jun-15,https://ClinicalTrials.gov/show/NCT01546142
1676,Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: Secukinumab (AIN457)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,20-Dec-18,https://ClinicalTrials.gov/show/NCT01544595
1677,Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study,Completed,Has Results,Irritable Bowel Syndrome With Diarrhea,Drug: open-label rifaximin|Drug: double-blind placebo|Drug: double-blind rifaximin,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,8-Jul-15,https://ClinicalTrials.gov/show/NCT01543178
1678,"Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",Completed,Has Results,Chronic Hepatitis C,Drug: SOF|Drug: RBV|Drug: Placebo to match SOF|Drug: Placebo to match RBV,Gilead Sciences,Phase 3,Industry,Interventional,17-Feb-14,https://ClinicalTrials.gov/show/NCT01542788
1679,Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,5-May-17,https://ClinicalTrials.gov/show/NCT01552343
1680,Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection|Drug: Placebo,Kythera Biopharmaceuticals,Phase 3,Industry,Interventional,15-Jun-15,https://ClinicalTrials.gov/show/NCT01542034
1681,A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp,Completed,Has Results,Actinic Keratosis,Procedure: Cryotherapy|Drug: Vehicle|Drug: Ingenol metabute,LEO Pharma,Phase 3,Industry,Interventional,28-Mar-14,https://ClinicalTrials.gov/show/NCT01541553
1682,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo|Drug: metformin,Novo Nordisk A/S,Phase 3,Industry,Interventional,11-Dec-18,https://ClinicalTrials.gov/show/NCT01541215
1683,"A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain",Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: morphine IV PCA,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,27-Mar-14,https://ClinicalTrials.gov/show/NCT01539538
1684,"A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)",Completed,Has Results,Chronic Lymphocytic Leukemia,Drug: Idelalisib|Drug: Rituximab|Drug: Placebo to match idelalisib,Gilead Sciences,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT01539512
1685,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery",Completed,Has Results,Post-Operative Pain,Drug: Sufentanil NanoTab PCA System/15 mcg|Drug: Placebo Sufentanil NanoTab PCA System,"AcelRx Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,3-Feb-14,https://ClinicalTrials.gov/show/NCT01539642
1686,Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: Androxal,Repros Therapeutics Inc.,Phase 3,Industry,Interventional,24-Jul-14,https://ClinicalTrials.gov/show/NCT01534208
1687,A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN),Completed,Has Results,Diabetic Peripheral Neuropathy|Pain,Drug: Capsaicin 8%|Drug: Placebo,Astellas Pharma Inc,Phase 3,Industry,Interventional,13-Mar-15,https://ClinicalTrials.gov/show/NCT01533428
1688,A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis,Completed,Has Results,"Sclerosis, Systemic",Drug: Placebo|Drug: tocilizumab [RoActemra/Actemra],Hoffmann-La Roche,Phase 3,Industry,Interventional,5-Nov-15,https://ClinicalTrials.gov/show/NCT01532869
1689,Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism,Completed,Has Results,Secondary Hypogonadism,Drug: Androxal|Drug: Placebo,Repros Therapeutics Inc.,Phase 3,Industry,Interventional,27-May-15,https://ClinicalTrials.gov/show/NCT01532414
1690,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo|Drug: Tiotropium + Olodaterol|Drug: tiotropium + Olodaterol|Drug: Tiotropium|Drug: Olodaterol|Device: Respimat,Boehringer Ingelheim,Phase 3,Industry,Interventional,15-Sep-15,https://ClinicalTrials.gov/show/NCT01533935
1691,A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PP3M 175 mg eq.|Drug: PP3M 263 mg eq.|Drug: PP3M 350 mg eq.|Drug: PP3M 525 mg eq.|Drug: Placebo (20% Intralipid emulsion),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,18-Jun-15,https://ClinicalTrials.gov/show/NCT01529515
1692,A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Respimat inhaler|Drug: tiotropium+olodaterol (low dose)|Drug: tiotropium + olodaterol (high dose)|Drug: placebo to tiotropium+olodaterol,Boehringer Ingelheim,Phase 3,Industry,Interventional,15-Sep-15,https://ClinicalTrials.gov/show/NCT01525615
1693,LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib|Drug: erlotinib,Boehringer Ingelheim,Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT01523587
1694,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol + Methotrexate (MTX)|Biological: Placebo + Methotrexate (MTX),UCB Pharma,Phase 3,Industry,Interventional,10-Jan-17,https://ClinicalTrials.gov/show/NCT01521923
1695,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol|Other: Placebo|Biological: Methotrexate,UCB Pharma SA|UCB Pharma,Phase 3,Industry,Interventional,22-Sep-15,https://ClinicalTrials.gov/show/NCT01519791
1696,Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Device: Self-injector pen device (OptiClik®)|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,14-Oct-16,https://ClinicalTrials.gov/show/NCT01517412
1697,Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Biological: Placebo|Drug: Atorvastatin|Drug: Ezetimibe|Other: Diet Only,Amgen,Phase 3,Industry,Interventional,29-Sep-15,https://ClinicalTrials.gov/show/NCT01516879
1698,Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: PP3M 175 mg eq.|Drug: PP3M 263 mg eq.|Drug: PP3M 350 mg eq.|Drug: PP3M 525 mg eq.|Drug: Placebo (20% Intralipid)|Drug: PP1M 50 mg eq.|Drug: PP1M 75 mg eq.|Drug: PP1M 100 mg eq.|Drug: PP1M 150 mg eq.,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,2-May-16,https://ClinicalTrials.gov/show/NCT01515423
1699,Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy,Completed,Has Results,Pulmonary Embolism|Acute Pulmonary Embolism|Sub-massive Pulmonary Embolism|Massive Pulmonary Embolism|Pulmonary Thromboembolism,Drug: recombinant tissue plasminogen activator|Device: EKOS EkoSonic Endovascular System,EKOS Corporation,Phase 3,Industry,Interventional,3-Jul-19,https://ClinicalTrials.gov/show/NCT01513759
1700,A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,12-Jan-16,https://ClinicalTrials.gov/show/NCT01513473
1701,Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab,Completed,Has Results,Melanoma,Biological: Ipilimumab,Bristol-Myers Squibb,Phase 3,Industry,Interventional,24-Mar-17,https://ClinicalTrials.gov/show/NCT01515189
1702,"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: Stribild,Gilead Sciences,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01533259
1703,Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Diclofenac,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,9-May-14,https://ClinicalTrials.gov/show/NCT01510912
1704,Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat,Completed,Has Results,Tophaceous Gout,Drug: Lesinurad|Drug: Placebo|Drug: Febuxostat,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01510769
1705,Combining Lesinurad With Allopurinol in Inadequate Responders,Completed,Has Results,Gout,Drug: Lesinurad|Drug: Placebo|Drug: Allopurinol,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,18-Aug-16,https://ClinicalTrials.gov/show/NCT01510158
1706,Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT01508936
1707,Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina,Completed,Has Results,Chronic Myocardial Ischemia|Refractory Angina Pectoris|Advanced Coronary Heart Disease,Biological: Auto-CD34+ cells|Biological: Placebo: Diluent used to suspend Auto-CD34+ cells|Other: Standard of care,"Caladrius Biosciences, Inc.",Phase 3,Industry,Interventional,15-Feb-17,https://ClinicalTrials.gov/show/NCT01508910
1708,Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors,Completed,Has Results,Gout,Drug: lesinurad|Drug: Placebo,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,12-Feb-16,https://ClinicalTrials.gov/show/NCT01508702
1709,Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis,Completed,Has Results,End Stage Renal Disease|Chronic Kidney Disease,Drug: SFP|Other: Placebo,"Rockwell Medical Technologies, Inc.",Phase 3,Industry,Interventional,21-Apr-15,https://ClinicalTrials.gov/show/NCT01503021
1710,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL),Completed,Has Results,Coronary Artery Disease,Device: PROMUS Element Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Phase 3,Industry,Interventional,14-Feb-12,https://ClinicalTrials.gov/show/NCT01500434
1711,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lantus (Insulin glargine)|Drug: HOE901-U300 (new formulation of insulin glargine),Sanofi,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01499095
1712,Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: HOE901-U300 (new formulation of insulin glargine)|Drug: Lantus (insulin glargine),Sanofi,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01499082
1713,Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature,Completed,Has Results,Type 1 Diabetes,Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump,Medtronic Diabetes,Phase 3,Industry,Interventional,17-Mar-14,https://ClinicalTrials.gov/show/NCT01497938
1714,Phase 3 Study of Sofosbuvir and Ribavirin,Completed,Has Results,Hepatitis C,Drug: Sofosbuvir|Drug: PEG|Drug: RBV,Gilead Sciences,Phase 3,Industry,Interventional,2-Apr-14,https://ClinicalTrials.gov/show/NCT01497366
1715,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: NNRTI|Drug: FTC/TDF|Drug: Stribild,Gilead Sciences,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01495702
1716,Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo|Drug: Glimepiride|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Phase 3,Industry,Interventional,1-Sep-14,https://ClinicalTrials.gov/show/NCT01494987
1717,"Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer",Completed,Has Results,Metastatic Pancreatic Cancer,Drug: MM-398|Drug: 5 Fluorouracil|Drug: Leucovorin,Merrimack Pharmaceuticals,Phase 3,Industry,Interventional,12-Feb-16,https://ClinicalTrials.gov/show/NCT01494506
1718,Phase 3 Papulopustular Rosacea Study,Completed,Has Results,Papulopustular Rosacea,Drug: CD5024|Drug: Azelaic acid 15% Gel,Galderma,Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT01494467
1719,Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT01493778
1720,Phase 3 Papulopustular Rosacea Study,Completed,Has Results,Papulopustular Rosacea (PPR),Drug: CD5024|Drug: Azelaic acid 15% Gel,Galderma,Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT01493687
1721,Combining Lesinurad With Allopurinol in Inadequate Responders,Completed,Has Results,Gout,Drug: Lesinurad|Drug: Placebo|Drug: Allopurinol,"Ardea Biosciences, Inc.",Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01493531
1722,Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection,Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Telaprevir|Drug: Peginterferon alfa-2a|Drug: Ribavirin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,3-Jun-16,https://ClinicalTrials.gov/show/NCT01492426
1723,Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Placebo|Drug: Tiotropium|Drug: Olodaterol|Drug: tiotropium + olodaterol|Drug: Tiotropium + Olodaterol|Device: Respimat,Boehringer Ingelheim,Phase 3,Industry,Interventional,15-Sep-15,https://ClinicalTrials.gov/show/NCT01533922
1724,"TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: TVR,Janssen R&D Ireland,Phase 3,Industry,Interventional,10-Apr-15,https://ClinicalTrials.gov/show/NCT01485991
1725,eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam,Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,Phase 3,Industry,Interventional,26-Nov-14,https://ClinicalTrials.gov/show/NCT01484977
1726,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,Completed,Has Results,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,Drug: Alisertib|Drug: Pralatrexate|Drug: Gemcitabine|Drug: Romidepsin,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 3,Industry,Interventional,31-Jul-18,https://ClinicalTrials.gov/show/NCT01482962
1727,A Study in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01481779
1728,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: PI|Drug: RTV|Drug: FTC/TDF|Drug: Stribild,Gilead Sciences,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01475838
1729,A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol,Completed,Has Results,Hypercholesterolemia|Heterozygous Familial,Drug: mipomersen sodium 200 mg|Drug: Placebo|Drug: mipomersen sodium 70 mg,"Kastle Therapeutics, LLC",Phase 3,Industry,Interventional,14-Mar-19,https://ClinicalTrials.gov/show/NCT01475825
1730,Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN),Completed,Has Results,Diabetic Peripheral Neuropathy,Drug: Pregabalin|Other: placebo,Pfizer,Phase 3,Industry,Interventional,18-Nov-14,https://ClinicalTrials.gov/show/NCT01474772
1731,A Phase 3 Study in Participants With Moderate to Severe Psoriasis,Completed,Has Results,Psoriasis,"Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Drug: Placebo",Eli Lilly and Company,Phase 3,Industry,Interventional,27-May-16,https://ClinicalTrials.gov/show/NCT01474512
1732,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,Completed,Has Results,Systemic Sclerosis|Ulcers,Drug: macitentan 3mg|Drug: macitentan 10mg|Drug: placebo,Actelion,Phase 3,Industry,Interventional,6-Jan-15,https://ClinicalTrials.gov/show/NCT01474109
1733,Second Study of the Effect of Teriparatide on Hip Fracture Healing,Completed,Has Results,Femur Neck Fracture,Drug: Teriparatide|Drug: Placebo|Dietary Supplement: Calcium supplementation|Dietary Supplement: Vitamin D supplementation,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Nov-14,https://ClinicalTrials.gov/show/NCT01473602
1734,Effect of Teriparatide on Hip Fracture Healing,Completed,Has Results,Femur Neck Fracture,Drug: Teriparatide|Drug: Placebo|Dietary Supplement: Calcium supplementation|Dietary Supplement: Vitamin D supplementation,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Nov-14,https://ClinicalTrials.gov/show/NCT01473589
1735,Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis,Completed,Has Results,Primary Biliary Cirrhosis,Drug: Obeticholic Acid (OCA)|Drug: Placebo,Intercept Pharmaceuticals,Phase 3,Industry,Interventional,13-Feb-17,https://ClinicalTrials.gov/show/NCT01473524
1736,Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Lispro|Drug: Insulin Aspart,Eli Lilly and Company,Phase 3,Industry,Interventional,20-Mar-14,https://ClinicalTrials.gov/show/NCT01474538
1737,Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ranolazine|Drug: Placebo|Behavioral: Diet|Behavioral: Exercise,Gilead Sciences,Phase 3,Industry,Interventional,15-Oct-14,https://ClinicalTrials.gov/show/NCT01472185
1738,"A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1",Completed,Has Results,Hepatitis C Virus Genotype-1,Drug: TMC435|Drug: Pegylated interferon alpha-2a|Drug: Ribavirin,Janssen R&D Ireland,Phase 3,Industry,Interventional,29-Oct-14,https://ClinicalTrials.gov/show/NCT01479868
1739,Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus,Completed,Has Results,"Hepatitis C, Genotype 1",Drug: Daclatasvir|Drug: Ribavirin|Drug: PEG-Interferon alfa 2a,Bristol-Myers Squibb,Phase 3,Industry,Interventional,17-Dec-15,https://ClinicalTrials.gov/show/NCT01471574
1740,Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure,Completed,Has Results,Acute Alcoholic Hepatitis,Biological: ELAD treatment|Other: Standard of care (Control),"Vital Therapies, Inc.",Phase 3,Industry,Interventional,15-Feb-19,https://ClinicalTrials.gov/show/NCT01471028
1741,"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: ALKS 9072|Drug: Placebo,"Alkermes, Inc.",Phase 3,Industry,Interventional,22-Jan-16,https://ClinicalTrials.gov/show/NCT01469039
1742,A Study in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2605541|Drug: Insulin Glargine|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01468987
1743,"A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: tofacitinib|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,7-Jun-16,https://ClinicalTrials.gov/show/NCT01465763
1744,"Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty",Completed,Has Results,Central Precocious Puberty,Drug: Triptorelin,Debiopharm International SA,Phase 3,Industry,Interventional,4-Sep-15,https://ClinicalTrials.gov/show/NCT01467882
1745,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke,Completed,Has Results,Post-stroke Spasticity of the Lower Limb,Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,7-Nov-16,https://ClinicalTrials.gov/show/NCT01464307
1746,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: Dulaglutide|Drug: Glimepiride,Eli Lilly and Company,Phase 3,Industry,Interventional,14-Oct-15,https://ClinicalTrials.gov/show/NCT01769378
1747,Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine,Completed,Has Results,Migraine Headache,Drug: Sumatriptan|Drug: Placebo,Optinose US Inc.,Phase 3,Industry,Interventional,6-May-15,https://ClinicalTrials.gov/show/NCT01462812
1748,Study of Diclofenac Capsules to Treat Osteoarthritis Pain,Completed,Has Results,Osteoarthritis,Drug: Diclofenac|Drug: Placebo,"Iroko Pharmaceuticals, LLC",Phase 3,Industry,Interventional,26-May-14,https://ClinicalTrials.gov/show/NCT01461369
1749,"A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,Drug: tofacitinib|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,1-Jun-16,https://ClinicalTrials.gov/show/NCT01458951
1750,"A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis",Completed,Has Results,Ulcerative Colitis,"Drug: Placebo|Drug: CP690,550|Drug: CP-690,550",Pfizer,Phase 3,Industry,Interventional,18-May-17,https://ClinicalTrials.gov/show/NCT01458574
1751,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR),Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,15-May-14,https://ClinicalTrials.gov/show/NCT01458275
1752,Efficacy and Safety of SPARC0921 in Subjects With Spasticity,Completed,Has Results,Spasticity,Drug: SPARC0921|Drug: Placebo0921,Sun Pharma Advanced Research Company Limited,Phase 3,Industry,Interventional,18-Jun-19,https://ClinicalTrials.gov/show/NCT01457352
1753,Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Fasiglifam,Takeda,Phase 3,Industry,Interventional,5-Apr-16,https://ClinicalTrials.gov/show/NCT01456195
1754,HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF),Completed,Has Results,Paroxysmal Atrial Fibrillation,Device: EAS-AC (HeartLight)|Procedure: Control Arm Ablation,CardioFocus,Phase 3,Industry,Interventional,8-Sep-16,https://ClinicalTrials.gov/show/NCT01456000
1755,Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain,Completed,Has Results,Painful Diabetic Peripheral Neuropathy,Drug: pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,23-Apr-15,https://ClinicalTrials.gov/show/NCT01455415
1756,Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A,Completed,Has Results,Hemophilia A,Drug: rFVIIIFc,Bioverativ Therapeutics Inc.,Phase 3,Industry,Interventional,22-Nov-18,https://ClinicalTrials.gov/show/NCT01454739
1757,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",Completed,Has Results,Non-Small Cell Lung Cancer (NSCLC),"Drug: Eribulin|Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed",Eisai Inc.,Phase 3,Industry,Interventional,1-Mar-17,https://ClinicalTrials.gov/show/NCT01454934
1758,A Study in Participants With Type I Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glargine|Drug: LY2605541|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01454284
1759,Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification,Completed,Has Results,Intraocular Lens Replacement,Drug: OMS302|Drug: Placebo,Omeros Corporation,Phase 3,Industry,Interventional,21-Aug-14,https://ClinicalTrials.gov/show/NCT01454063
1760,Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets|Drug: Placebo to match hydrocodone bitartrate q24h tablets,Purdue Pharma LP,Phase 3,Industry,Interventional,4-Dec-14,https://ClinicalTrials.gov/show/NCT01452529
1761,A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).,Completed,Has Results,Perennial Allergic Rhinitis|PAR,Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,6-May-14,https://ClinicalTrials.gov/show/NCT01451541
1762,Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: Technosphere® Insulin|Drug: Technosphere Powder,Mannkind Corporation,Phase 3,Industry,Interventional,17-Oct-14,https://ClinicalTrials.gov/show/NCT01451398
1763,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,Completed,Has Results,Small Cell Lung Carcinoma,Biological: Ipilimumab|Biological: Placebo matching Ipilimumab|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,18-Jul-16,https://ClinicalTrials.gov/show/NCT01450761
1764,Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Phase 3,Industry,Interventional,7-May-12,https://ClinicalTrials.gov/show/NCT01447719
1765,Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism,Completed,Has Results,Male Hypogonadism,Drug: Testosterone,Acerus Pharmaceuticals Corporation,Phase 3,Industry,Interventional,13-Jun-18,https://ClinicalTrials.gov/show/NCT01446042
1766,Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Technosphere® Insulin with MedTone C Inhaler|Drug: Technosphere ®Insulin with Gen2 Inhaler|Drug: Insulin Aspart in combination with a basal insulin,Mannkind Corporation,Phase 3,Industry,Interventional,22-Oct-14,https://ClinicalTrials.gov/show/NCT01445951
1767,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Completed,Has Results,Asthma,Drug: Symbicort pMDI|Drug: budesonide pMDI,AstraZeneca,Phase 3,Industry,Interventional,15-Dec-16,https://ClinicalTrials.gov/show/NCT01444430
1768,Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients,Completed,Has Results,Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura|Immune Thrombocytopenia,Drug: Romiplostim|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,19-Jan-17,https://ClinicalTrials.gov/show/NCT01444417
1769,Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI),Completed,Has Results,Coronary Artery Disease|Angina Pectoris,Drug: Ranolazine|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,15-Jul-16,https://ClinicalTrials.gov/show/NCT01442038
1770,Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients,Completed,Has Results,Chemotherapy-Induced Nausea and Vomiting,Drug: Palonosetron|Drug: Ondansetron|Drug: Placebo to Ondansetron|Drug: Placebo to Palonosetron,Helsinn Healthcare SA,Phase 3,Industry,Interventional,28-Jul-14,https://ClinicalTrials.gov/show/NCT01442376
1771,Safety Study of Entocort for Children With Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Entocort,Perrigo Company,Phase 3,Industry,Interventional,11-Aug-16,https://ClinicalTrials.gov/show/NCT01444092
1772,Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Formoterol Fumarate,AstraZeneca,Phase 3,Industry,Interventional,11-May-17,https://ClinicalTrials.gov/show/NCT01437540
1773,"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Aclidinium Bromide|Drug: Formoterol Fumarate|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,23-Mar-17,https://ClinicalTrials.gov/show/NCT01437397
1774,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Drug: Antidepressant + Placebo,Shire,Phase 3,Industry,Interventional,7-Nov-14,https://ClinicalTrials.gov/show/NCT01436162
1775,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: SPD489 (Lisdexamfetamine dimesylate )|Drug: Placebo,Shire,Phase 3,Industry,Interventional,19-Nov-14,https://ClinicalTrials.gov/show/NCT01436149
1776,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone furoate 50mcg|Drug: Fluticasone propionate 100mcg|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT01436110
1777,PEARL Schizophrenia Maintenance,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Matching Placebo,Sunovion,Phase 3,Industry,Interventional,25-Sep-14,https://ClinicalTrials.gov/show/NCT01435928
1778,A Study in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glargine|Drug: LY2605541,Eli Lilly and Company,Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT01435616
1779,Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole,Completed,Has Results,Schizophrenia,Drug: Aripiprazole (Abilify®) IM Depot Injection,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,27-Mar-15,https://ClinicalTrials.gov/show/NCT01432444
1780,Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO),Completed,Has Results,Renal Failure|Tremors,Drug: Prograf|Drug: LCP-Tacro,Veloxis Pharmaceuticals,Phase 3,Industry,Interventional,8-May-15,https://ClinicalTrials.gov/show/NCT01438710
1781,A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression,Completed,Has Results,Fibromyalgia,Drug: Pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,22-Oct-14,https://ClinicalTrials.gov/show/NCT01432236
1782,Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents,Completed,Has Results,Asthma,Drug: fluticasone furoate|Drug: albuterol/salbutamol,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT01431950
1783,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: IV Dalbavancin|Drug: Vancomycin/Linezolid,"Durata Therapeutics Inc., an affiliate of Allergan plc",Phase 3,Industry,Interventional,12-Feb-14,https://ClinicalTrials.gov/show/NCT01431339
1784,Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium + olodaterol|Drug: tiotropium|Drug: olodaterol|Device: Respimat,Boehringer Ingelheim,Phase 3,Industry,Interventional,16-Jul-15,https://ClinicalTrials.gov/show/NCT01431287
1785,Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium + olodaterol|Drug: tiotropium|Drug: olodaterol|Device: Respimat,Boehringer Ingelheim,Phase 3,Industry,Interventional,16-Jul-15,https://ClinicalTrials.gov/show/NCT01431274
1786,Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder,Completed,Has Results,Non-24-Hour Sleep-Wake Disorder,Drug: tasimelteon|Drug: Placebo,Vanda Pharmaceuticals,Phase 3,Industry,Interventional,10-Oct-14,https://ClinicalTrials.gov/show/NCT01430754
1787,Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma,Completed,Has Results,Asthma,Drug: Fluticasone furoate 50mcg|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT01436071
1788,Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole,Completed,Has Results,Vitreomacular Adhesion Including Macular Hole,Drug: Ocriplasmin|Other: Sham injection,ThromboGenics,Phase 3,Industry,Interventional,11-Jan-16,https://ClinicalTrials.gov/show/NCT01429441
1789,Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain,Completed,Has Results,Chronic Noncancer Pain,Drug: oxycodone HCl and naltrexone HCl extended-release capsules,Pfizer,Phase 3,Industry,Interventional,21-Nov-16,https://ClinicalTrials.gov/show/NCT01428583
1790,"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy",Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma SA|UCB Pharma,Phase 3,Industry,Interventional,2-Aug-17,https://ClinicalTrials.gov/show/NCT01728077
1791,Actual Use Trial of Naproxen Sodium,Completed,Has Results,Pain,Drug: Naproxen Sodium ER (BAYH6689),Bayer,Phase 3,Industry,Interventional,20-May-13,https://ClinicalTrials.gov/show/NCT01427803
1792,Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia,Completed,Has Results,AtrioVentricular Nodal Reentrant Tachycardia|Supraventricular Tachycardia|Heart Disease,Device: Freezor Xtra Cryoablation Catheter,Medtronic Cardiac Rhythm and Heart Failure,Phase 3,Industry,Interventional,31-Mar-17,https://ClinicalTrials.gov/show/NCT01426425
1793,Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area,Completed,Has Results,Moderate or Severe Submental Fullness,Drug: Deoxycholic acid injection,Kythera Biopharmaceuticals,Phase 3,Industry,Interventional,14-Jan-16,https://ClinicalTrials.gov/show/NCT01426373
1794,A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma,Completed,Has Results,Asthma,Drug: Placebo MDPI|Drug: Albuterol MDPI,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,20-May-15,https://ClinicalTrials.gov/show/NCT01424813
1795,Major Depressive Disorder With Mixed Features - Extension,Completed,Has Results,Major Depressive Disorder,Drug: Lurasidone,Sunovion,Phase 3,Industry,Interventional,14-Oct-15,https://ClinicalTrials.gov/show/NCT01423253
1796,TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: TR-701 FA|Drug: Linezolid,Trius Therapeutics LLC,Phase 3,Industry,Interventional,8-Sep-14,https://ClinicalTrials.gov/show/NCT01421511
1797,Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose,Completed,Has Results,Major Depressive Disorder With Mixed Features,Drug: Lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,9-Oct-15,https://ClinicalTrials.gov/show/NCT01421134
1798,Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1),Completed,Has Results,Keratoconjunctivitis Sicca|Dry Eye Disease,Drug: Lifitegrast|Drug: Placebo,Shire,Phase 3,Industry,Interventional,24-Feb-17,https://ClinicalTrials.gov/show/NCT01421498
1799,Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B,Completed,Has Results,Severe Hemophilia B,Biological: rFIXFc,Bioverativ Therapeutics Inc.,Phase 3,Industry,Interventional,22-Nov-18,https://ClinicalTrials.gov/show/NCT01425723
1800,A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy,Completed,Has Results,Breast Cancer,Drug: Trastuzumab emtansine|Drug: Treatment of physician's choice,Hoffmann-La Roche,Phase 3,Industry,Interventional,5-May-14,https://ClinicalTrials.gov/show/NCT01419197
1801,Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer,Completed,Has Results,Prostate Cancer,"Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA",GP-Pharm,Phase 3,Industry,Interventional,18-Jan-17,https://ClinicalTrials.gov/show/NCT01415960
1802,Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Epratuzumab,UCB Pharma,Phase 3,Industry,Interventional,3-Oct-18,https://ClinicalTrials.gov/show/NCT01408576
1803,Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Completed,Has Results,Mucopolysaccharidosis IV A|Morquio A Syndrome|MPS IVA,Drug: BMN 110 - Weekly|Drug: BMN 110 - Every Other Week,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,19-May-17,https://ClinicalTrials.gov/show/NCT01415427
1804,Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: AIN457 150mg|Drug: AIN457 300mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-May-15,https://ClinicalTrials.gov/show/NCT01406938
1805,"Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)",Completed,Has Results,Von Willebrand Disease,Biological: Recombinant von Willebrand factor (rVWF)|Drug: Placebo|Biological: Recombinant factor VIIII (rFVIII),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,21-Apr-16,https://ClinicalTrials.gov/show/NCT01410227
1806,Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System,Completed,Has Results,Typical Atrial Flutter,Device: Treatment Arm,Abbott Medical Devices,Phase 3,Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT01401361
1807,"Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray",Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide|Drug: mometasone,Sunovion,Phase 3,Industry,Interventional,30-Apr-13,https://ClinicalTrials.gov/show/NCT01401465
1808,Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline,Completed,Has Results,Progressive Cognitive Decline,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Phase 3,Industry,Interventional,22-Mar-13,https://ClinicalTrials.gov/show/NCT01400425
1809,Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.,Completed,Has Results,Chronic Nonmalignant and Nonneuropathic Pain,Drug: Hydrocodone bitartrate q24h film-coated tablets,Purdue Pharma LP,Phase 3,Industry,Interventional,4-Dec-14,https://ClinicalTrials.gov/show/NCT01400139
1810,Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4),Completed,Has Results,"Hepatitis C, Chronic",Drug: PegIFN/RBV|Drug: BI201335|Drug: BI201335 24W|Drug: Bi 201335,Boehringer Ingelheim,Phase 3,Industry,Interventional,4-Sep-15,https://ClinicalTrials.gov/show/NCT01399619
1811,Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: OPC-34712,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT01397786
1812,Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways,Completed,Has Results,Cystic Fibrosis|Pseudomonas Aeruginosa,Drug: AZLI,Gilead Sciences,Phase 3,Industry,Interventional,1-May-14,https://ClinicalTrials.gov/show/NCT01404234
1813,Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia,Completed,Has Results,Acute Schizophrenia,Drug: OPC-34712 [Brexpiprazole] High Dose|Drug: Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Drug: Experimental: OPC-34712 [Brexpiprazole] Low Dose|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,29-Oct-15,https://ClinicalTrials.gov/show/NCT01396421
1814,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc",Phase 3,Industry,Interventional,11-Jul-17,https://ClinicalTrials.gov/show/NCT01395914
1815,Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Phase 3,Industry,Interventional,9-May-18,https://ClinicalTrials.gov/show/NCT01395810
1816,A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,17-Jun-15,https://ClinicalTrials.gov/show/NCT01395524
1817,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,Completed,Has Results,Postoperative Nausea and Vomiting,Drug: Palonosetron|Drug: Ondansetron|Drug: Placebo to Ondansetron|Drug: Placebo to Palonosetron,Helsinn Healthcare SA,Phase 3,Industry,Interventional,30-Jul-14,https://ClinicalTrials.gov/show/NCT01395901
1818,Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia,Completed,Has Results,Acute Schizophrenia,Drug: OPC-34712|Drug: Placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,26-Nov-15,https://ClinicalTrials.gov/show/NCT01393613
1819,A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Jan-17,https://ClinicalTrials.gov/show/NCT01392573
1820,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",Completed,Has Results,Psoriatic Arthritis,Drug: Secukinumab (75 mg)|Drug: Secukinumab (150 mg)|Drug: Placebo Comparator,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,4-Feb-16,https://ClinicalTrials.gov/show/NCT01392326
1821,Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors,Drug: vatreptacog alfa (activated)|Drug: eptacog alfa (activated),Novo Nordisk A/S,Phase 3,Industry,Interventional,6-Dec-13,https://ClinicalTrials.gov/show/NCT01392547
1822,Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke,Completed,Has Results,Post-stroke Spasticity of the Upper Limb,Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,11-Feb-16,https://ClinicalTrials.gov/show/NCT01392300
1823,A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years,Completed,Has Results,"Epilepsy, Partial Seizures",Drug: Pregabalin add-on therapy,Pfizer,Phase 3,Industry,Interventional,21-Mar-17,https://ClinicalTrials.gov/show/NCT01389596
1824,"BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C",Completed,Has Results,Hepatitis C,Drug: Daclatasvir|Drug: Peg-Interferon Alfa-2a|Drug: Ribavirin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,16-Sep-15,https://ClinicalTrials.gov/show/NCT01389323
1825,Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty,Completed,Has Results,"Primary Generalized (Osteo)Arthritis|Post-traumatic Arthrosis of Other Joints, Upper Arm",Device: Simpliciti™ Shoulder System,"Tornier, Inc.",Phase 3,Industry,Interventional,14-Apr-16,https://ClinicalTrials.gov/show/NCT01390038
1826,Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms,Completed,Has Results,Hot Flashes,"Drug: Estradiol transdermal one 90 μL spray|Drug: Estradiol transdermal spray, two 90 μL sprays|Drug: Estradiol transdermal three 90 μL sprays|Drug: Placebo transdermal two 90 μL sprays|Drug: Placebo transdermal three 90 μL sprays|Drug: Placebo transdermal one 90 μL spray","Lumara Health, Inc.",Phase 3,Industry,Interventional,11-Jun-12,https://ClinicalTrials.gov/show/NCT01389102
1827,Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin aspart|Drug: liraglutide,Novo Nordisk A/S,Phase 3,Industry,Interventional,26-Nov-15,https://ClinicalTrials.gov/show/NCT01388361
1828,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc",Phase 3,Industry,Interventional,11-Jul-17,https://ClinicalTrials.gov/show/NCT01387282
1829,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),Completed,Has Results,Cachexia|Non-Small Cell Lung Cancer,Drug: Anamorelin HCl|Drug: Placebo,"Helsinn Therapeutics (U.S.), Inc",Phase 3,Industry,Interventional,11-Jul-17,https://ClinicalTrials.gov/show/NCT01387269
1830,THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation,Completed,Has Results,Heart Diseases|Arrhythmia|Atrial Fibrillation,Device: THERMOCOOL® SMARTTOUCH™ Catheter,"Biosense Webster, Inc.",Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01385202
1831,"A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema",Completed,Has Results,Hereditary Angioedema (HAE),Drug: icatibant,Shire,Phase 3,Industry,Interventional,25-Mar-19,https://ClinicalTrials.gov/show/NCT01386658
1832,Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,29-Oct-13,https://ClinicalTrials.gov/show/NCT01377194
1833,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents",Completed,Has Results,Rheumatoid Arthritis,Biological: Secukinumab (AIN457)|Biological: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,29-Mar-17,https://ClinicalTrials.gov/show/NCT01377012
1834,Efficacy and Safety of GTR in Comparison to Copaxone®,Completed,Has Results,Multiple Sclerosis,Drug: Glatiramer Acetate (GTR)|Drug: Glatiramer Acetate (Copaxone®)|Drug: Placebo,Synthon BV,Phase 3,Industry,Interventional,31-Oct-16,https://ClinicalTrials.gov/show/NCT01489254
1835,Self Selection Trial of Naproxen Sodium,Completed,Has Results,Pain,Drug: Naproxen sodium ER (BAYH6689)|Drug: Advil,Bayer,Phase 3,Industry,Interventional,29-Nov-12,https://ClinicalTrials.gov/show/NCT01383486
1836,Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease,Completed,Has Results,Cushing's Disease,Drug: pasireotide LAR|Drug: SOM230 LAR 30 mg|Drug: SOM230 LAR 10 mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,11-Apr-18,https://ClinicalTrials.gov/show/NCT01374906
1837,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Completed,Has Results,Major Depressive Disorder,Drug: desvenlafaxine succinate sustained release|Drug: fluoxetine|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,20-Nov-15,https://ClinicalTrials.gov/show/NCT01372150
1838,A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,20-Mar-17,https://ClinicalTrials.gov/show/NCT01371734
1839,"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD",Completed,Has Results,Major Depressive Disorder,Drug: DVS SR,Pfizer,Phase 3,Industry,Interventional,8-Feb-17,https://ClinicalTrials.gov/show/NCT01371721
1840,"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD",Completed,Has Results,Major Depressive Disorder,Drug: DVS SR,Pfizer,Phase 3,Industry,Interventional,8-Dec-16,https://ClinicalTrials.gov/show/NCT01371708
1841,Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Device: NEST-1 (NeoSync EEG Synchronized TMS)|Device: SHAM,"NeoSync, Inc.",Phase 3,Industry,Interventional,14-Jul-15,https://ClinicalTrials.gov/show/NCT01370733
1842,Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001,Completed,Has Results,Pain,Drug: Oxycodone hydrochloride controlled-release tablets,Purdue Pharma LP,Phase 3,Industry,Interventional,15-Jan-15,https://ClinicalTrials.gov/show/NCT01369615
1843,A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2),Completed,Has Results,Crohn's Disease|Inflammatory Bowel Disease|IBD|Colitis,Drug: Group 1: Placebo|Drug: Group 2 ustekinumab 130 mg|Drug: Group 3: ustekinumab approximately 6 mg/kg,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,6-Jan-17,https://ClinicalTrials.gov/show/NCT01369342
1844,A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1),Completed,Has Results,Crohn's Disease|IBD|Colitis|Inflammatory Bowel Disease,Drug: Group 2 ustekinumab 130 mg|Drug: Group 3: ustekinumab approximately 6 mg/kg|Drug: Group 1: Placebo,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,7-Dec-16,https://ClinicalTrials.gov/show/NCT01369329
1845,Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Nov-15,https://ClinicalTrials.gov/show/NCT01365507
1846,Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year,Completed,Has Results,Moderate to Severe Plaque-type Psoriasis,Drug: secukinumab 150 mg|Drug: placebo to secukinumab 150 mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,29-May-15,https://ClinicalTrials.gov/show/NCT01365455
1847,Safety Trial of Naproxen Sodium/ Diphenhydramine,Completed,Has Results,Pain,Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|Drug: Placebo,Bayer,Phase 3,Industry,Interventional,16-Jun-14,https://ClinicalTrials.gov/show/NCT01365052
1848,Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction,Completed,Has Results,Treatment Outcome,Drug: Vortioxetine|Drug: Escitalopram|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,9-Oct-14,https://ClinicalTrials.gov/show/NCT01364649
1849,Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec,Novo Nordisk A/S,Phase 3,Industry,Interventional,18-Nov-15,https://ClinicalTrials.gov/show/NCT01364428
1850,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: E/C/F/TDF|Drug: COBI|Drug: ATV|Drug: DRV|Drug: NRTI,Gilead Sciences,Phase 3,Industry,Interventional,31-Oct-14,https://ClinicalTrials.gov/show/NCT01363011
1851,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Completed,Has Results,Heartburn,Drug: Esomeprazole,AstraZeneca,Phase 3,Industry,Interventional,11-Apr-13,https://ClinicalTrials.gov/show/NCT01370538
1852,Efficacy of Esomeprazole in Patients With Frequent Heartburn,Completed,Has Results,Heartburn,Drug: Esomeprazole,AstraZeneca,Phase 3,Industry,Interventional,14-Mar-13,https://ClinicalTrials.gov/show/NCT01370525
1853,Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study,Completed,Has Results,Parkinson's Disease,Drug: IPX066,"Impax Laboratories, LLC|Michael J. Fox Foundation for Parkinson's Research",Phase 3,Industry|Other,Interventional,18-Apr-17,https://ClinicalTrials.gov/show/NCT01411137
1854,Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS),Completed,Has Results,Postmenopausal Symptoms,Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules,Noven Therapeutics,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT01361308
1855,Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712|Drug: Escitalopram|Drug: Fluoxetine|Drug: Paroxetine CR|Drug: Sertraline|Drug: Duloxetine|Drug: Venlafaxine XR,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,17-Sep-18,https://ClinicalTrials.gov/show/NCT01360866
1856,Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712 + ADT|Drug: Placebo + ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,26-Nov-15,https://ClinicalTrials.gov/show/NCT01360645
1857,Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial),Completed,Has Results,"Depressive Disorder|Depression|Depressive Disorder, Major|Mood Disorders|Mental Disorders",Drug: OPC-34712 + ADT|Drug: Placebo + ADT,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,1-Jan-16,https://ClinicalTrials.gov/show/NCT01360632
1858,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Dacomitinib (PF-00299804)|Drug: Active Comparator (erlotinib)|Drug: Placebo erlotinib|Drug: Placebo PF00299804,Pfizer,Phase 3,Industry,Interventional,24-May-17,https://ClinicalTrials.gov/show/NCT01360554
1859,New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day,Completed,Has Results,Asthma,Drug: Symbicort|Drug: Budesonide,AstraZeneca,Phase 3,Industry,Interventional,11-Mar-14,https://ClinicalTrials.gov/show/NCT01360021
1860,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3),Completed,Has Results,"Hepatitis C, Chronic",Drug: BI 201335|Drug: Pegylated Interferon-alpha (IFN)|Drug: Ribavirin (RBV)|Drug: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,28-Oct-15,https://ClinicalTrials.gov/show/NCT01358864
1861,Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: DHEA,EndoCeutics Inc.,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT01358760
1862,Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Oxycodone/Naloxone Controlled-release|Drug: Placebo,Purdue Pharma LP,Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT01358526
1863,Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex,Completed,Has Results,Bipolar I Disorder,Drug: Lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,26-Jul-16,https://ClinicalTrials.gov/show/NCT01358357
1864,Study Assessing Double-masked Uveitis Treatment,Completed,Has Results,"Uveitis; Posterior, Disorder",Drug: DE-109 44 ug|Drug: DE-109 440 ug|Drug: DE-109 880 ug,Santen Inc.,Phase 3,Industry,Interventional,16-Jul-19,https://ClinicalTrials.gov/show/NCT01358266
1865,"Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",Completed,Has Results,Chronic Plaque Psoriasis,Drug: Placebo|Drug: secukinumab (AIN457)|Drug: etanercept,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,23-Sep-15,https://ClinicalTrials.gov/show/NCT01358578
1866,Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients,Completed,Has Results,Acute Gouty Arthritis,Drug: Canakinumab pre-filled syringe|Drug: Canakinumab lyophilized powder|Drug: Triamcinolone Acetonide|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,29-Jan-14,https://ClinicalTrials.gov/show/NCT01356602
1867,Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout,Completed,Has Results,Gout,Biological: pegloticase,Savient Pharmaceuticals,Phase 3,Industry,Interventional,2-Dec-11,https://ClinicalTrials.gov/show/NCT01356498
1868,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,Completed,Has Results,Epilepsy,Drug: Brivaracetam tablets|Drug: Brivaracetam bolus|Drug: Brivaracetam infusion|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,13-Apr-16,https://ClinicalTrials.gov/show/NCT01405508
1869,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Muscle Wasting|Non Small Cell Lung Cancer,Drug: GTx-024|Drug: placebo,GTx,Phase 3,Industry,Interventional,3-Mar-16,https://ClinicalTrials.gov/show/NCT01355484
1870,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 Gel|Drug: Placebo,Galderma,Phase 3,Industry,Interventional,21-Nov-13,https://ClinicalTrials.gov/show/NCT01355471
1871,Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 gel|Drug: Placebo,Galderma,Phase 3,Industry,Interventional,21-Nov-13,https://ClinicalTrials.gov/show/NCT01355458
1872,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma SA|UCB Pharma,Phase 3,Industry,Interventional,15-Aug-16,https://ClinicalTrials.gov/show/NCT01653262
1873,"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.",Completed,Has Results,Healthy,Biological: rLP2086|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,23-Feb-16,https://ClinicalTrials.gov/show/NCT01352845
1874,A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years,Completed,Has Results,"Meningitis, Meningococcal",Biological: rLP2086 vaccine|Biological: control,Pfizer,Phase 3,Industry,Interventional,11-Mar-15,https://ClinicalTrials.gov/show/NCT01352793
1875,16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Drug: Secukinumab (75 mg)|Drug: Secukinumab (150 mg)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,27-Jan-17,https://ClinicalTrials.gov/show/NCT01358175
1876,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Bevacizumab|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed,Hoffmann-La Roche,Phase 3,Industry,Interventional,18-Sep-17,https://ClinicalTrials.gov/show/NCT01351415
1877,"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)",Completed,Has Results,Rheumatoid Arthritis,Biological: AIN457|Biological: Placebo|Biological: Abatacept,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,23-May-16,https://ClinicalTrials.gov/show/NCT01350804
1878,An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma,Completed,Has Results,Melanoma,Biological: Talimogene Laherparepvec|Drug: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF),BioVex Limited,Phase 3,Industry,Interventional,18-Dec-15,https://ClinicalTrials.gov/show/NCT01368276
1879,An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: Midazolam|Other: Caffeine|Drug: S-warfarin|Other: Vitamin K|Drug: Omeprazole|Drug: Dextromethorphan|Biological: BIIB019 (Daclizumab),Biogen,Phase 3,Industry,Interventional,14-Mar-17,https://ClinicalTrials.gov/show/NCT01462318
1880,3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection,Completed,Has Results,Hepatitis C,Drug: No treatment,Janssen R&D Ireland,Phase 3,Industry,Interventional,16-Feb-17,https://ClinicalTrials.gov/show/NCT01349465
1881,A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.,Completed,Has Results,Coronary Artery Disease,Drug: Flurpiridaz F18|Drug: 99mTechnicium (sestamibi or tetrofosmin),Lantheus Medical Imaging,Phase 3,Industry,Interventional,5-Apr-16,https://ClinicalTrials.gov/show/NCT01347710
1882,Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis|Measles|Polio,"Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,29-May-15,https://ClinicalTrials.gov/show/NCT01346293
1883,Gadobutrol Enhanced MRA of the Renal Arteries,Completed,Has Results,Renal Artery Obstruction,"Drug: Gadobutrol (Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,26-Aug-15,https://ClinicalTrials.gov/show/NCT01344460
1884,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,Completed,Has Results,Carotid Stenosis,"Drug: Gadobutrol (Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,26-Aug-15,https://ClinicalTrials.gov/show/NCT01344447
1885,Safety and Maintenance Study of Entocort for Children With Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: Entocort,Perrigo Company,Phase 3,Industry,Interventional,19-Jun-15,https://ClinicalTrials.gov/show/NCT01453946
1886,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,Completed,Has Results,Abscess|Wound Infection|Surgical Site Infection|Cellulitis,Drug: Dalbavancin|Drug: Vancomycin / Linezolid,"Durata Therapeutics Inc., an affiliate of Allergan plc",Phase 3,Industry,Interventional,25-Dec-13,https://ClinicalTrials.gov/show/NCT01339091
1887,Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder,Completed,Has Results,Attention Deficit/Hyperactivity Disorder,Drug: Ritalin LA (methylphenidate hydrochloride extended release),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,26-May-14,https://ClinicalTrials.gov/show/NCT01338818
1888,A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate/Vilanterol|Drug: Vilanterol|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Jul-15,https://ClinicalTrials.gov/show/NCT01336608
1889,Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Usual care,AstraZeneca,Phase 3,Industry,Interventional,20-Oct-14,https://ClinicalTrials.gov/show/NCT01336205
1890,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec|Drug: liraglutide,Novo Nordisk A/S,Phase 3,Industry,Interventional,2-Jun-17,https://ClinicalTrials.gov/show/NCT01336023
1891,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II,Completed,Has Results,Pulmonary Fibrosis,Drug: placebo|Drug: BIBF 1120,Boehringer Ingelheim,Phase 3,Industry,Interventional,13-Feb-15,https://ClinicalTrials.gov/show/NCT01335477
1892,Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients,Completed,Has Results,Pulmonary Fibrosis,Drug: placebo|Drug: BIBF 1120,Boehringer Ingelheim,Phase 3,Industry,Interventional,13-Feb-15,https://ClinicalTrials.gov/show/NCT01335464
1893,Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Phase 3,Industry,Interventional,28-Jul-17,https://ClinicalTrials.gov/show/NCT01333111
1894,A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients,Completed,Has Results,Hepatitis C,Drug: BI 201335|Drug: PegIFN/RBV,Boehringer Ingelheim,Phase 3,Industry,Interventional,31-Jul-15,https://ClinicalTrials.gov/show/NCT01330316
1895,Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Dalfampridine-ER 5mg|Drug: Dalfampridine-ER 10mg|Other: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,13-Aug-13,https://ClinicalTrials.gov/show/NCT01328379
1896,Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,"Drug: Eribulin mesylate 1.4 mg/m^2 intravenous|Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV",Eisai Inc.,Phase 3,Industry,Interventional,28-Feb-17,https://ClinicalTrials.gov/show/NCT01327885
1897,Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec,Novo Nordisk A/S,Phase 3,Industry,Interventional,17-Nov-15,https://ClinicalTrials.gov/show/NCT01326026
1898,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK 573719 +GW642444 125/25|Drug: GSK573719 + GW642444 62.5/25|Drug: GSK 573719 125|Drug: GSK 573719 62.5|Drug: GW642444 25|Drug: Plb,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Feb-14,https://ClinicalTrials.gov/show/NCT01328444
1899,"Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children",Completed,Has Results,Pain,Drug: Buprenorphine transdermal system,Purdue Pharma LP,Phase 3,Industry,Interventional,6-Jul-17,https://ClinicalTrials.gov/show/NCT01324570
1900,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,2-Jun-15,https://ClinicalTrials.gov/show/NCT01323790
1901,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719 125|Drug: GSK573719 62.5|Drug: GW642444 25|Device: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,11-Apr-14,https://ClinicalTrials.gov/show/NCT01323660
1902,Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg|Drug: Double-dummy placebo|Drug: Salbutamol as needed,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Feb-14,https://ClinicalTrials.gov/show/NCT01323621
1903,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2),Completed,Has Results,Renal Failure Chronic Requiring Hemodialysis,Drug: Soluble Ferric Pyrophosphate (SFP)|Device: Standard dialysate,"Rockwell Medical Technologies, Inc.",Phase 3,Industry,Interventional,24-Apr-15,https://ClinicalTrials.gov/show/NCT01322347
1904,Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,30-Jul-13,https://ClinicalTrials.gov/show/NCT01323634
1905,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Completed,Has Results,Thyroid Cancer,Drug: Lenvatinib|Drug: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,12-Dec-16,https://ClinicalTrials.gov/show/NCT01321554
1906,Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients,Completed,Has Results,Renal Failure Chronic Requiring Hemodialysis,Drug: Soluble Ferric Pyrophosphate (SFP)|Device: Standard dialysate,"Rockwell Medical Technologies, Inc.",Phase 3,Industry,Interventional,28-Apr-15,https://ClinicalTrials.gov/show/NCT01320202
1907,Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea,Completed,Has Results,Rosacea,Drug: CD07805/47 gel 0.5%,Galderma,Phase 3,Industry,Interventional,8-Jan-14,https://ClinicalTrials.gov/show/NCT01318733
1908,Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants,Completed,Has Results,Hepatitis C,Drug: Alisporivir|Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: ALV Placebo,Debiopharm International SA,Phase 3,Industry,Interventional,30-Sep-16,https://ClinicalTrials.gov/show/NCT01318694
1909,24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719|Drug: tiotropium bromide,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Feb-14,https://ClinicalTrials.gov/show/NCT01316913
1910,24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GW642444|Drug: tiotropium bromide,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Feb-14,https://ClinicalTrials.gov/show/NCT01316900
1911,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: 125/25 mcg once-daily GSK573719/GW642444|Drug: 125mcg once-daily GSK573719|Drug: Placebo once-daily,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Mar-14,https://ClinicalTrials.gov/show/NCT01316887
1912,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: AZLI|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,16-Apr-14,https://ClinicalTrials.gov/show/NCT01314716
1913,Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: fluticasone furoate/vilanterol|Drug: fluticasone furoate|Drug: vilanterol|Other: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,9-Aug-16,https://ClinicalTrials.gov/show/NCT01313676
1914,A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: 62.5/25mcg|Drug: 62.5mcg|Drug: 25mcg|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,4-Mar-14,https://ClinicalTrials.gov/show/NCT01313650
1915,A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719/GW642444 125/25mcg|Drug: GSK573719 125mcg|Drug: GW642444 25mcg|Drug: Placebo only,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Feb-14,https://ClinicalTrials.gov/show/NCT01313637
1916,Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: AZLI|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,16-Apr-14,https://ClinicalTrials.gov/show/NCT01313624
1917,Dysport® Adult Upper Limb Spasticity,Completed,Has Results,Nervous System Disorders,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,23-Oct-15,https://ClinicalTrials.gov/show/NCT01313299
1918,Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm,Completed,Has Results,Spasticity of the Upper and Lower Limb Due to Cerebral Causes,Drug: IncobotulinumtoxinA,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,3-Feb-17,https://ClinicalTrials.gov/show/NCT01603459
1919,Dysport® Adult Upper Limb Spasticity Extension Study,Completed,Has Results,Nervous System Disorders,Drug: Dysport®,Ipsen,Phase 3,Industry,Interventional,7-Jun-17,https://ClinicalTrials.gov/show/NCT01313312
1920,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: Placebo|Drug: Erlotinib|Drug: Second-Line Chemotherapy,Hoffmann-La Roche,Phase 3,Industry,Interventional,29-Feb-16,https://ClinicalTrials.gov/show/NCT01328951
1921,Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation,Completed,Has Results,Opioid-Induced Constipation (OIC),Drug: NKTR-118|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,1-Jun-15,https://ClinicalTrials.gov/show/NCT01309841
1922,"A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550|Drug: Placebo/CP-690,550",Pfizer,Phase 3,Industry,Interventional,19-Sep-14,https://ClinicalTrials.gov/show/NCT01309737
1923,"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TDF|Drug: EFV/FTC/TDF,Gilead Sciences,Phase 3,Industry,Interventional,27-Nov-13,https://ClinicalTrials.gov/show/NCT01309243
1924,Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Cabazitaxel (XRP6258)|Drug: Prednisone (or Prednisolone),Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT01308580
1925,Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Cabazitaxel (XRP6258)|Drug: Docetaxel (XRP6976)|Drug: Prednisone,Sanofi,Phase 3,Industry,Interventional,3-Mar-17,https://ClinicalTrials.gov/show/NCT01308567
1926,Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age,Completed,Has Results,Influenza,Biological: Influenza A (H5N1) Virus monovalent vaccine|Biological: Saline placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,31-Mar-14,https://ClinicalTrials.gov/show/NCT01310413
1927,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA),Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo,Celgene,Phase 3,Industry,Interventional,15-Aug-14,https://ClinicalTrials.gov/show/NCT01307423
1928,Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis|SAR,Drug: BDP HFA|Drug: Placebo nasal aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,20-Feb-15,https://ClinicalTrials.gov/show/NCT01307319
1929,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01305408
1930,"Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)",Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,28-May-15,https://ClinicalTrials.gov/show/NCT01347073
1931,Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Completed,Has Results,Onychomycosis of Toenails,"Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle",Pfizer,Phase 3,Industry,Interventional,15-Aug-14,https://ClinicalTrials.gov/show/NCT01302119
1932,LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy,Completed,Has Results,"Head and Neck Neoplasms|Carcinoma, Squamous Cell",Drug: Afatinib|Drug: Methotrexate,Boehringer Ingelheim,Phase 3,Industry,Interventional,14-Apr-15,https://ClinicalTrials.gov/show/NCT01345682
1933,A Study in Prevention of Re-emergence of Depression Symptoms,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01299272
1934,Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain,Completed,Has Results,Pain|Low Back Pain|Osteoarthritis|Neuropathic Pain,Drug: BEMA Buprenorphine,BioDelivery Sciences International,Phase 3,Industry,Interventional,7-Aug-18,https://ClinicalTrials.gov/show/NCT01298765
1935,Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2),Completed,Has Results,Hepatitis C,Drug: BI201335|Drug: PegIFN/RBV|Drug: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,18-Sep-15,https://ClinicalTrials.gov/show/NCT01297270
1936,Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD),Completed,Has Results,GVHD|Adult Acute Myeloid Leukemia|Adult Acute Lymphoid Leukemia|Myelodysplastic Syndrome,Biological: US-ATG-F|Biological: Placebo,Neovii Biotech,Phase 3,Industry,Interventional,20-Mar-19,https://ClinicalTrials.gov/show/NCT01295710
1937,"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",Completed,Has Results,Chronic Idiopathic Urticaria,Drug: Placebo|Drug: Omalizumab,"Genentech, Inc.",Phase 3,Industry,Interventional,2-Sep-13,https://ClinicalTrials.gov/show/NCT01292473
1938,"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.",Completed,Has Results,Partial Onset Seizures,Drug: Pregabalin Dose Level 1|Drug: Pregabalin Dose Level 2|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,9-Oct-18,https://ClinicalTrials.gov/show/NCT02072824
1939,Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: NAFT-600 (naftin 2 % gel)|Drug: Placebo,"Merz North America, Inc.",Phase 3,Industry,Interventional,26-Sep-13,https://ClinicalTrials.gov/show/NCT01290341
1940,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients",Completed,Has Results,Hepatitis C,Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Phase 3,Industry,Interventional,4-Jun-14,https://ClinicalTrials.gov/show/NCT01289782
1941,Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis,Completed,Has Results,Tinea Pedis,Drug: NAFT-600 ( naftin 2 % gel )|Drug: Placebo,"Merz North America, Inc.",Phase 3,Industry,Interventional,26-Sep-13,https://ClinicalTrials.gov/show/NCT01289015
1942,"An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants",Completed,Has Results,Hepatitis C,Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Phase 3,Industry,Interventional,13-Jun-14,https://ClinicalTrials.gov/show/NCT01290679
1943,A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment,Completed,Has Results,Chronic Idiopathic Urticaria,Drug: Omalizumab|Drug: Placebo,"Genentech, Inc.",Phase 3,Industry,Interventional,18-Oct-13,https://ClinicalTrials.gov/show/NCT01287117
1944,A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT01287039
1945,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,Completed,Has Results,Lung Cancer - Non Small Cell Squamous,Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Jun-16,https://ClinicalTrials.gov/show/NCT01285609
1946,A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT01285323
1947,Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression,Completed,Has Results,Bipolar Depression,Drug: Lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,14-Oct-13,https://ClinicalTrials.gov/show/NCT01284517
1948,"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy",Completed,Has Results,Hepatitis C,Drug: TMC435|Drug: Placebo|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV),Janssen R&D Ireland,Phase 3,Industry,Interventional,23-Apr-14,https://ClinicalTrials.gov/show/NCT01281839
1949,A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: GSK1605786A|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Sep-17,https://ClinicalTrials.gov/show/NCT01277666
1950,"A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550|Drug: Placebo/CP-690,550",Pfizer,Phase 3,Industry,Interventional,19-Sep-14,https://ClinicalTrials.gov/show/NCT01276639
1951,Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia B,Drug: nonacog beta pegol,Novo Nordisk A/S,Phase 3,Industry,Interventional,24-Jul-17,https://ClinicalTrials.gov/show/NCT01386528
1952,Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,9-Feb-15,https://ClinicalTrials.gov/show/NCT01272232
1953,Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,9-Feb-15,https://ClinicalTrials.gov/show/NCT01272219
1954,Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients,Completed,Has Results,Fibromyalgia,Drug: pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,14-Sep-18,https://ClinicalTrials.gov/show/NCT01271933
1955,Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail,Completed,Has Results,Onychomycosis of Toenails,"Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle",Pfizer,Phase 3,Industry,Interventional,15-Aug-14,https://ClinicalTrials.gov/show/NCT01270971
1956,Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia,Completed,Has Results,Post Herpetic Neuralgia,Drug: Pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,13-Jan-16,https://ClinicalTrials.gov/show/NCT01270828
1957,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Completed,Has Results,Eosinophilic Asthma,Drug: Reslizumab|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,6-Jun-16,https://ClinicalTrials.gov/show/NCT01270464
1958,Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis|PAR,Drug: ciclesonide nasal aerosol|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,26-May-14,https://ClinicalTrials.gov/show/NCT01378429
1959,Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Completed,Has Results,Hypoparathyroidism,Drug: NPSP558,Shire,Phase 3,Industry,Interventional,6-Mar-15,https://ClinicalTrials.gov/show/NCT01268098
1960,"A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists",Completed,Has Results,Chronic Idiopathic Urticaria,"Drug: Omalizumab|Drug: Placebo|Drug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Drug: Diphenhydramine","Genentech, Inc.",Phase 3,Industry,Interventional,26-Nov-13,https://ClinicalTrials.gov/show/NCT01264939
1961,Once-A-Day Pregabalin For Partial Seizures,Completed,Has Results,"Partial Seizures|Epilepsies, Partial",Drug: pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,5-Jun-18,https://ClinicalTrials.gov/show/NCT01262677
1962,Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,15-Oct-15,https://ClinicalTrials.gov/show/NCT01262456
1963,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus,Drug: Epratuzumab|Drug: Placebo,UCB Pharma,Phase 3,Industry,Interventional,29-Jun-18,https://ClinicalTrials.gov/show/NCT01262365
1964,Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE),Completed,Has Results,Systemic Lupus Erythematosus,Drug: Placebo|Drug: Epratuzumab,UCB Pharma,Phase 3,Industry,Interventional,29-Jun-18,https://ClinicalTrials.gov/show/NCT01261793
1965,Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures,Completed,Has Results,Epilepsy,Drug: Placebo|Drug: Brivaracetam|Drug: Antiepileptic drugs with market authorization available per country,UCB Pharma,Phase 3,Industry,Interventional,15-Aug-16,https://ClinicalTrials.gov/show/NCT01261325
1966,Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Completed,Has Results,"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",Biological: IgPro20,CSL Behring,Phase 3,Industry,Interventional,2-Oct-18,https://ClinicalTrials.gov/show/NCT02027701
1967,Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit/Hyperactivity Disorder,Drug: Placebo|Drug: Ritalin LA 20 mg|Drug: Ritalin LA 30 mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,29-Apr-14,https://ClinicalTrials.gov/show/NCT01259492
1968,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),Completed,Has Results,Gastrointestinal Stromal Tumors,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Drug: Best supportive care",Bayer,Phase 3,Industry,Interventional,25-Oct-13,https://ClinicalTrials.gov/show/NCT01271712
1969,DHEA Against Vaginal Atrophy - 3-Month Efficacy Study,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: DHEA,EndoCeutics Inc.,Phase 3,Industry,Interventional,25-Apr-17,https://ClinicalTrials.gov/show/NCT01256684
1970,DHEA Against Vaginal Atrophy - Safety Study of 12 Months,Completed,Has Results,Vaginal Atrophy,Drug: DHEA,EndoCeutics Inc.,Phase 3,Industry,Interventional,18-Oct-17,https://ClinicalTrials.gov/show/NCT01256671
1971,Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain,Completed,Has Results,Pain|Low Back Pain,Drug: Buprenorphine|Drug: Placebo,BioDelivery Sciences International,Phase 3,Industry,Interventional,8-Dec-15,https://ClinicalTrials.gov/show/NCT01256450
1972,A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis,Completed,Has Results,Restless Legs Syndrome|End-Stage Renal Disease,Drug: Rotigotine|Drug: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,Phase 3,Industry,Interventional,3-Nov-14,https://ClinicalTrials.gov/show/NCT01537042
1973,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,Completed,Has Results,Contraception,"Drug: Levonorgestrel IUD (LCS, BAY86-5028)|Drug: Yasmin (EE30/DRSP, BAY86-5131)",Bayer,Phase 3,Industry,Interventional,7-Apr-14,https://ClinicalTrials.gov/show/NCT01254292
1974,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,Completed,Has Results,HIV-1 Infection,Drug: FTC/RPV/TDF|Drug: PI|Drug: RTV|Drug: NRTIs,Gilead Sciences,Phase 3,Industry,Interventional,19-Apr-13,https://ClinicalTrials.gov/show/NCT01252940
1975,Dysport® Adult Lower Limb Spasticity Follow-on Study,Completed,Has Results,Post-stroke Spasticity|Spasticity Post-Traumatic Brain Injury,Drug: Dysport®,Ipsen,Phase 3,Industry,Interventional,9-Nov-17,https://ClinicalTrials.gov/show/NCT01251367
1976,A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis,Completed,Has Results,Chronic Sinusitis,Device: Sinus Stent with drug coating|Device: Non Coated Sinus Stent,Intersect ENT,Phase 3,Industry,Interventional,13-Apr-15,https://ClinicalTrials.gov/show/NCT01253577
1977,Dysport® Adult Lower Limb Spasticity Study,Completed,Has Results,Leg Spasticity,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,17-Oct-17,https://ClinicalTrials.gov/show/NCT01249404
1978,GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma,Completed,Has Results,Melanoma,Drug: GSK1120212|Drug: Chemotherapy,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Mar-13,https://ClinicalTrials.gov/show/NCT01245062
1979,A Study of AA4500 in Men With Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500,Endo Pharmaceuticals,Phase 3,Industry,Interventional,15-Apr-15,https://ClinicalTrials.gov/show/NCT01243411
1980,Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Drug: Atomoxetine Hydrochloride|Drug: Placebo Comparator,Shire,Phase 3,Industry,Interventional,14-Jul-14,https://ClinicalTrials.gov/show/NCT01244490
1981,Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER|Drug: Placebo,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,5-Jun-17,https://ClinicalTrials.gov/show/NCT01240863
1982,Study of Quadrivalent Influenza Vaccine Among Children,Completed,Has Results,Influenza,"Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|Biological: Quadrivalent Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,14-Jan-14,https://ClinicalTrials.gov/show/NCT01240746
1983,A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome,Completed,Has Results,Fibromyalgia,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,14-Aug-18,https://ClinicalTrials.gov/show/NCT01237587
1984,"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm",Completed,Has Results,Contraception,Drug: AG200-15|Drug: Levora,Agile Therapeutics,Phase 3,Industry,Interventional,15-Sep-17,https://ClinicalTrials.gov/show/NCT01236768
1985,Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain,Completed,Has Results,Ankle Sprain,Drug: Diclofenac sodium topical gel 1%|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,4-Oct-12,https://ClinicalTrials.gov/show/NCT01255423
1986,A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab 162 mg|Drug: Placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,23-Oct-13,https://ClinicalTrials.gov/show/NCT01232569
1987,Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.,Completed,Has Results,Plaque Psoriasis,Drug: Apremilast|Drug: Placebo|Other: Topical or Phototherapy Therapy,Celgene,Phase 3,Industry,Interventional,5-Nov-14,https://ClinicalTrials.gov/show/NCT01232283
1988,A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza,Completed,Has Results,"Influenza, Human",Drug: Zanamivir|Drug: Placebo to match zanamivir|Drug: Oseltamivir|Drug: Placebo to match oseltamivir,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Nov-17,https://ClinicalTrials.gov/show/NCT01231620
1989,A Study in Pediatric Participants With Generalized Anxiety Disorder,Completed,Has Results,"Anxiety Neuroses|Anxiety States, Neurotic|Neuroses, Anxiety",Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,5-Mar-14,https://ClinicalTrials.gov/show/NCT01226511
1990,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin",Completed,Has Results,Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke,Drug: Ticagrelor 90 mg|Drug: Ticagrelor 60 mg|Drug: Ticagrelor Placebo,AstraZeneca,Phase 3,Industry,Interventional,9-Dec-15,https://ClinicalTrials.gov/show/NCT01225562
1991,A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma,Completed,Has Results,Cancer,Drug: GSK2118436|Drug: Dacarbazine (DTIC),GlaxoSmithKline,Phase 3,Industry,Interventional,16-May-14,https://ClinicalTrials.gov/show/NCT01227889
1992,Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Jul-14,https://ClinicalTrials.gov/show/NCT01224171
1993,Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients,Completed,Has Results,Nocturia,Drug: Desmopressin|Drug: Placebo,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,15-Oct-15,https://ClinicalTrials.gov/show/NCT01223937
1994,Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time,Completed,Has Results,Chronic Pain,Drug: Hydrocodone ER,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,5-Apr-17,https://ClinicalTrials.gov/show/NCT01223365
1995,Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Completed,Has Results,Metastatic Renal Cell Carcinoma,Drug: Dovitinib|Drug: Sorafenib,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-Nov-15,https://ClinicalTrials.gov/show/NCT01223027
1996,Study of AA4500 in the Treatment of Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Endo Pharmaceuticals,Phase 3,Industry,Interventional,7-Apr-15,https://ClinicalTrials.gov/show/NCT01221623
1997,Study of AA4500 in the Treatment of Peyronie's Disease,Completed,Has Results,Peyronie's Disease,Biological: AA4500|Biological: Placebo,Endo Pharmaceuticals,Phase 3,Industry,Interventional,7-Apr-15,https://ClinicalTrials.gov/show/NCT01221597
1998,Long-Term Safety and Efficacy Study of Peginterferon Beta-1a,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: peginterferon beta-1a,Biogen,Phase 3,Industry,Interventional,13-Jan-17,https://ClinicalTrials.gov/show/NCT01332019
1999,Study of Quadrivalent Influenza Vaccine Among Adults,Completed,Has Results,Influenza,"Biological: Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|Biological: Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|Biological: Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,12-Sep-13,https://ClinicalTrials.gov/show/NCT01218646
2000,Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,"Arthritis, Rheumatoid",Biological: ABP 501|Biological: Adalimumab,Amgen,Phase 3,Industry,Interventional,13-Dec-16,https://ClinicalTrials.gov/show/NCT01970475
2001,Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life,Completed,Has Results,Meningococcal Disease|Meningococcal Meningitis,Biological: MenACWY-CRM|Biological: Routine Vaccines,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,2-Oct-14,https://ClinicalTrials.gov/show/NCT01214837
2002,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",Completed,Has Results,HIV|HIV Infections|Acquired Immunodeficiency Syndrome,Drug: TAF|Drug: Placebo|Drug: E/C/F/TAF|Drug: Current failing ARV regimen|Drug: ATV,Gilead Sciences,Phase 3,Industry,Interventional,12-Jun-17,https://ClinicalTrials.gov/show/NCT01967940
2003,PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo,Celgene,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT01212770
2004,PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast,Celgene,Phase 3,Industry,Interventional,19-May-14,https://ClinicalTrials.gov/show/NCT01212757
2005,Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions,Completed,Has Results,Diagnostic Self Evaluation|Central Nervous System Diseases,Drug: Dotarem (gadoterate meglumine)|Drug: Magnevist (gadopentetate dimeglumine),Guerbet,Phase 3,Industry,Interventional,29-May-14,https://ClinicalTrials.gov/show/NCT01211873
2006,Dysport® Pediatric Lower Limb Spasticity Follow-on Study,Completed,Has Results,Cerebral Palsy|Muscle Spasticity|Children,Drug: Botulinum type A toxin (Dysport®),Ipsen,Phase 3,Industry,Interventional,1-Jun-17,https://ClinicalTrials.gov/show/NCT01251380
2007,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Drug: LY2127399|Drug: Placebo every 2 weeks|Drug: Placebo every 4 weeks,Eli Lilly and Company,Phase 3,Industry,Interventional,19-Jun-18,https://ClinicalTrials.gov/show/NCT01205438
2008,Dysport® Pediatric Lower Limb Spasticity Study,Completed,Has Results,Cerebral Palsy|Muscle Spasticity|Children,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,3-Feb-17,https://ClinicalTrials.gov/show/NCT01249417
2009,A Rheumatoid Arthritis Study in Participants,Completed,Has Results,Rheumatoid Arthritis,Drug: LY2127399|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,25-Apr-18,https://ClinicalTrials.gov/show/NCT01202760
2010,"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: indacaterol and glycopyrronium (QVA149)|Drug: glycopyrronium (NVA237)|Drug: indacaterol (QAB149)|Drug: tiotropium|Drug: placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,3-May-13,https://ClinicalTrials.gov/show/NCT01202188
2011,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children,Completed,Has Results,Influenza,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A|Biological: Fluarix™ VB|Biological: Fluarix™ YB,GlaxoSmithKline,Phase 3,Industry,Interventional,12-Mar-13,https://ClinicalTrials.gov/show/NCT01198756
2012,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist,Completed,Has Results,Rheumatoid Arthritis,Drug: fostamatinib|Drug: placebo,AstraZeneca,Phase 3,Industry,Interventional,7-Apr-14,https://ClinicalTrials.gov/show/NCT01197755
2013,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.,Completed,Has Results,Rheumatoid Arthritis,"Drug: fostamatinib|Drug: placebo, fostamatinib",AstraZeneca,Phase 3,Industry,Interventional,17-Apr-14,https://ClinicalTrials.gov/show/NCT01197534
2014,Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.,Completed,Has Results,Rheumatoid Arthritis,"Drug: fostamatinib|Drug: placebo, fostamatinib",AstraZeneca,Phase 3,Industry,Interventional,7-Apr-14,https://ClinicalTrials.gov/show/NCT01197521
2015,Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children,Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2321138A|Biological: FluarixTM|Biological: Influenza vaccine GSK2604409A,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Mar-13,https://ClinicalTrials.gov/show/NCT01196988
2016,A Study of LY2127399 in Participants With Systemic Lupus Erythematosus,Completed,Has Results,Systemic Lupus Erythematosus|Connective Tissue Disease|Autoimmune Disease,Drug: LY2127399|Drug: Placebo every 2 weeks|Drug: Placebo every 4 weeks|Drug: Standard of Care,Eli Lilly and Company,Phase 3,Industry,Interventional,12-Jun-18,https://ClinicalTrials.gov/show/NCT01196091
2017,Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A),Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2321138A|Biological: FluarixTM|Biological: Influenza vaccine GSK2604409A,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Jun-13,https://ClinicalTrials.gov/show/NCT01204671
2018,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab SC|Drug: tocilizumab IV|Drug: placebo to tocilizumab SC|Drug: placebo to tocilizumab IV|Drug: Disease-modifying antirheumatic drugs (DMARDs),Hoffmann-La Roche,Phase 3,Industry,Interventional,12-Feb-13,https://ClinicalTrials.gov/show/NCT01194414
2019,Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.,Completed,Has Results,Prostate Cancer,Drug: Orteronel|Drug: Prednisone|Drug: Orteronel Placebo,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 3,Industry,Interventional,18-Dec-18,https://ClinicalTrials.gov/show/NCT01193257
2020,Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Orteronel|Drug: Placebo|Drug: Prednisone,"Millennium Pharmaceuticals, Inc.|Takeda",Phase 3,Industry,Interventional,17-May-17,https://ClinicalTrials.gov/show/NCT01193244
2021,A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder,Completed,Has Results,Schizoaffective Disorder,Drug: Placebo|Drug: paliperidone palmitate,"Janssen Scientific Affairs, LLC",Phase 3,Industry,Interventional,5-Jan-15,https://ClinicalTrials.gov/show/NCT01193153
2022,Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids,Completed,Has Results,Pain,Drug: Oxycodone HCl controlled-release tablets,Purdue Pharma LP,Phase 3,Industry,Interventional,6-Feb-15,https://ClinicalTrials.gov/show/NCT01192295
2023,TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery,Completed,Has Results,Hemorrhage,Biological: TachoSil®|Device: Surgicel® Original,Takeda,Phase 3,Industry,Interventional,25-Nov-15,https://ClinicalTrials.gov/show/NCT01192022
2024,Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML,Completed,Has Results,Acute Myeloid Leukemia,Drug: vosaroxin + cytarabine|Drug: placebo + cytarabine,Sunesis Pharmaceuticals,Phase 3,Industry,Interventional,9-May-17,https://ClinicalTrials.gov/show/NCT01191801
2025,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine|Drug: LY2189265|Drug: Insulin Lispro,Eli Lilly and Company,Phase 3,Industry,Interventional,8-Oct-14,https://ClinicalTrials.gov/show/NCT01191268
2026,A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis,Completed,Has Results,Hyperphosphatemia|Kidney Failure,"Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo",Keryx Biopharmaceuticals,Phase 3,Industry,Interventional,10-Dec-14,https://ClinicalTrials.gov/show/NCT01191255
2027,Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: USL255,Upsher-Smith Laboratories,Phase 3,Industry,Interventional,23-Feb-15,https://ClinicalTrials.gov/show/NCT01191086
2028,Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study,Completed,Has Results,"Infections, Papillomavirus",Biological: GSK580299 (Cervarix),GlaxoSmithKline,Phase 3,Industry,Interventional,17-Dec-18,https://ClinicalTrials.gov/show/NCT01190189
2029,LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs),Completed,Has Results,Psoriasis Vulgaris,"Drug: Calcipotriol plus betamethasone|Drug: Betamethasone-17,21-dipropionate|Drug: Calcipotriene|Drug: Topical suspension vehicle",LEO Pharma,Phase 3,Industry,Interventional,9-Apr-13,https://ClinicalTrials.gov/show/NCT01188928
2030,"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks",Completed,Has Results,Hereditary Angioedema,Drug: rhC1INH|Drug: Placebo (Saline),Pharming Technologies B.V.,Phase 3,Industry,Interventional,7-Aug-15,https://ClinicalTrials.gov/show/NCT01188564
2031,"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx",Completed,Has Results,Renal Failure,Drug: Prograf (tacrolimus)|Drug: LCP-Tacro,Veloxis Pharmaceuticals,Phase 3,Industry,Interventional,29-May-15,https://ClinicalTrials.gov/show/NCT01187953
2032,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,Completed,Has Results,Major Depressive Disorder (MDD),Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Phase 3,Industry,Interventional,24-Apr-18,https://ClinicalTrials.gov/show/NCT01187407
2033,"A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis",Completed,Has Results,Psoriasis,"Drug: CP-690,550",Pfizer,Phase 3,Industry,Interventional,4-Jun-14,https://ClinicalTrials.gov/show/NCT01186744
2034,"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo (Saxagliptin)|Drug: Metformin IR|Drug: Placebo (Metformin)|Drug: Metformin (Active Rescue),AstraZeneca,Phase 3,Industry,Interventional,18-Apr-17,https://ClinicalTrials.gov/show/NCT01204775
2035,A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Phase 3,Industry,Interventional,27-Apr-18,https://ClinicalTrials.gov/show/NCT01185340
2036,Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA),Completed,Has Results,Early Rheumatoid Arthritis,Biological: adalimumab|Drug: methotrexate,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,15-Nov-13,https://ClinicalTrials.gov/show/NCT01185301
2037,"Time to Eugonadal Range, Time to Steady State and Drying Time",Completed,Has Results,Male Hypogonadism,Drug: testosterone gel 2%,Endo Pharmaceuticals,Phase 3,Industry,Interventional,22-Jul-13,https://ClinicalTrials.gov/show/NCT01228071
2038,Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy,Completed,Has Results,Atrial Fibrillation|Stroke,Device: WATCHMAN Device|Drug: Warfarin,Boston Scientific Corporation,Phase 3,Industry,Interventional,26-Jul-18,https://ClinicalTrials.gov/show/NCT01182441
2039,Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System,Completed,Has Results,Contraception,Drug: AG200-15 (cycles 1-13)|Drug: Lessina crossover to AG200-15,Agile Therapeutics,Phase 3,Industry,Interventional,3-Jul-18,https://ClinicalTrials.gov/show/NCT01181479
2040,Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT01179516
2041,A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia,Completed,Has Results,Sickle Cell Anemia|Sickle ß0-Thalassemia,Drug: L-glutamine|Drug: Placebo,"Emmaus Medical, Inc.",Phase 3,Industry,Interventional,10-Aug-17,https://ClinicalTrials.gov/show/NCT01179217
2042,Tiotropium Bromide in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: tiotropium Respimat® inhaler|Drug: Placebo Respimat® inhaler,Boehringer Ingelheim,Phase 3,Industry,Interventional,26-Mar-13,https://ClinicalTrials.gov/show/NCT01179347
2043,Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,1-Mar-17,https://ClinicalTrials.gov/show/NCT01179048
2044,Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence,Completed,Has Results,Primary Myelofibrosis|MPN-associated Myelofibrosis,Drug: Pomalidomide 0.5 mg|Drug: Placebo|Drug: Pomalidomide,Celgene,Phase 3,Industry,Interventional,14-Mar-14,https://ClinicalTrials.gov/show/NCT01178281
2045,Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma,Completed,Has Results,Asthma,Drug: Vilanterol|Drug: Salmeterol Inhalation Powder|Drug: Placebo Inhalation Powder NDPI|Drug: Placebo Inhalation Powder Diskus,GlaxoSmithKline,Phase 3,Industry,Interventional,26-Aug-13,https://ClinicalTrials.gov/show/NCT01181895
2046,A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy,Completed,Has Results,Contraception|Female Contraception,Drug: DR-102,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,11-Dec-13,https://ClinicalTrials.gov/show/NCT01178125
2047,A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease,Completed,Has Results,Orthostatic Hypotension|Parkinson's Disease,Drug: Droxidopa|Other: Placebo,Chelsea Therapeutics,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT01176240
2048,Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: migalastat hydrochloride|Biological: agalsidase,Amicus Therapeutics,Phase 3,Industry,Interventional,1-Nov-18,https://ClinicalTrials.gov/show/NCT01218659
2049,A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: pimavanserin tartrate|Drug: placebo,ACADIA Pharmaceuticals Inc.,Phase 3,Industry,Interventional,26-Mar-14,https://ClinicalTrials.gov/show/NCT01174004
2050,A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: LY2216684|Drug: Placebo|Drug: SSRI,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01173601
2051,Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis,Completed,Has Results,Psoriatic Arthritis,Drug: Apremilast 20mg|Drug: Apremilast 30mg|Drug: Placebo + 20 mg Apremilast|Drug: Placebo + 30 mg Apremilast,Celgene,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT01172938
2052,Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID,Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|Biological: SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|Biological: IV treatment with IGSC, 10%",Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01175213
2053,TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.,Completed,Has Results,Skin and Subcutaneous Tissue Bacterial Infections,Drug: TR-701 FA|Drug: Linezolid,Trius Therapeutics LLC,Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT01170221
2054,A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma,Completed,Has Results,Gastric Cancer,Biological: Ramucirumab (IMC-1211B) DP|Drug: Placebo|Drug: Paclitaxel,Eli Lilly and Company,Phase 3,Industry,Interventional,31-Jul-14,https://ClinicalTrials.gov/show/NCT01170663
2055,"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",Completed,Has Results,Post Operative Pain,Drug: oxymorphone HCl,Endo Pharmaceuticals,Phase 3,Industry,Interventional,7-May-19,https://ClinicalTrials.gov/show/NCT01210352
2056,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Nov-17,https://ClinicalTrials.gov/show/NCT01165229
2057,"Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster Vaccine GSK1437173A|Biological: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,1-May-17,https://ClinicalTrials.gov/show/NCT01165177
2058,Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Completed,Has Results,Asthma,Drug: Fluticasone furoate/Vilanterol Inhalation Powder|Drug: Fluticasone Furoate Inhalation Powder|Drug: Placebo Inhaltion Powder,GlaxoSmithKline,Phase 3,Industry,Interventional,30-Jul-13,https://ClinicalTrials.gov/show/NCT01165138
2059,Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT01163266
2060,Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder,Completed,Has Results,Non-24-Hour Sleep-Wake Disorder,Drug: tasimelteon|Drug: Placebo,Vanda Pharmaceuticals,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT01163032
2061,Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects,Completed,Has Results,Influenza,Biological: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|Biological: Non-adjuvanted trivalent subunit influenza vaccine (TIV),Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,12-Jun-14,https://ClinicalTrials.gov/show/NCT01162122
2062,Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com),Completed,Has Results,Obstructive Sleep Apnea,Device: Inspire Upper Airway Stimulation System,"Inspire Medical Systems, Inc.",Phase 3,Industry,Interventional,15-Dec-14,https://ClinicalTrials.gov/show/NCT01161420
2063,Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents,Completed,Has Results,Asthma,Drug: Fluticasone propionate|Drug: Fluticasone furoate|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,8-Aug-13,https://ClinicalTrials.gov/show/NCT01159912
2064,Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures,Completed,Has Results,Elective Cranial Procedures With Dural Incision,Device: Adherus Dural Sealant,"HyperBranch Medical Technology, Inc",Phase 3,Industry,Interventional,8-Apr-14,https://ClinicalTrials.gov/show/NCT01158378
2065,A Safety Study in Participants With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684 (edivoxetine)|Drug: SSRI,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Apr-18,https://ClinicalTrials.gov/show/NCT01155661
2066,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,Completed,Has Results,Non Squamous Lung Cancer,Drug: treatment,Pfizer,Phase 3,Industry,Interventional,5-Jan-15,https://ClinicalTrials.gov/show/NCT01154140
2067,Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,18-Dec-13,https://ClinicalTrials.gov/show/NCT01153009
2068,"An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age",Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Enalapril,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-Mar-16,https://ClinicalTrials.gov/show/NCT01151410
2069,Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study,Completed,Has Results,Chronic Nonmalignant Pain,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Phase 3,Industry,Interventional,23-Sep-10,https://ClinicalTrials.gov/show/NCT01151098
2070,Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age,Completed,Has Results,Hypertension,Drug: Aliskiren (6.25/12.5/25 mg)|Drug: Aliskiren (37.5/75/150 mg)|Drug: Aliskiren (150/300/600 mg),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Oct-15,https://ClinicalTrials.gov/show/NCT01150357
2071,Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients,Completed,Has Results,Liver Transplant Recipient,Drug: Tacrolimus (reduced tacrolimus)|Drug: Everolimus (reduced tacrolimus)|Drug: Tacrolimus (tacrolimus elimination)|Drug: Everolimus (tacrolimus elimination)|Drug: Tacrolimus (tacrolimus control)|Drug: Corticosteroids,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-May-14,https://ClinicalTrials.gov/show/NCT01150097
2072,HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents,Completed,Has Results,Asthma,Drug: Fluticasone furoate/Vilanterol Inhalation Powder|Drug: Fluticasone propionate/salmeterol Inhalation Powder|Drug: Placebo (1)|Drug: Placebo (2),GlaxoSmithKline,Phase 3,Industry,Interventional,5-Sep-13,https://ClinicalTrials.gov/show/NCT01147848
2073,Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide),Completed,Has Results,Acute Coronary Syndrome,Drug: Lixisenatide (AVE0010)|Drug: Placebo,Sanofi,Phase 3,Industry,Interventional,14-Oct-16,https://ClinicalTrials.gov/show/NCT01147250
2074,"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",Completed,Has Results,Smallpox,Biological: IMVAMUNE®|Other: Placebo,Bavarian Nordic,Phase 3,Industry,Interventional,3-Jan-19,https://ClinicalTrials.gov/show/NCT01144637
2075,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide Once Weekly|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,8-Aug-18,https://ClinicalTrials.gov/show/NCT01144338
2076,A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl,Sunovion,Phase 3,Industry,Interventional,17-Dec-12,https://ClinicalTrials.gov/show/NCT01143090
2077,A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl,Sunovion,Phase 3,Industry,Interventional,16-Aug-12,https://ClinicalTrials.gov/show/NCT01143077
2078,Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: USL255|Drug: Placebo,Upsher-Smith Laboratories,Phase 3,Industry,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT01142193
2079,Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Methotrexate|Drug: Abatacept placebo|Drug: Methotrexate placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,17-Oct-14,https://ClinicalTrials.gov/show/NCT01142726
2080,Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Phase 3,Industry,Interventional,21-Sep-10,https://ClinicalTrials.gov/show/NCT01141283
2081,A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib,Completed,Has Results,Hepatocellular Carcinoma,Biological: Placebo|Biological: Ramucirumab DP (IMC-1121B)|Other: BSC,Eli Lilly and Company,Phase 3,Industry,Interventional,26-Mar-15,https://ClinicalTrials.gov/show/NCT01140347
2082,Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Phase 3,Industry,Interventional,11-Jun-14,https://ClinicalTrials.gov/show/NCT01138501
2083,The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Sitagliptin 100 mg|Drug: Canagliflozin 300 mg|Drug: Metformin|Drug: Sulphonylurea,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,17-May-13,https://ClinicalTrials.gov/show/NCT01137812
2084,Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™),Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,22-Jan-16,https://ClinicalTrials.gov/show/NCT01135992
2085,Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis),Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,23-May-12,https://ClinicalTrials.gov/show/NCT01134705
2086,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/Vilanterol Inhalation Powder|Drug: Fluticasone Furoate Inhalation Powder|Drug: Fluticasone Propionate Inhalation Powder|Other: Placebo Inhalation Powder 1|Other: Placebo Inhalation Powder 2,GlaxoSmithKline,Phase 3,Industry,Interventional,8-Aug-13,https://ClinicalTrials.gov/show/NCT01134042
2087,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,Completed,Has Results,Benign Prostatic Hyperplasia|Enlarged Prostate,Drug: Tadalafil|Drug: Placebo|Drug: Finasteride,Eli Lilly and Company,Phase 3,Industry,Interventional,27-Feb-13,https://ClinicalTrials.gov/show/NCT01139762
2088,A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: CLE,"Impax Laboratories, LLC",Phase 3,Industry,Interventional,13-Sep-17,https://ClinicalTrials.gov/show/NCT01130493
2089,Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis,Completed,Has Results,Plaque-type Psoriasis,Drug: secukinumab 150mg|Drug: secukinumab 10mg/kg i.v. regimen,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,18-Mar-15,https://ClinicalTrials.gov/show/NCT01412944
2090,A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: liraglutide,GlaxoSmithKline,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT01128894
2091,Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery,Completed,Has Results,Reducing Time to Vaginal Delivery|Cervical Ripening|Induction of Labor,Drug: MVI 200|Drug: Dinoprostone Vaginal Insert (DVI),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,7-Mar-14,https://ClinicalTrials.gov/show/NCT01127581
2092,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Metformin|Drug: LY2189265|Drug: Placebo (oral)|Drug: Placebo (subcutaneous),Eli Lilly and Company,Phase 3,Industry,Interventional,16-Jan-15,https://ClinicalTrials.gov/show/NCT01126580
2093,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium 18 mcg|Drug: tiotropium 1.25 mcg (2 actuations/day)|Drug: tiotropium 2.5 mcg (2 actuations/day),Boehringer Ingelheim,Phase 3,Industry,Interventional,20-Jun-14,https://ClinicalTrials.gov/show/NCT01126437
2094,LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment,Completed,Has Results,Breast Neoplasms,Drug: BIBW 2992|Drug: trastuzumab|Drug: vinorelbine,Boehringer Ingelheim,Phase 3,Industry,Interventional,21-Aug-14,https://ClinicalTrials.gov/show/NCT01125566
2095,The Kiva® System as a Vertebral Augmentation Treatment,Completed,Has Results,"Spinal Fractures|Fractures, Compression|Back Injuries",Device: Vertebral augmentation,"Benvenue Medical, Inc.",Phase 3,Industry,Interventional,21-Aug-14,https://ClinicalTrials.gov/show/NCT01123512
2096,Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: QVA149|Drug: NVA237|Drug: tiotropium|Drug: Salbutamol/albuterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Sep-13,https://ClinicalTrials.gov/show/NCT01120691
2097,Rollover Study of VX-770 in Cystic Fibrosis Subjects,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,7-Jul-15,https://ClinicalTrials.gov/show/NCT01117012
2098,Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain,Completed,Has Results,Chronic Pain,Drug: Hydrocodone Bitartrate,"Zogenix, Inc.",Phase 3,Industry,Interventional,25-Apr-14,https://ClinicalTrials.gov/show/NCT01115569
2099,Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients,Completed,Has Results,Phenylketonuria,Drug: Sapropterin dihydrochloride|Drug: Placebo,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,1-Feb-16,https://ClinicalTrials.gov/show/NCT01114737
2100,A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia,Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol,"AMAG Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,11-Jun-18,https://ClinicalTrials.gov/show/NCT01114217
2101,A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia,Completed,Has Results,Iron Deficiency Anemia,Drug: Ferumoxytol|Other: Placebo,"AMAG Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,11-Jun-18,https://ClinicalTrials.gov/show/NCT01114139
2102,Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin,Completed,Has Results,Urogential Chlamydia Trachomatis Infection,Drug: Doxycyline Hyclate tablet|Drug: Vibramycin (doxycyline hyclate) capsule,Warner Chilcott,Phase 3,Industry,Interventional,27-Jan-12,https://ClinicalTrials.gov/show/NCT01113931
2103,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: COBI|Drug: RTV|Drug: ATV|Drug: FTC/TDF|Drug: COBI placebo|Drug: RTV placebo,Gilead Sciences,Phase 3,Industry,Interventional,28-Oct-14,https://ClinicalTrials.gov/show/NCT01108510
2104,The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin|Drug: Pioglitazone,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,21-May-13,https://ClinicalTrials.gov/show/NCT01106690
2105,The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin immediate release,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,30-Jul-13,https://ClinicalTrials.gov/show/NCT01106677
2106,A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Antihyperglycemic agent(s)|Drug: Placebo,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,29-May-13,https://ClinicalTrials.gov/show/NCT01106651
2107,The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin|Drug: Placebo|Drug: Metformin|Drug: Sulphonylruea,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,29-May-13,https://ClinicalTrials.gov/show/NCT01106625
2108,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: Stribild|Drug: ATV|Drug: Ritonavir|Drug: FTC/TDF|Drug: Stribild Placebo|Drug: ATV Placebo|Drug: RTV Placebo|Drug: FTC/TDF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,22-Oct-12,https://ClinicalTrials.gov/show/NCT01106586
2109,Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin lispro 2 day reservoir in-use|Drug: Insulin lispro 6 day reservoir in-use|Drug: Insulin aspart 6 day reservoir in-use,Eli Lilly and Company,Phase 3,Industry,Interventional,30-Oct-12,https://ClinicalTrials.gov/show/NCT01109316
2110,Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: Lisdexamfetamine Dimesylate|Drug: Atomoxetine Hydrochloride,Shire,Phase 3,Industry,Interventional,24-Jun-13,https://ClinicalTrials.gov/show/NCT01106430
2111,Selexipag (ACT-293987) in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Selexipag|Drug: Placebo,Actelion,Phase 3,Industry,Interventional,1-Mar-16,https://ClinicalTrials.gov/show/NCT01106014
2112,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Completed,Has Results,Metastatic Colorectal Cancer,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Other: Best Supportive Care (BSC)",Bayer,Phase 3,Industry,Interventional,19-Nov-12,https://ClinicalTrials.gov/show/NCT01103323
2113,Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: DiaPep277|Drug: Placebo,Andromeda Biotech Ltd.,Phase 3,Industry,Interventional,26-May-16,https://ClinicalTrials.gov/show/NCT01103284
2114,Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,2-Apr-15,https://ClinicalTrials.gov/show/NCT01149655
2115,24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms,Completed,Has Results,Hot Flashes,Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules,Noven Therapeutics,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT01101841
2116,Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES),Completed,Has Results,Cardiovascular Disease,Drug: Febuxostat|Drug: Allopurinol,Takeda,Phase 3,Industry,Interventional,14-Jun-18,https://ClinicalTrials.gov/show/NCT01101035
2117,A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS),Completed,Has Results,Lambert Eaton Myasthenic Syndrome,Drug: Amifampridine Phosphate|Drug: Placebo,"Catalyst Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,4-Jan-18,https://ClinicalTrials.gov/show/NCT01377922
2118,Clinical Trial in Females With Female Pattern Hair Loss,Completed,Has Results,Alopecia,Drug: 5% Minoxidil|Drug: 2% Minoxidil,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide",Phase 3,Industry,Interventional,25-Apr-14,https://ClinicalTrials.gov/show/NCT01145625
2119,A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: sitagliptin,GlaxoSmithKline,Phase 3,Industry,Interventional,16-May-14,https://ClinicalTrials.gov/show/NCT01098539
2120,An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: IPX066 95 mg|Drug: IPX066 145 mg|Drug: IPX066 195 mg|Drug: IPX066 245 mg,"Impax Laboratories, LLC",Phase 3,Industry,Interventional,3-Mar-16,https://ClinicalTrials.gov/show/NCT01096186
2121,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",Completed,Has Results,HIV|HIV Infections,Drug: Stribild|Drug: Atripla|Drug: Stribild Placebo|Drug: Atripla Placebo,Gilead Sciences,Phase 3,Industry,Interventional,22-Oct-12,https://ClinicalTrials.gov/show/NCT01095796
2122,Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic,Completed,Has Results,Epilepsy,Drug: Eslicarbazepine acetate 1600 mg|Drug: Eslicarbazepine acetate 1200 mg,Sunovion,Phase 3,Industry,Interventional,21-Dec-15,https://ClinicalTrials.gov/show/NCT01091662
2123,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,Completed,Has Results,Healthy or Stable Chronic Illness,Biological: Q/LAIV (MEDI3250)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,Phase 3,Industry,Interventional,22-Sep-11,https://ClinicalTrials.gov/show/NCT01091246
2124,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI),Completed,Has Results,Breast Cancer,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,11-Nov-14,https://ClinicalTrials.gov/show/NCT01104584
2125,Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol|Drug: Salmeterol 50 μg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT01089127
2126,Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,Phase 3,Industry,Interventional,25-Feb-14,https://ClinicalTrials.gov/show/NCT01087788
2127,Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis,Completed,Has Results,Spondyloarthropathies,Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo,UCB BIOSCIENCES GmbH|UCB Pharma,Phase 3,Industry,Interventional,25-Dec-13,https://ClinicalTrials.gov/show/NCT01087762
2128,Asthma Exacerbation Study,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/GW642444|Drug: Fluticasone furoate,GlaxoSmithKline,Phase 3,Industry,Interventional,11-Sep-13,https://ClinicalTrials.gov/show/NCT01086384
2129,Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain,Completed,Has Results,Back Pain Lower Back Chronic,Drug: Placebo|Drug: Hydrocodone bitartrate,"Zogenix, Inc.",Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT01081912
2130,The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin|Drug: Placebo|Drug: Sitagliptin,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,3-Jun-13,https://ClinicalTrials.gov/show/NCT01081834
2131,Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention-deficit/Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Other: Placebo,Shire,Phase 3,Industry,Interventional,9-Jun-14,https://ClinicalTrials.gov/show/NCT01081145
2132,Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl,Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: Extended-release Guanfacine Hydrochloride|Other: Placebo,Shire,Phase 3,Industry,Interventional,23-May-14,https://ClinicalTrials.gov/show/NCT01081132
2133,"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",Completed,Has Results,Relapsed Multiple Myeloma,Drug: Dexamethasone|Drug: Lenalidomide|Drug: Carfilzomib,Amgen,Phase 3,Industry,Interventional,8-Jul-15,https://ClinicalTrials.gov/show/NCT01080391
2134,Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended Release|Drug: Placebo,Depomed,Phase 3,Industry,Interventional,26-Mar-14,https://ClinicalTrials.gov/show/NCT01080300
2135,Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.,Completed,Has Results,Acute Gout,Drug: Canakinumab 150 mg|Drug: Triamcinolone acetonide 40 mg|Drug: Placebo to canakinumab|Drug: Placebo to triamcinolone acetonide,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,26-Dec-11,https://ClinicalTrials.gov/show/NCT01080131
2136,Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,31-Dec-15,https://ClinicalTrials.gov/show/NCT01079234
2137,A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection,Completed,Has Results,"Chronic Hepatitis B Virus, Pediatric",Drug: Entecavir|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT01079806
2138,Efficacy and Safety of Different Doses of Indacaterol,Completed,Has Results,Asthma,Drug: Indacaterol|Drug: Salmeterol|Drug: Placebo to Indacaterol|Drug: Placebo to Salmeterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT01079130
2139,Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Completed,Has Results,Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome,Biological: Serostim,EMD Serono,Phase 3,Industry,Interventional,23-Jun-10,https://ClinicalTrials.gov/show/NCT01077960
2140,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,Completed,Has Results,"Arthritis, Psoriatic",Drug: placebo|Drug: ustekinumab 45 mg|Drug: ustekinumab 90 mg,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,27-Feb-14,https://ClinicalTrials.gov/show/NCT01077362
2141,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,10-Nov-15,https://ClinicalTrials.gov/show/NCT01076647
2142,A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease,Completed,Has Results,Hyperphosphatemia|End-Stage Renal Disease,Drug: ferric citrate,Keryx Biopharmaceuticals|Collaborative Study Group (CSG),Phase 3,Industry|Other,Interventional,4-Dec-14,https://ClinicalTrials.gov/show/NCT01074125
2143,Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL),Completed,Has Results,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Drug: Bendamustine|Drug: Rituximab,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,4-Apr-14,https://ClinicalTrials.gov/show/NCT01073163
2144,A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01072929
2145,Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder,Completed,Has Results,Depression,Drug: Armodafinil|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01072630
2146,12-week Efficacy of Indacaterol,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 75 μg|Drug: Placebo to indacaterol,Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT01072448
2147,A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura,Completed,Has Results,Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP,Biological: Romiplostim,Amgen,Phase 3,Industry,Interventional,29-Jan-19,https://ClinicalTrials.gov/show/NCT01071954
2148,Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.,Completed,Has Results,Hormone Replacement Therapy,Drug: Estradiol acetate|Drug: Estradiol|Drug: Conjugated equine estrogens,Warner Chilcott,Phase 3,Industry,Interventional,8-Apr-11,https://ClinicalTrials.gov/show/NCT01070979
2149,"Remission in Subjects With Crohn's Disease, Open Label Extension",Completed,Has Results,Crohn's Disease,Biological: Adalimumab 40 mg eow or ew,Abbott,Phase 3,Industry,Interventional,7-May-10,https://ClinicalTrials.gov/show/NCT01070303
2150,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep,Completed,Has Results,Bowel Preparation,Drug: PicoPrep|Drug: HalfLytely|Drug: bisacodyl,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,11-Sep-12,https://ClinicalTrials.gov/show/NCT01073943
2151,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,28-Dec-15,https://ClinicalTrials.gov/show/NCT01068678
2152,Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-Nov-15,https://ClinicalTrials.gov/show/NCT01068665
2153,Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol|Drug: Placebo to indacaterol,Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT01068600
2154,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE),Completed,Has Results,Gaucher Disease,Drug: Eliglustat tartrate,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,2-Dec-16,https://ClinicalTrials.gov/show/NCT01074944
2155,"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo",Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: Glatiramer acetate (GA)|Drug: Placebo,"Teva Pharmaceutical Industries, Ltd.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,9-Oct-18,https://ClinicalTrials.gov/show/NCT01067521
2156,A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Completed,Has Results,Perennial Allergic Rhinitis,Drug: ciclesonide HFA 160 μg,Sunovion,Phase 3,Industry,Interventional,11-Jun-12,https://ClinicalTrials.gov/show/NCT01067105
2157,Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes,Completed,Has Results,Breast Cancer|Melanoma,Drug: Lymphoseek,Navidea Biopharmaceuticals,Phase 3,Industry,Interventional,3-Jun-13,https://ClinicalTrials.gov/show/NCT01106040
2158,An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Romozosumab|Drug: Teriparatide,Amgen,Phase 3,Industry,Interventional,8-Nov-18,https://ClinicalTrials.gov/show/NCT01796301
2159,A Study in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Exenatide|Drug: Placebo|Drug: Metformin|Drug: Pioglitazone,Eli Lilly and Company,Phase 3,Industry,Interventional,26-Jan-15,https://ClinicalTrials.gov/show/NCT01064687
2160,"An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",Completed,Has Results,"Diabetes Mellitus, Type 2|Renal Insufficiency",Drug: Canagliflozin|Drug: Placebo,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,27-May-13,https://ClinicalTrials.gov/show/NCT01064414
2161,Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction|Sexual Dysfunction,Drug: Placebo|Drug: Dapoxetine|Drug: PDE5I (phosphodiesterase-5 inhibitor),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,5-Nov-12,https://ClinicalTrials.gov/show/NCT01063855
2162,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection,Completed,Has Results,Cystic Fibrosis|Burkholderia Infections,Drug: AZLI|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,11-Mar-14,https://ClinicalTrials.gov/show/NCT01059565
2163,Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,18-Aug-16,https://ClinicalTrials.gov/show/NCT01057810
2164,Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy,Completed,Has Results,"Diabetic Neuropathy, Painful",Drug: pregabalin (Lyrica)|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,22-Feb-13,https://ClinicalTrials.gov/show/NCT01057693
2165,Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep,Completed,Has Results,Bowel Preparation,Drug: PicoPrep|Drug: HalfLytely|Drug: bisacodyl,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,11-Sep-12,https://ClinicalTrials.gov/show/NCT01073930
2166,Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF Inhalation Powder|Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Aug-13,https://ClinicalTrials.gov/show/NCT01054885
2167,A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: FF Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Aug-13,https://ClinicalTrials.gov/show/NCT01053988
2168,A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza,Completed,Has Results,Influenza,Drug: Oseltamivir IV|Drug: Oseltamivir Oral,Hoffmann-La Roche,Phase 3,Industry,Interventional,1-Nov-13,https://ClinicalTrials.gov/show/NCT01050257
2169,Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: sitagliptin,Novo Nordisk A/S,Phase 3,Industry,Interventional,18-Nov-15,https://ClinicalTrials.gov/show/NCT01046110
2170,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Nov-15,https://ClinicalTrials.gov/show/NCT01045707
2171,"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,18-Nov-15,https://ClinicalTrials.gov/show/NCT01045447
2172,A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE),Completed,Has Results,Coronary Heart Disease,Drug: dalcetrapib|Drug: placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,6-Aug-18,https://ClinicalTrials.gov/show/NCT01323153
2173,"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,9-Dec-15,https://ClinicalTrials.gov/show/NCT01045161
2174,"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium Bromide 200 µg|Drug: Aclidinium Bromide 400 µg,AstraZeneca,Phase 3,Industry,Interventional,13-Sep-12,https://ClinicalTrials.gov/show/NCT01044459
2175,"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Disease-modifying antirheumatic drug",Pfizer,Phase 3,Industry,Interventional,6-Apr-18,https://ClinicalTrials.gov/show/NCT01039688
2176,Treatment of Erectile Dysfunction I,Completed,Has Results,Erectile Dysfunction,Drug: Udenafil|Drug: Placebo,Warner Chilcott,Phase 3,Industry,Interventional,22-Dec-11,https://ClinicalTrials.gov/show/NCT01037244
2177,Treatment of Erectile Dysfunction II,Completed,Has Results,Erectile Dysfunction,Drug: Udenafil|Drug: Placebo,Warner Chilcott,Phase 3,Industry,Interventional,22-Dec-11,https://ClinicalTrials.gov/show/NCT01037218
2178,Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.,Completed,Has Results,Carcinoma,Drug: Everolimus|Drug: Everolimus Placebo|Other: Best Supportive Care (BSC),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,27-Oct-14,https://ClinicalTrials.gov/show/NCT01035229
2179,A Study of Semagacestat for Alzheimer's Patients,Completed,Has Results,Alzheimer's Disease,Drug: semagacestat,Eli Lilly and Company,Phase 3,Industry,Interventional,25-Sep-14,https://ClinicalTrials.gov/show/NCT01035138
2180,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,25-Oct-13,https://ClinicalTrials.gov/show/NCT01034462
2181,"A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)",Completed,Has Results,Hodgkin's Lymphoma,Drug: Panobinostat|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-Jul-16,https://ClinicalTrials.gov/show/NCT01034163
2182,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil and hydrochlorothiazide,Takeda,Phase 3,Industry,Interventional,7-Feb-12,https://ClinicalTrials.gov/show/NCT01033071
2183,CANVAS - CANagliflozin cardioVascular Assessment Study,Completed,Has Results,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Drug: Placebo|Drug: Canagliflozin (JNJ-28431754) 100 mg|Drug: Canagliflozin (JNJ-28431754) 300 mg,"Janssen Research & Development, LLC|The George Institute for Global Health, Australia",Phase 3,Industry|Other,Interventional,7-Dec-18,https://ClinicalTrials.gov/show/NCT01032629
2184,"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Device: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Dec-13,https://ClinicalTrials.gov/show/NCT01072149
2185,Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients,Completed,Has Results,Kidney Transplant,Drug: Everolimus and tacrolimus|Drug: mycophenolate mofetil and tacrolimus,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-Jun-14,https://ClinicalTrials.gov/show/NCT01025817
2186,Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated,Completed,Has Results,Healthy,Other: Blood draw,Pfizer,Phase 3,Industry,Interventional,20-Jun-12,https://ClinicalTrials.gov/show/NCT01025336
2187,Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Alogliptin|Drug: Metformin|Drug: Alogliptin Placebo|Drug: Metformin Placebo,Takeda,Phase 3,Industry,Interventional,26-Mar-13,https://ClinicalTrials.gov/show/NCT01023581
2188,Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Panobinostat|Drug: Bortezomib|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,23-Oct-15,https://ClinicalTrials.gov/show/NCT01023308
2189,A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation,Completed,Has Results,Head Lice,Drug: Ivermectin Cream|Drug: vehicle control,Topaz Pharmaceuticals Inc,Phase 3,Industry,Interventional,4-Apr-12,https://ClinicalTrials.gov/show/NCT01066585
2190,Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Combivent CFC-MDI|Drug: Combivent Respimat 20/100 mcg|Drug: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg,Boehringer Ingelheim,Phase 3,Industry,Interventional,1-May-12,https://ClinicalTrials.gov/show/NCT01019694
2191,A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: Azelastine hydrochloride nasal spray 0.15%|Drug: Azelastine hydrochloride nasal spray 0.10%|Drug: Placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,11-Jun-12,https://ClinicalTrials.gov/show/NCT01018862
2192,A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,5-Oct-12,https://ClinicalTrials.gov/show/NCT01018680
2193,Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia,Completed,Has Results,Hepatitis C Virus,Biological: Pegylated-Interferon-lambda|Drug: Ribavirin|Drug: Daclatasvir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,24-Jun-19,https://ClinicalTrials.gov/show/NCT01741545
2194,Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study,Completed,Has Results,Asthma,Drug: Fluticasone Furoate/GW642444|Drug: Fluticasone propionate,GlaxoSmithKline,Phase 3,Industry,Interventional,29-Oct-13,https://ClinicalTrials.gov/show/NCT01018186
2195,A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Aug-13,https://ClinicalTrials.gov/show/NCT01017952
2196,LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer,Completed,Has Results,Ovarian Neoplasms|Peritoneal Neoplasms,Drug: Placebo|Drug: Paclitaxel|Drug: BIBF 1120|Drug: Carboplatin,Boehringer Ingelheim,Phase 3,Industry,Interventional,15-Jan-15,https://ClinicalTrials.gov/show/NCT01015118
2197,"Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis",Completed,Has Results,Cystinosis,Drug: RP103|Drug: Cystagon®,"Horizon Pharma USA, Inc.",Phase 3,Industry,Interventional,24-May-17,https://ClinicalTrials.gov/show/NCT01733316
2198,Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma,Completed,Has Results,"Lymphoma, Large-Cell, Diffuse",Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP,GlaxoSmithKline,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT01014208
2199,Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD),Completed,Has Results,"Muscular Dystrophy, Duchenne|Ambulatory Care",Drug: Placebo|Drug: Idebenone,Santhera Pharmaceuticals,Phase 3,Industry,Interventional,19-Oct-15,https://ClinicalTrials.gov/show/NCT01027884
2200,A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Aug-13,https://ClinicalTrials.gov/show/NCT01009463
2201,A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis,Completed,Has Results,"Arthritis, Psoriatic",Drug: Placebo|Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,13-Mar-14,https://ClinicalTrials.gov/show/NCT01009086
2202,Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,HER2/Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer,Drug: everolimus|Drug: Placebo|Drug: vinorelbine|Drug: trastuzumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,5-Apr-17,https://ClinicalTrials.gov/show/NCT01007942
2203,A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo to tocilizumab|Drug: Methotrexate|Drug: Placebo to methotrexate,Hoffmann-La Roche,Phase 3,Industry,Interventional,12-Jul-13,https://ClinicalTrials.gov/show/NCT01007435
2204,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),Completed,Has Results,Malignant Melanoma,Drug: Vemurafenib|Drug: Dacarbazine,Hoffmann-La Roche,Phase 3,Industry,Interventional,16-Nov-11,https://ClinicalTrials.gov/show/NCT01006980
2205,"A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Glycopyrronium bromide|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,12-Apr-12,https://ClinicalTrials.gov/show/NCT01005901
2206,C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf)|Drug: Placebo (saline),Shire,Phase 3,Industry,Interventional,3-Jun-10,https://ClinicalTrials.gov/show/NCT01005888
2207,"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",Completed,Has Results,Healthy,Biological: HEPLISAV and/or Placebo|Biological: Engerix-B,Dynavax Technologies Corporation,Phase 3,Industry,Interventional,11-Jan-18,https://ClinicalTrials.gov/show/NCT01005407
2208,Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access,Completed,Has Results,HIV,Drug: Atazanavir|Drug: Atazanavir/Ritonavir|Drug: Tenofovir/Emtricitabine|Drug: Lopinavir/ritonavir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,11-May-17,https://ClinicalTrials.gov/show/NCT01003990
2209,"Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients",Completed,Has Results,Fever,Drug: ibuprofen|Drug: acetaminophen,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,7-Nov-16,https://ClinicalTrials.gov/show/NCT01002573
2210,A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome),Completed,Has Results,MPS IV A,Drug: BMN 110 Weekly|Drug: Placebo|Drug: BMN 110 Every Other Week,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,15-Apr-14,https://ClinicalTrials.gov/show/NCT01275066
2211,Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants,Completed,Has Results,Haemophilus Influenzae Type b,Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Biological: ActHIB™|Biological: Pentacel™|Biological: Pediarix™|Biological: Prevnar 13™|Biological: Rotarix™|Biological: Engerix™-B|Biological: Infanrix™,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Aug-13,https://ClinicalTrials.gov/show/NCT01000974
2212,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Completed,Has Results,Acute Coronary Syndrome,Drug: Darapladib 160 mg|Drug: Placebo|Other: Standard Therapy,GlaxoSmithKline|The TIMI Study Group,Phase 3,Industry|Other,Interventional,10-Aug-17,https://ClinicalTrials.gov/show/NCT01000727
2213,"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months",Completed,Has Results,Meningococcal Disease,Biological: MenACWY-CRM|Biological: DTaP-IPV/Hib|Biological: HBV|Biological: PCV|Biological: MMR,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,26-Mar-14,https://ClinicalTrials.gov/show/NCT01000311
2214,Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study),Completed,Has Results,Attention-Deficit/Hyperactivity Disorder,Drug: extended-release guanfacine hydrochloride (SPD503)|Drug: placebo|Drug: extended-release guanfacine hydrochloride,Shire,Phase 3,Industry,Interventional,26-Oct-11,https://ClinicalTrials.gov/show/NCT00997984
2215,A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy,Completed,Has Results,Pregnancy Prevention,Drug: DR-103,Teva Women's Health|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,14-Jun-13,https://ClinicalTrials.gov/show/NCT00996580
2216,Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin|Drug: placebo,"Sprout Pharmaceuticals, Inc",Phase 3,Industry,Interventional,12-Jun-14,https://ClinicalTrials.gov/show/NCT00996372
2217,Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: Flibanserin|Drug: Placebo,"Sprout Pharmaceuticals, Inc",Phase 3,Industry,Interventional,19-May-14,https://ClinicalTrials.gov/show/NCT00996164
2218,Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders,Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100|Drug: Buphenyl (NaPBA),"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,12-Aug-13,https://ClinicalTrials.gov/show/NCT00992459
2219,Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance,Completed,Has Results,Restless Legs Syndrome,Drug: pregabalin|Drug: placebo|Drug: pramipexole,Pfizer,Phase 3,Industry,Interventional,8-Oct-12,https://ClinicalTrials.gov/show/NCT00991276
2220,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,23-May-12,https://ClinicalTrials.gov/show/NCT00988247
2221,Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Lenalidomide|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo,Celgene,Phase 3,Industry,Interventional,5-Sep-13,https://ClinicalTrials.gov/show/NCT00988208
2222,Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee,Completed,Has Results,Osteoarthritis of the Knee,Device: 1.2% Sodium Hyaluronate|Device: Buffered Saline,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,4-Jun-12,https://ClinicalTrials.gov/show/NCT00988091
2223,Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).,Completed,Has Results,Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Thromboembolism|Venous Thrombosis,Drug: edoxaban tosylate(DU-176b)|Drug: low molecular weight heparin/unfractionated heparin|Drug: warfarin,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,25-Feb-15,https://ClinicalTrials.gov/show/NCT00986154
2224,Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL),Completed,Has Results,Typical Atrial Flutter,Device: Therapy Cool Path Duo,Abbott Medical Devices,Phase 3,Industry,Interventional,20-Dec-13,https://ClinicalTrials.gov/show/NCT00984204
2225,"Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015",Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Phase 3,Industry,Interventional,27-Jul-17,https://ClinicalTrials.gov/show/NCT00984126
2226,Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-Nov-15,https://ClinicalTrials.gov/show/NCT00982644
2227,Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,29-Dec-15,https://ClinicalTrials.gov/show/NCT00982228
2228,A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis,Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: Tocilizumab|Drug: Placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,1-Nov-12,https://ClinicalTrials.gov/show/NCT00988221
2229,Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency,Completed,Has Results,Cystic Fibrosis|Exocrine Pancreatic Insufficiency,Drug: EUR-1008 (APT-1008),Forest Laboratories,Phase 3,Industry,Interventional,4-Apr-14,https://ClinicalTrials.gov/show/NCT00981214
2230,Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children,Completed,Has Results,Influenza,Biological: GSK investigational vaccine GSK1557482A|Biological: Fluzone®,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Feb-12,https://ClinicalTrials.gov/show/NCT00980005
2231,"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older",Completed,Has Results,Influenza,Biological: GSK2340274A|Biological: GSK2340273A,GlaxoSmithKline,Phase 3,Industry,Interventional,21-Sep-17,https://ClinicalTrials.gov/show/NCT00979602
2232,Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology,Completed,Has Results,Alzheimer Disease,Drug: Florbetaben (BAY94-9172),Life Molecular Imaging SA,Phase 3,Industry,Interventional,25-Mar-15,https://ClinicalTrials.gov/show/NCT01020838
2233,Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: insulin degludec/insulin aspart|Drug: insulin detemir|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,20-Nov-15,https://ClinicalTrials.gov/show/NCT00978627
2234,24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Drug: Lixisenatide Placebo|Device: Pen auto-injector|Drug: Sitagliptin|Drug: Sitagliptin Placebo|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT00976937
2235,Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-Dec-16,https://ClinicalTrials.gov/show/NCT00978380
2236,A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide + insulin glargine|Drug: insulin glargine + preprandial lispro insulin,GlaxoSmithKline,Phase 3,Industry,Interventional,16-Jul-14,https://ClinicalTrials.gov/show/NCT00976391
2237,24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Insulin glargine|Device: Pen auto-injector|Drug: Metformin|Drug: Thiazolidinedione (TZD),Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT00975286
2238,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,Completed,Has Results,"Hyperparathyroidism, Primary|Hypercalcemia",Drug: Cinacalcet|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,25-Jan-16,https://ClinicalTrials.gov/show/NCT00975221
2239,Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne,Completed,Has Results,Severe Nodular Acne,Drug: CIP-Isotretinoin|Drug: Isotretinoin,Cipher Pharmaceuticals Inc.,Phase 3,Industry,Interventional,4-Jul-14,https://ClinicalTrials.gov/show/NCT00975143
2240,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: IR CD-LD,"Impax Laboratories, LLC",Phase 3,Industry,Interventional,14-Jan-16,https://ClinicalTrials.gov/show/NCT00974974
2241,Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Completed,Has Results,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,Drug: Cinacalcet|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,29-Jan-16,https://ClinicalTrials.gov/show/NCT00975000
2242,Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System,Completed,Has Results,Human Papillomavirus Infection,Device: APTIMA HPV Assay|Device: FDA-Approved HPV DNA Test,"Gen-Probe, Incorporated",Phase 3,Industry,Interventional,6-Jan-17,https://ClinicalTrials.gov/show/NCT00973362
2243,Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: i.v. selexipag|Drug: oral selexipag (Uptravi),Actelion,Phase 3,Industry,Interventional,21-May-19,https://ClinicalTrials.gov/show/NCT03187678
2244,Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec|Drug: insulin glargine|Drug: insulin aspart,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-Nov-15,https://ClinicalTrials.gov/show/NCT00972283
2245,"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide,AstraZeneca,Phase 3,Industry,Interventional,14-Sep-12,https://ClinicalTrials.gov/show/NCT00970268
2246,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,25-Oct-13,https://ClinicalTrials.gov/show/NCT00969709
2247,Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Levomilnacipran ER|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,25-Oct-13,https://ClinicalTrials.gov/show/NCT00969150
2248,CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Glimepiride|Drug: Canagliflozin (JNJ-28431754)|Drug: Metformin,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,4-Jun-13,https://ClinicalTrials.gov/show/NCT00968812
2249,Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome,Completed,Has Results,"Diabetes Mellitus, Type 2|Acute Coronary Syndrome",Drug: Alogliptin|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,15-Apr-14,https://ClinicalTrials.gov/show/NCT00968708
2250,Genotropin Study Assessing Use of Injection Pen,Completed,Has Results,Growth Hormone Deficiency|Idiopathic Short Stature,Device: New Genotropin Pen,Pfizer,Phase 3,Industry,Interventional,23-Dec-10,https://ClinicalTrials.gov/show/NCT00965484
2251,Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients,Completed,Has Results,"Vaccines, Pneumococcal Conjugate Vaccine",Biological: 13vPnC|Biological: 23vPS,Pfizer,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT00980655
2252,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,Completed,Has Results,HIV Infections|Pneumococcal Infections,Biological: 13-valent pneumococcal conjugate vaccine|Procedure: Blood draw,Pfizer,Phase 3,Industry,Interventional,10-Jun-13,https://ClinicalTrials.gov/show/NCT00963235
2253,A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects,Completed,Has Results,Head Lice,Drug: 0.5% Ivermectin Cream|Drug: Placebo control,Topaz Pharmaceuticals Inc,Phase 3,Industry,Interventional,4-Apr-12,https://ClinicalTrials.gov/show/NCT01068158
2254,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI,Completed,Has Results,Breast Cancer|Diagnostic Imaging,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,11-Nov-14,https://ClinicalTrials.gov/show/NCT01067976
2255,"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Phase 3,Industry,Interventional,10-Jan-13,https://ClinicalTrials.gov/show/NCT00960440
2256,A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population,Completed,Has Results,Influenza,Biological: CSL's Influenza Virus Vaccine (Afluria)|Biological: Influenza Virus Vaccine (Fluzone),Seqirus,Phase 3,Industry,Interventional,29-Jul-11,https://ClinicalTrials.gov/show/NCT00959049
2257,A Study in Relapse Prevention of Treatment-Resistant Depression,Completed,Has Results,Treatment Resistant Depression,Drug: Olanzapine and Fluoxetine combination (OFC)|Drug: Fluoxetine,Eli Lilly and Company,Phase 3,Industry,Interventional,1-Apr-14,https://ClinicalTrials.gov/show/NCT00958568
2258,Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza,Completed,Has Results,Seasonal Influenza|Cough|Sore Throat|Nasal Congestion|Myalgia|Headache|Fatigue,Drug: Peramivir,BioCryst Pharmaceuticals|Department of Health and Human Services,Phase 3,Industry|U.S. Fed,Interventional,12-Feb-15,https://ClinicalTrials.gov/show/NCT00957996
2259,Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis,Completed,Has Results,Allergic Rhinitis Due to Grass Pollens,Drug: 300 IR|Drug: Placebo,Stallergenes Greer,Phase 3,Industry,Interventional,19-May-16,https://ClinicalTrials.gov/show/NCT00955825
2260,Naturlose (D-Tagatose) Efficacy Evaluation Trial,Completed,Has Results,Type 2 Diabetes,Drug: Tagatose|Drug: Sugar Substitute Splenda,Robert Lodder|University of Kentucky|Spherix Incorporated,Phase 3,Industry|Other,Interventional,19-Nov-14,https://ClinicalTrials.gov/show/NCT00955747
2261,A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older,Completed,Has Results,Allergic Rhinitis|Perennial Allergic Rhinitis,Drug: Ciclesonide HFA 80 mcg|Drug: Ciclesonide HFA 160 mcg|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,7-Jun-12,https://ClinicalTrials.gov/show/NCT00953147
2262,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age,Completed,Has Results,Healthy or Stable Underlying Chronic Medical Condition,Biological: Q/LAIV-BFS (MEDI8662)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,Phase 3,Industry,Interventional,13-Jan-12,https://ClinicalTrials.gov/show/NCT00952705
2263,COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial,Completed,Has Results,MPN (Myeloproliferative Neoplasms),Drug: Ruxolitinib|Drug: Placebo,Incyte Corporation,Phase 3,Industry,Interventional,24-Jan-12,https://ClinicalTrials.gov/show/NCT00952289
2264,6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Insulin glargine (HOE901)|Drug: Neutral Protamine Hagedorn (NPH) insulin|Drug: Insulin lispro,Sanofi,Phase 3,Industry,Interventional,22-Jun-12,https://ClinicalTrials.gov/show/NCT00993473
2265,Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD),Completed,Has Results,Urea Cycle Disorders,Drug: HPN-100,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,15-Aug-13,https://ClinicalTrials.gov/show/NCT00947297
2266,A Trial of Degarelix in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Goserelin acetate,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,2-Jun-14,https://ClinicalTrials.gov/show/NCT00946920
2267,An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Completed,Has Results,Factor XIII Deficiency,Biological: FXIII Concentrate (Human) (FXIII),CSL Behring,Phase 3,Industry,Interventional,12-Oct-12,https://ClinicalTrials.gov/show/NCT00945906
2268,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE),Completed,Has Results,"Gaucher Disease, Type 1",Drug: Eliglustat tartrate|Drug: Imiglucerase,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,4-Sep-14,https://ClinicalTrials.gov/show/NCT00943111
2269,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,Has Results,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Phase 3,Industry,Interventional,19-Mar-12,https://ClinicalTrials.gov/show/NCT00942604
2270,Evaluation of an Investigational Multi-Purpose Solution (MPS),Completed,Has Results,Study Focus is Healthy Contact Lens Wearers,Device: Investigational MPS|Device: Opti-Free,Abbott Medical Optics,Phase 3,Industry,Interventional,7-Jan-14,https://ClinicalTrials.gov/show/NCT00961051
2271,A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women,Completed,Has Results,"Osteoporosis, Postmenopausal",Drug: Oral Calcitonin Tablets|Drug: Intranasal Calcitonin|Drug: Placebo tablets and placebo intranasal spray,"Tarsa Therapeutics, Inc.",Phase 3,Industry,Interventional,19-Nov-13,https://ClinicalTrials.gov/show/NCT00959764
2272,A Study of Duloxetine in Patients With Osteoarthritis Knee Pain,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine (DLX)|Drug: Placebo (PLA),Eli Lilly and Company,Phase 3,Industry,Interventional,8-Mar-11,https://ClinicalTrials.gov/show/NCT00945945
2273,Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects,Completed,Has Results,"Infections, Papillomavirus",Procedure: Gynaecological follow-up,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Jan-15,https://ClinicalTrials.gov/show/NCT00937950
2274,An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Syndrome,Drug: mifepristone,Corcept Therapeutics,Phase 3,Industry,Interventional,2-Apr-14,https://ClinicalTrials.gov/show/NCT00936741
2275,Evaluation of Diagnostic HIV Ag/Ab Combo Assay,Completed,Has Results,Human Immunodeficiency Viruses,Device: ARCHITECT HIV Ag/Ab Combo,Abbott Diagnostics Division,Phase 3,Industry,Interventional,19-Aug-10,https://ClinicalTrials.gov/show/NCT00933933
2276,"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: PF-02341066|Drug: Pemetrexed|Drug: Docetaxel,Pfizer,Phase 3,Industry,Interventional,6-Jun-13,https://ClinicalTrials.gov/show/NCT00932893
2277,Study of Safety and Efficacy of an Oral Contraceptive,Completed,Has Results,Prevention of Pregnancy,Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days|Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days,Warner Chilcott,Phase 3,Industry,Interventional,22-Mar-11,https://ClinicalTrials.gov/show/NCT00932321
2278,Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: BI 1744 (Olodaterol) Low Dose|Drug: BI 1744 (Olodaterol) Medium Dose|Drug: Placebo|Drug: Foradil,Boehringer Ingelheim,Phase 3,Industry,Interventional,27-Jun-14,https://ClinicalTrials.gov/show/NCT00932646
2279,Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants,Completed,Has Results,Bronchopulmonary Dysplasia,Drug: Inhaled Nitric Oxide|Drug: Placebo,Mallinckrodt,Phase 3,Industry,Interventional,11-Aug-15,https://ClinicalTrials.gov/show/NCT00931632
2280,Abatacept Versus Adalimumab Head-to-Head,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Adalimumab,Bristol-Myers Squibb,Phase 3,Industry,Interventional,3-Jan-14,https://ClinicalTrials.gov/show/NCT00929864
2281,Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: BI 1744|Drug: bi1744|Drug: Placebo|Drug: Foradil,Boehringer Ingelheim,Phase 3,Industry,Interventional,1-Jul-14,https://ClinicalTrials.gov/show/NCT00931385
2282,"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Glycopyrronium bromide|Drug: Placebo to glycopyrronium bromide|Drug: Tiotropium,Novartis,Phase 3,Industry,Interventional,27-Jul-12,https://ClinicalTrials.gov/show/NCT00929110
2283,A Study of Degarelix in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Leuprolide,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,13-Dec-16,https://ClinicalTrials.gov/show/NCT00928434
2284,A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults,Completed,Has Results,Influenza,Biological: Quadrivalent seasonal influenza vaccine GSK2282512A|Biological: FluLavalTM-VB|Biological: FluLavalTM-YB,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Dec-12,https://ClinicalTrials.gov/show/NCT01196975
2285,A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma,Completed,Has Results,Glioblastoma,Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,20-May-13,https://ClinicalTrials.gov/show/NCT00943826
2286,Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss,Completed,Has Results,Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer,Biological: Denosumab|Biological: Placebo,Amgen,Phase 3,Industry,Interventional,30-May-17,https://ClinicalTrials.gov/show/NCT00925600
2287,Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease,Completed,Has Results,Fabry Disease,Drug: migalastat hydrochloride|Drug: Placebo,Amicus Therapeutics,Phase 3,Industry,Interventional,30-Oct-18,https://ClinicalTrials.gov/show/NCT00925301
2288,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,Completed,Has Results,Blood Coagulation Disorders|Hemophilia A,"Biological: Recombinant Factor VIII (BAY81-8973)|Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,Phase 3,Industry,Interventional,18-Nov-13,https://ClinicalTrials.gov/show/NCT01029340
2289,A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q,Completed,Has Results,Anemia,Drug: Lenalidomide|Other: Placebo,Celgene,Phase 3,Industry,Interventional,18-Jun-15,https://ClinicalTrials.gov/show/NCT01029262
2290,Study of Adalimumab in Patients With Axial Spondyloarthritis,Completed,Has Results,Axial Spondyloarthritis,Biological: Adalimumab|Biological: Placebo|Biological: Open-label Adalimumab,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,6-Mar-12,https://ClinicalTrials.gov/show/NCT00939003
2291,Contrast-enhanced MRI in Children 2 Months to <2 Years,Completed,Has Results,Magnetic Resonance Imaging,"Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)",Bayer,Phase 3,Industry,Interventional,13-Oct-11,https://ClinicalTrials.gov/show/NCT00937391
2292,Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Metformin XR|Drug: Placebo matching Metformin XR|Drug: Placebo matching Saxagliptin,AstraZeneca,Phase 3,Industry,Interventional,6-Oct-11,https://ClinicalTrials.gov/show/NCT00918138
2293,Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma,Completed,Has Results,Gastric Cancer|Adenocarcinoma,Biological: ramucirumab|Drug: Placebo|Other: Best Supportive Care (BSC),Eli Lilly and Company,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT00917384
2294,SPIRIT PRIME Clinical Trial,Completed,Has Results,Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis,Device: Core size Xience Prime|Device: Xience Prime Long Lesion (LL),Abbott Medical Devices,Phase 3,Industry,Interventional,1-Jun-12,https://ClinicalTrials.gov/show/NCT00916370
2295,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,Has Results,Actinic Keratosis,Drug: PEP005 Gel|Drug: Vehicle gel,Peplin,Phase 3,Industry,Interventional,21-Mar-12,https://ClinicalTrials.gov/show/NCT00916006
2296,"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)",Completed,Has Results,Actinic Keratosis,"Drug: PEP005 (Ingenol Mebutate) gel, 0.015%|Drug: Vehicle Gel",Peplin,Phase 3,Industry,Interventional,16-Mar-12,https://ClinicalTrials.gov/show/NCT00915551
2297,A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Placebo,Astellas Pharma Inc,Phase 3,Industry,Interventional,17-Oct-12,https://ClinicalTrials.gov/show/NCT00912964
2298,A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3),Completed,Has Results,Hereditary Angioedema,Drug: Icatibant|Drug: Placebo,Shire,Phase 3,Industry,Interventional,6-Aug-14,https://ClinicalTrials.gov/show/NCT00912093
2299,"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)",Completed,Has Results,Symptomatic Gastroesophageal Reflux Disease (sGERD),Drug: rabeprazole sodium|Drug: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,2-Feb-16,https://ClinicalTrials.gov/show/NCT00911534
2300,PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study,Completed,Has Results,Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer,Drug: Pegfilgrastim|Drug: Placebo|Biological: Bevacizumab|Drug: Standard Chemotherapy,Amgen,Phase 3,Industry,Interventional,7-Jan-14,https://ClinicalTrials.gov/show/NCT00911170
2301,Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial),Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Drug: Lenalidomide|Drug: Chlorambucil,Celgene,Phase 3,Industry,Interventional,21-Dec-16,https://ClinicalTrials.gov/show/NCT00910910
2302,Eslicarbazepine Acetate Monotherapy Long Term Study,Completed,Has Results,Epilepsy,Drug: Eslicarbazepine acetate,Sunovion,Phase 3,Industry,Interventional,17-Jul-18,https://ClinicalTrials.gov/show/NCT00910247
2303,Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers,Completed,Has Results,Venous Leg Ulcer,Device: Dermagraft(R)|Device: Profore,Organogenesis,Phase 3,Industry,Interventional,4-Feb-13,https://ClinicalTrials.gov/show/NCT00909870
2304,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Arformoterol|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,11-Nov-13,https://ClinicalTrials.gov/show/NCT00909779
2305,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,21-Aug-12,https://ClinicalTrials.gov/show/NCT00909727
2306,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Completed,Has Results,Cystic Fibrosis,Drug: Ivacaftor|Drug: Placebo,Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation,Phase 3,Industry|Other,Interventional,21-Aug-12,https://ClinicalTrials.gov/show/NCT00909532
2307,Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence,Completed,Has Results,Urge Urinary Incontinence|Urinary Frequency,Drug: Oxybutynin|Drug: Placebo,Antares Pharma Inc.,Phase 3,Industry,Interventional,19-Jan-11,https://ClinicalTrials.gov/show/NCT00909181
2308,Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy,Completed,Has Results,Partial Epilepsy,Drug: Oxcarbazepine XR,"Supernus Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,31-May-17,https://ClinicalTrials.gov/show/NCT00908349
2309,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: BIIB017 (peginterferon beta-1a)|Drug: Placebo,Biogen,Phase 3,Industry,Interventional,19-Sep-14,https://ClinicalTrials.gov/show/NCT00906399
2310,Effect on Primary Dysmenorrhea,Completed,Has Results,Primary Dysmenorrhea,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ethinyl estradiol, Levonorgestrel (Miranova)|Drug: Placebo Match to SH T00658ID|Drug: Placebo Match to SH D593B",Bayer,Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT00909857
2311,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Ciclesonide HFA 160 μg|Drug: Ciclesonide HFA 80 μg|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,8-Jun-12,https://ClinicalTrials.gov/show/NCT01010971
2312,"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",Completed,Has Results,Hypertriglyceridemia,Drug: Simvastatin + Lovaza® (omega-3-acid ethyl esters),GlaxoSmithKline,Phase 3,Industry,Interventional,4-Aug-09,https://ClinicalTrials.gov/show/NCT00903409
2313,Imatinib (QTI571) in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: imatinib mesylate|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,16-Jul-13,https://ClinicalTrials.gov/show/NCT00902174
2314,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Erlotinib (Tarceva)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,30-Sep-13,https://ClinicalTrials.gov/show/NCT00901901
2315,A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol|Drug: Placebo to tiotropium,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT00900731
2316,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,Completed,Has Results,Iliac Artery Stenosis,Device: Epic™ Nitinol Stent System|Drug: Anti-platelet therapy|Drug: Anti-coagulation therapy,Boston Scientific Corporation,Phase 3,Industry,Interventional,3-Jul-12,https://ClinicalTrials.gov/show/NCT00896337
2317,Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy,Completed,Has Results,Erectile Dysfunction,Drug: Placebo|Drug: Avanafil,"VIVUS, Inc.",Phase 3,Industry,Interventional,28-Jun-12,https://ClinicalTrials.gov/show/NCT00895011
2318,"Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",Completed,Has Results,Acute Decompensated Heart Failure|Congestive Heart Failure,Drug: Aliskiren|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,10-Oct-13,https://ClinicalTrials.gov/show/NCT00894387
2319,Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery,Completed,Has Results,Actinic Keratosis,Drug: imiquimod cream|Drug: placebo cream,"Graceway Pharmaceuticals, LLC",Phase 3,Industry,Interventional,23-Aug-10,https://ClinicalTrials.gov/show/NCT00894647
2320,FS VH S/D 500 S-apr in Vascular Surgery,Completed,Has Results,Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses,"Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Other: Surgical gauze pads",Baxter Healthcare Corporation,Phase 3,Industry,Interventional,27-Nov-12,https://ClinicalTrials.gov/show/NCT00892957
2321,A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR),Completed,Has Results,Age-related Macular Degeneration,Drug: Ranibizumab,"Genentech, Inc.",Phase 3,Industry,Interventional,18-Jan-13,https://ClinicalTrials.gov/show/NCT00891735
2322,Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Aclidinium bromide|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,13-Sep-12,https://ClinicalTrials.gov/show/NCT00891462
2323,A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs),Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: Nonbiologic DMARDs of investigator's choice,Hoffmann-La Roche,Phase 3,Industry,Interventional,17-Apr-12,https://ClinicalTrials.gov/show/NCT00891020
2324,Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA),Completed,Has Results,Systemic Juvenile Idiopathic Arthritis With Active Flare,Drug: canakinumab|Drug: placebo,Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization|Novartis,Phase 3,Industry|Other,Interventional,16-Oct-12,https://ClinicalTrials.gov/show/NCT00889863
2325,Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: UT-15C SR|Drug: Placebo,United Therapeutics,Phase 3,Industry,Interventional,15-Jan-13,https://ClinicalTrials.gov/show/NCT00887978
2326,Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine succinate sustained release 50 mg|Drug: Desvenlafaxine succinate sustained release 25 mg|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,27-Jun-12,https://ClinicalTrials.gov/show/NCT00887224
2327,Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Abiraterone acetate|Drug: Placebo|Drug: Prednisone,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,9-Apr-15,https://ClinicalTrials.gov/show/NCT00887198
2328,A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency,Completed,Has Results,Factor XIII Deficiency,Biological: FXIII Concentrate (Human),CSL Behring,Phase 3,Industry,Interventional,4-Jul-12,https://ClinicalTrials.gov/show/NCT00885742
2329,Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Saxagliptin plus metformin IR|Drug: Placebo plus metformin IR,AstraZeneca,Phase 3,Industry,Interventional,16-Dec-11,https://ClinicalTrials.gov/show/NCT00885378
2330,Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia|Sleep Disorders,Drug: Pregabalin|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00883740
2331,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: azelastineHcl|Drug: fluticasone propionate|Drug: azelastine Hcl/fluticasone propionate,Meda Pharmaceuticals,Phase 3,Industry,Interventional,7-Sep-12,https://ClinicalTrials.gov/show/NCT00883168
2332,Study of Mepolizumab Safety Syringe in Asthmatics,Completed,Has Results,Asthma,Drug: Mepolizumab,GlaxoSmithKline,Phase 3,Industry,Interventional,31-Jan-18,https://ClinicalTrials.gov/show/NCT03021304
2333,A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Placebo|Drug: IPX066 95 mg LD|Drug: IPX066 145 mg LD|Drug: IPX066 195 mg LD|Drug: IPX066 245 mg LD,"Impax Laboratories, LLC",Phase 3,Industry,Interventional,22-Feb-16,https://ClinicalTrials.gov/show/NCT00880620
2334,Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF),Completed,Has Results,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Ultrase® MT12,Forest Laboratories,Phase 3,Industry,Interventional,19-Feb-15,https://ClinicalTrials.gov/show/NCT00880100
2335,Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Hypertension,Drug: Telmisartan 80|Drug: Amlodipine 10,Boehringer Ingelheim,Phase 3,Industry,Interventional,7-Jun-11,https://ClinicalTrials.gov/show/NCT00877929
2336,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT00877383
2337,Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study,Completed,Has Results,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,Drug: bendamustine|Drug: rituximab|Drug: vincristine|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,28-Apr-14,https://ClinicalTrials.gov/show/NCT00877006
2338,Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Placebo|Drug: Trastuzumab|Drug: Paclitaxel,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Dec-18,https://ClinicalTrials.gov/show/NCT00876395
2339,Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects,Completed,Has Results,Sedation,Drug: Dexmedetomidine|Drug: Midazolam|Drug: Fentanyl|Drug: Morphine,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 3,Industry,Interventional,30-Oct-14,https://ClinicalTrials.gov/show/NCT00875550
2340,Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression,Completed,Has Results,Bipolar Depression,Drug: lurasidone,Sunovion,Phase 3,Industry,Interventional,1-Apr-14,https://ClinicalTrials.gov/show/NCT00868959
2341,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy),Completed,Has Results,Bipolar Depression,Drug: lurasidone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,2-Jul-13,https://ClinicalTrials.gov/show/NCT00868699
2342,Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on),Completed,Has Results,Bipolar Depression,Drug: lurasidone + (lithium or divalproex)|Drug: Placebo + (lithium or divalproex),Sunovion,Phase 3,Industry,Interventional,2-Apr-13,https://ClinicalTrials.gov/show/NCT00868452
2343,Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: GSK Biologicals'Kinrix®|Biological: Merck and Company's MMRII|Biological: Merck and Company's Varivax,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Feb-11,https://ClinicalTrials.gov/show/NCT00871117
2344,Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,7-Jan-10,https://ClinicalTrials.gov/show/NCT00868296
2345,Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs,Completed,Has Results,Epilepsy With Simple or Complex Partial Onset Seizures,Drug: Eslicarbazepine acetate,Sunovion,Phase 3,Industry,Interventional,4-Feb-16,https://ClinicalTrials.gov/show/NCT00866775
2346,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,Completed,Has Results,Malignant Melanoma,Drug: ABI-007|Drug: Dacarbazine,Celgene|University of Arizona,Phase 3,Industry|Other,Interventional,5-Jun-14,https://ClinicalTrials.gov/show/NCT00864253
2347,Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole,Completed,Has Results,Breast Cancer,Drug: Everolimus|Drug: Exemestane|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,31-Aug-12,https://ClinicalTrials.gov/show/NCT00863655
2348,Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,16-Mar-16,https://ClinicalTrials.gov/show/NCT00861614
2349,Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension,Completed,Has Results,Hypertension,Drug: amlodipine|Drug: telmisartan|Drug: telmisartan and amlodipine,Boehringer Ingelheim,Phase 3,Industry,Interventional,4-Jan-11,https://ClinicalTrials.gov/show/NCT00860262
2350,Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain,Completed,Has Results,Alzheimer's Disease,Drug: florbetapir F 18,Avid Radiopharmaceuticals,Phase 3,Industry,Interventional,7-May-12,https://ClinicalTrials.gov/show/NCT00857415
2351,Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia,Completed,Has Results,Insomnia|Attention Deficit Hyperactivity Disorder,Drug: eszopiclone,Sunovion,Phase 3,Industry,Interventional,22-Jul-13,https://ClinicalTrials.gov/show/NCT00857220
2352,The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: insulin detemir|Drug: metformin,Novo Nordisk A/S,Phase 3,Industry,Interventional,13-May-11,https://ClinicalTrials.gov/show/NCT00856986
2353,Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia,Completed,Has Results,Insomnia|Attention Deficit Hyperactivity Disorder,Drug: eszopiclone|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,10-Apr-13,https://ClinicalTrials.gov/show/NCT00856973
2354,"A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Phase 3,Industry,Interventional,10-Jan-13,https://ClinicalTrials.gov/show/NCT00856544
2355,Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin|Drug: Metformin|Drug: Glipizide,Takeda,Phase 3,Industry,Interventional,3-Dec-13,https://ClinicalTrials.gov/show/NCT00856284
2356,Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE),Completed,Has Results,Gout,Biological: Rilonacept|Other: Placebo,Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,28-Apr-17,https://ClinicalTrials.gov/show/NCT00856206
2357,Study Utilizing Rilonacept in Gout Exacerbations,Completed,Has Results,Acute Gout Flare,Drug: Rilonacept|Drug: Indomethacin|Other: Placebo (for Indomethacin)|Other: Placebo (for Rilonacept),Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,28-Apr-17,https://ClinicalTrials.gov/show/NCT00855920
2358,A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia,Completed,Has Results,Erectile Dysfunction|Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,30-Jun-11,https://ClinicalTrials.gov/show/NCT00855582
2359,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,Completed,Has Results,Pulmonary Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,11-Mar-14,https://ClinicalTrials.gov/show/NCT00855465
2360,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",Completed,Has Results,HIV|HIV Infections|Pregnancy,Drug: Darunavir|Drug: Ritonavir|Drug: Etravirine|Drug: Rilpivirine|Drug: Darunavir/Cobicistat (FDC),"Janssen Scientific Affairs, LLC",Phase 3,Industry,Interventional,15-Sep-17,https://ClinicalTrials.gov/show/NCT00855335
2361,A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Phase 3,Industry,Interventional,5-Jan-11,https://ClinicalTrials.gov/show/NCT00857454
2362,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",Completed,Has Results,Pediculosis,Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse (Nix Crème),Taro Pharmaceuticals USA,Phase 3,Industry,Interventional,13-Jun-14,https://ClinicalTrials.gov/show/NCT00963508
2363,Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients,Completed,Has Results,Coronary Artery Disease (CAD)|Coronary Atherosclerosis,Drug: Placebo|Drug: Aliskiren,Novartis Pharmaceuticals|The Cleveland Clinic|Novartis,Phase 3,Industry|Other,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT00853827
2364,Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure,Completed,Has Results,Chronic Heart Failure,Drug: Enalapril|Drug: Aliskiren,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,25-Nov-16,https://ClinicalTrials.gov/show/NCT00853658
2365,Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction,Completed,Has Results,Erectile Dysfunction,Drug: avanafil,"VIVUS, Inc.",Phase 3,Industry,Interventional,28-Jun-12,https://ClinicalTrials.gov/show/NCT00853606
2366,"A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",Completed,Has Results,Rheumatoid Arthritis,"Drug: CP 690,550|Drug: CP-690,550|Other: Placebo|Biological: Biologic TNFi",Pfizer,Phase 3,Industry,Interventional,9-Jan-13,https://ClinicalTrials.gov/show/NCT00853385
2367,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: duloxetine|Drug: Placebo|Drug: fluoxetine,Eli Lilly and Company,Phase 3,Industry,Interventional,6-Mar-12,https://ClinicalTrials.gov/show/NCT00849901
2368,A Study in the Treatment of Children and Adolescents With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Placebo|Drug: fluoxetine|Drug: duloxetine,Eli Lilly and Company,Phase 3,Industry,Interventional,19-Apr-12,https://ClinicalTrials.gov/show/NCT00849693
2369,Safety and Efficacy of Albiglutide in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Jul-14,https://ClinicalTrials.gov/show/NCT00849056
2370,Safety and Efficacy Study of Albiglutide in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Biological: albiglutide uptitration|Biological: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Jun-14,https://ClinicalTrials.gov/show/NCT00849017
2371,A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Tadalafil|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,14-Sep-10,https://ClinicalTrials.gov/show/NCT00848081
2372,Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole MR QD,Takeda,Phase 3,Industry,Interventional,29-Apr-11,https://ClinicalTrials.gov/show/NCT00847808
2373,Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone|Drug: Azilsartan medoxomil,Takeda,Phase 3,Industry,Interventional,7-Feb-12,https://ClinicalTrials.gov/show/NCT00847626
2374,"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Phase 3,Industry,Interventional,9-Jan-13,https://ClinicalTrials.gov/show/NCT00847613
2375,Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00846586
2376,Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil-hydrochlorothiazide,Takeda,Phase 3,Industry,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00846365
2377,Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas,Completed,Has Results,Metastatic Pancreatic Cancer,Drug: Albumin-bound paclitaxel (ABI-007)|Drug: Gemcitabine,Celgene,Phase 3,Industry,Interventional,11-Dec-13,https://ClinicalTrials.gov/show/NCT00844649
2378,Migraine Study in Adolescent Patients,Completed,Has Results,Migraine Disorders,Drug: Sumatriptan and Naproxen Sodium|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,9-May-11,https://ClinicalTrials.gov/show/NCT00843024
2379,Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects,Completed,Has Results,Congenital Bleeding Disorder|Haemophilia A,Drug: turoctocog alfa,Novo Nordisk A/S,Phase 3,Industry,Interventional,4-Sep-14,https://ClinicalTrials.gov/show/NCT00840086
2380,A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo to match albiglutide|Biological: albiglutide|Drug: metformin|Drug: glimepiride|Drug: pioglitazone|Drug: placebo to match pioglitazone,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Jul-14,https://ClinicalTrials.gov/show/NCT00839527
2381,A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: insulin glargine,GlaxoSmithKline,Phase 3,Industry,Interventional,4-Jun-14,https://ClinicalTrials.gov/show/NCT00838916
2382,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: albiglutide|Drug: sitagliptin|Drug: glimepiride|Drug: metformin|Biological: placebo albiglutide|Drug: placebo sitagliptin|Drug: placebo glimepiride,GlaxoSmithKline,Phase 3,Industry,Interventional,16-May-14,https://ClinicalTrials.gov/show/NCT00838903
2383,BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung|Adenocarcinoma",Drug: Pemetrexed|Drug: BIBW 2992|Drug: Cisplatin,Boehringer Ingelheim,Phase 3,Industry,Interventional,19-Nov-13,https://ClinicalTrials.gov/show/NCT00949650
2384,Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer,Completed,Has Results,Cancer|Carcinoma|Castrate-Resistant Prostate Cancer|Prostate Cancer|Tumors,Drug: Denosumab,Amgen,Phase 3,Industry,Interventional,24-Sep-13,https://ClinicalTrials.gov/show/NCT00838201
2385,Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.,Completed,Has Results,Tetanus|Acellular Pertussis|Diphtheria,Biological: Boostrix®|Biological: Decavac™,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Aug-10,https://ClinicalTrials.gov/show/NCT00835237
2386,Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC),Completed,Has Results,Advanced Gastric Cancer,Drug: Everolimus|Drug: Everolimus placebo|Drug: Best Supportive Care (BSC),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-Apr-15,https://ClinicalTrials.gov/show/NCT00879333
2387,Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Goserelin|Drug: Bicalutamide,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,27-Sep-12,https://ClinicalTrials.gov/show/NCT00833248
2388,ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals,Completed,Has Results,Opiate Dependence,Drug: Medisorb naltrexone 380 mg,"Alkermes, Inc.",Phase 3,Industry,Interventional,29-Jul-13,https://ClinicalTrials.gov/show/NCT00834080
2389,PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1,Completed,Has Results,Intercritical Gout,Other: Placebo|Drug: Rilonacept 80 mg|Drug: Rilonacept 160 mg,Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,28-Apr-17,https://ClinicalTrials.gov/show/NCT00829829
2390,A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Trastuzumab emtansine|Drug: Lapatinib|Drug: Capecitabine,Hoffmann-La Roche,Phase 3,Industry,Interventional,23-Apr-13,https://ClinicalTrials.gov/show/NCT00829166
2391,Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects,Completed,Has Results,Multiple Sclerosis,Device: single-use autoinjector with a prefilled liquid Avonex syringe|Device: Avonex prefilled syringe via manual IM injection|Drug: BG9418 (interferon beta-1a),Biogen,Phase 3,Industry,Interventional,9-Aug-11,https://ClinicalTrials.gov/show/NCT00828204
2392,Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI),Completed,Has Results,Coronary Artery Disease (CAD),Drug: regadenoson|Drug: overencapsulated caffeine|Radiation: technetium|Drug: placebo,Astellas Pharma Inc,Phase 3,Industry,Interventional,21-Oct-11,https://ClinicalTrials.gov/show/NCT00826280
2393,Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Placebo|Drug: tadalafil,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Nov-10,https://ClinicalTrials.gov/show/NCT00827242
2394,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions,Completed,Has Results,Coronary Artery Disease,Device: PROMUS Coronary Stent System|Device: PROMUS Element Coronary Stent System|Drug: Aspirin|Drug: Thienopyridine,Boston Scientific Corporation,Phase 3,Industry,Interventional,27-Jan-12,https://ClinicalTrials.gov/show/NCT00823212
2395,Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Indacaterol 150 µg|Drug: Salmeterol 50 µg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00821093
2396,Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer,Completed,Has Results,"Metastases, Brain",Drug: capecitabine|Drug: lapatinib|Drug: trastuzumab,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Mar-13,https://ClinicalTrials.gov/show/NCT00820222
2397,Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension,Completed,Has Results,Essential Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide,Takeda,Phase 3,Industry,Interventional,7-Feb-12,https://ClinicalTrials.gov/show/NCT00818883
2398,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,Completed,Has Results,Alzheimer´s Disease,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg",Baxalta now part of Shire|Alzheimer's Disease Cooperative Study (ADCS)|Shire,Phase 3,Industry|Other,Interventional,28-Oct-14,https://ClinicalTrials.gov/show/NCT00818662
2399,"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,1-Aug-11,https://ClinicalTrials.gov/show/NCT00819091
2400,Actuation Indicator Trial in Patients With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Ipratropium bromide,Boehringer Ingelheim,Phase 3,Industry,Interventional,28-Sep-10,https://ClinicalTrials.gov/show/NCT00928746
2401,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,Completed,Has Results,HIV Infections,Drug: Nevirapine XR|Drug: Nevirapine IR,Boehringer Ingelheim,Phase 3,Industry,Interventional,24-Feb-12,https://ClinicalTrials.gov/show/NCT00819052
2402,"A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550|Drug: Placebo",Pfizer,Phase 3,Industry,Interventional,11-Jan-13,https://ClinicalTrials.gov/show/NCT00814307
2403,Gammagard Liquid and rHuPH20 in PID,Completed,Has Results,Primary Immunodeficiency Diseases (PID),Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,3-Dec-15,https://ClinicalTrials.gov/show/NCT00814320
2404,Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,31-Dec-10,https://ClinicalTrials.gov/show/NCT00813488
2405,"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",Completed,Has Results,"Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia",Drug: ABT-143|Drug: simvastatin,AstraZeneca,Phase 3,Industry,Interventional,1-Aug-12,https://ClinicalTrials.gov/show/NCT00812955
2406,Pediatric Bipolar Depression,Completed,Has Results,Bipolar Depression,Drug: Quetiapine XR|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,1-Dec-11,https://ClinicalTrials.gov/show/NCT00811473
2407,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Pulmonary Hypertension,"Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,26-Feb-14,https://ClinicalTrials.gov/show/NCT00810693
2408,A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment,Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: methotrexate|Drug: placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,18-Jul-14,https://ClinicalTrials.gov/show/NCT00810199
2409,"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma",Completed,Has Results,Asthma,Drug: Levalbuterol|Drug: Levalbuterol UDV TID|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,28-Jul-14,https://ClinicalTrials.gov/show/NCT00809757
2410,Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D),Completed,Has Results,Erectile Dysfunction,Drug: placebo|Drug: avanafil,"VIVUS, Inc.",Phase 3,Industry,Interventional,28-Jun-12,https://ClinicalTrials.gov/show/NCT00809471
2411,Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis,Completed,Has Results,Menopause|Osteoporosis,Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|Drug: bazedoxifene 20 mg|Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,20-Dec-13,https://ClinicalTrials.gov/show/NCT00808132
2412,RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial,Completed,Has Results,Atrial Fibrillation,Drug: dabigatran dose 1|Drug: dabigatran dose 2,Boehringer Ingelheim,Phase 3,Industry,Interventional,8-Apr-14,https://ClinicalTrials.gov/show/NCT00808067
2413,Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Nintedanib (BIBF1120)|Drug: Pemetrexed|Drug: pemetrexed|Drug: B12|Drug: dexamethasone (or corticosteroid equivalent)|Drug: placebo|Drug: Folic Acid,Boehringer Ingelheim,Phase 3,Industry,Interventional,20-Nov-14,https://ClinicalTrials.gov/show/NCT00806819
2414,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months,Completed,Has Results,Migraine Disorders,Drug: NP101,NuPathe Inc.|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,20-Mar-13,https://ClinicalTrials.gov/show/NCT00806546
2415,Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients,Completed,Has Results,Idiopathic Restless Legs Syndrome,Drug: placebo and pregabalin|Drug: pramipexol|Drug: Pregabalin,Pfizer,Phase 3,Industry,Interventional,27-Sep-12,https://ClinicalTrials.gov/show/NCT00806026
2416,"An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure",Completed,Has Results,Reversal of Coagulopathy,Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma,CSL Behring,Phase 3,Industry,Interventional,25-Feb-14,https://ClinicalTrials.gov/show/NCT00803101
2417,Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Sodium Oxybate|Drug: Sodium Oxybate & 6 Tablets|Drug: Sodium Oxybate & 8 Tablets|Drug: Sodium Oxybate Oral Solution (6 grams),Jazz Pharmaceuticals,Phase 3,Industry,Interventional,16-Aug-11,https://ClinicalTrials.gov/show/NCT00803023
2418,"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BI 1356|Drug: placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,1-Feb-12,https://ClinicalTrials.gov/show/NCT00800683
2419,The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial,Completed,Has Results,Atherosclerosis,Drug: Darapladib|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Aug-17,https://ClinicalTrials.gov/show/NCT00799903
2420,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US,Completed,Has Results,"Infections, Papillomavirus",Biological: GSK Biological's HPV vaccine GSK580299 (Cervarix™),GlaxoSmithKline,Phase 3,Industry,Interventional,20-Sep-13,https://ClinicalTrials.gov/show/NCT00799825
2421,Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.,Completed,Has Results,Postoperative Pain,Drug: Oxymorphone IR,Endo Pharmaceuticals,Phase 3,Industry,Interventional,27-Feb-19,https://ClinicalTrials.gov/show/NCT00801398
2422,A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols,Completed,Has Results,"Hepatitis C, Chronic",Drug: Pegylated-interferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Phase 3,Industry,Interventional,13-Sep-13,https://ClinicalTrials.gov/show/NCT00800735
2423,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,6-Jun-11,https://ClinicalTrials.gov/show/NCT00798707
2424,Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.,Completed,Has Results,Vitreomacular Adhesion,Drug: Ocriplasmin 125µg|Drug: Placebo,ThromboGenics,Phase 3,Industry,Interventional,30-Jan-13,https://ClinicalTrials.gov/show/NCT00798317
2425,Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: No Treatment Added|Drug: Milnacipran Added,Forest Laboratories,Phase 3,Industry,Interventional,16-Feb-11,https://ClinicalTrials.gov/show/NCT00797797
2426,An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months,Completed,Has Results,Migraine Disorders,Drug: NP101,NuPathe Inc.|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,7-May-13,https://ClinicalTrials.gov/show/NCT00792103
2427,An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease,Completed,Has Results,Ulcerative Colitis|Crohn's Disease,Drug: Vedolizumab,Takeda,Phase 3,Industry,Interventional,12-Mar-19,https://ClinicalTrials.gov/show/NCT00790933
2428,Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED,Completed,Has Results,Erectile Dysfunction,Drug: placebo|Drug: avanafil,"VIVUS, Inc.",Phase 3,Industry,Interventional,28-Jun-12,https://ClinicalTrials.gov/show/NCT00790751
2429,Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Quetiapine XR|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,6-Oct-11,https://ClinicalTrials.gov/show/NCT00790192
2430,Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy,Completed,Has Results,Diffuse Large B-cell Lymphoma,Drug: Everolimus|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Jul-17,https://ClinicalTrials.gov/show/NCT00790036
2431,Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Colesevelam|Drug: Placebo|Drug: Pioglitazone,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,26-Jun-17,https://ClinicalTrials.gov/show/NCT00789750
2432,Welchol as Monotherapy for Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Welchol|Drug: Placebo,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,22-Jan-14,https://ClinicalTrials.gov/show/NCT00789737
2433,Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia,Completed,Has Results,Chronic Schizophrenia,Drug: Lurasidone HC1|Drug: Quetiapine XR,Sunovion,Phase 3,Industry,Interventional,21-Aug-12,https://ClinicalTrials.gov/show/NCT00789698
2434,Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF),Completed,Has Results,In Vitro Fertilization,Drug: Progesterone,IBSA Institut Biochimique SA,Phase 3,Industry,Interventional,26-Dec-12,https://ClinicalTrials.gov/show/NCT00828191
2435,Atorvastatin Three Year Pediatric Study,Completed,Has Results,Familial Hypercholesterolemia,Drug: atorvastatin,Pfizer,Phase 3,Industry,Interventional,2-Jun-15,https://ClinicalTrials.gov/show/NCT00827606
2436,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),Completed,Has Results,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Drug: Everolimus|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,1-May-12,https://ClinicalTrials.gov/show/NCT00789828
2437,Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO),Completed,Has Results,Hypertension|Heart Failure,Drug: Clevidipine|Drug: Standard of Care IV antihypertensive,The Medicines Company,Phase 3,Industry,Interventional,19-Aug-14,https://ClinicalTrials.gov/show/NCT00803634
2438,A Study of Nilotinib Versus Imatinib in GIST Patients,Completed,Has Results,Gastrointestinal Stromal Tumor (GIST),Drug: Nilotinib (AMN107)|Drug: imatinib (STI571),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-Apr-16,https://ClinicalTrials.gov/show/NCT00785785
2439,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,18-Jul-14,https://ClinicalTrials.gov/show/NCT00783718
2440,Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Drug: vedolizumab|Other: Placebo,"Millennium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,21-Jul-14,https://ClinicalTrials.gov/show/NCT00783692
2441,12 / 48 wk Pivotal PFT vs PBO in COPD II,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Olodaterol (BI 1744)|Drug: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Jun-14,https://ClinicalTrials.gov/show/NCT00782509
2442,12 / 48 Week Pivotal PFT vs PBO in COPD I,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Olodaterol (BI1744)|Drug: placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,30-Apr-14,https://ClinicalTrials.gov/show/NCT00782210
2443,Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin detemir|Drug: sitagliptin|Drug: metformin|Drug: sulphonylurea,Novo Nordisk A/S,Phase 3,Industry,Interventional,10-Dec-10,https://ClinicalTrials.gov/show/NCT00789191
2444,Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,Phase 3,Industry,Interventional,28-Nov-11,https://ClinicalTrials.gov/show/NCT00781937
2445,Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.,Completed,Has Results,Vitreomacular Adhesion,Drug: 125 µg Ocriplasmin|Drug: Placebo,ThromboGenics,Phase 3,Industry,Interventional,28-Jan-13,https://ClinicalTrials.gov/show/NCT00781859
2446,Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation,Completed,Has Results,Stroke|Atrial Fibrillation|Embolism,Drug: warfarin tablets|Drug: Edoxaban tablets (high dose regimen-60mg)|Drug: Edoxaban tablets (low dose regimen-30mg)|Drug: placebo warfarin|Drug: placebo edoxaban,"Daiichi Sankyo, Inc.|The TIMI Study Group",Phase 3,Industry|Other,Interventional,25-Mar-15,https://ClinicalTrials.gov/show/NCT00781391
2447,PROvenge Treatment and Early Cancer Treatment,Completed,Has Results,Prostate Cancer,Other: Control|Biological: Sipuleucel-T,Dendreon,Phase 3,Industry,Interventional,29-Jan-18,https://ClinicalTrials.gov/show/NCT00779402
2448,Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma,Completed,Has Results,Recurrent Glioblastoma,Drug: Cediranib|Drug: Lomustine Chemotherapy|Drug: Placebo Cediranib,AstraZeneca,Phase 3,Industry,Interventional,21-Dec-12,https://ClinicalTrials.gov/show/NCT00777153
2449,Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo,Depomed,Phase 3,Industry,Interventional,17-Feb-12,https://ClinicalTrials.gov/show/NCT00777023
2450,"A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.",Completed,Has Results,Major Depressive Disorder,Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets|Drug: Placebo,Labopharm Inc.,Phase 3,Industry,Interventional,7-Apr-10,https://ClinicalTrials.gov/show/NCT00775203
2451,An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome,Completed,Has Results,Carcinoid Syndrome,Drug: Lanreotide|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,9-Feb-16,https://ClinicalTrials.gov/show/NCT00774930
2452,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase Delayed Release,Solvay Pharmaceuticals,Phase 3,Industry,Interventional,1-Oct-10,https://ClinicalTrials.gov/show/NCT00775528
2453,"Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems",Device: FlexTouch®|Device: FlexPen®,Novo Nordisk A/S,Phase 3,Industry,Interventional,27-Mar-17,https://ClinicalTrials.gov/show/NCT00773279
2454,Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™,Completed,Has Results,Diphtheria|Tetanus|Haemophilus Infection|Pertussis|Polio,Biological: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®,Sanofi,Phase 3,Industry,Interventional,12-Feb-10,https://ClinicalTrials.gov/show/NCT00772928
2455,Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia,Completed,Has Results,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Drug: MCI-196,Mitsubishi Tanabe Pharma Corporation,Phase 3,Industry,Interventional,12-May-14,https://ClinicalTrials.gov/show/NCT00772382
2456,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,Completed,Has Results,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,Biological: Influenza Virus Vaccine USP Trivalent Types A and B,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00772109
2457,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",Completed,Has Results,Chronic Pancreatitis|Exocrine Pancreatic Insufficiency,Drug: Placebo|Drug: EUR-1008 (APT-1008) High Dose|Drug: EUR-1008 (APT-1008) Low Dose,Forest Laboratories,Phase 3,Industry,Interventional,12-Mar-14,https://ClinicalTrials.gov/show/NCT00788593
2458,Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study,Completed,Has Results,ADHD,Drug: Lisdexamfetamine Dimesylate (LDX),Shire,Phase 3,Industry,Interventional,28-Mar-11,https://ClinicalTrials.gov/show/NCT00764868
2459,Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children,Completed,Has Results,Influenza,Biological: Fluarix|Biological: Fluzone,GlaxoSmithKline,Phase 3,Industry,Interventional,27-Jul-10,https://ClinicalTrials.gov/show/NCT00764790
2460,Reverse Shoulder Prosthesis Study,Completed,Has Results,Rotator Cuff Arthropathy|Failed Total Shoulder|Failed Hemi-arthroplasty,Device: Reverse Shoulder Prosthesis,"Encore Medical, L.P.",Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00764504
2461,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone",Completed,Has Results,Diabetes Mellitus Type 2,Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Pioglitazone|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT00763815
2462,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: ABT-712|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT00763321
2463,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,25-Sep-14,https://ClinicalTrials.gov/show/NCT00762411
2464,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer,Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Biological: Bevacizumab,Eli Lilly and Company,Phase 3,Industry,Interventional,28-Nov-13,https://ClinicalTrials.gov/show/NCT00762034
2465,"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam",Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB Pharma,Phase 3,Industry,Interventional,23-Apr-18,https://ClinicalTrials.gov/show/NCT00761774
2466,Phase 3 Clinical Study for the Treatment of Cold Sore,Completed,Has Results,Herpes Labialis,Drug: Acyclovir Lauriad|Drug: Placebo,Onxeo,Phase 3,Industry,Interventional,21-Dec-12,https://ClinicalTrials.gov/show/NCT00769314
2467,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years,Completed,Has Results,Healthy Subjects,Biological: 13 valent pneumococcal conjugate vaccine,Pfizer,Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00761631
2468,BAY 0 9867 Cipro Pediatric Use Study (QUIP),Completed,Has Results,Infectious Diseases,Drug: Ciprofloxacin|Drug: Non-quinolone antibiotic,Bayer,Phase 3,Industry,Interventional,14-Apr-09,https://ClinicalTrials.gov/show/NCT00761462
2469,"Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis",Completed,Has Results,Candidemia,Drug: Anidulafungin|Drug: Fluconazole,Pfizer,Phase 3,Industry,Interventional,14-Sep-18,https://ClinicalTrials.gov/show/NCT00761267
2470,Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP),Completed,Has Results,Chronic Low Back Pain,Drug: ABT-712|Drug: Placebo,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,23-Dec-13,https://ClinicalTrials.gov/show/NCT00761150
2471,Performance of the Hedrocel(R) Cervical Fusion Device,Completed,Has Results,Symptomatic Cervical Disc Disease,Device: Anterior Cervical Discectomy and Fusion,Zimmer Biomet,Phase 3,Industry,Interventional,12-Aug-13,https://ClinicalTrials.gov/show/NCT00758758
2472,Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin,Completed,Has Results,Type 2 Diabetes,"Drug: Saxagliptin, 5 mg + insulin|Drug: Placebo + insulin",AstraZeneca,Phase 3,Industry,Interventional,13-Dec-11,https://ClinicalTrials.gov/show/NCT00757588
2473,Duloxetine for Multiple Sclerosis Pain,Completed,Has Results,Multiple Sclerosis,Drug: Duloxetine Hydrochloride (HCI)|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,9-Dec-11,https://ClinicalTrials.gov/show/NCT00755807
2474,Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women,Completed,Has Results,Hot Flashes,Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo,Depomed,Phase 3,Industry,Interventional,7-Mar-12,https://ClinicalTrials.gov/show/NCT00755417
2475,BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Completed,Has Results,Colon Cancer,Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Phase 3,Industry,Interventional,9-Aug-13,https://ClinicalTrials.gov/show/NCT00756977
2476,BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy,Completed,Has Results,Colon Cancer,Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation,Braintree Laboratories,Phase 3,Industry,Interventional,27-Dec-13,https://ClinicalTrials.gov/show/NCT00756548
2477,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),Completed,Has Results,Contraception,"Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Ortho Tri Cyclen Lo",Bayer,Phase 3,Industry,Interventional,28-Aug-12,https://ClinicalTrials.gov/show/NCT00754065
2478,Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: Certolizumab pegol,UCB Pharma,Phase 3,Industry,Interventional,14-Jun-12,https://ClinicalTrials.gov/show/NCT00753454
2479,Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older,Completed,Has Results,Influenza,Biological: GSK Bio's influenza vaccine GSK2186877A|Biological: Fluarix TM,GlaxoSmithKline,Phase 3,Industry,Interventional,19-Jun-12,https://ClinicalTrials.gov/show/NCT00753272
2480,Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly,Completed,Has Results,Influenza,Biological: Influenza vaccine GSK2186877A|Biological: GSK Biologicals' Fluarix™,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Apr-12,https://ClinicalTrials.gov/show/NCT00772889
2481,An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Placebo|Drug: Teriflunomide,Sanofi,Phase 3,Industry,Interventional,26-Jun-13,https://ClinicalTrials.gov/show/NCT00751881
2482,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis,Completed,Has Results,Tinea Pedis|Athlete's Foot,Drug: NAFT-500|Drug: Placebo 2-weeks|Drug: Naftin 1%|Drug: Placebo 4-weeks,"Merz North America, Inc.",Phase 3,Industry,Interventional,29-Jan-13,https://ClinicalTrials.gov/show/NCT00750139
2483,Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris,Completed,Has Results,Tinea Cruris|Jock Itch,Drug: NAFT-500|Drug: Placebo,"Merz North America, Inc.",Phase 3,Industry,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00750152
2484,Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance,Completed,Has Results,Restless Legs Syndrome|Restless Legs Syndrome (RLS),Drug: GSK1838262 Extended Release Tablets|Drug: Placebo,"XenoPort, Inc.",Phase 3,Industry,Interventional,18-May-11,https://ClinicalTrials.gov/show/NCT00748098
2485,Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy,Completed,Has Results,"Sarcoma, Soft Tissue",Drug: PAZOPANIB|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,21-Dec-11,https://ClinicalTrials.gov/show/NCT00753688
2486,A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty,Completed,Has Results,Postoperative Pain,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc",Phase 3,Industry,Interventional,6-Aug-13,https://ClinicalTrials.gov/show/NCT00745290
2487,Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL),Completed,Has Results,Cataract,Device: modified light transmission intraocular lens|Device: monofocal acrylic intraocular lens,Abbott Medical Optics,Phase 3,Industry,Interventional,11-Nov-11,https://ClinicalTrials.gov/show/NCT00747227
2488,Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy,Completed,Has Results,Hemorrhoids,Drug: Bupivacaine HCl|Drug: SKY0402,"Pacira Pharmaceuticals, Inc",Phase 3,Industry,Interventional,6-Aug-13,https://ClinicalTrials.gov/show/NCT00744848
2489,Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer,Completed,Has Results,Prostatic Neoplasms,Drug: Placebo|Drug: Dasatinib|Drug: Docetaxel|Drug: Prednisone,Bristol-Myers Squibb,Phase 3,Industry,Interventional,6-Feb-14,https://ClinicalTrials.gov/show/NCT00744497
2490,Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.,Completed,Has Results,Pneumococcal Disease|13-valent Pneumococcal Vaccine,Biological: 13-valent Pneumococcal Conjugate Vaccine,Pfizer,Phase 3,Industry,Interventional,10-Feb-12,https://ClinicalTrials.gov/show/NCT00743652
2491,A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations,Completed,Has Results,Actinic Keratoses,Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel,Peplin,Phase 3,Industry,Interventional,21-Mar-12,https://ClinicalTrials.gov/show/NCT00742391
2492,A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: azelastine HCl/fluticasone propionate|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,7-Sep-12,https://ClinicalTrials.gov/show/NCT00740792
2493,"A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin|Drug: Linagliptin Placebo|Drug: Glimepiride,Boehringer Ingelheim,Phase 3,Industry,Interventional,26-Oct-11,https://ClinicalTrials.gov/show/NCT00740051
2494,An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Paliperidone extended release (ER)|Drug: Aripiprazole,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,21-Jun-13,https://ClinicalTrials.gov/show/NCT01009047
2495,Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),Completed,Has Results,Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System Atrophy|Dopamine Beta Hydroxylase Deficiency,Drug: Droxidopa|Drug: Placebo,Chelsea Therapeutics,Phase 3,Industry,Interventional,16-May-14,https://ClinicalTrials.gov/show/NCT00738062
2496,GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis,Completed,Has Results,Renal Failure|Hemodialysis,Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Procedure: Percutaneous Transluminal Angioplasty,W.L.Gore & Associates,Phase 3,Industry,Interventional,21-Oct-14,https://ClinicalTrials.gov/show/NCT00737672
2497,Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,Has Results,Genital Warts,Drug: 2.5% imiquimod cream|Drug: 3.75% imiquimod cream|Drug: Placebo cream,"Graceway Pharmaceuticals, LLC",Phase 3,Industry,Interventional,20-Jul-11,https://ClinicalTrials.gov/show/NCT00735462
2498,Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptine 5 mg|Drug: linagliptine 5 mg and pioglitazone 30 mg,Boehringer Ingelheim,Phase 3,Industry,Interventional,8-Mar-12,https://ClinicalTrials.gov/show/NCT00736099
2499,Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Epilepsy,Drug: perampanel,Eisai Inc.,Phase 3,Industry,Interventional,26-Jan-16,https://ClinicalTrials.gov/show/NCT00735397
2500,Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,Attention Deficit Hyperactivity Disorder (ADHD),Drug: LDX 30 mg|Drug: LDX 50 mg|Drug: LDX 70 mg|Drug: Placebo,Shire,Phase 3,Industry,Interventional,23-Feb-10,https://ClinicalTrials.gov/show/NCT00735371
2501,Efficacy and Safety of SPD503 in Combination With Psychostimulants,Completed,Has Results,ADHD,Drug: SPD503-AM|Drug: SPD503-PM|Drug: Placebo,Shire,Phase 3,Industry,Interventional,23-Nov-10,https://ClinicalTrials.gov/show/NCT00734578
2502,Use of NPSP558 in the Treatment of Hypoparathyroidism,Completed,Has Results,Hypoparathyroidism,Drug: Placebo|Drug: NPSP558,Shire,Phase 3,Industry,Interventional,6-Mar-15,https://ClinicalTrials.gov/show/NCT00732615
2503,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Completed,Has Results,Non-Constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,28-Jul-14,https://ClinicalTrials.gov/show/NCT00731679
2504,Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.,Completed,Has Results,Diabetes Mellitus,Drug: Pioglitazone and metformin|Drug: Pioglitazone|Drug: Metformin,Takeda,Phase 3,Industry,Interventional,9-Mar-10,https://ClinicalTrials.gov/show/NCT00727857
2505,Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390,Completed,Has Results,Hepatitis C,Drug: Eltrombopag|Drug: Antiviral therapy,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Dec-13,https://ClinicalTrials.gov/show/NCT00996216
2506,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines,Completed,Has Results,Moderate to Severe Glabellar Frown Lines,Drug: IncobotulinumtoxinA (Xeomin) (20 Units)|Drug: Placebo,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,13-Sep-11,https://ClinicalTrials.gov/show/NCT00770211
2507,Oral Cladribine in Early Multiple Sclerosis (MS),Completed,Has Results,Multiple Sclerosis,Drug: Cladribine|Drug: Placebo|Drug: Rebif® new formulation (RNF),EMD Serono,Phase 3,Industry,Interventional,10-Oct-13,https://ClinicalTrials.gov/show/NCT00725985
2508,The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine,Completed,Has Results,Migraine Disorders,Drug: NP101 - Sumatriptan iontophoretic transdermal patch|Drug: Placebo,NuPathe Inc.|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,7-May-13,https://ClinicalTrials.gov/show/NCT00724815
2509,Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS),Completed,Has Results,Non-Constipation Irritable Bowel Syndrome,Drug: Rifaximin|Drug: Placebo,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,28-Jul-14,https://ClinicalTrials.gov/show/NCT00724126
2510,Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients,Completed,Has Results,Bipolar Disorder,Drug: lamictal,GlaxoSmithKline,Phase 3,Industry,Interventional,4-Jun-14,https://ClinicalTrials.gov/show/NCT00723450
2511,"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: CLONICEL (Clonidine HCl sustained release),Shionogi|Shionogi Inc.,Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT00723190
2512,Mobile - Bearing Knee Study,Completed,Has Results,Inflammatory Tissue Disorder|Osteoarthritis|Avascular Necrosis|Post-traumatic Arthritis|Secondary Arthritis,Device: Encore Mobile-Bearing Knee,"Encore Medical, L.P.",Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00765362
2513,An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Disease-modifying anti-rheumatic drugs|Drug: Non-steroidal anti-inflammatory drugs|Drug: Oral corticosteroids,Hoffmann-La Roche,Phase 3,Industry,Interventional,30-Sep-14,https://ClinicalTrials.gov/show/NCT00720798
2514,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: 0.15% azelastine hydrochloride,Meda Pharmaceuticals,Phase 3,Industry,Interventional,28-Jan-10,https://ClinicalTrials.gov/show/NCT00824473
2515,A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis,Completed,Has Results,Perennial Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride|Drug: Mometasone furoate,Meda Pharmaceuticals,Phase 3,Industry,Interventional,15-Jan-10,https://ClinicalTrials.gov/show/NCT00720382
2516,A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride 1644 mcg daily|Drug: 0.1% azelastine hydrochloride 1096 mcg daily|Drug: Placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,27-Oct-09,https://ClinicalTrials.gov/show/NCT00720278
2517,A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo nasal spray|Drug: 0.15% azelastine hydrochloride Nasal Spray,Meda Pharmaceuticals,Phase 3,Industry,Interventional,28-Jan-10,https://ClinicalTrials.gov/show/NCT00719862
2518,Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Certolizumab pegol (CZP)|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,6-May-11,https://ClinicalTrials.gov/show/NCT00717236
2519,Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: Asacol 400 mg,Warner Chilcott,Phase 3,Industry,Interventional,4-Apr-12,https://ClinicalTrials.gov/show/NCT00713310
2520,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies,Completed,Has Results,Perennial Allergic Rhinitis,Drug: 0.15% azelastine hydrochloride|Drug: 0.1% azelastine hydrochloride|Drug: Placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,15-Jan-10,https://ClinicalTrials.gov/show/NCT00712920
2521,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,Completed,Has Results,Post-menopausal Osteoporosis,Drug: Placebo|Drug: Zoledronic acid,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Dec-13,https://ClinicalTrials.gov/show/NCT00718861
2522,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa",Completed,Has Results,Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa,Drug: AZLI 75 mg three times daily (TID)|Drug: Placebo three times daily (TID),Gilead Sciences,Phase 3,Industry,Interventional,20-Dec-10,https://ClinicalTrials.gov/show/NCT00712166
2523,Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Phase 3,Industry,Interventional,14-Jul-14,https://ClinicalTrials.gov/show/NCT00713648
2524,Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: iloprost (5 µg)|Drug: placebo,Actelion,Phase 3,Industry,Interventional,26-Oct-12,https://ClinicalTrials.gov/show/NCT00709956
2525,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,Completed,Has Results,Diagnostic Imaging|Central Nervous System Diseases,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Drug: Gadoteridol (ProHance)",Bayer,Phase 3,Industry,Interventional,6-Mar-12,https://ClinicalTrials.gov/show/NCT00709852
2526,Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: iloprost,Actelion,Phase 3,Industry,Interventional,29-Oct-12,https://ClinicalTrials.gov/show/NCT00709098
2527,Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy,Completed,Has Results,Blood Coagulation Disorders|Acute Major Bleeding,Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma,CSL Behring,Phase 3,Industry,Interventional,13-Aug-13,https://ClinicalTrials.gov/show/NCT00708435
2528,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",Completed,Has Results,HIV Infection,Drug: Elvitegravir|Drug: Raltegravir|Drug: EVG placebo|Drug: RAL placebo|Drug: Background regimen,Gilead Sciences,Phase 3,Industry,Interventional,6-Nov-14,https://ClinicalTrials.gov/show/NCT00708162
2529,Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Glipizide,Takeda,Phase 3,Industry,Interventional,24-May-13,https://ClinicalTrials.gov/show/NCT00707993
2530,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole depot 300 or 400 mg|Drug: Aripiprazole 10-30 mg orally|Drug: Aripiprazole depot 25 or 50 mg|Drug: Placebo depot|Drug: Placebo tablets,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,14-Aug-13,https://ClinicalTrials.gov/show/NCT00706654
2531,Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Aripiprazole depot|Drug: Placebo depot,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,19-Jul-13,https://ClinicalTrials.gov/show/NCT00705783
2532,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: sitagliptin|Drug: metformin,Novo Nordisk A/S,Phase 3,Industry,Interventional,4-Aug-10,https://ClinicalTrials.gov/show/NCT00700817
2533,A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations,Completed,Has Results,Hypogonadism,Drug: Testosterone MD-Lotion,Eli Lilly and Company,Phase 3,Industry,Interventional,5-Jan-11,https://ClinicalTrials.gov/show/NCT00702650
2534,Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Seizures,Drug: E2007 (perampanel)|Drug: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,5-Feb-13,https://ClinicalTrials.gov/show/NCT00699972
2535,To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Seizures,Drug: E2007 (perampanel)|Drug: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,22-Nov-12,https://ClinicalTrials.gov/show/NCT00699582
2536,An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil|Drug: Valsartan|Drug: Olmesartan|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00696436
2537,A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,"Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Drug: Placebo",Takeda,Phase 3,Industry,Interventional,4-Jan-12,https://ClinicalTrials.gov/show/NCT00696384
2538,Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and olmesartan|Drug: Olmesartan|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00696241
2539,One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil with or without add-on chlorthalidone|Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00695955
2540,BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis,Completed,Has Results,Chronic Liver Disease,Device: c13 methacetin solution with breath analyzer,Exalenz Bioscience LTD.,Phase 3,Industry,Interventional,16-Mar-12,https://ClinicalTrials.gov/show/NCT00736840
2541,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Nexavar (Sorafenib, BAY43-9006)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,1-Dec-14,https://ClinicalTrials.gov/show/NCT00692770
2542,"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma",Completed,Has Results,Multiple Myeloma,"Drug: Lenalidomide and low-dose dexamethasone|Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|Drug: Melphalan, Prednisone and Thalidomide",Celgene,Phase 3,Industry,Interventional,11-Aug-17,https://ClinicalTrials.gov/show/NCT00689936
2543,Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Tolterodine|Drug: Placebo to Mirabegron|Drug: Placebo to Tolterodine,Astellas Pharma Inc,Phase 3,Industry,Interventional,19-Oct-12,https://ClinicalTrials.gov/show/NCT00688688
2544,Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris,Completed,Has Results,Severe Acne Vulgaris,Drug: Adapalene BPO Gel associated with Doxycyline Hyclate|Drug: Vehicle Gel associated with Doxycycline Hyclate,Galderma,Phase 3,Industry,Interventional,31-Mar-10,https://ClinicalTrials.gov/show/NCT00688064
2545,Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance,Completed,Has Results,Acne,Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Drug: Vehicle Gel,Galderma,Phase 3,Industry,Interventional,24-Sep-10,https://ClinicalTrials.gov/show/NCT00687908
2546,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Cisplatin|Drug: Etoposide|Drug: Vinorelbine|Drug: Paclitaxel|Drug: Carboplatin|Radiation: Thoracic Radiation Therapy (TRT),Eli Lilly and Company,Phase 3,Industry,Interventional,26-Nov-15,https://ClinicalTrials.gov/show/NCT00686959
2547,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),Completed,Has Results,"Skin Infections, Bacterial","Drug: Retapamulin Ointment, 1%|Drug: Placebo ointment",GlaxoSmithKline,Phase 3,Industry,Interventional,4-Aug-10,https://ClinicalTrials.gov/show/NCT00684177
2548,Add-on to Thiazolidinedione (TZD) Failures,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin|Drug: Thiazolidinedione (Pioglitazone),"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",Phase 3,Industry|Other,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT00683878
2549,Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF),Completed,Has Results,Cystic Fibrosis|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase Delayed Release|Drug: Placebo Comparator,Solvay Pharmaceuticals,Phase 3,Industry,Interventional,10-Mar-10,https://ClinicalTrials.gov/show/NCT00690820
2550,Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women,Completed,Has Results,Vasomotor Symptoms,Drug: desvenlafaxine succinate (DVS) SR|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,17-Aug-11,https://ClinicalTrials.gov/show/NCT00683800
2551,Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,10-Mar-10,https://ClinicalTrials.gov/show/NCT00683657
2552,Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease,Completed,Has Results,Symptomatic Refractory Resistant Carcinoid Disease,Drug: Pasireotide|Drug: Octreotide,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Jul-13,https://ClinicalTrials.gov/show/NCT00690430
2553,30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease,Completed,Has Results,Dyslipidemia|Kidney Disease,Drug: ABT-335 plus rosuvastatin|Drug: Rosuvastatin,AstraZeneca,Phase 3,Industry,Interventional,16-Jul-12,https://ClinicalTrials.gov/show/NCT00680017
2554,(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,"Procedure: Blood sampling, endoscopy|Drug: budesonide-MMX® 6 mg|Drug: budesonide-MMX® 9 mg|Drug: Placebo|Drug: Asacol® 400 mg","Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,1-Aug-14,https://ClinicalTrials.gov/show/NCT00679432
2555,Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: otelixizumab infusion plus physician determined standard of care|Biological: placebo infusion plus physician determined standard of care,GlaxoSmithKline|Juvenile Diabetes Research Foundation,Phase 3,Industry|Other,Interventional,3-Oct-17,https://ClinicalTrials.gov/show/NCT00678886
2556,Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer,Completed,Has Results,Kidney Neoplasms,Drug: Axitinib (AG-013736)|Drug: Sorafenib,Pfizer,Phase 3,Industry,Interventional,27-Mar-12,https://ClinicalTrials.gov/show/NCT00678392
2557,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,COPD,Drug: Indacaterol|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00677807
2558,Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE),Completed,Has Results,Thromboembolism,Drug: Warfarin|Drug: Dabigatran etexilate,Boehringer Ingelheim,Phase 3,Industry,Interventional,14-Jun-12,https://ClinicalTrials.gov/show/NCT00680186
2559,Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts,Completed,Has Results,Genital Warts,Drug: Imiquimod|Drug: 3.75% imiquimod cream|Drug: placebo cream,"Graceway Pharmaceuticals, LLC",Phase 3,Industry,Interventional,18-May-11,https://ClinicalTrials.gov/show/NCT00674739
2560,Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,Has Results,Lower Back Pain,Drug: Carisoprodol SR 700 mg|Drug: Carisoprodol SR 500 mg|Drug: Placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,21-Nov-12,https://ClinicalTrials.gov/show/NCT00671879
2561,A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back,Completed,Has Results,Lower Back Pain,Drug: Carisoprodol SR|Drug: Placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,9-Nov-11,https://ClinicalTrials.gov/show/NCT00671502
2562,Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma,Completed,Has Results,Breast Cancer|Melanoma,Drug: Lymphoseek,Navidea Biopharmaceuticals,Phase 3,Industry,Interventional,3-Jun-13,https://ClinicalTrials.gov/show/NCT00671918
2563,Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH),Completed,Has Results,Benign Prostatic Hypertrophy,Drug: Cetrorelix Pamoate,AEterna Zentaris,Phase 3,Industry,Interventional,19-Jan-11,https://ClinicalTrials.gov/show/NCT00670306
2564,Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis,Completed,Has Results,Bronchiectasis,Drug: Inhaled mannitol|Drug: Matched control,Pharmaxis,Phase 3,Industry,Interventional,29-Apr-16,https://ClinicalTrials.gov/show/NCT00669331
2565,Escitalopram in Adult Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,6-May-10,https://ClinicalTrials.gov/show/NCT00668525
2566,Corneal Collagen Cross-Linking for Ectasia (CXL),Completed,Has Results,Ectasia,Drug: riboflavin ophthalmic solution|Device: UVA Irradiation,"Avedro, Inc.",Phase 3,Industry,Interventional,27-Jan-17,https://ClinicalTrials.gov/show/NCT00674661
2567,"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)",Completed,Has Results,Major Depressive Disorder,Drug: vilazodone|Drug: placebo,Forest Laboratories,Phase 3,Industry,Interventional,27-Oct-10,https://ClinicalTrials.gov/show/NCT00683592
2568,Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD,Completed,Has Results,Cervical Degenerative Disc Disease,Device: PRESTIGE® LP Cervical Disc|Device: ATLANTIS Anterior Cervical Plate,Medtronic Spinal and Biologics,Phase 3,Industry,Interventional,22-Sep-14,https://ClinicalTrials.gov/show/NCT00667459
2569,Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty,Completed,Has Results,Precocious|Leuprolide Acetate|Luteinizing Hormone (LH)|Gonadotrophin-releasing Hormone Agonist (GnRHa)|Tanner Staging|Depot Formulation|Suppression of LH|Central Precocious Puberty (CPP)|Gonadotrophin-releasing Hormone (GnRH)|Lupron|GnRH Analog|Pediatrics Central Precocious Puberty,Drug: Leuprolide Acetate 3 Month Depot,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,10-Dec-13,https://ClinicalTrials.gov/show/NCT00667446
2570,Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE),Completed,Has Results,Hypertension|Hemorrhage,Drug: clevidipine,The Medicines Company,Phase 3,Industry,Interventional,8-Apr-13,https://ClinicalTrials.gov/show/NCT00666328
2571,Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy,Completed,Has Results,Multifocal Motor Neuropathy,"Biological: Immune Globulin Intravenous (human), 10%|Biological: 0.25% human albumin solution (Placebo)",Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,13-Mar-13,https://ClinicalTrials.gov/show/NCT00666263
2572,Phase IIIB Switching From Intravenous to Subcutaneous Study,Completed,Has Results,"Arthritis, Rheumatoid",Drug: Abatacept,Bristol-Myers Squibb,Phase 3,Industry,Interventional,26-Mar-12,https://ClinicalTrials.gov/show/NCT00663702
2573,"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",Completed,Has Results,Complicated Urinary Tract Infection|Pyelonephritis,Drug: CXA-201|Drug: Levofloxacin,Cubist Pharmaceuticals LLC,Phase 3,Industry,Interventional,15-Jan-15,https://ClinicalTrials.gov/show/NCT01345929
2574,A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Mirabegron|Drug: Placebo,Astellas Pharma Inc,Phase 3,Industry,Interventional,17-Oct-12,https://ClinicalTrials.gov/show/NCT00662909
2575,A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: celecoxib|Drug: tramadol HCL,Pfizer,Phase 3,Industry,Interventional,23-Nov-09,https://ClinicalTrials.gov/show/NCT00662558
2576,Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: macitentan (ACT-064992)|Drug: placebo,Actelion,Phase 3,Industry,Interventional,5-May-14,https://ClinicalTrials.gov/show/NCT00660179
2577,Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women,Completed,Has Results,Osteoporosis|Postmenopausal Osteoporosis,Drug: Placebo|Drug: BA058 80 mcg|Drug: teriparatide,"Radius Health, Inc.",Phase 3,Industry,Interventional,1-Mar-17,https://ClinicalTrials.gov/show/NCT01343004
2578,A Study for Patient With Chronic Low Back Pain,Completed,Has Results,Chronic Low Back Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,18-Oct-10,https://ClinicalTrials.gov/show/NCT00767806
2579,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Phase 3,Industry,Interventional,23-Jun-15,https://ClinicalTrials.gov/show/NCT00658632
2580,A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103),ACADIA Pharmaceuticals Inc.,Phase 3,Industry,Interventional,9-Sep-14,https://ClinicalTrials.gov/show/NCT00658567
2581,Black Widow Spider Antivenin for Patients With Systemic Latrodectism,Completed,Has Results,Latrodectism,Drug: Analatro|Drug: Saline,Instituto Bioclon S.A. de C.V.|Rare Disease Therapeutics Inc.,Phase 3,Industry|Other,Interventional,18-Sep-17,https://ClinicalTrials.gov/show/NCT00657540
2582,"Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis",Completed,Has Results,Psoriasis,Drug: clobetasol propionate spray 0.05%|Drug: calcitriol ointment,"Galderma Laboratories, L.P.",Phase 3,Industry,Interventional,27-Aug-14,https://ClinicalTrials.gov/show/NCT00658788
2583,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: placebo|Drug: BIBW 2992,Boehringer Ingelheim,Phase 3,Industry,Interventional,27-Nov-13,https://ClinicalTrials.gov/show/NCT00656136
2584,Study of APD421 as PONV Treatment (Prior Prophylaxis),Completed,Has Results,Postoperative Nausea and Vomiting,Drug: APD421|Drug: Placebo,Acacia Pharma Ltd,Phase 3,Industry,Interventional,18-Dec-18,https://ClinicalTrials.gov/show/NCT02646566
2585,A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency,Completed,Has Results,Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis,"Drug: Pancrease MT 10.5, or MT 21|Drug: Placebo for Pancrease MT 10.5 or MT 21","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,17-Mar-10,https://ClinicalTrials.gov/show/NCT00662675
2586,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR b.i.d. (Twice Daily),Acorda Therapeutics,Phase 3,Industry,Interventional,29-Feb-12,https://ClinicalTrials.gov/show/NCT00654927
2587,FUTURE 3 Study Extension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Bosentan,Actelion,Phase 3,Industry,Interventional,11-Dec-17,https://ClinicalTrials.gov/show/NCT01338415
2588,Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty,Completed,Has Results,Venous Thromboembolism,Drug: Enoxaparin|Drug: Dabigatran etexilate,Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Dec-10,https://ClinicalTrials.gov/show/NCT00657150
2589,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: Placebo|Drug: azelastine Hcl|Drug: azelastineHcl / fluticasone propionate|Drug: fluticasone propionate,Meda Pharmaceuticals,Phase 3,Industry,Interventional,26-Sep-12,https://ClinicalTrials.gov/show/NCT00651118
2590,Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: MR prednisone|Drug: Placebo,"Horizon Pharma Ireland, Ltd., Dublin Ireland",Phase 3,Industry,Interventional,13-Dec-12,https://ClinicalTrials.gov/show/NCT00650078
2591,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR,Acorda Therapeutics,Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT00649792
2592,Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension,Completed,Has Results,Hypertension,Drug: Olmesartan medoxomil|Drug: Amlodipine|Drug: Hydrochlorothiazide,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,1-Sep-10,https://ClinicalTrials.gov/show/NCT00649389
2593,"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial",Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR,Acorda Therapeutics,Phase 3,Industry,Interventional,27-Feb-12,https://ClinicalTrials.gov/show/NCT00648908
2594,"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing",Completed,Has Results,Rheumatoid Arthritis,Drug: adalimumab|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,10-May-10,https://ClinicalTrials.gov/show/NCT00647270
2595,A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD),Completed,Has Results,Major Depressive Disorder,Drug: vilazodone,Forest Laboratories,Phase 3,Industry,Interventional,25-Sep-17,https://ClinicalTrials.gov/show/NCT00644358
2596,An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Metformin XR,"AstraZeneca|Astra Zeneca, Bristol-Myers Squibb",Phase 3,Industry|Other,Interventional,23-Feb-17,https://ClinicalTrials.gov/show/NCT00643851
2597,A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA),Completed,Has Results,Juvenile Idiopathic Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: Placebo|Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)|Drug: methotrexate|Drug: corticosteroids,Hoffmann-La Roche,Phase 3,Industry,Interventional,26-Oct-11,https://ClinicalTrials.gov/show/NCT00642460
2598,Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia,Completed,Has Results,Schizophrenia|Schizoaffective Disorder,Drug: Lurasidone HCl|Drug: Risperidone,Sunovion,Phase 3,Industry,Interventional,6-Oct-11,https://ClinicalTrials.gov/show/NCT00641745
2599,CLARITY Extension Study,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: Cladribine|Drug: Placebo,EMD Serono,Phase 3,Industry,Interventional,2-Dec-13,https://ClinicalTrials.gov/show/NCT00641537
2600,Study of Lupron Depot In The Treatment of Central Precocious Puberty,Completed,Has Results,"Puberty, Precocious",Drug: Lupron (leuprolide acetate),Abbott,Phase 3,Industry,Interventional,20-Jul-10,https://ClinicalTrials.gov/show/NCT00660010
2601,Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164,Completed,Has Results,Parkinson Disease,Drug: Ropinirole XL (formerly CR),GlaxoSmithKline,Phase 3,Industry,Interventional,21-Apr-10,https://ClinicalTrials.gov/show/NCT00650104
2602,Corneal Collagen Cross-linking for Progressive Keratoconus,Completed,Has Results,Progressive Keratoconus,Drug: riboflavin ophthalmic solution|Device: UVA Irradiation,"Avedro, Inc.",Phase 3,Industry,Interventional,7-Jul-16,https://ClinicalTrials.gov/show/NCT00647699
2603,Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood,Completed,Has Results,Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipidemia,Drug: ABT-335|Drug: placebo|Drug: atorvastatin|Drug: ezetimibe,Abbott,Phase 3,Industry,Interventional,5-Nov-09,https://ClinicalTrials.gov/show/NCT00639158
2604,Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,Completed,Has Results,Prostatic Neoplasms,Drug: Placebo|Drug: Abiraterone acetate|Drug: Prednisone/prednisolone,"Cougar Biotechnology, Inc.",Phase 3,Industry,Interventional,16-May-13,https://ClinicalTrials.gov/show/NCT00638690
2605,Safety and Efficacy of Gabapentin in Postherpetic Neuralgia,Completed,Has Results,"Neuralgia,Postherpetic",Drug: Gabapentin Extended Release tablets|Drug: Placebo,Depomed,Phase 3,Industry,Interventional,13-Jan-12,https://ClinicalTrials.gov/show/NCT00636636
2606,A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty,Completed,Has Results,"Puberty, Precocious",Drug: Leuprolide acetate 11.25 mg|Drug: Leuprolide acetate 30 mg,Abbott,Phase 3,Industry,Interventional,9-Feb-11,https://ClinicalTrials.gov/show/NCT00635817
2607,An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease,Completed,Has Results,Parkinson Disease|Parkinson's Disease,Drug: Ropinirole XL (formerly CR),GlaxoSmithKline,Phase 3,Industry,Interventional,24-Dec-10,https://ClinicalTrials.gov/show/NCT00632736
2608,Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Bosentan,Actelion,Phase 3,Industry,Interventional,3-Aug-12,https://ClinicalTrials.gov/show/NCT00631475
2609,Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects,Completed,Has Results,Renal Cell Carcinoma,Drug: Bevacizumab|Drug: Temsirolimus|Drug: Interferon-Alfa 9MU,Pfizer,Phase 3,Industry,Interventional,4-Jun-13,https://ClinicalTrials.gov/show/NCT00631371
2610,Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin,Completed,Has Results,Dyslipidemia,Drug: Niacin extended-release (NER)|Drug: Niacin extended-release (NER) placebo|Drug: Aspirin (ASA)|Drug: Aspirin (ASA) placebo,Abbott,Phase 3,Industry,Interventional,9-Oct-09,https://ClinicalTrials.gov/show/NCT00630877
2611,Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects,Completed,Has Results,Influenza,Biological: Cell culture-derived influenza vaccine|Biological: Egg-derived influenza virus vaccine|Biological: Placebo,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,16-Jan-13,https://ClinicalTrials.gov/show/NCT00630331
2612,Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study,Completed,Has Results,Hepatic Veno-Occlusive Disease,Drug: Defibrotide,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,30-Nov-17,https://ClinicalTrials.gov/show/NCT00628498
2613,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months,Completed,Has Results,Allergic Rhinitis|Chronic Urticaria,Drug: Levocetirizine 1.25 mg|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,14-Oct-09,https://ClinicalTrials.gov/show/NCT00628108
2614,An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease,Completed,Has Results,"Gaucher Disease, Type 1",Biological: VPRIV®,Shire,Phase 3,Industry,Interventional,28-Jan-14,https://ClinicalTrials.gov/show/NCT00635427
2615,Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Smoking Cessation,"Drug: placebo|Drug: varenicline (CP-526,555)",Pfizer,Phase 3,Industry,Interventional,15-Apr-11,https://ClinicalTrials.gov/show/NCT00644969
2616,A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn,Completed,Has Results,Gastroesophageal Reflux,Drug: Dexlansoprazole|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,6-May-10,https://ClinicalTrials.gov/show/NCT00627016
2617,A Study of Leuprolide to Treat Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Leuprolide acetate - Formulation A|Drug: Leuprolide acetate - Formulation B,Abbott,Phase 3,Industry,Interventional,1-Nov-10,https://ClinicalTrials.gov/show/NCT00626431
2618,Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia,Completed,Has Results,Dyslipidemia,Drug: niacin extended-release (NER)|Drug: aspirin (ASA)|Drug: aspirin placebo (ASA Pbo),Abbott,Phase 3,Industry,Interventional,25-Aug-09,https://ClinicalTrials.gov/show/NCT00626392
2619,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,Completed,Has Results,Meningococcal Infections,Biological: MenACWY-CRM + MMRV|Biological: MMRV|Biological: MenACWY-CRM,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,15-Mar-13,https://ClinicalTrials.gov/show/NCT00626327
2620,Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 150 μg|Drug: Placebo to indacaterol,Novartis,Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00624286
2621,A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.,Completed,Has Results,Erectile Dysfunction,Drug: tadalafil once a day [T(OaD)]|Drug: sildenafil citrate as needed [S(PRN)]|Drug: tadalafil as needed [T(PRN)],Eli Lilly and Company,Phase 3,Industry,Interventional,18-Nov-10,https://ClinicalTrials.gov/show/NCT00734604
2622,Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure,Completed,Has Results,Hypertension,Drug: carvedilol controlled release/lisinopril|Drug: lisinopril + placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Aug-09,https://ClinicalTrials.gov/show/NCT00624065
2623,Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment,Completed,Has Results,Hemophilia A,"Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,Phase 3,Industry,Interventional,7-Aug-13,https://ClinicalTrials.gov/show/NCT00623480
2624,Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging,Completed,Has Results,Central Nervous System Diseases,"Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,6-Oct-11,https://ClinicalTrials.gov/show/NCT00623467
2625,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,Completed,Has Results,"Hepatitis C, Chronic",Drug: peginterferon alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Phase 3,Industry,Interventional,24-Jun-13,https://ClinicalTrials.gov/show/NCT00623428
2626,Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD),Completed,Has Results,Parkinson's Disease Dementia,Drug: Rivastigmine capsule|Drug: Rivastigmine transdermal patch,Novartis,Phase 3,Industry,Interventional,28-Nov-11,https://ClinicalTrials.gov/show/NCT00623103
2627,Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients,Completed,Has Results,Liver Transplantation,Drug: Tacrolimus (reduced tacrolimus)|Drug: Tacrolimus (tacrolimus elimination)|Drug: Tacrolimus (tacrolimus control)|Drug: Everolimus (reduced tacrolimus)|Drug: Everolimus (tacrolimus elimination)|Drug: Corticosteroids,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,20-May-13,https://ClinicalTrials.gov/show/NCT00622869
2628,Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide|Drug: Placebo,Sanofi,Phase 3,Industry,Interventional,19-Dec-14,https://ClinicalTrials.gov/show/NCT00622700
2629,Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo identical to BI 1356 5mg|Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Drug: BI 1356|Drug: Glimepiride,Boehringer Ingelheim,Phase 3,Industry,Interventional,20-Feb-12,https://ClinicalTrials.gov/show/NCT00622284
2630,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),Completed,Has Results,"Gaucher Disease, Type 1",Drug: Eliglustat tartrate|Drug: Placebo,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,3-Sep-14,https://ClinicalTrials.gov/show/NCT00891202
2631,CRESTOR Athero Imaging Head to Head IVUS Study,Completed,Has Results,Coronary Atherosclerosis,Drug: Rosuvastatin|Drug: Atorvastatin,AstraZeneca|The Cleveland Clinic,Phase 3,Industry|Other,Interventional,25-Jun-12,https://ClinicalTrials.gov/show/NCT00620542
2632,Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin,Completed,Has Results,Allergic Rhinitis|Chronic Urticaria,Drug: Levocetirizine|Drug: Placebo,UCB Pharma,Phase 3,Industry,Interventional,4-Sep-09,https://ClinicalTrials.gov/show/NCT00619801
2633,Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia,Completed,Has Results,Bacterial Pneumonia,Drug: Ceftaroline fosamil for Injection|Drug: IV Ceftriaxone|Drug: Placebo|Drug: Clarithromycin,Forest Laboratories,Phase 3,Industry,Interventional,10-Nov-10,https://ClinicalTrials.gov/show/NCT00621504
2634,An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.,Completed,Has Results,Systemic Juvenile Idiopathic Arthritis,Drug: Canakinumab,Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization|Novartis,Phase 3,Industry|Other,Interventional,10-Mar-17,https://ClinicalTrials.gov/show/NCT00891046
2635,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Docetaxel|Drug: ZD4054|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,31-May-12,https://ClinicalTrials.gov/show/NCT00617669
2636,Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years,Completed,Has Results,Influenza,"Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Biological: Placebo",GlaxoSmithKline,Phase 3,Industry,Interventional,7-Feb-14,https://ClinicalTrials.gov/show/NCT00616928
2637,"Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood",Completed,Has Results,Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia,Drug: ABT-335|Drug: Placebo|Other: Atorvastatin,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,20-Jan-14,https://ClinicalTrials.gov/show/NCT00616772
2638,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,Completed,Has Results,Meningococcal Infections,Biological: MenACWY-CRM|Biological: Licensed meningococcal ACWY vaccine,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,9-Jun-11,https://ClinicalTrials.gov/show/NCT00616421
2639,"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (""Melt"") Formulation of Desmopressin for the Treatment of Nocturia in Adults",Completed,Has Results,Nocturia,Drug: Desmopressin Melt,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,15-Dec-15,https://ClinicalTrials.gov/show/NCT00615836
2640,PREGNANT Short Cervix Trial,Completed,Has Results,Preterm Delivery|Short Cervix|Short Uterine Cervical Length,Drug: progesterone|Drug: placebo,"Juniper Pharmaceuticals, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",Phase 3,Industry|NIH,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00615550
2641,Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Lurasidone|Drug: Olanzapine|Drug: Placebo comparator|Drug: Lurasidone 40 mg tablets,Sunovion,Phase 3,Industry,Interventional,14-Feb-11,https://ClinicalTrials.gov/show/NCT00615433
2642,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014",Completed,Has Results,"Infections, Meningococcal",Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Biological: Infanrix®|Biological: ActHIB®|Biological: Pediarix®,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jul-12,https://ClinicalTrials.gov/show/NCT00614614
2643,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.,Completed,Has Results,Overactive Bladder,Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine,Pfizer,Phase 3,Industry,Interventional,12-Jan-11,https://ClinicalTrials.gov/show/NCT00611026
2644,TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy,Completed,Has Results,Lipodystrophy|HIV Infections,Drug: Tesamorelin|Drug: Placebo for Tesamorelin,Theratechnologies,Phase 3,Industry,Interventional,15-Jan-14,https://ClinicalTrials.gov/show/NCT00608023
2645,Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment,Completed,Has Results,Hypercholesterolemia,Biological: Evolocumab|Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis,Amgen,Phase 3,Industry,Interventional,19-Sep-17,https://ClinicalTrials.gov/show/NCT02585895
2646,Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody,Completed,Has Results,Renal Cell Carcinoma|Kidney Cancer,Drug: 124-Iodine-cG250 (124I-cG250)|Procedure: CT,Wilex,Phase 3,Industry,Interventional,14-Apr-14,https://ClinicalTrials.gov/show/NCT00606632
2647,Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs),Completed,Has Results,Actinic Keratoses,Drug: imiquimod cream|Drug: Placebo,"Graceway Pharmaceuticals, LLC",Phase 3,Industry,Interventional,22-Jun-10,https://ClinicalTrials.gov/show/NCT00605176
2648,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock,Completed,Has Results,Sepsis,Drug: Drotrecogin alfa (activated)|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,18-Sep-12,https://ClinicalTrials.gov/show/NCT00604214
2649,Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs),Completed,Has Results,Actinic Keratosis,Drug: Imiquimod cream|Drug: Placebo cream,"Graceway Pharmaceuticals, LLC",Phase 3,Industry,Interventional,22-Jun-10,https://ClinicalTrials.gov/show/NCT00603798
2650,"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",Completed,Has Results,Glaucoma,Drug: Timolol|Drug: latanoprost,Pfizer,Phase 3,Industry,Interventional,2-Dec-10,https://ClinicalTrials.gov/show/NCT00716859
2651,Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin,Boehringer Ingelheim,Phase 3,Industry,Interventional,7-Jun-11,https://ClinicalTrials.gov/show/NCT00601250
2652,A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.,Completed,Has Results,"Nausea and Vomiting, Chemotherapy-Induced",Drug: Casopitant|Drug: Dexamethasone|Drug: Placebo|Drug: Ondansetron,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Jan-18,https://ClinicalTrials.gov/show/NCT00601172
2653,Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly,Completed,Has Results,Acromegaly,Drug: Pasireotide|Drug: Octreotide,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,30-Jan-15,https://ClinicalTrials.gov/show/NCT00600886
2654,Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies,Completed,Has Results,Allergic Rhinitis,Biological: Standardized Ragweed Allergenic Extract|Biological: Placebo,Greer Laboratories,Phase 3,Industry,Interventional,14-Jan-15,https://ClinicalTrials.gov/show/NCT00599872
2655,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Completed,Has Results,Acne Vulgaris,Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle,Galderma,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00599521
2656,"Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%",Completed,Has Results,Acne Vulgaris,Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle,Galderma,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00598832
2657,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612),Completed,Has Results,Bladder Cancer,Drug: Apaziquone|Drug: Placebo|Procedure: TURBT,"Spectrum Pharmaceuticals, Inc",Phase 3,Industry,Interventional,15-Aug-17,https://ClinicalTrials.gov/show/NCT00598806
2658,Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC),Completed,Has Results,Hepatocellular Carcinoma,Drug: ThermoDox|Drug: 5% Dextrose Solution,Celsion,Phase 3,Industry,Interventional,24-Mar-17,https://ClinicalTrials.gov/show/NCT00617981
2659,Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients,Completed,Has Results,Pain|Fever,Drug: IV Acetaminophen,Mallinckrodt,Phase 3,Industry,Interventional,6-Jan-11,https://ClinicalTrials.gov/show/NCT00598702
2660,Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients,Completed,Has Results,Acute Pain|Fever,Drug: IV Acetaminophen,Mallinckrodt,Phase 3,Industry,Interventional,10-Dec-10,https://ClinicalTrials.gov/show/NCT00598559
2661,Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures,Completed,Has Results,Epilepsy,Drug: pregabalin,Pfizer,Phase 3,Industry,Interventional,11-Sep-12,https://ClinicalTrials.gov/show/NCT00596466
2662,Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).,Completed,Has Results,Parkinson Disease,Drug: Placebo|Drug: Pramipexole,Boehringer Ingelheim,Phase 3,Industry,Interventional,25-Aug-11,https://ClinicalTrials.gov/show/NCT00601523
2663,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,25-Sep-14,https://ClinicalTrials.gov/show/NCT00594568
2664,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine,UCB Pharma,Phase 3,Industry,Interventional,18-Dec-09,https://ClinicalTrials.gov/show/NCT00594386
2665,An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.,Completed,Has Results,Early-Stage Parkinson's Disease,Drug: Rotigotine,UCB Pharma,Phase 3,Industry,Interventional,25-Feb-10,https://ClinicalTrials.gov/show/NCT00594165
2666,Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil and chlorthalidone|Drug: Chlorthalidone,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00591773
2667,Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan Medoxomil|Drug: Valsartan,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00591578
2668,"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension",Completed,Has Results,Hypertension,Drug: Azilsartan Medoxomil and amlodipine|Drug: Amlodipine,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00591266
2669,Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension,Completed,Has Results,Hypertension,Drug: Azilsartan medoxomil|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00591253
2670,"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia",Completed,Has Results,Schizophrenia,Drug: Paliperidone palmitate 25 mg eq.|Drug: Paliperidone palmitate 150 mg eq.|Drug: Placebo|Drug: Paliperidone palmitate 100 mg eq.,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,5-Oct-09,https://ClinicalTrials.gov/show/NCT00590577
2671,Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: RISPERDAL CONSTA|Drug: Paliperidone palmitate,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,4-Oct-11,https://ClinicalTrials.gov/show/NCT00589914
2672,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,Completed,Has Results,Hormone Refractory Prostate Cancer|Bone Metastases,"Drug: Radium-223 dichloride (Xofigo, BAY88-8223)|Drug: Placebo|Drug: Best standard of care (BSoC)",Bayer,Phase 3,Industry,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT00699751
2673,An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder,Completed,Has Results,Mood Disorders,Drug: Lamotrigine,GlaxoSmithKline,Phase 3,Industry,Interventional,3-Aug-09,https://ClinicalTrials.gov/show/NCT00579982
2674,Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing,Completed,Has Results,Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hypertension|Cardiomyopathy,Drug: Nitric Oxide for inhalation|Drug: Oxygen|Drug: Nitric Oxide plus Oxygen,Mallinckrodt,Phase 3,Industry,Interventional,16-Sep-10,https://ClinicalTrials.gov/show/NCT00626028
2675,PCM Cervical Disc System,Completed,Has Results,Radiculopathy|Myelopathy,Device: Anterior Cervical Discectomy and Fusion (ACDF)|Device: PCM Cervical Disc,NuVasive,Phase 3,Industry,Interventional,12-Feb-13,https://ClinicalTrials.gov/show/NCT00578812
2676,Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy,Completed,Has Results,Osteoporosis,Drug: teriparatide,Eli Lilly and Company,Phase 3,Industry,Interventional,24-Jun-09,https://ClinicalTrials.gov/show/NCT00577863
2677,Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I),Completed,Has Results,Ulcerative Colitis,Drug: mesalamine,Warner Chilcott,Phase 3,Industry,Interventional,22-Jun-11,https://ClinicalTrials.gov/show/NCT00577473
2678,Albuterol HFA MDI in Pediatric Participants With Asthma,Completed,Has Results,Asthma,Drug: Albuterol|Drug: Placebo|Drug: Proventil® HFA,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",Phase 3,Industry,Interventional,3-Dec-09,https://ClinicalTrials.gov/show/NCT00577655
2679,Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS,Completed,Has Results,Pseudobulbar Affect (PBA),Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Drug: Placebo,Avanir Pharmaceuticals|Syneos Health,Phase 3,Industry|Other,Interventional,10-Jul-13,https://ClinicalTrials.gov/show/NCT00573443
2680,TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults,Completed,Has Results,"Migraine Disorders|Migraine, Acute",Drug: TREXIMET®|Drug: Butalbital-containing Combination Medications (BCM)|Drug: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,29-Dec-10,https://ClinicalTrials.gov/show/NCT00573170
2681,"Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.",Completed,Has Results,Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes,Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,13-Jul-10,https://ClinicalTrials.gov/show/NCT00570739
2682,Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay,Completed,Has Results,Healthy Donors|HIV Positive,Device: collection of follow-up sample based on PRISM HIV O Plus result,Abbott Diagnostics Division,Phase 3,Industry,Interventional,5-Jul-10,https://ClinicalTrials.gov/show/NCT00686205
2683,A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome,Completed,Has Results,Cushing's Syndrome,Drug: mifepristone,Corcept Therapeutics,Phase 3,Industry,Interventional,28-May-12,https://ClinicalTrials.gov/show/NCT00569582
2684,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc",Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT00567255
2685,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,Completed,Has Results,"Contraception|Ovulation Inhibition|Contraceptives, Oral","Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP (YAZ, BAY86-5300)",Bayer,Phase 3,Industry,Interventional,12-Mar-14,https://ClinicalTrials.gov/show/NCT00567164
2686,Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy,Completed,Has Results,Psoriasis,Biological: adalimumab,Abbott,Phase 3,Industry,Interventional,28-May-10,https://ClinicalTrials.gov/show/NCT00566722
2687,Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain,Completed,Has Results,Pain,Drug: IV Placebo|Drug: IV Acetaminophen,Mallinckrodt,Phase 3,Industry,Interventional,30-Nov-10,https://ClinicalTrials.gov/show/NCT00564486
2688,Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure,Completed,Has Results,Pneumothorax,Device: Bio-Seal Plug,Angiotech Pharmaceuticals,Phase 3,Industry,Interventional,27-Mar-13,https://ClinicalTrials.gov/show/NCT00562302
2689,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,Completed,Has Results,HIV Infections,Drug: nevirapine IR|Drug: nevirapine XR,Boehringer Ingelheim,Phase 3,Industry,Interventional,19-Jan-12,https://ClinicalTrials.gov/show/NCT00561925
2690,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine,Eli Lilly and Company,Phase 3,Industry,Interventional,14-Dec-10,https://ClinicalTrials.gov/show/NCT00560417
2691,Methotrexate-Inadequate Response Study,Completed,Has Results,Rheumatoid Arthritis (RA),Drug: Subcutaneous (SC) Abatacept|Drug: Intravenous (IV) Abatacept,Bristol-Myers Squibb,Phase 3,Industry,Interventional,6-Jul-11,https://ClinicalTrials.gov/show/NCT00559585
2692,Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,Completed,Has Results,Venous Thromboembolism,Drug: dabigatran etexilate 150 mg twice daily (BID)|Drug: matching placebo twice daily (BID),Boehringer Ingelheim,Phase 3,Industry,Interventional,2-Mar-12,https://ClinicalTrials.gov/show/NCT00558259
2693,Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia,Completed,Has Results,"Leukaemia, Lymphocytic, Chronic",Drug: OFC Infusion|Drug: FC infusion,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,25-Jul-16,https://ClinicalTrials.gov/show/NCT00824265
2694,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,Completed,Has Results,Prostate Cancer,Drug: ZD4054|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,31-May-12,https://ClinicalTrials.gov/show/NCT00554229
2695,Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease,Completed,Has Results,Crohn Disease,"Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo",UCB Pharma,Phase 3,Industry,Interventional,30-Dec-10,https://ClinicalTrials.gov/show/NCT00552058
2696,Surgical Pain After Inguinal Hernia Repair (SPAIHR),Completed,Has Results,"Pain, Postoperative|Hernia, Inguinal",Drug: Pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,15-Jul-10,https://ClinicalTrials.gov/show/NCT00551135
2697,A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103),ACADIA Pharmaceuticals Inc.,Phase 3,Industry,Interventional,24-Jun-19,https://ClinicalTrials.gov/show/NCT00550238
2698,A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies,Completed,Has Results,Seasonal Allergic Rhinitis,Drug: MP29-02|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo,Meda Pharmaceuticals,Phase 3,Industry,Interventional,23-Jul-12,https://ClinicalTrials.gov/show/NCT00660517
2699,Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia,Completed,Has Results,Schizophrenia,Drug: Lurasidone HCl,Sunovion,Phase 3,Industry,Interventional,14-Dec-10,https://ClinicalTrials.gov/show/NCT00549718
2700,Celebrex In Acute Gouty Arthritis Study,Completed,Has Results,"Arthritis, Gouty",Drug: Indomethacin|Drug: Celecoxib,Pfizer,Phase 3,Industry,Interventional,24-Feb-11,https://ClinicalTrials.gov/show/NCT00549549
2701,AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Device: AtriCure Bipolar System,"AtriCure, Inc.",Phase 3,Industry,Interventional,14-Mar-13,https://ClinicalTrials.gov/show/NCT00560885
2702,VEC-162 Study in Adult Patients With Primary Insomnia,Completed,Has Results,Primary Insomnia,Drug: VEC-162 20 mg|Drug: Placebo|Drug: VEC-162 50 mg,Vanda Pharmaceuticals,Phase 3,Industry,Interventional,15-Oct-14,https://ClinicalTrials.gov/show/NCT00548340
2703,Phase IIIB Subcutaneous Abatacept Monotherapy Study,Completed,Has Results,Rheumatoid Arthritis (RA),Drug: abatacept|Drug: Methotrexate (MTX),Bristol-Myers Squibb,Phase 3,Industry,Interventional,24-Jan-11,https://ClinicalTrials.gov/show/NCT00547521
2704,Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies|Partial Onset Seizures,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 3,Industry,Interventional,20-Oct-10,https://ClinicalTrials.gov/show/NCT00655551
2705,Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures,Completed,Has Results,Partial Epilepsies|Partial Onset Seizures,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 3,Industry,Interventional,15-Jul-11,https://ClinicalTrials.gov/show/NCT00655486
2706,"Fesoterodine ""add-on"" Male Overactive Bladder Study",Completed,Has Results,Overactive Bladder Syndrome,Drug: Fesoterodine|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,22-Nov-10,https://ClinicalTrials.gov/show/NCT00546637
2707,"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)",Completed,Has Results,Pneumococcal Infections,Biological: 13 valent Pneumococcal Conjugate Vaccine|Biological: 23vPS,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,30-May-11,https://ClinicalTrials.gov/show/NCT00546572
2708,Prevention of Recurrence of Diverticulitis,Completed,Has Results,Diverticulitis,Drug: SPD476 (1.2g)|Drug: SPD476 (2.4 g)|Drug: SPD476 (4.8 g)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,25-Jan-13,https://ClinicalTrials.gov/show/NCT00545740
2709,A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.,Completed,Has Results,"Influenza, Human",Drug: oseltamivir|Other: placebo,Hoffmann-La Roche,Phase 3,Industry,Interventional,12-Jul-18,https://ClinicalTrials.gov/show/NCT00545532
2710,Prevention of Recurrence of Diverticulitis,Completed,Has Results,Diverticulitis,"Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet|Drug: Placebo",Shire,Phase 3,Industry,Interventional,19-Dec-12,https://ClinicalTrials.gov/show/NCT00545103
2711,TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors,Completed,Has Results,HIV Infections|HIV-1,Drug: TMC278|Drug: efavirenz,"Tibotec Pharmaceuticals, Ireland",Phase 3,Industry,Interventional,12-Jul-11,https://ClinicalTrials.gov/show/NCT00543725
2712,Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: bosentan,Actelion,Phase 3,Industry,Interventional,29-Jun-17,https://ClinicalTrials.gov/show/NCT01223352
2713,Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles,Completed,Has Results,Bilateral Nasolabial Fold Wrinkles,Biological: Autologous Human Fibroblast (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.",Phase 3,Industry,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00649428
2714,A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: risedronate,Warner Chilcott,Phase 3,Industry,Interventional,21-Jun-11,https://ClinicalTrials.gov/show/NCT00541658
2715,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Carcinoma,Drug: Albumin-bound paclitaxel|Drug: Paclitaxel|Drug: Carboplatin,Celgene,Phase 3,Industry,Interventional,19-Aug-13,https://ClinicalTrials.gov/show/NCT00540514
2716,TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.,Completed,Has Results,HIV Infections|HIV-1|Human Immunodeficiency Virus Type 1,Drug: TMC278|Drug: Efavirenz,"Tibotec Pharmaceuticals, Ireland",Phase 3,Industry,Interventional,11-Jul-11,https://ClinicalTrials.gov/show/NCT00540449
2717,"Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",Completed,Has Results,Primary Immune Deficiency Disorders (PIDD),Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%],Biotest Pharmaceuticals Corporation,Phase 3,Industry,Interventional,26-Mar-12,https://ClinicalTrials.gov/show/NCT00538915
2718,Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain,Completed,Has Results,Cancer|Pain,Drug: Fentanyl sublingual spray,INSYS Therapeutics Inc,Phase 3,Industry,Interventional,11-Oct-13,https://ClinicalTrials.gov/show/NCT00538863
2719,Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Device: acoustical pulse energy (extracorporeal shockwave)|Other: Sham,"SANUWAVE, Inc.",Phase 3,Industry,Interventional,14-Apr-14,https://ClinicalTrials.gov/show/NCT00536744
2720,Fesoterodine Flexible Dose Study,Completed,Has Results,Overactive Bladder,Drug: Fesoterodine|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,11-Sep-09,https://ClinicalTrials.gov/show/NCT00536484
2721,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo|Drug: Methotrexate,Hoffmann-La Roche,Phase 3,Industry,Interventional,14-Nov-12,https://ClinicalTrials.gov/show/NCT00535782
2722,Generalized Anxiety Disorder Adjunct Study,Completed,Has Results,Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States,Drug: Placebo|Drug: quetiapine fumarate XR,AstraZeneca,Phase 3,Industry,Interventional,5-Apr-11,https://ClinicalTrials.gov/show/NCT00534599
2723,Phase IIIB Subcutaneous Missed Dose Study,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,3-Jun-11,https://ClinicalTrials.gov/show/NCT00533897
2724,A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects,Completed,Has Results,Obesity|Overweight,Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day|Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc",Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT00532779
2725,A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Tocilizumab|Drug: Placebo|Drug: Permitted DMARDs,Hoffmann-La Roche,Phase 3,Industry,Interventional,4-Aug-10,https://ClinicalTrials.gov/show/NCT00531817
2726,Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis,Completed,Has Results,Aspergillosis,Drug: voriconazole|Drug: anidulafungin,Pfizer,Phase 3,Industry,Interventional,30-Apr-12,https://ClinicalTrials.gov/show/NCT00531479
2727,Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee,Completed,Has Results,Chronic Pain|Osteoarthritis of the Knee,Drug: Buprenorphine|Drug: Placebo,Purdue Pharma LP,Phase 3,Industry,Interventional,21-Sep-10,https://ClinicalTrials.gov/show/NCT00531427
2728,Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide,UCB Pharma,Phase 3,Industry,Interventional,3-Jun-15,https://ClinicalTrials.gov/show/NCT00530855
2729,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease,Completed,Has Results,"Hepatitis C, Chronic",Drug: eltrombopag|Drug: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,17-May-12,https://ClinicalTrials.gov/show/NCT00529568
2730,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Completed,Has Results,Asthma,Drug: Indacaterol 300 μg|Drug: Salmeterol 50 μg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Aug-11,https://ClinicalTrials.gov/show/NCT00529529
2731,BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Bevacizumab|Drug: Standard adjuvant chemotherapy,Hoffmann-La Roche,Phase 3,Industry,Interventional,10-Sep-13,https://ClinicalTrials.gov/show/NCT00528567
2732,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,Completed,Has Results,Contraception,Drug: LCS12|Drug: LCS16,Bayer,Phase 3,Industry,Interventional,24-Sep-12,https://ClinicalTrials.gov/show/NCT00528112
2733,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture",Completed,Has Results,Dupuytren's Contracture,Biological: collagenase clostridium histolyticum|Biological: Placebo,Endo Pharmaceuticals,Phase 3,Industry,Interventional,22-Oct-10,https://ClinicalTrials.gov/show/NCT00528606
2734,"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Completed,Has Results,Advanced Dupuytren's Disease,Biological: AA4500,Endo Pharmaceuticals,Phase 3,Industry,Interventional,22-Oct-10,https://ClinicalTrials.gov/show/NCT00528424
2735,"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease",Completed,Has Results,Advanced Dupuytren's Disease,Biological: collagenase clostridium histolyticum,Endo Pharmaceuticals,Phase 3,Industry,Interventional,22-Oct-10,https://ClinicalTrials.gov/show/NCT00528840
2736,Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension,Completed,Has Results,Hypertension,Drug: Amlodipine|Drug: Olmesartan medoxomil plus amlodipine,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,23-Sep-09,https://ClinicalTrials.gov/show/NCT00527514
2737,A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN),Completed,Has Results,Human Immunodeficiency Virus - Type 1,Drug: Darunavir (DRV)|Drug: Ritonavir (rtv),"Tibotec Pharmaceuticals, Ireland",Phase 3,Industry,Interventional,22-Sep-10,https://ClinicalTrials.gov/show/NCT00524368
2738,Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM),Completed,Has Results,Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM),Drug: Everolimus (RAD001)|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,28-Aug-12,https://ClinicalTrials.gov/show/NCT00790400
2739,Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis,Completed,Has Results,Adult Periodontitis,Drug: minocycline HCl 2.1%|Procedure: Scaling and root planing,Sunstar Americas,Phase 3,Industry,Interventional,9-May-14,https://ClinicalTrials.gov/show/NCT00529555
2740,Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103),Completed,Has Results,Cystinosis,Drug: Cysteamine Bitartrate Delayed-release Capsules,"Horizon Pharma USA, Inc.",Phase 3,Industry,Interventional,24-Jul-18,https://ClinicalTrials.gov/show/NCT01197378
2741,Endometrial Safety Study,Completed,Has Results,Postmenopause,Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.5mg NETA / 1.0mg E2 (Activella),"Bayer|Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco",Phase 3,Industry|Other,Interventional,28-Jun-12,https://ClinicalTrials.gov/show/NCT00522873
2742,Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,10-Dec-12,https://ClinicalTrials.gov/show/NCT00522379
2743,Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures,Completed,Has Results,Partial Epilepsies,Drug: lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 3,Industry,Interventional,22-Nov-10,https://ClinicalTrials.gov/show/NCT00522275
2744,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 300 μg|Drug: Placebo to indacaterol|Drug: Salmeterol 50 μg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00622635
2745,Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine,Completed,Has Results,Influenza,Biological: 13 valent pneumococcal conjugate vaccine,Pfizer,Phase 3,Industry,Interventional,9-Apr-15,https://ClinicalTrials.gov/show/NCT00521586
2746,Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures,Completed,Has Results,Epilepsy,Drug: Lacosamide,"UCB BIOSCIENCES, Inc.|UCB Pharma",Phase 3,Industry,Interventional,23-Apr-14,https://ClinicalTrials.gov/show/NCT00520741
2747,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: exenatide,Novo Nordisk A/S,Phase 3,Industry,Interventional,23-Mar-10,https://ClinicalTrials.gov/show/NCT00518882
2748,Clobazam in Patients With Lennox-Gastaut Syndrome,Completed,Has Results,"Epilepsy|Epilepsy, Generalized|Seizures",Drug: Clobazam Low Dose|Drug: Clobazam Medium Dose|Drug: Clobazam High Dose|Drug: Placebo,Lundbeck LLC,Phase 3,Industry,Interventional,9-Feb-12,https://ClinicalTrials.gov/show/NCT00518713
2749,Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults,Completed,Has Results,Influenza,Biological: Fluarix|Biological: GSK Biologicals Influenza Vaccine GSK576389A,GlaxoSmithKline,Phase 3,Industry,Interventional,30-May-12,https://ClinicalTrials.gov/show/NCT00529516
2750,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease,Completed,Has Results,"Hepatitis C, Chronic",Drug: eltrombopag|Drug: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,30-Jul-12,https://ClinicalTrials.gov/show/NCT00516321
2751,Lamotrigine Extended-Release In Elderly Patients With Epilepsy,Completed,Has Results,Epilepsy,Drug: Lamotrigine,GlaxoSmithKline,Phase 3,Industry,Interventional,13-Jan-12,https://ClinicalTrials.gov/show/NCT00516139
2752,Tailored Treatment of Permanent Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Procedure: Medtronic Cardiac Ablation System|Drug: Class I or III Antiarrhythmic Medications,Medtronic Cardiac Rhythm and Heart Failure,Phase 3,Industry,Interventional,9-May-12,https://ClinicalTrials.gov/show/NCT00514735
2753,"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients",Completed,Has Results,Schizophrenia,Drug: Paliperidone ER|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,9-Jun-10,https://ClinicalTrials.gov/show/NCT00518323
2754,Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Pancrelipase Delayed Release|Drug: Placebo Comparator,Solvay Pharmaceuticals,Phase 3,Industry,Interventional,20-Jul-09,https://ClinicalTrials.gov/show/NCT00510484
2755,Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors,Completed,Has Results,Advanced Neuroendocrine Tumors of Pancreatic Origin,Drug: Everolimus|Drug: Everolimus Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Dec-11,https://ClinicalTrials.gov/show/NCT00510068
2756,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Glargine,Eli Lilly and Company,Phase 3,Industry,Interventional,3-Nov-09,https://ClinicalTrials.gov/show/NCT00510952
2757,"Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone",Completed,Has Results,Multiple Myeloma,Drug: Bortezomib|Drug: Dexamethasone|Drug: Melphalan|Drug: Prednisone|Drug: Thalidomide,"Millennium Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,1-May-14,https://ClinicalTrials.gov/show/NCT00507416
2758,MPC-004 for the Treatment of an Acute Gout Flare,Completed,Has Results,Gout,Drug: High Dose Colchicine (4.8 mg total dose)|Drug: Low Dose Colchicine (1.8mg total dose)|Other: Placebo Control,Takeda,Phase 3,Industry,Interventional,22-Sep-09,https://ClinicalTrials.gov/show/NCT00506883
2759,"A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia",Completed,Has Results,Chronic Kidney Disease|Dialysis|Hyperphosphatemia,Drug: MCI-196|Drug: Placebo,Mitsubishi Tanabe Pharma Corporation,Phase 3,Industry,Interventional,25-Jul-14,https://ClinicalTrials.gov/show/NCT00506441
2760,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",Completed,Has Results,Alzheimer Disease,Drug: Rivastigmine 5 cm^2|Drug: Rivastigmine 10 cm^2|Drug: Rivastigmine 15 cm^2|Drug: Placebo to 15 cm^2 patch|Drug: Placebo to 10 cm^2 patch,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Sep-12,https://ClinicalTrials.gov/show/NCT00506415
2761,Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent,Completed,Has Results,Atrial Fibrillation,Device: Cardioblate Surgical Ablation System|Procedure: Surgical RF Ablation,Medtronic Cardiovascular,Phase 3,Industry,Interventional,16-Oct-13,https://ClinicalTrials.gov/show/NCT00506493
2762,A Comparison of Once a Day Dose Compared to 2 Doses/Day,Completed,Has Results,Ulcerative Colitis,Drug: Mesalamine Once-Daily|Drug: Mesalamine Twice-Daily,Warner Chilcott,Phase 3,Industry,Interventional,12-May-11,https://ClinicalTrials.gov/show/NCT00505778
2763,Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,Completed,Has Results,ADHD,Drug: Methylphenidate Transdermal System,Noven Therapeutics,Phase 3,Industry,Interventional,15-Jan-10,https://ClinicalTrials.gov/show/NCT00501293
2764,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,Completed,Has Results,Moderate Risk of CVD,"Drug: Aspirin (Acetylsalicylic acid, BAYE4465)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,8-Jan-18,https://ClinicalTrials.gov/show/NCT00501059
2765,A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Aclidinium Bromide|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,17-Dec-12,https://ClinicalTrials.gov/show/NCT00500318
2766,Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,Completed,Has Results,ADHD,Drug: methylphenidate transdermal system|Drug: Placebo,Noven Therapeutics,Phase 3,Industry,Interventional,11-Jun-09,https://ClinicalTrials.gov/show/NCT00499863
2767,Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects,Completed,Has Results,Pneumococcal Infections,Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC),Pfizer,Phase 3,Industry,Interventional,16-Sep-11,https://ClinicalTrials.gov/show/NCT00500266
2768,Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients,Completed,Has Results,Cytomegalovirus Infections,Drug: maribavir|Drug: ganciclovir,Shire,Phase 3,Industry,Interventional,4-Jun-15,https://ClinicalTrials.gov/show/NCT00497796
2769,The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4,Completed,Has Results,Chronic Kidney Disease|Left Ventricular Hypertrophy,Drug: paricalcitol|Drug: placebo,"AbbVie (prior sponsor, Abbott)|Massachusetts General Hospital|AbbVie",Phase 3,Industry|Other,Interventional,23-Dec-11,https://ClinicalTrials.gov/show/NCT00497146
2770,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY),Completed,Has Results,Diabetes Mellitus Type 2,Drug: Insulin Lispro Protamine Suspension|Drug: Detemir,Eli Lilly and Company,Phase 3,Industry,Interventional,4-Nov-09,https://ClinicalTrials.gov/show/NCT00494013
2771,BAY12-8039: 5 Days for Sinusitis vs Placebo,Completed,Has Results,Sinusitis,"Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,2-Dec-09,https://ClinicalTrials.gov/show/NCT00492024
2772,An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: Rotigotine,UCB Pharma,Phase 3,Industry,Interventional,12-Jan-10,https://ClinicalTrials.gov/show/NCT00505687
2773,A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder,Completed,Has Results,Bipolar Disorder,Drug: Olanzapine|Drug: Paliperidone ER|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,5-Mar-12,https://ClinicalTrials.gov/show/NCT00490971
2774,Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain,Completed,Has Results,Low Back Pain,Drug: Buprenorphine transdermal system|Drug: Placebo,Purdue Pharma LP,Phase 3,Industry,Interventional,9-Sep-10,https://ClinicalTrials.gov/show/NCT00490919
2775,"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",Completed,Has Results,Acellular Pertussis|Tetanus|Diphtheria,Procedure: Taking of blood samples|Biological: Boostrix|Biological: Adacel,GlaxoSmithKline,Phase 3,Industry,Interventional,11-Aug-10,https://ClinicalTrials.gov/show/NCT00489970
2776,TAXUS PERSEUS Small Vessel,Completed,Has Results,Coronary Artery Disease,Device: Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation,Boston Scientific Corporation,Phase 3,Industry,Interventional,28-Jun-11,https://ClinicalTrials.gov/show/NCT00489541
2777,Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents,Completed,Has Results,Migraine Disorders,Drug: Combination Tablet of Treximet (sumatriptan/naproxen sodium),GlaxoSmithKline,Phase 3,Industry,Interventional,6-Sep-10,https://ClinicalTrials.gov/show/NCT00488514
2778,Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.,Completed,Has Results,Schizophrenia|Schizophrenic Disorders|Psychotic Disorders|Dementia Praecox,Drug: Paliperidone ER,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,6-Jan-14,https://ClinicalTrials.gov/show/NCT00488319
2779,"Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)",Completed,Has Results,"Hereditary Inclusion Body Myopathy|Distal Myopathy With Rimmed Vacuoles|Distal Myopathy, Nonaka Type|GNE Myopathy",Drug: aceneuramic acid extended-release (Ace-ER)|Drug: Placebo,Ultragenyx Pharmaceutical Inc,Phase 3,Industry,Interventional,9-Jul-18,https://ClinicalTrials.gov/show/NCT02377921
2780,A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD,Drug: Vyvanse (lisdexamfetamine dimesylate)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,5-Jun-09,https://ClinicalTrials.gov/show/NCT00500149
2781,"Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study",Completed,Has Results,Inflammatory Bowel Disease|Ulcerative Colitis,Drug: Balsalazide Disodium,"Bausch Health Americas, Inc.",Phase 3,Industry,Interventional,19-Jan-18,https://ClinicalTrials.gov/show/NCT00486031
2782,"Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin",Completed,Has Results,Type 2 Diabetes|Hyperlipidemia,Drug: Colesevelam HCl|Drug: rosiglitazone maleate|Drug: sitagliptin phosphate,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,17-Jun-09,https://ClinicalTrials.gov/show/NCT00484419
2783,TAXUS PERSEUS Workhorse,Completed,Has Results,Coronary Artery Disease,Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|Device: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement,Boston Scientific Corporation,Phase 3,Industry,Interventional,28-Jun-11,https://ClinicalTrials.gov/show/NCT00484315
2784,Study of Fampridine-SR Tablets in Multiple Sclerosis Patients,Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR|Drug: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,14-Apr-11,https://ClinicalTrials.gov/show/NCT00483652
2785,Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers,Completed,Has Results,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|Biological: Measles-mumps-rubella-varicella vaccine|Biological: Routine paediatric vaccine - Pneumococcal conjugate (PCV)|Biological: Routine paediatric vaccine - Hepatitis A,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,6-Jul-11,https://ClinicalTrials.gov/show/NCT00483574
2786,Adjunctive Ziprasidone in the Treatment of Bipolar I Depression,Completed,Has Results,"Bipolar Disorder|Depression, Bipolar",Drug: Ziprasidone|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,23-Feb-10,https://ClinicalTrials.gov/show/NCT00483548
2787,"Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients",Completed,Has Results,Early Parkinson Disease (Early PD),Drug: Pramipexol Extended Release|Drug: Pramipexol Immediate Release|Drug: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,15-Apr-10,https://ClinicalTrials.gov/show/NCT00479401
2788,Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia,Completed,Has Results,Hyponatremia,Drug: Conivaptan|Drug: Placebo,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,21-Apr-10,https://ClinicalTrials.gov/show/NCT00478192
2789,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,Completed,Has Results,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate (ACP-103)|Drug: Placebo,ACADIA Pharmaceuticals Inc.,Phase 3,Industry,Interventional,26-Mar-14,https://ClinicalTrials.gov/show/NCT00477672
2790,Study of Safety and Efficacy of an Oral Contraceptive,Completed,Has Results,Contraception,Drug: Norethindrone/ethinyl estradiol,Warner Chilcott,Phase 3,Industry,Interventional,24-Jan-11,https://ClinicalTrials.gov/show/NCT00477633
2791,Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia,Completed,Has Results,Nocturia,Drug: desmopressin acetate|Drug: Placebo,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,2-Nov-15,https://ClinicalTrials.gov/show/NCT00477490
2792,A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure,Completed,Has Results,Heart Decompensation,Drug: Nesiritide|Drug: Placebo,"Scios, Inc.",Phase 3,Industry,Interventional,10-May-12,https://ClinicalTrials.gov/show/NCT00475852
2793,Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib,Completed,Has Results,Renal Cell Carcinoma,Drug: Sorafenib|Drug: temsirolimus (Torisel),Pfizer,Phase 3,Industry,Interventional,7-Mar-13,https://ClinicalTrials.gov/show/NCT00474786
2794,A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes,Completed,Has Results,"Obesity|Overweight|Diabetes Mellitus, Type 2",Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day|Drug: Placebo|Behavioral: Ancillary therapy,"Orexigen Therapeutics, Inc",Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT00474630
2795,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants,Completed,Has Results,"Meningitis, Meningococcal",Biological: Meningococcal ACWY Conjugate Vaccine|Biological: DTaP-IPV-HBV|Biological: Hib|Biological: Rotavirus|Biological: Pneumococcal 7-valent Conjugate Vaccine|Biological: HAV|Biological: MMR-V|Biological: DTaP,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,24-Mar-14,https://ClinicalTrials.gov/show/NCT00474526
2796,Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.,Completed,Has Results,"Carcinoma, Pancreatic Ductal",Drug: AG-013736|Drug: Gemcitabine|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,16-Jul-12,https://ClinicalTrials.gov/show/NCT00471146
2797,Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib,Completed,Has Results,Gastrointestinal Stromal Tumors,Drug: Nilotinib|Other: Best Supportive Care (BSC) +/- imatinib or sunitinib,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-May-11,https://ClinicalTrials.gov/show/NCT00471328
2798,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),Completed,Has Results,Clostridium Infections|Diarrhea,Drug: PAR-101/OPT-80|Drug: Vancomycin,Optimer Pharmaceuticals LLC,Phase 3,Industry,Interventional,29-Jul-11,https://ClinicalTrials.gov/show/NCT00468728
2799,Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy,Completed,Has Results,"Pain, Postoperative",Drug: pregabalin (Lyrica)|Drug: matched placebo,Pfizer,Phase 3,Industry,Interventional,26-May-11,https://ClinicalTrials.gov/show/NCT00468845
2800,Phase 3/Safety & Efficacy of Esomeprazole in Infants,Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Open Label Run In Esomeprazole|Drug: Double Blind Esomeprazole|Drug: Double Blind Placebo,AstraZeneca,Phase 3,Industry,Interventional,2-Jun-14,https://ClinicalTrials.gov/show/NCT00468559
2801,Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age,Completed,Has Results,Tetanus|Diphtheria|Pertussis,Biological: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|Biological: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed),"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,3-Dec-10,https://ClinicalTrials.gov/show/NCT00467519
2802,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,Completed,Has Results,Hypoactive Sexual Desire Disorder,Drug: Testosterone Transdermal System|Drug: Placebo patch,Warner Chilcott,Phase 3,Industry,Interventional,15-Dec-11,https://ClinicalTrials.gov/show/NCT00467259
2803,An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME),Completed,Has Results,Hyperlipidemia|Mixed Dyslipidemia,Drug: Niacin ER/Simvastatin Tablets|Drug: atorvastatin,Abbott,Phase 3,Industry,Interventional,13-May-09,https://ClinicalTrials.gov/show/NCT00465088
2804,"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures",Completed,Has Results,Epilepsy,Other: Placebo|Drug: Brivaracetam 2.5 mg|Drug: Brivaracetam 10 mg|Drug: Brivaracetam 25 mg,UCB Pharma,Phase 3,Industry,Interventional,13-Apr-16,https://ClinicalTrials.gov/show/NCT00464269
2805,A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia,Completed,Has Results,Hypercholesterolemia|Dyslipidemia,Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium,AstraZeneca,Phase 3,Industry,Interventional,1-Aug-12,https://ClinicalTrials.gov/show/NCT00463606
2806,Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain,Completed,Has Results,Chronic Pain,Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,14-Dec-10,https://ClinicalTrials.gov/show/NCT00463047
2807,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf),Shire,Phase 3,Industry,Interventional,3-May-10,https://ClinicalTrials.gov/show/NCT00462709
2808,Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611),Completed,Has Results,Bladder Cancer,Drug: Apaziquone|Drug: Placebo|Procedure: TURBT,"Spectrum Pharmaceuticals, Inc",Phase 3,Industry,Interventional,15-Aug-17,https://ClinicalTrials.gov/show/NCT00461591
2809,"Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII",Completed,Has Results,Hemophilia A,Biological: Moroctocog alfa (AF-CC),Pfizer,Phase 3,Industry,Interventional,11-Jan-19,https://ClinicalTrials.gov/show/NCT00543439
2810,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting","Drug: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,Phase 3,Industry,Interventional,17-Aug-09,https://ClinicalTrials.gov/show/NCT00459667
2811,A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone,Completed,Has Results,"Carcinoma, Non-Small Cell Lung",Drug: erlotinib|Drug: sunitinib|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,2-Aug-11,https://ClinicalTrials.gov/show/NCT00457392
2812,Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),"Drug: ecallantide|Drug: Phosphate Buffer Saline (PBS), pH 7.0",Shire,Phase 3,Industry,Interventional,4-May-10,https://ClinicalTrials.gov/show/NCT00457015
2813,Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness,Completed,Has Results,Venous Thrombosis|Pulmonary Embolism,Drug: Apixaban|Drug: Enoxaparin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,20-May-14,https://ClinicalTrials.gov/show/NCT00457002
2814,Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE),Completed,Has Results,Hereditary Angioedema (HAE),Drug: ecallantide,Shire,Phase 3,Industry,Interventional,28-Dec-12,https://ClinicalTrials.gov/show/NCT00456508
2815,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,Completed,Has Results,Neural Tube Defects|Contraception|Oral Contraceptives (OC),Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|Drug: Drospirenone/Ethinylestradiol (Yaz),Bayer,Phase 3,Industry,Interventional,25-Jan-11,https://ClinicalTrials.gov/show/NCT00468481
2816,A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy,Completed,Has Results,Prostate Cancer,Drug: Degarelix 80 mg / Degarelix 80 mg|Drug: Degarelix 160 mg / Degarelix 160 mg|Drug: Leuprolide 7.5 mg / Degarelix 80 mg|Drug: Leuprolide 7.5 mg / Degarelix 160 mg,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,21-Mar-13,https://ClinicalTrials.gov/show/NCT00451958
2817,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: BG00012|Drug: Placebo|Drug: Glatiramer Acetate,Biogen,Phase 3,Industry,Interventional,2-Jun-14,https://ClinicalTrials.gov/show/NCT00451451
2818,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,Completed,Has Results,Meningococcal Infections|Meningococcal Meningitis,Biological: MenACWY CRM|Biological: Meningococcal ACWY Conjugate vaccine,Novartis Vaccines|Novartis,Phase 3,Industry,Interventional,24-Sep-10,https://ClinicalTrials.gov/show/NCT00450437
2819,Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura,Completed,Has Results,Migraine With Aura,Device: Active Transcranial Magnetic Stimulation (TMS) Device|Device: Sham TMS Device,Neuralieve,Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00449540
2820,Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures,Completed,Has Results,"Epilepsies, Partial",Drug: Pregabalin,Pfizer,Phase 3,Industry,Interventional,2-Dec-14,https://ClinicalTrials.gov/show/NCT00448916
2821,Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Completed,Has Results,Refractory Partial Onset Seizures,Drug: Rufinamide|Drug: Placebo,Eisai Inc.,Phase 3,Industry,Interventional,10-Dec-12,https://ClinicalTrials.gov/show/NCT00448539
2822,"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.",Completed,Has Results,Diagnosis of Adult Growth Hormone Deficiency (AGDH),Drug: AEZS-130 (formerly ARD-07)|Drug: L-ARG+GHRH,AEterna Zentaris,Phase 3,Industry,Interventional,23-Jul-19,https://ClinicalTrials.gov/show/NCT00448747
2823,"Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease",Completed,Has Results,Cryopyrin-Associated Periodic Syndromes|Familial Cold Autoinflammatory Syndrome|Muckle Wells Syndrome|Neonatal Onset Multisystem Inflammatory Disease,Drug: Canakinumab (ACZ885),Novartis,Phase 3,Industry,Interventional,27-May-11,https://ClinicalTrials.gov/show/NCT00685373
2824,Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel,Completed,Has Results,Acromegaly,Drug: Somatuline Autogel (lanreotide acetate)|Behavioral: Home administration,Ipsen,Phase 3,Industry,Interventional,20-Dec-10,https://ClinicalTrials.gov/show/NCT00447499
2825,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,Completed,Has Results,Vasomotor Symptoms|Hot Flashes,Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: Estradiol (E2 0.3mg)|Drug: Placebo,Bayer,Phase 3,Industry,Interventional,18-Apr-12,https://ClinicalTrials.gov/show/NCT00446199
2826,A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program,Completed,Has Results,Obesity|Overweight,Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|Drug: Placebo|Behavioral: Intensive group lifestyle modification counseling,"Orexigen Therapeutics, Inc",Phase 3,Industry,Interventional,21-Nov-14,https://ClinicalTrials.gov/show/NCT00456521
2827,Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB),Completed,Has Results,Overactive Bladder,Drug: fesoterodine fumarate|Drug: placebo|Drug: tolterodine tartrate,Pfizer,Phase 3,Industry,Interventional,3-Sep-09,https://ClinicalTrials.gov/show/NCT00444925
2828,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants,Completed,Has Results,"Vaccines, Pneumococcal",Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7vPnC,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,14-Jul-10,https://ClinicalTrials.gov/show/NCT00444457
2829,"Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Completed,Has Results,Onychomycosis,Drug: terbinafine|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,20-Apr-11,https://ClinicalTrials.gov/show/NCT00443898
2830,"Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail",Completed,Has Results,Onychomycosis,Drug: terbinafine|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00443820
2831,Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement,Completed,Has Results,Osteoarthritis|Postoperative Pain,Drug: pregabalin|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,18-Aug-10,https://ClinicalTrials.gov/show/NCT00442546
2832,Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA),Completed,Has Results,Gastric Ulcer|Duodenal Ulcer,Drug: Esomeprazole 40 mg|Drug: Esomeprazole 20 mg|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,13-Feb-12,https://ClinicalTrials.gov/show/NCT00441727
2833,Head to Head Study Against Sevelamer Hydrochloride,Completed,Has Results,"Chronic Kidney Disease, Stage 5",Drug: Fosrenol (Lanthanum Carbonate)|Drug: Sevelamer hydrochloride,Shire,Phase 3,Industry,Interventional,13-Aug-09,https://ClinicalTrials.gov/show/NCT00441545
2834,A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma,Completed,Has Results,Asthma,Drug: fluticasone propionate|Drug: fluticasone propionate/salmeterol,GlaxoSmithKline,Phase 3,Industry,Interventional,23-Sep-10,https://ClinicalTrials.gov/show/NCT00441441
2835,"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.",Completed,Has Results,Anemia,Drug: Mircera|Drug: Darbepoetin alfa,Hoffmann-La Roche,Phase 3,Industry,Interventional,3-Oct-11,https://ClinicalTrials.gov/show/NCT00442702
2836,An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease,Completed,Has Results,Anemia,Drug: Epoetin alfa 3 times weekly /once weekly|Drug: Epoetin alfa once weekly|Drug: Epoetin alfa once every two weeks,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,8-Feb-10,https://ClinicalTrials.gov/show/NCT00440557
2837,PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients,Completed,Has Results,Anemia|Renal Diseases,Drug: epoetin alfa,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,14-Apr-11,https://ClinicalTrials.gov/show/NCT00440466
2838,Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis,Completed,Has Results,Osteoporosis,Drug: Zoledronic acid|Drug: Placebo|Drug: Teriparatide,Novartis,Phase 3,Industry,Interventional,20-Apr-11,https://ClinicalTrials.gov/show/NCT00439244
2839,Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf),Shire,Phase 3,Industry,Interventional,9-Jun-10,https://ClinicalTrials.gov/show/NCT00438815
2840,Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization,Completed,Has Results,Macular Degeneration|Choroidal Neovascularization,Drug: Verteporfin Photodynamic Therapy|Drug: Ranibizumab|Drug: Verteporfin Placebo|Drug: Ranibizumab Placebo,Novartis,Phase 3,Industry,Interventional,19-Apr-11,https://ClinicalTrials.gov/show/NCT00436553
2841,ORTHOVISC Shoulder Osteoarthritis Study,Completed,Has Results,Glenohumeral Osteoarthritis,Device: Orthovisc|Drug: Control,DePuy Mitek,Phase 3,Industry,Interventional,11-Apr-14,https://ClinicalTrials.gov/show/NCT00436969
2842,A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Sunitinib + Capecitabine|Drug: Capecitabine,Pfizer,Phase 3,Industry,Interventional,13-Jan-11,https://ClinicalTrials.gov/show/NCT00435409
2843,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Pioglitazone|Drug: Metformin|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,4-Apr-13,https://ClinicalTrials.gov/show/NCT00432276
2844,Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study,Completed,Has Results,Atrial Fibrillation,Device: Cardioblate System Surgical Ablation System|Procedure: Surgical RF Ablation,Medtronic Cardiovascular,Phase 3,Industry,Interventional,16-Oct-13,https://ClinicalTrials.gov/show/NCT00431834
2845,Efficacy and Safety of Oral Febuxostat in Participants With Gout,Completed,Has Results,Gout,Drug: Febuxostat|Drug: Allopurinol,Takeda,Phase 3,Industry,Interventional,16-Jul-09,https://ClinicalTrials.gov/show/NCT00430248
2846,"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease",Completed,Has Results,Cushing's Disease,Drug: Pasireotide,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-Feb-13,https://ClinicalTrials.gov/show/NCT00434148
2847,A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction,Completed,Has Results,"Cholestasis, Extrahepatic",Device: WallFlex™ Biliary Fully Covered Metal Stent placement,Boston Scientific Corporation,Phase 3,Industry,Interventional,9-Feb-10,https://ClinicalTrials.gov/show/NCT00433771
2848,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Rivastigmine 5 cm^2 transdermal patch|Drug: Rivastigmine 10 cm^2 transdermal patch,Novartis,Phase 3,Industry,Interventional,27-Jun-11,https://ClinicalTrials.gov/show/NCT00428389
2849,Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Rosiglitazone,GlaxoSmithKline,Phase 3,Industry,Interventional,19-May-17,https://ClinicalTrials.gov/show/NCT00428090
2850,Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,Completed,Has Results,Pneumococcal Infections,Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)|Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS),Pfizer,Phase 3,Industry,Interventional,5-Sep-12,https://ClinicalTrials.gov/show/NCT00427895
2851,Expanded Access Program for Maraviroc At Multiple Centers,Completed,Has Results,HIV Infections,Drug: maraviroc,ViiV Healthcare,Phase 3,Industry,Interventional,17-Oct-11,https://ClinicalTrials.gov/show/NCT00426660
2852,A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients,Completed,Has Results,Overactive Bladder,Drug: fesoterodine fumarate,Pfizer,Phase 3,Industry,Interventional,10-Feb-09,https://ClinicalTrials.gov/show/NCT00425100
2853,A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.,Completed,Has Results,Fibromyalgia,Drug: placebo|Drug: Xyrem®,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,10-Jan-12,https://ClinicalTrials.gov/show/NCT00423813
2854,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Completed,Has Results,Bacterial Infections,Drug: ceftaroline|Drug: vancomycin plus aztreonam|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,18-Nov-10,https://ClinicalTrials.gov/show/NCT00423657
2855,Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.,Completed,Has Results,Fibromyalgia,Drug: Xyrem®,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,20-Oct-11,https://ClinicalTrials.gov/show/NCT00423605
2856,Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3),Completed,Has Results,Deep Vein Thrombosis|Pulmonary Embolism,Drug: Enoxaparin|Drug: Apixaban|Drug: Enoxaparin-matching placebo|Drug: Apixaban-matching placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,14-May-14,https://ClinicalTrials.gov/show/NCT00423319
2857,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,Completed,Has Results,Bacterial Infections,Drug: IV Vancomycin plus IV Aztreonam|Drug: Ceftaroline,Forest Laboratories,Phase 3,Industry,Interventional,8-Nov-10,https://ClinicalTrials.gov/show/NCT00424190
2858,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,Completed,Has Results,"Infections, Papillomavirus",Biological: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Biological: Gardasil ® (Merck & Co. Inc)|Biological: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Aug-10,https://ClinicalTrials.gov/show/NCT00423046
2859,Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers,Completed,Has Results,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,"Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Measles, Mumps, Rubella and Varicella","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,2-Jun-11,https://ClinicalTrials.gov/show/NCT00422292
2860,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,Completed,Has Results,Acne Vulgaris,Drug: Adapalene/Benzoyl Peroxide|Drug: Adapalene|Drug: Benzoyl Peroxide|Drug: Topical Gel Vehicle,Galderma,Phase 3,Industry,Interventional,11-Mar-09,https://ClinicalTrials.gov/show/NCT00421993
2861,"A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee",Completed,Has Results,Osteoarthritis|Chronic Pain,Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,30-Oct-09,https://ClinicalTrials.gov/show/NCT00420992
2862,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: BG00012|Drug: Placebo,Biogen,Phase 3,Industry,Interventional,2-Jun-14,https://ClinicalTrials.gov/show/NCT00420212
2863,A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.,Completed,Has Results,Asthma,Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI,AstraZeneca,Phase 3,Industry,Interventional,30-Oct-12,https://ClinicalTrials.gov/show/NCT00419952
2864,"An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",Completed,Has Results,Asthma,Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI,AstraZeneca,Phase 3,Industry,Interventional,27-Aug-12,https://ClinicalTrials.gov/show/NCT00419757
2865,A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Formoterol Turbuhaler,AstraZeneca,Phase 3,Industry,Interventional,16-Sep-10,https://ClinicalTrials.gov/show/NCT00419744
2866,Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures,Completed,Has Results,Epilepsy,Drug: Keppra XR (Levetiracetam XR),UCB Pharma,Phase 3,Industry,Interventional,13-Jul-11,https://ClinicalTrials.gov/show/NCT00419393
2867,Conversion to Monotherapy Study With Keppra XR for Partial Seizures,Completed,Has Results,Epilepsy,Drug: Keppra XR,UCB Pharma,Phase 3,Industry,Interventional,20-Dec-10,https://ClinicalTrials.gov/show/NCT00419094
2868,Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy,Completed,Has Results,Primary Immune Deficiency,Biological: Human Normal Immunoglobulin for Subcutaneous Administration,CSL Behring,Phase 3,Industry,Interventional,25-Jan-13,https://ClinicalTrials.gov/show/NCT00419341
2869,Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions,Completed,Has Results,Cerebral Palsy|Neurological Conditions|Mental Retardation|Sialorrhea,Drug: Oral Glycopyrrolate Liquid,Shionogi|Shionogi Inc.,Phase 3,Industry,Interventional,9-Jul-12,https://ClinicalTrials.gov/show/NCT00491894
2870,"Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain",Completed,Has Results,Pain,Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER),Pfizer,Phase 3,Industry,Interventional,29-Oct-09,https://ClinicalTrials.gov/show/NCT00415597
2871,A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy,Completed,Has Results,Chronic Pancreatitis|Pancreatectomy|Pancreatic Exocrine Insufficiency,Drug: Pancrelipase delayed release capsule|Drug: Placebo Comparator,Solvay Pharmaceuticals,Phase 3,Industry,Interventional,16-Sep-09,https://ClinicalTrials.gov/show/NCT00414908
2872,A Study for Patients With Head and Neck Cancer,Completed,Has Results,Head and Neck Neoplasms,Drug: pemetrexed|Drug: cisplatin|Drug: placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,6-Apr-11,https://ClinicalTrials.gov/show/NCT00415194
2873,"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis",Completed,Has Results,"Arthritis, Rheumatoid","Drug: CP-690,550",Pfizer,Phase 3,Industry,Interventional,27-Mar-18,https://ClinicalTrials.gov/show/NCT00413699
2874,Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).,Completed,Has Results,Generalized Anxiety Disorder,Drug: pregabalin|Drug: placebo,Pfizer,Phase 3,Industry,Interventional,2-Dec-09,https://ClinicalTrials.gov/show/NCT00413010
2875,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Drug: warfarin|Drug: apixaban,Bristol-Myers Squibb,Phase 3,Industry,Interventional,29-Apr-13,https://ClinicalTrials.gov/show/NCT00412984
2876,Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor,Completed,Has Results,Carcinoid Tumor|Malignant Carcinoid Syndrome,Drug: Octreotide|Drug: Placebo|Drug: Everolimus,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,12-Mar-12,https://ClinicalTrials.gov/show/NCT00412061
2877,Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients,Completed,Has Results,Cytomegalovirus Infections,Drug: maribavir|Other: placebo,Shire,Phase 3,Industry,Interventional,3-Jun-15,https://ClinicalTrials.gov/show/NCT00411645
2878,A Study of Abatacept in Patients With Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: abatacept (ABA)|Drug: placebo|Drug: abatacept,Bristol-Myers Squibb,Phase 3,Industry,Interventional,2-Dec-10,https://ClinicalTrials.gov/show/NCT00410410
2879,RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib,Completed,Has Results,Metastatic Renal Cell Carcinoma,Drug: RAD001|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,15-Jan-13,https://ClinicalTrials.gov/show/NCT00410124
2880,Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B,Completed,Has Results,"Hepatitis B, Chronic",Drug: Entecavir|Drug: Entecavir + Tenofovir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,3-Feb-12,https://ClinicalTrials.gov/show/NCT00410072
2881,Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: Adalimumab,Abbott,Phase 3,Industry,Interventional,4-Aug-11,https://ClinicalTrials.gov/show/NCT00409682
2882,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Biological: adalimumab|Biological: placebo,Abbott,Phase 3,Industry,Interventional,31-Mar-11,https://ClinicalTrials.gov/show/NCT00408629
2883,Duloxetine Versus Placebo for Osteoarthritis Knee Pain,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine|Drug: placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,19-Aug-09,https://ClinicalTrials.gov/show/NCT00408421
2884,A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury,Completed,Has Results,Neuralgia|Spinal Cord Injuries,Drug: placebo|Drug: pregabalin,Pfizer,Phase 3,Industry,Interventional,8-Dec-11,https://ClinicalTrials.gov/show/NCT00407745
2885,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women,Completed,Has Results,"Depression|Depressive Disorder|Depressive Disorder, Major",Drug: Desvenlafaxine succinate sustained-release (DVS SR)|Drug: Escitalopram,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,29-Jun-10,https://ClinicalTrials.gov/show/NCT00406640
2886,"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation",Completed,Has Results,"Fibrillation, Atrial",Drug: omega-3-acid ethyl esters|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Oct-10,https://ClinicalTrials.gov/show/NCT00402363
2887,The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms,Completed,Has Results,Vasomotor Symptoms,Drug: desvenlafaxine succinate sustained release|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,12-Oct-11,https://ClinicalTrials.gov/show/NCT00401245
2888,Efficacy and Safety of XP12B in Women With Menorrhagia,Completed,Has Results,Menorrhagia|Heavy Menstrual Bleeding,Drug: Tranexamic acid tablets|Drug: Placebo tablets,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,24-Feb-10,https://ClinicalTrials.gov/show/NCT00401193
2889,A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children,Completed,Has Results,Influenza,Biological: Influsplit Tetra™ vaccine produced by investigational process (IP)|Biological: Influsplit Tetra™ vaccine produced by licensed process (LP),GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jun-16,https://ClinicalTrials.gov/show/NCT02207413
2890,Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine,Completed,Has Results,Parkinson's Disease,Drug: Rotigotine|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,12-Apr-10,https://ClinicalTrials.gov/show/NCT00474058
2891,Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Atrovent Respimat (20 mcg)|Drug: COMBIVENT MDI (36/206 mcg)|Drug: Combivent Respimat (20 mcg/100 mcg)|Drug: Placebo via corresponding inhaler for blinding purposes,Boehringer Ingelheim,Phase 3,Industry,Interventional,1-Jun-09,https://ClinicalTrials.gov/show/NCT00400153
2892,Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery,Completed,Has Results,Postoperative Pain|Hysterectomy,Drug: IV Acetaminophen|Drug: IV Placebo 100 mL solution,Mallinckrodt,Phase 3,Industry,Interventional,10-Dec-10,https://ClinicalTrials.gov/show/NCT00399568
2893,Fluticasone Nasal Spray Patient Preference Study,Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: fluticasone propionate (FP)|Drug: fluticasone furoate (FF),GlaxoSmithKline,Phase 3,Industry,Interventional,29-Jan-18,https://ClinicalTrials.gov/show/NCT00398476
2894,"Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature",Completed,Has Results,Idiopathic Short Stature,Drug: Genotropin,Pfizer,Phase 3,Industry,Interventional,13-Nov-13,https://ClinicalTrials.gov/show/NCT00396097
2895,Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Pioglitazone|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,27-Mar-13,https://ClinicalTrials.gov/show/NCT00395512
2896,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),Completed,Has Results,Early Breast Cancer,Biological: PF-05280014|Drug: Taxotere®|Drug: Paraplatin®|Biological: Trastuzumab-EU,Pfizer,Phase 3,Industry,Interventional,7-Apr-17,https://ClinicalTrials.gov/show/NCT02187744
2897,A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome,Completed,Has Results,Acute Coronary Syndrome,Drug: Ticagrelor|Drug: Clopidogrel,AstraZeneca,Phase 3,Industry,Interventional,13-Mar-12,https://ClinicalTrials.gov/show/NCT00391872
2898,Study of Safety and Efficacy of an Oral Contraceptive,Completed,Has Results,Contraception,Drug: Norethindrone acetate/ethinyl estradiol,Warner Chilcott,Phase 3,Industry,Interventional,22-Dec-10,https://ClinicalTrials.gov/show/NCT00391807
2899,BUILD 3: Bosentan Use in Interstitial Lung Disease,Completed,Has Results,Idiopathic Pulmonary Fibrosis,Drug: Bosentan|Drug: Placebo,Actelion,Phase 3,Industry,Interventional,25-May-12,https://ClinicalTrials.gov/show/NCT00391443
2900,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly",Completed,Has Results,Orthomyxoviridae Infection|Influenza|Myxovirus Infection,"Biological: High-Dose Inactivated, Split-Virion Influenza Vaccine|Biological: Inactivated, Split-Virion Influenza Vaccine","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,30-Apr-10,https://ClinicalTrials.gov/show/NCT00391053
2901,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,Completed,Has Results,"Lung Cancer, Non-Small Cell","Drug: HYCAMTIN, oral capsules|Radiation: Radiation",GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jan-14,https://ClinicalTrials.gov/show/NCT00390806
2902,Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients,Completed,Has Results,HIV Infections,Drug: miconazole Lauriad|Drug: Clotrimazole,Onxeo,Phase 3,Industry,Interventional,29-Aug-13,https://ClinicalTrials.gov/show/NCT00390780
2903,Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder,Completed,Has Results,Anxiety Disorders,Drug: Quetiapine XR|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,23-Jun-09,https://ClinicalTrials.gov/show/NCT00389064
2904,Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis,Drug: Tobramycin Inhalation Powder|Drug: Tobramycin Solution for Inhalation,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,24-Jul-12,https://ClinicalTrials.gov/show/NCT00388505
2905,Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Quetiapine,AstraZeneca,Phase 3,Industry,Interventional,1-Apr-10,https://ClinicalTrials.gov/show/NCT00388973
2906,TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1),Completed,Has Results,"Migraine, Without Aura",Drug: sumatriptan succinate / naproxen sodium|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Jul-09,https://ClinicalTrials.gov/show/NCT00387881
2907,Tiotropium / Respimat One Year Study in COPD.,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Device: Respimat|Drug: Tiotropium,Boehringer Ingelheim,Phase 3,Industry,Interventional,22-Jan-10,https://ClinicalTrials.gov/show/NCT00387088
2908,ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,Completed,Has Results,Metastatic Colorectal Cancer,Drug: Cetuximab|Drug: Panitumumab,Amgen,Phase 3,Industry,Interventional,24-Mar-14,https://ClinicalTrials.gov/show/NCT01001377
2909,Efficacy and Safety Study of XP12B in Women With Menorrhagia,Completed,Has Results,Menorrhagia|Heavy Menstrual Bleeding,Drug: Tranexamic acid tablets|Drug: Placebo tablets,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,22-Feb-10,https://ClinicalTrials.gov/show/NCT00386308
2910,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Biological: adalimumab|Biological: placebo,Abbott,Phase 3,Industry,Interventional,27-May-10,https://ClinicalTrials.gov/show/NCT00385736
2911,"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers",Completed,Has Results,Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella,Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,2-Jun-11,https://ClinicalTrials.gov/show/NCT00384397
2912,"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults",Completed,Has Results,Acellular Pertussis|Diphtheria|Tetanus,Biological: Fluarix®|Biological: Boostrix®,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Sep-18,https://ClinicalTrials.gov/show/NCT00385255
2913,Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection,Completed,Has Results,"Hepatitis B, Chronic",Drug: entecavir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,31-May-12,https://ClinicalTrials.gov/show/NCT00395018
2914,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: Placebo|Drug: Duloxetine 60 mg/day,Pfizer,Phase 3,Industry,Interventional,15-Mar-12,https://ClinicalTrials.gov/show/NCT00384033
2915,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2),Completed,Has Results,Migraine Disorders,Drug: Combination Product (sumatriptan succinate / naproxen sodium)|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Feb-10,https://ClinicalTrials.gov/show/NCT00383162
2916,Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children,Completed,Has Results,Influenza,Biological: Fluarix™|Biological: Fluzone,GlaxoSmithKline,Phase 3,Industry,Interventional,4-Dec-08,https://ClinicalTrials.gov/show/NCT00383123
2917,A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2),Completed,Has Results,Migraine Disorders,Drug: Placebo|Drug: Combination Product (sumatriptan succinate/naproxen sodium),GlaxoSmithKline,Phase 3,Industry,Interventional,20-Apr-10,https://ClinicalTrials.gov/show/NCT00382993
2918,Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy,Completed,Has Results,"Colonoscopy|Endoscopy, Digestive System|Conscious Sedation",Device: Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|Other: benzodiazepines and opioid sedation,Ethicon Endo-Surgery,Phase 3,Industry,Interventional,25-Jan-11,https://ClinicalTrials.gov/show/NCT00452426
2919,Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension,Completed,Has Results,Pulmonary Hypertension,Drug: Ambrisentan,Gilead Sciences,Phase 3,Industry,Interventional,19-Nov-10,https://ClinicalTrials.gov/show/NCT00380068
2920,A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,Completed,Has Results,Kidney Neoplasms,Drug: Sunitinib malate|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,18-Aug-17,https://ClinicalTrials.gov/show/NCT00375674
2921,Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: lapatinib|Other: placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,18-Aug-14,https://ClinicalTrials.gov/show/NCT00374322
2922,Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine,Completed,Has Results,"Vaccines, Pneumococcal",Biological: 13 valent pneumococcal conjugate vaccine|Biological: 7vPnc pneumococcal conjugate vaccine,Pfizer,Phase 3,Industry,Interventional,21-Feb-13,https://ClinicalTrials.gov/show/NCT00373958
2923,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Erlotinib|Drug: Placebo,OSI Pharmaceuticals|Astellas Pharma Inc,Phase 3,Industry,Interventional,3-Jun-14,https://ClinicalTrials.gov/show/NCT00373425
2924,Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease|GERD|Heartburn,Drug: nizatidine (axid)|Drug: placebo,Braintree Laboratories,Phase 3,Industry,Interventional,17-Nov-09,https://ClinicalTrials.gov/show/NCT00373334
2925,A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Sunitinib|Drug: paclitaxel|Drug: bevacizumab,Pfizer,Phase 3,Industry,Interventional,8-Oct-10,https://ClinicalTrials.gov/show/NCT00373256
2926,Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery,Completed,Has Results,Deep Vein Thrombosis|Pulmonary Embolism,Drug: Enoxaparin + Placebo|Drug: Apixaban + Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,30-Dec-15,https://ClinicalTrials.gov/show/NCT00371683
2927,A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia,Completed,Has Results,Fibromyalgia,Drug: Xyrem®|Drug: Placebo,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,30-Nov-11,https://ClinicalTrials.gov/show/NCT00371137
2928,RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag,Completed,Has Results,"Purpura, Thrombocytopaenic, Idiopathic",Drug: eltrombopag|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,23-Feb-10,https://ClinicalTrials.gov/show/NCT00370331
2929,Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects,Completed,Has Results,"Infections, Papillomavirus",Biological: Different formulations of GSK Biologicals' HPV vaccine (580299)|Biological: Menactra TM|Biological: Boostrix TM,GlaxoSmithKline,Phase 3,Industry,Interventional,8-Oct-09,https://ClinicalTrials.gov/show/NCT00369824
2930,Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women,Completed,Has Results,"Depression|Depressive Disorder|Depressive Disorder, Major",Drug: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|Drug: Placebo,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,7-May-12,https://ClinicalTrials.gov/show/NCT00369343
2931,"Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations",Completed,Has Results,Parkinson's Disease,Drug: 2 mg perampanel|Drug: 4 mg perampanel|Drug: placebo comparator,Eisai Inc.,Phase 3,Industry,Interventional,5-Feb-13,https://ClinicalTrials.gov/show/NCT00368108
2932,SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms,Completed,Has Results,ADHD,Drug: SPD503 (Guanfacine hydrochloride)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,26-Nov-09,https://ClinicalTrials.gov/show/NCT00367835
2933,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Sunitinib malate|Drug: Taxotere,Pfizer,Phase 3,Industry,Interventional,28-Feb-11,https://ClinicalTrials.gov/show/NCT00393939
2934,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,Completed,Has Results,Bacterial Infections|Diabetic Foot|Osteomyelitis,Drug: Tigecycline|Drug: Ertapenem,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,21-Aug-09,https://ClinicalTrials.gov/show/NCT00366249
2935,Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole|Drug: Placebo,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,7-Jan-10,https://ClinicalTrials.gov/show/NCT00365300
2936,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Vandetanib|Drug: Erlotinib,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,24-May-11,https://ClinicalTrials.gov/show/NCT00364351
2937,Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer,Completed,Has Results,Small Cell Lung Cancer,Drug: pemetrexed|Drug: etoposide|Drug: carboplatin,Eli Lilly and Company,Phase 3,Industry,Interventional,6-Oct-09,https://ClinicalTrials.gov/show/NCT00363415
2938,A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects,Completed,Has Results,"HIV Infection|Infection, Human Immunodeficiency Virus",Drug: Half-boosted Fosamprenavir|Drug: Full Boosted Fosamprenavir,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Sep-09,https://ClinicalTrials.gov/show/NCT00363142
2939,Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD,Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,14-May-10,https://ClinicalTrials.gov/show/NCT00362609
2940,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,Completed,Has Results,Venous Thromboembolism,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Enoxaparin|Drug: Placebo: tablet of Rivaroxaban|Drug: Placebo: syringes of Enoxaparin",Bayer,Phase 3,Industry,Interventional,13-Jun-12,https://ClinicalTrials.gov/show/NCT00362232
2941,"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy",Completed,Has Results,Menopause,Drug: DR-2041a|Drug: DR-2041b|Other: Placebo,Duramed Research|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,14-Apr-09,https://ClinicalTrials.gov/show/NCT00361569
2942,Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin|Drug: flibanserin 50mg|Drug: flibanserin 100mg|Drug: placebo,"Sprout Pharmaceuticals, Inc",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT00360555
2943,24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin,"Sprout Pharmaceuticals, Inc",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT00360529
2944,Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS),Completed,Has Results,Menorrhagia,"Drug: Levonorgestrel IUS (Mirena, BAY86-5028)|Drug: Medroxyprogesterone acetate",Bayer,Phase 3,Industry,Interventional,19-Nov-09,https://ClinicalTrials.gov/show/NCT00360490
2945,6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA,Completed,Has Results,"Sexual Dysfunctions, Psychological",Drug: flibanserin|Drug: placebo,"Sprout Pharmaceuticals, Inc",Phase 3,Industry,Interventional,27-Jun-16,https://ClinicalTrials.gov/show/NCT00360243
2946,"Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB",Completed,Has Results,Neisseria Meningitidis|Haemophilus Influenzae Type b,Biological: MenHibrix (Hib-MenCY-TT)|Biological: Hib conjugate vaccine (ActHIB),GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jul-12,https://ClinicalTrials.gov/show/NCT00359983
2947,An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).,Completed,Has Results,HIV-1,Drug: TMC125,"Tibotec Pharmaceuticals, Ireland",Phase 3,Industry,Interventional,7-Mar-13,https://ClinicalTrials.gov/show/NCT00359021
2948,Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients,Completed,Has Results,Severe Hepatic Veno-Occlusive Disease,Drug: Defibrotide,Jazz Pharmaceuticals|FDA Office of Orphan Products Development,Phase 3,Industry|U.S. Fed,Interventional,30-Jan-17,https://ClinicalTrials.gov/show/NCT00358501
2949,Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Aclidinium bromide|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,1-Nov-12,https://ClinicalTrials.gov/show/NCT00358436
2950,RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial,Completed,Has Results,Heart Failure|Anemia|Cardiovascular Disease|Ventricular Dysfunction|Congestive Heart Failure,Drug: Darbepoetin alfa|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,13-Dec-13,https://ClinicalTrials.gov/show/NCT00358215
2951,"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease",Completed,Has Results,Crohn's Disease,Biological: Certolizumab pegol,UCB Pharma,Phase 3,Industry,Interventional,25-May-11,https://ClinicalTrials.gov/show/NCT00356408
2952,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Fingolimod|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,26-Jun-12,https://ClinicalTrials.gov/show/NCT00355134
2953,Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy,Completed,Has Results,"Epilepsy, Partial","Drug: lamotrigine, 300 mg/day|Drug: lamotrigine, 250 mg/day",GlaxoSmithKline,Phase 3,Industry,Interventional,25-Nov-09,https://ClinicalTrials.gov/show/NCT00355082
2954,EXTEND (Eltrombopag Extended Dosing Study),Completed,Has Results,"Purpura, Thrombocytopaenic, Idiopathic",Drug: eltrombopag olamine (SB-497115-GR),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-Apr-17,https://ClinicalTrials.gov/show/NCT00351468
2955,A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo,Completed,Has Results,Overactive Bladder,Drug: Oxybutynin topical gel|Other: Placebo topical gel,Watson Pharmaceuticals,Phase 3,Industry,Interventional,10-May-10,https://ClinicalTrials.gov/show/NCT00350636
2956,Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes,Completed,Has Results,Diabetes Mellitus,Drug: Insulin Lispro|Drug: Exubera,Pfizer,Phase 3,Industry,Interventional,16-Mar-10,https://ClinicalTrials.gov/show/NCT00348374
2957,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Sep-17,https://ClinicalTrials.gov/show/NCT00348140
2958,The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial,Completed,Has Results,Hypertension,Drug: lisinopril|Drug: carvedilol controlled release formulation,GlaxoSmithKline,Phase 3,Industry,Interventional,9-Nov-09,https://ClinicalTrials.gov/show/NCT00347360
2959,Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years,Completed,Has Results,Acellular Pertussis|Diphtheria|Tetanus,Biological: Boostrix™|Biological: ADACEL®,GlaxoSmithKline,Phase 3,Industry,Interventional,7-Aug-18,https://ClinicalTrials.gov/show/NCT00346073
2960,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",Completed,Has Results,Haemophilus Influenzae Type b|Neisseria Meningitidis,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Biological: PedvaxHIB|Biological: Prevnar|Biological: M-M-R II|Biological: Varivax,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jul-12,https://ClinicalTrials.gov/show/NCT00345683
2961,Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device,Completed,Has Results,"Angioplasty, Transluminal, Percutaneous Coronary|Coronary Arteriosclerosis|Peripheral Arteriosclerosis",Other: Manual Compression|Device: Vascular Closure Device,Cordis Corporation,Phase 3,Industry,Interventional,19-Mar-12,https://ClinicalTrials.gov/show/NCT00345631
2962,"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",Completed,Has Results,Haemophilus Influenzae Type b|Neisseria Meningitidis,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|Biological: ActHIB|Biological: Pediarix/Infanrix Penta,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jul-12,https://ClinicalTrials.gov/show/NCT00345579
2963,APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer,Completed,Has Results,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",Drug: APF530|Drug: dexamethasone|Drug: Palonosetron Hydrochloride|Other: placebo,Heron Therapeutics,Phase 3,Industry,Interventional,28-Dec-16,https://ClinicalTrials.gov/show/NCT00343460
2964,Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis,Completed,Has Results,"Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture",Drug: teriparatide|Drug: risedronate|Drug: placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,12-Jul-10,https://ClinicalTrials.gov/show/NCT00343252
2965,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,Completed,Has Results,Multiple Sclerosis,Drug: Fingolimod 1.25 mg|Drug: Fingolimod 0.5 mg|Drug: Interferon β-1a 30 µg,Novartis,Phase 3,Industry,Interventional,16-May-11,https://ClinicalTrials.gov/show/NCT00340834
2966,Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children,Completed,Has Results,HIV Infections,Drug: Tenofovir DF|Drug: Zidovudine|Drug: Stavudine,Gilead Sciences,Phase 3,Industry,Interventional,22-Mar-12,https://ClinicalTrials.gov/show/NCT00528957
2967,A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy,Completed,Has Results,Breast Cancer|Neoplasm Metastasis,Other: Standard supportive care (packed RBC transfusion)|Drug: epoetin alfa + packed RBC transfusion,"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,24-Mar-16,https://ClinicalTrials.gov/show/NCT00338286
2968,E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes,Completed,Has Results,Metastatic Breast Cancer,Drug: Eribulin Mesylate|Drug: Capecitabine,Eisai Inc.,Phase 3,Industry,Interventional,30-Sep-13,https://ClinicalTrials.gov/show/NCT00337103
2969,A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Biological: infliximab,"Centocor, Inc.",Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00336492
2970,Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia,Completed,Has Results,Pneumonia,Drug: Cethromycin|Drug: Clarithromycin,"Advanced Life Sciences, Inc.",Phase 3,Industry,Interventional,26-Feb-10,https://ClinicalTrials.gov/show/NCT00336544
2971,Cancer Venous Thromboembolism (VTE),Completed,Has Results,Venous Thromboembolism (VTE)|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Cancer,Drug: Edoxaban|Drug: Dalteparin|Drug: Low molecular weight heparin,"Daiichi Sankyo, Inc.",Phase 3,Industry,Interventional,24-Oct-18,https://ClinicalTrials.gov/show/NCT02073682
2972,Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures,Completed,Has Results,Epilepsy,Drug: Placebo|Drug: Rufinamide,Eisai Inc.,Phase 3,Industry,Interventional,5-Feb-13,https://ClinicalTrials.gov/show/NCT00334958
2973,Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia,Completed,Has Results,Chronic Myelogenous Leukemia,Drug: imatinib mesilate|Drug: interferon-alpha (INF-a)|Drug: cytarabine (ARA-C),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,14-Oct-13,https://ClinicalTrials.gov/show/NCT00333840
2974,Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: Certolizumab pegol (CDP870),UCB Pharma,Phase 3,Industry,Interventional,12-Jul-11,https://ClinicalTrials.gov/show/NCT00333788
2975,Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Technosphere Insulin|Drug: Metformin & Secretagogues|Drug: Technosphere Insulin & Metformin,Mannkind Corporation,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT00332488
2976,PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,Completed,Has Results,Non Hodgkin Lymphoma,Drug: enzastaurin|Drug: placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,10-Sep-18,https://ClinicalTrials.gov/show/NCT00332202
2977,Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006,Completed,Has Results,Phenylketonuria,Drug: sapropterin dihydrochloride,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,16-Nov-12,https://ClinicalTrials.gov/show/NCT00332189
2978,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease,Completed,Has Results,Pneumococcal Conjugate Vaccine,Biological: 13-valent Pneumoccocal Conjugate Vaccine,Pfizer,Phase 3,Industry,Interventional,21-Apr-14,https://ClinicalTrials.gov/show/NCT00918580
2979,Secondary Prevention of Venous Thrombo Embolism (VTE).,Completed,Has Results,Thromboembolism,Drug: Dabigatran|Drug: Warfarin,Boehringer Ingelheim,Phase 3,Industry,Interventional,14-Sep-11,https://ClinicalTrials.gov/show/NCT00329238
2980,Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin|Drug: Alogliptin placebo|Drug: Pioglitazone|Drug: Pioglitazone placebo,Takeda,Phase 3,Industry,Interventional,4-Apr-13,https://ClinicalTrials.gov/show/NCT00328627
2981,A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Completed,Has Results,Diabetes,Drug: Saxagliptin|Drug: Metformin|Drug: Placebo|Drug: pioglitazone,AstraZeneca,Phase 3,Industry,Interventional,25-Sep-09,https://ClinicalTrials.gov/show/NCT00327015
2982,FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Pulmonary Hypertension,Drug: Oral treprostinil (UT-15C) sustained release tablets|Drug: Placebo,United Therapeutics,Phase 3,Industry,Interventional,10-Jun-13,https://ClinicalTrials.gov/show/NCT00325442
2983,FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Pulmonary Hypertension,Drug: Oral treprostinil (UT-15C) Sustained Release Tablets|Other: Placebo,United Therapeutics,Phase 3,Industry,Interventional,18-Mar-13,https://ClinicalTrials.gov/show/NCT00325403
2984,Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout,Completed,Has Results,Gout,Other: placebo|Biological: pegloticase,Savient Pharmaceuticals,Phase 3,Industry,Interventional,25-Feb-11,https://ClinicalTrials.gov/show/NCT00325195
2985,A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma,Completed,Has Results,Open-Angle Glaucoma,Device: iStent plus Cataract Surgery|Procedure: Cataract surgery only,Glaukos Corporation,Phase 3,Industry,Interventional,4-Oct-12,https://ClinicalTrials.gov/show/NCT00323284
2986,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,Completed,Has Results,Dementia of the Alzheimer's Type,Drug: memantine ER|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,16-Sep-10,https://ClinicalTrials.gov/show/NCT00322153
2987,Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours,Completed,Has Results,Endocrine Tumors,Drug: lanreotide (Autogel formulation)|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,18-Feb-15,https://ClinicalTrials.gov/show/NCT00353496
2988,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00321984
2989,Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis,Completed,Has Results,"Esophagitis, Reflux|Esophagitis, Peptic",Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,28-Aug-09,https://ClinicalTrials.gov/show/NCT00321737
2990,Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Zoledronic acid|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,4-Aug-14,https://ClinicalTrials.gov/show/NCT00320710
2991,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib|Biological: Trastuzumab,GlaxoSmithKline,Phase 3,Industry,Interventional,30-Nov-11,https://ClinicalTrials.gov/show/NCT00320385
2992,Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia,Completed,Has Results,Schizophrenia,Drug: olanzapine|Drug: olanzapine pamoate depot,Eli Lilly and Company,Phase 3,Industry,Interventional,22-Oct-10,https://ClinicalTrials.gov/show/NCT00320489
2993,Bosentan in Digital Ulcers,Completed,Has Results,Digital Ulcers,Drug: Bosentan 62.5 mg|Drug: Bosentan 125 mg,Actelion,Phase 3,Industry,Interventional,8-Aug-12,https://ClinicalTrials.gov/show/NCT00319696
2994,Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.,Completed,Has Results,"Seizures|Epilepsies, Partial|Epilepsy, Complex Partial|Epilepsy, Generalized|Epilepsy",Drug: Placebo|Drug: Vanquix Auto-Injector (Diazepam Injection),Pfizer,Phase 3,Industry,Interventional,16-Aug-16,https://ClinicalTrials.gov/show/NCT00319501
2995,A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I),Completed,Has Results,Acute Myelogenous Leukemia,Drug: clofarabine (IV formulation)|Drug: placebo|Drug: cytarabine,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,15-Sep-11,https://ClinicalTrials.gov/show/NCT00317642
2996,Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID),Completed,Has Results,Agammaglobulinemia|IgG Deficiency|Common Variable Immunodeficiency,Drug: Immunoglobulins Intravenous (Human),CSL Behring,Phase 3,Industry,Interventional,26-Oct-12,https://ClinicalTrials.gov/show/NCT00322556
2997,Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Completed,Has Results,Diabetes,Drug: Saxagliptin|Drug: Placebo|Drug: metformin,AstraZeneca,Phase 3,Industry,Interventional,25-Sep-09,https://ClinicalTrials.gov/show/NCT00316082
2998,The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.,Completed,Has Results,Back Pain,Drug: Buprenorphine transdermal patch|Drug: Placebo oxycodone/acetaminophen tablets|Drug: OXY/APAP|Drug: Placebo transdermal patch (TDS),Purdue Pharma LP,Phase 3,Industry,Interventional,10-Aug-11,https://ClinicalTrials.gov/show/NCT00315445
2999,Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.,Completed,Has Results,Encephalitis|Japanese Encephalitis,"Biological: ChimeriVax-JE, Japanese Encephalitis vaccine|Biological: 0.9% Saline",Sanofi,Phase 3,Industry,Interventional,5-Dec-12,https://ClinicalTrials.gov/show/NCT00314132
3000,Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch|Drug: Placebo,Purdue Pharma LP,Phase 3,Industry,Interventional,28-Sep-10,https://ClinicalTrials.gov/show/NCT00313846
3001,A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas,Completed,Has Results,Diabetes,Drug: Saxagliptin|Drug: Glyburide|Drug: Placebo|Drug: Metformin,AstraZeneca,Phase 3,Industry,Interventional,25-Sep-09,https://ClinicalTrials.gov/show/NCT00313313
3002,Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain,Completed,Has Results,Osteoarthritis,Drug: Buprenorphine transdermal patch,Purdue Pharma LP,Phase 3,Industry,Interventional,23-Sep-10,https://ClinicalTrials.gov/show/NCT00312572
3003,3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects,Completed,Has Results,Bipolar Disorder,Drug: Placebo|Drug: Ziprasidone,Pfizer,Phase 3,Industry,Interventional,22-Jan-10,https://ClinicalTrials.gov/show/NCT00312494
3004,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,Completed,Has Results,Non-small Cell Lung Cancer|Lung Cancer,Drug: Docetaxel|Drug: Vandetanib,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,24-May-11,https://ClinicalTrials.gov/show/NCT00312377
3005,Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial,Completed,Has Results,Epilepsy,Drug: Ezogabine: USAN Retigabine (International Nonproprietary Name),GlaxoSmithKline,Phase 3,Industry,Interventional,25-Nov-16,https://ClinicalTrials.gov/show/NCT00310375
3006,Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up,Completed,Has Results,Diabetes Type 2,Drug: Technosphere® Insulin Inhalation Powder|Drug: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin),Mannkind Corporation,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT00309244
3007,Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes,Completed,Has Results,"Diabetes, Type 1|Diabetes, Type 2",Drug: Technosphere® Insulin Inhalation Powder|Drug: Usual Care,Mannkind Corporation,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT00308737
3008,Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor,Completed,Has Results,"Cervical Ripening|Labor, Induced",Drug: Misoprostol vaginal insert 100 mcg|Drug: Misoprostol vaginal insert 50 mcg|Drug: Dinoprostone vaginal insert (Cervidil),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,19-Feb-10,https://ClinicalTrials.gov/show/NCT00308711
3009,Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab,Completed,Has Results,Crohn's Disease,Biological: Certolizumab pegol|Other: Placebo,UCB Pharma,Phase 3,Industry,Interventional,17-Nov-09,https://ClinicalTrials.gov/show/NCT00308581
3010,Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes,Completed,Has Results,"Diabetes, Type I",Drug: Technosphere Insulin|Drug: Active comparator,Mannkind Corporation,Phase 3,Industry,Interventional,16-Oct-14,https://ClinicalTrials.gov/show/NCT00308308
3011,Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1),Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: exenatide, long acting release|Drug: exenatide",AstraZeneca,Phase 3,Industry,Interventional,17-Aug-12,https://ClinicalTrials.gov/show/NCT00308139
3012,A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis,Completed,Has Results,Psoriasis,Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Drug: Ustekinumab (CNTO 1275) 45 mg|Drug: Ustekinumab (CNTO 1275) 90 mg,"Centocor Research & Development, Inc.",Phase 3,Industry,Interventional,2-Nov-12,https://ClinicalTrials.gov/show/NCT00307437
3013,SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System,Completed,Has Results,Coronary Artery Disease,Device: XIENCE V® Everolimus Eluting Coronary Stent|Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent,Abbott Medical Devices,Phase 3,Industry,Interventional,21-Oct-10,https://ClinicalTrials.gov/show/NCT00307047
3014,Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes,Completed,Has Results,Genital Herpes,Drug: Famciclovir|Drug: Valacyclovir|Drug: Placebo matching famciclovir|Drug: Placebo matching valacyclovir,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-Jun-11,https://ClinicalTrials.gov/show/NCT00306787
3015,Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin,Takeda,Phase 3,Industry,Interventional,22-Mar-13,https://ClinicalTrials.gov/show/NCT00306384
3016,Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection,Completed,Has Results,Graft Rejection,Drug: everolimus|Drug: mycophenolate mofetil|Drug: cyclosporine|Drug: corticosteroids,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,16-Aug-12,https://ClinicalTrials.gov/show/NCT00300274
3017,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Roflumilast|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,19-May-11,https://ClinicalTrials.gov/show/NCT00297115
3018,Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124),Completed,Has Results,Chronic Obstructive Pulmonary Disease (COPD),Drug: Roflumilast|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,19-May-11,https://ClinicalTrials.gov/show/NCT00297102
3019,The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix|Drug: Leuprolide 7.5 mg,Ferring Pharmaceuticals,Phase 3,Industry,Interventional,16-Apr-09,https://ClinicalTrials.gov/show/NCT00295750
3020,A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Saxagliptin|Drug: Placebo|Drug: pioglitazone|Drug: rosiglitazone|Drug: metformin,AstraZeneca,Phase 3,Industry,Interventional,25-Sep-09,https://ClinicalTrials.gov/show/NCT00295633
3021,IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients,Completed,Has Results,Cytomegalovirus Infections,Drug: Valganciclovir,Hoffmann-La Roche,Phase 3,Industry,Interventional,5-Jul-10,https://ClinicalTrials.gov/show/NCT00294515
3022,Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older,Completed,Has Results,"Infections, Papillomavirus",Biological: Cervarix|Biological: Placebo control,GlaxoSmithKline,Phase 3,Industry,Interventional,27-Mar-12,https://ClinicalTrials.gov/show/NCT00294047
3023,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,Completed,Has Results,Metrorrhagia,"Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,6-Jun-11,https://ClinicalTrials.gov/show/NCT00293059
3024,C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study),Completed,Has Results,Hereditary Angioedema,Drug: C1 Esterase Inhibitor,CSL Behring,Phase 3,Industry,Interventional,23-Jun-11,https://ClinicalTrials.gov/show/NCT00292981
3025,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,Completed,Has Results,Thromboembolism,Drug: dabigatran etexilate 150 mg|Drug: warfarin (INR 2-3),Boehringer Ingelheim,Phase 3,Industry,Interventional,11-Feb-11,https://ClinicalTrials.gov/show/NCT00291330
3026,VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia,Completed,Has Results,Insomnia,Drug: 20 mg VEC-162|Drug: 50 mg VEC-162|Drug: 100 mg VEC-162|Drug: Placebo,Vanda Pharmaceuticals,Phase 3,Industry,Interventional,15-Oct-14,https://ClinicalTrials.gov/show/NCT00291187
3027,Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine,Completed,Has Results,Haemophilus Influenzae Type b|Neisseria Meningitidis,Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|Biological: ActHIB|Biological: PedvaxHIB|Biological: Pediarix|Biological: Prevnar|Biological: M-M-R II|Biological: Varivax,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Aug-12,https://ClinicalTrials.gov/show/NCT00289783
3028,Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients,Completed,Has Results,Pain,Drug: Caldolor|Other: Normal Saline,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,8-Dec-11,https://ClinicalTrials.gov/show/NCT00470600
3029,C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 esterase inhibitor [human] (C1INH-nf)|Drug: Placebo (saline),Shire,Phase 3,Industry,Interventional,2-Jun-10,https://ClinicalTrials.gov/show/NCT00289211
3030,Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS),Completed,Has Results,"Familial Cold Autoinflammatory Syndrome (FCAS)|Familial Cold Urticaria|Muckle-Wells Syndrome (MWS)|Genetic Diseases, Inborn",Drug: rilonacept 160 mg|Drug: Placebo,Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,13-Nov-09,https://ClinicalTrials.gov/show/NCT00288704
3031,Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia,Completed,Has Results,Cervical Dystonia,Drug: abobotulinumtoxinA (Dysport) 250-1000 units,Ipsen,Phase 3,Industry,Interventional,2-Apr-10,https://ClinicalTrials.gov/show/NCT00288509
3032,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and pioglitazone|Drug: Pioglitazone,Takeda,Phase 3,Industry,Interventional,27-Sep-11,https://ClinicalTrials.gov/show/NCT00286494
3033,Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and glyburide|Drug: Glyburide,Takeda,Phase 3,Industry,Interventional,25-Aug-11,https://ClinicalTrials.gov/show/NCT00286468
3034,Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,29-Aug-11,https://ClinicalTrials.gov/show/NCT00286455
3035,Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and metformin|Drug: Metformin,Takeda,Phase 3,Industry,Interventional,25-Aug-11,https://ClinicalTrials.gov/show/NCT00286442
3036,Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin and insulin|Drug: Insulin,Takeda,Phase 3,Industry,Interventional,12-Aug-11,https://ClinicalTrials.gov/show/NCT00286429
3037,Treatment for Migraines With an Implantable Device,Completed,Has Results,Migraine,Device: Precision,Boston Scientific Corporation,Phase 3,Industry,Interventional,9-Aug-16,https://ClinicalTrials.gov/show/NCT00286078
3038,Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).,Completed,Has Results,Smoking Cessation,Drug: placebo|Drug: Varenicline Tartarate,Pfizer,Phase 3,Industry,Interventional,3-Dec-09,https://ClinicalTrials.gov/show/NCT00285012
3039,A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.,Completed,Has Results,Bipolar Disorder,Drug: Placebo|Drug: Geodon (Ziprasidone),Pfizer,Phase 3,Industry,Interventional,2-Jun-09,https://ClinicalTrials.gov/show/NCT00282464
3040,Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension,Completed,Has Results,Hypertension,Drug: Amlodipine 5 mg|Drug: Placebo|Drug: Telmisartan 20 mg|Drug: Telmisartan 40 mg|Drug: Amlodipine 10 mg|Drug: Telmisartan 80 mg|Drug: Amlodipine 2.5 mg,Boehringer Ingelheim,Phase 3,Industry,Interventional,28-Apr-10,https://ClinicalTrials.gov/show/NCT00281580
3041,Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed),Completed,Has Results,Bipolar Mania|Bipolar Disorder,Drug: Placebo|Drug: Ziprasidone Oral Capsule,Pfizer,Phase 3,Industry,Interventional,14-Dec-09,https://ClinicalTrials.gov/show/NCT00280566
3042,COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension,Completed,Has Results,Hypertension,Drug: Carvedilol Phosphate modified release formulation|Drug: metoprolol succinate,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Feb-10,https://ClinicalTrials.gov/show/NCT00273052
3043,Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon,Completed,Has Results,Crohn's Disease,Biological: adalimumab|Biological: placebo,Abbott,Phase 3,Industry,Interventional,11-Feb-10,https://ClinicalTrials.gov/show/NCT00348283
3044,Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q),Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: Beclomethasone dipropionate|Drug: Flunisolide,GlaxoSmithKline,Phase 3,Industry,Interventional,6-Dec-17,https://ClinicalTrials.gov/show/NCT00346775
3045,The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency,Completed,Has Results,Alpha 1-Antitrypsin Deficiency,Drug: alpha-1 proteinase inhibitor (human),Grifols Therapeutics LLC,Phase 3,Industry,Interventional,19-Aug-14,https://ClinicalTrials.gov/show/NCT00301366
3046,A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis,Completed,Has Results,Psoriasis,Drug: ustekinumab|Drug: placebo,"Centocor Research & Development, Inc.",Phase 3,Industry,Interventional,24-Aug-12,https://ClinicalTrials.gov/show/NCT00267969
3047,Treatment for Completers of the Study B7A-MC-MBCM,Completed,Has Results,Diabetic Retinopathy,Drug: Ruboxistaurin,"Chromaderm, Inc.",Phase 3,Industry,Interventional,28-Jan-16,https://ClinicalTrials.gov/show/NCT00266695
3048,Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed),Completed,Has Results,Bipolar Disorder,Drug: Ziprasidone oral capsules,Pfizer,Phase 3,Industry,Interventional,3-Apr-09,https://ClinicalTrials.gov/show/NCT00265330
3049,Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy,Completed,Has Results,Peripheral Neuropathy|HIV Infections,Drug: pregabalin,Pfizer,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00264875
3050,RNS® System Pivotal Study,Completed,Has Results,Epilepsy,Procedure: RNS® System implantation|Device: RNS® System responsive stimulation,NeuroPace,Phase 3,Industry,Interventional,28-Aug-13,https://ClinicalTrials.gov/show/NCT00264810
3051,"Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults",Completed,Has Results,Alpha 1-Antitrypsin Deficiency,Drug: Alpha-1 MP|Drug: alpha-1 proteinase inhibitor (human),Grifols Therapeutics LLC,Phase 3,Industry,Interventional,9-Sep-14,https://ClinicalTrials.gov/show/NCT00295061
3052,Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet,Completed,Has Results,Phenylketonurias,Drug: Sapropterin Dihydrochloride|Drug: Placebo,BioMarin Pharmaceutical,Phase 3,Industry,Interventional,9-Jul-09,https://ClinicalTrials.gov/show/NCT00272792
3053,Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate,Completed,Has Results,Atrial Fibrillation|Stroke,Drug: warfarin|Drug: Dabigatran dose 1|Drug: Dabigatran dose 2,Boehringer Ingelheim|Population Health Research Institute|Uppsala University,Phase 3,Industry|Other,Interventional,10-Feb-11,https://ClinicalTrials.gov/show/NCT00262600
3054,"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects",Completed,Has Results,Human Immunodeficiency Virus Infections,Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs),Abbott,Phase 3,Industry,Interventional,20-Aug-09,https://ClinicalTrials.gov/show/NCT00262522
3055,Trial of Decitabine in Patients With Acute Myeloid Leukemia,Completed,Has Results,Acute Myeloid Leukemia,Drug: Cytarabine or Supportive Care|Drug: Dacogen (decitabine) only,Eisai Inc.,Phase 3,Industry,Interventional,21-Sep-11,https://ClinicalTrials.gov/show/NCT00260832
3056,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR),Completed,Has Results,"Rhinitis, Allergic, Perennial",Drug: FF|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,13-Apr-18,https://ClinicalTrials.gov/show/NCT00289198
3057,Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®,Completed,Has Results,Diphtheria|Tetanus|Pertussis,Biological: DAPTACEL®: DTaP,"Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,28-Sep-09,https://ClinicalTrials.gov/show/NCT00258895
3058,"Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",Completed,Has Results,Cervical Dystonia,Drug: Botulinum type A toxin (Dysport®)|Drug: Placebo,Ipsen,Phase 3,Industry,Interventional,10-May-10,https://ClinicalTrials.gov/show/NCT00257660
3059,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),Completed,Has Results,Non-Small Cell Lung Cancer,Drug: bevacizumab|Drug: placebo|Drug: erlotinib HCl,"Genentech, Inc.",Phase 3,Industry,Interventional,15-Mar-16,https://ClinicalTrials.gov/show/NCT00257608
3060,Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed),Completed,Has Results,Bipolar Disorder,Drug: Ziprasidone oral capsules|Drug: placebo oral capsules,Pfizer,Phase 3,Industry,Interventional,19-Jul-13,https://ClinicalTrials.gov/show/NCT00257166
3061,A Study In Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: GSK523338,GlaxoSmithKline,Phase 3,Industry,Interventional,23-Mar-18,https://ClinicalTrials.gov/show/NCT00256867
3062,Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome),Completed,Has Results,Restless Legs Syndrome|Restless Legs Syndrome (RLS),Drug: Ropinirole IR 1 mg|Drug: Ropinirole IR 2 mg|Drug: Ropinirole IR 1 mg Placebo|Drug: Ropinirole IR 2 mg Placebo|Drug: Ropinirole CR 2 mg|Drug: Ropinirole CR 3 mg|Drug: Ropinirole CR 2 mg Placebo|Drug: Ropinirole CR 3 mg Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,15-Mar-19,https://ClinicalTrials.gov/show/NCT00256854
3063,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT),Completed,Has Results,Kidney Transplantation|Chronic Kidney Failure,Drug: Cyclosporine (CsA)|Drug: Belatacept LI (less intensive)|Drug: Belatacept MI (more intensive),Bristol-Myers Squibb,Phase 3,Industry,Interventional,19-Aug-16,https://ClinicalTrials.gov/show/NCT00256750
3064,Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Dexlansoprazole MR,Takeda,Phase 3,Industry,Interventional,12-Aug-09,https://ClinicalTrials.gov/show/NCT00255190
3065,Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis,Completed,Has Results,"Esophagitis, Reflux|Esophagitis, Peptic",Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,28-Aug-09,https://ClinicalTrials.gov/show/NCT00255164
3066,Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis,Completed,Has Results,"Esophagitis, Reflux|Esophagitis, Peptic",Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,28-Aug-09,https://ClinicalTrials.gov/show/NCT00255151
3067,Safety and Immune Response of Different Pediatric Combination Vaccines.,Completed,Has Results,Diphtheria|Polio|Pertussis,"Biological: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|Biological: Pentacel®: DTaP-IPV/Hib combined|Biological: DTaP-IPV and ActHIB®","Sanofi Pasteur, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,10-Nov-10,https://ClinicalTrials.gov/show/NCT00255047
3068,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00251758
3069,Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn,Completed,Has Results,Gastroesophageal Reflux Disease,Drug: Dexlansoprazole MR|Drug: Placebo,Takeda,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00251745
3070,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,Completed,Has Results,"Esophagitis, Reflux|Esophagitis, Peptic",Drug: Dexlansoprazole MR|Drug: Lansoprazole,Takeda,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00251719
3071,Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis,Completed,Has Results,"Esophagitis, Reflux|Esophagitis, Peptic",Drug: Dexlansoprazole MR|Drug: Lansoprazole,Takeda,Phase 3,Industry,Interventional,23-Mar-09,https://ClinicalTrials.gov/show/NCT00251693
3072,Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease|Bronchitis|Emphysema,Drug: Arformoterol tartrate inhalation solution|Drug: Arformoterol 25 ųg BID|Drug: Formoterol 12 ųg BID|Drug: Placebo,Sunovion,Phase 3,Industry,Interventional,19-Feb-09,https://ClinicalTrials.gov/show/NCT00250679
3073,Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Letrozole|Drug: Anastrozole,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,9-Oct-15,https://ClinicalTrials.gov/show/NCT00248170
3074,Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age,Completed,Has Results,Hypertension,Drug: candesartan cilexetil (Atacand),AstraZeneca,Phase 3,Industry,Interventional,15-Sep-09,https://ClinicalTrials.gov/show/NCT00244621
3075,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,Completed,Has Results,HIV Infections,Drug: ATV|Drug: RTV|Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet|Drug: LPV,Bristol-Myers Squibb,Phase 3,Industry,Interventional,9-May-11,https://ClinicalTrials.gov/show/NCT00272779
3076,Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,Completed,Has Results,Computed Tomography|Diagnostic Imaging,Drug: Iopromide 370 mg I/mL|Drug: Iopromide 300 mg I/mL,Bayer,Phase 3,Industry,Interventional,20-Jul-09,https://ClinicalTrials.gov/show/NCT00244140
3077,Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL,Completed,Has Results,Chronic Shift Work Sleep Disorder,Drug: PROVIGIL 200 mg|Drug: Armodafinil 250 mg|Drug: Armodafinil 200 mg|Drug: Armodafinil 150 mg|Drug: Placebo,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,3-Feb-10,https://ClinicalTrials.gov/show/NCT00236080
3078,Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload,Completed,Has Results,Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Myelofibrosis,Drug: Deferasirox,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,2-May-11,https://ClinicalTrials.gov/show/NCT00235391
3079,Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy,Completed,Has Results,Bladder Cancer,Drug: Hexvix|Procedure: Standard white light cystoscopy,Photocure,Phase 3,Industry,Interventional,11-Oct-13,https://ClinicalTrials.gov/show/NCT00233402
3080,A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines,Completed,Has Results,Heart Failure,Drug: Eplerenone,Pfizer,Phase 3,Industry,Interventional,27-Jun-11,https://ClinicalTrials.gov/show/NCT00232180
3081,Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy,Completed,Has Results,HIV Infections|Peripheral Neuropathy,Drug: pregabalin|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,11-Aug-09,https://ClinicalTrials.gov/show/NCT00232141
3082,Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters,Completed,Has Results,Infection,Drug: Omiganan 1% gel|Drug: Povidone-Iodine 10%,Mallinckrodt,Phase 3,Industry,Interventional,13-Aug-09,https://ClinicalTrials.gov/show/NCT00231153
3083,Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome,Completed,Has Results,Tumor Lysis Syndrome|Cancer|Hyperuricemia,Drug: Rasburicase (SR29142)|Drug: Allopurinol,Sanofi,Phase 3,Industry,Interventional,31-Dec-09,https://ClinicalTrials.gov/show/NCT00230178
3084,Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome,Completed,Has Results,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS),Drug: Armodafinil,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,25-Jun-10,https://ClinicalTrials.gov/show/NCT00228566
3085,Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness,Completed,Has Results,Excessive Daytime Sleepiness|Narcolepsy|Obstructive Sleep Apnea/Hypopnea Syndrome|Chronic Shift Work Sleep Disorder,Drug: Armodafinil 100 to 250 mg/day,Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,31-Mar-10,https://ClinicalTrials.gov/show/NCT00228553
3086,Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder,Completed,Has Results,Schizophrenia|Bipolar I Disorder,Drug: quetiapine fumarate,AstraZeneca,Phase 3,Industry,Interventional,5-Oct-12,https://ClinicalTrials.gov/show/NCT00227305
3087,Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Pioglitazone|Drug: Glimepiride,Takeda,Phase 3,Industry,Interventional,10-Jun-09,https://ClinicalTrials.gov/show/NCT00225277
3088,Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old,Completed,Has Results,Herpes Simplex,Biological: GSK208141|Biological: Havrix (investigational formulation)|Biological: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Apr-17,https://ClinicalTrials.gov/show/NCT00224484
3089,Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients,Completed,Has Results,Pain,Other: Normal saline as placebo comparator|Drug: Intravenous ibuprofen,Cumberland Pharmaceuticals,Phase 3,Industry,Interventional,15-Sep-11,https://ClinicalTrials.gov/show/NCT00225732
3090,Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women,Completed,Has Results,Endometrial Hyperplasia|Osteoporosis,Drug: Bazedoxifene/Conjugated Estrogen|Drug: CE 0.45 mg/MPA 1.5mg|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,20-Dec-13,https://ClinicalTrials.gov/show/NCT00242710
3091,The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Silodosin,Watson Pharmaceuticals,Phase 3,Industry,Interventional,27-Apr-10,https://ClinicalTrials.gov/show/NCT00224133
3092,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Completed,Has Results,Benign Prostatic Hyperplasia,Drug: Silodosin|Other: Placebo,Watson Pharmaceuticals,Phase 3,Industry,Interventional,3-Dec-09,https://ClinicalTrials.gov/show/NCT00224120
3093,A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo,Completed,Has Results,Benign Prostatic Hyperplasia (BPH),Drug: Silodosin|Other: Placebo,Watson Pharmaceuticals,Phase 3,Industry,Interventional,3-Dec-09,https://ClinicalTrials.gov/show/NCT00224107
3094,IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2,Completed,Has Results,Moderate to Severe Glabellar Frown Lines,Drug: IncobotulinumtoxinA (Xeomin) (20 Units)|Drug: Placebo,Merz Pharmaceuticals GmbH,Phase 3,Industry,Interventional,13-Sep-11,https://ClinicalTrials.gov/show/NCT00770029
3095,Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women,Completed,Has Results,Osteoporosis,Drug: Bazedoxifene Acetate|Other: Placebo,Pfizer,Phase 3,Industry,Interventional,10-Apr-13,https://ClinicalTrials.gov/show/NCT00205777
3096,"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months",Completed,Has Results,Hepatitis A,Biological: Havrix™|Biological: Infanrix™|Biological: ActHIB™,GlaxoSmithKline,Phase 3,Industry,Interventional,24-Jul-09,https://ClinicalTrials.gov/show/NCT00197236
3097,Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children,Completed,Has Results,Hepatitis A,Biological: Havrix®|Biological: M-M-R®II|Biological: VARIVAX®,GlaxoSmithKline,Phase 3,Industry,Interventional,1-Apr-10,https://ClinicalTrials.gov/show/NCT00197015
3098,Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age,Completed,Has Results,Hepatitis A,Biological: GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Biological: Prevnar™,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Feb-17,https://ClinicalTrials.gov/show/NCT00197002
3099,"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive",Completed,Has Results,Contraception,Drug: DR-1011,Duramed Research|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,15-Apr-09,https://ClinicalTrials.gov/show/NCT00196326
3100,Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: Adalimumab,Abbott,Phase 3,Industry,Interventional,7-Jan-10,https://ClinicalTrials.gov/show/NCT00195715
3101,Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.,Completed,Has Results,Rheumatoid Arthritis,Biological: Adalimumab|Drug: Placebo,Abbott,Phase 3,Industry,Interventional,1-Mar-10,https://ClinicalTrials.gov/show/NCT00195702
3102,Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,Completed,Has Results,Psoriasis,Drug: adalimumab,Abbott,Phase 3,Industry,Interventional,19-Nov-10,https://ClinicalTrials.gov/show/NCT00195676
3103,Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis,Completed,Has Results,Early Rheumatoid Arthritis,Biological: Adalimumab|Drug: Methotrexate|Biological: Adalimumab placebo|Drug: Methotrexate placebo,"AbbVie (prior sponsor, Abbott)|AbbVie",Phase 3,Industry,Interventional,25-Feb-10,https://ClinicalTrials.gov/show/NCT00195663
3104,Long Term Open Label Continuation Study,Completed,Has Results,Rheumatoid Arthritis,Biological: Adalimumab,Abbott,Phase 3,Industry,Interventional,31-Jul-12,https://ClinicalTrials.gov/show/NCT00195650
3105,"An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy",Completed,Has Results,"Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|Peritoneal Neoplasms",Drug: Gemcitabine|Drug: Paclitaxel|Drug: Carboplatin,Eli Lilly and Company,Phase 3,Industry,Interventional,9-Sep-10,https://ClinicalTrials.gov/show/NCT00191646
3106,A Phase III Trial For Patients With Metastatic Breast Cancer,Completed,Has Results,Breast Cancer|Breast Neoplasms|Cancer of the Breast,Drug: gemcitabine|Drug: docetaxel|Drug: capecitabine,Eli Lilly and Company,Phase 3,Industry,Interventional,8-Dec-09,https://ClinicalTrials.gov/show/NCT00191152
3107,"Long-Term, Open Label Atomoxetine Study",Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: atomoxetine,Eli Lilly and Company,Phase 3,Industry,Interventional,17-Jan-11,https://ClinicalTrials.gov/show/NCT00190684
3108,SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS),Completed,Has Results,Stents|Coronary Artery Disease|Total Coronary Occlusion|Coronary Artery Restenosis|Stent Thrombosis|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis,Device: XIENCE V® Everolimus Eluting Coronary Stent|Device: TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent,Abbott Medical Devices,Phase 3,Industry,Interventional,15-Dec-08,https://ClinicalTrials.gov/show/NCT00180479
3109,A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol,UCB Pharma,Phase 3,Industry,Interventional,8-Mar-13,https://ClinicalTrials.gov/show/NCT00175877
3110,Tiotropium / Respimat One-Year Study,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium Inhalation Solution|Other: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,7-Oct-09,https://ClinicalTrials.gov/show/NCT00168844
3111,Tiotropium / Respimat One-Year Study,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Tiotropium Inhalation Solution|Other: Placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,7-Oct-09,https://ClinicalTrials.gov/show/NCT00168831
3112,Study for the Treatment of Crohn's Disease With Adacolumn,Completed,Has Results,Crohn's Disease,Device: Adacolumn|Device: Sham,Otsuka America Pharmaceutical,Phase 3,Industry,Interventional,7-Apr-09,https://ClinicalTrials.gov/show/NCT00162942
3113,A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease,Completed,Has Results,Kawasaki Disease,Drug: Sestamibi,Lantheus Medical Imaging,Phase 3,Industry,Interventional,6-Dec-13,https://ClinicalTrials.gov/show/NCT00162032
3114,Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity,Completed,Has Results,"Obesity, Morbid",Device: Swedish Adjustable Gastric Band,Ethicon Endo-Surgery,Phase 3,Industry,Interventional,11-Dec-08,https://ClinicalTrials.gov/show/NCT00166205
3115,A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease,Completed,Has Results,Crohn's Disease,Biological: Certolizumab Pegol (CDP870),UCB Pharma SA|UCB Pharma,Phase 3,Industry,Interventional,4-Jul-13,https://ClinicalTrials.gov/show/NCT00160706
3116,Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol,UCB Pharma,Phase 3,Industry,Interventional,9-Jul-12,https://ClinicalTrials.gov/show/NCT00160693
3117,A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425],Completed,Has Results,Crohn's Disease,Biological: Certolizumab Pegol (CDP870),UCB Pharma SA|UCB Pharma,Phase 3,Industry,Interventional,10-Oct-13,https://ClinicalTrials.gov/show/NCT00160524
3118,The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH,Completed,Has Results,Pulmonary Hypertension,Drug: Sildenafil citrate,Pfizer,Phase 3,Industry,Interventional,12-Jan-11,https://ClinicalTrials.gov/show/NCT00159861
3119,Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients,Completed,Has Results,Hemophilia A,Biological: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,15-Jul-11,https://ClinicalTrials.gov/show/NCT00157157
3120,Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement,Completed,Has Results,"Arthroplasty, Replacement, Knee|Thromboembolism",Drug: Dabigatran Dose 1 - day 2 to completion|Drug: Dabigatran Dose 1 - day 1|Drug: Dabigatran Dose 2 - day 2 to completion|Drug: Dabigatran Dose 2 - day 1|Drug: Enoxaparin,Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Dec-10,https://ClinicalTrials.gov/show/NCT00152971
3121,"Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures",Completed,Has Results,"Epilepsy, Partial",Drug: levetiracetam (LEV),UCB Pharma,Phase 3,Industry,Interventional,13-Jan-10,https://ClinicalTrials.gov/show/NCT00152516
3122,Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: SPD476|Drug: Asacol,Shire,Phase 3,Industry,Interventional,21-Sep-10,https://ClinicalTrials.gov/show/NCT00151892
3123,A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Biological: Certolizumab Pegol,UCB Pharma,Phase 3,Industry,Interventional,7-Mar-13,https://ClinicalTrials.gov/show/NCT00160641
3124,"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment",Completed,Has Results,Epilepsy,Drug: Brivaracetam,UCB PHARMA Inc. (US)|UCB Pharma,Phase 3,Industry,Interventional,5-Dec-18,https://ClinicalTrials.gov/show/NCT00150800
3125,A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Sildenafil citrate,Pfizer,Phase 3,Industry,Interventional,11-Aug-14,https://ClinicalTrials.gov/show/NCT00159874
3126,Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH),Completed,Has Results,Pulmonary Hypertension,Drug: Inhaled treprostinil|Drug: Placebo inhalation solution,United Therapeutics,Phase 3,Industry,Interventional,12-Aug-13,https://ClinicalTrials.gov/show/NCT00147199
3127,Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis),Completed,Has Results,Osteoporosis,Drug: Zoledronic Acid|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,20-Apr-11,https://ClinicalTrials.gov/show/NCT00145327
3128,Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium|Drug: placebo,Boehringer Ingelheim,Phase 3,Industry,Interventional,17-Aug-09,https://ClinicalTrials.gov/show/NCT00144339
3129,Study Evaluating Pantoprazole in Children With GERD,Completed,Has Results,Gastroesophageal Reflux,Drug: pantoprazole for approximately 9 weeks.,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,28-Dec-11,https://ClinicalTrials.gov/show/NCT00141817
3130,A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression,Completed,Has Results,Bipolar Disorder,Drug: Geodon (Ziprasidone)|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,24-Mar-09,https://ClinicalTrials.gov/show/NCT00141271
3131,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma,Completed,Has Results,Asthma|Diabetes Mellitus,Drug: Inhaled Insulin|Drug: Subcutaneous Insulin,Pfizer,Phase 3,Industry,Interventional,12-May-10,https://ClinicalTrials.gov/show/NCT00139659
3132,"A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.",Completed,Has Results,"Pulmonary Arterial Hypertension, Children",Drug: Sildenafil citrate|Drug: Placebo,Pfizer,Phase 3,Industry,Interventional,21-Jul-09,https://ClinicalTrials.gov/show/NCT00159913
3133,An Implantable Spinal Cord Stimulation Pain Management System,Completed,Has Results,"Chronic Pain|Pain, Intractable|Pain|Back Pain|Failed Back Surgery Syndrome",Device: Precision SCS,Boston Scientific Corporation,Phase 3,Industry,Interventional,26-Oct-12,https://ClinicalTrials.gov/show/NCT00205855
3134,Effect of Ruboxistaurin on Clinically Significant Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Ruboxistaurin|Drug: Placebo,"Chromaderm, Inc.",Phase 3,Industry,Interventional,28-Jan-16,https://ClinicalTrials.gov/show/NCT00133952
3135,A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes,Completed,Has Results,Bipolar Disorder,Drug: Risperdal Consta|Drug: Placebo,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,27-Feb-09,https://ClinicalTrials.gov/show/NCT00132678
3136,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458),Completed,Has Results,Short Bowel Syndrome,Drug: teduglutide 0.05 mg/kg/d|Drug: teduglutide 0.10 mg/kg/d,Shire,Phase 3,Industry,Interventional,23-Apr-13,https://ClinicalTrials.gov/show/NCT00172185
3137,An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome,Completed,Has Results,Overactive Bladder,Device: bion,Boston Scientific Corporation,Phase 3,Industry,Interventional,19-Nov-13,https://ClinicalTrials.gov/show/NCT00131573
3138,"Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery",Completed,Has Results,Hemophilia A,Biological: ReFacto AF,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,Industry,Interventional,20-Jul-09,https://ClinicalTrials.gov/show/NCT00243659
3139,Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children,Completed,Has Results,Respiratory Syncytial Virus Infections,Biological: motavizumab (MEDI-524)|Biological: palivizumab,MedImmune LLC,Phase 3,Industry,Interventional,28-Aug-13,https://ClinicalTrials.gov/show/NCT00129766
3140,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA),Completed,Has Results,Cystic Fibrosis,Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID),Gilead Sciences,Phase 3,Industry,Interventional,11-Mar-11,https://ClinicalTrials.gov/show/NCT00128492
3141,Study of Oral Fampridine-SR in Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Fampridine-SR|Drug: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,6-May-11,https://ClinicalTrials.gov/show/NCT00127530
3142,Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|Drug: Anti-Tumor Necrosing Factor (TNF) Therapy,Bristol-Myers Squibb,Phase 3,Industry,Interventional,2-Jun-11,https://ClinicalTrials.gov/show/NCT00124982
3143,Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML,Completed,Has Results,"Myeloid Leukemia, Chronic, Accelerated Phase|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",Drug: dasatinib,Bristol-Myers Squibb,Phase 3,Industry,Interventional,22-Oct-14,https://ClinicalTrials.gov/show/NCT00123487
3144,Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML,Completed,Has Results,"Myeloid Leukemia, Chronic, Chronic-Phase",Drug: dasatinib,Bristol-Myers Squibb,Phase 3,Industry,Interventional,26-Aug-15,https://ClinicalTrials.gov/show/NCT00123474
3145,Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18,Completed,Has Results,"Infections, Papillomavirus",Biological: Cervarix™|Biological: Havrix™-based investigational formulation,GlaxoSmithKline,Phase 3,Industry,Interventional,20-Jan-10,https://ClinicalTrials.gov/show/NCT00122681
3146,Remission and Joint Damage Progression in Early Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: placebo|Drug: methotrexate,Bristol-Myers Squibb,Phase 3,Industry,Interventional,13-Jul-10,https://ClinicalTrials.gov/show/NCT00122382
3147,Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH),Completed,Has Results,"Paroxysmal Hemoglobinuria, Nocturnal",Drug: eculizumab,Alexion Pharmaceuticals,Phase 3,Industry,Interventional,5-Jun-17,https://ClinicalTrials.gov/show/NCT00122317
3148,Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Saxagliptin + Metformin|Drug: Placebo + Metformin|Drug: Pioglitazone,AstraZeneca,Phase 3,Industry,Interventional,8-Apr-11,https://ClinicalTrials.gov/show/NCT00121667
3149,Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Saxagliptin|Drug: Placebo matching Saxagliptin|Drug: Metformin|Drug: Placebo matching Metformin,AstraZeneca,Phase 3,Industry,Interventional,11-May-11,https://ClinicalTrials.gov/show/NCT00121641
3150,5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis,Completed,Has Results,Atopic Dermatitis,Drug: Pimecrolimus|Drug: Topical corticosteroids,MEDA Pharma GmbH & Co. KG,Phase 3,Industry,Interventional,16-Jan-13,https://ClinicalTrials.gov/show/NCT00120523
3151,A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.,Completed,Has Results,Hydrocephalus|Normal Pressure Hydrocephalus,Device: Codman VPV System,Codman & Shurtleff,Phase 3,Industry,Interventional,5-Dec-08,https://ClinicalTrials.gov/show/NCT00196196
3152,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis,Completed,Has Results,"Vasomotor Rhinitis|Rhinitis, Vasomotor",Drug: GW685698X,GlaxoSmithKline,Phase 3,Industry,Interventional,2-May-17,https://ClinicalTrials.gov/show/NCT00118703
3153,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B,Completed,Has Results,Chronic Hepatitis B,Drug: TDF|Drug: ADV|Drug: TDF placebo|Drug: ADV placebo|Drug: FTC/TDF,Gilead Sciences,Phase 3,Industry,Interventional,19-May-10,https://ClinicalTrials.gov/show/NCT00117676
3154,Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL),Completed,Has Results,Lymphoma,Drug: Temsirolimus (CCI-779)|Drug: Investigator's choice,Pfizer,Phase 3,Industry,Interventional,6-Mar-12,https://ClinicalTrials.gov/show/NCT00117598
3155,Study Of Adults And Adolescents With Vasomotor Rhinitis,Completed,Has Results,"Rhinitis, Vasomotor",Drug: GW685698X,GlaxoSmithKline,Phase 3,Industry,Interventional,13-Mar-18,https://ClinicalTrials.gov/show/NCT00117325
3156,Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes,Completed,Has Results,Atherosclerosis,Drug: Glipizide|Drug: rosiglitazone maleate,GlaxoSmithKline,Phase 3,Industry,Interventional,31-Mar-10,https://ClinicalTrials.gov/show/NCT00116831
3157,A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B,Completed,Has Results,Chronic Hepatitis B,Drug: TDF|Drug: ADV|Drug: TDF placebo|Drug: ADV placebo|Drug: FTC/TDF,Gilead Sciences,Phase 3,Industry,Interventional,19-May-10,https://ClinicalTrials.gov/show/NCT00116805
3158,NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation,Completed,Has Results,Heart Diseases|Arrhythmia|Atrial Fibrillation,Device: NAVISTAR® THERMOCOOL® Catheter|Drug: Antiarrhythmic drug,"Biosense Webster, Inc.",Phase 3,Industry,Interventional,14-Mar-13,https://ClinicalTrials.gov/show/NCT00116428
3159,Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant,Completed,Has Results,Renal Transplantation,Drug: Cyclosporin A|Drug: Belatacept Less Intensive Regimen (LI)|Drug: Belatacept More Intensive Regimen (MI),Bristol-Myers Squibb,Phase 3,Industry,Interventional,7-Jul-17,https://ClinicalTrials.gov/show/NCT00114777
3160,Safety Study of XP12B in Women With Menorrhagia,Completed,Has Results,Menorrhagia|Heavy Menstrual Bleeding,Drug: Tranexamic acid tablets (XP12B),Ferring Pharmaceuticals,Phase 3,Industry,Interventional,20-Jan-10,https://ClinicalTrials.gov/show/NCT00113568
3161,International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Completed,Has Results,Cystic Fibrosis,Drug: AZLI 75 mg three times a day (TID)|Drug: Placebo three times a day (TID),Gilead Sciences,Phase 3,Industry,Interventional,21-Apr-11,https://ClinicalTrials.gov/show/NCT00112359
3162,Aripiprazole in Children and Adolescents With Bipolar I Disorder,Completed,Has Results,Bipolar Disorder,Drug: Aripiprazole|Drug: placebo,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,21-May-12,https://ClinicalTrials.gov/show/NCT00110461
3163,The CLEVER Study - Coreg And Left Ventricular Mass Regression,Completed,Has Results,"Hypertrophy, Left Ventricular",Drug: carvedilol MR|Drug: atenolol|Drug: lisinopril,GlaxoSmithKline,Phase 3,Industry,Interventional,9-Nov-09,https://ClinicalTrials.gov/show/NCT00108082
3164,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol|Drug: Salmeterol/fluticasone (50/500 μg)|Drug: Salbutamol (200 µg)|Drug: Placebo to Indacaterol|Drug: Placebo to Salmeterol/fluticasone|Drug: Placebo to salbutamol,Novartis,Phase 3,Industry,Interventional,17-Aug-11,https://ClinicalTrials.gov/show/NCT00669617
3165,Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency,Completed,Has Results,Childhood-onset Growth Hormone Deficiency|Pituitary Dwarfism,Biological: recombinant human growth hormone,EMD Serono,Phase 3,Industry,Interventional,22-Jun-10,https://ClinicalTrials.gov/show/NCT00109733
3166,The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: Escitalopram|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,4-Nov-09,https://ClinicalTrials.gov/show/NCT00107120
3167,A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA),Completed,Has Results,Rheumatoid Arthritis,Drug: tocilizumab [RoActemra/Actemra]|Drug: Placebo|Drug: Methotrexate,Hoffmann-La Roche,Phase 3,Industry,Interventional,7-Jun-11,https://ClinicalTrials.gov/show/NCT00106535
3168,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003),Completed,Has Results,Bacterial Conjunctivitis,Drug: AzaSite|Other: Vehicle,Merck Sharp & Dohme Corp.,Phase 3,Industry,Interventional,27-Oct-11,https://ClinicalTrials.gov/show/NCT00105534
3169,Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia,Completed,Has Results,Parkinson's Disease|Dyskinesia,Drug: Sarizotan|Drug: Placebo,EMD Serono,Phase 3,Industry,Interventional,2-Apr-18,https://ClinicalTrials.gov/show/NCT00105521
3170,Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia,Completed,Has Results,Parkinson's Disease|Dyskinesia,Drug: Sarizotan|Drug: Placebo,EMD Serono,Phase 3,Industry,Interventional,25-Jul-18,https://ClinicalTrials.gov/show/NCT00105508
3171,Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004),Completed,Has Results,Bacterial Conjunctivitis,Drug: AzaSite|Drug: Tobramycin,Merck Sharp & Dohme Corp.,Phase 3,Industry,Interventional,27-Oct-11,https://ClinicalTrials.gov/show/NCT00105469
3172,A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,Completed,Has Results,"Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,27-Sep-10,https://ClinicalTrials.gov/show/NCT00105443
3173,EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection,Completed,Has Results,Chronic Obstructive Pulmonary|Idiopathic Pulmonary Fibrosis|Cystic Fibrosis|Bronchiectasis|Pulmonary Vascular Disease,Biological: Placebo|Biological: EZ-2053|Biological: EZ-2053 5mg/kg,Neovii Biotech,Phase 3,Industry,Interventional,8-Jun-12,https://ClinicalTrials.gov/show/NCT00105183
3174,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,Completed,Has Results,HIV Infections,Drug: saquinavir [Invirase]|Drug: Lopinavir/ritonavir|Drug: Emtricitabine/tenofovir disoproxil fumarate|Drug: Ritonavir,Hoffmann-La Roche,Phase 3,Industry,Interventional,2-Nov-11,https://ClinicalTrials.gov/show/NCT00105079
3175,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Completed,Has Results,Cystic Fibrosis,Drug: AZLI 75 mg two times a day (BID)/three times a day (TID)|Drug: Placebo two times a day (BID)/three times a day (TID),Gilead Sciences,Phase 3,Industry,Interventional,11-Mar-11,https://ClinicalTrials.gov/show/NCT00104520
3176,Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures,Completed,Has Results,"Epilepsy, Tonic-Clonic",Drug: lamotrigine (LAMICTAL) extended-release|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,18-May-10,https://ClinicalTrials.gov/show/NCT00104416
3177,Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels,Completed,Has Results,Phenylketonurias,"Drug: sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin",BioMarin Pharmaceutical,Phase 3,Industry,Interventional,16-Apr-09,https://ClinicalTrials.gov/show/NCT00104247
3178,"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease",Completed,Has Results,Gaucher Disease Type 1,Drug: Miglustat,Actelion,Phase 3,Industry,Interventional,23-May-12,https://ClinicalTrials.gov/show/NCT00319046
3179,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients,Completed,Has Results,Multiple Myeloma,Drug: Granulocyte colony-stimulating factor plus plerixafor|Drug: Granulocyte colony-stimulating factor plus placebo,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,29-Sep-10,https://ClinicalTrials.gov/show/NCT00103662
3180,Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients,Completed,Has Results,"Lymphoma, Non-Hodgkin",Drug: Granulocyte colony-stimulating factor plus plerixafor|Drug: Granulocyte colony-stimulating factor plus placebo,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,29-Sep-10,https://ClinicalTrials.gov/show/NCT00103610
3181,Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: Bortezomib (VELCADE)|Drug: Doxorubicin hydrochloride (DOXIL/CAELYX),"Janssen Research & Development, LLC",Phase 3,Industry,Interventional,25-May-15,https://ClinicalTrials.gov/show/NCT00103506
3182,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Completed,Has Results,Paget's Disease of Bone,Drug: zoledronic acid|Drug: placebo to zoledronic acid|Drug: Risedronate|Drug: Placebo to risedronate|Drug: Calcium and vitamin D supplements,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,2-May-12,https://ClinicalTrials.gov/show/NCT00103740
3183,"Aripiprazole Open-Label, Safety and Tolerability Study",Completed,Has Results,Schizophrenia|Bipolar Disorder,Drug: Aripiprazole,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,31-Aug-12,https://ClinicalTrials.gov/show/NCT00102518
3184,Aripiprazole in Adolescents With Schizophrenia,Completed,Has Results,Schizophrenia,"Drug: Aripiprazole tablet, 10 mg|Drug: Aripiprazole tablet, 30 mg|Drug: Placebo tablet","Otsuka Pharmaceutical Development & Commercialization, Inc.",Phase 3,Industry,Interventional,1-Aug-12,https://ClinicalTrials.gov/show/NCT00102063
3185,Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.,Completed,Has Results,Colorectal Neoplasms,Drug: Modified Bolus 5-FU/LV with Irinotecan|Drug: FOLFIRI + bevacizumab|Drug: miFL + bevacizumab|Drug: Infusional 5-FU/LV with Irinotecan|Drug: Oral Capecitabine with Irinotecan,Pfizer,Phase 3,Industry,Interventional,26-Nov-09,https://ClinicalTrials.gov/show/NCT00101686
3186,Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection,Completed,Has Results,Herpes Simplex,Drug: Famciclovir,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-May-09,https://ClinicalTrials.gov/show/NCT00098059
3187,Experimental Medication For the Treatment of Generalized Anxiety Disorder,Completed,Has Results,Anxiety Disorder,Drug: experimental anti-anxiety drug,Jazz Pharmaceuticals,Phase 3,Industry,Interventional,3-Oct-14,https://ClinicalTrials.gov/show/NCT00097708
3188,Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection,Completed,Has Results,Hepatitis B|Chronic Disease,Drug: entecavir|Drug: adefovir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,6-Jan-10,https://ClinicalTrials.gov/show/NCT00096785
3189,Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,"Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Drug: Infliximab (INF) + MTX, DB|Drug: Placebo (PLA) + MTX, DB|Drug: PLA + MTX switched to ABA+ MTX, DB|Drug: ABA, open-label (OL)",Bristol-Myers Squibb,Phase 3,Industry,Interventional,21-Jan-11,https://ClinicalTrials.gov/show/NCT00095147
3190,"MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",Completed,Has Results,Melanoma|Metastases,Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine,Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Jun-11,https://ClinicalTrials.gov/show/NCT00094653
3191,BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis,Completed,Has Results,Juvenile Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,18-Jan-17,https://ClinicalTrials.gov/show/NCT00095173
3192,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Docetaxel|Drug: DOXIL,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Phase 3,Industry,Interventional,2-Oct-12,https://ClinicalTrials.gov/show/NCT00091442
3193,"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",Completed,Has Results,Anemia,Drug: Methoxy Polyethylene Glycol-Epoetin Beta|Drug: Epoetin alfa|Drug: Epoetin beta|Drug: Darbepoetin alfa,Hoffmann-La Roche,Phase 3,Industry,Interventional,5-Jan-12,https://ClinicalTrials.gov/show/NCT00090753
3194,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,Completed,Has Results,Diabetic Retinopathy,Drug: ruboxistaurin|Drug: placebo,"Chromaderm, Inc.",Phase 3,Industry,Interventional,16-May-16,https://ClinicalTrials.gov/show/NCT00090519
3195,Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment,Completed,Has Results,Prostatic Hyperplasia,Drug: dutasteride 0.5mg once daily for 4 years|Drug: tamsulosin 0.4mg once daily for 4 years,GlaxoSmithKline,Phase 3,Industry,Interventional,16-Mar-10,https://ClinicalTrials.gov/show/NCT00090103
3196,Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,Completed,Has Results,Schizophrenic Disorders|Schizoaffective Disorder,Drug: Intramuscular olanzapine depot,Eli Lilly and Company,Phase 3,Industry,Interventional,11-Jan-12,https://ClinicalTrials.gov/show/NCT00088465
3197,Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Completed,Has Results,"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)",Grifols Therapeutics LLC,Phase 3,Industry,Interventional,10-Sep-15,https://ClinicalTrials.gov/show/NCT00220740
3198,Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer,Completed,Has Results,Kidney Cancer,Biological: girentuximab|Other: placebo,Wilex,Phase 3,Industry,Interventional,12-Sep-18,https://ClinicalTrials.gov/show/NCT00087022
3199,Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: tiotropium + olodaterol|Drug: tiotropium|Drug: olodaterol|Drug: Placebo|Device: Respimat,Boehringer Ingelheim,Phase 3,Industry,Interventional,16-Jul-15,https://ClinicalTrials.gov/show/NCT01559116
3200,An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload,Completed,Has Results,Transfusional Iron Overload in β-thalassemia,Drug: Deferasirox,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,2-May-11,https://ClinicalTrials.gov/show/NCT00171210
3201,"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)",Completed,Has Results,"Lymphoma, Non-Hodgkin","Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab",CTI BioPharma,Phase 3,Industry,Interventional,1-Jun-17,https://ClinicalTrials.gov/show/NCT00088530
3202,Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis,Completed,Has Results,Ankylosing Spondylitis,Biological: adalimumab (D2E7)|Biological: placebo,Abbott,Phase 3,Industry,Interventional,11-Mar-10,https://ClinicalTrials.gov/show/NCT00085644
3203,SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma,Completed,Has Results,"Carcinoma, Renal Cell",Drug: Interferon-alfa|Drug: SU011248,Pfizer,Phase 3,Industry,Interventional,10-Dec-09,https://ClinicalTrials.gov/show/NCT00083889
3204,"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",Completed,Has Results,Idiopathic Thrombocytopenic Purpura,Drug: Eltrombopag|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,29-Sep-14,https://ClinicalTrials.gov/show/NCT01520909
3205,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,Completed,Has Results,HIV Infections|Lipodystrophy,Drug: Placebo|Drug: Serostim® 4 mg|Drug: Serostim® 2 mg,EMD Serono,Phase 3,Industry,Interventional,20-Jul-18,https://ClinicalTrials.gov/show/NCT00082628
3206,Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Completed,Has Results,Cancer|Breast Cancer,Drug: Ixabepilone + Capecitabine|Drug: Capecitabine,R-Pharm,Phase 3,Industry,Interventional,17-Aug-09,https://ClinicalTrials.gov/show/NCT00082433
3207,Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome,Completed,Has Results,Short Bowel Syndrome,Drug: Placebo|Drug: Teduglutide 0.05 mg/kg/d|Drug: Teduglutide 0.1 mg/kg/d,Shire,Phase 3,Industry,Interventional,15-Jul-13,https://ClinicalTrials.gov/show/NCT00081458
3208,An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence,Completed,Has Results,Urinary Incontinence,Device: bion,Boston Scientific Corporation,Phase 3,Industry,Interventional,10-Oct-13,https://ClinicalTrials.gov/show/NCT00080470
3209,Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer,Completed,Has Results,Breast Cancer|Metastases,Drug: Ixabepilone + Capecitabine|Drug: Capecitabine,R-Pharm,Phase 3,Industry,Interventional,17-Aug-09,https://ClinicalTrials.gov/show/NCT00080301
3210,"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma",Completed,Has Results,Asthma,Drug: Omalizumab|Drug: Placebo|Drug: Fluticasone,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,3-Aug-11,https://ClinicalTrials.gov/show/NCT00079937
3211,A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer,Completed,Has Results,Colorectal Cancer,Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Capecitabine [Xeloda],Hoffmann-La Roche,Phase 3,Industry,Interventional,22-Jun-16,https://ClinicalTrials.gov/show/NCT00009737
3212,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Completed,Has Results,Prostate Cancer,Biological: sipuleucel-T|Biological: Placebo,Dendreon,Phase 3,Industry,Interventional,1-Nov-10,https://ClinicalTrials.gov/show/NCT00005947
3213,"Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder",Completed,Has Results,"Narcolepsy|Sleep Apnea, Obstructive|Sleep Apnea Syndromes|Shift-Work Sleep Disorder",Drug: CEP-10953 (Armodafinil),Cephalon|Teva Pharmaceutical Industries,Phase 3,Industry,Interventional,22-Feb-10,https://ClinicalTrials.gov/show/NCT00078312
3214,A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.,Completed,Has Results,Anemia,Drug: epoetin alfa or beta|Drug: methoxy polyethylene glycol-epoetin beta (Mircera),Hoffmann-La Roche,Phase 3,Industry,Interventional,26-Apr-16,https://ClinicalTrials.gov/show/NCT00077623
3215,A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients,Completed,Has Results,Anemia,Drug: Epoetin alfa or beta|Drug: RO0503821 (1x/2 Weeks)|Drug: RO0503821 (1x/4 Weeks),Hoffmann-La Roche,Phase 3,Industry,Interventional,29-Feb-16,https://ClinicalTrials.gov/show/NCT00077610
3216,Zinc for the Treatment of Herpes Simplex Labialis (HSL),Completed,Has Results,Herpes Simplex Labialis,Drug: Zicam (Ionic zinc)|Drug: placebo,"Integrative Medicine Institute|Women's Health Services, Santa Fe, New Mexico|Southwest College of Naturopathic Medicine|Beth Israel Medical Center|Matrixx Initiatives, Inc.",Phase 3,Other|Industry,Interventional,8-Jan-14,https://ClinicalTrials.gov/show/NCT00809809
3217,Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C,Completed,Has Results,Hepatitis C,Drug: BMS-790052 (NS5A Replication Complex Inhibitor)|Drug: Placebo matching BMS-790052|Drug: Pegylated-interferon alfa 2a|Drug: Ribavirin,Bristol-Myers Squibb,Phase 3,Industry,Interventional,7-Sep-15,https://ClinicalTrials.gov/show/NCT01448044
3218,Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections,Completed,Has Results,Complicated Intra-abdominal Infection,Drug: CXA-201 and metronidazole|Drug: Meropenem,Cubist Pharmaceuticals LLC,Phase 3,Industry,Interventional,15-Jan-15,https://ClinicalTrials.gov/show/NCT01445678
3219,Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: Paclitaxel|Drug: GW572016 (Lapatinib),GlaxoSmithKline,Phase 3,Industry,Interventional,31-Mar-14,https://ClinicalTrials.gov/show/NCT00075270
3220,A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST),Completed,Has Results,Gastrointestinal Stromal Tumor,Drug: Placebo|Drug: SU011248,Pfizer,Phase 3,Industry,Interventional,28-Sep-09,https://ClinicalTrials.gov/show/NCT00075218
3221,Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery,Completed,Has Results,"Neoplasms, Head and Neck",Drug: Lapatinib|Radiation: Chemoradiation|Other: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,11-Feb-14,https://ClinicalTrials.gov/show/NCT00424255
3222,Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer,Completed,Has Results,"Neoplasms, Breast",Drug: Lapatinib (GW572016)|Drug: Letrozole,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-May-12,https://ClinicalTrials.gov/show/NCT00073528
3223,Administration of Two Injections for Multiple Dupuytren's Contractures,Completed,Has Results,Dupuytren's Contracture,Biological: AA4500 collagenase clostridium histolyticum,Endo Pharmaceuticals,Phase 3,Industry,Interventional,20-Feb-15,https://ClinicalTrials.gov/show/NCT01407068
3224,Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis,Completed,Has Results,Ulcerative Colitis,Drug: Asacol 800 mg (mesalamine)|Drug: Asacol 400 mg (mesalamine),Warner Chilcott,Phase 3,Industry,Interventional,28-Jul-11,https://ClinicalTrials.gov/show/NCT00073021
3225,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Placebo|Other: Best Supportive Care,Eli Lilly and Company,Phase 3,Industry,Interventional,29-Dec-14,https://ClinicalTrials.gov/show/NCT00102804
3226,Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis,Completed,Has Results,"Hepatitis|Hepatitis B, Chronic|Cirrhosis",Drug: Telbivudine|Drug: Lamivudine|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,5-Sep-11,https://ClinicalTrials.gov/show/NCT00076336
3227,Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine,Completed,Has Results,Schizophrenia|Schizoaffective Disorders,Drug: olanzapine|Drug: amantadine|Drug: metformin|Drug: zonisamide|Behavioral: Wellness education,Eli Lilly and Company,Phase 3,Industry,Interventional,30-Sep-09,https://ClinicalTrials.gov/show/NCT00401973
3228,Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: GSK573719|Other: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,11-Feb-14,https://ClinicalTrials.gov/show/NCT01387230
3229,A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer,Completed,Has Results,Colorectal Cancer,Drug: capecitabine [Xeloda]|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5 FU,Hoffmann-La Roche,Phase 3,Industry,Interventional,29-Jul-11,https://ClinicalTrials.gov/show/NCT00069121
3230,A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Drug: Oxaliplatin 130 mg/m^2|Drug: Capecitabine 1000 mg/m^2|Drug: Bevacizumab 7.5 mg/kg|Drug: Placebo for bevacizumab 7.5 mg/kg|Drug: Oxaliplatin 85 mg/m^2|Drug: Leucovorin 200 mg/m^2|Drug: Fluorouracil 400 mg/m^2|Drug: Bevacizumab 5 mg/kg|Drug: Placebo for bevacizumab 5 mg/kg,Hoffmann-La Roche,Phase 3,Industry,Interventional,22-Jan-16,https://ClinicalTrials.gov/show/NCT00069095
3231,A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care,Completed,Has Results,Myelodysplastic Syndromes,Drug: Azacitidine|Other: Physician Choice,Celgene Corporation|Celgene,Phase 3,Industry,Interventional,5-Jul-10,https://ClinicalTrials.gov/show/NCT00071799
3232,Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy,Completed,Has Results,Narcolepsy,Drug: Xyrem|Drug: Xyrem Placebo|Drug: Modafinil at established dose|Drug: Modafinil (Placebo),Jazz Pharmaceuticals,Phase 3,Industry,Interventional,30-Nov-11,https://ClinicalTrials.gov/show/NCT00066170
3233,Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation,Completed,Has Results,Hepatitis B,Drug: Entecavir (ETV)|Drug: Adefovir (ADV),Bristol-Myers Squibb,Phase 3,Industry,Interventional,2-Jul-10,https://ClinicalTrials.gov/show/NCT00065507
3234,Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma,Completed,Has Results,"Carcinoma, Renal Cell|Kidney Neoplasms",Drug: Interferon Alfa|Drug: CCI-779|Drug: Interferon Alfa and CCI-779,Pfizer,Phase 3,Industry,Interventional,25-Oct-12,https://ClinicalTrials.gov/show/NCT00065468
3235,Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T|Biological: APC-Placebo,Dendreon,Phase 3,Industry,Interventional,6-Sep-10,https://ClinicalTrials.gov/show/NCT00065442
3236,Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B,Completed,Has Results,Hemophilia B,Drug: Recombinant Coagulation Factor IX (BeneFIX),Pfizer,Phase 3,Industry,Interventional,23-Aug-11,https://ClinicalTrials.gov/show/NCT00364182
3237,Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients,Completed,Has Results,Kidney Transplantation,Drug: Tacrolimus Modified Release (MR)|Drug: Tacrolimus|Drug: cyclosporine microemulsion|Drug: mycophenolate mofetil,Astellas Pharma Inc,Phase 3,Industry,Interventional,26-Sep-13,https://ClinicalTrials.gov/show/NCT00064701
3238,A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer,Completed,Has Results,Colorectal Cancer,Drug: 5 FU|Drug: Leucovorin|Drug: Oxaliplatin|Drug: capecitabine [Xeloda],Hoffmann-La Roche,Phase 3,Industry,Interventional,24-Feb-16,https://ClinicalTrials.gov/show/NCT00069108
3239,HerpeVac Trial for Young Women,Completed,Has Results,Herpes Simplex Infection,"Biological: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|Biological: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",GlaxoSmithKline,Phase 3,Industry,Interventional,3-Nov-11,https://ClinicalTrials.gov/show/NCT00057330
3240,A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX,Completed,Has Results,Japanese Encephalitis,Biological: ChimeriVax™-JE|Biological: JE-VAX®,Sanofi,Phase 3,Industry,Interventional,5-Dec-12,https://ClinicalTrials.gov/show/NCT00314145
3241,"""REDUCE"" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk",Completed,Has Results,"Neoplasms, Prostate",Drug: Dutasteride|Drug: Placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,5-Mar-10,https://ClinicalTrials.gov/show/NCT00056407
3242,CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Drug: CC-5013|Drug: Dexamethasone,Celgene,Phase 3,Industry,Interventional,3-Mar-10,https://ClinicalTrials.gov/show/NCT00056160
3243,"Remission in Subjects With Crohn's Disease, 1 Year Phase",Completed,Has Results,Crohn's Disease,Biological: Double-blind (DB) adalimumab placebo|Biological: DB adalimumab 40 mg eow|Biological: DB adalimumab 40 mg ew|Biological: OL adalimumab 40 mg,Abbott,Phase 3,Industry,Interventional,18-May-10,https://ClinicalTrials.gov/show/NCT00055497
3244,Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency,Completed,Has Results,Congenital Bleeding Disorder|Congenital FXIII Deficiency,Drug: catridecacog,Novo Nordisk A/S,Phase 3,Industry,Interventional,12-Jun-14,https://ClinicalTrials.gov/show/NCT01230021
3245,Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),Completed,Has Results,HIV Infections,Drug: Tipranavir|Drug: Ritonavir(r)|Drug: Comparator Protease Inhibitor (CPI),Boehringer Ingelheim,Phase 3,Industry,Interventional,19-Nov-09,https://ClinicalTrials.gov/show/NCT00054717
3246,"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period",Completed,Has Results,Paget's Disease of Bone,Drug: Zoledronic Acid|Drug: Risedronate|Drug: Placebo to Risedronate|Drug: Placebo to Zoledronic Acid|Dietary Supplement: Calcium and Vitamin D,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-May-12,https://ClinicalTrials.gov/show/NCT00051636
3247,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Completed,Has Results,Non-small Cell Lung Cancer,Drug: bexarotene with carboplatin and paclitaxel|Drug: carboplatin and paclitaxel,Eisai Inc.,Phase 3,Industry,Interventional,24-Aug-10,https://ClinicalTrials.gov/show/NCT00050960
3248,Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy,Completed,Has Results,Breast Neoplasms|Osteoporosis,Drug: Zoledronic Acid|Drug: Letrozole,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,28-Jan-14,https://ClinicalTrials.gov/show/NCT00050011
3249,A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis,Completed,Has Results,Rheumatoid Arthritis,Drug: Double-blind Abatacept|Drug: Double-blind Placebo|Drug: Open-label Abatacept,Bristol-Myers Squibb,Phase 3,Industry,Interventional,3-May-11,https://ClinicalTrials.gov/show/NCT00048932
3250,Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,23-Jun-11,https://ClinicalTrials.gov/show/NCT00048581
3251,A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,Completed,Has Results,Rheumatoid Arthritis,Drug: Abatacept|Drug: Methotrexate|Drug: Placebo,Bristol-Myers Squibb,Phase 3,Industry,Interventional,5-Dec-11,https://ClinicalTrials.gov/show/NCT00048568
3252,Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA),Completed,Has Results,"Arthritis, Juvenile Idiopathic",Biological: Double-Blind Adalimumab/Placebo + MTX|Biological: Double-Blind Adalimumab/Placebo|Drug: OLE BSA Adalimumab +/- MTX|Drug: OLE FD Adalimumab +/- MTX,Abbott,Phase 3,Industry,Interventional,11-Jan-10,https://ClinicalTrials.gov/show/NCT00048542
3253,DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis,Completed,Has Results,Post Menopausal Osteoporosis,Drug: ibandronate [Bonviva/Boniva],Hoffmann-La Roche,Phase 3,Industry,Interventional,3-Feb-16,https://ClinicalTrials.gov/show/NCT00048074
3254,MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis,Completed,Has Results,Post Menopausal Osteoporosis,Drug: Ibandronate [Bonviva/Boniva]|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D,Hoffmann-La Roche,Phase 3,Industry,Interventional,30-May-16,https://ClinicalTrials.gov/show/NCT00048061
3255,Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly,Completed,Has Results,Acromegaly,Drug: Pasireotide|Drug: octreotide LAR 30mg|Drug: lanreotide ATG 120mg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,21-Jan-15,https://ClinicalTrials.gov/show/NCT01137682
3256,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,Completed,Has Results,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,Biological: alglucosidase alfa|Drug: Placebo,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,23-Jul-10,https://ClinicalTrials.gov/show/NCT00158600
3257,Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury,Completed,Has Results,Spinal Cord Injury|Muscle Spasticity,Drug: Fampridine-SR|Other: Placebo,Acorda Therapeutics,Phase 3,Industry,Interventional,31-May-13,https://ClinicalTrials.gov/show/NCT00041717
3258,Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis,Completed,Has Results,Asthma,Drug: Placebo Inhalation Powder|Drug: Fluticasone Furoate/GW642444 Inhalation Powder|Drug: Placebo Oral Capsule|Drug: Prednisolone Oral Capsule,GlaxoSmithKline,Phase 3,Industry,Interventional,8-Aug-13,https://ClinicalTrials.gov/show/NCT01086410
3259,Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Tamoxifen|Drug: Exemestane,Pfizer|International Collaborative Cancer Group (ICCG),Phase 3,Industry|Other,Interventional,10-Apr-14,https://ClinicalTrials.gov/show/NCT00038467
3260,Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane,Completed,Has Results,Breast Neoplasms,Drug: exemestane (Aromasin)|Drug: tamoxifen + exemestane,Pfizer,Phase 3,Industry,Interventional,4-Dec-09,https://ClinicalTrials.gov/show/NCT00036270
3261,"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",Completed,Has Results,HIV Infections,Drug: Atazanavir + ritonavir + tenofovir + nucleoside|Drug: Atazanavir + saquinavir + tenofovir + nucleoside|Drug: Lopinavir/ritonavir + tenofovir + nucleoside,Bristol-Myers Squibb,Phase 3,Industry,Interventional,24-Dec-10,https://ClinicalTrials.gov/show/NCT00035932
3262,"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries",Completed,Has Results,Encephalitis,Biological: IC51,Valneva Austria GmbH,Phase 3,Industry,Interventional,19-Dec-14,https://ClinicalTrials.gov/show/NCT01047839
3263,Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children,Completed,Has Results,Osteogenesis Imperfecta,Drug: risedronate sodium (Actonel)|Drug: Placebo,Warner Chilcott,Phase 3,Industry,Interventional,28-Jun-10,https://ClinicalTrials.gov/show/NCT00106028
3264,Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis,Completed,Has Results,Osteoporosis,Drug: Teriparatide|Drug: Alendronate Sodium|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,13-Feb-09,https://ClinicalTrials.gov/show/NCT00051558
3265,Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease,Completed,Has Results,Fabry Disease,Biological: Replagal,Shire,Phase 3,Industry,Interventional,6-Jun-14,https://ClinicalTrials.gov/show/NCT00864851
3266,Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide (HMR1726),Sanofi,Phase 3,Industry,Interventional,30-Jan-17,https://ClinicalTrials.gov/show/NCT00803049
3267,"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17",Completed,Has Results,ADHD,Drug: Lisdexamfetamine dimesylate (LDX)|Drug: Placebo,Shire,Phase 3,Industry,Interventional,2-Oct-12,https://ClinicalTrials.gov/show/NCT00784654
3268,Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro Protamine Suspension|Drug: Insulin Levemir,Eli Lilly and Company,Phase 3,Industry,Interventional,25-Sep-09,https://ClinicalTrials.gov/show/NCT00487240
3269,Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults,Completed,Has Results,Unverricht-Lundborg Disease,Other: Placebo|Drug: BRV 2.5 mg|Drug: BRV 25 mg|Drug: BRV 50 mg,UCB Pharma,Phase 3,Industry,Interventional,13-Apr-16,https://ClinicalTrials.gov/show/NCT00368251
3270,PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin,Completed,Has Results,Familial Hypercholesterolemia,Drug: Rosuvastatin|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,20-Jul-09,https://ClinicalTrials.gov/show/NCT00355615
3271,A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis,Completed,Has Results,Osteoporosis in Men,Biological: Romosozumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,27-May-19,https://ClinicalTrials.gov/show/NCT02186171
3272,To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: placebo to tiotropium + olodaterol|Drug: tiotropium+olodaterol|Drug: tiotropium +olodaterol|Drug: tiotropium,Boehringer Ingelheim,Phase 3,Industry,Interventional,6-Jan-17,https://ClinicalTrials.gov/show/NCT02085161
3273,"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age",Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine (GSK 1437173A),GlaxoSmithKline,Phase 3,Industry,Interventional,24-May-17,https://ClinicalTrials.gov/show/NCT02075515
3274,Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers,Completed,Has Results,Hereditary Periodic Fevers,Drug: Canakinumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,17-Mar-17,https://ClinicalTrials.gov/show/NCT02059291
3275,Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema,Completed,Has Results,Hereditary Angioedema (HAE),Biological: CINRYZE 500|Biological: CINRYZE 1000,Shire,Phase 3,Industry,Interventional,28-Aug-18,https://ClinicalTrials.gov/show/NCT02052141
3276,Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older,Completed,Has Results,Herpes Zoster,"Biological: Herpes Zoster vaccine GSK 1437173A|Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™",GlaxoSmithKline,Phase 3,Industry,Interventional,5-Jul-17,https://ClinicalTrials.gov/show/NCT02045836
3277,Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older,Completed,Has Results,Herpes Zoster,Biological: Herpes Zoster vaccine GSK 1437173A|Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A,GlaxoSmithKline,Phase 3,Industry,Interventional,10-Feb-16,https://ClinicalTrials.gov/show/NCT01954251
3278,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium/Vilanterol 62.5/25 mcg|Drug: Tiotropium 18 mcg,GlaxoSmithKline,Phase 3,Industry,Interventional,25-Feb-16,https://ClinicalTrials.gov/show/NCT01899742
3279,Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,Completed,Has Results,Urinary Tract Infection Symptomatic|Acute Pyelonephritis|Urinary Tract Infection Complicated,Drug: ZTI-01|Drug: Piperacillin-tazobactam,"Nabriva Therapeutics AG|Medpace, Inc.",Phase 2|Phase 3,Industry,Interventional,11-Dec-18,https://ClinicalTrials.gov/show/NCT02753946
3280,"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients",Completed,Has Results,Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant,Drug: RAD001|Drug: MMF,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,31-May-19,https://ClinicalTrials.gov/show/NCT01544491
3281,Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery,Completed,Has Results,Prevent Bleeding in Major Surgery,Biological: human VWF/FVIII concentrate,Octapharma,Phase 3,Industry,Interventional,9-Mar-15,https://ClinicalTrials.gov/show/NCT01365546
3282,Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects,Completed,Has Results,"Infections, Papillomavirus",Procedure: Gynaecological follow-up|Biological: Cervarix|Biological: Placebo control,GlaxoSmithKline,Phase 3,Industry,Interventional,17-Oct-18,https://ClinicalTrials.gov/show/NCT01190176
3283,"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Olodaterol (BI1744) Low|Drug: Olodaterol (BI1744) High|Drug: Tiotropium 18 mcg|Drug: Placebo (for Olodaterol (BI1744)l)|Drug: Placebo (for Tiotropium),Boehringer Ingelheim,Phase 3,Industry,Interventional,30-Jun-14,https://ClinicalTrials.gov/show/NCT01040728
3284,Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis,Completed,Has Results,Cystinosis,Drug: Cystagon® (Cysteamine Bitartrate)|Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103),"Horizon Pharma USA, Inc.",Phase 3,Industry,Interventional,19-Nov-14,https://ClinicalTrials.gov/show/NCT01000961
3285,Phase III Study in Refractory Behcet's Disease,Completed,Has Results,Behcet Disease,Drug: AIN457|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,31-Aug-15,https://ClinicalTrials.gov/show/NCT00995709
3286,A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency,Completed,Has Results,Alpha₁-Antitrypsin Deficiency,Biological: Liquid Alpha₁-PI|Biological: Prolastin-C,Grifols Therapeutics LLC,Phase 2|Phase 3,Industry,Interventional,13-Mar-17,https://ClinicalTrials.gov/show/NCT02282527
3287,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,Completed,Has Results,Carcinoma|Non-Small-Cell Lung,"Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo",Bayer,Phase 3,Industry,Interventional,30-Jul-13,https://ClinicalTrials.gov/show/NCT00863746
3288,The Plecanatide Chronic Idiopathic Constipation (CIC) Study,Completed,Has Results,Chronic Idiopathic Constipation,Drug: plecanatide|Other: Placebo,"Bausch Health Americas, Inc.|Parexel",Phase 2|Phase 3,Industry,Interventional,29-Nov-17,https://ClinicalTrials.gov/show/NCT01429987
3289,Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine,Completed,Has Results,Hepatitis B,Drug: TDF|Drug: FTC/TDF|Drug: TDF Placebo|Drug: FTC/TDF Placebo,Gilead Sciences,Phase 3,Industry,Interventional,11-Apr-13,https://ClinicalTrials.gov/show/NCT00737568
3290,Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection,Completed,Has Results,Hepatitis B Virus (HBV),Drug: Tenofovir disoproxil fumarate (TDF)|Drug: Placebo,Gilead Sciences,Phase 3,Industry,Interventional,7-Nov-12,https://ClinicalTrials.gov/show/NCT00734162
3291,Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase,Completed,Has Results,Gaucher Disease,Drug: Taliglucerase alfa,Pfizer,Phase 3,Industry,Interventional,5-Jun-14,https://ClinicalTrials.gov/show/NCT00712348
3292,"A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms",Completed,Has Results,Fabry Disease,Biological: Agalsidase beta,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,29-Jun-16,https://ClinicalTrials.gov/show/NCT00701415
3293,"Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome",Completed,Has Results,Muckle Wells Syndrome,Drug: ACZ885|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,11-Feb-11,https://ClinicalTrials.gov/show/NCT00465985
3294,Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients,Completed,Has Results,Rheumatoid Arthritis,Drug: Sarilumab|Drug: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic Acid,Sanofi|Regeneron Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,28-Jun-17,https://ClinicalTrials.gov/show/NCT01061736
3295,Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device,Completed,Has Results,Intracranial Aneurysms,Device: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.),"Microvention-Terumo, Inc.",Phase 2|Phase 3,Industry,Interventional,15-Sep-14,https://ClinicalTrials.gov/show/NCT01541254
3296,Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain,Completed,Has Results,Osteoarthritis Knee Pain,Drug: Duloxetine|Drug: Placebo,Eli Lilly and Company,Phase 3,Industry,Interventional,24-Aug-09,https://ClinicalTrials.gov/show/NCT00433290
3297,"Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months",Completed,Has Results,Influenza,Biological: MF59-eH1N1_f,Novartis Vaccines|Novartis,Phase 2|Phase 3,Industry,Interventional,25-May-11,https://ClinicalTrials.gov/show/NCT00996307
3298,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults,Completed,Has Results,Influenza,Biological: MF59-eH1N1_f,Novartis|Novartis Vaccines,Phase 2|Phase 3,Industry,Interventional,25-May-11,https://ClinicalTrials.gov/show/NCT00973349
3299,A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease,Completed,Has Results,Gaucher Disease,Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD),Pfizer,Phase 3,Industry,Interventional,26-Jul-12,https://ClinicalTrials.gov/show/NCT00376168
3300,Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH),Completed,Has Results,Pulmonary Hypertension,Drug: bosentan,Actelion,Phase 3,Industry,Interventional,31-Dec-12,https://ClinicalTrials.gov/show/NCT00319111
3301,Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking,Completed,Has Results,Smoking Cessation,Drug: placebo|Drug: Varenicline,Pfizer,Phase 3,Industry,Interventional,29-Apr-09,https://ClinicalTrials.gov/show/NCT00282984
3302,Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 2|Phase 3,Industry,Interventional,10-Feb-17,https://ClinicalTrials.gov/show/NCT00663260
3303,Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents,Completed,Has Results,Influenza,Biological: Cell culture-derived influenza subunit vaccine (cTIV)|Biological: Egg derived influenza subunit vaccine (eTIV),Novartis|Novartis Vaccines,Phase 2|Phase 3,Industry,Interventional,16-Jan-13,https://ClinicalTrials.gov/show/NCT00645411
3304,Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery,Completed,Has Results,Antithrombin III Deficiency,Biological: Recombinant human antithrombin (rhAT),rEVO Biologics,Phase 3,Industry,Interventional,11-May-12,https://ClinicalTrials.gov/show/NCT00110513
3305,Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE),Completed,Has Results,"Lupus Erythematosus, Systemic",Drug: Atacicept 75 mg|Drug: Atacicept 150 mg|Other: Placebo Comparator,"EMD Serono|Merck KGaA, Darmstadt, Germany",Phase 2|Phase 3,Industry,Interventional,14-Mar-16,https://ClinicalTrials.gov/show/NCT00624338
3306,An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis,Completed,Has Results,"Colitis, Ulcerative",Biological: Placebo|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg|Biological: Golimumab 400 mg|Biological: Golimumab 50 mg,"Janssen Research & Development, LLC|Merck Sharp & Dohme Corp.",Phase 2|Phase 3,Industry,Interventional,17-Feb-14,https://ClinicalTrials.gov/show/NCT00487539
3307,A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Placebo,AstraZeneca|Bristol-Myers Squibb,Phase 2|Phase 3,Industry,Interventional,11-May-17,https://ClinicalTrials.gov/show/NCT00357370
3308,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Optimized Background Therapy (OBT)|Drug: maraviroc (UK-427,857)",ViiV Healthcare|Pfizer,Phase 2|Phase 3,Industry,Interventional,21-Oct-10,https://ClinicalTrials.gov/show/NCT00098748
3309,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Maraviroc (UK-427,857)|Drug: optimized background therapy",ViiV Healthcare|Pfizer,Phase 2|Phase 3,Industry,Interventional,16-May-12,https://ClinicalTrials.gov/show/NCT00098722
3310,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects",Completed,Has Results,HIV Infections,"Drug: Maraviroc (UK-427,857)|Drug: Optimized Background Therapy|Drug: Placebo",ViiV Healthcare|Pfizer,Phase 2|Phase 3,Industry,Interventional,27-Apr-12,https://ClinicalTrials.gov/show/NCT00098306
3311,Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome,Completed,Has Results,Nephrotic Syndrome,Drug: ACTH,Emory University|Mallinckrodt,Phase 3,Other|Industry,Interventional,10-May-19,https://ClinicalTrials.gov/show/NCT02132195
3312,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,Completed,Has Results,HIV Infection,Drug: dolutegravir|Drug: lamivudine|Drug: Continue current antiretroviral regimen,Babafemi Taiwo|ViiV Healthcare|Northwestern University,Phase 3,Other|Industry,Interventional,12-Nov-18,https://ClinicalTrials.gov/show/NCT02263326
3313,SPECTACL: SPECTroscopic Assessment of Coronary Lipid,Completed,Has Results,"Angina Pectoris|Angina, Unstable|Myocardial Infarction",Device: Near Infrared Spectroscopy (NIRS) Imaging|Device: intravascular ultrasound (IVUS),InfraReDx,Phase 2|Phase 3,Industry,Interventional,28-May-09,https://ClinicalTrials.gov/show/NCT00330928
3314,Effects of SAMe in Patients With Alcoholic Liver Disease,Completed,Has Results,"Liver Disease, Alcoholic",Drug: S-adenosylmethionine|Drug: Placebo,"University of California, Davis|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Abbott|Joint Clinical Research Center|University of Colorado, Denver|University of California, Los Angeles",Phase 3,Other|NIH|Industry,Interventional,10-Jun-13,https://ClinicalTrials.gov/show/NCT00573313
3315,Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Eli Lilly and Company|Jaeb Center for Health Research|Locemia Solutions ULC,Phase 2|Phase 3,Industry|Other,Interventional,6-Mar-17,https://ClinicalTrials.gov/show/NCT01997411
3316,A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Ixabepilone (Ixempra)|Drug: Paclitaxel (Taxol),"SCRI Development Innovations, LLC|Bristol-Myers Squibb",Phase 3,Other|Industry,Interventional,12-Apr-17,https://ClinicalTrials.gov/show/NCT00789581
3317,Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects,Completed,Has Results,HIV Infections,Drug: raltegravir,Kaiser Permanente|Merck Sharp & Dohme Corp.,Phase 3,Other|Industry,Interventional,8-Jun-11,https://ClinicalTrials.gov/show/NCT00529243
3318,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Docetaxel|Drug: Vinorelbine|Drug: Carboplatin|Drug: Gemcitabine,H. Lee Moffitt Cancer Center and Research Institute|Sanofi,Phase 3,Other|Industry,Interventional,26-Mar-14,https://ClinicalTrials.gov/show/NCT00499109
3319,High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms,Completed,Has Results,Schizophrenia,Drug: Ziprasidone 80-160 mg/d|Drug: Placebo|Drug: Ziprasidone 160 mg/d,"Donald C. Goff, MD|Pfizer|Massachusetts General Hospital",Phase 3,Other|Industry,Interventional,6-Jun-17,https://ClinicalTrials.gov/show/NCT00403546
3320,Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease,Completed,Has Results,Degenerative Disc Disease,Device: HEALOS and Leopard Cage|Device: Leopard Cage and Autograft,"Advanced Technologies and Regenerative Medicine, LLC (ATRM)|DePuy Spine",Phase 3,Other|Industry,Interventional,3-Mar-11,https://ClinicalTrials.gov/show/NCT00316121
3321,Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma,Completed,Has Results,Prostate Cancer,Drug: Docetaxel|Drug: Prednisone,VA Office of Research and Development|Sanofi,Phase 3,U.S. Fed|Industry,Interventional,25-Jun-18,https://ClinicalTrials.gov/show/NCT00132301
3322,PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C,Completed,Has Results,Chronic Hepatitis C,Drug: Pegylated Interferon/ribavirin,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Roche Pharma AG,Phase 3,NIH|Industry,Interventional,1-Jul-13,https://ClinicalTrials.gov/show/NCT00100659
3323,Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI,Completed,Has Results,Acute Coronary Syndromes,Drug: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin,Medstar Health Research Institute|GlaxoSmithKline,Phase 3,Other|Industry,Interventional,1-Aug-13,https://ClinicalTrials.gov/show/NCT00464087
3324,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY2189265|Drug: Sitagliptin|Drug: Placebo solution|Drug: Placebo tablet|Drug: Metformin,Eli Lilly and Company|United BioSource Corporation|Tessella Inc.|Berry Consultants,Phase 2|Phase 3,Industry|Other,Interventional,28-Jan-15,https://ClinicalTrials.gov/show/NCT00734474
3325,Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study,Completed,Has Results,HIV Infection|Hyperlipidemia,Drug: Atazanavir|Drug: current antiretroviral regimen,Northwestern University|Bristol-Myers Squibb,Phase 3,Other|Industry,Interventional,2-Aug-12,https://ClinicalTrials.gov/show/NCT00225017
3326,Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients,Completed,Has Results,Critical Illness|Sepsis|Multiple Organ Failure,Other: Glutamine|Other: Antioxidants|Other: Glutamine + Antioxidants|Other: Placebo,Daren K. Heyland|Fresenius Kabi|Clinical Evaluation Research Unit at Kingston General Hospital,Phase 3,Other|Industry,Interventional,9-Sep-14,https://ClinicalTrials.gov/show/NCT00133978
3327,An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy,Completed,Has Results,HIV Infections,Drug: Recombinant interleukin-2 (rIL-2),National Institute of Allergy and Infectious Diseases (NIAID)|Chiron Corporation,Phase 3,NIH|Industry,Interventional,25-Apr-11,https://ClinicalTrials.gov/show/NCT00004978
3328,ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab,Completed,Has Results,Systemic Juvenile Idiopathic Arthritis (SJIA),Drug: ACZ885 150 mg (Canakinumab),Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,9-Jul-19,https://ClinicalTrials.gov/show/NCT02296424
3329,"Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A",Completed,Has Results,Congenital Hemophilia A,Biological: rVIII-SingleChain,CSL Behring,Phase 3,Industry,Interventional,27-Jan-17,https://ClinicalTrials.gov/show/NCT02093897
3330,A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis,Completed,Has Results,Postmenopausal Osteoporosis,Drug: Romosozumab 90 mg/mL|Drug: Placebo 90 mg/mL|Drug: Romosozumab 70 mg/mL|Drug: Placebo 70 mg/mL,Amgen,Phase 3,Industry,Interventional,8-Nov-18,https://ClinicalTrials.gov/show/NCT02016716
3331,Topical DHEA Against Vaginal Atrophy,Completed,Has Results,Vaginal Atrophy,Drug: Placebo|Drug: DHEA (0.25%)|Drug: DHEA (0.5%)|Drug: DHEA (1.0%),EndoCeutics Inc.,Phase 3,Industry,Interventional,28-Apr-17,https://ClinicalTrials.gov/show/NCT01846442
3332,Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2,Completed,Has Results,Hyperlipidemia,Biological: Evolocumab|Drug: Placebo,Amgen,Phase 3,Industry,Interventional,22-Dec-15,https://ClinicalTrials.gov/show/NCT01763918
3333,BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity,Completed,Has Results,Muscle Spasticity,Biological: botulinum toxin Type A|Drug: Normal Saline,Allergan,Phase 3,Industry,Interventional,1-Feb-16,https://ClinicalTrials.gov/show/NCT01575054
3334,A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Solifenacin Succinate Suspension|Drug: Placebo|Behavioral: Urotherapy,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,30-Jan-17,https://ClinicalTrials.gov/show/NCT01565707
3335,"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity",Completed,Has Results,Neurogenic Detrusor Overactivity,Drug: Solifenacin succinate,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,6-May-19,https://ClinicalTrials.gov/show/NCT01565694
3336,Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients,Completed,Has Results,HIV,Drug: Atazanavir Sulphate|Drug: Ritonavir,Bristol-Myers Squibb,Phase 3,Industry,Interventional,8-Feb-16,https://ClinicalTrials.gov/show/NCT01335698
3337,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,Completed,Has Results,Hemophilia A,Biological: rFVIII (BAY81-8973) on demand|Biological: rFVIII (BAY81-8973) prophylaxis low-dose|Biological: rFVIII (BAY81-8973) prophylaxis high-dose,Bayer,Phase 3,Industry,Interventional,11-Feb-14,https://ClinicalTrials.gov/show/NCT01233258
3338,Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease,Completed,Has Results,Fabry Disease,Biological: Replagal,Shire,Phase 3,Industry,Interventional,22-Aug-14,https://ClinicalTrials.gov/show/NCT01124643
3339,Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML),Completed,Has Results,Acute Myeloid Leukemia,Drug: Azacitidine|Drug: Conventional Care Regimen,Celgene,Phase 3,Industry,Interventional,26-Feb-15,https://ClinicalTrials.gov/show/NCT01074047
3340,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,Completed,Has Results,Intraabdominal Infections,"Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Ertapenem|Drug: Amoxicillin/Clavulanate|Drug: Moxifloxacin placebo|Drug: Ertapenem placebo|Drug: Amoxicillin/Clavulanate placebo",Bayer,Phase 3,Industry,Interventional,8-Dec-15,https://ClinicalTrials.gov/show/NCT01069900
3341,"Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia",Completed,Has Results,Familial Hypercholesterolemia,Drug: lomitapide,"Aegerion Pharmaceuticals, Inc.",Phase 3,Industry,Interventional,10-May-18,https://ClinicalTrials.gov/show/NCT00943306
3342,Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor,Completed,Has Results,Hemophilia A or B With Inhibitors|Hemophilia A|Hemophilia B,"Biological: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)",Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,14-Mar-14,https://ClinicalTrials.gov/show/NCT00851721
3343,Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour,Completed,Has Results,Non Functioning Entero-pancreatic Endocrine Tumour,Drug: lanreotide (Autogel formulation),Ipsen,Phase 3,Industry,Interventional,17-Feb-17,https://ClinicalTrials.gov/show/NCT00842348
3344,A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH),Completed,Has Results,Homozygous Familial Hypercholesterolemia,Drug: AEGR-733,"Aegerion Pharmaceuticals, Inc.|FDA Office of Orphan Products Development",Phase 3,Industry|U.S. Fed,Interventional,22-Feb-13,https://ClinicalTrials.gov/show/NCT00730236
3345,Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial,Completed,Has Results,Gaucher Disease,Drug: Taliglucerase alfa,Pfizer,Phase 3,Industry,Interventional,15-Jul-14,https://ClinicalTrials.gov/show/NCT00705939
3346,The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: Indacaterol 300 μg|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,17-Aug-11,https://ClinicalTrials.gov/show/NCT00620022
3347,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,Completed,Has Results,Non-Small-Cell Lung Carcinoma,Drug: ZD6474 (vandetanib)|Other: Best Supportive Care,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,26-Mar-12,https://ClinicalTrials.gov/show/NCT00404924
3348,Bosentan in Children With Pulmonary Arterial Hypertension Extension Study,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Bosentan,Actelion,Phase 3,Industry,Interventional,29-Mar-17,https://ClinicalTrials.gov/show/NCT00319020
3349,Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion,Completed,Has Results,Retinal Vein Occlusion,Drug: ranibizumab|Other: Peripheral Laser,"Peter A Campochiaro, MD|The Macula Foundation, Inc.|Genentech, Inc.|Johns Hopkins University",Phase 3,Other|Industry,Interventional,13-Jan-14,https://ClinicalTrials.gov/show/NCT01198327
3350,Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.,Completed,Has Results,"Antithrombin Deficiency, Congenital",Biological: Recombinant Human Antithrombin (rhAT),rEVO Biologics,Phase 3,Industry,Interventional,16-Oct-12,https://ClinicalTrials.gov/show/NCT00056550
3351,Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD),Completed,Has Results,ADHD|Smoking,Drug: Osmotic-Release Methylphenidate|Drug: Placebo,"University of Cincinnati|National Institute on Drug Abuse (NIDA)|Ortho-McNeil Janssen Scientific Affairs, LLC",Phase 3,Other|NIH|Industry,Interventional,17-Sep-12,https://ClinicalTrials.gov/show/NCT00253747
3352,Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide,Completed,Has Results,Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)|Bronchopulmonary Dysplasia,Drug: Infasurf (ONY Inc.)|Drug: Sham,"University of California, San Francisco|Mallinckrodt|ONY",Phase 3,Other|Industry,Interventional,28-Jun-16,https://ClinicalTrials.gov/show/NCT00569530
3353,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease,Drug: dl-alpha-tocopherol|Drug: Memantine|Drug: Placebo,"US Department of Veterans Affairs|Forest Laboratories|DSM Nutritional Products, Inc.|VA Office of Research and Development",Phase 3,U.S. Fed|Industry,Interventional,29-Jan-14,https://ClinicalTrials.gov/show/NCT00235716
3354,"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature",Completed,Has Results,Idiopathic Short Stature,Drug: Aromatase Inhibitor|Drug: Growth Hormone|Drug: Aromatase Inhibitor and Growth Hormone,"Nemours Children's Clinic|Thrasher Research Fund|Genentech, Inc.|Novartis|AstraZeneca|Pfizer",Phase 3,Other|Industry,Interventional,7-Jun-18,https://ClinicalTrials.gov/show/NCT01248416
3355,"A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period",Completed,Has Results,Actinic Keratosis (AK),Drug: Low dose DFD07 once daily|Drug: High dose DFD07 once daily|Drug: High dose DFD07 twice daily|Drug: Placebo twice daily,Dr. Reddy's Laboratories Limited,Phase 2|Phase 3,Industry,Interventional,24-Apr-19,https://ClinicalTrials.gov/show/NCT03116698
3356,"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",Completed,Has Results,"Migraine, With or Without Aura",Drug: Atogepant|Drug: Placebo-matching Atogepant,Allergan,Phase 2|Phase 3,Industry,Interventional,6-Dec-18,https://ClinicalTrials.gov/show/NCT02848326
3357,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Completed,Has Results,Acute Migraine,Drug: ZP-Zolmitriptan|Drug: Placebo,Zosano Pharma Corporation,Phase 2|Phase 3,Industry,Interventional,14-Feb-18,https://ClinicalTrials.gov/show/NCT02745392
3358,Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma,Completed,Has Results,Asthma,Drug: NVA237 (glycopyrronium bromide)|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,16-Jan-19,https://ClinicalTrials.gov/show/NCT03137784
3359,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",Completed,Has Results,"Type 2 Diabetes Mellitus, CKD and Albuminuria",Drug: Dapagliflozin 10 mg|Drug: Dapagliflozin 10mg+Saxagliptin 2.5mg|Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,AstraZeneca,Phase 2|Phase 3,Industry,Interventional,4-Jun-19,https://ClinicalTrials.gov/show/NCT02547935
3360,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,Completed,Has Results,"Leukemia, Myeloid, Acute",Drug: Decitabine 20 mg/m^2|Drug: Talacotuzumab 9 mg/kg,"Janssen Research & Development, LLC",Phase 2|Phase 3,Industry,Interventional,28-Feb-19,https://ClinicalTrials.gov/show/NCT02472145
3361,Aim to Reduce Movements in Tardive Dyskinesia,Completed,Has Results,Tardive Dyskinesia,Drug: SD-809|Drug: Placebo,"Auspex Pharmaceuticals, Inc.|Teva Pharmaceutical Industries",Phase 2|Phase 3,Industry,Interventional,20-Mar-18,https://ClinicalTrials.gov/show/NCT02195700
3362,Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study),Completed,Has Results,Delayed Graft Function,Drug: Eculizumab|Drug: Placebo,Alexion Pharmaceuticals|CTI Clinical Trial and Consulting Services,Phase 2|Phase 3,Industry|Other,Interventional,17-Dec-18,https://ClinicalTrials.gov/show/NCT02145182
3363,A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ),Completed,Has Results,"ADHD|Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type",Drug: MG01CI (1400 mg)|Drug: placebo,Alcobra Ltd.,Phase 2|Phase 3,Industry,Interventional,28-Mar-17,https://ClinicalTrials.gov/show/NCT02059642
3364,"Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",Completed,Has Results,Sporadic Inclusion Body Myositis,Drug: BYM338/bimagrumab|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,12-May-17,https://ClinicalTrials.gov/show/NCT01925209
3365,BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT),Completed,Has Results,Primary Fibromyalgia,Drug: TNX-102 SL 2.8mg|Drug: Placebo,"Tonix Pharmaceuticals, Inc.",Phase 2|Phase 3,Industry,Interventional,23-Dec-16,https://ClinicalTrials.gov/show/NCT01903265
3366,Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer),Completed,Has Results,Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer,Drug: nab-Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine,Celgene,Phase 2|Phase 3,Industry,Interventional,8-Mar-18,https://ClinicalTrials.gov/show/NCT01881230
3367,Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study),Completed,Has Results,Hemophilia A,Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Biological: PEGylated Recombinant Factor VIII,Baxalta now part of Shire|Shire,Phase 2|Phase 3,Industry,Interventional,7-Sep-16,https://ClinicalTrials.gov/show/NCT01736475
3368,Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps,Completed,Has Results,Chronic Sinusitis|Nasal Polyps,Drug: S8 Sinus Implant|Procedure: Sham procedure|Drug: Mometasone furoate nasal spray,Intersect ENT,Phase 2|Phase 3,Industry,Interventional,20-Jul-18,https://ClinicalTrials.gov/show/NCT01732536
3369,Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy,Completed,Has Results,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Drug: Inotersen|Drug: Placebo,"Ionis Pharmaceuticals, Inc.",Phase 2|Phase 3,Industry,Interventional,23-Jan-19,https://ClinicalTrials.gov/show/NCT01737398
3370,BIOHELIX-I Bare Metal Stent Study,Completed,Has Results,Coronary Arteries Disease,Device: PRO-Kinetic Energy Stent,"Biotronik, Inc.",Phase 2|Phase 3,Industry,Interventional,30-May-17,https://ClinicalTrials.gov/show/NCT01612767
3371,"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents",Completed,Has Results,Acquired Immunodeficiency Syndrome|HIV Infections,Drug: EVG/COBI/FTC/TDF,Gilead Sciences,Phase 2|Phase 3,Industry,Interventional,10-Apr-17,https://ClinicalTrials.gov/show/NCT01721109
3372,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",Completed,Has Results,Breast Cancer,Drug: Paclitaxel|Drug: BKM120 matching placebo|Drug: BKM120,Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,27-Jan-17,https://ClinicalTrials.gov/show/NCT01572727
3373,Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,Completed,Has Results,Acute Upper Respiratory Tract Infection,Drug: Mucinex|Drug: Immediate-release Guaifenesin|Drug: Placebo,Reckitt Benckiser LLC,Phase 2|Phase 3,Industry,Interventional,12-Sep-13,https://ClinicalTrials.gov/show/NCT01537081
3374,"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: Immune Globulin Infusion (Human), 10%|Biological: Recombinant human hyaluronidase",Baxalta now part of Shire|Shire,Phase 2|Phase 3,Industry,Interventional,24-Apr-17,https://ClinicalTrials.gov/show/NCT01485796
3375,"An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A",Completed,Has Results,Hemophilia A,Biological: rVIII-SingleChain|Biological: Octocog alfa,CSL Behring,Phase 2|Phase 3,Industry,Interventional,9-Aug-16,https://ClinicalTrials.gov/show/NCT01486927
3376,Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder,Completed,Has Results,Major Depressive Disorder,Drug: tasimelteon|Drug: placebo,Vanda Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,19-Jun-15,https://ClinicalTrials.gov/show/NCT01428661
3377,Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),Completed,Has Results,Dyskinesia|Levodopa Induced Dyskinesia|Parkinson's Disease,Drug: ADS-5102 (extended release amantadine HCl),"Adamas Pharmaceuticals, Inc.",Phase 2|Phase 3,Industry,Interventional,6-Nov-17,https://ClinicalTrials.gov/show/NCT01397422
3378,Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders,Completed,Has Results,Severe Familial Hypercholesterolemia,Biological: Evolocumab,Amgen,Phase 2|Phase 3,Industry,Interventional,28-Jan-19,https://ClinicalTrials.gov/show/NCT01624142
3379,Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis,Completed,Has Results,Peripheral Arterial Disease,Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|Procedure: Balloon angioplasty,Spectranetics Corporation,Phase 2|Phase 3,Industry,Interventional,15-Jun-16,https://ClinicalTrials.gov/show/NCT01330628
3380,Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcers,Device: Epiflo|Other: Moist Wound Therapy,"Neogenix, LLC dba Ogenix",Phase 2|Phase 3,Industry,Interventional,13-May-14,https://ClinicalTrials.gov/show/NCT01291160
3381,Vigabatrin for the Treatment of Cocaine Dependency,Completed,Has Results,Cocaine Addiction|Cocaine Dependence,Drug: Vigabatrin|Drug: Matching Placebo,"Catalyst Pharmaceuticals, Inc.|National Institute on Drug Abuse (NIDA)|VA Office of Research and Development",Phase 2|Phase 3,Industry|NIH|U.S. Fed,Interventional,23-Feb-16,https://ClinicalTrials.gov/show/NCT01281202
3382,Epanova® for Lowering Very High Triglycerides,Completed,Has Results,Severe Hypertriglyceridemia,Drug: placebo|Drug: omefas,AstraZeneca,Phase 2|Phase 3,Industry,Interventional,6-Sep-13,https://ClinicalTrials.gov/show/NCT01242527
3383,"Phase 2/3 Study of IGSC, 20% in PIDD",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Biological: Immune Globulin Intravenous (Human), 10% Solution|Drug: Immune Globulin Subcutaneous (Human), 20% Solution",Baxalta now part of Shire|Shire,Phase 2|Phase 3,Industry,Interventional,15-Feb-17,https://ClinicalTrials.gov/show/NCT01218438
3384,Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),Completed,Has Results,Diffuse Large B-cell Lymphoma,Drug: Lenalidomide|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Rituximab|Drug: Etoposide,Celgene,Phase 2|Phase 3,Industry,Interventional,20-Aug-14,https://ClinicalTrials.gov/show/NCT01197560
3385,"Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age",Completed,Has Results,Sedation,Drug: Midazolam|Drug: Fentanyl/Morphine|Drug: Dexmedetomidine,"Hospira, now a wholly owned subsidiary of Pfizer",Phase 2|Phase 3,Industry,Interventional,12-Dec-14,https://ClinicalTrials.gov/show/NCT01159262
3386,Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A,Completed,Has Results,Acquired Hemophilia A,Biological: OBI-1,Baxalta now part of Shire|Shire,Phase 2|Phase 3,Industry,Interventional,21-Dec-15,https://ClinicalTrials.gov/show/NCT01178294
3387,"Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)",Completed,Has Results,Preterm Delivery,"Drug: 17-alpha-hydroxy-progesterone caproate, Makena®|Drug: Castor Oil (Placebo)","Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Phase 2|Phase 3,Industry,Interventional,30-May-18,https://ClinicalTrials.gov/show/NCT01119963
3388,Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy,Completed,Has Results,Infantile Hemangioma,Drug: Propranolol|Drug: Placebo,Pierre Fabre Dermatology,Phase 2|Phase 3,Industry,Interventional,24-Jun-14,https://ClinicalTrials.gov/show/NCT01056341
3389,Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years),Completed,Has Results,Influenza,Biological: MF59-eH1N1,Novartis Vaccines|Novartis,Phase 2|Phase 3,Industry,Interventional,27-Jan-11,https://ClinicalTrials.gov/show/NCT00972816
3390,A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder,Completed,Has Results,Attention Deficit Hyperactivity Disorder,Drug: LY2216684|Drug: Methylphenidate|Drug: Placebo (tablet)|Drug: Placebo (capsule),Eli Lilly and Company,Phase 2|Phase 3,Industry,Interventional,18-Aug-14,https://ClinicalTrials.gov/show/NCT00922636
3391,"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients",Completed,Has Results,Acute Myeloid Leukemia,Drug: AZD1152|Drug: LDAC,AstraZeneca,Phase 2|Phase 3,Industry,Interventional,31-Mar-14,https://ClinicalTrials.gov/show/NCT00952588
3392,A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age,Completed,Has Results,Healthy or Stable Underlying Chronic Medical Condition,Biological: Q/LAIV (MEDI3250)|Biological: FluMist/B/Yamagata|Biological: FluMist/B/Victoria,MedImmune LLC,Phase 2|Phase 3,Industry,Interventional,12-Aug-11,https://ClinicalTrials.gov/show/NCT00860067
3393,A Study in Adult Patients With Major Depressive Disorder,Completed,Has Results,"Depressive Disorder, Major",Drug: LY2216684|Drug: Placebo,Eli Lilly and Company,Phase 2|Phase 3,Industry,Interventional,20-Mar-18,https://ClinicalTrials.gov/show/NCT00795821
3394,"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",Completed,Has Results,Hemophilia B,Biological: IB1001|Biological: nonacog alfa,Aptevo BioTherapeutics|Aptevo Therapeutics,Phase 2|Phase 3,Industry,Interventional,10-Sep-18,https://ClinicalTrials.gov/show/NCT00768287
3395,Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder,Completed,Has Results,"Bladder, Neurogenic",Drug: tamsulosin hydrochloride|Drug: Placebo,Boehringer Ingelheim,Phase 2|Phase 3,Industry,Interventional,12-Sep-12,https://ClinicalTrials.gov/show/NCT00796614
3396,Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase,Completed,Has Results,Hunter Syndrome|Mucopolysaccharidosis II (MPS II),Biological: Idursulfase,Shire,Phase 2|Phase 3,Industry,Interventional,17-Mar-14,https://ClinicalTrials.gov/show/NCT00630747
3397,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",Completed,Has Results,Macular Edema Associated With Diabetes Mellitus,Drug: Standard of Care|Drug: Macugen,Pfizer,Phase 2|Phase 3,Industry,Interventional,30-Mar-11,https://ClinicalTrials.gov/show/NCT00605280
3398,Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring,Completed,Has Results,Acne Scarring of the Face,Biological: Autologous Human Fibroblasts (azficel-T)|Biological: Placebo,"Fibrocell Technologies, Inc.",Phase 2|Phase 3,Industry,Interventional,21-Aug-13,https://ClinicalTrials.gov/show/NCT00642642
3399,Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years,Completed,Has Results,Eosinophilic Esophagitis,Biological: Reslizumab|Other: Saline,Ception Therapeutics|Teva Pharmaceutical Industries,Phase 2|Phase 3,Industry,Interventional,2-Sep-16,https://ClinicalTrials.gov/show/NCT00538434
3400,"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects",Completed,Has Results,Primary Immunodeficiency Diseases (PID),"Drug: Immune Globulin Intravenous (Human), 10%",Baxalta now part of Shire|Shire,Phase 2|Phase 3,Industry,Interventional,23-Aug-12,https://ClinicalTrials.gov/show/NCT00546871
3401,Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase,Completed,Has Results,Gaucher Disease,Biological: GA-GCB (velaglucerase alfa),Shire,Phase 2|Phase 3,Industry,Interventional,2-Sep-10,https://ClinicalTrials.gov/show/NCT00478647
3402,"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)",Completed,Has Results,"Pulmonary Disease, Chronic Obstructive|COPD|Lung Diseases, Obstructive",Drug: Indacaterol|Drug: Formoterol (12 µg b.i.d.)|Drug: Tiotropium (18 µg o.d.)|Drug: Placebo to Indacaterol|Drug: Placebo to Formoterol,Novartis,Phase 2|Phase 3,Industry,Interventional,18-Aug-11,https://ClinicalTrials.gov/show/NCT00463567
3403,Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents,Completed,Has Results,HIV,Drug: E/C/F/TAF,Gilead Sciences,Phase 2|Phase 3,Industry,Interventional,22-Feb-18,https://ClinicalTrials.gov/show/NCT02276612
3404,First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX,Completed,Has Results,Colorectal Cancer,Drug: Cediranib|Drug: Bevacizumab|Drug: 5-fluorouracil ( in FOLFOX)|Drug: Leucovorin (in FOLFOX)|Drug: Oxaliplatin (in FOLFOX),AstraZeneca,Phase 2|Phase 3,Industry,Interventional,28-Nov-12,https://ClinicalTrials.gov/show/NCT00384176
3405,A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.,Completed,Has Results,Procedural Sedation,Drug: AQUAVAN® (fospropofol disodium) Injection,Eisai Inc.,Phase 2|Phase 3,Industry,Interventional,20-Jun-12,https://ClinicalTrials.gov/show/NCT00327392
3406,A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy,Completed,Has Results,Diabetic Neuropathy,Drug: lacosamide,UCB Pharma,Phase 2|Phase 3,Industry,Interventional,5-Oct-09,https://ClinicalTrials.gov/show/NCT00235443
3407,2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.,Completed,Has Results,Iron Deficiency Anemia,Drug: Sodium Ferric Gluconate Complex|Drug: Oral Iron,Watson Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,28-Sep-09,https://ClinicalTrials.gov/show/NCT00223977
3408,Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks,Completed,Has Results,Hereditary Angioedema,Biological: C1 Esterase Inhibitor|Biological: Placebo,CSL Behring,Phase 2|Phase 3,Industry,Interventional,24-Aug-10,https://ClinicalTrials.gov/show/NCT00168103
3409,17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies,Completed,Has Results,Preterm Birth,Drug: 17-alpha-hydroxyprogesterone caproate injectable|Drug: Placebo,"Obstetrix Medical Group|Mednax Center for Research, Education, Quality and Safety",Phase 2|Phase 3,Industry,Interventional,7-Nov-12,https://ClinicalTrials.gov/show/NCT00163020
3410,Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,Completed,Has Results,Hypertension,Drug: olmesartan medoxomil|Drug: placebo,"Daiichi Sankyo, Inc.",Phase 2|Phase 3,Industry,Interventional,2-Apr-10,https://ClinicalTrials.gov/show/NCT00151775
3411,Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects,Completed,Has Results,HIV Infections,Drug: Tipranavir,Boehringer Ingelheim,Phase 2|Phase 3,Industry,Interventional,16-Jul-09,https://ClinicalTrials.gov/show/NCT00146328
3412,WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Stroke,Device: WATCHMAN Left Atrial Appendage Closure Technology|Drug: Warfarin,Boston Scientific Corporation,Phase 2|Phase 3,Industry,Interventional,15-May-15,https://ClinicalTrials.gov/show/NCT00129545
3413,Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Degarelix,Ferring Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,21-Oct-10,https://ClinicalTrials.gov/show/NCT00117286
3414,A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B,Completed,Has Results,Hemophilia B,Biological: rIX-FP,CSL Behring,Phase 2|Phase 3,Industry,Interventional,9-May-16,https://ClinicalTrials.gov/show/NCT01496274
3415,A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients,Completed,Has Results,Cytomegalovirus Infections,Drug: valganciclovir [Valcyte],Hoffmann-La Roche,Phase 2|Phase 3,Industry,Interventional,31-Oct-16,https://ClinicalTrials.gov/show/NCT00090766
3416,12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.,Completed,Has Results,Multiple Sclerosis,Drug: Rebif® New Formulation (RNF) using RebiSmartTM,EMD Serono,Phase 3,Industry,Interventional,11-Aug-10,https://ClinicalTrials.gov/show/NCT00735007
3417,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",Completed,Has Results,Chronic Kidney Disease Requiring Chronic Dialysis,Drug: PA21 (2.5 g tablet containing 500 mg iron)|Drug: Sevelamer carbonate,Vifor Inc.|Fresenius Medical Care North America,Phase 3,Industry,Interventional,17-Feb-14,https://ClinicalTrials.gov/show/NCT01464190
3418,"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",Completed,Has Results,Chronic Kidney Disease Requiring Chronic Dialysis,Drug: PA21 (2.5 g tablet containing 500 mg iron)|Drug: Sevelamer carbonate|Drug: PA21-1 (1.25 g tablet containing 250 mg iron),Vifor Inc.|Fresenius Medical Care North America,Phase 3,Industry,Interventional,1-Apr-14,https://ClinicalTrials.gov/show/NCT01324128
3419,Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.,Completed,Has Results,Asthma,Drug: Ciclesonide|Drug: Placebo,AstraZeneca,Phase 3,Industry,Interventional,30-Dec-09,https://ClinicalTrials.gov/show/NCT00392288
3420,Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation,Completed,Has Results,"Heart Defects, Congenital",Drug: Clopidogrel|Drug: placebo,Sanofi|Bristol-Myers Squibb,Phase 3,Industry,Interventional,16-Aug-11,https://ClinicalTrials.gov/show/NCT00833703
3421,A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches,Completed,Has Results,Migraine Disorders,Biological: Botulinum Toxin Type A|Other: placebo (saline),Allergan,Phase 3,Industry,Interventional,7-Dec-10,https://ClinicalTrials.gov/show/NCT00168428
3422,Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II),Completed,Has Results,Mucopolysaccharidosis II,Biological: Iduronate-2-sulfatase enzyme replacement therapy|Biological: iduronate-2-sulfatase enzyme replacement therapy|Biological: Placebo,Shire,Phase 2|Phase 3,Industry,Interventional,13-May-15,https://ClinicalTrials.gov/show/NCT00069641
3423,Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs,Completed,Has Results,"Hypertension, Pulmonary",Drug: tadalafil,Eli Lilly and Company|ICOS Corporation,Phase 3,Industry,Interventional,18-Feb-13,https://ClinicalTrials.gov/show/NCT00549302
3424,A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,Completed,Has Results,Carcinoma|Non Small Cell Lung,"Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Docetaxel (Taxotere®)|Drug: Dexamethasone (pre- and post-medication for docetaxel)",Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,1-Jan-13,https://ClinicalTrials.gov/show/NCT00532155
3425,Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer,Completed,Has Results,Prostatic Neoplasms|Neoplasm Metastasis,Drug: Aflibercept|Drug: Placebo (for aflibercept)|Drug: Docetaxel|Drug: Prednisone or Prednisolone,Sanofi|Regeneron Pharmaceuticals,Phase 3,Industry,Interventional,10-Oct-13,https://ClinicalTrials.gov/show/NCT00519285
3426,Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation,Completed,Has Results,"Heart Defects, Congenital",Drug: Clopidogrel (SR25990)|Drug: placebo,Sanofi|Bristol-Myers Squibb,Phase 3,Industry,Interventional,11-Mar-11,https://ClinicalTrials.gov/show/NCT00396877
3427,Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment,Completed,Has Results,Hunter Syndrome,Biological: idursulfase-IT|Other: No IT treatment,Shire,Phase 2|Phase 3,Industry,Interventional,13-Dec-18,https://ClinicalTrials.gov/show/NCT02055118
3428,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,Completed,Has Results,Acute Coronary Disease|Angina Unstable,Drug: Clopidogrel|Drug: acetylsalicyclic acid (ASA),Sanofi|Bristol-Myers Squibb,Phase 3,Industry,Interventional,7-Oct-10,https://ClinicalTrials.gov/show/NCT00335452
3429,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A),Completed,Has Results,Atrial Fibrillation|Vascular Risk,Drug: clopidogrel (SR25990C)|Drug: placebo,Sanofi|Bristol-Myers Squibb,Phase 3,Industry,Interventional,26-Mar-10,https://ClinicalTrials.gov/show/NCT00249873
3430,Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I),Completed,Has Results,Atrial Fibrillation|Cardiovascular Disease,Drug: Irbesartan|Drug: placebo,Sanofi|Bristol-Myers Squibb,Phase 3,Industry,Interventional,15-Oct-10,https://ClinicalTrials.gov/show/NCT00249795
3431,Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens,Completed,Has Results,Heart Diseases|Heart Transplantation,Drug: Tacrolimus|Drug: Cyclosporine|Drug: Mycophenolate mofetil|Drug: Methylprednisolone|Drug: Prednisone,"Astellas Pharma Inc|Astellas Pharma Canada, Inc.",Phase 3,Industry,Interventional,21-Feb-11,https://ClinicalTrials.gov/show/NCT00157014
3432,Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD),Completed,Has Results,Iron Deficiency Anaemia|Chronic Kidney Disease,Drug: FCM (Ferric carboxymaltose) high ferritin target|Drug: FCM (Ferric carboxymaltose) low ferritin target|Drug: Oral Iron (Ferrous sulphate),"Vifor Inc.|American Regent, Inc.|ICON Clinical Research",Phase 3,Industry,Interventional,7-May-14,https://ClinicalTrials.gov/show/NCT00994318
3433,Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP),Completed,Has Results,Hypophosphatasia,Drug: asfotase alfa,Alexion Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,26-Feb-18,https://ClinicalTrials.gov/show/NCT01176266
3434,Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension,Completed,Has Results,Pulmonary Arterial Hypertension,Drug: Imatinib mesylate|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,23-Mar-15,https://ClinicalTrials.gov/show/NCT00477269
3435,Antibiotic Safety (SCAMP),Completed,Has Results,Complicated Intra Abdominal Infections,"Drug: ampicillin and metronidazole and gentamicin|Drug: ampicillin and gentamicin and clindamycin|Drug: gentamicin and Piperacillin- tazobactam|Drug: standard of care antibiotics and metronidazole|Drug: metronidazole, clindamycin, or piperacillin-tazobactam","Michael Cohen-Wolkowiez|The Emmes Company, LLC|Duke University",Phase 2|Phase 3,Other|Industry,Interventional,27-Feb-18,https://ClinicalTrials.gov/show/NCT01994993
3436,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,Completed,Has Results,Proliferative Diabetic Retinopathy,Other: Prompt Panretinal Photocoagulation|Drug: 0.5-mg Ranibizumab|Other: Deferred panretinal photocoagulation,"Jaeb Center for Health Research|National Eye Institute (NEI)|Genentech, Inc.",Phase 3,Other|NIH|Industry,Interventional,1-Jun-16,https://ClinicalTrials.gov/show/NCT01489189
3437,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Cisplatin|Drug: Etoposide|Radiation: Radiation|Drug: Docetaxel,"Nasser Hanna, M.D.|Sanofi|Walther Cancer Institute|Hoosier Cancer Research Network",Phase 3,Other|Industry,Interventional,8-Feb-16,https://ClinicalTrials.gov/show/NCT00216125
3438,Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial,Completed,Has Results,Parkinson's Disease,Device: Bilateral Deep Brain Stimulation,US Department of Veterans Affairs|National Institute of Neurological Disorders and Stroke (NINDS)|Medtronic|VA Office of Research and Development,Phase 3,U.S. Fed|NIH|Industry,Interventional,15-Jan-14,https://ClinicalTrials.gov/show/NCT01076452
3439,Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study),Completed,Has Results,Heart Failure,Drug: Placebo|Drug: Sildenafil,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Phase 3,Other|NIH|Industry,Interventional,3-Jul-13,https://ClinicalTrials.gov/show/NCT00763867
3440,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),Completed,Has Results,Heart Failure,Drug: Stepped pharmacologic care|Device: Ultrafiltration,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)|CHF Solutions",Phase 3,Other|NIH|Industry,Interventional,24-Jun-13,https://ClinicalTrials.gov/show/NCT00608491
3441,Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis,Completed,Has Results,"Pulmonary Fibrosis|Hypertension, Pulmonary",Drug: Sildenafil Citrate|Other: Placebo,"Duke University|National Heart, Lung, and Blood Institute (NHLBI)|Pfizer",Phase 3,Other|NIH|Industry,Interventional,23-Aug-13,https://ClinicalTrials.gov/show/NCT00517933
3442,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",Completed,Has Results,Alzheimer's Disease,Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo,"Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|DSM Nutritional Products, Inc.",Phase 3,Other|NIH|Industry,Interventional,30-Aug-10,https://ClinicalTrials.gov/show/NCT00440050
3443,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,Completed,Has Results,"Fatigue|Unspecified Adult Solid Tumor, Protocol Specific",Drug: methylphenidate hydrochloride|Other: placebo,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",Phase 3,Other|NIH|Industry,Interventional,10-Oct-14,https://ClinicalTrials.gov/show/NCT00376675
3444,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Procedure: Standard of Care Group|Drug: 1mg triamcinolone acetonide|Drug: 4mg triamcinolone acetonide,Jaeb Center for Health Research|National Eye Institute (NEI)|Allergan,Phase 3,Other|NIH|Industry,Interventional,9-Jul-10,https://ClinicalTrials.gov/show/NCT00367133
3445,Actos Now for Prevention of Diabetes (ACT NOW),Completed,Has Results,Impaired Glucose Tolerance|Type 2 Diabetes,Drug: Pioglitazone|Drug: Placebo,"The University of Texas Health Science Center at San Antonio|University of Texas|Takeda Pharmaceuticals North America, Inc.",Phase 3,Other|Industry,Interventional,11-Aug-16,https://ClinicalTrials.gov/show/NCT00220961
3446,Antenatal Micronutrient Supplementation and Infant Survival,Completed,Has Results,Infant Mortality|Preterm Birth|Low Birth Weight|Neonatal Mortality|Perinatal Mortality,Dietary Supplement: Iron (27 mg) - folic acid (600 ug)|Dietary Supplement: Multiple micronutrient,"Johns Hopkins Bloomberg School of Public Health|Bill and Melinda Gates Foundation|United States Agency for International Development (USAID)|Mahidol University|Johns Hopkins University|Beximco|DSM Nutritional Products, Inc.",Phase 3,Other|U.S. Fed|Industry,Interventional,27-May-15,https://ClinicalTrials.gov/show/NCT00860470
3447,Insulin Resistance Intervention After Stroke Trial,Completed,Has Results,Stroke|Myocardial Infarction|Diabetes,Drug: pioglitazone|Drug: placebo,"Yale University|National Institute of Neurological Disorders and Stroke (NINDS)|Takeda Pharmaceuticals North America, Inc.",Phase 3,Other|NIH|Industry,Interventional,28-Oct-16,https://ClinicalTrials.gov/show/NCT00091949
3448,Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin|Drug: Glimepiride|Drug: Rosiglitazone|Drug: Metformin,VA Office of Research and Development|National Eye Institute (NEI)|SmithKline Beecham,Phase 3,U.S. Fed|NIH|Industry,Interventional,12-Feb-14,https://ClinicalTrials.gov/show/NCT00032487
3449,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,Completed,Has Results,Solid Tumors,Drug: dovitinib|Drug: fulvestrant,Novartis Pharmaceuticals|Novartis,Phase 2|Phase 3,Industry,Interventional,1-Feb-18,https://ClinicalTrials.gov/show/NCT02116803
3450,Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities,Completed,Has Results,Homozygous Familial Hypercholesterolemia,Biological: Evolocumab|Drug: Placebo,Amgen,Phase 2|Phase 3,Industry,Interventional,2-Oct-15,https://ClinicalTrials.gov/show/NCT01588496
3451,Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site,Completed,Has Results,"Neoplasms, Unknown Primary",Drug: Etoposide|Drug: Gemcitabine|Drug: Irinotecan|Drug: Paclitaxel|Drug: Carboplatin,"SCRI Development Innovations, LLC|AstraZeneca|Pharmacia and Upjohn|Eli Lilly and Company",Phase 3,Other|Industry,Interventional,3-May-13,https://ClinicalTrials.gov/show/NCT00193596
3452,The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome,Completed,Has Results,Deep Venous Thrombosis,"Device: Knee-length, graduated elastic compression stocking|Device: Knee-length, placebo stocking",Sir Mortimer B. Davis - Jewish General Hospital|Canadian Institutes of Health Research (CIHR)|Sigvaris Corporation,Phase 3,Other|Industry,Interventional,18-Aug-14,https://ClinicalTrials.gov/show/NCT00143598
3453,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B,Completed,Has Results,"Kidney, Polycystic",Drug: Lisinopril|Drug: Telmisartan|Drug: Placebo,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Boehringer Ingelheim|Merck Sharp & Dohme Corp.|Polycystic Kidney Disease Foundation,Phase 3,NIH|Industry|Other,Interventional,10-Mar-15,https://ClinicalTrials.gov/show/NCT01885559
3454,Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery,Completed,Has Results,Congenital Fibrinogen Deficiency,Drug: Octafibrin,Octapharma,Phase 3,Industry,Interventional,20-Feb-19,https://ClinicalTrials.gov/show/NCT02267226
3455,A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease,Completed,Has Results,"Pulmonary Disease, Chronic Obstructive",Drug: Umeclidinium|Drug: Umeclidinium matching placebo|Drug: Tiotropium|Drug: Tiotropium matching placebo,GlaxoSmithKline,Phase 3,Industry,Interventional,9-Feb-16,https://ClinicalTrials.gov/show/NCT02207829
3456,Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant,Completed,Has Results,Heart Transplantation|Liver Transplantation|Kidney Transplantation,Drug: FK506E,Astellas Pharma Europe Ltd.|Astellas Pharma Inc,Phase 3,Industry,Interventional,15-Mar-16,https://ClinicalTrials.gov/show/NCT02118896
3457,HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A,Completed,Has Results,"Kidney, Polycystic",Drug: Lisinopril|Drug: Telmisartan|Drug: Placebo|Other: Standard Blood Pressure Control|Other: Low Blood Pressure Control,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Boehringer Ingelheim|Merck Sharp & Dohme Corp.|Polycystic Kidney Disease Foundation,Phase 3,NIH|Industry|Other,Interventional,27-Feb-15,https://ClinicalTrials.gov/show/NCT00283686
3458,A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),Completed,Has Results,Immune Thrombocytopenic Purpura,Drug: Fostamatinib Disodium|Drug: Placebo,Rigel Pharmaceuticals,Phase 3,Industry,Interventional,25-Jan-19,https://ClinicalTrials.gov/show/NCT02076412
3459,"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)",Completed,Has Results,Neurogenic Detrusor Overactivity|Pediatric,Drug: Solifenacin succinate,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,21-Jun-18,https://ClinicalTrials.gov/show/NCT01981954
3460,Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III,Completed,Has Results,Intraventricular Hemorrhage,Drug: Alteplase|Other: Normal saline,"Johns Hopkins University|National Institute of Neurological Disorders and Stroke (NINDS)|Genentech, Inc.|Emissary International LLC",Phase 3,Other|NIH|Industry,Interventional,2-Jul-17,https://ClinicalTrials.gov/show/NCT00784134
3461,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),Completed,Has Results,Coronary Artery Disease,"Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)",Bayer,Phase 3,Industry,Interventional,16-May-18,https://ClinicalTrials.gov/show/NCT01890421
3462,A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence,Completed,Has Results,Overactive Bladder|Urinary Incontinence,Biological: BOTOX®|Drug: solifenacin|Drug: Botox placebo (normal saline)|Drug: solifenacin placebo,Allergan,Phase 3,Industry,Interventional,12-Jan-16,https://ClinicalTrials.gov/show/NCT01767519
3463,Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen,Completed,Has Results,Hemophilia A|Hemophilia B,Biological: Recombinant Factor VIIa BI (rFVIIa BI),Baxalta now part of Shire|Shire,Phase 3,Industry,Interventional,25-Oct-16,https://ClinicalTrials.gov/show/NCT01757405
3464,A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076,Completed,Has Results,"Urinary Bladder, Overactive",Drug: Solifenacin succinate suspension,Astellas Pharma Europe B.V.|Astellas Pharma Inc,Phase 3,Industry,Interventional,11-Dec-17,https://ClinicalTrials.gov/show/NCT01655069
3465,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),Completed,Has Results,Urinary Incontinence|Multiple Sclerosis|Neurogenic Bladder,Biological: OnabotulinumtoxinA|Drug: Placebo (Normal Saline),Allergan,Phase 3,Industry,Interventional,22-Mar-16,https://ClinicalTrials.gov/show/NCT01600716
3466,"A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome",Completed,Has Results,Familial Chylomicronemia Syndrome (FCS),Drug: LCQ908|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,3-Jun-15,https://ClinicalTrials.gov/show/NCT01514461
3467,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,Completed,Has Results,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,Drug: Ranibizumab|Drug: Triamcinolone Acetonide|Behavioral: Sham injection|Procedure: Focal/grid laser,"Jaeb Center for Health Research|National Eye Institute (NEI)|Genentech, Inc.|Allergan",Phase 3,Other|NIH|Industry,Interventional,13-Jul-11,https://ClinicalTrials.gov/show/NCT00445003
3468,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,Completed,Has Results,Diabetic Retinopathy|Diabetic Macular Edema,Drug: Triamcinolone Acetonide + laser|Drug: Ranibizumab + laser|Drug: Sham injection + laser|Drug: Ranibizumab + deferred laser,"Jaeb Center for Health Research|National Eye Institute (NEI)|Allergan|Genentech, Inc.",Phase 3,Other|NIH|Industry,Interventional,12-Jul-11,https://ClinicalTrials.gov/show/NCT00444600
3469,Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly,Completed,Has Results,Acromegaly,Drug: Octreotide capsules,"Chiasma, Inc.",Phase 3,Industry,Interventional,1-Dec-15,https://ClinicalTrials.gov/show/NCT01412424
3470,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study",Completed,Has Results,Multiple Myeloma,Drug: pomalidomide|Drug: Dexamethasone,Celgene,Phase 3,Industry,Interventional,30-Apr-14,https://ClinicalTrials.gov/show/NCT01311687
3471,Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension,Completed,Has Results,Glaucoma|Ocular Hypertension,Drug: bimatoprost /timolol formulation A fixed combination ophthalmic solution|Drug: bimatoprost/timolol fixed combination ophthalmic solution,Allergan,Phase 3,Industry,Interventional,12-Mar-13,https://ClinicalTrials.gov/show/NCT01177098
3472,Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD),Completed,Has Results,Chronic Obstructive Pulmonary Disease,Drug: NVA237|Drug: Placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,7-May-12,https://ClinicalTrials.gov/show/NCT01154127
3473,An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia,Completed,Has Results,Familial Hypercholesterolaemia,Drug: rosuvastatin calcium,AstraZeneca,Phase 3,Industry,Interventional,2-Feb-15,https://ClinicalTrials.gov/show/NCT01078675
3474,Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Completed,Has Results,Overactive Bladder|Urinary Incontinence,Biological: botulinum toxin Type A,Allergan,Phase 3,Industry,Interventional,18-Dec-15,https://ClinicalTrials.gov/show/NCT00915525
3475,Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence,Completed,Has Results,Overactive Bladder,Biological: onabotulinumtoxinA|Drug: normal saline,Allergan,Phase 3,Industry,Interventional,5-Mar-13,https://ClinicalTrials.gov/show/NCT00910520
3476,Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis,Completed,Has Results,Atopic Conjunctivitis,Drug: Cyclosporine Vehicle|Drug: Cyclosporine 0.010%,Allergan,Phase 3,Industry,Interventional,5-Nov-12,https://ClinicalTrials.gov/show/NCT00884585
3477,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,Completed,Has Results,Overactive Bladder,Biological: Botulinum Toxin Type A 300U|Biological: Botulinum Toxin Type A 200U,Allergan,Phase 3,Industry,Interventional,14-Jul-14,https://ClinicalTrials.gov/show/NCT00876447
3478,Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin Glargine|Drug: Sitagliptin|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,4-Oct-12,https://ClinicalTrials.gov/show/NCT00851903
3479,Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Amlodipine|Drug: Hydrochlorothiazide (HCTZ)|Drug: Placebo,Novartis,Phase 3,Industry,Interventional,9-May-11,https://ClinicalTrials.gov/show/NCT00765674
3480,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,14-Dec-16,https://ClinicalTrials.gov/show/NCT00763451
3481,Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension,Completed,Has Results,Hypertension,Drug: Placebo|Drug: Aliskiren 150 mg tablet|Drug: Aliskiren 300 mg tablet|Drug: Amlodipine 5 mg capsule|Drug: Amlodipine 10 mg capsule|Drug: Aliskiren/amlodipine 150/5 mg tablet|Drug: Aliskiren/amlodipine 150/10 mg tablet|Drug: Aliskiren/amlodipine 300/5 mg tablet|Drug: Aliskiren/amlodipine 300/10 mg tablet,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,3-May-11,https://ClinicalTrials.gov/show/NCT00739973
3482,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Basal Insulin|Drug: Metformin|Device: Pen auto-injector,Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT00715624
3483,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Sulfonylurea|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,14-Dec-16,https://ClinicalTrials.gov/show/NCT00713830
3484,"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,15-Dec-16,https://ClinicalTrials.gov/show/NCT00712673
3485,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Device: Pen auto-injector|Drug: Exenatide|Device: Prefilled pen injector|Drug: Metformin,Sanofi,Phase 3,Industry,Interventional,11-Oct-16,https://ClinicalTrials.gov/show/NCT00707031
3486,Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension,Completed,Has Results,Hypertension,Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|Drug: Aliskiren (300 mg),Novartis,Phase 3,Industry,Interventional,21-Jan-11,https://ClinicalTrials.gov/show/NCT00705575
3487,Docetaxel in Node Positive Adjuvant Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Docetaxel|Drug: 5-fluorouracil|Drug: Doxorubicin|Drug: Cyclophosphamide,Sanofi|Cancer International Research Group (CIRG),Phase 3,Industry|Other,Interventional,14-Feb-11,https://ClinicalTrials.gov/show/NCT00688740
3488,GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector,Sanofi,Phase 3,Industry,Interventional,12-Dec-16,https://ClinicalTrials.gov/show/NCT00688701
3489,"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Phase 3,Industry,Interventional,23-Jun-15,https://ClinicalTrials.gov/show/NCT00658775
3490,Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD),Completed,Has Results,Gastroesophageal Reflux Disease (GERD),Drug: Rabeprazole sodium|Drug: Esomeprazole,Eisai Inc.,Phase 3,Industry,Interventional,23-Jun-15,https://ClinicalTrials.gov/show/NCT00658528
3491,Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea,Completed,Has Results,Exocrine Pancreatic Insufficiency|Chronic Pancreatitis|Pancreatectomy,Drug: Viokase® 16|Drug: Placebo|Drug: Proton pump inhibitor (PPI)|Drug: Omeprazole,Forest Laboratories,Phase 3,Industry,Interventional,12-Mar-14,https://ClinicalTrials.gov/show/NCT00559364
3492,Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease,Completed,Has Results,"Gaucher Disease, Type 1",Biological: velaglucerase alfa|Biological: imiglucerase,Shire,Phase 3,Industry,Interventional,4-Jan-11,https://ClinicalTrials.gov/show/NCT00553631
3493,Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia,Completed,Has Results,Leukemia|Myelodysplastic Syndromes,Biological: filgrastim|Biological: sargramostim|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: zosuquidar trihydrochloride|Drug: Placebo,Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals,Phase 3,Other|NIH|Industry,Interventional,6-Sep-10,https://ClinicalTrials.gov/show/NCT00046930
3494,Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction,Completed,Has Results,Neurogenic Urinary Bladder,Drug: Alfuzosin|Drug: Placebo,Sanofi,Phase 3,Industry,Interventional,8-Feb-11,https://ClinicalTrials.gov/show/NCT00549939
3495,"12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe",Completed,Has Results,Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis,Drug: Rosuvastatin (Crestor)|Drug: Ezetimibe|Drug: Simvastatin,AstraZeneca,Phase 3,Industry,Interventional,7-Oct-09,https://ClinicalTrials.gov/show/NCT00525824
3496,Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia,Completed,Has Results,Bacterial Pneumonia,Drug: Ceftaroline fosamil for Injection|Drug: Ceftriaxone|Drug: Placebo,Forest Laboratories,Phase 3,Industry,Interventional,8-Nov-10,https://ClinicalTrials.gov/show/NCT00509106
3497,Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation,Drug: dronedarone (SR33589)|Drug: amiodarone,Sanofi,Phase 3,Industry,Interventional,9-Nov-09,https://ClinicalTrials.gov/show/NCT00489736
3498,The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE),Completed,Has Results,"Hepatitis C, Chronic",Drug: Pegylated-interferon Alfa-2a|Drug: Ribavirin,Hoffmann-La Roche,Phase 3,Industry,Interventional,23-Jan-17,https://ClinicalTrials.gov/show/NCT00483938
3499,A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia,Completed,Has Results,"Myeloid Leukemia, Chronic",Drug: Dasatinib|Drug: Imatinib,Bristol-Myers Squibb,Phase 3,Industry,Interventional,15-Mar-11,https://ClinicalTrials.gov/show/NCT00481247
3500,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Completed,Has Results,Overactive Bladder,Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal saline (Placebo); botulinum toxin Type A (200U)|Other: Normal saline (Placebo); botulinum toxin Type A (300U),Allergan,Phase 3,Industry,Interventional,17-Oct-11,https://ClinicalTrials.gov/show/NCT00461292
3501,"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension",Completed,Has Results,Hypertension,Drug: Valsartan|Drug: Enalapril|Drug: placebo matched to enalapril|Drug: placebo matched to valsartan,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,6-Jun-11,https://ClinicalTrials.gov/show/NCT00446511
3502,Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure,Completed,Has Results,Hypertension,Drug: Valsartan 0.25 mg/kg|Drug: Valsartan 1.0 mg/kg|Drug: Valsartan 4.0 mg/kg,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,9-May-11,https://ClinicalTrials.gov/show/NCT00435162
3503,Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure,Completed,Has Results,Hypertension,Drug: Valsartan|Drug: Enalapril,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,19-May-11,https://ClinicalTrials.gov/show/NCT00433836
3504,XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer,Completed,Has Results,Neoplasms|Prostatic Neoplasms,Drug: cabazitaxel (XRP6258) (RPR116258)|Drug: mitoxantrone|Drug: prednisone,Sanofi,Phase 3,Industry,Interventional,23-Dec-10,https://ClinicalTrials.gov/show/NCT00417079
3505,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),Completed,Has Results,Myocardial Infarction,Drug: Aliskiren|Drug: placebo,Novartis,Phase 3,Industry,Interventional,13-Jul-11,https://ClinicalTrials.gov/show/NCT00414609
3506,Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus,Completed,Has Results,"Hepatitis B, Chronic",Drug: Entecavir|Drug: Tenofovir|Drug: Adefovir|Drug: Lamivudine,Bristol-Myers Squibb,Phase 3,Industry,Interventional,4-Jul-12,https://ClinicalTrials.gov/show/NCT00410202
3507,An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure,Completed,Has Results,Hypertension,Drug: Aliskiren|Drug: Amlodipine|Drug: Hydrochlorothiazide,Novartis,Phase 3,Industry,Interventional,11-Jan-11,https://ClinicalTrials.gov/show/NCT00402103
3508,Docetaxel in Breast Cancer,Completed,Has Results,Breast Cancer,"Drug: docetaxel, doxorubicin, cyclophosphamide|Drug: Docetaxel,doxorubicin, cyclophosphamide",Sanofi|Cancer International Research Group (CIRG),Phase 3,Industry|Other,Interventional,17-Feb-10,https://ClinicalTrials.gov/show/NCT00312208
3509,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,Completed,Has Results,Overactive Bladder,Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal Saline (Placebo); botulinum toxin Type A (200U)|Other: Normal Saline (Placebo); botulinum toxin Type A (300U),Allergan,Phase 3,Industry,Interventional,17-Oct-11,https://ClinicalTrials.gov/show/NCT00311376
3510,Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy,Completed,Has Results,Prostatic Neoplasms,Drug: Docetaxel (TAXOTERE®) Chemotherapy|Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy,Sanofi,Phase 3,Industry,Interventional,23-Jan-12,https://ClinicalTrials.gov/show/NCT00283062
3511,Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension,Completed,Has Results,Hypertension|Left Ventricular Hypertrophy|Overweight,Drug: Aliskiren 150/300 mg|Drug: Losartan 50/100 mg|Drug: Aliskiren placebo|Drug: Losartan 50/100 mg placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,10-May-11,https://ClinicalTrials.gov/show/NCT00219141
3512,A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation,Completed,Has Results,Atrial Fibrillation|Atrial Flutter,Drug: dronedarone (SR33589)|Drug: placebo,Sanofi,Phase 3,Industry,Interventional,23-Dec-09,https://ClinicalTrials.gov/show/NCT00174785
3513,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Dexamethasone|Other: Sham,Allergan,Phase 3,Industry,Interventional,4-Aug-14,https://ClinicalTrials.gov/show/NCT00168389
3514,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Dexamethasone|Other: Sham,Allergan,Phase 3,Industry,Interventional,4-Aug-14,https://ClinicalTrials.gov/show/NCT00168337
3515,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Completed,Has Results,Macular Edema|Retinal Vein Occlusion,Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection,Allergan,Phase 3,Industry,Interventional,26-Aug-09,https://ClinicalTrials.gov/show/NCT00168324
3516,A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion,Completed,Has Results,Macular Edema|Retinal Vein Occlusion,Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection,Allergan,Phase 3,Industry,Interventional,26-Aug-09,https://ClinicalTrials.gov/show/NCT00168298
3517,Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis,Completed,Has Results,Multiple Sclerosis,Drug: Teriflunomide|Drug: Placebo (for teriflunomide),Sanofi,Phase 3,Industry,Interventional,6-Nov-12,https://ClinicalTrials.gov/show/NCT00134563
3518,Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Valsartan 160 mg + nateglinide 60 mg|Drug: Valsartan 160 mg + nateglinide placebo|Drug: Nateglinide 60 mg + valsartan placebo|Drug: Valsartan placebo + nateglinide placebo,Novartis Pharmaceuticals|Novartis,Phase 3,Industry,Interventional,24-May-11,https://ClinicalTrials.gov/show/NCT00097786
3519,"Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients",Completed,Has Results,B-Cell Chronic Lymphocytic Leukemia,Biological: FluCAM [Fludara + Campath]|Biological: fludarabine phosphate,"Genzyme, a Sanofi Company|Sanofi",Phase 3,Industry,Interventional,11-Aug-11,https://ClinicalTrials.gov/show/NCT00086580
3520,The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention),Completed,Has Results,"Diabetes Mellitus, Non-Insulin-Dependent",Drug: insulin glargine (HOE901)|Drug: omega-3 polyunsaturated fatty acids (PUFA)|Drug: placebo|Device: reusable pen device for insulin injection,Sanofi|Population Health Research Institute,Phase 3,Industry|Other,Interventional,25-Jan-13,https://ClinicalTrials.gov/show/NCT00069784
3521,Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer,Completed,Has Results,Breast Neoplasms,Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Herceptin|Drug: Carboplatin,Sanofi|Cancer International Research Group (CIRG),Phase 3,Industry|Other,Interventional,15-Nov-16,https://ClinicalTrials.gov/show/NCT00021255
3522,Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites,Completed,Has Results,Ovarian Neoplasms|Ascites,"Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo",Sanofi|Regeneron Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,1-Jan-13,https://ClinicalTrials.gov/show/NCT00327444
3523,Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis,Completed,Has Results,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis,Drug: Rituximab plus cyclophosphamide placebo (rituximab group)|Drug: Cyclophosphamide plus rituximab placebo (control group)|Drug: Azathioprine|Drug: Methylprednisolone (or other glucocorticoid)|Drug: Prednisone,"National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Genentech, Inc.",Phase 2|Phase 3,NIH|Other|Industry,Interventional,25-Aug-11,https://ClinicalTrials.gov/show/NCT00104299
3524,Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia,Completed,Has Results,Anal Cancer|Neoplasm of Uncertain Malignant Potential|Nonneoplastic Condition|Precancerous Condition,Other: clinical observation|Device: infrared photocoagulation therapy,"AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas",Phase 3,Other|NIH|Industry,Interventional,31-Oct-16,https://ClinicalTrials.gov/show/NCT01164722
3525,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),Completed,Has Results,High Risk Polycythemia Vera|High Risk Essential Thrombocythemia,Drug: PEGASYS|Drug: Hydroxyurea|Drug: Aspirin,Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Roche Pharma AG|Icahn School of Medicine at Mount Sinai,Phase 3,Other|NIH|Industry,Interventional,24-Jul-18,https://ClinicalTrials.gov/show/NCT01259856
3526,Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh,Completed,Has Results,Vitamin A Deficiency|Maternal Mortality|Infant Mortality,Dietary Supplement: Vitamin A or Beta-Carotene Supplements,Johns Hopkins Bloomberg School of Public Health|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Canadian International Development Agency|The Sight and Life Research Institute|Access Business Group,Phase 3,Other|U.S. Fed|Industry,Interventional,12-Oct-11,https://ClinicalTrials.gov/show/NCT00198822
3527,Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial,Completed,Has Results,Amyotrophic Lateral Sclerosis,"Drug: Insulin like growth factor, type 1|Drug: Placebo",Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS)|ALS Association|Cephalon,Phase 3,Other|NIH|Industry,Interventional,15-Feb-13,https://ClinicalTrials.gov/show/NCT00035815
3528,"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",Completed,Has Results,Lysosomal Acid Lipase Deficiency|Wolman Disease,Drug: Sebelipase alfa (SBC-102),Alexion Pharmaceuticals,Phase 2|Phase 3,Industry,Interventional,18-Apr-16,https://ClinicalTrials.gov/show/NCT01371825
3529,Trial of CF101 to Treat Patients With Psoriasis,Completed,Has Results,Plaque Psoriasis,Drug: CF101|Drug: Placebo,Can-Fite BioPharma,Phase 2|Phase 3,Industry,Interventional,20-Sep-17,https://ClinicalTrials.gov/show/NCT01265667
3530,Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis,Completed,Has Results,Familial Amyloid Polyneuropathy,Drug: Fx-1006A|Drug: Placebo,Pfizer,Phase 2|Phase 3,Industry,Interventional,17-Dec-12,https://ClinicalTrials.gov/show/NCT00409175
3531,A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis,Completed,Has Results,Intermediate Uveitis|Posterior Uveitis,Drug: Dexamethasone|Drug: dexamethasone|Drug: Sham injection,Allergan,Phase 2|Phase 3,Industry,Interventional,14-Apr-11,https://ClinicalTrials.gov/show/NCT00333814
3532,Contraceptive Effectiveness and Safety of the SILCS Diaphragm,Completed,Has Results,Contraception,Device: SILCS Diaphragm|Combination Product: Nonoxynol-9 Gel|Combination Product: Buffer Gel,CONRAD|United States Agency for International Development (USAID)|FHI 360|ReProtect Inc,Phase 2|Phase 3,Other|U.S. Fed|Industry,Interventional,24-Aug-17,https://ClinicalTrials.gov/show/NCT00578877
3533,Comparative Study of Three NNRTI-Sparing HAART Regimens,Completed,Has Results,HIV Infection,Drug: Emtricitabine/tenofovir disoproxil fumarate|Drug: Raltegravir|Drug: Darunavir|Drug: Ritonavir|Drug: Atazanavir,"AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Gilead Sciences|Merck Sharp & Dohme Corp.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Phase 3,Other|NIH|Industry,Interventional,5-Sep-14,https://ClinicalTrials.gov/show/NCT00811954
3534,"Pragmatic, Randomized Optimal Platelet and Plasma Ratios",Completed,Has Results,Trauma,Biological: 1:1:1 Blood Transfusion Ratio|Biological: 1:1:2 Blood Transfusion Ratio,"The University of Texas Health Science Center, Houston|United States Department of Defense|National Heart, Lung, and Blood Institute (NHLBI)|Resuscitation Outcomes Consortium|Defence Research and Development Canada",Phase 3,Other|U.S. Fed|NIH|Industry,Interventional,3-Jun-15,https://ClinicalTrials.gov/show/NCT01545232
3535,Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment,Completed,Has Results,"Chronic Hepatitis c|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis",Drug: Peginterferon alfa-2a + Ribavirin|Drug: Peginterferon alfa-2a,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute on Minority Health and Health Disparities (NIMHD)|National Cancer Institute (NCI)|Hoffmann-La Roche,Phase 3,NIH|Industry,Interventional,4-Sep-09,https://ClinicalTrials.gov/show/NCT00006164
3536,The Testosterone Trials in Older Men,Completed,Has Results,Andropause,Drug: AndroGel® (testosterone gel)|Drug: Placebo,"University of Pennsylvania|National Institute on Aging (NIA)|National Institute of Neurological Disorders and Stroke (NINDS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)|Abbott",Phase 3,Other|NIH|Industry,Interventional,28-Aug-17,https://ClinicalTrials.gov/show/NCT00799617
3537,Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases,Completed,Has Results,Metastatic Cancer|Prostate Cancer,Drug: zoledronic acid|Other: placebo|Drug: androgen deprivation therapy|Drug: GnRH agonist|Dietary Supplement: Calcium supplement|Dietary Supplement: Vitamin D,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Novartis Pharmaceuticals,Phase 3,Other|NIH|Industry,Interventional,30-Oct-14,https://ClinicalTrials.gov/show/NCT00079001
3538,Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis,Completed,Has Results,Deep Vein Thrombosis|Venous Thrombosis|Postphlebitic Syndrome|Venous Thromboembolism|Post Thrombotic Syndrome,Drug: Recombinant tissue plasminogen activator (rt-PA),"Washington University School of Medicine|McMaster University|Ontario Clinical Oncology Group (OCOG)|National Heart, Lung, and Blood Institute (NHLBI)|BSN Medical Inc|Genentech, Inc.|Medtronic - MITG|Boston Scientific Corporation|Mid America Heart Institute|Society of Interventional Radiology Foundation|Massachusetts General Hospital",Phase 3,Other|NIH|Industry,Interventional,29-Mar-18,https://ClinicalTrials.gov/show/NCT00790335
3539,"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia",Completed,Has Results,Cardiac Arrest,Drug: amiodarone|Drug: Lidocaine|Other: Normal saline,"University of Washington|National Heart, Lung, and Blood Institute (NHLBI)|Canadian Institutes of Health Research (CIHR)|Heart and Stroke Foundation of Canada|American Heart Association|Defence Research and Development Canada|U.S. Army Medical Research and Development Command",Phase 3,Other|NIH|Industry|U.S. Fed,Interventional,30-Jan-17,https://ClinicalTrials.gov/show/NCT01401647
3540,A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD),Completed,Has Results,Seasonal Affective Disorder,Device: Negative Ion Generator|Device: Light-emitting Photodiode light treatment device,"Yale University|The Litebook Company Ltd.|University of British Columbia|McGill University Health Center|Harvard University|University of Toronto|Clinical Associates Research, Maryland|Dalhousie University",Phase 2|Phase 3,Other|Industry,Interventional,6-Mar-13,https://ClinicalTrials.gov/show/NCT00809523
